[
    {
        "protocol_id": "1875 v.5",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Trastuzumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "17 cycles (in the neoadjuvant/adjuvant setting) or continuous until no longer clinically appropriate (metastatic setting)",
                    "dose": "600 mg",
                    "day": "1",
                    "route": "Subcut"
                }
            ],
            [
                {
                    "drug_name": "Trastuzumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "17 cycles (in the neoadjuvant/adjuvant setting) or continuous until no longer clinically appropriate (metastatic setting)",
                    "dose": "600 mg",
                    "day": "1",
                    "route": "Subcut"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/1875-breast-trastuzumab-subcutaneous"
    },
    {
        "protocol_id": "4168 v.2",
        "protocol_status": "Under review",
        "drug_sequence": [
            [
                {
                    "drug_name": "Abemaciclib",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "150 mg TWICE a day",
                    "day": null,
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Abemaciclib",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "150 mg TWICE a day",
                    "day": null,
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/neoadjuvant-adjuvant/4168-breast-adjuvant-abemaciclib"
    },
    {
        "protocol_id": "1607 v.5",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "cyclophosphamide",
                    "is_adjuvant": true,
                    "is_neoadjuvant": true,
                    "frequency": "14 days",
                    "cycles": "4",
                    "dose": "",
                    "day": 1,
                    "route": "IV"
                },
                {
                    "drug_name": "doxorubicin",
                    "is_adjuvant": true,
                    "is_neoadjuvant": true,
                    "frequency": "14 days",
                    "cycles": "4",
                    "dose": "",
                    "day": 1,
                    "route": "IV"
                }
            ],
            [
                {
                    "drug_name": "paclitaxel",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "4",
                    "dose": "",
                    "day": 1,
                    "route": "IV"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/neoadjuvant-adjuvant/1607-breast-adjuvant-ac-doxorubicin-and-cyclophos"
    },
    {
        "protocol_id": "4010 v.1",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "cyclophosphamide",
                    "is_adjuvant": true,
                    "is_neoadjuvant": true,
                    "frequency": "14 days",
                    "cycles": "4",
                    "dose": "",
                    "day": 1,
                    "route": "IV"
                },
                {
                    "drug_name": "doxorubicin",
                    "is_adjuvant": true,
                    "is_neoadjuvant": true,
                    "frequency": "14 days",
                    "cycles": "4",
                    "dose": "",
                    "day": 1,
                    "route": "IV"
                }
            ],
            [
                {
                    "drug_name": "paclitaxel",
                    "is_adjuvant": true,
                    "is_neoadjuvant": true,
                    "frequency": "14 days",
                    "cycles": "4",
                    "dose": "",
                    "day": 1,
                    "route": "IV"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/neoadjuvant-adjuvant/4010-breast-adjuvant-ac-doxorubicin-and-cyclophos"
    },
    {
        "protocol_id": "1606 v.4",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "cyclophosphamide",
                    "is_adjuvant": true,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "4",
                    "dose": "",
                    "day": 1,
                    "route": "IV"
                },
                {
                    "drug_name": "doxorubicin",
                    "is_adjuvant": true,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "4",
                    "dose": "",
                    "day": 1,
                    "route": "IV"
                }
            ],
            [
                {
                    "drug_name": "trastuzumab",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4",
                    "dose": "",
                    "day": 1,
                    "route": "IV"
                },
                {
                    "drug_name": "paclitaxel",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4",
                    "dose": "",
                    "day": 1,
                    "route": "IV"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/neoadjuvant-adjuvant/1606-breast-adjuvant-ac-doxorubicin-and-cyclophos"
    },
    {
        "protocol_id": "122 v.6",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "cyclophosphamide",
                    "is_adjuvant": true,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "4",
                    "dose": "",
                    "day": 1,
                    "route": "IV"
                },
                {
                    "drug_name": "doxorubicin",
                    "is_adjuvant": true,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "4",
                    "dose": "",
                    "day": 1,
                    "route": "IV"
                }
            ],
            [
                {
                    "drug_name": "trastuzumab",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4",
                    "dose": "",
                    "day": 1,
                    "route": "IV"
                },
                {
                    "drug_name": "docetaxel",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4",
                    "dose": "",
                    "day": 1,
                    "route": "IV"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/neoadjuvant-adjuvant/122-breast-adjuvant-ac-th-doxorubicin-cyclophosph"
    },
    {
        "protocol_id": "19 v.7",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Anastrozole",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "1 mg ONCE a day",
                    "day": null,
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Anastrozole",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "1 mg ONCE a day",
                    "day": null,
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/neoadjuvant-adjuvant/19-breast-adjuvant-anastrozole"
    },
    {
        "protocol_id": "3503 v.4",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Capecitabine",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6(or 8 cycles if toxicity allows)",
                    "dose": "1,250 mg/m2 TWICE a day *",
                    "day": "1 to 14",
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Capecitabine",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6(or 8 cycles if toxicity allows)",
                    "dose": "1,250 mg/m2 TWICE a day *",
                    "day": "1 to 14",
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/neoadjuvant-adjuvant/3503-breast-adjuvant-capecitabine-post-neoadjuvan"
    },
    {
        "protocol_id": "4167 v.2",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Capecitabine",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "650 mg/m2 TWICE a day *",
                    "day": null,
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Capecitabine",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "650 mg/m2 TWICE a day *",
                    "day": null,
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/neoadjuvant-adjuvant/4167-breast-adjuvant-capecitabine-metronomic"
    },
    {
        "protocol_id": "21 v.8",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "6",
                    "dose": "600 mg/m2",
                    "day": "1 and 8",
                    "route": "IV"
                },
                {
                    "drug_name": "Methotrexate",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "6",
                    "dose": "40 mg/m2",
                    "day": "1 and 8",
                    "route": "IV bolus"
                },
                {
                    "drug_name": "CYCLOPHOSPHamide",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "6",
                    "dose": "100 mg/m2 ONCE a day *",
                    "day": "1 to 14 *",
                    "route": "PO *"
                }
            ],
            [
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "6",
                    "dose": "600 mg/m2",
                    "day": "1 and 8",
                    "route": "IV"
                },
                {
                    "drug_name": "Methotrexate",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "6",
                    "dose": "40 mg/m2",
                    "day": "1 and 8",
                    "route": "IV bolus"
                },
                {
                    "drug_name": "CYCLOPHOSPHamide",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "6",
                    "dose": "100 mg/m2 ONCE a day *",
                    "day": "1 to 14 *",
                    "route": "PO *"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/neoadjuvant-adjuvant/21-breast-adjuvant-cmf-classical-cyclophosphamide"
    },
    {
        "protocol_id": "4133 v.2",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Epirubicin",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4",
                    "dose": "90 mg/m2",
                    "day": "1",
                    "route": "IV"
                },
                {
                    "drug_name": "CYCLOPHOSPHamide",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4",
                    "dose": "600 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Epirubicin",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4",
                    "dose": "90 mg/m2",
                    "day": "1",
                    "route": "IV"
                },
                {
                    "drug_name": "CYCLOPHOSPHamide",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4",
                    "dose": "600 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/neoadjuvant-adjuvant/4133-breast-adjuvant-ec-epirubicin-and-cyclophosp"
    },
    {
        "protocol_id": "3913 v.1",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "cyclophosphamide",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4",
                    "dose": "",
                    "day": 1,
                    "route": "IV"
                },
                {
                    "drug_name": "epirubicin",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4",
                    "dose": "",
                    "day": 1,
                    "route": "IV"
                }
            ],
            [
                {
                    "drug_name": "docetaxel",
                    "is_adjuvant": true,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "4",
                    "dose": "",
                    "day": 1,
                    "route": "IV"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/neoadjuvant-adjuvant/3913-breast-adjuvant-ec-d-epirubicin-and-cyclopho"
    },
    {
        "protocol_id": "25 v.6",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Exemestane",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "25 mg ONCE a day",
                    "day": null,
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Exemestane",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "25 mg ONCE a day",
                    "day": null,
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/neoadjuvant-adjuvant/25-breast-adjuvant-exemestane"
    },
    {
        "protocol_id": "1785 v.4",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Goserelin",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous for up to 5 years for goserelin, and 5 to 10 years for exemestane",
                    "dose": "3.6 mg",
                    "day": "1",
                    "route": "Subcut"
                },
                {
                    "drug_name": "Exemestane *",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous for up to 5 years for goserelin, and 5 to 10 years for exemestane",
                    "dose": "25 mg ONCE a day",
                    "day": "1 to 28",
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Goserelin",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous for up to 5 years for goserelin, and 5 to 10 years for exemestane",
                    "dose": "3.6 mg",
                    "day": "1",
                    "route": "Subcut"
                },
                {
                    "drug_name": "Exemestane *",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous for up to 5 years for goserelin, and 5 to 10 years for exemestane",
                    "dose": "25 mg ONCE a day",
                    "day": "1 to 28",
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/neoadjuvant-adjuvant/1785-breast-adjuvant-exemestane-and-goserelin"
    },
    {
        "protocol_id": "29 v.7",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Goserelin",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous for up to 5 years",
                    "dose": "3.6 mg",
                    "day": "1",
                    "route": "Subcut"
                }
            ],
            [
                {
                    "drug_name": "Goserelin",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous for up to 5 years",
                    "dose": "3.6 mg",
                    "day": "1",
                    "route": "Subcut"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/neoadjuvant-adjuvant/29-breast-adjuvant-goserelin"
    },
    {
        "protocol_id": "30 v.7",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Letrozole",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "2.5 mg ONCE a day",
                    "day": null,
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Letrozole",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "2.5 mg ONCE a day",
                    "day": null,
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/neoadjuvant-adjuvant/30-breast-adjuvant-letrozole"
    },
    {
        "protocol_id": "160 v.11",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "PACLitaxel",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "4",
                    "dose": "175 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Pegfilgrastim",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "4",
                    "dose": "6 mg",
                    "day": "2",
                    "route": "Subcut"
                }
            ],
            [
                {
                    "drug_name": "PACLitaxel",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "4",
                    "dose": "175 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Pegfilgrastim",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "4",
                    "dose": "6 mg",
                    "day": "2",
                    "route": "Subcut"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/neoadjuvant-adjuvant/160-breast-adjuvant-paclitaxel-dose-dense"
    },
    {
        "protocol_id": "153 v.12",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "PACLitaxel",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "17(4 cycles of paclitaxel and trastuzumab followed by 13 cycles of trastuzumab; total trastuzumab treatment equal to 17 cycles)",
                    "dose": "80 mg/m2",
                    "day": "1, 8, 15",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Trastuzumab",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "17(4 cycles of paclitaxel and trastuzumab followed by 13 cycles of trastuzumab; total trastuzumab treatment equal to 17 cycles)",
                    "dose": "8 mg/kg (loading dose only)",
                    "day": "1",
                    "route": "IV infusion *"
                }
            ],
            [
                {
                    "drug_name": "PACLitaxel",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "17(4 cycles of paclitaxel and trastuzumab followed by 13 cycles of trastuzumab; total trastuzumab treatment equal to 17 cycles)",
                    "dose": "80 mg/m2",
                    "day": "1, 8, 15",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Trastuzumab",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "17(4 cycles of paclitaxel and trastuzumab followed by 13 cycles of trastuzumab; total trastuzumab treatment equal to 17 cycles)",
                    "dose": "6 mg/kg (subsequent doses)",
                    "day": "1",
                    "route": "IV infusion *"
                }
            ],
            [
                {
                    "drug_name": "Trastuzumab",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "17(4 cycles of paclitaxel and trastuzumab followed by 13 cycles of trastuzumab; total trastuzumab treatment equal to 17 cycles)",
                    "dose": "6 mg/kg (subsequent doses)",
                    "day": "1",
                    "route": "IV infusion *"
                }
            ],
            [
                {
                    "drug_name": "PACLitaxel",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "17(4 cycles of paclitaxel and trastuzumab followed by 13 cycles of trastuzumab; total trastuzumab treatment equal to 17 cycles)",
                    "dose": "80 mg/m2",
                    "day": "1, 8, 15",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Trastuzumab",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "17(4 cycles of paclitaxel and trastuzumab followed by 13 cycles of trastuzumab; total trastuzumab treatment equal to 17 cycles)",
                    "dose": "8 mg/kg (loading dose only)",
                    "day": "1",
                    "route": "IV infusion *"
                }
            ],
            [
                {
                    "drug_name": "PACLitaxel",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "17(4 cycles of paclitaxel and trastuzumab followed by 13 cycles of trastuzumab; total trastuzumab treatment equal to 17 cycles)",
                    "dose": "80 mg/m2",
                    "day": "1, 8, 15",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Trastuzumab",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "17(4 cycles of paclitaxel and trastuzumab followed by 13 cycles of trastuzumab; total trastuzumab treatment equal to 17 cycles)",
                    "dose": "6 mg/kg (subsequent doses)",
                    "day": "1",
                    "route": "IV infusion *"
                }
            ],
            [
                {
                    "drug_name": "Trastuzumab",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "17(4 cycles of paclitaxel and trastuzumab followed by 13 cycles of trastuzumab; total trastuzumab treatment equal to 17 cycles)",
                    "dose": "6 mg/kg (subsequent doses)",
                    "day": "1",
                    "route": "IV infusion *"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/neoadjuvant-adjuvant/153-breast-adjuvant-paclitaxel-weekly-and-trastuzu"
    },
    {
        "protocol_id": "32 v.7",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Tamoxifen",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "20 mg ONCE a day",
                    "day": null,
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Tamoxifen",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "20 mg ONCE a day",
                    "day": null,
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/neoadjuvant-adjuvant/32-breast-adjuvant-tamoxifen"
    },
    {
        "protocol_id": "24 v.9",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "DOCEtaxel",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4(up to 6 cycles- see note)",
                    "dose": "75 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "CYCLOPHOSPHamide",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4(up to 6 cycles- see note)",
                    "dose": "600 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Pegfilgrastim",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4(up to 6 cycles- see note)",
                    "dose": "6 mg",
                    "day": "2",
                    "route": "Subcut"
                }
            ],
            [
                {
                    "drug_name": "DOCEtaxel",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4(up to 6 cycles- see note)",
                    "dose": "75 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "CYCLOPHOSPHamide",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4(up to 6 cycles- see note)",
                    "dose": "600 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Pegfilgrastim",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4(up to 6 cycles- see note)",
                    "dose": "6 mg",
                    "day": "2",
                    "route": "Subcut"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/neoadjuvant-adjuvant/24-breast-adjuvant-tc-docetaxel-and-cyclophospham"
    },
    {
        "protocol_id": "53 v.11",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "DOCEtaxel",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "17(6 cycles of TCH followed by 11 cycles of trastuzumab; total trastuzumab treatment equal to 17 cycles)",
                    "dose": "75 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "17(6 cycles of TCH followed by 11 cycles of trastuzumab; total trastuzumab treatment equal to 17 cycles)",
                    "dose": "6 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Trastuzumab",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "17(6 cycles of TCH followed by 11 cycles of trastuzumab; total trastuzumab treatment equal to 17 cycles)",
                    "dose": "8 mg/kg (loading dose only)",
                    "day": "1",
                    "route": "IV infusion **"
                },
                {
                    "drug_name": "Pegfilgrastim",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "17(6 cycles of TCH followed by 11 cycles of trastuzumab; total trastuzumab treatment equal to 17 cycles)",
                    "dose": "6 mg",
                    "day": "2",
                    "route": "Subcut"
                }
            ],
            [
                {
                    "drug_name": "DOCEtaxel",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "17(6 cycles of TCH followed by 11 cycles of trastuzumab; total trastuzumab treatment equal to 17 cycles)",
                    "dose": "75 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "17(6 cycles of TCH followed by 11 cycles of trastuzumab; total trastuzumab treatment equal to 17 cycles)",
                    "dose": "6 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Trastuzumab",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "17(6 cycles of TCH followed by 11 cycles of trastuzumab; total trastuzumab treatment equal to 17 cycles)",
                    "dose": "6 mg/kg (subsequent doses)",
                    "day": "1",
                    "route": "IV infusion **"
                },
                {
                    "drug_name": "Pegfilgrastim",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "17(6 cycles of TCH followed by 11 cycles of trastuzumab; total trastuzumab treatment equal to 17 cycles)",
                    "dose": "6 mg",
                    "day": "2",
                    "route": "Subcut"
                }
            ],
            [
                {
                    "drug_name": "Trastuzumab",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "17(6 cycles of TCH followed by 11 cycles of trastuzumab; total trastuzumab treatment equal to 17 cycles)",
                    "dose": "6 mg/kg (subsequent doses)",
                    "day": "1",
                    "route": "IV infusion **"
                }
            ],
            [
                {
                    "drug_name": "DOCEtaxel",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "17(6 cycles of TCH followed by 11 cycles of trastuzumab; total trastuzumab treatment equal to 17 cycles)",
                    "dose": "75 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "17(6 cycles of TCH followed by 11 cycles of trastuzumab; total trastuzumab treatment equal to 17 cycles)",
                    "dose": "6 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Trastuzumab",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "17(6 cycles of TCH followed by 11 cycles of trastuzumab; total trastuzumab treatment equal to 17 cycles)",
                    "dose": "8 mg/kg (loading dose only)",
                    "day": "1",
                    "route": "IV infusion **"
                },
                {
                    "drug_name": "Pegfilgrastim",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "17(6 cycles of TCH followed by 11 cycles of trastuzumab; total trastuzumab treatment equal to 17 cycles)",
                    "dose": "6 mg",
                    "day": "2",
                    "route": "Subcut"
                }
            ],
            [
                {
                    "drug_name": "DOCEtaxel",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "17(6 cycles of TCH followed by 11 cycles of trastuzumab; total trastuzumab treatment equal to 17 cycles)",
                    "dose": "75 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "17(6 cycles of TCH followed by 11 cycles of trastuzumab; total trastuzumab treatment equal to 17 cycles)",
                    "dose": "6 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Trastuzumab",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "17(6 cycles of TCH followed by 11 cycles of trastuzumab; total trastuzumab treatment equal to 17 cycles)",
                    "dose": "6 mg/kg (subsequent doses)",
                    "day": "1",
                    "route": "IV infusion **"
                },
                {
                    "drug_name": "Pegfilgrastim",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "17(6 cycles of TCH followed by 11 cycles of trastuzumab; total trastuzumab treatment equal to 17 cycles)",
                    "dose": "6 mg",
                    "day": "2",
                    "route": "Subcut"
                }
            ],
            [
                {
                    "drug_name": "Trastuzumab",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "17(6 cycles of TCH followed by 11 cycles of trastuzumab; total trastuzumab treatment equal to 17 cycles)",
                    "dose": "6 mg/kg (subsequent doses)",
                    "day": "1",
                    "route": "IV infusion **"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/neoadjuvant-adjuvant/53-breast-adjuvant-tch-docetaxel-carboplatin-tras"
    },
    {
        "protocol_id": "138 v.9",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "DOCEtaxel",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "17(4 cycles of TH followed by 13 cycles of trastuzumab; total trastuzumab treatment equal to 17 cycles)",
                    "dose": "100 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Trastuzumab",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "17(4 cycles of TH followed by 13 cycles of trastuzumab; total trastuzumab treatment equal to 17 cycles)",
                    "dose": "8 mg/kg (loading dose only)",
                    "day": "1",
                    "route": "IV infusion *"
                }
            ],
            [
                {
                    "drug_name": "DOCEtaxel",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "17(4 cycles of TH followed by 13 cycles of trastuzumab; total trastuzumab treatment equal to 17 cycles)",
                    "dose": "100 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Trastuzumab",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "17(4 cycles of TH followed by 13 cycles of trastuzumab; total trastuzumab treatment equal to 17 cycles)",
                    "dose": "6 mg/kg (subsequent doses)",
                    "day": "1",
                    "route": "IV infusion *"
                }
            ],
            [
                {
                    "drug_name": "Trastuzumab",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "17(4 cycles of TH followed by 13 cycles of trastuzumab; total trastuzumab treatment equal to 17 cycles)",
                    "dose": "6 mg/kg (subsequent doses)",
                    "day": "1",
                    "route": "IV infusion *"
                }
            ],
            [
                {
                    "drug_name": "DOCEtaxel",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "17(4 cycles of TH followed by 13 cycles of trastuzumab; total trastuzumab treatment equal to 17 cycles)",
                    "dose": "100 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Trastuzumab",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "17(4 cycles of TH followed by 13 cycles of trastuzumab; total trastuzumab treatment equal to 17 cycles)",
                    "dose": "8 mg/kg (loading dose only)",
                    "day": "1",
                    "route": "IV infusion *"
                }
            ],
            [
                {
                    "drug_name": "DOCEtaxel",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "17(4 cycles of TH followed by 13 cycles of trastuzumab; total trastuzumab treatment equal to 17 cycles)",
                    "dose": "100 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Trastuzumab",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "17(4 cycles of TH followed by 13 cycles of trastuzumab; total trastuzumab treatment equal to 17 cycles)",
                    "dose": "6 mg/kg (subsequent doses)",
                    "day": "1",
                    "route": "IV infusion *"
                }
            ],
            [
                {
                    "drug_name": "Trastuzumab",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "17(4 cycles of TH followed by 13 cycles of trastuzumab; total trastuzumab treatment equal to 17 cycles)",
                    "dose": "6 mg/kg (subsequent doses)",
                    "day": "1",
                    "route": "IV infusion *"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/neoadjuvant-adjuvant/138-breast-adjuvant-th-docetaxel-and-trastuzumab"
    },
    {
        "protocol_id": "3813 v.2",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Trastuzumab emtansine",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "14",
                    "dose": "3.6 mg/kg",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Trastuzumab emtansine",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "14",
                    "dose": "3.6 mg/kg",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/neoadjuvant-adjuvant/3813-breast-adjuvant-trastuzumab-emtansine"
    },
    {
        "protocol_id": "1875 v.5",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Trastuzumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "17 cycles (in the neoadjuvant/adjuvant setting) or continuous until no longer clinically appropriate (metastatic setting)",
                    "dose": "600 mg",
                    "day": "1",
                    "route": "Subcut"
                }
            ],
            [
                {
                    "drug_name": "Trastuzumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "17 cycles (in the neoadjuvant/adjuvant setting) or continuous until no longer clinically appropriate (metastatic setting)",
                    "dose": "600 mg",
                    "day": "1",
                    "route": "Subcut"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/neoadjuvant-adjuvant/3306-1875-redirect"
    },
    {
        "protocol_id": "1364 v.4",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "cyclophosphamide",
                    "is_adjuvant": true,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "4",
                    "dose": "",
                    "day": 1,
                    "route": "IV"
                },
                {
                    "drug_name": "doxorubicin",
                    "is_adjuvant": true,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "4",
                    "dose": "",
                    "day": 1,
                    "route": "IV"
                }
            ],
            [
                {
                    "drug_name": "docetaxel",
                    "is_adjuvant": true,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "4",
                    "dose": "",
                    "day": 1,
                    "route": "IV"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/neoadjuvant-adjuvant/1364-breast-neoadjuvant-ac-doxorubicin-and-cyclop"
    },
    {
        "protocol_id": "1714 v.10",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "PACLitaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "4",
                    "dose": "80 mg/m2",
                    "day": "1, 8, 15",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "4",
                    "dose": "6 AUC * #",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Filgrastim",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "4",
                    "dose": "5 micrograms/kg",
                    "day": "2 to 6",
                    "route": "Subcut"
                }
            ],
            [
                {
                    "drug_name": "PACLitaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "4",
                    "dose": "80 mg/m2",
                    "day": "1, 8, 15",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "4",
                    "dose": "6 AUC * #",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Filgrastim",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "4",
                    "dose": "5 micrograms/kg",
                    "day": "2 to 6",
                    "route": "Subcut"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/neoadjuvant-adjuvant/1714-breast-neoadjuvant-carboplatin-three-weekly-a"
    },
    {
        "protocol_id": "1870 v.4",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "paclitaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "4",
                    "dose": "",
                    "day": 1,
                    "route": "IV"
                },
                {
                    "drug_name": "carboplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "4",
                    "dose": "",
                    "day": 1,
                    "route": "IV"
                }
            ],
            [
                {
                    "drug_name": "cyclophosphamide",
                    "is_adjuvant": true,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "4",
                    "dose": "",
                    "day": 1,
                    "route": "IV"
                },
                {
                    "drug_name": "doxorubicin",
                    "is_adjuvant": true,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "4",
                    "dose": "",
                    "day": 1,
                    "route": "IV"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/neoadjuvant-adjuvant/1870-breast-neoadjuvant-carboplatin-three-weekly-a"
    },
    {
        "protocol_id": "3812 v.4",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "PACLitaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "7 days",
                    "cycles": "12",
                    "dose": "80 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "7 days",
                    "cycles": "12",
                    "dose": "2 AUC * #",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "PACLitaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "7 days",
                    "cycles": "12",
                    "dose": "80 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "7 days",
                    "cycles": "12",
                    "dose": "2 AUC * #",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/neoadjuvant-adjuvant/3812-breast-neoadjuvant-carboplatin-weekly-and-pac"
    },
    {
        "protocol_id": "4009 v.1",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "paclitaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "7 days",
                    "cycles": "12",
                    "dose": "",
                    "day": 1,
                    "route": "IV"
                },
                {
                    "drug_name": "carboplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "7 days",
                    "cycles": "12",
                    "dose": "",
                    "day": 1,
                    "route": "IV"
                }
            ],
            [
                {
                    "drug_name": "cyclophosphamide",
                    "is_adjuvant": true,
                    "is_neoadjuvant": true,
                    "frequency": "7 days",
                    "cycles": "12",
                    "dose": "",
                    "day": 1,
                    "route": "IV"
                },
                {
                    "drug_name": "doxorubicin",
                    "is_adjuvant": true,
                    "is_neoadjuvant": true,
                    "frequency": "7 days",
                    "cycles": "12",
                    "dose": "",
                    "day": 1,
                    "route": "IV"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/neoadjuvant-adjuvant/4009-breast-neoadjuvant-carboplatin-weekly-and-pac"
    },
    {
        "protocol_id": "1969 v.6",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "pERTUZumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "4cycles prior to surgery",
                    "dose": "840 mg (loading dose only)",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Trastuzumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "4cycles prior to surgery",
                    "dose": "8 mg/kg (loading dose only)",
                    "day": "1",
                    "route": "IV infusion *"
                },
                {
                    "drug_name": "DOCEtaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "4cycles prior to surgery",
                    "dose": "75 mg/m2 **",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "pERTUZumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "4cycles prior to surgery",
                    "dose": "420 mg (subsequent doses)",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Trastuzumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "4cycles prior to surgery",
                    "dose": "6 mg/kg (subsequent doses)",
                    "day": "1",
                    "route": "IV infusion *"
                },
                {
                    "drug_name": "DOCEtaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "4cycles prior to surgery",
                    "dose": "75 mg/m2 **",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "pERTUZumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "4cycles prior to surgery",
                    "dose": "840 mg (loading dose only)",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Trastuzumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "4cycles prior to surgery",
                    "dose": "8 mg/kg (loading dose only)",
                    "day": "1",
                    "route": "IV infusion *"
                },
                {
                    "drug_name": "DOCEtaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "4cycles prior to surgery",
                    "dose": "75 mg/m2 **",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "pERTUZumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "4cycles prior to surgery",
                    "dose": "420 mg (subsequent doses)",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Trastuzumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "4cycles prior to surgery",
                    "dose": "6 mg/kg (subsequent doses)",
                    "day": "1",
                    "route": "IV infusion *"
                },
                {
                    "drug_name": "DOCEtaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "4cycles prior to surgery",
                    "dose": "75 mg/m2 **",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/neoadjuvant-adjuvant/1969-breast-neoadjuvant-docetaxel-pertuzumab-and"
    },
    {
        "protocol_id": "3643 v.5",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "pERTUZumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "4cycles prior to surgery",
                    "dose": "840 mg (loading dose only)",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Trastuzumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "4cycles prior to surgery",
                    "dose": "8 mg/kg (loading dose only)",
                    "day": "1",
                    "route": "IV infusion *"
                },
                {
                    "drug_name": "PACLitaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "4cycles prior to surgery",
                    "dose": "80 mg/m2",
                    "day": "1, 8, 15",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "pERTUZumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "4cycles prior to surgery",
                    "dose": "420 mg (subsequent doses)",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Trastuzumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "4cycles prior to surgery",
                    "dose": "6 mg/kg (subsequent doses)",
                    "day": "1",
                    "route": "IV infusion *"
                },
                {
                    "drug_name": "PACLitaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "4cycles prior to surgery",
                    "dose": "80 mg/m2",
                    "day": "1, 8, 15",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "pERTUZumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "4cycles prior to surgery",
                    "dose": "840 mg (loading dose only)",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Trastuzumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "4cycles prior to surgery",
                    "dose": "8 mg/kg (loading dose only)",
                    "day": "1",
                    "route": "IV infusion *"
                },
                {
                    "drug_name": "PACLitaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "4cycles prior to surgery",
                    "dose": "80 mg/m2",
                    "day": "1, 8, 15",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "pERTUZumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "4cycles prior to surgery",
                    "dose": "420 mg (subsequent doses)",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Trastuzumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "4cycles prior to surgery",
                    "dose": "6 mg/kg (subsequent doses)",
                    "day": "1",
                    "route": "IV infusion *"
                },
                {
                    "drug_name": "PACLitaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "4cycles prior to surgery",
                    "dose": "80 mg/m2",
                    "day": "1, 8, 15",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/neoadjuvant-adjuvant/3643-breast-neoadjuvant-paclitaxel-weekly-pertuzu"
    },
    {
        "protocol_id": "3736 v.3",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "pERTUZumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "6cycles prior to surgery",
                    "dose": "840 mg (loading dose only)",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Trastuzumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "6cycles prior to surgery",
                    "dose": "8 mg/kg (loading dose only)",
                    "day": "1",
                    "route": "IV infusion *"
                },
                {
                    "drug_name": "DOCEtaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "6cycles prior to surgery",
                    "dose": "75 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "6cycles prior to surgery",
                    "dose": "6 AUC **",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Pegfilgrastim",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "6cycles prior to surgery",
                    "dose": "6 mg",
                    "day": "2",
                    "route": "Subcut"
                }
            ],
            [
                {
                    "drug_name": "pERTUZumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "6cycles prior to surgery",
                    "dose": "420 mg (subsequent doses)",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Trastuzumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "6cycles prior to surgery",
                    "dose": "6 mg/kg (subsequent doses)",
                    "day": "1",
                    "route": "IV infusion *"
                },
                {
                    "drug_name": "DOCEtaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "6cycles prior to surgery",
                    "dose": "75 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "6cycles prior to surgery",
                    "dose": "6 AUC **",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Pegfilgrastim",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "6cycles prior to surgery",
                    "dose": "6 mg",
                    "day": "2",
                    "route": "Subcut"
                }
            ],
            [
                {
                    "drug_name": "pERTUZumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "6cycles prior to surgery",
                    "dose": "840 mg (loading dose only)",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Trastuzumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "6cycles prior to surgery",
                    "dose": "8 mg/kg (loading dose only)",
                    "day": "1",
                    "route": "IV infusion *"
                },
                {
                    "drug_name": "DOCEtaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "6cycles prior to surgery",
                    "dose": "75 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "6cycles prior to surgery",
                    "dose": "6 AUC **",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Pegfilgrastim",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "6cycles prior to surgery",
                    "dose": "6 mg",
                    "day": "2",
                    "route": "Subcut"
                }
            ],
            [
                {
                    "drug_name": "pERTUZumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "6cycles prior to surgery",
                    "dose": "420 mg (subsequent doses)",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Trastuzumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "6cycles prior to surgery",
                    "dose": "6 mg/kg (subsequent doses)",
                    "day": "1",
                    "route": "IV infusion *"
                },
                {
                    "drug_name": "DOCEtaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "6cycles prior to surgery",
                    "dose": "75 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "6cycles prior to surgery",
                    "dose": "6 AUC **",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Pegfilgrastim",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "6cycles prior to surgery",
                    "dose": "6 mg",
                    "day": "2",
                    "route": "Subcut"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/neoadjuvant-adjuvant/3736-breast-neoadjuvant-tchp-docetaxel-carboplat"
    },
    {
        "protocol_id": "1875 v.5",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Trastuzumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "17 cycles (in the neoadjuvant/adjuvant setting) or continuous until no longer clinically appropriate (metastatic setting)",
                    "dose": "600 mg",
                    "day": "1",
                    "route": "Subcut"
                }
            ],
            [
                {
                    "drug_name": "Trastuzumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "17 cycles (in the neoadjuvant/adjuvant setting) or continuous until no longer clinically appropriate (metastatic setting)",
                    "dose": "600 mg",
                    "day": "1",
                    "route": "Subcut"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/neoadjuvant-adjuvant/3307-1875-redirect"
    },
    {
        "protocol_id": "4102 v.2",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "DOXOrubicin",
                    "is_adjuvant": true,
                    "is_neoadjuvant": true,
                    "frequency": "14 days",
                    "cycles": "4",
                    "dose": "60 mg/m2",
                    "day": "1",
                    "route": "IV"
                },
                {
                    "drug_name": "CYCLOPHOSPHamide",
                    "is_adjuvant": true,
                    "is_neoadjuvant": true,
                    "frequency": "14 days",
                    "cycles": "4",
                    "dose": "600 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Pegfilgrastim",
                    "is_adjuvant": true,
                    "is_neoadjuvant": true,
                    "frequency": "14 days",
                    "cycles": "4",
                    "dose": "6 mg",
                    "day": "2",
                    "route": "Subcut"
                }
            ],
            [
                {
                    "drug_name": "DOXOrubicin",
                    "is_adjuvant": true,
                    "is_neoadjuvant": true,
                    "frequency": "14 days",
                    "cycles": "4",
                    "dose": "60 mg/m2",
                    "day": "1",
                    "route": "IV"
                },
                {
                    "drug_name": "CYCLOPHOSPHamide",
                    "is_adjuvant": true,
                    "is_neoadjuvant": true,
                    "frequency": "14 days",
                    "cycles": "4",
                    "dose": "600 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Pegfilgrastim",
                    "is_adjuvant": true,
                    "is_neoadjuvant": true,
                    "frequency": "14 days",
                    "cycles": "4",
                    "dose": "6 mg",
                    "day": "2",
                    "route": "Subcut"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/neoadjuvant-adjuvant/4102-breast-neoadjuvant-adjuvant-ac-doxorubicin-a"
    },
    {
        "protocol_id": "4104 v.3",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "DOXOrubicin",
                    "is_adjuvant": true,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "4",
                    "dose": "60 mg/m2",
                    "day": "1",
                    "route": "IV"
                },
                {
                    "drug_name": "CYCLOPHOSPHamide",
                    "is_adjuvant": true,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "4",
                    "dose": "600 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "DOXOrubicin",
                    "is_adjuvant": true,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "4",
                    "dose": "60 mg/m2",
                    "day": "1",
                    "route": "IV"
                },
                {
                    "drug_name": "CYCLOPHOSPHamide",
                    "is_adjuvant": true,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "4",
                    "dose": "600 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/neoadjuvant-adjuvant/4104-breast-neoadjuvant-adjuvant-ac-doxorubicin-a"
    },
    {
        "protocol_id": "4113 v.1",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "cyclophosphamide",
                    "is_adjuvant": true,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "4",
                    "dose": "",
                    "day": 1,
                    "route": "IV"
                },
                {
                    "drug_name": "doxorubicin",
                    "is_adjuvant": true,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "4",
                    "dose": "",
                    "day": 1,
                    "route": "IV"
                }
            ],
            [
                {
                    "drug_name": "paclitaxel",
                    "is_adjuvant": true,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "4",
                    "dose": "",
                    "day": 1,
                    "route": "IV"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/neoadjuvant-adjuvant/4113-breast-neoadjuvant-adjuvant-ac-followed-by-pa"
    },
    {
        "protocol_id": "4152 v.1",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "pembrolizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "4",
                    "dose": "",
                    "day": 1,
                    "route": "IV"
                },
                {
                    "drug_name": "paclitaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "4",
                    "dose": "",
                    "day": 1,
                    "route": "IV"
                },
                {
                    "drug_name": "carboplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "4",
                    "dose": "",
                    "day": 1,
                    "route": "IV"
                }
            ],
            [
                {
                    "drug_name": "pembrolizumab",
                    "is_adjuvant": true,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "4",
                    "dose": "",
                    "day": 1,
                    "route": "IV"
                },
                {
                    "drug_name": "cyclophosphamide",
                    "is_adjuvant": true,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "4",
                    "dose": "",
                    "day": 1,
                    "route": "IV"
                },
                {
                    "drug_name": "doxorubicin",
                    "is_adjuvant": true,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "4",
                    "dose": "",
                    "day": 1,
                    "route": "IV"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/neoadjuvant-adjuvant/4152-breast-neoadjuvant-adjuvant-carboplatin-pacl"
    },
    {
        "protocol_id": "4134 v.2",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "DOCEtaxel",
                    "is_adjuvant": true,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "4",
                    "dose": "100 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Pegfilgrastim",
                    "is_adjuvant": true,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "4",
                    "dose": "6 mg",
                    "day": "2",
                    "route": "Subcut"
                }
            ],
            [
                {
                    "drug_name": "DOCEtaxel",
                    "is_adjuvant": true,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "4",
                    "dose": "100 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Pegfilgrastim",
                    "is_adjuvant": true,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "4",
                    "dose": "6 mg",
                    "day": "2",
                    "route": "Subcut"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/neoadjuvant-adjuvant/4134-breast-neoadjuvant-adjuvant-docetaxel"
    },
    {
        "protocol_id": "4103 v.3",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "PACLitaxel",
                    "is_adjuvant": true,
                    "is_neoadjuvant": true,
                    "frequency": "7 days",
                    "cycles": "12",
                    "dose": "80 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "PACLitaxel",
                    "is_adjuvant": true,
                    "is_neoadjuvant": true,
                    "frequency": "7 days",
                    "cycles": "12",
                    "dose": "80 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/neoadjuvant-adjuvant/4103-breast-neoadjuvant-adjuvant-paclitaxel-weekly"
    },
    {
        "protocol_id": "4114 v.2",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "DOXOrubicin",
                    "is_adjuvant": true,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "6(up to 8 cycles for neoadjuvant treatment)",
                    "dose": "50 mg/m2",
                    "day": "1",
                    "route": "IV"
                },
                {
                    "drug_name": "DOCEtaxel",
                    "is_adjuvant": true,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "6(up to 8 cycles for neoadjuvant treatment)",
                    "dose": "75 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "CYCLOPHOSPHamide",
                    "is_adjuvant": true,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "6(up to 8 cycles for neoadjuvant treatment)",
                    "dose": "500 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Pegfilgrastim",
                    "is_adjuvant": true,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "6(up to 8 cycles for neoadjuvant treatment)",
                    "dose": "6 mg",
                    "day": "2",
                    "route": "Subcut"
                }
            ],
            [
                {
                    "drug_name": "DOXOrubicin",
                    "is_adjuvant": true,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "6(up to 8 cycles for neoadjuvant treatment)",
                    "dose": "50 mg/m2",
                    "day": "1",
                    "route": "IV"
                },
                {
                    "drug_name": "DOCEtaxel",
                    "is_adjuvant": true,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "6(up to 8 cycles for neoadjuvant treatment)",
                    "dose": "75 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "CYCLOPHOSPHamide",
                    "is_adjuvant": true,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "6(up to 8 cycles for neoadjuvant treatment)",
                    "dose": "500 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Pegfilgrastim",
                    "is_adjuvant": true,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "6(up to 8 cycles for neoadjuvant treatment)",
                    "dose": "6 mg",
                    "day": "2",
                    "route": "Subcut"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/neoadjuvant-adjuvant/4114-breast-neoadjuvant-adjuvant-tac-docetaxel-do"
    },
    {
        "protocol_id": "4115 v.2",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Trastuzumab",
                    "is_adjuvant": true,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "17(combined total adjuvant and neoadjuvant treatment)",
                    "dose": "8 mg/kg (loading dose only)",
                    "day": "1",
                    "route": "IV infusion *"
                }
            ],
            [
                {
                    "drug_name": "Trastuzumab",
                    "is_adjuvant": true,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "17(combined total adjuvant and neoadjuvant treatment)",
                    "dose": "6 mg/kg (subsequent doses)",
                    "day": "1",
                    "route": "IV infusion *"
                }
            ],
            [
                {
                    "drug_name": "Trastuzumab",
                    "is_adjuvant": true,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "17(combined total adjuvant and neoadjuvant treatment)",
                    "dose": "8 mg/kg (loading dose only)",
                    "day": "1",
                    "route": "IV infusion *"
                }
            ],
            [
                {
                    "drug_name": "Trastuzumab",
                    "is_adjuvant": true,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "17(combined total adjuvant and neoadjuvant treatment)",
                    "dose": "6 mg/kg (subsequent doses)",
                    "day": "1",
                    "route": "IV infusion *"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/neoadjuvant-adjuvant/4115-breast-neoadjuvant-adjuvant-trastuzumab-three"
    },
    {
        "protocol_id": "3656 v.4",
        "protocol_status": "Superseded",
        "drug_sequence": [
            [
                {
                    "drug_name": "Neratinib",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "240 mg ONCE a day *",
                    "day": null,
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Neratinib",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "240 mg ONCE a day *",
                    "day": null,
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/neoadjuvant-adjuvant/3656-breast-adjuvant-neratinib-superseded"
    },
    {
        "protocol_id": "22 v.2",
        "protocol_status": "Discontinued",
        "drug_sequence": [],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/neoadjuvant-adjuvant/22-breast-adjuvant-cmf-iv-cyclophosphamide-metho"
    },
    {
        "protocol_id": "135 v.6",
        "protocol_status": "Discontinued",
        "drug_sequence": [],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/neoadjuvant-adjuvant/135-breast-adjuvant-d-docetaxel-part-2-of-fec-d"
    },
    {
        "protocol_id": "26 v.4",
        "protocol_status": "Discontinued",
        "drug_sequence": [],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/neoadjuvant-adjuvant/26-breast-adjuvant-fac-fluorouracil-doxorubicin-c"
    },
    {
        "protocol_id": "136 v.7",
        "protocol_status": "Discontinued",
        "drug_sequence": [],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/neoadjuvant-adjuvant/136-breast-adjuvant-fec-fluorouracil-epirubicin-c"
    },
    {
        "protocol_id": "27 v.7",
        "protocol_status": "Discontinued",
        "drug_sequence": [],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/neoadjuvant-adjuvant/27-breast-adjuvant-fec-100-fluorouracil-epirubic"
    },
    {
        "protocol_id": "28 v.4",
        "protocol_status": "Discontinued",
        "drug_sequence": [],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/neoadjuvant-adjuvant/28-breast-adjuvant-fec-d-fluorouracil-epirubicin"
    },
    {
        "protocol_id": "152 v.2",
        "protocol_status": "Discontinued",
        "drug_sequence": [],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/neoadjuvant-adjuvant/152-breast-adjuvant-paclitaxel-and-trastuzumab-thr"
    },
    {
        "protocol_id": "131 v.3",
        "protocol_status": "Discontinued",
        "drug_sequence": [],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/neoadjuvant-adjuvant/131-breast-adjuvant-paclitaxel-three-weekly-discon"
    },
    {
        "protocol_id": "126 v.4",
        "protocol_status": "Discontinued",
        "drug_sequence": [],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/neoadjuvant-adjuvant/126-breast-adjuvant-trastuzumab-weekly-discontinue"
    },
    {
        "protocol_id": "1624 v.5",
        "protocol_status": "Discontinued",
        "drug_sequence": [],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/neoadjuvant-adjuvant/1624-breast-neoadjuvant-d-docetaxel-part-2-of-f"
    },
    {
        "protocol_id": "1623 v.5",
        "protocol_status": "Discontinued",
        "drug_sequence": [],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/neoadjuvant-adjuvant/1623-breast-neoadjuvant-fec-fluorouracil-epirubic"
    },
    {
        "protocol_id": "1622 v.4",
        "protocol_status": "Discontinued",
        "drug_sequence": [],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/neoadjuvant-adjuvant/1622-breast-neoadjuvant-fec-d-overv-discont"
    },
    {
        "protocol_id": "3737 v.4",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Olaparib (tablets)",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "300 mg TWICE a day",
                    "day": null,
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Olaparib (tablets)",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "300 mg TWICE a day",
                    "day": null,
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/metastatic/3627-redirect-id-3737"
    },
    {
        "protocol_id": "3625 v.2",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Abemaciclib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "150 mg TWICE a day",
                    "day": null,
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Abemaciclib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "150 mg TWICE a day",
                    "day": null,
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/metastatic/3625-breast-metastatic-abemaciclib"
    },
    {
        "protocol_id": "18 v.7",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "DOXOrubicin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity. Reassess after 3 cycles.",
                    "dose": "60 mg/m2",
                    "day": "1",
                    "route": "IV"
                },
                {
                    "drug_name": "CYCLOPHOSPHamide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity. Reassess after 3 cycles.",
                    "dose": "600 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "DOXOrubicin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity. Reassess after 3 cycles.",
                    "dose": "60 mg/m2",
                    "day": "1",
                    "route": "IV"
                },
                {
                    "drug_name": "CYCLOPHOSPHamide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity. Reassess after 3 cycles.",
                    "dose": "600 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/metastatic/18-breast-metastatic-ac-doxorubicin-and-cyclophos"
    },
    {
        "protocol_id": "1302 v.4",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Anastrozole",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "1 mg ONCE a day",
                    "day": null,
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Anastrozole",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "1 mg ONCE a day",
                    "day": null,
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/metastatic/1302-breast-metastatic-anastrozole"
    },
    {
        "protocol_id": "37 v.8",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Capecitabine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "1,000 mg/m2 TWICE a day *#",
                    "day": "1 to 14",
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Capecitabine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "1,000 mg/m2 TWICE a day *#",
                    "day": "1 to 14",
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/metastatic/37-breast-metastatic-capecitabine"
    },
    {
        "protocol_id": "36 v.7",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Capecitabine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "1,000 mg/m2 TWICE a day *",
                    "day": "1 to 14",
                    "route": "PO"
                },
                {
                    "drug_name": "laPAtinib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "1,250 mg ONCE a day",
                    "day": "1 to 21",
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Capecitabine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "1,000 mg/m2 TWICE a day *",
                    "day": "1 to 14",
                    "route": "PO"
                },
                {
                    "drug_name": "laPAtinib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "1,250 mg ONCE a day",
                    "day": "1 to 21",
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/metastatic/36-breast-metastatic-capecitabine-and-lapatinib"
    },
    {
        "protocol_id": "1814 v.7",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Trastuzumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "8 mg/kg (loading dose only)",
                    "day": "1",
                    "route": "IV infusion *"
                },
                {
                    "drug_name": "Capecitabine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "1,000 mg/m2 TWICE a day **",
                    "day": "1 to 14",
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Trastuzumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "6 mg/kg (subsequent doses)",
                    "day": "1",
                    "route": "IV infusion *"
                },
                {
                    "drug_name": "Capecitabine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "1,000 mg/m2 TWICE a day **",
                    "day": "1 to 14",
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Trastuzumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "8 mg/kg (loading dose only)",
                    "day": "1",
                    "route": "IV infusion *"
                },
                {
                    "drug_name": "Capecitabine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "1,000 mg/m2 TWICE a day **",
                    "day": "1 to 14",
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Trastuzumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "6 mg/kg (subsequent doses)",
                    "day": "1",
                    "route": "IV infusion *"
                },
                {
                    "drug_name": "Capecitabine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "1,000 mg/m2 TWICE a day **",
                    "day": "1 to 14",
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/metastatic/1814-breast-metastatic-capecitabine-and-trastuzuma"
    },
    {
        "protocol_id": "3505 v.2",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "6 AUC * #",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "6 AUC * #",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/metastatic/3505-breast-metastatic-carboplatin"
    },
    {
        "protocol_id": "1324 v.7",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Gemcitabine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "1,000 mg/m2",
                    "day": "1 and 8",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "5 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Gemcitabine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "1,000 mg/m2",
                    "day": "1 and 8",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "5 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/metastatic/1324-breast-metastatic-carboplatin-and-gemcitabine"
    },
    {
        "protocol_id": "4298 v.1",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Pembrolizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression, unacceptable toxicity or up to 24 months for pembrolizumab (as per clinical trial)",
                    "dose": "200 mg",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Gemcitabine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression, unacceptable toxicity or up to 24 months for pembrolizumab (as per clinical trial)",
                    "dose": "1,000 mg/m2",
                    "day": "1 and 8",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression, unacceptable toxicity or up to 24 months for pembrolizumab (as per clinical trial)",
                    "dose": "2 AUC *",
                    "day": "1 and 8",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Pembrolizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression, unacceptable toxicity or up to 24 months for pembrolizumab (as per clinical trial)",
                    "dose": "200 mg",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Gemcitabine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression, unacceptable toxicity or up to 24 months for pembrolizumab (as per clinical trial)",
                    "dose": "1,000 mg/m2",
                    "day": "1 and 8",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression, unacceptable toxicity or up to 24 months for pembrolizumab (as per clinical trial)",
                    "dose": "2 AUC *",
                    "day": "1 and 8",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/metastatic/4298-breast-metastatic-carboplatin-gemcitabine-an"
    },
    {
        "protocol_id": "51 v.8",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity; usually 6 to 8 cycles",
                    "dose": "600 mg/m2",
                    "day": "1 and 8",
                    "route": "IV"
                },
                {
                    "drug_name": "Methotrexate",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity; usually 6 to 8 cycles",
                    "dose": "40 mg/m2",
                    "day": "1 and 8",
                    "route": "IV bolus"
                },
                {
                    "drug_name": "CYCLOPHOSPHamide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity; usually 6 to 8 cycles",
                    "dose": "100 mg/m2 ONCE a day *",
                    "day": "1 to 14 *",
                    "route": "PO *"
                }
            ],
            [
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity; usually 6 to 8 cycles",
                    "dose": "600 mg/m2",
                    "day": "1 and 8",
                    "route": "IV"
                },
                {
                    "drug_name": "Methotrexate",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity; usually 6 to 8 cycles",
                    "dose": "40 mg/m2",
                    "day": "1 and 8",
                    "route": "IV bolus"
                },
                {
                    "drug_name": "CYCLOPHOSPHamide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity; usually 6 to 8 cycles",
                    "dose": "100 mg/m2 ONCE a day *",
                    "day": "1 to 14 *",
                    "route": "PO *"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/metastatic/51-breast-metastatic-cmf-classical-cyclophosphami"
    },
    {
        "protocol_id": "50 v.7",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Methotrexate",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "7 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity; reassess every 8 weeks",
                    "dose": "2.5 mg TWICE a day on day 1 and 2 each week*",
                    "day": "1 and 2",
                    "route": "PO"
                },
                {
                    "drug_name": "CYCLOPHOSPHamide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "7 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity; reassess every 8 weeks",
                    "dose": "50 mg ONCE a day *",
                    "day": "1 to 7",
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Methotrexate",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "7 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity; reassess every 8 weeks",
                    "dose": "2.5 mg TWICE a day on day 1 and 2 each week*",
                    "day": "1 and 2",
                    "route": "PO"
                },
                {
                    "drug_name": "CYCLOPHOSPHamide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "7 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity; reassess every 8 weeks",
                    "dose": "50 mg ONCE a day *",
                    "day": "1 to 7",
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/metastatic/50-breast-metastatic-cyclophosphamide-and-methotre"
    },
    {
        "protocol_id": "1300 v.6",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Denosumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until unacceptable toxicity (there is no information regarding how long denosumab treatment should be continued)",
                    "dose": "120 mg",
                    "day": "1",
                    "route": "Subcut"
                }
            ],
            [
                {
                    "drug_name": "Denosumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until unacceptable toxicity (there is no information regarding how long denosumab treatment should be continued)",
                    "dose": "120 mg",
                    "day": "1",
                    "route": "Subcut"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/metastatic/1300-breast-metastatic-denosumab"
    },
    {
        "protocol_id": "40 v.9",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "DOCEtaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (in the clinical trial docetaxel and trastuzumab were given for 6 cycles, after which trastuzumab monotherapy should be continued)",
                    "dose": "75 mg/m2 *",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Trastuzumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (in the clinical trial docetaxel and trastuzumab were given for 6 cycles, after which trastuzumab monotherapy should be continued)",
                    "dose": "8 mg/kg (loading dose only)",
                    "day": "1",
                    "route": "IV infusion **"
                }
            ],
            [
                {
                    "drug_name": "DOCEtaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (in the clinical trial docetaxel and trastuzumab were given for 6 cycles, after which trastuzumab monotherapy should be continued)",
                    "dose": "75 mg/m2 *",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Trastuzumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (in the clinical trial docetaxel and trastuzumab were given for 6 cycles, after which trastuzumab monotherapy should be continued)",
                    "dose": "6 mg/kg (subsequent doses)",
                    "day": "1",
                    "route": "IV infusion **"
                }
            ],
            [
                {
                    "drug_name": "Trastuzumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (in the clinical trial docetaxel and trastuzumab were given for 6 cycles, after which trastuzumab monotherapy should be continued)",
                    "dose": "6 mg/kg (subsequent doses)",
                    "day": "1",
                    "route": "IV infusion **"
                }
            ],
            [
                {
                    "drug_name": "DOCEtaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (in the clinical trial docetaxel and trastuzumab were given for 6 cycles, after which trastuzumab monotherapy should be continued)",
                    "dose": "75 mg/m2 *",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Trastuzumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (in the clinical trial docetaxel and trastuzumab were given for 6 cycles, after which trastuzumab monotherapy should be continued)",
                    "dose": "8 mg/kg (loading dose only)",
                    "day": "1",
                    "route": "IV infusion **"
                }
            ],
            [
                {
                    "drug_name": "DOCEtaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (in the clinical trial docetaxel and trastuzumab were given for 6 cycles, after which trastuzumab monotherapy should be continued)",
                    "dose": "75 mg/m2 *",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Trastuzumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (in the clinical trial docetaxel and trastuzumab were given for 6 cycles, after which trastuzumab monotherapy should be continued)",
                    "dose": "6 mg/kg (subsequent doses)",
                    "day": "1",
                    "route": "IV infusion **"
                }
            ],
            [
                {
                    "drug_name": "Trastuzumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (in the clinical trial docetaxel and trastuzumab were given for 6 cycles, after which trastuzumab monotherapy should be continued)",
                    "dose": "6 mg/kg (subsequent doses)",
                    "day": "1",
                    "route": "IV infusion **"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/metastatic/40-breast-metastatic-docetaxel-and-trastuzumab-thr"
    },
    {
        "protocol_id": "34 v.7",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "DOCEtaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "75 mg/m2 *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "DOCEtaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "75 mg/m2 *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/metastatic/34-breast-metastatic-docetaxel-three-weekly"
    },
    {
        "protocol_id": "1596 v.8",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "pERTUZumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (In the clinical trial it was recommended that patients receive at least 6 cycles of docetaxel. If docetaxel is stopped for toxicity, dual anti-HER-2 antibodies should be continued until disease progression or unacceptable toxicity)",
                    "dose": "840 mg (loading dose only)",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Trastuzumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (In the clinical trial it was recommended that patients receive at least 6 cycles of docetaxel. If docetaxel is stopped for toxicity, dual anti-HER-2 antibodies should be continued until disease progression or unacceptable toxicity)",
                    "dose": "8 mg/kg (loading dose only)",
                    "day": "1",
                    "route": "IV infusion *"
                },
                {
                    "drug_name": "DOCEtaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (In the clinical trial it was recommended that patients receive at least 6 cycles of docetaxel. If docetaxel is stopped for toxicity, dual anti-HER-2 antibodies should be continued until disease progression or unacceptable toxicity)",
                    "dose": "75 mg/m2 **",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "pERTUZumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (In the clinical trial it was recommended that patients receive at least 6 cycles of docetaxel. If docetaxel is stopped for toxicity, dual anti-HER-2 antibodies should be continued until disease progression or unacceptable toxicity)",
                    "dose": "420 mg (subsequent doses)",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Trastuzumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (In the clinical trial it was recommended that patients receive at least 6 cycles of docetaxel. If docetaxel is stopped for toxicity, dual anti-HER-2 antibodies should be continued until disease progression or unacceptable toxicity)",
                    "dose": "6 mg/kg (subsequent doses)",
                    "day": "1",
                    "route": "IV infusion *"
                },
                {
                    "drug_name": "DOCEtaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (In the clinical trial it was recommended that patients receive at least 6 cycles of docetaxel. If docetaxel is stopped for toxicity, dual anti-HER-2 antibodies should be continued until disease progression or unacceptable toxicity)",
                    "dose": "75 mg/m2 **",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "pERTUZumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (In the clinical trial it was recommended that patients receive at least 6 cycles of docetaxel. If docetaxel is stopped for toxicity, dual anti-HER-2 antibodies should be continued until disease progression or unacceptable toxicity)",
                    "dose": "840 mg (loading dose only)",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Trastuzumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (In the clinical trial it was recommended that patients receive at least 6 cycles of docetaxel. If docetaxel is stopped for toxicity, dual anti-HER-2 antibodies should be continued until disease progression or unacceptable toxicity)",
                    "dose": "8 mg/kg (loading dose only)",
                    "day": "1",
                    "route": "IV infusion *"
                },
                {
                    "drug_name": "DOCEtaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (In the clinical trial it was recommended that patients receive at least 6 cycles of docetaxel. If docetaxel is stopped for toxicity, dual anti-HER-2 antibodies should be continued until disease progression or unacceptable toxicity)",
                    "dose": "75 mg/m2 **",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "pERTUZumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (In the clinical trial it was recommended that patients receive at least 6 cycles of docetaxel. If docetaxel is stopped for toxicity, dual anti-HER-2 antibodies should be continued until disease progression or unacceptable toxicity)",
                    "dose": "420 mg (subsequent doses)",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Trastuzumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (In the clinical trial it was recommended that patients receive at least 6 cycles of docetaxel. If docetaxel is stopped for toxicity, dual anti-HER-2 antibodies should be continued until disease progression or unacceptable toxicity)",
                    "dose": "6 mg/kg (subsequent doses)",
                    "day": "1",
                    "route": "IV infusion *"
                },
                {
                    "drug_name": "DOCEtaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (In the clinical trial it was recommended that patients receive at least 6 cycles of docetaxel. If docetaxel is stopped for toxicity, dual anti-HER-2 antibodies should be continued until disease progression or unacceptable toxicity)",
                    "dose": "75 mg/m2 **",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/metastatic/1596-breast-metastatic-docetaxel-pertuzumab-and-t"
    },
    {
        "protocol_id": "35 v.6",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "DOXOrubicin liposomal",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until maximum improvement or unacceptable toxicity",
                    "dose": "40 mg/m2 *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "DOXOrubicin liposomal",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until maximum improvement or unacceptable toxicity",
                    "dose": "40 mg/m2 *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/metastatic/35-breast-metastatic-doxorubicin-pegylated-liposom"
    },
    {
        "protocol_id": "48 v.7",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "DOXOrubicin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (up to 6 cycles)",
                    "dose": "60 mg/m2 *",
                    "day": "1",
                    "route": "IV"
                }
            ],
            [
                {
                    "drug_name": "DOXOrubicin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (up to 6 cycles)",
                    "dose": "60 mg/m2 *",
                    "day": "1",
                    "route": "IV"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/metastatic/48-breast-metastatic-doxorubicin-three-weekly"
    },
    {
        "protocol_id": "1331 v.5",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "DOXOrubicin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "7 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "20 mg/m2 *",
                    "day": "1",
                    "route": "IV"
                }
            ],
            [
                {
                    "drug_name": "DOXOrubicin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "7 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "20 mg/m2 *",
                    "day": "1",
                    "route": "IV"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/metastatic/1331-breast-metastatic-doxorubicin-weekly"
    },
    {
        "protocol_id": "1306 v.6",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Epirubicin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until maximum improvement (usually 6 cycles), disease progression, or unacceptable toxicity. Reassess after 2 to 3 cycles.",
                    "dose": "75 mg/m2",
                    "day": "1",
                    "route": "IV"
                },
                {
                    "drug_name": "CYCLOPHOSPHamide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until maximum improvement (usually 6 cycles), disease progression, or unacceptable toxicity. Reassess after 2 to 3 cycles.",
                    "dose": "600 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Epirubicin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until maximum improvement (usually 6 cycles), disease progression, or unacceptable toxicity. Reassess after 2 to 3 cycles.",
                    "dose": "75 mg/m2",
                    "day": "1",
                    "route": "IV"
                },
                {
                    "drug_name": "CYCLOPHOSPHamide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until maximum improvement (usually 6 cycles), disease progression, or unacceptable toxicity. Reassess after 2 to 3 cycles.",
                    "dose": "600 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/metastatic/1306-breast-metastatic-ec-epirubicin-and-cyclopho"
    },
    {
        "protocol_id": "1597 v.5",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Eribulin mesilate",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "1.4 mg/m2",
                    "day": "1 and 8",
                    "route": "IV"
                }
            ],
            [
                {
                    "drug_name": "Eribulin mesilate",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "1.4 mg/m2",
                    "day": "1 and 8",
                    "route": "IV"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/metastatic/1597-breast-metastatic-eribulin"
    },
    {
        "protocol_id": "1590 v.6",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Everolimus",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "10 mg ONCE a day",
                    "day": null,
                    "route": "PO"
                },
                {
                    "drug_name": "Exemestane",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "25 mg ONCE a day",
                    "day": null,
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Everolimus",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "10 mg ONCE a day",
                    "day": null,
                    "route": "PO"
                },
                {
                    "drug_name": "Exemestane",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "25 mg ONCE a day",
                    "day": null,
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/metastatic/1590-breast-metastatic-everolimus-and-exemestane"
    },
    {
        "protocol_id": "1304 v.4",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Exemestane",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "25 mg ONCE a day",
                    "day": null,
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Exemestane",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "25 mg ONCE a day",
                    "day": null,
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/metastatic/1304-breast-metastatic-exemestane"
    },
    {
        "protocol_id": "1305 v.6",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Fulvestrant",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "500 mg",
                    "day": "1 and 15",
                    "route": "IM"
                }
            ],
            [
                {
                    "drug_name": "Fulvestrant",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "500 mg",
                    "day": "1",
                    "route": "IM"
                }
            ],
            [
                {
                    "drug_name": "Fulvestrant",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "500 mg",
                    "day": "1 and 15",
                    "route": "IM"
                }
            ],
            [
                {
                    "drug_name": "Fulvestrant",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "500 mg",
                    "day": "1",
                    "route": "IM"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/metastatic/1305-breast-metastatic-fulvestrant"
    },
    {
        "protocol_id": "1315 v.4",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Goserelin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "3.6 mg",
                    "day": "1",
                    "route": "Subcut"
                }
            ],
            [
                {
                    "drug_name": "Goserelin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "3.6 mg",
                    "day": "1",
                    "route": "Subcut"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/metastatic/1315-breast-metastatic-goserelin"
    },
    {
        "protocol_id": "1303 v.4",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Letrozole",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "2.5 mg ONCE a day",
                    "day": null,
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Letrozole",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "2.5 mg ONCE a day",
                    "day": null,
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/metastatic/1303-breast-metastatic-letrozole"
    },
    {
        "protocol_id": "4307 v.1",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Pembrolizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "84 days(This reflects the original trial protocol of nab-paclitaxel given days 1, 8 and 15 every 28 days and pembrolizumab every21 days)",
                    "cycles": "Continuous until disease progression or unacceptable toxicity or up to 24 months for pembrolizumab (as per clinical trial)",
                    "dose": "200 mg",
                    "day": "1, 22, 43, 64",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "nab-PACLitaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "84 days(This reflects the original trial protocol of nab-paclitaxel given days 1, 8 and 15 every 28 days and pembrolizumab every21 days)",
                    "cycles": "Continuous until disease progression or unacceptable toxicity or up to 24 months for pembrolizumab (as per clinical trial)",
                    "dose": "100 mg/m2",
                    "day": "1, 8, 15, 29, 36, 43, 57, 64, 71",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Pembrolizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "84 days(This reflects the original trial protocol of nab-paclitaxel given days 1, 8 and 15 every 28 days and pembrolizumab every21 days)",
                    "cycles": "Continuous until disease progression or unacceptable toxicity or up to 24 months for pembrolizumab (as per clinical trial)",
                    "dose": "200 mg",
                    "day": "1, 22, 43, 64",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "nab-PACLitaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "84 days(This reflects the original trial protocol of nab-paclitaxel given days 1, 8 and 15 every 28 days and pembrolizumab every21 days)",
                    "cycles": "Continuous until disease progression or unacceptable toxicity or up to 24 months for pembrolizumab (as per clinical trial)",
                    "dose": "100 mg/m2",
                    "day": "1, 8, 15, 29, 36, 43, 57, 64, 71",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/metastatic/4307-breast-metastatic-nab-paclitaxel-and-pembroli"
    },
    {
        "protocol_id": "1299 v.6",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "nab-PACLitaxel **",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "100 mg/m2 *",
                    "day": "1, 8, 15",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "nab-PACLitaxel **",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "100 mg/m2 *",
                    "day": "1, 8, 15",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/metastatic/1299-breast-metastatic-nab-paclitaxel-weekly"
    },
    {
        "protocol_id": "4309 v.1",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Pembrolizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "84 days(This reflects the original trial protocol of paclitaxel given days 1, 8 and 15 every 28 days and pembrolizumab every21 days)",
                    "cycles": "Continuous until disease progression or unacceptable toxicity or up to 24 months for pembrolizumab (as per clinical trial)",
                    "dose": "200 mg",
                    "day": "1, 22, 43, 64",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "PACLitaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "84 days(This reflects the original trial protocol of paclitaxel given days 1, 8 and 15 every 28 days and pembrolizumab every21 days)",
                    "cycles": "Continuous until disease progression or unacceptable toxicity or up to 24 months for pembrolizumab (as per clinical trial)",
                    "dose": "90 mg/m2",
                    "day": "1, 8, 15, 29, 36, 43, 57, 64, 71",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Pembrolizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "84 days(This reflects the original trial protocol of paclitaxel given days 1, 8 and 15 every 28 days and pembrolizumab every21 days)",
                    "cycles": "Continuous until disease progression or unacceptable toxicity or up to 24 months for pembrolizumab (as per clinical trial)",
                    "dose": "200 mg",
                    "day": "1, 22, 43, 64",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "PACLitaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "84 days(This reflects the original trial protocol of paclitaxel given days 1, 8 and 15 every 28 days and pembrolizumab every21 days)",
                    "cycles": "Continuous until disease progression or unacceptable toxicity or up to 24 months for pembrolizumab (as per clinical trial)",
                    "dose": "90 mg/m2",
                    "day": "1, 8, 15, 29, 36, 43, 57, 64, 71",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/metastatic/4309-breast-metastatic-paclitaxel-and-pembrolizuma"
    },
    {
        "protocol_id": "42 v.10",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "PACLitaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "7 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "80 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "PACLitaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "7 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "80 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/metastatic/42-breast-metastatic-paclitaxel-weekly"
    },
    {
        "protocol_id": "167 v.12",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "PACLitaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "80 mg/m2",
                    "day": "1, 8, 15",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Trastuzumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "8 mg/kg (loading dose only)",
                    "day": "1",
                    "route": "IV infusion *"
                }
            ],
            [
                {
                    "drug_name": "PACLitaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "80 mg/m2",
                    "day": "1, 8, 15",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Trastuzumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "6 mg/kg (subsequent doses)",
                    "day": "1",
                    "route": "IV infusion *"
                }
            ],
            [
                {
                    "drug_name": "PACLitaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "80 mg/m2",
                    "day": "1, 8, 15",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Trastuzumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "8 mg/kg (loading dose only)",
                    "day": "1",
                    "route": "IV infusion *"
                }
            ],
            [
                {
                    "drug_name": "PACLitaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "80 mg/m2",
                    "day": "1, 8, 15",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Trastuzumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "6 mg/kg (subsequent doses)",
                    "day": "1",
                    "route": "IV infusion *"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/metastatic/167-breast-metastatic-paclitaxel-weekly-and-trastu"
    },
    {
        "protocol_id": "1812 v.10",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "pERTUZumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (in the clinical trial paclitaxel was continued for 6 months, after which dual anti-HER-2 antibodies were continued until disease progression or unacceptable toxicity)",
                    "dose": "840 mg (loading dose only)",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Trastuzumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (in the clinical trial paclitaxel was continued for 6 months, after which dual anti-HER-2 antibodies were continued until disease progression or unacceptable toxicity)",
                    "dose": "8 mg/kg (loading dose only)",
                    "day": "1",
                    "route": "IV infusion *"
                },
                {
                    "drug_name": "PACLitaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (in the clinical trial paclitaxel was continued for 6 months, after which dual anti-HER-2 antibodies were continued until disease progression or unacceptable toxicity)",
                    "dose": "80 mg/m2",
                    "day": "1, 8, 15",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "pERTUZumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (in the clinical trial paclitaxel was continued for 6 months, after which dual anti-HER-2 antibodies were continued until disease progression or unacceptable toxicity)",
                    "dose": "420 mg (subsequent doses)",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Trastuzumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (in the clinical trial paclitaxel was continued for 6 months, after which dual anti-HER-2 antibodies were continued until disease progression or unacceptable toxicity)",
                    "dose": "6 mg/kg (subsequent doses)",
                    "day": "1",
                    "route": "IV infusion *"
                },
                {
                    "drug_name": "PACLitaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (in the clinical trial paclitaxel was continued for 6 months, after which dual anti-HER-2 antibodies were continued until disease progression or unacceptable toxicity)",
                    "dose": "80 mg/m2",
                    "day": "1, 8, 15",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "pERTUZumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (in the clinical trial paclitaxel was continued for 6 months, after which dual anti-HER-2 antibodies were continued until disease progression or unacceptable toxicity)",
                    "dose": "840 mg (loading dose only)",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Trastuzumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (in the clinical trial paclitaxel was continued for 6 months, after which dual anti-HER-2 antibodies were continued until disease progression or unacceptable toxicity)",
                    "dose": "8 mg/kg (loading dose only)",
                    "day": "1",
                    "route": "IV infusion *"
                },
                {
                    "drug_name": "PACLitaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (in the clinical trial paclitaxel was continued for 6 months, after which dual anti-HER-2 antibodies were continued until disease progression or unacceptable toxicity)",
                    "dose": "80 mg/m2",
                    "day": "1, 8, 15",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "pERTUZumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (in the clinical trial paclitaxel was continued for 6 months, after which dual anti-HER-2 antibodies were continued until disease progression or unacceptable toxicity)",
                    "dose": "420 mg (subsequent doses)",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Trastuzumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (in the clinical trial paclitaxel was continued for 6 months, after which dual anti-HER-2 antibodies were continued until disease progression or unacceptable toxicity)",
                    "dose": "6 mg/kg (subsequent doses)",
                    "day": "1",
                    "route": "IV infusion *"
                },
                {
                    "drug_name": "PACLitaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (in the clinical trial paclitaxel was continued for 6 months, after which dual anti-HER-2 antibodies were continued until disease progression or unacceptable toxicity)",
                    "dose": "80 mg/m2",
                    "day": "1, 8, 15",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/metastatic/1812-breast-metastatic-paclitaxel-weekly-pertuzum"
    },
    {
        "protocol_id": "3369 v.5",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Palbociclib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "125 mg ONCE a day",
                    "day": "1 to 21 *",
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Palbociclib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "125 mg ONCE a day",
                    "day": "1 to 21 *",
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/metastatic/3369-breast-metastatic-palbociclib"
    },
    {
        "protocol_id": "3379 v.4",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Ribociclib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "600 mg ONCE a day *",
                    "day": "1 to 21 **",
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Ribociclib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "600 mg ONCE a day *",
                    "day": "1 to 21 **",
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/metastatic/3379-breast-metastatic-ribociclib"
    },
    {
        "protocol_id": "4079 v.2",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Sacituzumab govitecan",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "10 mg/kg",
                    "day": "1 and 8",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Sacituzumab govitecan",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "10 mg/kg",
                    "day": "1 and 8",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/metastatic/4079-breast-metastatic-sacituzumab-govitecan"
    },
    {
        "protocol_id": "1327 v.4",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Tamoxifen",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "20 mg ONCE a day",
                    "day": null,
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Tamoxifen",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "20 mg ONCE a day",
                    "day": null,
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/metastatic/1327-breast-metastatic-tamoxifen"
    },
    {
        "protocol_id": "4150 v.3",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Trastuzumab deruxtecan",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "5.4 mg/kg",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Trastuzumab deruxtecan",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "5.4 mg/kg",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/metastatic/4150-breast-metastatic-trastuzumab-deruxtecan"
    },
    {
        "protocol_id": "1598 v.6",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Trastuzumab emtansine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "3.6 mg/kg",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Trastuzumab emtansine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "3.6 mg/kg",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/metastatic/1598-breast-metastatic-trastuzumab-emtansine"
    },
    {
        "protocol_id": "1875 v.5",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Trastuzumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "17 cycles (in the neoadjuvant/adjuvant setting) or continuous until no longer clinically appropriate (metastatic setting)",
                    "dose": "600 mg",
                    "day": "1",
                    "route": "Subcut"
                }
            ],
            [
                {
                    "drug_name": "Trastuzumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "17 cycles (in the neoadjuvant/adjuvant setting) or continuous until no longer clinically appropriate (metastatic setting)",
                    "dose": "600 mg",
                    "day": "1",
                    "route": "Subcut"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/metastatic/3308-1875-redirect"
    },
    {
        "protocol_id": "33 v.9",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Trastuzumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "8 mg/kg (loading dose only)",
                    "day": "1",
                    "route": "IV infusion *"
                }
            ],
            [
                {
                    "drug_name": "Trastuzumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "6 mg/kg (subsequent doses)",
                    "day": "1",
                    "route": "IV infusion *"
                }
            ],
            [
                {
                    "drug_name": "Trastuzumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "8 mg/kg (loading dose only)",
                    "day": "1",
                    "route": "IV infusion *"
                }
            ],
            [
                {
                    "drug_name": "Trastuzumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "6 mg/kg (subsequent doses)",
                    "day": "1",
                    "route": "IV infusion *"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/metastatic/33-breast-metastatic-trastuzumab-three-weekly"
    },
    {
        "protocol_id": "1626 v.6",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "vinORELBine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity. Trastuzumab monotherapy should be continued if vinorelbine is stopped for toxicity.",
                    "dose": "30 mg/m2 *",
                    "day": "1 and 8",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Trastuzumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity. Trastuzumab monotherapy should be continued if vinorelbine is stopped for toxicity.",
                    "dose": "8 mg/kg (loading dose only)",
                    "day": "1",
                    "route": "IV infusion **"
                }
            ],
            [
                {
                    "drug_name": "vinORELBine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity. Trastuzumab monotherapy should be continued if vinorelbine is stopped for toxicity.",
                    "dose": "30 mg/m2 *",
                    "day": "1 and 8",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Trastuzumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity. Trastuzumab monotherapy should be continued if vinorelbine is stopped for toxicity.",
                    "dose": "6 mg/kg (subsequent doses)",
                    "day": "1",
                    "route": "IV infusion **"
                }
            ],
            [
                {
                    "drug_name": "vinORELBine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity. Trastuzumab monotherapy should be continued if vinorelbine is stopped for toxicity.",
                    "dose": "30 mg/m2 *",
                    "day": "1 and 8",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Trastuzumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity. Trastuzumab monotherapy should be continued if vinorelbine is stopped for toxicity.",
                    "dose": "8 mg/kg (loading dose only)",
                    "day": "1",
                    "route": "IV infusion **"
                }
            ],
            [
                {
                    "drug_name": "vinORELBine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity. Trastuzumab monotherapy should be continued if vinorelbine is stopped for toxicity.",
                    "dose": "30 mg/m2 *",
                    "day": "1 and 8",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Trastuzumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity. Trastuzumab monotherapy should be continued if vinorelbine is stopped for toxicity.",
                    "dose": "6 mg/kg (subsequent doses)",
                    "day": "1",
                    "route": "IV infusion **"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/metastatic/1626-breast-metastatic-trastuzumab-three-weekly-an"
    },
    {
        "protocol_id": "1627 v.5",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Trastuzumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity. Trastuzumab monotherapy should be continued if vinorelbine is stopped for toxicity.",
                    "dose": "8 mg/kg (loading dose only)",
                    "day": "1",
                    "route": "IV infusion *"
                },
                {
                    "drug_name": "vinORELBine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity. Trastuzumab monotherapy should be continued if vinorelbine is stopped for toxicity.",
                    "dose": "60 mg/m2 ONCE a week **",
                    "day": "1 and 8",
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Trastuzumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity. Trastuzumab monotherapy should be continued if vinorelbine is stopped for toxicity.",
                    "dose": "6 mg/kg (subsequent doses)",
                    "day": "1",
                    "route": "IV infusion *"
                },
                {
                    "drug_name": "vinORELBine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity. Trastuzumab monotherapy should be continued if vinorelbine is stopped for toxicity.",
                    "dose": "60 mg/m2 ONCE a week **",
                    "day": "1 and 8",
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Trastuzumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity. Trastuzumab monotherapy should be continued if vinorelbine is stopped for toxicity.",
                    "dose": "8 mg/kg (loading dose only)",
                    "day": "1",
                    "route": "IV infusion *"
                },
                {
                    "drug_name": "vinORELBine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity. Trastuzumab monotherapy should be continued if vinorelbine is stopped for toxicity.",
                    "dose": "60 mg/m2 ONCE a week **",
                    "day": "1 and 8",
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Trastuzumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity. Trastuzumab monotherapy should be continued if vinorelbine is stopped for toxicity.",
                    "dose": "6 mg/kg (subsequent doses)",
                    "day": "1",
                    "route": "IV infusion *"
                },
                {
                    "drug_name": "vinORELBine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity. Trastuzumab monotherapy should be continued if vinorelbine is stopped for toxicity.",
                    "dose": "60 mg/m2 ONCE a week **",
                    "day": "1 and 8",
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/metastatic/1627-breast-metastatic-trastuzumab-three-weekly-an"
    },
    {
        "protocol_id": "38 v.7",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "vinORELBine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "30 mg/m2",
                    "day": "1 and 8",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "vinORELBine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "30 mg/m2",
                    "day": "1 and 8",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/metastatic/38-breast-metastatic-vinorelbine-iv"
    },
    {
        "protocol_id": "1545 v.6",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "vinORELBine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "7 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "60 mg/m2 *",
                    "day": "1",
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "vinORELBine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "7 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "60 mg/m2 *",
                    "day": "1",
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/metastatic/1545-breast-metastatic-vinorelbine-oral"
    },
    {
        "protocol_id": "149 v.7",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Zoledronic acid",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous (standard cycle length is 21 to 28 days; extended cycles of 12 weeks may be considered after 9 doses)",
                    "dose": "4 mg",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Zoledronic acid",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous (standard cycle length is 21 to 28 days; extended cycles of 12 weeks may be considered after 9 doses)",
                    "dose": "4 mg",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/metastatic/149-breast-metastatic-zoledronic-acid"
    },
    {
        "protocol_id": "45 v.6",
        "protocol_status": "Superseded",
        "drug_sequence": [
            [
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity; usually up to 6 cycles",
                    "dose": "600 mg/m2",
                    "day": "1",
                    "route": "IV"
                },
                {
                    "drug_name": "Methotrexate",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity; usually up to 6 cycles",
                    "dose": "40 mg/m2",
                    "day": "1",
                    "route": "IV bolus"
                },
                {
                    "drug_name": "CYCLOPHOSPHamide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity; usually up to 6 cycles",
                    "dose": "600 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity; usually up to 6 cycles",
                    "dose": "600 mg/m2",
                    "day": "1",
                    "route": "IV"
                },
                {
                    "drug_name": "Methotrexate",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity; usually up to 6 cycles",
                    "dose": "40 mg/m2",
                    "day": "1",
                    "route": "IV bolus"
                },
                {
                    "drug_name": "CYCLOPHOSPHamide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity; usually up to 6 cycles",
                    "dose": "600 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/metastatic/45-breast-metastatic-cmf-iv-cyclophosphamide-meth"
    },
    {
        "protocol_id": "1629 v.8",
        "protocol_status": "Superseded",
        "drug_sequence": [
            [
                {
                    "drug_name": "PACLitaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "80 mg/m2",
                    "day": "1, 8, 15",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Gemcitabine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "800 mg/m2",
                    "day": "1, 8, 15",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "PACLitaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "80 mg/m2",
                    "day": "1, 8, 15",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Gemcitabine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "800 mg/m2",
                    "day": "1, 8, 15",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/metastatic/1629-breast-metastatic-gemcitabine-and-paclitaxel"
    },
    {
        "protocol_id": "90 v.8",
        "protocol_status": "Superseded",
        "drug_sequence": [
            [
                {
                    "drug_name": "nab-PACLitaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity; usually 6 cycles",
                    "dose": "260 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "nab-PACLitaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity; usually 6 cycles",
                    "dose": "260 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/metastatic/90-breast-metastatic-nab-paclitaxel-three-weekly-s"
    },
    {
        "protocol_id": "307 v.5",
        "protocol_status": "Superseded",
        "drug_sequence": [
            [
                {
                    "drug_name": "Pamidronate",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous (cycle length may be 21 to 28 days)",
                    "dose": "90 mg",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Pamidronate",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous (cycle length may be 21 to 28 days)",
                    "dose": "90 mg",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/metastatic/307-breast-metastatic-pamidronate-superseded"
    },
    {
        "protocol_id": "52 v.5",
        "protocol_status": "Discontinued",
        "drug_sequence": [],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/metastatic/52-breast-metastatic-capecitabine-and-docetaxel-di"
    },
    {
        "protocol_id": "39 v.4",
        "protocol_status": "Discontinued",
        "drug_sequence": [],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/metastatic/39-breast-metastatic-carboplatin-paclitaxel-trastu"
    },
    {
        "protocol_id": "49 v.3",
        "protocol_status": "Discontinued",
        "drug_sequence": [],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/metastatic/49-breast-metastatic-docetaxel-weekly-discontinued"
    },
    {
        "protocol_id": "47 v.4",
        "protocol_status": "Discontinued",
        "drug_sequence": [],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/metastatic/47-breast-metastatic-fac-fluorouracil-doxorubicin"
    },
    {
        "protocol_id": "46 v.7",
        "protocol_status": "Discontinued",
        "drug_sequence": [],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/metastatic/46-breast-metastatic-fec-fluorouracil-epirubicin"
    },
    {
        "protocol_id": "1599 v.4",
        "protocol_status": "Discontinued",
        "drug_sequence": [],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/metastatic/1599-breast-metastatic-gemcitabine-and-nab-paclita"
    },
    {
        "protocol_id": "43 v.4",
        "protocol_status": "Discontinued",
        "drug_sequence": [],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/metastatic/43-breast-metastatic-gemcitabine-and-paclitaxel-di"
    },
    {
        "protocol_id": "44 v.5",
        "protocol_status": "Discontinued",
        "drug_sequence": [],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/metastatic/44-breast-metastatic-mmm-mitomycin-mitozantrone-m"
    },
    {
        "protocol_id": "4091 v.2",
        "protocol_status": "Discontinued",
        "drug_sequence": [],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/metastatic/4091-breast-metastatic-nab-paclitaxel-and-atezoliz"
    },
    {
        "protocol_id": "1625 v.6",
        "protocol_status": "Discontinued",
        "drug_sequence": [],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/metastatic/1625-breast-metastatic-nab-paclitaxel-weekly-and-t"
    },
    {
        "protocol_id": "129 v.3",
        "protocol_status": "Discontinued",
        "drug_sequence": [],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/metastatic/129-breast-metastatic-paclitaxel-and-trastuzumab-t"
    },
    {
        "protocol_id": "130 v.3",
        "protocol_status": "Discontinued",
        "drug_sequence": [],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/metastatic/130-breast-metastatic-paclitaxel-three-weekly-and"
    },
    {
        "protocol_id": "41 v.3",
        "protocol_status": "Discontinued",
        "drug_sequence": [],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/metastatic/41-breast-metastatic-paclitaxel-three-weekly-disco"
    },
    {
        "protocol_id": "54 v.4",
        "protocol_status": "Discontinued",
        "drug_sequence": [],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/metastatic/54-breast-metastatic-trastuzumab-weekly-discontinu"
    },
    {
        "protocol_id": "4168 v.2",
        "protocol_status": "Under review",
        "drug_sequence": [
            [
                {
                    "drug_name": "Abemaciclib",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "150 mg TWICE a day",
                    "day": null,
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Abemaciclib",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "150 mg TWICE a day",
                    "day": null,
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/neoadjuvant-adjuvant/4168-breast-adjuvant-abemaciclib"
    },
    {
        "protocol_id": "1607 v.5",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "cyclophosphamide",
                    "is_adjuvant": true,
                    "is_neoadjuvant": true,
                    "frequency": "14 days",
                    "cycles": "4",
                    "dose": "",
                    "day": 1,
                    "route": "IV"
                },
                {
                    "drug_name": "doxorubicin",
                    "is_adjuvant": true,
                    "is_neoadjuvant": true,
                    "frequency": "14 days",
                    "cycles": "4",
                    "dose": "",
                    "day": 1,
                    "route": "IV"
                }
            ],
            [
                {
                    "drug_name": "paclitaxel",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "4",
                    "dose": "",
                    "day": 1,
                    "route": "IV"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/neoadjuvant-adjuvant/1607-breast-adjuvant-ac-doxorubicin-and-cyclophos"
    },
    {
        "protocol_id": "4010 v.1",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "cyclophosphamide",
                    "is_adjuvant": true,
                    "is_neoadjuvant": true,
                    "frequency": "14 days",
                    "cycles": "4",
                    "dose": "",
                    "day": 1,
                    "route": "IV"
                },
                {
                    "drug_name": "doxorubicin",
                    "is_adjuvant": true,
                    "is_neoadjuvant": true,
                    "frequency": "14 days",
                    "cycles": "4",
                    "dose": "",
                    "day": 1,
                    "route": "IV"
                }
            ],
            [
                {
                    "drug_name": "paclitaxel",
                    "is_adjuvant": true,
                    "is_neoadjuvant": true,
                    "frequency": "14 days",
                    "cycles": "4",
                    "dose": "",
                    "day": 1,
                    "route": "IV"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/neoadjuvant-adjuvant/4010-breast-adjuvant-ac-doxorubicin-and-cyclophos"
    },
    {
        "protocol_id": "1606 v.4",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "cyclophosphamide",
                    "is_adjuvant": true,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "4",
                    "dose": "",
                    "day": 1,
                    "route": "IV"
                },
                {
                    "drug_name": "doxorubicin",
                    "is_adjuvant": true,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "4",
                    "dose": "",
                    "day": 1,
                    "route": "IV"
                }
            ],
            [
                {
                    "drug_name": "trastuzumab",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4",
                    "dose": "",
                    "day": 1,
                    "route": "IV"
                },
                {
                    "drug_name": "paclitaxel",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4",
                    "dose": "",
                    "day": 1,
                    "route": "IV"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/neoadjuvant-adjuvant/1606-breast-adjuvant-ac-doxorubicin-and-cyclophos"
    },
    {
        "protocol_id": "122 v.6",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "cyclophosphamide",
                    "is_adjuvant": true,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "4",
                    "dose": "",
                    "day": 1,
                    "route": "IV"
                },
                {
                    "drug_name": "doxorubicin",
                    "is_adjuvant": true,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "4",
                    "dose": "",
                    "day": 1,
                    "route": "IV"
                }
            ],
            [
                {
                    "drug_name": "trastuzumab",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4",
                    "dose": "",
                    "day": 1,
                    "route": "IV"
                },
                {
                    "drug_name": "docetaxel",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4",
                    "dose": "",
                    "day": 1,
                    "route": "IV"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/neoadjuvant-adjuvant/122-breast-adjuvant-ac-th-doxorubicin-cyclophosph"
    },
    {
        "protocol_id": "19 v.7",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Anastrozole",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "1 mg ONCE a day",
                    "day": null,
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Anastrozole",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "1 mg ONCE a day",
                    "day": null,
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/neoadjuvant-adjuvant/19-breast-adjuvant-anastrozole"
    },
    {
        "protocol_id": "3503 v.4",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Capecitabine",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6(or 8 cycles if toxicity allows)",
                    "dose": "1,250 mg/m2 TWICE a day *",
                    "day": "1 to 14",
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Capecitabine",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6(or 8 cycles if toxicity allows)",
                    "dose": "1,250 mg/m2 TWICE a day *",
                    "day": "1 to 14",
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/neoadjuvant-adjuvant/3503-breast-adjuvant-capecitabine-post-neoadjuvan"
    },
    {
        "protocol_id": "4167 v.2",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Capecitabine",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "650 mg/m2 TWICE a day *",
                    "day": null,
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Capecitabine",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "650 mg/m2 TWICE a day *",
                    "day": null,
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/neoadjuvant-adjuvant/4167-breast-adjuvant-capecitabine-metronomic"
    },
    {
        "protocol_id": "21 v.8",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "6",
                    "dose": "600 mg/m2",
                    "day": "1 and 8",
                    "route": "IV"
                },
                {
                    "drug_name": "Methotrexate",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "6",
                    "dose": "40 mg/m2",
                    "day": "1 and 8",
                    "route": "IV bolus"
                },
                {
                    "drug_name": "CYCLOPHOSPHamide",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "6",
                    "dose": "100 mg/m2 ONCE a day *",
                    "day": "1 to 14 *",
                    "route": "PO *"
                }
            ],
            [
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "6",
                    "dose": "600 mg/m2",
                    "day": "1 and 8",
                    "route": "IV"
                },
                {
                    "drug_name": "Methotrexate",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "6",
                    "dose": "40 mg/m2",
                    "day": "1 and 8",
                    "route": "IV bolus"
                },
                {
                    "drug_name": "CYCLOPHOSPHamide",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "6",
                    "dose": "100 mg/m2 ONCE a day *",
                    "day": "1 to 14 *",
                    "route": "PO *"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/neoadjuvant-adjuvant/21-breast-adjuvant-cmf-classical-cyclophosphamide"
    },
    {
        "protocol_id": "4133 v.2",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Epirubicin",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4",
                    "dose": "90 mg/m2",
                    "day": "1",
                    "route": "IV"
                },
                {
                    "drug_name": "CYCLOPHOSPHamide",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4",
                    "dose": "600 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Epirubicin",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4",
                    "dose": "90 mg/m2",
                    "day": "1",
                    "route": "IV"
                },
                {
                    "drug_name": "CYCLOPHOSPHamide",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4",
                    "dose": "600 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/neoadjuvant-adjuvant/4133-breast-adjuvant-ec-epirubicin-and-cyclophosp"
    },
    {
        "protocol_id": "25 v.6",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Exemestane",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "25 mg ONCE a day",
                    "day": null,
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Exemestane",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "25 mg ONCE a day",
                    "day": null,
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/neoadjuvant-adjuvant/25-breast-adjuvant-exemestane"
    },
    {
        "protocol_id": "1785 v.4",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Goserelin",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous for up to 5 years for goserelin, and 5 to 10 years for exemestane",
                    "dose": "3.6 mg",
                    "day": "1",
                    "route": "Subcut"
                },
                {
                    "drug_name": "Exemestane *",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous for up to 5 years for goserelin, and 5 to 10 years for exemestane",
                    "dose": "25 mg ONCE a day",
                    "day": "1 to 28",
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Goserelin",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous for up to 5 years for goserelin, and 5 to 10 years for exemestane",
                    "dose": "3.6 mg",
                    "day": "1",
                    "route": "Subcut"
                },
                {
                    "drug_name": "Exemestane *",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous for up to 5 years for goserelin, and 5 to 10 years for exemestane",
                    "dose": "25 mg ONCE a day",
                    "day": "1 to 28",
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/neoadjuvant-adjuvant/1785-breast-adjuvant-exemestane-and-goserelin"
    },
    {
        "protocol_id": "29 v.7",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Goserelin",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous for up to 5 years",
                    "dose": "3.6 mg",
                    "day": "1",
                    "route": "Subcut"
                }
            ],
            [
                {
                    "drug_name": "Goserelin",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous for up to 5 years",
                    "dose": "3.6 mg",
                    "day": "1",
                    "route": "Subcut"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/neoadjuvant-adjuvant/29-breast-adjuvant-goserelin"
    },
    {
        "protocol_id": "30 v.7",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Letrozole",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "2.5 mg ONCE a day",
                    "day": null,
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Letrozole",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "2.5 mg ONCE a day",
                    "day": null,
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/neoadjuvant-adjuvant/30-breast-adjuvant-letrozole"
    },
    {
        "protocol_id": "160 v.11",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "PACLitaxel",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "4",
                    "dose": "175 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Pegfilgrastim",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "4",
                    "dose": "6 mg",
                    "day": "2",
                    "route": "Subcut"
                }
            ],
            [
                {
                    "drug_name": "PACLitaxel",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "4",
                    "dose": "175 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Pegfilgrastim",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "4",
                    "dose": "6 mg",
                    "day": "2",
                    "route": "Subcut"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/neoadjuvant-adjuvant/160-breast-adjuvant-paclitaxel-dose-dense"
    },
    {
        "protocol_id": "153 v.12",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "PACLitaxel",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "17(4 cycles of paclitaxel and trastuzumab followed by 13 cycles of trastuzumab; total trastuzumab treatment equal to 17 cycles)",
                    "dose": "80 mg/m2",
                    "day": "1, 8, 15",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Trastuzumab",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "17(4 cycles of paclitaxel and trastuzumab followed by 13 cycles of trastuzumab; total trastuzumab treatment equal to 17 cycles)",
                    "dose": "8 mg/kg (loading dose only)",
                    "day": "1",
                    "route": "IV infusion *"
                }
            ],
            [
                {
                    "drug_name": "PACLitaxel",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "17(4 cycles of paclitaxel and trastuzumab followed by 13 cycles of trastuzumab; total trastuzumab treatment equal to 17 cycles)",
                    "dose": "80 mg/m2",
                    "day": "1, 8, 15",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Trastuzumab",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "17(4 cycles of paclitaxel and trastuzumab followed by 13 cycles of trastuzumab; total trastuzumab treatment equal to 17 cycles)",
                    "dose": "6 mg/kg (subsequent doses)",
                    "day": "1",
                    "route": "IV infusion *"
                }
            ],
            [
                {
                    "drug_name": "Trastuzumab",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "17(4 cycles of paclitaxel and trastuzumab followed by 13 cycles of trastuzumab; total trastuzumab treatment equal to 17 cycles)",
                    "dose": "6 mg/kg (subsequent doses)",
                    "day": "1",
                    "route": "IV infusion *"
                }
            ],
            [
                {
                    "drug_name": "PACLitaxel",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "17(4 cycles of paclitaxel and trastuzumab followed by 13 cycles of trastuzumab; total trastuzumab treatment equal to 17 cycles)",
                    "dose": "80 mg/m2",
                    "day": "1, 8, 15",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Trastuzumab",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "17(4 cycles of paclitaxel and trastuzumab followed by 13 cycles of trastuzumab; total trastuzumab treatment equal to 17 cycles)",
                    "dose": "8 mg/kg (loading dose only)",
                    "day": "1",
                    "route": "IV infusion *"
                }
            ],
            [
                {
                    "drug_name": "PACLitaxel",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "17(4 cycles of paclitaxel and trastuzumab followed by 13 cycles of trastuzumab; total trastuzumab treatment equal to 17 cycles)",
                    "dose": "80 mg/m2",
                    "day": "1, 8, 15",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Trastuzumab",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "17(4 cycles of paclitaxel and trastuzumab followed by 13 cycles of trastuzumab; total trastuzumab treatment equal to 17 cycles)",
                    "dose": "6 mg/kg (subsequent doses)",
                    "day": "1",
                    "route": "IV infusion *"
                }
            ],
            [
                {
                    "drug_name": "Trastuzumab",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "17(4 cycles of paclitaxel and trastuzumab followed by 13 cycles of trastuzumab; total trastuzumab treatment equal to 17 cycles)",
                    "dose": "6 mg/kg (subsequent doses)",
                    "day": "1",
                    "route": "IV infusion *"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/neoadjuvant-adjuvant/153-breast-adjuvant-paclitaxel-weekly-and-trastuzu"
    },
    {
        "protocol_id": "32 v.7",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Tamoxifen",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "20 mg ONCE a day",
                    "day": null,
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Tamoxifen",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "20 mg ONCE a day",
                    "day": null,
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/neoadjuvant-adjuvant/32-breast-adjuvant-tamoxifen"
    },
    {
        "protocol_id": "24 v.9",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "DOCEtaxel",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4(up to 6 cycles- see note)",
                    "dose": "75 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "CYCLOPHOSPHamide",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4(up to 6 cycles- see note)",
                    "dose": "600 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Pegfilgrastim",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4(up to 6 cycles- see note)",
                    "dose": "6 mg",
                    "day": "2",
                    "route": "Subcut"
                }
            ],
            [
                {
                    "drug_name": "DOCEtaxel",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4(up to 6 cycles- see note)",
                    "dose": "75 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "CYCLOPHOSPHamide",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4(up to 6 cycles- see note)",
                    "dose": "600 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Pegfilgrastim",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4(up to 6 cycles- see note)",
                    "dose": "6 mg",
                    "day": "2",
                    "route": "Subcut"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/neoadjuvant-adjuvant/24-breast-adjuvant-tc-docetaxel-and-cyclophospham"
    },
    {
        "protocol_id": "53 v.11",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "DOCEtaxel",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "17(6 cycles of TCH followed by 11 cycles of trastuzumab; total trastuzumab treatment equal to 17 cycles)",
                    "dose": "75 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "17(6 cycles of TCH followed by 11 cycles of trastuzumab; total trastuzumab treatment equal to 17 cycles)",
                    "dose": "6 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Trastuzumab",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "17(6 cycles of TCH followed by 11 cycles of trastuzumab; total trastuzumab treatment equal to 17 cycles)",
                    "dose": "8 mg/kg (loading dose only)",
                    "day": "1",
                    "route": "IV infusion **"
                },
                {
                    "drug_name": "Pegfilgrastim",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "17(6 cycles of TCH followed by 11 cycles of trastuzumab; total trastuzumab treatment equal to 17 cycles)",
                    "dose": "6 mg",
                    "day": "2",
                    "route": "Subcut"
                }
            ],
            [
                {
                    "drug_name": "DOCEtaxel",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "17(6 cycles of TCH followed by 11 cycles of trastuzumab; total trastuzumab treatment equal to 17 cycles)",
                    "dose": "75 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "17(6 cycles of TCH followed by 11 cycles of trastuzumab; total trastuzumab treatment equal to 17 cycles)",
                    "dose": "6 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Trastuzumab",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "17(6 cycles of TCH followed by 11 cycles of trastuzumab; total trastuzumab treatment equal to 17 cycles)",
                    "dose": "6 mg/kg (subsequent doses)",
                    "day": "1",
                    "route": "IV infusion **"
                },
                {
                    "drug_name": "Pegfilgrastim",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "17(6 cycles of TCH followed by 11 cycles of trastuzumab; total trastuzumab treatment equal to 17 cycles)",
                    "dose": "6 mg",
                    "day": "2",
                    "route": "Subcut"
                }
            ],
            [
                {
                    "drug_name": "Trastuzumab",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "17(6 cycles of TCH followed by 11 cycles of trastuzumab; total trastuzumab treatment equal to 17 cycles)",
                    "dose": "6 mg/kg (subsequent doses)",
                    "day": "1",
                    "route": "IV infusion **"
                }
            ],
            [
                {
                    "drug_name": "DOCEtaxel",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "17(6 cycles of TCH followed by 11 cycles of trastuzumab; total trastuzumab treatment equal to 17 cycles)",
                    "dose": "75 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "17(6 cycles of TCH followed by 11 cycles of trastuzumab; total trastuzumab treatment equal to 17 cycles)",
                    "dose": "6 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Trastuzumab",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "17(6 cycles of TCH followed by 11 cycles of trastuzumab; total trastuzumab treatment equal to 17 cycles)",
                    "dose": "8 mg/kg (loading dose only)",
                    "day": "1",
                    "route": "IV infusion **"
                },
                {
                    "drug_name": "Pegfilgrastim",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "17(6 cycles of TCH followed by 11 cycles of trastuzumab; total trastuzumab treatment equal to 17 cycles)",
                    "dose": "6 mg",
                    "day": "2",
                    "route": "Subcut"
                }
            ],
            [
                {
                    "drug_name": "DOCEtaxel",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "17(6 cycles of TCH followed by 11 cycles of trastuzumab; total trastuzumab treatment equal to 17 cycles)",
                    "dose": "75 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "17(6 cycles of TCH followed by 11 cycles of trastuzumab; total trastuzumab treatment equal to 17 cycles)",
                    "dose": "6 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Trastuzumab",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "17(6 cycles of TCH followed by 11 cycles of trastuzumab; total trastuzumab treatment equal to 17 cycles)",
                    "dose": "6 mg/kg (subsequent doses)",
                    "day": "1",
                    "route": "IV infusion **"
                },
                {
                    "drug_name": "Pegfilgrastim",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "17(6 cycles of TCH followed by 11 cycles of trastuzumab; total trastuzumab treatment equal to 17 cycles)",
                    "dose": "6 mg",
                    "day": "2",
                    "route": "Subcut"
                }
            ],
            [
                {
                    "drug_name": "Trastuzumab",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "17(6 cycles of TCH followed by 11 cycles of trastuzumab; total trastuzumab treatment equal to 17 cycles)",
                    "dose": "6 mg/kg (subsequent doses)",
                    "day": "1",
                    "route": "IV infusion **"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/neoadjuvant-adjuvant/53-breast-adjuvant-tch-docetaxel-carboplatin-tras"
    },
    {
        "protocol_id": "138 v.9",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "DOCEtaxel",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "17(4 cycles of TH followed by 13 cycles of trastuzumab; total trastuzumab treatment equal to 17 cycles)",
                    "dose": "100 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Trastuzumab",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "17(4 cycles of TH followed by 13 cycles of trastuzumab; total trastuzumab treatment equal to 17 cycles)",
                    "dose": "8 mg/kg (loading dose only)",
                    "day": "1",
                    "route": "IV infusion *"
                }
            ],
            [
                {
                    "drug_name": "DOCEtaxel",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "17(4 cycles of TH followed by 13 cycles of trastuzumab; total trastuzumab treatment equal to 17 cycles)",
                    "dose": "100 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Trastuzumab",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "17(4 cycles of TH followed by 13 cycles of trastuzumab; total trastuzumab treatment equal to 17 cycles)",
                    "dose": "6 mg/kg (subsequent doses)",
                    "day": "1",
                    "route": "IV infusion *"
                }
            ],
            [
                {
                    "drug_name": "Trastuzumab",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "17(4 cycles of TH followed by 13 cycles of trastuzumab; total trastuzumab treatment equal to 17 cycles)",
                    "dose": "6 mg/kg (subsequent doses)",
                    "day": "1",
                    "route": "IV infusion *"
                }
            ],
            [
                {
                    "drug_name": "DOCEtaxel",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "17(4 cycles of TH followed by 13 cycles of trastuzumab; total trastuzumab treatment equal to 17 cycles)",
                    "dose": "100 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Trastuzumab",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "17(4 cycles of TH followed by 13 cycles of trastuzumab; total trastuzumab treatment equal to 17 cycles)",
                    "dose": "8 mg/kg (loading dose only)",
                    "day": "1",
                    "route": "IV infusion *"
                }
            ],
            [
                {
                    "drug_name": "DOCEtaxel",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "17(4 cycles of TH followed by 13 cycles of trastuzumab; total trastuzumab treatment equal to 17 cycles)",
                    "dose": "100 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Trastuzumab",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "17(4 cycles of TH followed by 13 cycles of trastuzumab; total trastuzumab treatment equal to 17 cycles)",
                    "dose": "6 mg/kg (subsequent doses)",
                    "day": "1",
                    "route": "IV infusion *"
                }
            ],
            [
                {
                    "drug_name": "Trastuzumab",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "17(4 cycles of TH followed by 13 cycles of trastuzumab; total trastuzumab treatment equal to 17 cycles)",
                    "dose": "6 mg/kg (subsequent doses)",
                    "day": "1",
                    "route": "IV infusion *"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/neoadjuvant-adjuvant/138-breast-adjuvant-th-docetaxel-and-trastuzumab"
    },
    {
        "protocol_id": "3813 v.2",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Trastuzumab emtansine",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "14",
                    "dose": "3.6 mg/kg",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Trastuzumab emtansine",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "14",
                    "dose": "3.6 mg/kg",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/neoadjuvant-adjuvant/3813-breast-adjuvant-trastuzumab-emtansine"
    },
    {
        "protocol_id": "1875 v.5",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Trastuzumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "17 cycles (in the neoadjuvant/adjuvant setting) or continuous until no longer clinically appropriate (metastatic setting)",
                    "dose": "600 mg",
                    "day": "1",
                    "route": "Subcut"
                }
            ],
            [
                {
                    "drug_name": "Trastuzumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "17 cycles (in the neoadjuvant/adjuvant setting) or continuous until no longer clinically appropriate (metastatic setting)",
                    "dose": "600 mg",
                    "day": "1",
                    "route": "Subcut"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/neoadjuvant-adjuvant/3306-1875-redirect"
    },
    {
        "protocol_id": "1364 v.4",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "cyclophosphamide",
                    "is_adjuvant": true,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "4",
                    "dose": "",
                    "day": 1,
                    "route": "IV"
                },
                {
                    "drug_name": "doxorubicin",
                    "is_adjuvant": true,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "4",
                    "dose": "",
                    "day": 1,
                    "route": "IV"
                }
            ],
            [
                {
                    "drug_name": "docetaxel",
                    "is_adjuvant": true,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "4",
                    "dose": "",
                    "day": 1,
                    "route": "IV"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/neoadjuvant-adjuvant/1364-breast-neoadjuvant-ac-doxorubicin-and-cyclop"
    },
    {
        "protocol_id": "1714 v.10",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "PACLitaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "4",
                    "dose": "80 mg/m2",
                    "day": "1, 8, 15",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "4",
                    "dose": "6 AUC * #",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Filgrastim",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "4",
                    "dose": "5 micrograms/kg",
                    "day": "2 to 6",
                    "route": "Subcut"
                }
            ],
            [
                {
                    "drug_name": "PACLitaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "4",
                    "dose": "80 mg/m2",
                    "day": "1, 8, 15",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "4",
                    "dose": "6 AUC * #",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Filgrastim",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "4",
                    "dose": "5 micrograms/kg",
                    "day": "2 to 6",
                    "route": "Subcut"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/neoadjuvant-adjuvant/1714-breast-neoadjuvant-carboplatin-three-weekly-a"
    },
    {
        "protocol_id": "1870 v.4",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "paclitaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "4",
                    "dose": "",
                    "day": 1,
                    "route": "IV"
                },
                {
                    "drug_name": "carboplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "4",
                    "dose": "",
                    "day": 1,
                    "route": "IV"
                }
            ],
            [
                {
                    "drug_name": "cyclophosphamide",
                    "is_adjuvant": true,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "4",
                    "dose": "",
                    "day": 1,
                    "route": "IV"
                },
                {
                    "drug_name": "doxorubicin",
                    "is_adjuvant": true,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "4",
                    "dose": "",
                    "day": 1,
                    "route": "IV"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/neoadjuvant-adjuvant/1870-breast-neoadjuvant-carboplatin-three-weekly-a"
    },
    {
        "protocol_id": "3812 v.4",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "PACLitaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "7 days",
                    "cycles": "12",
                    "dose": "80 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "7 days",
                    "cycles": "12",
                    "dose": "2 AUC * #",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "PACLitaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "7 days",
                    "cycles": "12",
                    "dose": "80 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "7 days",
                    "cycles": "12",
                    "dose": "2 AUC * #",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/neoadjuvant-adjuvant/3812-breast-neoadjuvant-carboplatin-weekly-and-pac"
    },
    {
        "protocol_id": "4009 v.1",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "paclitaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "7 days",
                    "cycles": "12",
                    "dose": "",
                    "day": 1,
                    "route": "IV"
                },
                {
                    "drug_name": "carboplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "7 days",
                    "cycles": "12",
                    "dose": "",
                    "day": 1,
                    "route": "IV"
                }
            ],
            [
                {
                    "drug_name": "cyclophosphamide",
                    "is_adjuvant": true,
                    "is_neoadjuvant": true,
                    "frequency": "7 days",
                    "cycles": "12",
                    "dose": "",
                    "day": 1,
                    "route": "IV"
                },
                {
                    "drug_name": "doxorubicin",
                    "is_adjuvant": true,
                    "is_neoadjuvant": true,
                    "frequency": "7 days",
                    "cycles": "12",
                    "dose": "",
                    "day": 1,
                    "route": "IV"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/neoadjuvant-adjuvant/4009-breast-neoadjuvant-carboplatin-weekly-and-pac"
    },
    {
        "protocol_id": "1969 v.6",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "pERTUZumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "4cycles prior to surgery",
                    "dose": "840 mg (loading dose only)",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Trastuzumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "4cycles prior to surgery",
                    "dose": "8 mg/kg (loading dose only)",
                    "day": "1",
                    "route": "IV infusion *"
                },
                {
                    "drug_name": "DOCEtaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "4cycles prior to surgery",
                    "dose": "75 mg/m2 **",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "pERTUZumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "4cycles prior to surgery",
                    "dose": "420 mg (subsequent doses)",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Trastuzumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "4cycles prior to surgery",
                    "dose": "6 mg/kg (subsequent doses)",
                    "day": "1",
                    "route": "IV infusion *"
                },
                {
                    "drug_name": "DOCEtaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "4cycles prior to surgery",
                    "dose": "75 mg/m2 **",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "pERTUZumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "4cycles prior to surgery",
                    "dose": "840 mg (loading dose only)",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Trastuzumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "4cycles prior to surgery",
                    "dose": "8 mg/kg (loading dose only)",
                    "day": "1",
                    "route": "IV infusion *"
                },
                {
                    "drug_name": "DOCEtaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "4cycles prior to surgery",
                    "dose": "75 mg/m2 **",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "pERTUZumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "4cycles prior to surgery",
                    "dose": "420 mg (subsequent doses)",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Trastuzumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "4cycles prior to surgery",
                    "dose": "6 mg/kg (subsequent doses)",
                    "day": "1",
                    "route": "IV infusion *"
                },
                {
                    "drug_name": "DOCEtaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "4cycles prior to surgery",
                    "dose": "75 mg/m2 **",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/neoadjuvant-adjuvant/1969-breast-neoadjuvant-docetaxel-pertuzumab-and"
    },
    {
        "protocol_id": "3643 v.5",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "pERTUZumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "4cycles prior to surgery",
                    "dose": "840 mg (loading dose only)",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Trastuzumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "4cycles prior to surgery",
                    "dose": "8 mg/kg (loading dose only)",
                    "day": "1",
                    "route": "IV infusion *"
                },
                {
                    "drug_name": "PACLitaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "4cycles prior to surgery",
                    "dose": "80 mg/m2",
                    "day": "1, 8, 15",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "pERTUZumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "4cycles prior to surgery",
                    "dose": "420 mg (subsequent doses)",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Trastuzumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "4cycles prior to surgery",
                    "dose": "6 mg/kg (subsequent doses)",
                    "day": "1",
                    "route": "IV infusion *"
                },
                {
                    "drug_name": "PACLitaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "4cycles prior to surgery",
                    "dose": "80 mg/m2",
                    "day": "1, 8, 15",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "pERTUZumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "4cycles prior to surgery",
                    "dose": "840 mg (loading dose only)",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Trastuzumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "4cycles prior to surgery",
                    "dose": "8 mg/kg (loading dose only)",
                    "day": "1",
                    "route": "IV infusion *"
                },
                {
                    "drug_name": "PACLitaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "4cycles prior to surgery",
                    "dose": "80 mg/m2",
                    "day": "1, 8, 15",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "pERTUZumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "4cycles prior to surgery",
                    "dose": "420 mg (subsequent doses)",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Trastuzumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "4cycles prior to surgery",
                    "dose": "6 mg/kg (subsequent doses)",
                    "day": "1",
                    "route": "IV infusion *"
                },
                {
                    "drug_name": "PACLitaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "4cycles prior to surgery",
                    "dose": "80 mg/m2",
                    "day": "1, 8, 15",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/neoadjuvant-adjuvant/3643-breast-neoadjuvant-paclitaxel-weekly-pertuzu"
    },
    {
        "protocol_id": "3736 v.3",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "pERTUZumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "6cycles prior to surgery",
                    "dose": "840 mg (loading dose only)",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Trastuzumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "6cycles prior to surgery",
                    "dose": "8 mg/kg (loading dose only)",
                    "day": "1",
                    "route": "IV infusion *"
                },
                {
                    "drug_name": "DOCEtaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "6cycles prior to surgery",
                    "dose": "75 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "6cycles prior to surgery",
                    "dose": "6 AUC **",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Pegfilgrastim",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "6cycles prior to surgery",
                    "dose": "6 mg",
                    "day": "2",
                    "route": "Subcut"
                }
            ],
            [
                {
                    "drug_name": "pERTUZumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "6cycles prior to surgery",
                    "dose": "420 mg (subsequent doses)",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Trastuzumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "6cycles prior to surgery",
                    "dose": "6 mg/kg (subsequent doses)",
                    "day": "1",
                    "route": "IV infusion *"
                },
                {
                    "drug_name": "DOCEtaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "6cycles prior to surgery",
                    "dose": "75 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "6cycles prior to surgery",
                    "dose": "6 AUC **",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Pegfilgrastim",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "6cycles prior to surgery",
                    "dose": "6 mg",
                    "day": "2",
                    "route": "Subcut"
                }
            ],
            [
                {
                    "drug_name": "pERTUZumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "6cycles prior to surgery",
                    "dose": "840 mg (loading dose only)",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Trastuzumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "6cycles prior to surgery",
                    "dose": "8 mg/kg (loading dose only)",
                    "day": "1",
                    "route": "IV infusion *"
                },
                {
                    "drug_name": "DOCEtaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "6cycles prior to surgery",
                    "dose": "75 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "6cycles prior to surgery",
                    "dose": "6 AUC **",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Pegfilgrastim",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "6cycles prior to surgery",
                    "dose": "6 mg",
                    "day": "2",
                    "route": "Subcut"
                }
            ],
            [
                {
                    "drug_name": "pERTUZumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "6cycles prior to surgery",
                    "dose": "420 mg (subsequent doses)",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Trastuzumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "6cycles prior to surgery",
                    "dose": "6 mg/kg (subsequent doses)",
                    "day": "1",
                    "route": "IV infusion *"
                },
                {
                    "drug_name": "DOCEtaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "6cycles prior to surgery",
                    "dose": "75 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "6cycles prior to surgery",
                    "dose": "6 AUC **",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Pegfilgrastim",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "6cycles prior to surgery",
                    "dose": "6 mg",
                    "day": "2",
                    "route": "Subcut"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/neoadjuvant-adjuvant/3736-breast-neoadjuvant-tchp-docetaxel-carboplat"
    },
    {
        "protocol_id": "1875 v.5",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Trastuzumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "17 cycles (in the neoadjuvant/adjuvant setting) or continuous until no longer clinically appropriate (metastatic setting)",
                    "dose": "600 mg",
                    "day": "1",
                    "route": "Subcut"
                }
            ],
            [
                {
                    "drug_name": "Trastuzumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "17 cycles (in the neoadjuvant/adjuvant setting) or continuous until no longer clinically appropriate (metastatic setting)",
                    "dose": "600 mg",
                    "day": "1",
                    "route": "Subcut"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/neoadjuvant-adjuvant/3307-1875-redirect"
    },
    {
        "protocol_id": "4102 v.2",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "DOXOrubicin",
                    "is_adjuvant": true,
                    "is_neoadjuvant": true,
                    "frequency": "14 days",
                    "cycles": "4",
                    "dose": "60 mg/m2",
                    "day": "1",
                    "route": "IV"
                },
                {
                    "drug_name": "CYCLOPHOSPHamide",
                    "is_adjuvant": true,
                    "is_neoadjuvant": true,
                    "frequency": "14 days",
                    "cycles": "4",
                    "dose": "600 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Pegfilgrastim",
                    "is_adjuvant": true,
                    "is_neoadjuvant": true,
                    "frequency": "14 days",
                    "cycles": "4",
                    "dose": "6 mg",
                    "day": "2",
                    "route": "Subcut"
                }
            ],
            [
                {
                    "drug_name": "DOXOrubicin",
                    "is_adjuvant": true,
                    "is_neoadjuvant": true,
                    "frequency": "14 days",
                    "cycles": "4",
                    "dose": "60 mg/m2",
                    "day": "1",
                    "route": "IV"
                },
                {
                    "drug_name": "CYCLOPHOSPHamide",
                    "is_adjuvant": true,
                    "is_neoadjuvant": true,
                    "frequency": "14 days",
                    "cycles": "4",
                    "dose": "600 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Pegfilgrastim",
                    "is_adjuvant": true,
                    "is_neoadjuvant": true,
                    "frequency": "14 days",
                    "cycles": "4",
                    "dose": "6 mg",
                    "day": "2",
                    "route": "Subcut"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/neoadjuvant-adjuvant/4102-breast-neoadjuvant-adjuvant-ac-doxorubicin-a"
    },
    {
        "protocol_id": "4104 v.3",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "DOXOrubicin",
                    "is_adjuvant": true,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "4",
                    "dose": "60 mg/m2",
                    "day": "1",
                    "route": "IV"
                },
                {
                    "drug_name": "CYCLOPHOSPHamide",
                    "is_adjuvant": true,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "4",
                    "dose": "600 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "DOXOrubicin",
                    "is_adjuvant": true,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "4",
                    "dose": "60 mg/m2",
                    "day": "1",
                    "route": "IV"
                },
                {
                    "drug_name": "CYCLOPHOSPHamide",
                    "is_adjuvant": true,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "4",
                    "dose": "600 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/neoadjuvant-adjuvant/4104-breast-neoadjuvant-adjuvant-ac-doxorubicin-a"
    },
    {
        "protocol_id": "4113 v.1",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "cyclophosphamide",
                    "is_adjuvant": true,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "4",
                    "dose": "",
                    "day": 1,
                    "route": "IV"
                },
                {
                    "drug_name": "doxorubicin",
                    "is_adjuvant": true,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "4",
                    "dose": "",
                    "day": 1,
                    "route": "IV"
                }
            ],
            [
                {
                    "drug_name": "paclitaxel",
                    "is_adjuvant": true,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "4",
                    "dose": "",
                    "day": 1,
                    "route": "IV"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/neoadjuvant-adjuvant/4113-breast-neoadjuvant-adjuvant-ac-followed-by-pa"
    },
    {
        "protocol_id": "4152 v.1",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "pembrolizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "4",
                    "dose": "",
                    "day": 1,
                    "route": "IV"
                },
                {
                    "drug_name": "paclitaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "4",
                    "dose": "",
                    "day": 1,
                    "route": "IV"
                },
                {
                    "drug_name": "carboplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "4",
                    "dose": "",
                    "day": 1,
                    "route": "IV"
                }
            ],
            [
                {
                    "drug_name": "pembrolizumab",
                    "is_adjuvant": true,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "4",
                    "dose": "",
                    "day": 1,
                    "route": "IV"
                },
                {
                    "drug_name": "cyclophosphamide",
                    "is_adjuvant": true,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "4",
                    "dose": "",
                    "day": 1,
                    "route": "IV"
                },
                {
                    "drug_name": "doxorubicin",
                    "is_adjuvant": true,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "4",
                    "dose": "",
                    "day": 1,
                    "route": "IV"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/neoadjuvant-adjuvant/4152-breast-neoadjuvant-adjuvant-carboplatin-pacl"
    },
    {
        "protocol_id": "4134 v.2",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "DOCEtaxel",
                    "is_adjuvant": true,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "4",
                    "dose": "100 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Pegfilgrastim",
                    "is_adjuvant": true,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "4",
                    "dose": "6 mg",
                    "day": "2",
                    "route": "Subcut"
                }
            ],
            [
                {
                    "drug_name": "DOCEtaxel",
                    "is_adjuvant": true,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "4",
                    "dose": "100 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Pegfilgrastim",
                    "is_adjuvant": true,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "4",
                    "dose": "6 mg",
                    "day": "2",
                    "route": "Subcut"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/neoadjuvant-adjuvant/4134-breast-neoadjuvant-adjuvant-docetaxel"
    },
    {
        "protocol_id": "4103 v.3",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "PACLitaxel",
                    "is_adjuvant": true,
                    "is_neoadjuvant": true,
                    "frequency": "7 days",
                    "cycles": "12",
                    "dose": "80 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "PACLitaxel",
                    "is_adjuvant": true,
                    "is_neoadjuvant": true,
                    "frequency": "7 days",
                    "cycles": "12",
                    "dose": "80 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/neoadjuvant-adjuvant/4103-breast-neoadjuvant-adjuvant-paclitaxel-weekly"
    },
    {
        "protocol_id": "4114 v.2",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "DOXOrubicin",
                    "is_adjuvant": true,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "6(up to 8 cycles for neoadjuvant treatment)",
                    "dose": "50 mg/m2",
                    "day": "1",
                    "route": "IV"
                },
                {
                    "drug_name": "DOCEtaxel",
                    "is_adjuvant": true,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "6(up to 8 cycles for neoadjuvant treatment)",
                    "dose": "75 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "CYCLOPHOSPHamide",
                    "is_adjuvant": true,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "6(up to 8 cycles for neoadjuvant treatment)",
                    "dose": "500 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Pegfilgrastim",
                    "is_adjuvant": true,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "6(up to 8 cycles for neoadjuvant treatment)",
                    "dose": "6 mg",
                    "day": "2",
                    "route": "Subcut"
                }
            ],
            [
                {
                    "drug_name": "DOXOrubicin",
                    "is_adjuvant": true,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "6(up to 8 cycles for neoadjuvant treatment)",
                    "dose": "50 mg/m2",
                    "day": "1",
                    "route": "IV"
                },
                {
                    "drug_name": "DOCEtaxel",
                    "is_adjuvant": true,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "6(up to 8 cycles for neoadjuvant treatment)",
                    "dose": "75 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "CYCLOPHOSPHamide",
                    "is_adjuvant": true,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "6(up to 8 cycles for neoadjuvant treatment)",
                    "dose": "500 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Pegfilgrastim",
                    "is_adjuvant": true,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "6(up to 8 cycles for neoadjuvant treatment)",
                    "dose": "6 mg",
                    "day": "2",
                    "route": "Subcut"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/neoadjuvant-adjuvant/4114-breast-neoadjuvant-adjuvant-tac-docetaxel-do"
    },
    {
        "protocol_id": "4115 v.2",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Trastuzumab",
                    "is_adjuvant": true,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "17(combined total adjuvant and neoadjuvant treatment)",
                    "dose": "8 mg/kg (loading dose only)",
                    "day": "1",
                    "route": "IV infusion *"
                }
            ],
            [
                {
                    "drug_name": "Trastuzumab",
                    "is_adjuvant": true,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "17(combined total adjuvant and neoadjuvant treatment)",
                    "dose": "6 mg/kg (subsequent doses)",
                    "day": "1",
                    "route": "IV infusion *"
                }
            ],
            [
                {
                    "drug_name": "Trastuzumab",
                    "is_adjuvant": true,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "17(combined total adjuvant and neoadjuvant treatment)",
                    "dose": "8 mg/kg (loading dose only)",
                    "day": "1",
                    "route": "IV infusion *"
                }
            ],
            [
                {
                    "drug_name": "Trastuzumab",
                    "is_adjuvant": true,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "17(combined total adjuvant and neoadjuvant treatment)",
                    "dose": "6 mg/kg (subsequent doses)",
                    "day": "1",
                    "route": "IV infusion *"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/neoadjuvant-adjuvant/4115-breast-neoadjuvant-adjuvant-trastuzumab-three"
    },
    {
        "protocol_id": "3656 v.4",
        "protocol_status": "Superseded",
        "drug_sequence": [
            [
                {
                    "drug_name": "Neratinib",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "240 mg ONCE a day *",
                    "day": null,
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Neratinib",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "240 mg ONCE a day *",
                    "day": null,
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/neoadjuvant-adjuvant/3656-breast-adjuvant-neratinib-superseded"
    },
    {
        "protocol_id": "22 v.2",
        "protocol_status": "Discontinued",
        "drug_sequence": [],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/neoadjuvant-adjuvant/22-breast-adjuvant-cmf-iv-cyclophosphamide-metho"
    },
    {
        "protocol_id": "135 v.6",
        "protocol_status": "Discontinued",
        "drug_sequence": [],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/neoadjuvant-adjuvant/135-breast-adjuvant-d-docetaxel-part-2-of-fec-d"
    },
    {
        "protocol_id": "26 v.4",
        "protocol_status": "Discontinued",
        "drug_sequence": [],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/neoadjuvant-adjuvant/26-breast-adjuvant-fac-fluorouracil-doxorubicin-c"
    },
    {
        "protocol_id": "136 v.7",
        "protocol_status": "Discontinued",
        "drug_sequence": [],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/neoadjuvant-adjuvant/136-breast-adjuvant-fec-fluorouracil-epirubicin-c"
    },
    {
        "protocol_id": "27 v.7",
        "protocol_status": "Discontinued",
        "drug_sequence": [],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/neoadjuvant-adjuvant/27-breast-adjuvant-fec-100-fluorouracil-epirubic"
    },
    {
        "protocol_id": "28 v.4",
        "protocol_status": "Discontinued",
        "drug_sequence": [],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/neoadjuvant-adjuvant/28-breast-adjuvant-fec-d-fluorouracil-epirubicin"
    },
    {
        "protocol_id": "152 v.2",
        "protocol_status": "Discontinued",
        "drug_sequence": [],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/neoadjuvant-adjuvant/152-breast-adjuvant-paclitaxel-and-trastuzumab-thr"
    },
    {
        "protocol_id": "131 v.3",
        "protocol_status": "Discontinued",
        "drug_sequence": [],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/neoadjuvant-adjuvant/131-breast-adjuvant-paclitaxel-three-weekly-discon"
    },
    {
        "protocol_id": "126 v.4",
        "protocol_status": "Discontinued",
        "drug_sequence": [],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/neoadjuvant-adjuvant/126-breast-adjuvant-trastuzumab-weekly-discontinue"
    },
    {
        "protocol_id": "1624 v.5",
        "protocol_status": "Discontinued",
        "drug_sequence": [],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/neoadjuvant-adjuvant/1624-breast-neoadjuvant-d-docetaxel-part-2-of-f"
    },
    {
        "protocol_id": "1623 v.5",
        "protocol_status": "Discontinued",
        "drug_sequence": [],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/neoadjuvant-adjuvant/1623-breast-neoadjuvant-fec-fluorouracil-epirubic"
    },
    {
        "protocol_id": "1622 v.4",
        "protocol_status": "Discontinued",
        "drug_sequence": [],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/neoadjuvant-adjuvant/1622-breast-neoadjuvant-fec-d-overv-discont"
    },
    {
        "protocol_id": "3737 v.4",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Olaparib (tablets)",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "300 mg TWICE a day",
                    "day": null,
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Olaparib (tablets)",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "300 mg TWICE a day",
                    "day": null,
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/metastatic/3627-redirect-id-3737"
    },
    {
        "protocol_id": "3625 v.2",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Abemaciclib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "150 mg TWICE a day",
                    "day": null,
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Abemaciclib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "150 mg TWICE a day",
                    "day": null,
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/metastatic/3625-breast-metastatic-abemaciclib"
    },
    {
        "protocol_id": "18 v.7",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "DOXOrubicin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity. Reassess after 3 cycles.",
                    "dose": "60 mg/m2",
                    "day": "1",
                    "route": "IV"
                },
                {
                    "drug_name": "CYCLOPHOSPHamide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity. Reassess after 3 cycles.",
                    "dose": "600 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "DOXOrubicin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity. Reassess after 3 cycles.",
                    "dose": "60 mg/m2",
                    "day": "1",
                    "route": "IV"
                },
                {
                    "drug_name": "CYCLOPHOSPHamide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity. Reassess after 3 cycles.",
                    "dose": "600 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/metastatic/18-breast-metastatic-ac-doxorubicin-and-cyclophos"
    },
    {
        "protocol_id": "1302 v.4",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Anastrozole",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "1 mg ONCE a day",
                    "day": null,
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Anastrozole",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "1 mg ONCE a day",
                    "day": null,
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/metastatic/1302-breast-metastatic-anastrozole"
    },
    {
        "protocol_id": "37 v.8",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Capecitabine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "1,000 mg/m2 TWICE a day *#",
                    "day": "1 to 14",
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Capecitabine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "1,000 mg/m2 TWICE a day *#",
                    "day": "1 to 14",
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/metastatic/37-breast-metastatic-capecitabine"
    },
    {
        "protocol_id": "36 v.7",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Capecitabine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "1,000 mg/m2 TWICE a day *",
                    "day": "1 to 14",
                    "route": "PO"
                },
                {
                    "drug_name": "laPAtinib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "1,250 mg ONCE a day",
                    "day": "1 to 21",
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Capecitabine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "1,000 mg/m2 TWICE a day *",
                    "day": "1 to 14",
                    "route": "PO"
                },
                {
                    "drug_name": "laPAtinib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "1,250 mg ONCE a day",
                    "day": "1 to 21",
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/metastatic/36-breast-metastatic-capecitabine-and-lapatinib"
    },
    {
        "protocol_id": "1814 v.7",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Trastuzumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "8 mg/kg (loading dose only)",
                    "day": "1",
                    "route": "IV infusion *"
                },
                {
                    "drug_name": "Capecitabine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "1,000 mg/m2 TWICE a day **",
                    "day": "1 to 14",
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Trastuzumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "6 mg/kg (subsequent doses)",
                    "day": "1",
                    "route": "IV infusion *"
                },
                {
                    "drug_name": "Capecitabine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "1,000 mg/m2 TWICE a day **",
                    "day": "1 to 14",
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Trastuzumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "8 mg/kg (loading dose only)",
                    "day": "1",
                    "route": "IV infusion *"
                },
                {
                    "drug_name": "Capecitabine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "1,000 mg/m2 TWICE a day **",
                    "day": "1 to 14",
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Trastuzumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "6 mg/kg (subsequent doses)",
                    "day": "1",
                    "route": "IV infusion *"
                },
                {
                    "drug_name": "Capecitabine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "1,000 mg/m2 TWICE a day **",
                    "day": "1 to 14",
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/metastatic/1814-breast-metastatic-capecitabine-and-trastuzuma"
    },
    {
        "protocol_id": "3505 v.2",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "6 AUC * #",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "6 AUC * #",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/metastatic/3505-breast-metastatic-carboplatin"
    },
    {
        "protocol_id": "1324 v.7",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Gemcitabine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "1,000 mg/m2",
                    "day": "1 and 8",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "5 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Gemcitabine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "1,000 mg/m2",
                    "day": "1 and 8",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "5 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/metastatic/1324-breast-metastatic-carboplatin-and-gemcitabine"
    },
    {
        "protocol_id": "4298 v.1",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Pembrolizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression, unacceptable toxicity or up to 24 months for pembrolizumab (as per clinical trial)",
                    "dose": "200 mg",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Gemcitabine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression, unacceptable toxicity or up to 24 months for pembrolizumab (as per clinical trial)",
                    "dose": "1,000 mg/m2",
                    "day": "1 and 8",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression, unacceptable toxicity or up to 24 months for pembrolizumab (as per clinical trial)",
                    "dose": "2 AUC *",
                    "day": "1 and 8",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Pembrolizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression, unacceptable toxicity or up to 24 months for pembrolizumab (as per clinical trial)",
                    "dose": "200 mg",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Gemcitabine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression, unacceptable toxicity or up to 24 months for pembrolizumab (as per clinical trial)",
                    "dose": "1,000 mg/m2",
                    "day": "1 and 8",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression, unacceptable toxicity or up to 24 months for pembrolizumab (as per clinical trial)",
                    "dose": "2 AUC *",
                    "day": "1 and 8",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/metastatic/4298-breast-metastatic-carboplatin-gemcitabine-an"
    },
    {
        "protocol_id": "51 v.8",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity; usually 6 to 8 cycles",
                    "dose": "600 mg/m2",
                    "day": "1 and 8",
                    "route": "IV"
                },
                {
                    "drug_name": "Methotrexate",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity; usually 6 to 8 cycles",
                    "dose": "40 mg/m2",
                    "day": "1 and 8",
                    "route": "IV bolus"
                },
                {
                    "drug_name": "CYCLOPHOSPHamide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity; usually 6 to 8 cycles",
                    "dose": "100 mg/m2 ONCE a day *",
                    "day": "1 to 14 *",
                    "route": "PO *"
                }
            ],
            [
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity; usually 6 to 8 cycles",
                    "dose": "600 mg/m2",
                    "day": "1 and 8",
                    "route": "IV"
                },
                {
                    "drug_name": "Methotrexate",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity; usually 6 to 8 cycles",
                    "dose": "40 mg/m2",
                    "day": "1 and 8",
                    "route": "IV bolus"
                },
                {
                    "drug_name": "CYCLOPHOSPHamide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity; usually 6 to 8 cycles",
                    "dose": "100 mg/m2 ONCE a day *",
                    "day": "1 to 14 *",
                    "route": "PO *"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/metastatic/51-breast-metastatic-cmf-classical-cyclophosphami"
    },
    {
        "protocol_id": "50 v.7",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Methotrexate",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "7 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity; reassess every 8 weeks",
                    "dose": "2.5 mg TWICE a day on day 1 and 2 each week*",
                    "day": "1 and 2",
                    "route": "PO"
                },
                {
                    "drug_name": "CYCLOPHOSPHamide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "7 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity; reassess every 8 weeks",
                    "dose": "50 mg ONCE a day *",
                    "day": "1 to 7",
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Methotrexate",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "7 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity; reassess every 8 weeks",
                    "dose": "2.5 mg TWICE a day on day 1 and 2 each week*",
                    "day": "1 and 2",
                    "route": "PO"
                },
                {
                    "drug_name": "CYCLOPHOSPHamide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "7 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity; reassess every 8 weeks",
                    "dose": "50 mg ONCE a day *",
                    "day": "1 to 7",
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/metastatic/50-breast-metastatic-cyclophosphamide-and-methotre"
    },
    {
        "protocol_id": "1300 v.6",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Denosumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until unacceptable toxicity (there is no information regarding how long denosumab treatment should be continued)",
                    "dose": "120 mg",
                    "day": "1",
                    "route": "Subcut"
                }
            ],
            [
                {
                    "drug_name": "Denosumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until unacceptable toxicity (there is no information regarding how long denosumab treatment should be continued)",
                    "dose": "120 mg",
                    "day": "1",
                    "route": "Subcut"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/metastatic/1300-breast-metastatic-denosumab"
    },
    {
        "protocol_id": "40 v.9",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "DOCEtaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (in the clinical trial docetaxel and trastuzumab were given for 6 cycles, after which trastuzumab monotherapy should be continued)",
                    "dose": "75 mg/m2 *",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Trastuzumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (in the clinical trial docetaxel and trastuzumab were given for 6 cycles, after which trastuzumab monotherapy should be continued)",
                    "dose": "8 mg/kg (loading dose only)",
                    "day": "1",
                    "route": "IV infusion **"
                }
            ],
            [
                {
                    "drug_name": "DOCEtaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (in the clinical trial docetaxel and trastuzumab were given for 6 cycles, after which trastuzumab monotherapy should be continued)",
                    "dose": "75 mg/m2 *",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Trastuzumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (in the clinical trial docetaxel and trastuzumab were given for 6 cycles, after which trastuzumab monotherapy should be continued)",
                    "dose": "6 mg/kg (subsequent doses)",
                    "day": "1",
                    "route": "IV infusion **"
                }
            ],
            [
                {
                    "drug_name": "Trastuzumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (in the clinical trial docetaxel and trastuzumab were given for 6 cycles, after which trastuzumab monotherapy should be continued)",
                    "dose": "6 mg/kg (subsequent doses)",
                    "day": "1",
                    "route": "IV infusion **"
                }
            ],
            [
                {
                    "drug_name": "DOCEtaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (in the clinical trial docetaxel and trastuzumab were given for 6 cycles, after which trastuzumab monotherapy should be continued)",
                    "dose": "75 mg/m2 *",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Trastuzumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (in the clinical trial docetaxel and trastuzumab were given for 6 cycles, after which trastuzumab monotherapy should be continued)",
                    "dose": "8 mg/kg (loading dose only)",
                    "day": "1",
                    "route": "IV infusion **"
                }
            ],
            [
                {
                    "drug_name": "DOCEtaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (in the clinical trial docetaxel and trastuzumab were given for 6 cycles, after which trastuzumab monotherapy should be continued)",
                    "dose": "75 mg/m2 *",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Trastuzumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (in the clinical trial docetaxel and trastuzumab were given for 6 cycles, after which trastuzumab monotherapy should be continued)",
                    "dose": "6 mg/kg (subsequent doses)",
                    "day": "1",
                    "route": "IV infusion **"
                }
            ],
            [
                {
                    "drug_name": "Trastuzumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (in the clinical trial docetaxel and trastuzumab were given for 6 cycles, after which trastuzumab monotherapy should be continued)",
                    "dose": "6 mg/kg (subsequent doses)",
                    "day": "1",
                    "route": "IV infusion **"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/metastatic/40-breast-metastatic-docetaxel-and-trastuzumab-thr"
    },
    {
        "protocol_id": "34 v.7",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "DOCEtaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "75 mg/m2 *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "DOCEtaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "75 mg/m2 *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/metastatic/34-breast-metastatic-docetaxel-three-weekly"
    },
    {
        "protocol_id": "1596 v.8",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "pERTUZumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (In the clinical trial it was recommended that patients receive at least 6 cycles of docetaxel. If docetaxel is stopped for toxicity, dual anti-HER-2 antibodies should be continued until disease progression or unacceptable toxicity)",
                    "dose": "840 mg (loading dose only)",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Trastuzumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (In the clinical trial it was recommended that patients receive at least 6 cycles of docetaxel. If docetaxel is stopped for toxicity, dual anti-HER-2 antibodies should be continued until disease progression or unacceptable toxicity)",
                    "dose": "8 mg/kg (loading dose only)",
                    "day": "1",
                    "route": "IV infusion *"
                },
                {
                    "drug_name": "DOCEtaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (In the clinical trial it was recommended that patients receive at least 6 cycles of docetaxel. If docetaxel is stopped for toxicity, dual anti-HER-2 antibodies should be continued until disease progression or unacceptable toxicity)",
                    "dose": "75 mg/m2 **",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "pERTUZumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (In the clinical trial it was recommended that patients receive at least 6 cycles of docetaxel. If docetaxel is stopped for toxicity, dual anti-HER-2 antibodies should be continued until disease progression or unacceptable toxicity)",
                    "dose": "420 mg (subsequent doses)",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Trastuzumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (In the clinical trial it was recommended that patients receive at least 6 cycles of docetaxel. If docetaxel is stopped for toxicity, dual anti-HER-2 antibodies should be continued until disease progression or unacceptable toxicity)",
                    "dose": "6 mg/kg (subsequent doses)",
                    "day": "1",
                    "route": "IV infusion *"
                },
                {
                    "drug_name": "DOCEtaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (In the clinical trial it was recommended that patients receive at least 6 cycles of docetaxel. If docetaxel is stopped for toxicity, dual anti-HER-2 antibodies should be continued until disease progression or unacceptable toxicity)",
                    "dose": "75 mg/m2 **",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "pERTUZumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (In the clinical trial it was recommended that patients receive at least 6 cycles of docetaxel. If docetaxel is stopped for toxicity, dual anti-HER-2 antibodies should be continued until disease progression or unacceptable toxicity)",
                    "dose": "840 mg (loading dose only)",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Trastuzumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (In the clinical trial it was recommended that patients receive at least 6 cycles of docetaxel. If docetaxel is stopped for toxicity, dual anti-HER-2 antibodies should be continued until disease progression or unacceptable toxicity)",
                    "dose": "8 mg/kg (loading dose only)",
                    "day": "1",
                    "route": "IV infusion *"
                },
                {
                    "drug_name": "DOCEtaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (In the clinical trial it was recommended that patients receive at least 6 cycles of docetaxel. If docetaxel is stopped for toxicity, dual anti-HER-2 antibodies should be continued until disease progression or unacceptable toxicity)",
                    "dose": "75 mg/m2 **",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "pERTUZumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (In the clinical trial it was recommended that patients receive at least 6 cycles of docetaxel. If docetaxel is stopped for toxicity, dual anti-HER-2 antibodies should be continued until disease progression or unacceptable toxicity)",
                    "dose": "420 mg (subsequent doses)",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Trastuzumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (In the clinical trial it was recommended that patients receive at least 6 cycles of docetaxel. If docetaxel is stopped for toxicity, dual anti-HER-2 antibodies should be continued until disease progression or unacceptable toxicity)",
                    "dose": "6 mg/kg (subsequent doses)",
                    "day": "1",
                    "route": "IV infusion *"
                },
                {
                    "drug_name": "DOCEtaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (In the clinical trial it was recommended that patients receive at least 6 cycles of docetaxel. If docetaxel is stopped for toxicity, dual anti-HER-2 antibodies should be continued until disease progression or unacceptable toxicity)",
                    "dose": "75 mg/m2 **",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/metastatic/1596-breast-metastatic-docetaxel-pertuzumab-and-t"
    },
    {
        "protocol_id": "35 v.6",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "DOXOrubicin liposomal",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until maximum improvement or unacceptable toxicity",
                    "dose": "40 mg/m2 *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "DOXOrubicin liposomal",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until maximum improvement or unacceptable toxicity",
                    "dose": "40 mg/m2 *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/metastatic/35-breast-metastatic-doxorubicin-pegylated-liposom"
    },
    {
        "protocol_id": "48 v.7",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "DOXOrubicin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (up to 6 cycles)",
                    "dose": "60 mg/m2 *",
                    "day": "1",
                    "route": "IV"
                }
            ],
            [
                {
                    "drug_name": "DOXOrubicin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (up to 6 cycles)",
                    "dose": "60 mg/m2 *",
                    "day": "1",
                    "route": "IV"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/metastatic/48-breast-metastatic-doxorubicin-three-weekly"
    },
    {
        "protocol_id": "1331 v.5",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "DOXOrubicin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "7 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "20 mg/m2 *",
                    "day": "1",
                    "route": "IV"
                }
            ],
            [
                {
                    "drug_name": "DOXOrubicin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "7 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "20 mg/m2 *",
                    "day": "1",
                    "route": "IV"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/metastatic/1331-breast-metastatic-doxorubicin-weekly"
    },
    {
        "protocol_id": "1306 v.6",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Epirubicin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until maximum improvement (usually 6 cycles), disease progression, or unacceptable toxicity. Reassess after 2 to 3 cycles.",
                    "dose": "75 mg/m2",
                    "day": "1",
                    "route": "IV"
                },
                {
                    "drug_name": "CYCLOPHOSPHamide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until maximum improvement (usually 6 cycles), disease progression, or unacceptable toxicity. Reassess after 2 to 3 cycles.",
                    "dose": "600 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Epirubicin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until maximum improvement (usually 6 cycles), disease progression, or unacceptable toxicity. Reassess after 2 to 3 cycles.",
                    "dose": "75 mg/m2",
                    "day": "1",
                    "route": "IV"
                },
                {
                    "drug_name": "CYCLOPHOSPHamide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until maximum improvement (usually 6 cycles), disease progression, or unacceptable toxicity. Reassess after 2 to 3 cycles.",
                    "dose": "600 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/metastatic/1306-breast-metastatic-ec-epirubicin-and-cyclopho"
    },
    {
        "protocol_id": "1597 v.5",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Eribulin mesilate",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "1.4 mg/m2",
                    "day": "1 and 8",
                    "route": "IV"
                }
            ],
            [
                {
                    "drug_name": "Eribulin mesilate",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "1.4 mg/m2",
                    "day": "1 and 8",
                    "route": "IV"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/metastatic/1597-breast-metastatic-eribulin"
    },
    {
        "protocol_id": "1590 v.6",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Everolimus",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "10 mg ONCE a day",
                    "day": null,
                    "route": "PO"
                },
                {
                    "drug_name": "Exemestane",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "25 mg ONCE a day",
                    "day": null,
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Everolimus",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "10 mg ONCE a day",
                    "day": null,
                    "route": "PO"
                },
                {
                    "drug_name": "Exemestane",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "25 mg ONCE a day",
                    "day": null,
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/metastatic/1590-breast-metastatic-everolimus-and-exemestane"
    },
    {
        "protocol_id": "1304 v.4",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Exemestane",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "25 mg ONCE a day",
                    "day": null,
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Exemestane",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "25 mg ONCE a day",
                    "day": null,
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/metastatic/1304-breast-metastatic-exemestane"
    },
    {
        "protocol_id": "1305 v.6",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Fulvestrant",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "500 mg",
                    "day": "1 and 15",
                    "route": "IM"
                }
            ],
            [
                {
                    "drug_name": "Fulvestrant",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "500 mg",
                    "day": "1",
                    "route": "IM"
                }
            ],
            [
                {
                    "drug_name": "Fulvestrant",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "500 mg",
                    "day": "1 and 15",
                    "route": "IM"
                }
            ],
            [
                {
                    "drug_name": "Fulvestrant",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "500 mg",
                    "day": "1",
                    "route": "IM"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/metastatic/1305-breast-metastatic-fulvestrant"
    },
    {
        "protocol_id": "1315 v.4",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Goserelin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "3.6 mg",
                    "day": "1",
                    "route": "Subcut"
                }
            ],
            [
                {
                    "drug_name": "Goserelin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "3.6 mg",
                    "day": "1",
                    "route": "Subcut"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/metastatic/1315-breast-metastatic-goserelin"
    },
    {
        "protocol_id": "1303 v.4",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Letrozole",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "2.5 mg ONCE a day",
                    "day": null,
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Letrozole",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "2.5 mg ONCE a day",
                    "day": null,
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/metastatic/1303-breast-metastatic-letrozole"
    },
    {
        "protocol_id": "4307 v.1",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Pembrolizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "84 days(This reflects the original trial protocol of nab-paclitaxel given days 1, 8 and 15 every 28 days and pembrolizumab every21 days)",
                    "cycles": "Continuous until disease progression or unacceptable toxicity or up to 24 months for pembrolizumab (as per clinical trial)",
                    "dose": "200 mg",
                    "day": "1, 22, 43, 64",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "nab-PACLitaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "84 days(This reflects the original trial protocol of nab-paclitaxel given days 1, 8 and 15 every 28 days and pembrolizumab every21 days)",
                    "cycles": "Continuous until disease progression or unacceptable toxicity or up to 24 months for pembrolizumab (as per clinical trial)",
                    "dose": "100 mg/m2",
                    "day": "1, 8, 15, 29, 36, 43, 57, 64, 71",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Pembrolizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "84 days(This reflects the original trial protocol of nab-paclitaxel given days 1, 8 and 15 every 28 days and pembrolizumab every21 days)",
                    "cycles": "Continuous until disease progression or unacceptable toxicity or up to 24 months for pembrolizumab (as per clinical trial)",
                    "dose": "200 mg",
                    "day": "1, 22, 43, 64",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "nab-PACLitaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "84 days(This reflects the original trial protocol of nab-paclitaxel given days 1, 8 and 15 every 28 days and pembrolizumab every21 days)",
                    "cycles": "Continuous until disease progression or unacceptable toxicity or up to 24 months for pembrolizumab (as per clinical trial)",
                    "dose": "100 mg/m2",
                    "day": "1, 8, 15, 29, 36, 43, 57, 64, 71",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/metastatic/4307-breast-metastatic-nab-paclitaxel-and-pembroli"
    },
    {
        "protocol_id": "1299 v.6",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "nab-PACLitaxel **",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "100 mg/m2 *",
                    "day": "1, 8, 15",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "nab-PACLitaxel **",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "100 mg/m2 *",
                    "day": "1, 8, 15",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/metastatic/1299-breast-metastatic-nab-paclitaxel-weekly"
    },
    {
        "protocol_id": "4309 v.1",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Pembrolizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "84 days(This reflects the original trial protocol of paclitaxel given days 1, 8 and 15 every 28 days and pembrolizumab every21 days)",
                    "cycles": "Continuous until disease progression or unacceptable toxicity or up to 24 months for pembrolizumab (as per clinical trial)",
                    "dose": "200 mg",
                    "day": "1, 22, 43, 64",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "PACLitaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "84 days(This reflects the original trial protocol of paclitaxel given days 1, 8 and 15 every 28 days and pembrolizumab every21 days)",
                    "cycles": "Continuous until disease progression or unacceptable toxicity or up to 24 months for pembrolizumab (as per clinical trial)",
                    "dose": "90 mg/m2",
                    "day": "1, 8, 15, 29, 36, 43, 57, 64, 71",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Pembrolizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "84 days(This reflects the original trial protocol of paclitaxel given days 1, 8 and 15 every 28 days and pembrolizumab every21 days)",
                    "cycles": "Continuous until disease progression or unacceptable toxicity or up to 24 months for pembrolizumab (as per clinical trial)",
                    "dose": "200 mg",
                    "day": "1, 22, 43, 64",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "PACLitaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "84 days(This reflects the original trial protocol of paclitaxel given days 1, 8 and 15 every 28 days and pembrolizumab every21 days)",
                    "cycles": "Continuous until disease progression or unacceptable toxicity or up to 24 months for pembrolizumab (as per clinical trial)",
                    "dose": "90 mg/m2",
                    "day": "1, 8, 15, 29, 36, 43, 57, 64, 71",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/metastatic/4309-breast-metastatic-paclitaxel-and-pembrolizuma"
    },
    {
        "protocol_id": "42 v.10",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "PACLitaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "7 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "80 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "PACLitaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "7 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "80 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/metastatic/42-breast-metastatic-paclitaxel-weekly"
    },
    {
        "protocol_id": "167 v.12",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "PACLitaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "80 mg/m2",
                    "day": "1, 8, 15",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Trastuzumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "8 mg/kg (loading dose only)",
                    "day": "1",
                    "route": "IV infusion *"
                }
            ],
            [
                {
                    "drug_name": "PACLitaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "80 mg/m2",
                    "day": "1, 8, 15",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Trastuzumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "6 mg/kg (subsequent doses)",
                    "day": "1",
                    "route": "IV infusion *"
                }
            ],
            [
                {
                    "drug_name": "PACLitaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "80 mg/m2",
                    "day": "1, 8, 15",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Trastuzumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "8 mg/kg (loading dose only)",
                    "day": "1",
                    "route": "IV infusion *"
                }
            ],
            [
                {
                    "drug_name": "PACLitaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "80 mg/m2",
                    "day": "1, 8, 15",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Trastuzumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "6 mg/kg (subsequent doses)",
                    "day": "1",
                    "route": "IV infusion *"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/metastatic/167-breast-metastatic-paclitaxel-weekly-and-trastu"
    },
    {
        "protocol_id": "1812 v.10",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "pERTUZumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (in the clinical trial paclitaxel was continued for 6 months, after which dual anti-HER-2 antibodies were continued until disease progression or unacceptable toxicity)",
                    "dose": "840 mg (loading dose only)",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Trastuzumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (in the clinical trial paclitaxel was continued for 6 months, after which dual anti-HER-2 antibodies were continued until disease progression or unacceptable toxicity)",
                    "dose": "8 mg/kg (loading dose only)",
                    "day": "1",
                    "route": "IV infusion *"
                },
                {
                    "drug_name": "PACLitaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (in the clinical trial paclitaxel was continued for 6 months, after which dual anti-HER-2 antibodies were continued until disease progression or unacceptable toxicity)",
                    "dose": "80 mg/m2",
                    "day": "1, 8, 15",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "pERTUZumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (in the clinical trial paclitaxel was continued for 6 months, after which dual anti-HER-2 antibodies were continued until disease progression or unacceptable toxicity)",
                    "dose": "420 mg (subsequent doses)",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Trastuzumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (in the clinical trial paclitaxel was continued for 6 months, after which dual anti-HER-2 antibodies were continued until disease progression or unacceptable toxicity)",
                    "dose": "6 mg/kg (subsequent doses)",
                    "day": "1",
                    "route": "IV infusion *"
                },
                {
                    "drug_name": "PACLitaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (in the clinical trial paclitaxel was continued for 6 months, after which dual anti-HER-2 antibodies were continued until disease progression or unacceptable toxicity)",
                    "dose": "80 mg/m2",
                    "day": "1, 8, 15",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "pERTUZumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (in the clinical trial paclitaxel was continued for 6 months, after which dual anti-HER-2 antibodies were continued until disease progression or unacceptable toxicity)",
                    "dose": "840 mg (loading dose only)",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Trastuzumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (in the clinical trial paclitaxel was continued for 6 months, after which dual anti-HER-2 antibodies were continued until disease progression or unacceptable toxicity)",
                    "dose": "8 mg/kg (loading dose only)",
                    "day": "1",
                    "route": "IV infusion *"
                },
                {
                    "drug_name": "PACLitaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (in the clinical trial paclitaxel was continued for 6 months, after which dual anti-HER-2 antibodies were continued until disease progression or unacceptable toxicity)",
                    "dose": "80 mg/m2",
                    "day": "1, 8, 15",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "pERTUZumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (in the clinical trial paclitaxel was continued for 6 months, after which dual anti-HER-2 antibodies were continued until disease progression or unacceptable toxicity)",
                    "dose": "420 mg (subsequent doses)",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Trastuzumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (in the clinical trial paclitaxel was continued for 6 months, after which dual anti-HER-2 antibodies were continued until disease progression or unacceptable toxicity)",
                    "dose": "6 mg/kg (subsequent doses)",
                    "day": "1",
                    "route": "IV infusion *"
                },
                {
                    "drug_name": "PACLitaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (in the clinical trial paclitaxel was continued for 6 months, after which dual anti-HER-2 antibodies were continued until disease progression or unacceptable toxicity)",
                    "dose": "80 mg/m2",
                    "day": "1, 8, 15",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/metastatic/1812-breast-metastatic-paclitaxel-weekly-pertuzum"
    },
    {
        "protocol_id": "3369 v.5",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Palbociclib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "125 mg ONCE a day",
                    "day": "1 to 21 *",
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Palbociclib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "125 mg ONCE a day",
                    "day": "1 to 21 *",
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/metastatic/3369-breast-metastatic-palbociclib"
    },
    {
        "protocol_id": "3379 v.4",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Ribociclib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "600 mg ONCE a day *",
                    "day": "1 to 21 **",
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Ribociclib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "600 mg ONCE a day *",
                    "day": "1 to 21 **",
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/metastatic/3379-breast-metastatic-ribociclib"
    },
    {
        "protocol_id": "4079 v.2",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Sacituzumab govitecan",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "10 mg/kg",
                    "day": "1 and 8",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Sacituzumab govitecan",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "10 mg/kg",
                    "day": "1 and 8",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/metastatic/4079-breast-metastatic-sacituzumab-govitecan"
    },
    {
        "protocol_id": "1327 v.4",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Tamoxifen",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "20 mg ONCE a day",
                    "day": null,
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Tamoxifen",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "20 mg ONCE a day",
                    "day": null,
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/metastatic/1327-breast-metastatic-tamoxifen"
    },
    {
        "protocol_id": "4150 v.3",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Trastuzumab deruxtecan",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "5.4 mg/kg",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Trastuzumab deruxtecan",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "5.4 mg/kg",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/metastatic/4150-breast-metastatic-trastuzumab-deruxtecan"
    },
    {
        "protocol_id": "1598 v.6",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Trastuzumab emtansine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "3.6 mg/kg",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Trastuzumab emtansine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "3.6 mg/kg",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/metastatic/1598-breast-metastatic-trastuzumab-emtansine"
    },
    {
        "protocol_id": "1875 v.5",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Trastuzumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "17 cycles (in the neoadjuvant/adjuvant setting) or continuous until no longer clinically appropriate (metastatic setting)",
                    "dose": "600 mg",
                    "day": "1",
                    "route": "Subcut"
                }
            ],
            [
                {
                    "drug_name": "Trastuzumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "17 cycles (in the neoadjuvant/adjuvant setting) or continuous until no longer clinically appropriate (metastatic setting)",
                    "dose": "600 mg",
                    "day": "1",
                    "route": "Subcut"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/metastatic/3308-1875-redirect"
    },
    {
        "protocol_id": "33 v.9",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Trastuzumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "8 mg/kg (loading dose only)",
                    "day": "1",
                    "route": "IV infusion *"
                }
            ],
            [
                {
                    "drug_name": "Trastuzumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "6 mg/kg (subsequent doses)",
                    "day": "1",
                    "route": "IV infusion *"
                }
            ],
            [
                {
                    "drug_name": "Trastuzumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "8 mg/kg (loading dose only)",
                    "day": "1",
                    "route": "IV infusion *"
                }
            ],
            [
                {
                    "drug_name": "Trastuzumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "6 mg/kg (subsequent doses)",
                    "day": "1",
                    "route": "IV infusion *"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/metastatic/33-breast-metastatic-trastuzumab-three-weekly"
    },
    {
        "protocol_id": "1626 v.6",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "vinORELBine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity. Trastuzumab monotherapy should be continued if vinorelbine is stopped for toxicity.",
                    "dose": "30 mg/m2 *",
                    "day": "1 and 8",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Trastuzumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity. Trastuzumab monotherapy should be continued if vinorelbine is stopped for toxicity.",
                    "dose": "8 mg/kg (loading dose only)",
                    "day": "1",
                    "route": "IV infusion **"
                }
            ],
            [
                {
                    "drug_name": "vinORELBine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity. Trastuzumab monotherapy should be continued if vinorelbine is stopped for toxicity.",
                    "dose": "30 mg/m2 *",
                    "day": "1 and 8",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Trastuzumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity. Trastuzumab monotherapy should be continued if vinorelbine is stopped for toxicity.",
                    "dose": "6 mg/kg (subsequent doses)",
                    "day": "1",
                    "route": "IV infusion **"
                }
            ],
            [
                {
                    "drug_name": "vinORELBine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity. Trastuzumab monotherapy should be continued if vinorelbine is stopped for toxicity.",
                    "dose": "30 mg/m2 *",
                    "day": "1 and 8",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Trastuzumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity. Trastuzumab monotherapy should be continued if vinorelbine is stopped for toxicity.",
                    "dose": "8 mg/kg (loading dose only)",
                    "day": "1",
                    "route": "IV infusion **"
                }
            ],
            [
                {
                    "drug_name": "vinORELBine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity. Trastuzumab monotherapy should be continued if vinorelbine is stopped for toxicity.",
                    "dose": "30 mg/m2 *",
                    "day": "1 and 8",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Trastuzumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity. Trastuzumab monotherapy should be continued if vinorelbine is stopped for toxicity.",
                    "dose": "6 mg/kg (subsequent doses)",
                    "day": "1",
                    "route": "IV infusion **"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/metastatic/1626-breast-metastatic-trastuzumab-three-weekly-an"
    },
    {
        "protocol_id": "1627 v.5",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Trastuzumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity. Trastuzumab monotherapy should be continued if vinorelbine is stopped for toxicity.",
                    "dose": "8 mg/kg (loading dose only)",
                    "day": "1",
                    "route": "IV infusion *"
                },
                {
                    "drug_name": "vinORELBine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity. Trastuzumab monotherapy should be continued if vinorelbine is stopped for toxicity.",
                    "dose": "60 mg/m2 ONCE a week **",
                    "day": "1 and 8",
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Trastuzumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity. Trastuzumab monotherapy should be continued if vinorelbine is stopped for toxicity.",
                    "dose": "6 mg/kg (subsequent doses)",
                    "day": "1",
                    "route": "IV infusion *"
                },
                {
                    "drug_name": "vinORELBine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity. Trastuzumab monotherapy should be continued if vinorelbine is stopped for toxicity.",
                    "dose": "60 mg/m2 ONCE a week **",
                    "day": "1 and 8",
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Trastuzumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity. Trastuzumab monotherapy should be continued if vinorelbine is stopped for toxicity.",
                    "dose": "8 mg/kg (loading dose only)",
                    "day": "1",
                    "route": "IV infusion *"
                },
                {
                    "drug_name": "vinORELBine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity. Trastuzumab monotherapy should be continued if vinorelbine is stopped for toxicity.",
                    "dose": "60 mg/m2 ONCE a week **",
                    "day": "1 and 8",
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Trastuzumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity. Trastuzumab monotherapy should be continued if vinorelbine is stopped for toxicity.",
                    "dose": "6 mg/kg (subsequent doses)",
                    "day": "1",
                    "route": "IV infusion *"
                },
                {
                    "drug_name": "vinORELBine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity. Trastuzumab monotherapy should be continued if vinorelbine is stopped for toxicity.",
                    "dose": "60 mg/m2 ONCE a week **",
                    "day": "1 and 8",
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/metastatic/1627-breast-metastatic-trastuzumab-three-weekly-an"
    },
    {
        "protocol_id": "38 v.7",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "vinORELBine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "30 mg/m2",
                    "day": "1 and 8",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "vinORELBine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "30 mg/m2",
                    "day": "1 and 8",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/metastatic/38-breast-metastatic-vinorelbine-iv"
    },
    {
        "protocol_id": "1545 v.6",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "vinORELBine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "7 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "60 mg/m2 *",
                    "day": "1",
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "vinORELBine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "7 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "60 mg/m2 *",
                    "day": "1",
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/metastatic/1545-breast-metastatic-vinorelbine-oral"
    },
    {
        "protocol_id": "149 v.7",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Zoledronic acid",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous (standard cycle length is 21 to 28 days; extended cycles of 12 weeks may be considered after 9 doses)",
                    "dose": "4 mg",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Zoledronic acid",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous (standard cycle length is 21 to 28 days; extended cycles of 12 weeks may be considered after 9 doses)",
                    "dose": "4 mg",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/metastatic/149-breast-metastatic-zoledronic-acid"
    },
    {
        "protocol_id": "45 v.6",
        "protocol_status": "Superseded",
        "drug_sequence": [
            [
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity; usually up to 6 cycles",
                    "dose": "600 mg/m2",
                    "day": "1",
                    "route": "IV"
                },
                {
                    "drug_name": "Methotrexate",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity; usually up to 6 cycles",
                    "dose": "40 mg/m2",
                    "day": "1",
                    "route": "IV bolus"
                },
                {
                    "drug_name": "CYCLOPHOSPHamide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity; usually up to 6 cycles",
                    "dose": "600 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity; usually up to 6 cycles",
                    "dose": "600 mg/m2",
                    "day": "1",
                    "route": "IV"
                },
                {
                    "drug_name": "Methotrexate",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity; usually up to 6 cycles",
                    "dose": "40 mg/m2",
                    "day": "1",
                    "route": "IV bolus"
                },
                {
                    "drug_name": "CYCLOPHOSPHamide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity; usually up to 6 cycles",
                    "dose": "600 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/metastatic/45-breast-metastatic-cmf-iv-cyclophosphamide-meth"
    },
    {
        "protocol_id": "1629 v.8",
        "protocol_status": "Superseded",
        "drug_sequence": [
            [
                {
                    "drug_name": "PACLitaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "80 mg/m2",
                    "day": "1, 8, 15",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Gemcitabine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "800 mg/m2",
                    "day": "1, 8, 15",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "PACLitaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "80 mg/m2",
                    "day": "1, 8, 15",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Gemcitabine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "800 mg/m2",
                    "day": "1, 8, 15",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/metastatic/1629-breast-metastatic-gemcitabine-and-paclitaxel"
    },
    {
        "protocol_id": "90 v.8",
        "protocol_status": "Superseded",
        "drug_sequence": [
            [
                {
                    "drug_name": "nab-PACLitaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity; usually 6 cycles",
                    "dose": "260 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "nab-PACLitaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity; usually 6 cycles",
                    "dose": "260 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/metastatic/90-breast-metastatic-nab-paclitaxel-three-weekly-s"
    },
    {
        "protocol_id": "307 v.5",
        "protocol_status": "Superseded",
        "drug_sequence": [
            [
                {
                    "drug_name": "Pamidronate",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous (cycle length may be 21 to 28 days)",
                    "dose": "90 mg",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Pamidronate",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous (cycle length may be 21 to 28 days)",
                    "dose": "90 mg",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/metastatic/307-breast-metastatic-pamidronate-superseded"
    },
    {
        "protocol_id": "52 v.5",
        "protocol_status": "Discontinued",
        "drug_sequence": [],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/metastatic/52-breast-metastatic-capecitabine-and-docetaxel-di"
    },
    {
        "protocol_id": "39 v.4",
        "protocol_status": "Discontinued",
        "drug_sequence": [],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/metastatic/39-breast-metastatic-carboplatin-paclitaxel-trastu"
    },
    {
        "protocol_id": "49 v.3",
        "protocol_status": "Discontinued",
        "drug_sequence": [],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/metastatic/49-breast-metastatic-docetaxel-weekly-discontinued"
    },
    {
        "protocol_id": "47 v.4",
        "protocol_status": "Discontinued",
        "drug_sequence": [],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/metastatic/47-breast-metastatic-fac-fluorouracil-doxorubicin"
    },
    {
        "protocol_id": "46 v.7",
        "protocol_status": "Discontinued",
        "drug_sequence": [],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/metastatic/46-breast-metastatic-fec-fluorouracil-epirubicin"
    },
    {
        "protocol_id": "1599 v.4",
        "protocol_status": "Discontinued",
        "drug_sequence": [],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/metastatic/1599-breast-metastatic-gemcitabine-and-nab-paclita"
    },
    {
        "protocol_id": "43 v.4",
        "protocol_status": "Discontinued",
        "drug_sequence": [],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/metastatic/43-breast-metastatic-gemcitabine-and-paclitaxel-di"
    },
    {
        "protocol_id": "44 v.5",
        "protocol_status": "Discontinued",
        "drug_sequence": [],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/metastatic/44-breast-metastatic-mmm-mitomycin-mitozantrone-m"
    },
    {
        "protocol_id": "4091 v.2",
        "protocol_status": "Discontinued",
        "drug_sequence": [],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/metastatic/4091-breast-metastatic-nab-paclitaxel-and-atezoliz"
    },
    {
        "protocol_id": "1625 v.6",
        "protocol_status": "Discontinued",
        "drug_sequence": [],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/metastatic/1625-breast-metastatic-nab-paclitaxel-weekly-and-t"
    },
    {
        "protocol_id": "129 v.3",
        "protocol_status": "Discontinued",
        "drug_sequence": [],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/metastatic/129-breast-metastatic-paclitaxel-and-trastuzumab-t"
    },
    {
        "protocol_id": "130 v.3",
        "protocol_status": "Discontinued",
        "drug_sequence": [],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/metastatic/130-breast-metastatic-paclitaxel-three-weekly-and"
    },
    {
        "protocol_id": "41 v.3",
        "protocol_status": "Discontinued",
        "drug_sequence": [],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/metastatic/41-breast-metastatic-paclitaxel-three-weekly-disco"
    },
    {
        "protocol_id": "54 v.4",
        "protocol_status": "Discontinued",
        "drug_sequence": [],
        "section_name": "medical-oncology",
        "category_name": "breast",
        "url": "https://www.eviq.org.au/medical-oncology/breast/metastatic/54-breast-metastatic-trastuzumab-weekly-discontinu"
    },
    {
        "protocol_id": "4019 v.6",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Oxaliplatin",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "8",
                    "dose": "130 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Capecitabine",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "8",
                    "dose": "1,000 mg/m2 TWICE a day *",
                    "day": "1 to 14",
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Oxaliplatin",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "8",
                    "dose": "130 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Capecitabine",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "8",
                    "dose": "1,000 mg/m2 TWICE a day *",
                    "day": "1 to 14",
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "colorectal",
        "url": "https://www.eviq.org.au/medical-oncology/colorectal/adjuvant-and-neoadjuvant/4019-adjuvant-capox-xelox-capecitabine-and-oxal"
    },
    {
        "protocol_id": "74 v.7",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Capecitabine",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "8",
                    "dose": "1,250 mg/m2 TWICE a day *",
                    "day": "1 to 14",
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Capecitabine",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "8",
                    "dose": "1,250 mg/m2 TWICE a day *",
                    "day": "1 to 14",
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "colorectal",
        "url": "https://www.eviq.org.au/medical-oncology/colorectal/adjuvant-and-neoadjuvant/74-colorectal-adjuvant-capecitabine"
    },
    {
        "protocol_id": "76 v.8",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Calcium folinate (Leucovorin)",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "12",
                    "dose": "50 mg *",
                    "day": "1",
                    "route": "IV bolus"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "12",
                    "dose": "400 mg/m2",
                    "day": "1",
                    "route": "IV"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "12",
                    "dose": "2,400 mg/m2",
                    "day": "1",
                    "route": "CIV via pump over 46 hours**"
                }
            ],
            [
                {
                    "drug_name": "Calcium folinate (Leucovorin)",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "12",
                    "dose": "50 mg *",
                    "day": "1",
                    "route": "IV bolus"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "12",
                    "dose": "400 mg/m2",
                    "day": "1",
                    "route": "IV"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "12",
                    "dose": "2,400 mg/m2",
                    "day": "1",
                    "route": "CIV via pump over 46 hours**"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "colorectal",
        "url": "https://www.eviq.org.au/medical-oncology/colorectal/adjuvant-and-neoadjuvant/76-colorectal-adjuvant-de-gramont-modified-fluo"
    },
    {
        "protocol_id": "637 v.11",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Oxaliplatin",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "12",
                    "dose": "85 mg/m2 *",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Calcium folinate (Leucovorin)",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "12",
                    "dose": "50 mg *",
                    "day": "1",
                    "route": "IV bolus"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "12",
                    "dose": "400 mg/m2",
                    "day": "1",
                    "route": "IV"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "12",
                    "dose": "2,400 mg/m2",
                    "day": "1",
                    "route": "CIV via pump over 46 hours"
                }
            ],
            [
                {
                    "drug_name": "Oxaliplatin",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "12",
                    "dose": "85 mg/m2 *",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Calcium folinate (Leucovorin)",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "12",
                    "dose": "50 mg *",
                    "day": "1",
                    "route": "IV bolus"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "12",
                    "dose": "400 mg/m2",
                    "day": "1",
                    "route": "IV"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "12",
                    "dose": "2,400 mg/m2",
                    "day": "1",
                    "route": "CIV via pump over 46 hours"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "colorectal",
        "url": "https://www.eviq.org.au/medical-oncology/colorectal/adjuvant-and-neoadjuvant/637-colorectal-adjuvant-folfox6-modified-fluoro"
    },
    {
        "protocol_id": "1494 v.7",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Calcium folinate (Leucovorin)",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "7 days",
                    "cycles": "30",
                    "dose": "50 mg *",
                    "day": "1",
                    "route": "IV bolus"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "7 days",
                    "cycles": "30",
                    "dose": "370 mg/m2",
                    "day": "1",
                    "route": "IV"
                }
            ],
            [
                {
                    "drug_name": "Calcium folinate (Leucovorin)",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "7 days",
                    "cycles": "30",
                    "dose": "50 mg *",
                    "day": "1",
                    "route": "IV bolus"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "7 days",
                    "cycles": "30",
                    "dose": "370 mg/m2",
                    "day": "1",
                    "route": "IV"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "colorectal",
        "url": "https://www.eviq.org.au/medical-oncology/colorectal/adjuvant-and-neoadjuvant/1494-colorectal-adjuvant-quasar-modified-fluorou"
    },
    {
        "protocol_id": "1271 v.6",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Calcium folinate (Leucovorin)",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "56 days(weekly for six weeks followed by a two week break)",
                    "cycles": "3",
                    "dose": "50 mg *",
                    "day": "1, 8, 15, 22, 29, 36",
                    "route": "IV bolus"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "56 days(weekly for six weeks followed by a two week break)",
                    "cycles": "3",
                    "dose": "500 mg/m2",
                    "day": "1, 8, 15, 22, 29, 36",
                    "route": "IV"
                }
            ],
            [
                {
                    "drug_name": "Calcium folinate (Leucovorin)",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "56 days(weekly for six weeks followed by a two week break)",
                    "cycles": "3",
                    "dose": "50 mg *",
                    "day": "1, 8, 15, 22, 29, 36",
                    "route": "IV bolus"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "56 days(weekly for six weeks followed by a two week break)",
                    "cycles": "3",
                    "dose": "500 mg/m2",
                    "day": "1, 8, 15, 22, 29, 36",
                    "route": "IV"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "colorectal",
        "url": "https://www.eviq.org.au/medical-oncology/colorectal/adjuvant-and-neoadjuvant/1271-colorectal-adjuvant-roswell-park-modified-f"
    },
    {
        "protocol_id": "75 v.7",
        "protocol_status": "Superseded",
        "drug_sequence": [
            [
                {
                    "drug_name": "Calcium folinate (Leucovorin)",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "12",
                    "dose": "200 mg/m2 *",
                    "day": "1 and 2",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "12",
                    "dose": "400 mg/m2",
                    "day": "1 and 2",
                    "route": "IV"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "12",
                    "dose": "600 mg/m2",
                    "day": "1 and 2",
                    "route": "CIV via pump over 22 hours"
                }
            ],
            [
                {
                    "drug_name": "Calcium folinate (Leucovorin)",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "12",
                    "dose": "200 mg/m2 *",
                    "day": "1 and 2",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "12",
                    "dose": "400 mg/m2",
                    "day": "1 and 2",
                    "route": "IV"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "12",
                    "dose": "600 mg/m2",
                    "day": "1 and 2",
                    "route": "CIV via pump over 22 hours"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "colorectal",
        "url": "https://www.eviq.org.au/medical-oncology/colorectal/adjuvant-and-neoadjuvant/75-colorectal-adjuvant-de-gramont-fluorouracil-an"
    },
    {
        "protocol_id": "77 v.9",
        "protocol_status": "Superseded",
        "drug_sequence": [
            [
                {
                    "drug_name": "Oxaliplatin",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "56 days",
                    "cycles": "3",
                    "dose": "85 mg/m2",
                    "day": "1, 15, 29",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Calcium folinate (Leucovorin)",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "56 days",
                    "cycles": "3",
                    "dose": "50 mg *",
                    "day": "1, 8, 15, 22, 29, 36",
                    "route": "IV bolus"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "56 days",
                    "cycles": "3",
                    "dose": "500 mg/m2",
                    "day": "1, 8, 15, 22, 29, 36",
                    "route": "IV"
                }
            ],
            [
                {
                    "drug_name": "Oxaliplatin",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "56 days",
                    "cycles": "3",
                    "dose": "85 mg/m2",
                    "day": "1, 15, 29",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Calcium folinate (Leucovorin)",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "56 days",
                    "cycles": "3",
                    "dose": "50 mg *",
                    "day": "1, 8, 15, 22, 29, 36",
                    "route": "IV bolus"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "56 days",
                    "cycles": "3",
                    "dose": "500 mg/m2",
                    "day": "1, 8, 15, 22, 29, 36",
                    "route": "IV"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "colorectal",
        "url": "https://www.eviq.org.au/medical-oncology/colorectal/adjuvant-and-neoadjuvant/77-colorectal-adjuvant-flox-fluorouracil-leucovor"
    },
    {
        "protocol_id": "78 v.10",
        "protocol_status": "Discontinued",
        "drug_sequence": [],
        "section_name": "medical-oncology",
        "category_name": "colorectal",
        "url": "https://www.eviq.org.au/medical-oncology/colorectal/adjuvant-and-neoadjuvant/78-colorectal-adjuvant-folfox4-fluorouracil-leuco"
    },
    {
        "protocol_id": "17 v.8",
        "protocol_status": "Discontinued",
        "drug_sequence": [],
        "section_name": "medical-oncology",
        "category_name": "colorectal",
        "url": "https://www.eviq.org.au/medical-oncology/colorectal/adjuvant-and-neoadjuvant/17-colorectal-adjuvant-folfox4-modified-fluorou"
    },
    {
        "protocol_id": "79 v.3",
        "protocol_status": "Discontinued",
        "drug_sequence": [],
        "section_name": "medical-oncology",
        "category_name": "colorectal",
        "url": "https://www.eviq.org.au/medical-oncology/colorectal/adjuvant-and-neoadjuvant/79-colorectal-adjuvant-mayo-fluorouracil-and-leuc"
    },
    {
        "protocol_id": "4043 v.2",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Irinotecan",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "180 mg/m2 *",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Calcium folinate (Leucovorin)",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "50 mg **",
                    "day": "1",
                    "route": "IV bolus"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "400 mg/m2",
                    "day": "1",
                    "route": "IV"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "2,400 mg/m2",
                    "day": "1",
                    "route": "CIV via pump over 46 hours"
                }
            ],
            [
                {
                    "drug_name": "Irinotecan",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "180 mg/m2 *",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Calcium folinate (Leucovorin)",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "50 mg **",
                    "day": "1",
                    "route": "IV bolus"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "400 mg/m2",
                    "day": "1",
                    "route": "IV"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "2,400 mg/m2",
                    "day": "1",
                    "route": "CIV via pump over 46 hours"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "colorectal",
        "url": "https://www.eviq.org.au/medical-oncology/colorectal/metastatic/99-redirect-id-4043"
    },
    {
        "protocol_id": "3840 v.9",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Pembrolizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (see Indications and patient population section)",
                    "dose": "200 mg *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Pembrolizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (see Indications and patient population section)",
                    "dose": "200 mg *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "colorectal",
        "url": "https://www.eviq.org.au/medical-oncology/colorectal/metastatic/3991-redirect-id-3840"
    },
    {
        "protocol_id": "94 v.6",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Capecitabine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "1,250 mg/m2 TWICE a day *",
                    "day": "1 to 14",
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Capecitabine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "1,250 mg/m2 TWICE a day *",
                    "day": "1 to 14",
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "colorectal",
        "url": "https://www.eviq.org.au/medical-oncology/colorectal/metastatic/94-colorectal-metastatic-capecitabine"
    },
    {
        "protocol_id": "1175 v.10",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "beVACizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "7.5 mg/kg",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Capecitabine *",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "1,250 mg/m2 TWICE a day",
                    "day": "1 to 14",
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "beVACizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "7.5 mg/kg",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Capecitabine *",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "1,250 mg/m2 TWICE a day",
                    "day": "1 to 14",
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "colorectal",
        "url": "https://www.eviq.org.au/medical-oncology/colorectal/metastatic/1175-colorectal-metastatic-capecitabine-and-bevaci"
    },
    {
        "protocol_id": "1243 v.6",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Irinotecan",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "240 mg/m2 *",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Capecitabine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "1,000 mg/m2 TWICE a day **",
                    "day": "1 to 14",
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Irinotecan",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "240 mg/m2 *",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Capecitabine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "1,000 mg/m2 TWICE a day **",
                    "day": "1 to 14",
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "colorectal",
        "url": "https://www.eviq.org.au/medical-oncology/colorectal/metastatic/1243-colorectal-metastatic-capiri-xeliri-capeci"
    },
    {
        "protocol_id": "1184 v.9",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "beVACizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "7.5 mg/kg",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Irinotecan",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "240 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Capecitabine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "1,000 mg/m2 TWICE a day *",
                    "day": "1 to 14",
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "beVACizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "7.5 mg/kg",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Irinotecan",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "240 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Capecitabine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "1,000 mg/m2 TWICE a day *",
                    "day": "1 to 14",
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "colorectal",
        "url": "https://www.eviq.org.au/medical-oncology/colorectal/metastatic/1184-colorectal-metastatic-capiri-xeliri-capeci"
    },
    {
        "protocol_id": "117 v.10",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Oxaliplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity; usually 6 cycles",
                    "dose": "130 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Capecitabine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity; usually 6 cycles",
                    "dose": "1,000 mg/m2 TWICE a day *",
                    "day": "1 to 14",
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Oxaliplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity; usually 6 cycles",
                    "dose": "130 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Capecitabine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity; usually 6 cycles",
                    "dose": "1,000 mg/m2 TWICE a day *",
                    "day": "1 to 14",
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "colorectal",
        "url": "https://www.eviq.org.au/medical-oncology/colorectal/metastatic/117-colorectal-metastatic-capox-xelox-capecitab"
    },
    {
        "protocol_id": "1180 v.13",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "beVACizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6or until disease progression or unacceptable toxicity. Consider continuation with capecitabine and bevacizumab; oxaliplatin may be reintroduced at a later date.",
                    "dose": "7.5 mg/kg",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Oxaliplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6or until disease progression or unacceptable toxicity. Consider continuation with capecitabine and bevacizumab; oxaliplatin may be reintroduced at a later date.",
                    "dose": "130 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Capecitabine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6or until disease progression or unacceptable toxicity. Consider continuation with capecitabine and bevacizumab; oxaliplatin may be reintroduced at a later date.",
                    "dose": "1,000 mg/m2 TWICE a day *",
                    "day": "1 to 14",
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "beVACizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6or until disease progression or unacceptable toxicity. Consider continuation with capecitabine and bevacizumab; oxaliplatin may be reintroduced at a later date.",
                    "dose": "7.5 mg/kg",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Oxaliplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6or until disease progression or unacceptable toxicity. Consider continuation with capecitabine and bevacizumab; oxaliplatin may be reintroduced at a later date.",
                    "dose": "130 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Capecitabine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6or until disease progression or unacceptable toxicity. Consider continuation with capecitabine and bevacizumab; oxaliplatin may be reintroduced at a later date.",
                    "dose": "1,000 mg/m2 TWICE a day *",
                    "day": "1 to 14",
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "colorectal",
        "url": "https://www.eviq.org.au/medical-oncology/colorectal/metastatic/1180-colorectal-metastatic-capox-xelox-capecita"
    },
    {
        "protocol_id": "1681 v.5",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Cetuximab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "500 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Cetuximab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "500 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "colorectal",
        "url": "https://www.eviq.org.au/medical-oncology/colorectal/metastatic/1681-colorectal-metastatic-cetuximab-two-weekly"
    },
    {
        "protocol_id": "4111 v.2",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Encorafenib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "7 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "300 mg ONCE a day",
                    "day": "1 to 7",
                    "route": "PO"
                },
                {
                    "drug_name": "Cetuximab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "7 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "400 mg/m2 (loading dose only)*",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Encorafenib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "7 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "300 mg ONCE a day",
                    "day": "1 to 7",
                    "route": "PO"
                },
                {
                    "drug_name": "Cetuximab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "7 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "250 mg/m2 (subsequent doses)*",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Encorafenib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "7 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "300 mg ONCE a day",
                    "day": "1 to 7",
                    "route": "PO"
                },
                {
                    "drug_name": "Cetuximab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "7 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "400 mg/m2 (loading dose only)*",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Encorafenib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "7 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "300 mg ONCE a day",
                    "day": "1 to 7",
                    "route": "PO"
                },
                {
                    "drug_name": "Cetuximab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "7 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "250 mg/m2 (subsequent doses)*",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "colorectal",
        "url": "https://www.eviq.org.au/medical-oncology/colorectal/metastatic/4111-colorectal-metastatic-cetuximab-and-encorafen"
    },
    {
        "protocol_id": "1260 v.7",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Cetuximab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "500 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Irinotecan",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "180 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Cetuximab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "500 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Irinotecan",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "180 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "colorectal",
        "url": "https://www.eviq.org.au/medical-oncology/colorectal/metastatic/1260-colorectal-metastatic-cetuximab-and-irinoteca"
    },
    {
        "protocol_id": "97 v.7",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Calcium folinate (Leucovorin)",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "50 mg *",
                    "day": "1",
                    "route": "IV bolus"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "400 mg/m2",
                    "day": "1",
                    "route": "IV"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "2,400 mg/m2",
                    "day": "1",
                    "route": "CIV via pump over 46 hours **"
                }
            ],
            [
                {
                    "drug_name": "Calcium folinate (Leucovorin)",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "50 mg *",
                    "day": "1",
                    "route": "IV bolus"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "400 mg/m2",
                    "day": "1",
                    "route": "IV"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "2,400 mg/m2",
                    "day": "1",
                    "route": "CIV via pump over 46 hours **"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "colorectal",
        "url": "https://www.eviq.org.au/medical-oncology/colorectal/metastatic/97-colorectal-metastatic-de-gramont-modified-fl"
    },
    {
        "protocol_id": "89 v.10",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "beVACizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "5 mg/kg",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Irinotecan",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "180 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Calcium folinate (Leucovorin)",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "50 mg *",
                    "day": "1",
                    "route": "IV bolus"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "400 mg/m2",
                    "day": "1",
                    "route": "IV"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "2,400 mg/m2",
                    "day": "1",
                    "route": "CIV via pump over 46 hours"
                }
            ],
            [
                {
                    "drug_name": "beVACizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "5 mg/kg",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Irinotecan",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "180 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Calcium folinate (Leucovorin)",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "50 mg *",
                    "day": "1",
                    "route": "IV bolus"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "400 mg/m2",
                    "day": "1",
                    "route": "IV"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "2,400 mg/m2",
                    "day": "1",
                    "route": "CIV via pump over 46 hours"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "colorectal",
        "url": "https://www.eviq.org.au/medical-oncology/colorectal/metastatic/89-colorectal-metastatic-folfiri-modified-fluor"
    },
    {
        "protocol_id": "1682 v.6",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Cetuximab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "500 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Irinotecan",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "180 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Calcium folinate (Leucovorin)",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "50 mg *",
                    "day": "1",
                    "route": "IV bolus"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "400 mg/m2",
                    "day": "1",
                    "route": "IV"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "2,400 mg/m2",
                    "day": "1",
                    "route": "CIV via pump over 46 hours"
                }
            ],
            [
                {
                    "drug_name": "Cetuximab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "500 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Irinotecan",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "180 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Calcium folinate (Leucovorin)",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "50 mg *",
                    "day": "1",
                    "route": "IV bolus"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "400 mg/m2",
                    "day": "1",
                    "route": "IV"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "2,400 mg/m2",
                    "day": "1",
                    "route": "CIV via pump over 46 hours"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "colorectal",
        "url": "https://www.eviq.org.au/medical-oncology/colorectal/metastatic/1682-colorectal-metastatic-folfiri-modified-flu"
    },
    {
        "protocol_id": "1536 v.6",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "pANITUMumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "6 mg/kg",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Irinotecan",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "180 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Calcium folinate (Leucovorin)",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "50 mg *",
                    "day": "1",
                    "route": "IV bolus"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "400 mg/m2",
                    "day": "1",
                    "route": "IV"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "2,400 mg/m2",
                    "day": "1",
                    "route": "CIV via pump over 46 hours"
                }
            ],
            [
                {
                    "drug_name": "pANITUMumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "6 mg/kg",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Irinotecan",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "180 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Calcium folinate (Leucovorin)",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "50 mg *",
                    "day": "1",
                    "route": "IV bolus"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "400 mg/m2",
                    "day": "1",
                    "route": "IV"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "2,400 mg/m2",
                    "day": "1",
                    "route": "CIV via pump over 46 hours"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "colorectal",
        "url": "https://www.eviq.org.au/medical-oncology/colorectal/metastatic/1536-colorectal-metastatic-folfiri-modified-flu"
    },
    {
        "protocol_id": "114 v.10",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Oxaliplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity.",
                    "dose": "85 mg/m2 *",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Calcium folinate (Leucovorin)",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity.",
                    "dose": "50 mg *",
                    "day": "1",
                    "route": "IV bolus"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity.",
                    "dose": "400 mg/m2",
                    "day": "1",
                    "route": "IV"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity.",
                    "dose": "2,400 mg/m2",
                    "day": "1",
                    "route": "CIV via pump over 46 hours"
                }
            ],
            [
                {
                    "drug_name": "Oxaliplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity.",
                    "dose": "85 mg/m2 *",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Calcium folinate (Leucovorin)",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity.",
                    "dose": "50 mg *",
                    "day": "1",
                    "route": "IV bolus"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity.",
                    "dose": "400 mg/m2",
                    "day": "1",
                    "route": "IV"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity.",
                    "dose": "2,400 mg/m2",
                    "day": "1",
                    "route": "CIV via pump over 46 hours"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "colorectal",
        "url": "https://www.eviq.org.au/medical-oncology/colorectal/metastatic/114-colorectal-metastatic-folfox6-modified-fluo"
    },
    {
        "protocol_id": "986 v.12",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "beVACizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "5 mg/kg",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Oxaliplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "85 mg/m2 #",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Calcium folinate (Leucovorin)",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "50 mg *",
                    "day": "1",
                    "route": "IV bolus"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "400 mg/m2",
                    "day": "1",
                    "route": "IV"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "2,400 mg/m2",
                    "day": "1",
                    "route": "CIV via pump over 46 hours"
                }
            ],
            [
                {
                    "drug_name": "beVACizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "5 mg/kg",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Oxaliplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "85 mg/m2 #",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Calcium folinate (Leucovorin)",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "50 mg *",
                    "day": "1",
                    "route": "IV bolus"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "400 mg/m2",
                    "day": "1",
                    "route": "IV"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "2,400 mg/m2",
                    "day": "1",
                    "route": "CIV via pump over 46 hours"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "colorectal",
        "url": "https://www.eviq.org.au/medical-oncology/colorectal/metastatic/986-colorectal-metastatic-folfox6-modified-fluo"
    },
    {
        "protocol_id": "1756 v.7",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Cetuximab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "500 mg/m2 *",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Oxaliplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "85 mg/m2 #",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Calcium folinate (Leucovorin)",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "50 mg #",
                    "day": "1",
                    "route": "IV bolus"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "400 mg/m2",
                    "day": "1",
                    "route": "IV"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "2,400 mg/m2",
                    "day": "1",
                    "route": "CIV via pump over 46 hrs"
                }
            ],
            [
                {
                    "drug_name": "Cetuximab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "500 mg/m2 *",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Oxaliplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "85 mg/m2 #",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Calcium folinate (Leucovorin)",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "50 mg #",
                    "day": "1",
                    "route": "IV bolus"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "400 mg/m2",
                    "day": "1",
                    "route": "IV"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "2,400 mg/m2",
                    "day": "1",
                    "route": "CIV via pump over 46 hrs"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "colorectal",
        "url": "https://www.eviq.org.au/medical-oncology/colorectal/metastatic/1756-colorectal-metastatic-folfox6-modified-flu"
    },
    {
        "protocol_id": "1542 v.8",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "pANITUMumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "6 mg/kg",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Oxaliplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "85 mg/m2 *",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Calcium folinate (Leucovorin)",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "50 mg *",
                    "day": "1",
                    "route": "IV bolus"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "400 mg/m2",
                    "day": "1",
                    "route": "IV"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "2,400 mg/m2",
                    "day": "1",
                    "route": "CIV via pump over 46 hours"
                }
            ],
            [
                {
                    "drug_name": "pANITUMumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "6 mg/kg",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Oxaliplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "85 mg/m2 *",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Calcium folinate (Leucovorin)",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "50 mg *",
                    "day": "1",
                    "route": "IV bolus"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "400 mg/m2",
                    "day": "1",
                    "route": "IV"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "2,400 mg/m2",
                    "day": "1",
                    "route": "CIV via pump over 46 hours"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "colorectal",
        "url": "https://www.eviq.org.au/medical-oncology/colorectal/metastatic/1542-colorectal-metastatic-folfox6-modified-flu"
    },
    {
        "protocol_id": "1534 v.9",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Irinotecan",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "165 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Oxaliplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "85 mg/m2 #",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Calcium folinate (Leucovorin)",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "50 mg *",
                    "day": "1",
                    "route": "IV bolus"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "3,200 mg/m2",
                    "day": "1",
                    "route": "CIV via pump over 48 hours (equivalent to 1600 mg/m2/day)"
                }
            ],
            [
                {
                    "drug_name": "Irinotecan",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "165 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Oxaliplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "85 mg/m2 #",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Calcium folinate (Leucovorin)",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "50 mg *",
                    "day": "1",
                    "route": "IV bolus"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "3,200 mg/m2",
                    "day": "1",
                    "route": "CIV via pump over 48 hours (equivalent to 1600 mg/m2/day)"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "colorectal",
        "url": "https://www.eviq.org.au/medical-oncology/colorectal/metastatic/1534-colorectal-metastatic-folfoxiri-modified-f"
    },
    {
        "protocol_id": "1715 v.10",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "beVACizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "5 mg/kg",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Irinotecan",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "165 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Oxaliplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "85 mg/m2 #",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Calcium folinate (Leucovorin)",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "50 mg *",
                    "day": "1",
                    "route": "IV bolus"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "3,200 mg/m2",
                    "day": "1",
                    "route": "CIV via pump over 48 hours (equivalent to 1600 mg/m2/day)"
                }
            ],
            [
                {
                    "drug_name": "beVACizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "5 mg/kg",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Irinotecan",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "165 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Oxaliplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "85 mg/m2 #",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Calcium folinate (Leucovorin)",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "50 mg *",
                    "day": "1",
                    "route": "IV bolus"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "3,200 mg/m2",
                    "day": "1",
                    "route": "CIV via pump over 48 hours (equivalent to 1600 mg/m2/day)"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "colorectal",
        "url": "https://www.eviq.org.au/medical-oncology/colorectal/metastatic/1715-colorectal-metastatic-folfoxiri-modified-f"
    },
    {
        "protocol_id": "85 v.6",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Irinotecan",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity; maximum 8 cycles",
                    "dose": "350 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Irinotecan",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity; maximum 8 cycles",
                    "dose": "350 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "colorectal",
        "url": "https://www.eviq.org.au/medical-oncology/colorectal/metastatic/85-colorectal-metastatic-irinotecan-three-weekly"
    },
    {
        "protocol_id": "101 v.5",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "pANITUMumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "6 mg/kg",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "pANITUMumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "6 mg/kg",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "colorectal",
        "url": "https://www.eviq.org.au/medical-oncology/colorectal/metastatic/101-colorectal-metastatic-panitumumab"
    },
    {
        "protocol_id": "98 v.6",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Calcium folinate (Leucovorin)",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "7 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "50 mg *",
                    "day": "1",
                    "route": "IV bolus"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "7 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "370 mg/m2",
                    "day": "1",
                    "route": "IV"
                }
            ],
            [
                {
                    "drug_name": "Calcium folinate (Leucovorin)",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "7 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "50 mg *",
                    "day": "1",
                    "route": "IV bolus"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "7 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "370 mg/m2",
                    "day": "1",
                    "route": "IV"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "colorectal",
        "url": "https://www.eviq.org.au/medical-oncology/colorectal/metastatic/98-colorectal-metastatic-quasar-modified-fluorou"
    },
    {
        "protocol_id": "606 v.6",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Raltitrexed",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "3 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Raltitrexed",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "3 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "colorectal",
        "url": "https://www.eviq.org.au/medical-oncology/colorectal/metastatic/606-colorectal-metastatic-raltitrexed"
    },
    {
        "protocol_id": "1544 v.3",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Regorafenib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Until disease progression or unacceptable toxicity",
                    "dose": "160 mg ONCE a day *",
                    "day": "1 to 21 **",
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Regorafenib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Until disease progression or unacceptable toxicity",
                    "dose": "160 mg ONCE a day *",
                    "day": "1 to 21 **",
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "colorectal",
        "url": "https://www.eviq.org.au/medical-oncology/colorectal/metastatic/1544-colorectal-metastatic-regorafenib"
    },
    {
        "protocol_id": "1275 v.5",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Calcium folinate (Leucovorin)",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "56 days(weekly for six weeks followed bya two week break)",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "50 mg *",
                    "day": "1, 8, 15, 22, 29, 36",
                    "route": "IV bolus"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "56 days(weekly for six weeks followed bya two week break)",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "500 mg/m2",
                    "day": "1, 8, 15, 22, 29, 36",
                    "route": "IV"
                }
            ],
            [
                {
                    "drug_name": "Calcium folinate (Leucovorin)",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "56 days(weekly for six weeks followed bya two week break)",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "50 mg *",
                    "day": "1, 8, 15, 22, 29, 36",
                    "route": "IV bolus"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "56 days(weekly for six weeks followed bya two week break)",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "500 mg/m2",
                    "day": "1, 8, 15, 22, 29, 36",
                    "route": "IV"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "colorectal",
        "url": "https://www.eviq.org.au/medical-oncology/colorectal/metastatic/1275-colorectal-metastatic-roswell-park-modified"
    },
    {
        "protocol_id": "86 v.10",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "beVACizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "56 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "5 mg/kg",
                    "day": "1, 15, 29, 43",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Calcium folinate (Leucovorin)",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "56 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "50 mg *",
                    "day": "1, 8, 15, 22, 29, 36",
                    "route": "IV bolus"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "56 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "500 mg/m2",
                    "day": "1, 8, 15, 22, 29, 36",
                    "route": "IV"
                }
            ],
            [
                {
                    "drug_name": "beVACizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "56 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "5 mg/kg",
                    "day": "1, 15, 29, 43",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Calcium folinate (Leucovorin)",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "56 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "50 mg *",
                    "day": "1, 8, 15, 22, 29, 36",
                    "route": "IV bolus"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "56 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "500 mg/m2",
                    "day": "1, 8, 15, 22, 29, 36",
                    "route": "IV"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "colorectal",
        "url": "https://www.eviq.org.au/medical-oncology/colorectal/metastatic/86-colorectal-metastatic-roswell-park-modified-f"
    },
    {
        "protocol_id": "4324 v.2",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Raltitrexed",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity; usually 6 cycles",
                    "dose": "3 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Oxaliplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity; usually 6 cycles",
                    "dose": "130 mg/m2 #",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Raltitrexed",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity; usually 6 cycles",
                    "dose": "3 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Oxaliplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity; usually 6 cycles",
                    "dose": "130 mg/m2 #",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "colorectal",
        "url": "https://www.eviq.org.au/medical-oncology/colorectal/metastatic/4324-colorectal-metastatic-tomox-raltitrexed-and"
    },
    {
        "protocol_id": "3806 v.2",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Trifluridine/tipiracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "35 mg/m2 TWICE a day *\n                            \n                                (Cap dose at 80 mg)",
                    "day": "1 to 5 and 8 to 12",
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Trifluridine/tipiracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "35 mg/m2 TWICE a day *\n                            \n                                (Cap dose at 80 mg)",
                    "day": "1 to 5 and 8 to 12",
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "colorectal",
        "url": "https://www.eviq.org.au/medical-oncology/colorectal/metastatic/1940-redirect-id-3806"
    },
    {
        "protocol_id": "1567 v.7",
        "protocol_status": "Superseded",
        "drug_sequence": [
            [
                {
                    "drug_name": "Cetuximab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "400 mg/m2 (loading dose only)",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Cetuximab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "250 mg/m2 (subsequent doses)",
                    "day": "8",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Irinotecan",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "180 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Cetuximab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "250 mg/m2",
                    "day": "1 and 8",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Irinotecan",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "180 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Cetuximab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "400 mg/m2 (loading dose only)",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Cetuximab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "250 mg/m2 (subsequent doses)",
                    "day": "8",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Irinotecan",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "180 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Cetuximab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "250 mg/m2",
                    "day": "1 and 8",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Irinotecan",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "180 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "colorectal",
        "url": "https://www.eviq.org.au/medical-oncology/colorectal/metastatic/1567-colorectal-metastatic-cetuximab-weekly-and"
    },
    {
        "protocol_id": "825 v.7",
        "protocol_status": "Superseded",
        "drug_sequence": [
            [
                {
                    "drug_name": "Cetuximab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "7 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "400 mg/m2 (loading dose only)",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Cetuximab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "7 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "250 mg/m2 (subsequent doses)",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Cetuximab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "7 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "400 mg/m2 (loading dose only)",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Cetuximab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "7 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "250 mg/m2 (subsequent doses)",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "colorectal",
        "url": "https://www.eviq.org.au/medical-oncology/colorectal/metastatic/825-colorectal-metastatic-cetuximab-superseded"
    },
    {
        "protocol_id": "96 v.6",
        "protocol_status": "Superseded",
        "drug_sequence": [
            [
                {
                    "drug_name": "Calcium folinate (Leucovorin)",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "200 mg/m2 *",
                    "day": "1 and 2",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "400 mg/m2",
                    "day": "1 and 2",
                    "route": "IV"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "600 mg/m2",
                    "day": "1 and 2",
                    "route": "CIV via pump over 22 hours"
                }
            ],
            [
                {
                    "drug_name": "Calcium folinate (Leucovorin)",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "200 mg/m2 *",
                    "day": "1 and 2",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "400 mg/m2",
                    "day": "1 and 2",
                    "route": "IV"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "600 mg/m2",
                    "day": "1 and 2",
                    "route": "CIV via pump over 22 hours"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "colorectal",
        "url": "https://www.eviq.org.au/medical-oncology/colorectal/metastatic/96-colorectal-metastatic-de-gramont-fluorouracil"
    },
    {
        "protocol_id": "1212 v.8",
        "protocol_status": "Superseded",
        "drug_sequence": [
            [
                {
                    "drug_name": "Cetuximab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "400 mg/m2 (loading dose only)",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Irinotecan",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "180 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Calcium folinate (Leucovorin)",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "50 mg *",
                    "day": "1",
                    "route": "IV bolus"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "400 mg/m2",
                    "day": "1",
                    "route": "IV"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "2,400 mg/m2",
                    "day": "1",
                    "route": "CIV via pump over 46 hours"
                },
                {
                    "drug_name": "Cetuximab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "250 mg/m2 (subsequent doses)",
                    "day": "8",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Cetuximab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "250 mg/m2",
                    "day": "1 and 8",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Irinotecan",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "180 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Calcium folinate (Leucovorin)",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "50 mg *",
                    "day": "1",
                    "route": "IV bolus"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "400 mg/m2",
                    "day": "1",
                    "route": "IV"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "2,400 mg/m2",
                    "day": "1",
                    "route": "CIV via pump over 46 hours"
                }
            ],
            [
                {
                    "drug_name": "Cetuximab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "400 mg/m2 (loading dose only)",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Irinotecan",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "180 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Calcium folinate (Leucovorin)",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "50 mg *",
                    "day": "1",
                    "route": "IV bolus"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "400 mg/m2",
                    "day": "1",
                    "route": "IV"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "2,400 mg/m2",
                    "day": "1",
                    "route": "CIV via pump over 46 hours"
                },
                {
                    "drug_name": "Cetuximab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "250 mg/m2 (subsequent doses)",
                    "day": "8",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Cetuximab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "250 mg/m2",
                    "day": "1 and 8",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Irinotecan",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "180 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Calcium folinate (Leucovorin)",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "50 mg *",
                    "day": "1",
                    "route": "IV bolus"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "400 mg/m2",
                    "day": "1",
                    "route": "IV"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "2,400 mg/m2",
                    "day": "1",
                    "route": "CIV via pump over 46 hours"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "colorectal",
        "url": "https://www.eviq.org.au/medical-oncology/colorectal/metastatic/1212-colorectal-metastatic-folfiri-modified-flu"
    },
    {
        "protocol_id": "115 v.8",
        "protocol_status": "Superseded",
        "drug_sequence": [
            [
                {
                    "drug_name": "Oxaliplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "100 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Calcium folinate (Leucovorin)",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "200 mg/m2 *",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "400 mg/m2",
                    "day": "1",
                    "route": "IV"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "2,400 mg/m2",
                    "day": "1",
                    "route": "CIV via pump over 46 hours"
                }
            ],
            [
                {
                    "drug_name": "Oxaliplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "100 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Calcium folinate (Leucovorin)",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "200 mg/m2 *",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "400 mg/m2",
                    "day": "1",
                    "route": "IV"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "2,400 mg/m2",
                    "day": "1",
                    "route": "CIV via pump over 46 hours"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "colorectal",
        "url": "https://www.eviq.org.au/medical-oncology/colorectal/metastatic/115-colorectal-metastatic-folfox6-fluorouracil-le"
    },
    {
        "protocol_id": "83 v.6",
        "protocol_status": "Superseded",
        "drug_sequence": [
            [
                {
                    "drug_name": "Irinotecan",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "42 days(this regimen is given weekly for four weeks, then a two week break before commencing next cycle i.e. cycle length = 42 days)",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "125 mg/m2",
                    "day": "1, 8, 15, 22",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Irinotecan",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "42 days(this regimen is given weekly for four weeks, then a two week break before commencing next cycle i.e. cycle length = 42 days)",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "125 mg/m2",
                    "day": "1, 8, 15, 22",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "colorectal",
        "url": "https://www.eviq.org.au/medical-oncology/colorectal/metastatic/83-colorectal-metastatic-irinotecan-weekly-superse"
    },
    {
        "protocol_id": "1383 v.5",
        "protocol_status": "Discontinued",
        "drug_sequence": [],
        "section_name": "medical-oncology",
        "category_name": "colorectal",
        "url": "https://www.eviq.org.au/medical-oncology/colorectal/metastatic/1383-colorectal-metastatic-capecitabine-and-mitomy"
    },
    {
        "protocol_id": "95 v.5",
        "protocol_status": "Discontinued",
        "drug_sequence": [],
        "section_name": "medical-oncology",
        "category_name": "colorectal",
        "url": "https://www.eviq.org.au/medical-oncology/colorectal/metastatic/95-colorectal-metastatic-cetuximab-and-irinotecan"
    },
    {
        "protocol_id": "87 v.7",
        "protocol_status": "Discontinued",
        "drug_sequence": [],
        "section_name": "medical-oncology",
        "category_name": "colorectal",
        "url": "https://www.eviq.org.au/medical-oncology/colorectal/metastatic/87-colorectal-metastatic-folfiri-fluorouracil-leu"
    },
    {
        "protocol_id": "1213 v.4",
        "protocol_status": "Discontinued",
        "drug_sequence": [],
        "section_name": "medical-oncology",
        "category_name": "colorectal",
        "url": "https://www.eviq.org.au/medical-oncology/colorectal/metastatic/1213-colorectal-metastatic-folfiri-fluorouracil-l"
    },
    {
        "protocol_id": "93 v.5",
        "protocol_status": "Discontinued",
        "drug_sequence": [],
        "section_name": "medical-oncology",
        "category_name": "colorectal",
        "url": "https://www.eviq.org.au/medical-oncology/colorectal/metastatic/93-colorectal-metastatic-folfiri-fluorouracil-leu"
    },
    {
        "protocol_id": "1533 v.3",
        "protocol_status": "Discontinued",
        "drug_sequence": [],
        "section_name": "medical-oncology",
        "category_name": "colorectal",
        "url": "https://www.eviq.org.au/medical-oncology/colorectal/metastatic/1533-colorectal-metastatic-folfiri-mod-fluorour"
    },
    {
        "protocol_id": "596 v.7",
        "protocol_status": "Discontinued",
        "drug_sequence": [],
        "section_name": "medical-oncology",
        "category_name": "colorectal",
        "url": "https://www.eviq.org.au/medical-oncology/colorectal/metastatic/596-colorectal-metastatic-folfox4-fluorouracil-le"
    },
    {
        "protocol_id": "102 v.6",
        "protocol_status": "Discontinued",
        "drug_sequence": [],
        "section_name": "medical-oncology",
        "category_name": "colorectal",
        "url": "https://www.eviq.org.au/medical-oncology/colorectal/metastatic/102-colorectal-metastatic-folfox4-fluorouracil-le"
    },
    {
        "protocol_id": "107 v.6",
        "protocol_status": "Discontinued",
        "drug_sequence": [],
        "section_name": "medical-oncology",
        "category_name": "colorectal",
        "url": "https://www.eviq.org.au/medical-oncology/colorectal/metastatic/107-colorectal-metastatic-folfox4-modified-fluo"
    },
    {
        "protocol_id": "1535 v.2",
        "protocol_status": "Discontinued",
        "drug_sequence": [],
        "section_name": "medical-oncology",
        "category_name": "colorectal",
        "url": "https://www.eviq.org.au/medical-oncology/colorectal/metastatic/1535-colorectal-metastatic-irinotecan-and-panitumu"
    },
    {
        "protocol_id": "118 v.3",
        "protocol_status": "Discontinued",
        "drug_sequence": [],
        "section_name": "medical-oncology",
        "category_name": "colorectal",
        "url": "https://www.eviq.org.au/medical-oncology/colorectal/metastatic/118-colorectal-metastatic-mayo-fluorouracil-and-l"
    },
    {
        "protocol_id": "3621 v.3",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "PACLitaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "6unless disease progression or unacceptable toxicity",
                    "dose": "80 mg/m2",
                    "day": "1, 8, 15",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "6unless disease progression or unacceptable toxicity",
                    "dose": "5 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "PACLitaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "6unless disease progression or unacceptable toxicity",
                    "dose": "80 mg/m2",
                    "day": "1, 8, 15",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "6unless disease progression or unacceptable toxicity",
                    "dose": "5 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "colorectal",
        "url": "https://www.eviq.org.au/medical-oncology/colorectal/anal/3621-anal-advanced-carboplatin-and-paclitaxel"
    },
    {
        "protocol_id": "81 v.7",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": "1with concurrent radiation therapy",
                    "dose": "60 mg/m2",
                    "day": "1 and 29",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": "1with concurrent radiation therapy",
                    "dose": "4,000 mg/m2 (equivalent to 1000 mg/m2/day)",
                    "day": "1 and 29",
                    "route": "CIV via pump over 96 hours"
                }
            ],
            [
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": "1with concurrent radiation therapy",
                    "dose": "60 mg/m2",
                    "day": "1 and 29",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": "1with concurrent radiation therapy",
                    "dose": "4,000 mg/m2 (equivalent to 1000 mg/m2/day)",
                    "day": "1 and 29",
                    "route": "CIV via pump over 96 hours"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "colorectal",
        "url": "https://www.eviq.org.au/medical-oncology/colorectal/anal/81-anal-definitive-cisplatin-and-fluorouracil-chem"
    },
    {
        "protocol_id": "1959 v.5",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Mitomycin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": "1with concurrent radiation therapy",
                    "dose": "12 mg/m2\n(Cap dose at 20 mg)",
                    "day": "1",
                    "route": "IV"
                },
                {
                    "drug_name": "Capecitabine *",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": "1with concurrent radiation therapy",
                    "dose": "825 mg/m2 TWICE a day",
                    "day": "1 to 5, 8 to 12, 15 to 19, 22 to 26, 29 to 33, 36 to 40",
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Mitomycin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": "1with concurrent radiation therapy",
                    "dose": "12 mg/m2\n(Cap dose at 20 mg)",
                    "day": "1",
                    "route": "IV"
                },
                {
                    "drug_name": "Capecitabine *",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": "1with concurrent radiation therapy",
                    "dose": "825 mg/m2 TWICE a day",
                    "day": "1 to 5, 8 to 12, 15 to 19, 22 to 26, 29 to 33, 36 to 40",
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "colorectal",
        "url": "https://www.eviq.org.au/medical-oncology/colorectal/anal/1959-anal-definitive-mitomycin-and-capecitabine-ch"
    },
    {
        "protocol_id": "82 v.7",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Mitomycin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": "1with concurrent radiation therapy",
                    "dose": "12 mg/m2\n(Cap dose at 20 mg)",
                    "day": "1 *",
                    "route": "IV"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": "1with concurrent radiation therapy",
                    "dose": "4,000 mg/m2 (equivalent to 1000 mg/m2/day)",
                    "day": "1 and 29",
                    "route": "CIV via pump over 96 hours"
                }
            ],
            [
                {
                    "drug_name": "Mitomycin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": "1with concurrent radiation therapy",
                    "dose": "12 mg/m2\n(Cap dose at 20 mg)",
                    "day": "1 *",
                    "route": "IV"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": "1with concurrent radiation therapy",
                    "dose": "4,000 mg/m2 (equivalent to 1000 mg/m2/day)",
                    "day": "1 and 29",
                    "route": "CIV via pump over 96 hours"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "colorectal",
        "url": "https://www.eviq.org.au/medical-oncology/colorectal/anal/82-anal-definitive-mitomycin-and-fluorouracil-chem"
    },
    {
        "protocol_id": "4019 v.6",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Oxaliplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "8",
                    "dose": "130 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Capecitabine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "8",
                    "dose": "1,000 mg/m2 TWICE a day *",
                    "day": "1 to 14",
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Oxaliplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "8",
                    "dose": "130 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Capecitabine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "8",
                    "dose": "1,000 mg/m2 TWICE a day *",
                    "day": "1 to 14",
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "colorectal",
        "url": "https://www.eviq.org.au/medical-oncology/colorectal/rectal/4020-redirect-id-4019"
    },
    {
        "protocol_id": "3974 v.3",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Oxaliplatin",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "8",
                    "dose": "85 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Calcium folinate (Leucovorin)",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "8",
                    "dose": "50 mg *",
                    "day": "1",
                    "route": "IV bolus"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "8",
                    "dose": "400 mg/m2",
                    "day": "1",
                    "route": "IV"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "8",
                    "dose": "2,400 mg/m2",
                    "day": "1",
                    "route": "CIV via pump over 46 hours"
                }
            ],
            [
                {
                    "drug_name": "Oxaliplatin",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "8",
                    "dose": "85 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Calcium folinate (Leucovorin)",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "8",
                    "dose": "50 mg *",
                    "day": "1",
                    "route": "IV bolus"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "8",
                    "dose": "400 mg/m2",
                    "day": "1",
                    "route": "IV"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "8",
                    "dose": "2,400 mg/m2",
                    "day": "1",
                    "route": "CIV via pump over 46 hours"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "colorectal",
        "url": "https://www.eviq.org.au/medical-oncology/colorectal/rectal/3974-rectal-adjuvant-folfox6-modified-fluoroura"
    },
    {
        "protocol_id": "84 v.7",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Capecitabine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "7 days",
                    "cycles": "Continuous with concurrent radiation therapy (usually for 5 to 6 weeks)",
                    "dose": "825 mg/m2 TWICE a day *",
                    "day": "1 to 5",
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Capecitabine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "7 days",
                    "cycles": "Continuous with concurrent radiation therapy (usually for 5 to 6 weeks)",
                    "dose": "825 mg/m2 TWICE a day *",
                    "day": "1 to 5",
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "colorectal",
        "url": "https://www.eviq.org.au/medical-oncology/colorectal/rectal/84-rectal-locally-advanced-capecitabine-chemoradia"
    },
    {
        "protocol_id": "73 v.7",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "7 days",
                    "cycles": "Continuous with concurrent radiation therapy (usually 5 to 6 weeks)",
                    "dose": "1,575 mg/m2 (equivalent to 225 mg/m2/day)",
                    "day": "1",
                    "route": "CIV via pump over 7 days"
                }
            ],
            [
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "7 days",
                    "cycles": "Continuous with concurrent radiation therapy (usually 5 to 6 weeks)",
                    "dose": "1,575 mg/m2 (equivalent to 225 mg/m2/day)",
                    "day": "1",
                    "route": "CIV via pump over 7 days"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "colorectal",
        "url": "https://www.eviq.org.au/medical-oncology/colorectal/rectal/73-rectal-locally-advanced-fluorouracil-protracte"
    },
    {
        "protocol_id": "3930 v.3",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Oxaliplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "6(after pre-operative short-course external beam radiation therapy)",
                    "dose": "130 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Capecitabine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "6(after pre-operative short-course external beam radiation therapy)",
                    "dose": "1,000 mg/m2 TWICE a day *",
                    "day": "1 to 14",
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Oxaliplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "6(after pre-operative short-course external beam radiation therapy)",
                    "dose": "130 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Capecitabine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "6(after pre-operative short-course external beam radiation therapy)",
                    "dose": "1,000 mg/m2 TWICE a day *",
                    "day": "1 to 14",
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "colorectal",
        "url": "https://www.eviq.org.au/medical-oncology/colorectal/rectal/3930-rectal-neoadjuvant-capox-xelox-capecitabin"
    },
    {
        "protocol_id": "4076 v.4",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Oxaliplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "14 days",
                    "cycles": "6",
                    "dose": "85 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Irinotecan",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "14 days",
                    "cycles": "6",
                    "dose": "180 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Calcium folinate (Leucovorin)",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "14 days",
                    "cycles": "6",
                    "dose": "50 mg *",
                    "day": "1",
                    "route": "IV bolus"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "14 days",
                    "cycles": "6",
                    "dose": "2,400 mg/m2",
                    "day": "1",
                    "route": "CIV via pump over 46 hours"
                },
                {
                    "drug_name": "Pegfilgrastim",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "14 days",
                    "cycles": "6",
                    "dose": "6 mg",
                    "day": "4",
                    "route": "Subcut"
                }
            ],
            [
                {
                    "drug_name": "Oxaliplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "14 days",
                    "cycles": "6",
                    "dose": "85 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Irinotecan",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "14 days",
                    "cycles": "6",
                    "dose": "180 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Calcium folinate (Leucovorin)",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "14 days",
                    "cycles": "6",
                    "dose": "50 mg *",
                    "day": "1",
                    "route": "IV bolus"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "14 days",
                    "cycles": "6",
                    "dose": "2,400 mg/m2",
                    "day": "1",
                    "route": "CIV via pump over 46 hours"
                },
                {
                    "drug_name": "Pegfilgrastim",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "14 days",
                    "cycles": "6",
                    "dose": "6 mg",
                    "day": "4",
                    "route": "Subcut"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "colorectal",
        "url": "https://www.eviq.org.au/medical-oncology/colorectal/rectal/4076-rectal-neoadjuvant-folfirinox-modified"
    },
    {
        "protocol_id": "3931 v.3",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Oxaliplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "14 days",
                    "cycles": "9(after pre-operative short-course external beam radiation therapy)",
                    "dose": "85 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Calcium folinate (Leucovorin)",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "14 days",
                    "cycles": "9(after pre-operative short-course external beam radiation therapy)",
                    "dose": "50 mg *",
                    "day": "1",
                    "route": "IV bolus"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "14 days",
                    "cycles": "9(after pre-operative short-course external beam radiation therapy)",
                    "dose": "400 mg/m2",
                    "day": "1",
                    "route": "IV"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "14 days",
                    "cycles": "9(after pre-operative short-course external beam radiation therapy)",
                    "dose": "2,400 mg/m2 **",
                    "day": "1",
                    "route": "CIV via pump over 46 hours"
                }
            ],
            [
                {
                    "drug_name": "Oxaliplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "14 days",
                    "cycles": "9(after pre-operative short-course external beam radiation therapy)",
                    "dose": "85 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Calcium folinate (Leucovorin)",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "14 days",
                    "cycles": "9(after pre-operative short-course external beam radiation therapy)",
                    "dose": "50 mg *",
                    "day": "1",
                    "route": "IV bolus"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "14 days",
                    "cycles": "9(after pre-operative short-course external beam radiation therapy)",
                    "dose": "400 mg/m2",
                    "day": "1",
                    "route": "IV"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "14 days",
                    "cycles": "9(after pre-operative short-course external beam radiation therapy)",
                    "dose": "2,400 mg/m2 **",
                    "day": "1",
                    "route": "CIV via pump over 46 hours"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "colorectal",
        "url": "https://www.eviq.org.au/medical-oncology/colorectal/rectal/3931-rectal-neoadjuvant-folfox6-modified-fluoro"
    },
    {
        "protocol_id": "4019 v.6",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Oxaliplatin",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "8",
                    "dose": "130 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Capecitabine",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "8",
                    "dose": "1,000 mg/m2 TWICE a day *",
                    "day": "1 to 14",
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Oxaliplatin",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "8",
                    "dose": "130 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Capecitabine",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "8",
                    "dose": "1,000 mg/m2 TWICE a day *",
                    "day": "1 to 14",
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "colorectal",
        "url": "https://www.eviq.org.au/medical-oncology/colorectal/adjuvant-and-neoadjuvant/4019-adjuvant-capox-xelox-capecitabine-and-oxal"
    },
    {
        "protocol_id": "74 v.7",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Capecitabine",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "8",
                    "dose": "1,250 mg/m2 TWICE a day *",
                    "day": "1 to 14",
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Capecitabine",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "8",
                    "dose": "1,250 mg/m2 TWICE a day *",
                    "day": "1 to 14",
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "colorectal",
        "url": "https://www.eviq.org.au/medical-oncology/colorectal/adjuvant-and-neoadjuvant/74-colorectal-adjuvant-capecitabine"
    },
    {
        "protocol_id": "76 v.8",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Calcium folinate (Leucovorin)",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "12",
                    "dose": "50 mg *",
                    "day": "1",
                    "route": "IV bolus"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "12",
                    "dose": "400 mg/m2",
                    "day": "1",
                    "route": "IV"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "12",
                    "dose": "2,400 mg/m2",
                    "day": "1",
                    "route": "CIV via pump over 46 hours**"
                }
            ],
            [
                {
                    "drug_name": "Calcium folinate (Leucovorin)",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "12",
                    "dose": "50 mg *",
                    "day": "1",
                    "route": "IV bolus"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "12",
                    "dose": "400 mg/m2",
                    "day": "1",
                    "route": "IV"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "12",
                    "dose": "2,400 mg/m2",
                    "day": "1",
                    "route": "CIV via pump over 46 hours**"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "colorectal",
        "url": "https://www.eviq.org.au/medical-oncology/colorectal/adjuvant-and-neoadjuvant/76-colorectal-adjuvant-de-gramont-modified-fluo"
    },
    {
        "protocol_id": "637 v.11",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Oxaliplatin",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "12",
                    "dose": "85 mg/m2 *",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Calcium folinate (Leucovorin)",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "12",
                    "dose": "50 mg *",
                    "day": "1",
                    "route": "IV bolus"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "12",
                    "dose": "400 mg/m2",
                    "day": "1",
                    "route": "IV"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "12",
                    "dose": "2,400 mg/m2",
                    "day": "1",
                    "route": "CIV via pump over 46 hours"
                }
            ],
            [
                {
                    "drug_name": "Oxaliplatin",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "12",
                    "dose": "85 mg/m2 *",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Calcium folinate (Leucovorin)",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "12",
                    "dose": "50 mg *",
                    "day": "1",
                    "route": "IV bolus"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "12",
                    "dose": "400 mg/m2",
                    "day": "1",
                    "route": "IV"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "12",
                    "dose": "2,400 mg/m2",
                    "day": "1",
                    "route": "CIV via pump over 46 hours"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "colorectal",
        "url": "https://www.eviq.org.au/medical-oncology/colorectal/adjuvant-and-neoadjuvant/637-colorectal-adjuvant-folfox6-modified-fluoro"
    },
    {
        "protocol_id": "1494 v.7",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Calcium folinate (Leucovorin)",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "7 days",
                    "cycles": "30",
                    "dose": "50 mg *",
                    "day": "1",
                    "route": "IV bolus"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "7 days",
                    "cycles": "30",
                    "dose": "370 mg/m2",
                    "day": "1",
                    "route": "IV"
                }
            ],
            [
                {
                    "drug_name": "Calcium folinate (Leucovorin)",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "7 days",
                    "cycles": "30",
                    "dose": "50 mg *",
                    "day": "1",
                    "route": "IV bolus"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "7 days",
                    "cycles": "30",
                    "dose": "370 mg/m2",
                    "day": "1",
                    "route": "IV"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "colorectal",
        "url": "https://www.eviq.org.au/medical-oncology/colorectal/adjuvant-and-neoadjuvant/1494-colorectal-adjuvant-quasar-modified-fluorou"
    },
    {
        "protocol_id": "1271 v.6",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Calcium folinate (Leucovorin)",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "56 days(weekly for six weeks followed by a two week break)",
                    "cycles": "3",
                    "dose": "50 mg *",
                    "day": "1, 8, 15, 22, 29, 36",
                    "route": "IV bolus"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "56 days(weekly for six weeks followed by a two week break)",
                    "cycles": "3",
                    "dose": "500 mg/m2",
                    "day": "1, 8, 15, 22, 29, 36",
                    "route": "IV"
                }
            ],
            [
                {
                    "drug_name": "Calcium folinate (Leucovorin)",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "56 days(weekly for six weeks followed by a two week break)",
                    "cycles": "3",
                    "dose": "50 mg *",
                    "day": "1, 8, 15, 22, 29, 36",
                    "route": "IV bolus"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "56 days(weekly for six weeks followed by a two week break)",
                    "cycles": "3",
                    "dose": "500 mg/m2",
                    "day": "1, 8, 15, 22, 29, 36",
                    "route": "IV"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "colorectal",
        "url": "https://www.eviq.org.au/medical-oncology/colorectal/adjuvant-and-neoadjuvant/1271-colorectal-adjuvant-roswell-park-modified-f"
    },
    {
        "protocol_id": "75 v.7",
        "protocol_status": "Superseded",
        "drug_sequence": [
            [
                {
                    "drug_name": "Calcium folinate (Leucovorin)",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "12",
                    "dose": "200 mg/m2 *",
                    "day": "1 and 2",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "12",
                    "dose": "400 mg/m2",
                    "day": "1 and 2",
                    "route": "IV"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "12",
                    "dose": "600 mg/m2",
                    "day": "1 and 2",
                    "route": "CIV via pump over 22 hours"
                }
            ],
            [
                {
                    "drug_name": "Calcium folinate (Leucovorin)",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "12",
                    "dose": "200 mg/m2 *",
                    "day": "1 and 2",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "12",
                    "dose": "400 mg/m2",
                    "day": "1 and 2",
                    "route": "IV"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "12",
                    "dose": "600 mg/m2",
                    "day": "1 and 2",
                    "route": "CIV via pump over 22 hours"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "colorectal",
        "url": "https://www.eviq.org.au/medical-oncology/colorectal/adjuvant-and-neoadjuvant/75-colorectal-adjuvant-de-gramont-fluorouracil-an"
    },
    {
        "protocol_id": "77 v.9",
        "protocol_status": "Superseded",
        "drug_sequence": [
            [
                {
                    "drug_name": "Oxaliplatin",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "56 days",
                    "cycles": "3",
                    "dose": "85 mg/m2",
                    "day": "1, 15, 29",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Calcium folinate (Leucovorin)",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "56 days",
                    "cycles": "3",
                    "dose": "50 mg *",
                    "day": "1, 8, 15, 22, 29, 36",
                    "route": "IV bolus"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "56 days",
                    "cycles": "3",
                    "dose": "500 mg/m2",
                    "day": "1, 8, 15, 22, 29, 36",
                    "route": "IV"
                }
            ],
            [
                {
                    "drug_name": "Oxaliplatin",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "56 days",
                    "cycles": "3",
                    "dose": "85 mg/m2",
                    "day": "1, 15, 29",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Calcium folinate (Leucovorin)",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "56 days",
                    "cycles": "3",
                    "dose": "50 mg *",
                    "day": "1, 8, 15, 22, 29, 36",
                    "route": "IV bolus"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "56 days",
                    "cycles": "3",
                    "dose": "500 mg/m2",
                    "day": "1, 8, 15, 22, 29, 36",
                    "route": "IV"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "colorectal",
        "url": "https://www.eviq.org.au/medical-oncology/colorectal/adjuvant-and-neoadjuvant/77-colorectal-adjuvant-flox-fluorouracil-leucovor"
    },
    {
        "protocol_id": "78 v.10",
        "protocol_status": "Discontinued",
        "drug_sequence": [],
        "section_name": "medical-oncology",
        "category_name": "colorectal",
        "url": "https://www.eviq.org.au/medical-oncology/colorectal/adjuvant-and-neoadjuvant/78-colorectal-adjuvant-folfox4-fluorouracil-leuco"
    },
    {
        "protocol_id": "17 v.8",
        "protocol_status": "Discontinued",
        "drug_sequence": [],
        "section_name": "medical-oncology",
        "category_name": "colorectal",
        "url": "https://www.eviq.org.au/medical-oncology/colorectal/adjuvant-and-neoadjuvant/17-colorectal-adjuvant-folfox4-modified-fluorou"
    },
    {
        "protocol_id": "79 v.3",
        "protocol_status": "Discontinued",
        "drug_sequence": [],
        "section_name": "medical-oncology",
        "category_name": "colorectal",
        "url": "https://www.eviq.org.au/medical-oncology/colorectal/adjuvant-and-neoadjuvant/79-colorectal-adjuvant-mayo-fluorouracil-and-leuc"
    },
    {
        "protocol_id": "4043 v.2",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Irinotecan",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "180 mg/m2 *",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Calcium folinate (Leucovorin)",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "50 mg **",
                    "day": "1",
                    "route": "IV bolus"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "400 mg/m2",
                    "day": "1",
                    "route": "IV"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "2,400 mg/m2",
                    "day": "1",
                    "route": "CIV via pump over 46 hours"
                }
            ],
            [
                {
                    "drug_name": "Irinotecan",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "180 mg/m2 *",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Calcium folinate (Leucovorin)",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "50 mg **",
                    "day": "1",
                    "route": "IV bolus"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "400 mg/m2",
                    "day": "1",
                    "route": "IV"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "2,400 mg/m2",
                    "day": "1",
                    "route": "CIV via pump over 46 hours"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "colorectal",
        "url": "https://www.eviq.org.au/medical-oncology/colorectal/metastatic/99-redirect-id-4043"
    },
    {
        "protocol_id": "3840 v.9",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Pembrolizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (see Indications and patient population section)",
                    "dose": "200 mg *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Pembrolizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (see Indications and patient population section)",
                    "dose": "200 mg *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "colorectal",
        "url": "https://www.eviq.org.au/medical-oncology/colorectal/metastatic/3991-redirect-id-3840"
    },
    {
        "protocol_id": "94 v.6",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Capecitabine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "1,250 mg/m2 TWICE a day *",
                    "day": "1 to 14",
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Capecitabine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "1,250 mg/m2 TWICE a day *",
                    "day": "1 to 14",
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "colorectal",
        "url": "https://www.eviq.org.au/medical-oncology/colorectal/metastatic/94-colorectal-metastatic-capecitabine"
    },
    {
        "protocol_id": "1175 v.10",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "beVACizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "7.5 mg/kg",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Capecitabine *",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "1,250 mg/m2 TWICE a day",
                    "day": "1 to 14",
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "beVACizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "7.5 mg/kg",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Capecitabine *",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "1,250 mg/m2 TWICE a day",
                    "day": "1 to 14",
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "colorectal",
        "url": "https://www.eviq.org.au/medical-oncology/colorectal/metastatic/1175-colorectal-metastatic-capecitabine-and-bevaci"
    },
    {
        "protocol_id": "1243 v.6",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Irinotecan",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "240 mg/m2 *",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Capecitabine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "1,000 mg/m2 TWICE a day **",
                    "day": "1 to 14",
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Irinotecan",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "240 mg/m2 *",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Capecitabine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "1,000 mg/m2 TWICE a day **",
                    "day": "1 to 14",
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "colorectal",
        "url": "https://www.eviq.org.au/medical-oncology/colorectal/metastatic/1243-colorectal-metastatic-capiri-xeliri-capeci"
    },
    {
        "protocol_id": "1184 v.9",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "beVACizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "7.5 mg/kg",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Irinotecan",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "240 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Capecitabine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "1,000 mg/m2 TWICE a day *",
                    "day": "1 to 14",
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "beVACizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "7.5 mg/kg",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Irinotecan",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "240 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Capecitabine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "1,000 mg/m2 TWICE a day *",
                    "day": "1 to 14",
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "colorectal",
        "url": "https://www.eviq.org.au/medical-oncology/colorectal/metastatic/1184-colorectal-metastatic-capiri-xeliri-capeci"
    },
    {
        "protocol_id": "117 v.10",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Oxaliplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity; usually 6 cycles",
                    "dose": "130 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Capecitabine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity; usually 6 cycles",
                    "dose": "1,000 mg/m2 TWICE a day *",
                    "day": "1 to 14",
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Oxaliplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity; usually 6 cycles",
                    "dose": "130 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Capecitabine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity; usually 6 cycles",
                    "dose": "1,000 mg/m2 TWICE a day *",
                    "day": "1 to 14",
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "colorectal",
        "url": "https://www.eviq.org.au/medical-oncology/colorectal/metastatic/117-colorectal-metastatic-capox-xelox-capecitab"
    },
    {
        "protocol_id": "1180 v.13",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "beVACizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6or until disease progression or unacceptable toxicity. Consider continuation with capecitabine and bevacizumab; oxaliplatin may be reintroduced at a later date.",
                    "dose": "7.5 mg/kg",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Oxaliplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6or until disease progression or unacceptable toxicity. Consider continuation with capecitabine and bevacizumab; oxaliplatin may be reintroduced at a later date.",
                    "dose": "130 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Capecitabine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6or until disease progression or unacceptable toxicity. Consider continuation with capecitabine and bevacizumab; oxaliplatin may be reintroduced at a later date.",
                    "dose": "1,000 mg/m2 TWICE a day *",
                    "day": "1 to 14",
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "beVACizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6or until disease progression or unacceptable toxicity. Consider continuation with capecitabine and bevacizumab; oxaliplatin may be reintroduced at a later date.",
                    "dose": "7.5 mg/kg",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Oxaliplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6or until disease progression or unacceptable toxicity. Consider continuation with capecitabine and bevacizumab; oxaliplatin may be reintroduced at a later date.",
                    "dose": "130 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Capecitabine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6or until disease progression or unacceptable toxicity. Consider continuation with capecitabine and bevacizumab; oxaliplatin may be reintroduced at a later date.",
                    "dose": "1,000 mg/m2 TWICE a day *",
                    "day": "1 to 14",
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "colorectal",
        "url": "https://www.eviq.org.au/medical-oncology/colorectal/metastatic/1180-colorectal-metastatic-capox-xelox-capecita"
    },
    {
        "protocol_id": "1681 v.5",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Cetuximab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "500 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Cetuximab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "500 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "colorectal",
        "url": "https://www.eviq.org.au/medical-oncology/colorectal/metastatic/1681-colorectal-metastatic-cetuximab-two-weekly"
    },
    {
        "protocol_id": "4111 v.2",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Encorafenib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "7 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "300 mg ONCE a day",
                    "day": "1 to 7",
                    "route": "PO"
                },
                {
                    "drug_name": "Cetuximab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "7 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "400 mg/m2 (loading dose only)*",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Encorafenib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "7 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "300 mg ONCE a day",
                    "day": "1 to 7",
                    "route": "PO"
                },
                {
                    "drug_name": "Cetuximab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "7 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "250 mg/m2 (subsequent doses)*",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Encorafenib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "7 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "300 mg ONCE a day",
                    "day": "1 to 7",
                    "route": "PO"
                },
                {
                    "drug_name": "Cetuximab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "7 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "400 mg/m2 (loading dose only)*",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Encorafenib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "7 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "300 mg ONCE a day",
                    "day": "1 to 7",
                    "route": "PO"
                },
                {
                    "drug_name": "Cetuximab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "7 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "250 mg/m2 (subsequent doses)*",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "colorectal",
        "url": "https://www.eviq.org.au/medical-oncology/colorectal/metastatic/4111-colorectal-metastatic-cetuximab-and-encorafen"
    },
    {
        "protocol_id": "1260 v.7",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Cetuximab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "500 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Irinotecan",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "180 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Cetuximab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "500 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Irinotecan",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "180 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "colorectal",
        "url": "https://www.eviq.org.au/medical-oncology/colorectal/metastatic/1260-colorectal-metastatic-cetuximab-and-irinoteca"
    },
    {
        "protocol_id": "97 v.7",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Calcium folinate (Leucovorin)",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "50 mg *",
                    "day": "1",
                    "route": "IV bolus"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "400 mg/m2",
                    "day": "1",
                    "route": "IV"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "2,400 mg/m2",
                    "day": "1",
                    "route": "CIV via pump over 46 hours **"
                }
            ],
            [
                {
                    "drug_name": "Calcium folinate (Leucovorin)",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "50 mg *",
                    "day": "1",
                    "route": "IV bolus"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "400 mg/m2",
                    "day": "1",
                    "route": "IV"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "2,400 mg/m2",
                    "day": "1",
                    "route": "CIV via pump over 46 hours **"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "colorectal",
        "url": "https://www.eviq.org.au/medical-oncology/colorectal/metastatic/97-colorectal-metastatic-de-gramont-modified-fl"
    },
    {
        "protocol_id": "89 v.10",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "beVACizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "5 mg/kg",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Irinotecan",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "180 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Calcium folinate (Leucovorin)",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "50 mg *",
                    "day": "1",
                    "route": "IV bolus"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "400 mg/m2",
                    "day": "1",
                    "route": "IV"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "2,400 mg/m2",
                    "day": "1",
                    "route": "CIV via pump over 46 hours"
                }
            ],
            [
                {
                    "drug_name": "beVACizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "5 mg/kg",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Irinotecan",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "180 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Calcium folinate (Leucovorin)",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "50 mg *",
                    "day": "1",
                    "route": "IV bolus"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "400 mg/m2",
                    "day": "1",
                    "route": "IV"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "2,400 mg/m2",
                    "day": "1",
                    "route": "CIV via pump over 46 hours"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "colorectal",
        "url": "https://www.eviq.org.au/medical-oncology/colorectal/metastatic/89-colorectal-metastatic-folfiri-modified-fluor"
    },
    {
        "protocol_id": "1682 v.6",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Cetuximab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "500 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Irinotecan",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "180 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Calcium folinate (Leucovorin)",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "50 mg *",
                    "day": "1",
                    "route": "IV bolus"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "400 mg/m2",
                    "day": "1",
                    "route": "IV"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "2,400 mg/m2",
                    "day": "1",
                    "route": "CIV via pump over 46 hours"
                }
            ],
            [
                {
                    "drug_name": "Cetuximab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "500 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Irinotecan",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "180 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Calcium folinate (Leucovorin)",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "50 mg *",
                    "day": "1",
                    "route": "IV bolus"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "400 mg/m2",
                    "day": "1",
                    "route": "IV"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "2,400 mg/m2",
                    "day": "1",
                    "route": "CIV via pump over 46 hours"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "colorectal",
        "url": "https://www.eviq.org.au/medical-oncology/colorectal/metastatic/1682-colorectal-metastatic-folfiri-modified-flu"
    },
    {
        "protocol_id": "1536 v.6",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "pANITUMumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "6 mg/kg",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Irinotecan",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "180 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Calcium folinate (Leucovorin)",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "50 mg *",
                    "day": "1",
                    "route": "IV bolus"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "400 mg/m2",
                    "day": "1",
                    "route": "IV"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "2,400 mg/m2",
                    "day": "1",
                    "route": "CIV via pump over 46 hours"
                }
            ],
            [
                {
                    "drug_name": "pANITUMumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "6 mg/kg",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Irinotecan",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "180 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Calcium folinate (Leucovorin)",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "50 mg *",
                    "day": "1",
                    "route": "IV bolus"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "400 mg/m2",
                    "day": "1",
                    "route": "IV"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "2,400 mg/m2",
                    "day": "1",
                    "route": "CIV via pump over 46 hours"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "colorectal",
        "url": "https://www.eviq.org.au/medical-oncology/colorectal/metastatic/1536-colorectal-metastatic-folfiri-modified-flu"
    },
    {
        "protocol_id": "114 v.10",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Oxaliplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity.",
                    "dose": "85 mg/m2 *",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Calcium folinate (Leucovorin)",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity.",
                    "dose": "50 mg *",
                    "day": "1",
                    "route": "IV bolus"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity.",
                    "dose": "400 mg/m2",
                    "day": "1",
                    "route": "IV"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity.",
                    "dose": "2,400 mg/m2",
                    "day": "1",
                    "route": "CIV via pump over 46 hours"
                }
            ],
            [
                {
                    "drug_name": "Oxaliplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity.",
                    "dose": "85 mg/m2 *",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Calcium folinate (Leucovorin)",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity.",
                    "dose": "50 mg *",
                    "day": "1",
                    "route": "IV bolus"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity.",
                    "dose": "400 mg/m2",
                    "day": "1",
                    "route": "IV"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity.",
                    "dose": "2,400 mg/m2",
                    "day": "1",
                    "route": "CIV via pump over 46 hours"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "colorectal",
        "url": "https://www.eviq.org.au/medical-oncology/colorectal/metastatic/114-colorectal-metastatic-folfox6-modified-fluo"
    },
    {
        "protocol_id": "986 v.12",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "beVACizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "5 mg/kg",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Oxaliplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "85 mg/m2 #",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Calcium folinate (Leucovorin)",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "50 mg *",
                    "day": "1",
                    "route": "IV bolus"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "400 mg/m2",
                    "day": "1",
                    "route": "IV"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "2,400 mg/m2",
                    "day": "1",
                    "route": "CIV via pump over 46 hours"
                }
            ],
            [
                {
                    "drug_name": "beVACizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "5 mg/kg",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Oxaliplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "85 mg/m2 #",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Calcium folinate (Leucovorin)",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "50 mg *",
                    "day": "1",
                    "route": "IV bolus"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "400 mg/m2",
                    "day": "1",
                    "route": "IV"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "2,400 mg/m2",
                    "day": "1",
                    "route": "CIV via pump over 46 hours"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "colorectal",
        "url": "https://www.eviq.org.au/medical-oncology/colorectal/metastatic/986-colorectal-metastatic-folfox6-modified-fluo"
    },
    {
        "protocol_id": "1756 v.7",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Cetuximab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "500 mg/m2 *",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Oxaliplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "85 mg/m2 #",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Calcium folinate (Leucovorin)",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "50 mg #",
                    "day": "1",
                    "route": "IV bolus"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "400 mg/m2",
                    "day": "1",
                    "route": "IV"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "2,400 mg/m2",
                    "day": "1",
                    "route": "CIV via pump over 46 hrs"
                }
            ],
            [
                {
                    "drug_name": "Cetuximab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "500 mg/m2 *",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Oxaliplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "85 mg/m2 #",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Calcium folinate (Leucovorin)",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "50 mg #",
                    "day": "1",
                    "route": "IV bolus"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "400 mg/m2",
                    "day": "1",
                    "route": "IV"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "2,400 mg/m2",
                    "day": "1",
                    "route": "CIV via pump over 46 hrs"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "colorectal",
        "url": "https://www.eviq.org.au/medical-oncology/colorectal/metastatic/1756-colorectal-metastatic-folfox6-modified-flu"
    },
    {
        "protocol_id": "1542 v.8",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "pANITUMumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "6 mg/kg",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Oxaliplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "85 mg/m2 *",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Calcium folinate (Leucovorin)",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "50 mg *",
                    "day": "1",
                    "route": "IV bolus"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "400 mg/m2",
                    "day": "1",
                    "route": "IV"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "2,400 mg/m2",
                    "day": "1",
                    "route": "CIV via pump over 46 hours"
                }
            ],
            [
                {
                    "drug_name": "pANITUMumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "6 mg/kg",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Oxaliplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "85 mg/m2 *",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Calcium folinate (Leucovorin)",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "50 mg *",
                    "day": "1",
                    "route": "IV bolus"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "400 mg/m2",
                    "day": "1",
                    "route": "IV"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "2,400 mg/m2",
                    "day": "1",
                    "route": "CIV via pump over 46 hours"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "colorectal",
        "url": "https://www.eviq.org.au/medical-oncology/colorectal/metastatic/1542-colorectal-metastatic-folfox6-modified-flu"
    },
    {
        "protocol_id": "1534 v.9",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Irinotecan",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "165 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Oxaliplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "85 mg/m2 #",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Calcium folinate (Leucovorin)",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "50 mg *",
                    "day": "1",
                    "route": "IV bolus"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "3,200 mg/m2",
                    "day": "1",
                    "route": "CIV via pump over 48 hours (equivalent to 1600 mg/m2/day)"
                }
            ],
            [
                {
                    "drug_name": "Irinotecan",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "165 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Oxaliplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "85 mg/m2 #",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Calcium folinate (Leucovorin)",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "50 mg *",
                    "day": "1",
                    "route": "IV bolus"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "3,200 mg/m2",
                    "day": "1",
                    "route": "CIV via pump over 48 hours (equivalent to 1600 mg/m2/day)"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "colorectal",
        "url": "https://www.eviq.org.au/medical-oncology/colorectal/metastatic/1534-colorectal-metastatic-folfoxiri-modified-f"
    },
    {
        "protocol_id": "1715 v.10",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "beVACizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "5 mg/kg",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Irinotecan",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "165 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Oxaliplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "85 mg/m2 #",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Calcium folinate (Leucovorin)",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "50 mg *",
                    "day": "1",
                    "route": "IV bolus"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "3,200 mg/m2",
                    "day": "1",
                    "route": "CIV via pump over 48 hours (equivalent to 1600 mg/m2/day)"
                }
            ],
            [
                {
                    "drug_name": "beVACizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "5 mg/kg",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Irinotecan",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "165 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Oxaliplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "85 mg/m2 #",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Calcium folinate (Leucovorin)",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "50 mg *",
                    "day": "1",
                    "route": "IV bolus"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "3,200 mg/m2",
                    "day": "1",
                    "route": "CIV via pump over 48 hours (equivalent to 1600 mg/m2/day)"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "colorectal",
        "url": "https://www.eviq.org.au/medical-oncology/colorectal/metastatic/1715-colorectal-metastatic-folfoxiri-modified-f"
    },
    {
        "protocol_id": "85 v.6",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Irinotecan",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity; maximum 8 cycles",
                    "dose": "350 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Irinotecan",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity; maximum 8 cycles",
                    "dose": "350 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "colorectal",
        "url": "https://www.eviq.org.au/medical-oncology/colorectal/metastatic/85-colorectal-metastatic-irinotecan-three-weekly"
    },
    {
        "protocol_id": "101 v.5",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "pANITUMumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "6 mg/kg",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "pANITUMumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "6 mg/kg",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "colorectal",
        "url": "https://www.eviq.org.au/medical-oncology/colorectal/metastatic/101-colorectal-metastatic-panitumumab"
    },
    {
        "protocol_id": "98 v.6",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Calcium folinate (Leucovorin)",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "7 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "50 mg *",
                    "day": "1",
                    "route": "IV bolus"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "7 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "370 mg/m2",
                    "day": "1",
                    "route": "IV"
                }
            ],
            [
                {
                    "drug_name": "Calcium folinate (Leucovorin)",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "7 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "50 mg *",
                    "day": "1",
                    "route": "IV bolus"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "7 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "370 mg/m2",
                    "day": "1",
                    "route": "IV"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "colorectal",
        "url": "https://www.eviq.org.au/medical-oncology/colorectal/metastatic/98-colorectal-metastatic-quasar-modified-fluorou"
    },
    {
        "protocol_id": "606 v.6",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Raltitrexed",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "3 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Raltitrexed",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "3 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "colorectal",
        "url": "https://www.eviq.org.au/medical-oncology/colorectal/metastatic/606-colorectal-metastatic-raltitrexed"
    },
    {
        "protocol_id": "1544 v.3",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Regorafenib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Until disease progression or unacceptable toxicity",
                    "dose": "160 mg ONCE a day *",
                    "day": "1 to 21 **",
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Regorafenib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Until disease progression or unacceptable toxicity",
                    "dose": "160 mg ONCE a day *",
                    "day": "1 to 21 **",
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "colorectal",
        "url": "https://www.eviq.org.au/medical-oncology/colorectal/metastatic/1544-colorectal-metastatic-regorafenib"
    },
    {
        "protocol_id": "1275 v.5",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Calcium folinate (Leucovorin)",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "56 days(weekly for six weeks followed bya two week break)",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "50 mg *",
                    "day": "1, 8, 15, 22, 29, 36",
                    "route": "IV bolus"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "56 days(weekly for six weeks followed bya two week break)",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "500 mg/m2",
                    "day": "1, 8, 15, 22, 29, 36",
                    "route": "IV"
                }
            ],
            [
                {
                    "drug_name": "Calcium folinate (Leucovorin)",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "56 days(weekly for six weeks followed bya two week break)",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "50 mg *",
                    "day": "1, 8, 15, 22, 29, 36",
                    "route": "IV bolus"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "56 days(weekly for six weeks followed bya two week break)",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "500 mg/m2",
                    "day": "1, 8, 15, 22, 29, 36",
                    "route": "IV"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "colorectal",
        "url": "https://www.eviq.org.au/medical-oncology/colorectal/metastatic/1275-colorectal-metastatic-roswell-park-modified"
    },
    {
        "protocol_id": "86 v.10",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "beVACizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "56 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "5 mg/kg",
                    "day": "1, 15, 29, 43",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Calcium folinate (Leucovorin)",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "56 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "50 mg *",
                    "day": "1, 8, 15, 22, 29, 36",
                    "route": "IV bolus"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "56 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "500 mg/m2",
                    "day": "1, 8, 15, 22, 29, 36",
                    "route": "IV"
                }
            ],
            [
                {
                    "drug_name": "beVACizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "56 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "5 mg/kg",
                    "day": "1, 15, 29, 43",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Calcium folinate (Leucovorin)",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "56 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "50 mg *",
                    "day": "1, 8, 15, 22, 29, 36",
                    "route": "IV bolus"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "56 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "500 mg/m2",
                    "day": "1, 8, 15, 22, 29, 36",
                    "route": "IV"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "colorectal",
        "url": "https://www.eviq.org.au/medical-oncology/colorectal/metastatic/86-colorectal-metastatic-roswell-park-modified-f"
    },
    {
        "protocol_id": "4324 v.2",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Raltitrexed",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity; usually 6 cycles",
                    "dose": "3 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Oxaliplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity; usually 6 cycles",
                    "dose": "130 mg/m2 #",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Raltitrexed",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity; usually 6 cycles",
                    "dose": "3 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Oxaliplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity; usually 6 cycles",
                    "dose": "130 mg/m2 #",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "colorectal",
        "url": "https://www.eviq.org.au/medical-oncology/colorectal/metastatic/4324-colorectal-metastatic-tomox-raltitrexed-and"
    },
    {
        "protocol_id": "3806 v.2",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Trifluridine/tipiracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "35 mg/m2 TWICE a day *\n                            \n                                (Cap dose at 80 mg)",
                    "day": "1 to 5 and 8 to 12",
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Trifluridine/tipiracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "35 mg/m2 TWICE a day *\n                            \n                                (Cap dose at 80 mg)",
                    "day": "1 to 5 and 8 to 12",
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "colorectal",
        "url": "https://www.eviq.org.au/medical-oncology/colorectal/metastatic/1940-redirect-id-3806"
    },
    {
        "protocol_id": "1567 v.7",
        "protocol_status": "Superseded",
        "drug_sequence": [
            [
                {
                    "drug_name": "Cetuximab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "400 mg/m2 (loading dose only)",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Cetuximab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "250 mg/m2 (subsequent doses)",
                    "day": "8",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Irinotecan",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "180 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Cetuximab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "250 mg/m2",
                    "day": "1 and 8",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Irinotecan",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "180 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Cetuximab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "400 mg/m2 (loading dose only)",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Cetuximab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "250 mg/m2 (subsequent doses)",
                    "day": "8",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Irinotecan",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "180 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Cetuximab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "250 mg/m2",
                    "day": "1 and 8",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Irinotecan",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "180 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "colorectal",
        "url": "https://www.eviq.org.au/medical-oncology/colorectal/metastatic/1567-colorectal-metastatic-cetuximab-weekly-and"
    },
    {
        "protocol_id": "825 v.7",
        "protocol_status": "Superseded",
        "drug_sequence": [
            [
                {
                    "drug_name": "Cetuximab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "7 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "400 mg/m2 (loading dose only)",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Cetuximab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "7 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "250 mg/m2 (subsequent doses)",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Cetuximab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "7 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "400 mg/m2 (loading dose only)",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Cetuximab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "7 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "250 mg/m2 (subsequent doses)",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "colorectal",
        "url": "https://www.eviq.org.au/medical-oncology/colorectal/metastatic/825-colorectal-metastatic-cetuximab-superseded"
    },
    {
        "protocol_id": "96 v.6",
        "protocol_status": "Superseded",
        "drug_sequence": [
            [
                {
                    "drug_name": "Calcium folinate (Leucovorin)",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "200 mg/m2 *",
                    "day": "1 and 2",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "400 mg/m2",
                    "day": "1 and 2",
                    "route": "IV"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "600 mg/m2",
                    "day": "1 and 2",
                    "route": "CIV via pump over 22 hours"
                }
            ],
            [
                {
                    "drug_name": "Calcium folinate (Leucovorin)",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "200 mg/m2 *",
                    "day": "1 and 2",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "400 mg/m2",
                    "day": "1 and 2",
                    "route": "IV"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "600 mg/m2",
                    "day": "1 and 2",
                    "route": "CIV via pump over 22 hours"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "colorectal",
        "url": "https://www.eviq.org.au/medical-oncology/colorectal/metastatic/96-colorectal-metastatic-de-gramont-fluorouracil"
    },
    {
        "protocol_id": "1212 v.8",
        "protocol_status": "Superseded",
        "drug_sequence": [
            [
                {
                    "drug_name": "Cetuximab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "400 mg/m2 (loading dose only)",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Irinotecan",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "180 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Calcium folinate (Leucovorin)",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "50 mg *",
                    "day": "1",
                    "route": "IV bolus"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "400 mg/m2",
                    "day": "1",
                    "route": "IV"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "2,400 mg/m2",
                    "day": "1",
                    "route": "CIV via pump over 46 hours"
                },
                {
                    "drug_name": "Cetuximab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "250 mg/m2 (subsequent doses)",
                    "day": "8",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Cetuximab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "250 mg/m2",
                    "day": "1 and 8",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Irinotecan",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "180 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Calcium folinate (Leucovorin)",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "50 mg *",
                    "day": "1",
                    "route": "IV bolus"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "400 mg/m2",
                    "day": "1",
                    "route": "IV"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "2,400 mg/m2",
                    "day": "1",
                    "route": "CIV via pump over 46 hours"
                }
            ],
            [
                {
                    "drug_name": "Cetuximab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "400 mg/m2 (loading dose only)",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Irinotecan",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "180 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Calcium folinate (Leucovorin)",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "50 mg *",
                    "day": "1",
                    "route": "IV bolus"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "400 mg/m2",
                    "day": "1",
                    "route": "IV"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "2,400 mg/m2",
                    "day": "1",
                    "route": "CIV via pump over 46 hours"
                },
                {
                    "drug_name": "Cetuximab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "250 mg/m2 (subsequent doses)",
                    "day": "8",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Cetuximab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "250 mg/m2",
                    "day": "1 and 8",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Irinotecan",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "180 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Calcium folinate (Leucovorin)",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "50 mg *",
                    "day": "1",
                    "route": "IV bolus"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "400 mg/m2",
                    "day": "1",
                    "route": "IV"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "2,400 mg/m2",
                    "day": "1",
                    "route": "CIV via pump over 46 hours"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "colorectal",
        "url": "https://www.eviq.org.au/medical-oncology/colorectal/metastatic/1212-colorectal-metastatic-folfiri-modified-flu"
    },
    {
        "protocol_id": "115 v.8",
        "protocol_status": "Superseded",
        "drug_sequence": [
            [
                {
                    "drug_name": "Oxaliplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "100 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Calcium folinate (Leucovorin)",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "200 mg/m2 *",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "400 mg/m2",
                    "day": "1",
                    "route": "IV"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "2,400 mg/m2",
                    "day": "1",
                    "route": "CIV via pump over 46 hours"
                }
            ],
            [
                {
                    "drug_name": "Oxaliplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "100 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Calcium folinate (Leucovorin)",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "200 mg/m2 *",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "400 mg/m2",
                    "day": "1",
                    "route": "IV"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "2,400 mg/m2",
                    "day": "1",
                    "route": "CIV via pump over 46 hours"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "colorectal",
        "url": "https://www.eviq.org.au/medical-oncology/colorectal/metastatic/115-colorectal-metastatic-folfox6-fluorouracil-le"
    },
    {
        "protocol_id": "83 v.6",
        "protocol_status": "Superseded",
        "drug_sequence": [
            [
                {
                    "drug_name": "Irinotecan",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "42 days(this regimen is given weekly for four weeks, then a two week break before commencing next cycle i.e. cycle length = 42 days)",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "125 mg/m2",
                    "day": "1, 8, 15, 22",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Irinotecan",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "42 days(this regimen is given weekly for four weeks, then a two week break before commencing next cycle i.e. cycle length = 42 days)",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "125 mg/m2",
                    "day": "1, 8, 15, 22",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "colorectal",
        "url": "https://www.eviq.org.au/medical-oncology/colorectal/metastatic/83-colorectal-metastatic-irinotecan-weekly-superse"
    },
    {
        "protocol_id": "1383 v.5",
        "protocol_status": "Discontinued",
        "drug_sequence": [],
        "section_name": "medical-oncology",
        "category_name": "colorectal",
        "url": "https://www.eviq.org.au/medical-oncology/colorectal/metastatic/1383-colorectal-metastatic-capecitabine-and-mitomy"
    },
    {
        "protocol_id": "95 v.5",
        "protocol_status": "Discontinued",
        "drug_sequence": [],
        "section_name": "medical-oncology",
        "category_name": "colorectal",
        "url": "https://www.eviq.org.au/medical-oncology/colorectal/metastatic/95-colorectal-metastatic-cetuximab-and-irinotecan"
    },
    {
        "protocol_id": "87 v.7",
        "protocol_status": "Discontinued",
        "drug_sequence": [],
        "section_name": "medical-oncology",
        "category_name": "colorectal",
        "url": "https://www.eviq.org.au/medical-oncology/colorectal/metastatic/87-colorectal-metastatic-folfiri-fluorouracil-leu"
    },
    {
        "protocol_id": "1213 v.4",
        "protocol_status": "Discontinued",
        "drug_sequence": [],
        "section_name": "medical-oncology",
        "category_name": "colorectal",
        "url": "https://www.eviq.org.au/medical-oncology/colorectal/metastatic/1213-colorectal-metastatic-folfiri-fluorouracil-l"
    },
    {
        "protocol_id": "93 v.5",
        "protocol_status": "Discontinued",
        "drug_sequence": [],
        "section_name": "medical-oncology",
        "category_name": "colorectal",
        "url": "https://www.eviq.org.au/medical-oncology/colorectal/metastatic/93-colorectal-metastatic-folfiri-fluorouracil-leu"
    },
    {
        "protocol_id": "1533 v.3",
        "protocol_status": "Discontinued",
        "drug_sequence": [],
        "section_name": "medical-oncology",
        "category_name": "colorectal",
        "url": "https://www.eviq.org.au/medical-oncology/colorectal/metastatic/1533-colorectal-metastatic-folfiri-mod-fluorour"
    },
    {
        "protocol_id": "596 v.7",
        "protocol_status": "Discontinued",
        "drug_sequence": [],
        "section_name": "medical-oncology",
        "category_name": "colorectal",
        "url": "https://www.eviq.org.au/medical-oncology/colorectal/metastatic/596-colorectal-metastatic-folfox4-fluorouracil-le"
    },
    {
        "protocol_id": "102 v.6",
        "protocol_status": "Discontinued",
        "drug_sequence": [],
        "section_name": "medical-oncology",
        "category_name": "colorectal",
        "url": "https://www.eviq.org.au/medical-oncology/colorectal/metastatic/102-colorectal-metastatic-folfox4-fluorouracil-le"
    },
    {
        "protocol_id": "107 v.6",
        "protocol_status": "Discontinued",
        "drug_sequence": [],
        "section_name": "medical-oncology",
        "category_name": "colorectal",
        "url": "https://www.eviq.org.au/medical-oncology/colorectal/metastatic/107-colorectal-metastatic-folfox4-modified-fluo"
    },
    {
        "protocol_id": "1535 v.2",
        "protocol_status": "Discontinued",
        "drug_sequence": [],
        "section_name": "medical-oncology",
        "category_name": "colorectal",
        "url": "https://www.eviq.org.au/medical-oncology/colorectal/metastatic/1535-colorectal-metastatic-irinotecan-and-panitumu"
    },
    {
        "protocol_id": "118 v.3",
        "protocol_status": "Discontinued",
        "drug_sequence": [],
        "section_name": "medical-oncology",
        "category_name": "colorectal",
        "url": "https://www.eviq.org.au/medical-oncology/colorectal/metastatic/118-colorectal-metastatic-mayo-fluorouracil-and-l"
    },
    {
        "protocol_id": "3621 v.3",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "PACLitaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "6unless disease progression or unacceptable toxicity",
                    "dose": "80 mg/m2",
                    "day": "1, 8, 15",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "6unless disease progression or unacceptable toxicity",
                    "dose": "5 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "PACLitaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "6unless disease progression or unacceptable toxicity",
                    "dose": "80 mg/m2",
                    "day": "1, 8, 15",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "6unless disease progression or unacceptable toxicity",
                    "dose": "5 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "colorectal",
        "url": "https://www.eviq.org.au/medical-oncology/colorectal/anal/3621-anal-advanced-carboplatin-and-paclitaxel"
    },
    {
        "protocol_id": "81 v.7",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": "1with concurrent radiation therapy",
                    "dose": "60 mg/m2",
                    "day": "1 and 29",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": "1with concurrent radiation therapy",
                    "dose": "4,000 mg/m2 (equivalent to 1000 mg/m2/day)",
                    "day": "1 and 29",
                    "route": "CIV via pump over 96 hours"
                }
            ],
            [
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": "1with concurrent radiation therapy",
                    "dose": "60 mg/m2",
                    "day": "1 and 29",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": "1with concurrent radiation therapy",
                    "dose": "4,000 mg/m2 (equivalent to 1000 mg/m2/day)",
                    "day": "1 and 29",
                    "route": "CIV via pump over 96 hours"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "colorectal",
        "url": "https://www.eviq.org.au/medical-oncology/colorectal/anal/81-anal-definitive-cisplatin-and-fluorouracil-chem"
    },
    {
        "protocol_id": "1959 v.5",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Mitomycin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": "1with concurrent radiation therapy",
                    "dose": "12 mg/m2\n(Cap dose at 20 mg)",
                    "day": "1",
                    "route": "IV"
                },
                {
                    "drug_name": "Capecitabine *",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": "1with concurrent radiation therapy",
                    "dose": "825 mg/m2 TWICE a day",
                    "day": "1 to 5, 8 to 12, 15 to 19, 22 to 26, 29 to 33, 36 to 40",
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Mitomycin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": "1with concurrent radiation therapy",
                    "dose": "12 mg/m2\n(Cap dose at 20 mg)",
                    "day": "1",
                    "route": "IV"
                },
                {
                    "drug_name": "Capecitabine *",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": "1with concurrent radiation therapy",
                    "dose": "825 mg/m2 TWICE a day",
                    "day": "1 to 5, 8 to 12, 15 to 19, 22 to 26, 29 to 33, 36 to 40",
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "colorectal",
        "url": "https://www.eviq.org.au/medical-oncology/colorectal/anal/1959-anal-definitive-mitomycin-and-capecitabine-ch"
    },
    {
        "protocol_id": "82 v.7",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Mitomycin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": "1with concurrent radiation therapy",
                    "dose": "12 mg/m2\n(Cap dose at 20 mg)",
                    "day": "1 *",
                    "route": "IV"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": "1with concurrent radiation therapy",
                    "dose": "4,000 mg/m2 (equivalent to 1000 mg/m2/day)",
                    "day": "1 and 29",
                    "route": "CIV via pump over 96 hours"
                }
            ],
            [
                {
                    "drug_name": "Mitomycin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": "1with concurrent radiation therapy",
                    "dose": "12 mg/m2\n(Cap dose at 20 mg)",
                    "day": "1 *",
                    "route": "IV"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": "1with concurrent radiation therapy",
                    "dose": "4,000 mg/m2 (equivalent to 1000 mg/m2/day)",
                    "day": "1 and 29",
                    "route": "CIV via pump over 96 hours"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "colorectal",
        "url": "https://www.eviq.org.au/medical-oncology/colorectal/anal/82-anal-definitive-mitomycin-and-fluorouracil-chem"
    },
    {
        "protocol_id": "4019 v.6",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Oxaliplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "8",
                    "dose": "130 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Capecitabine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "8",
                    "dose": "1,000 mg/m2 TWICE a day *",
                    "day": "1 to 14",
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Oxaliplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "8",
                    "dose": "130 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Capecitabine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "8",
                    "dose": "1,000 mg/m2 TWICE a day *",
                    "day": "1 to 14",
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "colorectal",
        "url": "https://www.eviq.org.au/medical-oncology/colorectal/rectal/4020-redirect-id-4019"
    },
    {
        "protocol_id": "3974 v.3",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Oxaliplatin",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "8",
                    "dose": "85 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Calcium folinate (Leucovorin)",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "8",
                    "dose": "50 mg *",
                    "day": "1",
                    "route": "IV bolus"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "8",
                    "dose": "400 mg/m2",
                    "day": "1",
                    "route": "IV"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "8",
                    "dose": "2,400 mg/m2",
                    "day": "1",
                    "route": "CIV via pump over 46 hours"
                }
            ],
            [
                {
                    "drug_name": "Oxaliplatin",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "8",
                    "dose": "85 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Calcium folinate (Leucovorin)",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "8",
                    "dose": "50 mg *",
                    "day": "1",
                    "route": "IV bolus"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "8",
                    "dose": "400 mg/m2",
                    "day": "1",
                    "route": "IV"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "8",
                    "dose": "2,400 mg/m2",
                    "day": "1",
                    "route": "CIV via pump over 46 hours"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "colorectal",
        "url": "https://www.eviq.org.au/medical-oncology/colorectal/rectal/3974-rectal-adjuvant-folfox6-modified-fluoroura"
    },
    {
        "protocol_id": "84 v.7",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Capecitabine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "7 days",
                    "cycles": "Continuous with concurrent radiation therapy (usually for 5 to 6 weeks)",
                    "dose": "825 mg/m2 TWICE a day *",
                    "day": "1 to 5",
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Capecitabine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "7 days",
                    "cycles": "Continuous with concurrent radiation therapy (usually for 5 to 6 weeks)",
                    "dose": "825 mg/m2 TWICE a day *",
                    "day": "1 to 5",
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "colorectal",
        "url": "https://www.eviq.org.au/medical-oncology/colorectal/rectal/84-rectal-locally-advanced-capecitabine-chemoradia"
    },
    {
        "protocol_id": "73 v.7",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "7 days",
                    "cycles": "Continuous with concurrent radiation therapy (usually 5 to 6 weeks)",
                    "dose": "1,575 mg/m2 (equivalent to 225 mg/m2/day)",
                    "day": "1",
                    "route": "CIV via pump over 7 days"
                }
            ],
            [
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "7 days",
                    "cycles": "Continuous with concurrent radiation therapy (usually 5 to 6 weeks)",
                    "dose": "1,575 mg/m2 (equivalent to 225 mg/m2/day)",
                    "day": "1",
                    "route": "CIV via pump over 7 days"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "colorectal",
        "url": "https://www.eviq.org.au/medical-oncology/colorectal/rectal/73-rectal-locally-advanced-fluorouracil-protracte"
    },
    {
        "protocol_id": "3930 v.3",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Oxaliplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "6(after pre-operative short-course external beam radiation therapy)",
                    "dose": "130 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Capecitabine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "6(after pre-operative short-course external beam radiation therapy)",
                    "dose": "1,000 mg/m2 TWICE a day *",
                    "day": "1 to 14",
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Oxaliplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "6(after pre-operative short-course external beam radiation therapy)",
                    "dose": "130 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Capecitabine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "6(after pre-operative short-course external beam radiation therapy)",
                    "dose": "1,000 mg/m2 TWICE a day *",
                    "day": "1 to 14",
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "colorectal",
        "url": "https://www.eviq.org.au/medical-oncology/colorectal/rectal/3930-rectal-neoadjuvant-capox-xelox-capecitabin"
    },
    {
        "protocol_id": "4076 v.4",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Oxaliplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "14 days",
                    "cycles": "6",
                    "dose": "85 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Irinotecan",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "14 days",
                    "cycles": "6",
                    "dose": "180 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Calcium folinate (Leucovorin)",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "14 days",
                    "cycles": "6",
                    "dose": "50 mg *",
                    "day": "1",
                    "route": "IV bolus"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "14 days",
                    "cycles": "6",
                    "dose": "2,400 mg/m2",
                    "day": "1",
                    "route": "CIV via pump over 46 hours"
                },
                {
                    "drug_name": "Pegfilgrastim",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "14 days",
                    "cycles": "6",
                    "dose": "6 mg",
                    "day": "4",
                    "route": "Subcut"
                }
            ],
            [
                {
                    "drug_name": "Oxaliplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "14 days",
                    "cycles": "6",
                    "dose": "85 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Irinotecan",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "14 days",
                    "cycles": "6",
                    "dose": "180 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Calcium folinate (Leucovorin)",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "14 days",
                    "cycles": "6",
                    "dose": "50 mg *",
                    "day": "1",
                    "route": "IV bolus"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "14 days",
                    "cycles": "6",
                    "dose": "2,400 mg/m2",
                    "day": "1",
                    "route": "CIV via pump over 46 hours"
                },
                {
                    "drug_name": "Pegfilgrastim",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "14 days",
                    "cycles": "6",
                    "dose": "6 mg",
                    "day": "4",
                    "route": "Subcut"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "colorectal",
        "url": "https://www.eviq.org.au/medical-oncology/colorectal/rectal/4076-rectal-neoadjuvant-folfirinox-modified"
    },
    {
        "protocol_id": "3931 v.3",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Oxaliplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "14 days",
                    "cycles": "9(after pre-operative short-course external beam radiation therapy)",
                    "dose": "85 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Calcium folinate (Leucovorin)",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "14 days",
                    "cycles": "9(after pre-operative short-course external beam radiation therapy)",
                    "dose": "50 mg *",
                    "day": "1",
                    "route": "IV bolus"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "14 days",
                    "cycles": "9(after pre-operative short-course external beam radiation therapy)",
                    "dose": "400 mg/m2",
                    "day": "1",
                    "route": "IV"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "14 days",
                    "cycles": "9(after pre-operative short-course external beam radiation therapy)",
                    "dose": "2,400 mg/m2 **",
                    "day": "1",
                    "route": "CIV via pump over 46 hours"
                }
            ],
            [
                {
                    "drug_name": "Oxaliplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "14 days",
                    "cycles": "9(after pre-operative short-course external beam radiation therapy)",
                    "dose": "85 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Calcium folinate (Leucovorin)",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "14 days",
                    "cycles": "9(after pre-operative short-course external beam radiation therapy)",
                    "dose": "50 mg *",
                    "day": "1",
                    "route": "IV bolus"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "14 days",
                    "cycles": "9(after pre-operative short-course external beam radiation therapy)",
                    "dose": "400 mg/m2",
                    "day": "1",
                    "route": "IV"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "14 days",
                    "cycles": "9(after pre-operative short-course external beam radiation therapy)",
                    "dose": "2,400 mg/m2 **",
                    "day": "1",
                    "route": "CIV via pump over 46 hours"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "colorectal",
        "url": "https://www.eviq.org.au/medical-oncology/colorectal/rectal/3931-rectal-neoadjuvant-folfox6-modified-fluoro"
    },
    {
        "protocol_id": "336 v.9",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "7 days",
                    "cycles": "Continuous with concurrent radiation therapy; usually 5 or 6 cycles depending on duration of radiation therapy",
                    "dose": "40 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "7 days",
                    "cycles": "Continuous with concurrent radiation therapy; usually 5 or 6 cycles depending on duration of radiation therapy",
                    "dose": "40 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "gynaecological",
        "url": "https://www.eviq.org.au/medical-oncology/gynaecological/cervical/336-cervical-locally-advanced-scc-cisplatin-chemor"
    },
    {
        "protocol_id": "667 v.8",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "PACLitaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity; usually 6 cycles",
                    "dose": "175 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity; usually 6 cycles",
                    "dose": "5 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "PACLitaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity; usually 6 cycles",
                    "dose": "175 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity; usually 6 cycles",
                    "dose": "5 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "gynaecological",
        "url": "https://www.eviq.org.au/medical-oncology/gynaecological/cervical/667-cervical-recurrent-or-metastatic-carboplatin-a"
    },
    {
        "protocol_id": "1989 v.11",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "beVACizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "15 mg/kg",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "PACLitaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "175 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "5 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "beVACizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "15 mg/kg",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "PACLitaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "175 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "5 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "gynaecological",
        "url": "https://www.eviq.org.au/medical-oncology/gynaecological/cervical/1989-cervical-recurrent-or-metastatic-carboplatin"
    },
    {
        "protocol_id": "4170 v.3",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Pembrolizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease recurrence or unacceptable toxicity. In the Keynote-826 clinical trial, 6 cycles of carboplatin, paclitaxel and pembrolizumab were given, after which pembrolizumab was continued up to a maximum of 35 cycles. Patients with ongoing clinical benefit could continue carboplatin and paclitaxel beyond 6 cycles at clinician discretion.",
                    "dose": "200 mg",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "PACLitaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease recurrence or unacceptable toxicity. In the Keynote-826 clinical trial, 6 cycles of carboplatin, paclitaxel and pembrolizumab were given, after which pembrolizumab was continued up to a maximum of 35 cycles. Patients with ongoing clinical benefit could continue carboplatin and paclitaxel beyond 6 cycles at clinician discretion.",
                    "dose": "175 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin *",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease recurrence or unacceptable toxicity. In the Keynote-826 clinical trial, 6 cycles of carboplatin, paclitaxel and pembrolizumab were given, after which pembrolizumab was continued up to a maximum of 35 cycles. Patients with ongoing clinical benefit could continue carboplatin and paclitaxel beyond 6 cycles at clinician discretion.",
                    "dose": "5 AUC **",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Pembrolizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease recurrence or unacceptable toxicity. In the Keynote-826 clinical trial, 6 cycles of carboplatin, paclitaxel and pembrolizumab were given, after which pembrolizumab was continued up to a maximum of 35 cycles. Patients with ongoing clinical benefit could continue carboplatin and paclitaxel beyond 6 cycles at clinician discretion.",
                    "dose": "200 mg ***",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Pembrolizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease recurrence or unacceptable toxicity. In the Keynote-826 clinical trial, 6 cycles of carboplatin, paclitaxel and pembrolizumab were given, after which pembrolizumab was continued up to a maximum of 35 cycles. Patients with ongoing clinical benefit could continue carboplatin and paclitaxel beyond 6 cycles at clinician discretion.",
                    "dose": "200 mg",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "PACLitaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease recurrence or unacceptable toxicity. In the Keynote-826 clinical trial, 6 cycles of carboplatin, paclitaxel and pembrolizumab were given, after which pembrolizumab was continued up to a maximum of 35 cycles. Patients with ongoing clinical benefit could continue carboplatin and paclitaxel beyond 6 cycles at clinician discretion.",
                    "dose": "175 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin *",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease recurrence or unacceptable toxicity. In the Keynote-826 clinical trial, 6 cycles of carboplatin, paclitaxel and pembrolizumab were given, after which pembrolizumab was continued up to a maximum of 35 cycles. Patients with ongoing clinical benefit could continue carboplatin and paclitaxel beyond 6 cycles at clinician discretion.",
                    "dose": "5 AUC **",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Pembrolizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease recurrence or unacceptable toxicity. In the Keynote-826 clinical trial, 6 cycles of carboplatin, paclitaxel and pembrolizumab were given, after which pembrolizumab was continued up to a maximum of 35 cycles. Patients with ongoing clinical benefit could continue carboplatin and paclitaxel beyond 6 cycles at clinician discretion.",
                    "dose": "200 mg ***",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "gynaecological",
        "url": "https://www.eviq.org.au/medical-oncology/gynaecological/cervical/4170-cervical-recurrent-or-metastatic-carboplatin"
    },
    {
        "protocol_id": "4169 v.3",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Pembrolizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease recurrence or unacceptable toxicity. In the Keynote-826 clinical trial, 6 cycles of carboplatin, paclitaxel, bevacizumab and pembrolizumab were given, after which bevacizumab and pembrolizumab were continued up to a maximum of 35 cycles. Patients with ongoing clinical benefit could continue carboplatin and paclitaxel beyond 6 cycles at clinician discretion.",
                    "dose": "200 mg",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "beVACizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease recurrence or unacceptable toxicity. In the Keynote-826 clinical trial, 6 cycles of carboplatin, paclitaxel, bevacizumab and pembrolizumab were given, after which bevacizumab and pembrolizumab were continued up to a maximum of 35 cycles. Patients with ongoing clinical benefit could continue carboplatin and paclitaxel beyond 6 cycles at clinician discretion.",
                    "dose": "15 mg/kg",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "PACLitaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease recurrence or unacceptable toxicity. In the Keynote-826 clinical trial, 6 cycles of carboplatin, paclitaxel, bevacizumab and pembrolizumab were given, after which bevacizumab and pembrolizumab were continued up to a maximum of 35 cycles. Patients with ongoing clinical benefit could continue carboplatin and paclitaxel beyond 6 cycles at clinician discretion.",
                    "dose": "175 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin *",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease recurrence or unacceptable toxicity. In the Keynote-826 clinical trial, 6 cycles of carboplatin, paclitaxel, bevacizumab and pembrolizumab were given, after which bevacizumab and pembrolizumab were continued up to a maximum of 35 cycles. Patients with ongoing clinical benefit could continue carboplatin and paclitaxel beyond 6 cycles at clinician discretion.",
                    "dose": "5 AUC **",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Pembrolizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease recurrence or unacceptable toxicity. In the Keynote-826 clinical trial, 6 cycles of carboplatin, paclitaxel, bevacizumab and pembrolizumab were given, after which bevacizumab and pembrolizumab were continued up to a maximum of 35 cycles. Patients with ongoing clinical benefit could continue carboplatin and paclitaxel beyond 6 cycles at clinician discretion.",
                    "dose": "200 mg",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "beVACizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease recurrence or unacceptable toxicity. In the Keynote-826 clinical trial, 6 cycles of carboplatin, paclitaxel, bevacizumab and pembrolizumab were given, after which bevacizumab and pembrolizumab were continued up to a maximum of 35 cycles. Patients with ongoing clinical benefit could continue carboplatin and paclitaxel beyond 6 cycles at clinician discretion.",
                    "dose": "15 mg/kg",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Pembrolizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease recurrence or unacceptable toxicity. In the Keynote-826 clinical trial, 6 cycles of carboplatin, paclitaxel, bevacizumab and pembrolizumab were given, after which bevacizumab and pembrolizumab were continued up to a maximum of 35 cycles. Patients with ongoing clinical benefit could continue carboplatin and paclitaxel beyond 6 cycles at clinician discretion.",
                    "dose": "200 mg",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "beVACizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease recurrence or unacceptable toxicity. In the Keynote-826 clinical trial, 6 cycles of carboplatin, paclitaxel, bevacizumab and pembrolizumab were given, after which bevacizumab and pembrolizumab were continued up to a maximum of 35 cycles. Patients with ongoing clinical benefit could continue carboplatin and paclitaxel beyond 6 cycles at clinician discretion.",
                    "dose": "15 mg/kg",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "PACLitaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease recurrence or unacceptable toxicity. In the Keynote-826 clinical trial, 6 cycles of carboplatin, paclitaxel, bevacizumab and pembrolizumab were given, after which bevacizumab and pembrolizumab were continued up to a maximum of 35 cycles. Patients with ongoing clinical benefit could continue carboplatin and paclitaxel beyond 6 cycles at clinician discretion.",
                    "dose": "175 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin *",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease recurrence or unacceptable toxicity. In the Keynote-826 clinical trial, 6 cycles of carboplatin, paclitaxel, bevacizumab and pembrolizumab were given, after which bevacizumab and pembrolizumab were continued up to a maximum of 35 cycles. Patients with ongoing clinical benefit could continue carboplatin and paclitaxel beyond 6 cycles at clinician discretion.",
                    "dose": "5 AUC **",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Pembrolizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease recurrence or unacceptable toxicity. In the Keynote-826 clinical trial, 6 cycles of carboplatin, paclitaxel, bevacizumab and pembrolizumab were given, after which bevacizumab and pembrolizumab were continued up to a maximum of 35 cycles. Patients with ongoing clinical benefit could continue carboplatin and paclitaxel beyond 6 cycles at clinician discretion.",
                    "dose": "200 mg",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "beVACizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease recurrence or unacceptable toxicity. In the Keynote-826 clinical trial, 6 cycles of carboplatin, paclitaxel, bevacizumab and pembrolizumab were given, after which bevacizumab and pembrolizumab were continued up to a maximum of 35 cycles. Patients with ongoing clinical benefit could continue carboplatin and paclitaxel beyond 6 cycles at clinician discretion.",
                    "dose": "15 mg/kg",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "gynaecological",
        "url": "https://www.eviq.org.au/medical-oncology/gynaecological/cervical/4169-cervical-recurrent-or-metastatic-carboplatin"
    },
    {
        "protocol_id": "1988 v.10",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "beVACizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "15 mg/kg",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "PACLitaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "175 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "50 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "beVACizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "15 mg/kg",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "PACLitaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "175 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "50 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "gynaecological",
        "url": "https://www.eviq.org.au/medical-oncology/gynaecological/cervical/1988-cervical-recurrent-or-metastatic-cisplatin-p"
    },
    {
        "protocol_id": "4181 v.3",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Pembrolizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity. In the Keynote-826 clinical trial, 6 cycles of cisplatin, paclitaxel and pembrolizumab were given, after which pembrolizumab was continued up to a maximum of 35 cycles. Patients with ongoing clinical benefit could continue cisplatin and paclitaxel beyond 6 cycles at clinician discretion.",
                    "dose": "200 mg",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "PACLitaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity. In the Keynote-826 clinical trial, 6 cycles of cisplatin, paclitaxel and pembrolizumab were given, after which pembrolizumab was continued up to a maximum of 35 cycles. Patients with ongoing clinical benefit could continue cisplatin and paclitaxel beyond 6 cycles at clinician discretion.",
                    "dose": "175 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "ciSplatin *",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity. In the Keynote-826 clinical trial, 6 cycles of cisplatin, paclitaxel and pembrolizumab were given, after which pembrolizumab was continued up to a maximum of 35 cycles. Patients with ongoing clinical benefit could continue cisplatin and paclitaxel beyond 6 cycles at clinician discretion.",
                    "dose": "50 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Pembrolizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity. In the Keynote-826 clinical trial, 6 cycles of cisplatin, paclitaxel and pembrolizumab were given, after which pembrolizumab was continued up to a maximum of 35 cycles. Patients with ongoing clinical benefit could continue cisplatin and paclitaxel beyond 6 cycles at clinician discretion.",
                    "dose": "200 mg **",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Pembrolizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity. In the Keynote-826 clinical trial, 6 cycles of cisplatin, paclitaxel and pembrolizumab were given, after which pembrolizumab was continued up to a maximum of 35 cycles. Patients with ongoing clinical benefit could continue cisplatin and paclitaxel beyond 6 cycles at clinician discretion.",
                    "dose": "200 mg",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "PACLitaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity. In the Keynote-826 clinical trial, 6 cycles of cisplatin, paclitaxel and pembrolizumab were given, after which pembrolizumab was continued up to a maximum of 35 cycles. Patients with ongoing clinical benefit could continue cisplatin and paclitaxel beyond 6 cycles at clinician discretion.",
                    "dose": "175 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "ciSplatin *",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity. In the Keynote-826 clinical trial, 6 cycles of cisplatin, paclitaxel and pembrolizumab were given, after which pembrolizumab was continued up to a maximum of 35 cycles. Patients with ongoing clinical benefit could continue cisplatin and paclitaxel beyond 6 cycles at clinician discretion.",
                    "dose": "50 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Pembrolizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity. In the Keynote-826 clinical trial, 6 cycles of cisplatin, paclitaxel and pembrolizumab were given, after which pembrolizumab was continued up to a maximum of 35 cycles. Patients with ongoing clinical benefit could continue cisplatin and paclitaxel beyond 6 cycles at clinician discretion.",
                    "dose": "200 mg **",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "gynaecological",
        "url": "https://www.eviq.org.au/medical-oncology/gynaecological/cervical/4181-cervical-recurrent-or-metastatic-cisplatin-p"
    },
    {
        "protocol_id": "4180 v.3",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Pembrolizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity. In the Keynote-826 clinical trial, 6 cycles of cisplatin, paclitaxel, bevacizumab and pembrolizumab were given, after which bevacizumab and pembrolizumab were continued up to a maximum of 35 cycles. Patients with ongoing clinical benefit could continue cisplatin and paclitaxel beyond 6 cycles at clinician discretion",
                    "dose": "200 mg",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "beVACizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity. In the Keynote-826 clinical trial, 6 cycles of cisplatin, paclitaxel, bevacizumab and pembrolizumab were given, after which bevacizumab and pembrolizumab were continued up to a maximum of 35 cycles. Patients with ongoing clinical benefit could continue cisplatin and paclitaxel beyond 6 cycles at clinician discretion",
                    "dose": "15 mg/kg",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "PACLitaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity. In the Keynote-826 clinical trial, 6 cycles of cisplatin, paclitaxel, bevacizumab and pembrolizumab were given, after which bevacizumab and pembrolizumab were continued up to a maximum of 35 cycles. Patients with ongoing clinical benefit could continue cisplatin and paclitaxel beyond 6 cycles at clinician discretion",
                    "dose": "175 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "ciSplatin *",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity. In the Keynote-826 clinical trial, 6 cycles of cisplatin, paclitaxel, bevacizumab and pembrolizumab were given, after which bevacizumab and pembrolizumab were continued up to a maximum of 35 cycles. Patients with ongoing clinical benefit could continue cisplatin and paclitaxel beyond 6 cycles at clinician discretion",
                    "dose": "50 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Pembrolizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity. In the Keynote-826 clinical trial, 6 cycles of cisplatin, paclitaxel, bevacizumab and pembrolizumab were given, after which bevacizumab and pembrolizumab were continued up to a maximum of 35 cycles. Patients with ongoing clinical benefit could continue cisplatin and paclitaxel beyond 6 cycles at clinician discretion",
                    "dose": "200 mg",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "beVACizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity. In the Keynote-826 clinical trial, 6 cycles of cisplatin, paclitaxel, bevacizumab and pembrolizumab were given, after which bevacizumab and pembrolizumab were continued up to a maximum of 35 cycles. Patients with ongoing clinical benefit could continue cisplatin and paclitaxel beyond 6 cycles at clinician discretion",
                    "dose": "15 mg/kg",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Pembrolizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity. In the Keynote-826 clinical trial, 6 cycles of cisplatin, paclitaxel, bevacizumab and pembrolizumab were given, after which bevacizumab and pembrolizumab were continued up to a maximum of 35 cycles. Patients with ongoing clinical benefit could continue cisplatin and paclitaxel beyond 6 cycles at clinician discretion",
                    "dose": "200 mg",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "beVACizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity. In the Keynote-826 clinical trial, 6 cycles of cisplatin, paclitaxel, bevacizumab and pembrolizumab were given, after which bevacizumab and pembrolizumab were continued up to a maximum of 35 cycles. Patients with ongoing clinical benefit could continue cisplatin and paclitaxel beyond 6 cycles at clinician discretion",
                    "dose": "15 mg/kg",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "PACLitaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity. In the Keynote-826 clinical trial, 6 cycles of cisplatin, paclitaxel, bevacizumab and pembrolizumab were given, after which bevacizumab and pembrolizumab were continued up to a maximum of 35 cycles. Patients with ongoing clinical benefit could continue cisplatin and paclitaxel beyond 6 cycles at clinician discretion",
                    "dose": "175 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "ciSplatin *",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity. In the Keynote-826 clinical trial, 6 cycles of cisplatin, paclitaxel, bevacizumab and pembrolizumab were given, after which bevacizumab and pembrolizumab were continued up to a maximum of 35 cycles. Patients with ongoing clinical benefit could continue cisplatin and paclitaxel beyond 6 cycles at clinician discretion",
                    "dose": "50 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Pembrolizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity. In the Keynote-826 clinical trial, 6 cycles of cisplatin, paclitaxel, bevacizumab and pembrolizumab were given, after which bevacizumab and pembrolizumab were continued up to a maximum of 35 cycles. Patients with ongoing clinical benefit could continue cisplatin and paclitaxel beyond 6 cycles at clinician discretion",
                    "dose": "200 mg",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "beVACizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity. In the Keynote-826 clinical trial, 6 cycles of cisplatin, paclitaxel, bevacizumab and pembrolizumab were given, after which bevacizumab and pembrolizumab were continued up to a maximum of 35 cycles. Patients with ongoing clinical benefit could continue cisplatin and paclitaxel beyond 6 cycles at clinician discretion",
                    "dose": "15 mg/kg",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "gynaecological",
        "url": "https://www.eviq.org.au/medical-oncology/gynaecological/cervical/4180-cervical-recurrent-or-metastatic-cisplatin-p"
    },
    {
        "protocol_id": "3730 v.4",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "PACLitaxel",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6",
                    "dose": "175 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6",
                    "dose": "6 AUC *#",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "PACLitaxel",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6",
                    "dose": "175 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6",
                    "dose": "6 AUC *#",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "gynaecological",
        "url": "https://www.eviq.org.au/medical-oncology/gynaecological/endometrial/3730-endometrial-adjuvant-carboplatin-and-paclitax"
    },
    {
        "protocol_id": "3664 v.5",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "PACLitaxel",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4(this treatment is commenced within 3 weeks after the completion of radiation therapy)",
                    "dose": "175 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4(this treatment is commenced within 3 weeks after the completion of radiation therapy)",
                    "dose": "5 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "PACLitaxel",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4(this treatment is commenced within 3 weeks after the completion of radiation therapy)",
                    "dose": "175 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4(this treatment is commenced within 3 weeks after the completion of radiation therapy)",
                    "dose": "5 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "gynaecological",
        "url": "https://www.eviq.org.au/medical-oncology/gynaecological/endometrial/3664-endometrial-adjuvant-carboplatin-and-paclitax"
    },
    {
        "protocol_id": "3663 v.4",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": "1with concurrent radiation therapy (week 1 and 4) (this treatment is followed by chemotherapy commencing within 3 weeks after the completion of radiation therapy)",
                    "dose": "50 mg/m2",
                    "day": "1 and 22",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": "1with concurrent radiation therapy (week 1 and 4) (this treatment is followed by chemotherapy commencing within 3 weeks after the completion of radiation therapy)",
                    "dose": "50 mg/m2",
                    "day": "1 and 22",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "gynaecological",
        "url": "https://www.eviq.org.au/medical-oncology/gynaecological/endometrial/3663-endometrial-adjuvant-cisplatin-chemoradiation"
    },
    {
        "protocol_id": "3661 v.1",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "cisplatin",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "21days",
                    "cycles": "1",
                    "dose": "",
                    "day": 1,
                    "route": "IV"
                }
            ],
            [
                {
                    "drug_name": "paclitaxel",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "21days",
                    "cycles": "1",
                    "dose": "",
                    "day": 1,
                    "route": "IV"
                },
                {
                    "drug_name": "carboplatin",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "21days",
                    "cycles": "1",
                    "dose": "",
                    "day": 1,
                    "route": "IV"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "gynaecological",
        "url": "https://www.eviq.org.au/medical-oncology/gynaecological/endometrial/3661-endometrial-adjuvant-cisplatin-chemoradiation"
    },
    {
        "protocol_id": "1914 v.3",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Medroxyprogesterone acetate",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "200 mg ONCE a day",
                    "day": null,
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Medroxyprogesterone acetate",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "200 mg ONCE a day",
                    "day": null,
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "gynaecological",
        "url": "https://www.eviq.org.au/medical-oncology/gynaecological/endometrial/1914-endometrial-recurrent-medroxyprogesterone-ace"
    },
    {
        "protocol_id": "708 v.8",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "PACLitaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity; usually 6 cycles",
                    "dose": "175 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity; usually 6 cycles",
                    "dose": "5 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "PACLitaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity; usually 6 cycles",
                    "dose": "175 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity; usually 6 cycles",
                    "dose": "5 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "gynaecological",
        "url": "https://www.eviq.org.au/medical-oncology/gynaecological/endometrial/708-endometrial-recurrent-or-metastatic-carboplati"
    },
    {
        "protocol_id": "4322 v.1",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Pembrolizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (up to 35 cycles of pembrolizumab). Lenvatinib monotherapy can be continued beyond 35 cycles until disease progression or unacceptable toxicity.",
                    "dose": "200 mg *",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "leNVAtinib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (up to 35 cycles of pembrolizumab). Lenvatinib monotherapy can be continued beyond 35 cycles until disease progression or unacceptable toxicity.",
                    "dose": "20 mg ONCE a day **",
                    "day": "1 to 21",
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Pembrolizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (up to 35 cycles of pembrolizumab). Lenvatinib monotherapy can be continued beyond 35 cycles until disease progression or unacceptable toxicity.",
                    "dose": "200 mg *",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "leNVAtinib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (up to 35 cycles of pembrolizumab). Lenvatinib monotherapy can be continued beyond 35 cycles until disease progression or unacceptable toxicity.",
                    "dose": "20 mg ONCE a day **",
                    "day": "1 to 21",
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "gynaecological",
        "url": "https://www.eviq.org.au/medical-oncology/gynaecological/endometrial/4163-redirect-id-4322"
    },
    {
        "protocol_id": "1602 v.5",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "pAZOPanib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "800 mg ONCE a day",
                    "day": null,
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "pAZOPanib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "800 mg ONCE a day",
                    "day": null,
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "gynaecological",
        "url": "https://www.eviq.org.au/medical-oncology/gynaecological/endometrial/3394-1602-redirect"
    },
    {
        "protocol_id": "1554 v.5",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "DOXOrubicin *",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (up to 6 cycles)",
                    "dose": "75 mg/m2",
                    "day": "1",
                    "route": "IV **"
                },
                {
                    "drug_name": "Pegfilgrastim",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (up to 6 cycles)",
                    "dose": "6 mg",
                    "day": "2",
                    "route": "Subcut"
                }
            ],
            [
                {
                    "drug_name": "DOXOrubicin *",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (up to 6 cycles)",
                    "dose": "75 mg/m2",
                    "day": "1",
                    "route": "IV **"
                },
                {
                    "drug_name": "Pegfilgrastim",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (up to 6 cycles)",
                    "dose": "6 mg",
                    "day": "2",
                    "route": "Subcut"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "gynaecological",
        "url": "https://www.eviq.org.au/medical-oncology/gynaecological/endometrial/3395-1554-redirect"
    },
    {
        "protocol_id": "1659 v.8",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "DOXOrubicin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (maximum 6 cycles)",
                    "dose": "25 mg/m2",
                    "day": "1 to 3",
                    "route": "IV"
                },
                {
                    "drug_name": "Mesna",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (maximum 6 cycles)",
                    "dose": "500 mg/m2",
                    "day": "1 to 4",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "iFOSFamide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (maximum 6 cycles)",
                    "dose": "2,500 mg/m2",
                    "day": "1 to 4",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Mesna *",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (maximum 6 cycles)",
                    "dose": "1,500 mg/m2",
                    "day": "1 to 4",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Mesna **",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (maximum 6 cycles)",
                    "dose": "2,000 mg",
                    "day": "1 to 4",
                    "route": "PO"
                },
                {
                    "drug_name": "Pegfilgrastim",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (maximum 6 cycles)",
                    "dose": "6 mg",
                    "day": "5",
                    "route": "Subcut"
                }
            ],
            [
                {
                    "drug_name": "DOXOrubicin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (maximum 6 cycles)",
                    "dose": "25 mg/m2",
                    "day": "1 to 3",
                    "route": "IV"
                },
                {
                    "drug_name": "Mesna",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (maximum 6 cycles)",
                    "dose": "500 mg/m2",
                    "day": "1 to 4",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "iFOSFamide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (maximum 6 cycles)",
                    "dose": "2,500 mg/m2",
                    "day": "1 to 4",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Mesna *",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (maximum 6 cycles)",
                    "dose": "1,500 mg/m2",
                    "day": "1 to 4",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Mesna **",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (maximum 6 cycles)",
                    "dose": "2,000 mg",
                    "day": "1 to 4",
                    "route": "PO"
                },
                {
                    "drug_name": "Pegfilgrastim",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (maximum 6 cycles)",
                    "dose": "6 mg",
                    "day": "5",
                    "route": "Subcut"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "gynaecological",
        "url": "https://www.eviq.org.au/medical-oncology/gynaecological/endometrial/3396-1659-redirect"
    },
    {
        "protocol_id": "1898 v.5",
        "protocol_status": "Under review",
        "drug_sequence": [
            [
                {
                    "drug_name": "Gemcitabine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "until disease progression or unacceptable toxicity (usually 6 cycles)",
                    "dose": "900 mg/m2 *",
                    "day": "1 and 8",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "DOCEtaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "until disease progression or unacceptable toxicity (usually 6 cycles)",
                    "dose": "75 mg/m2 *",
                    "day": "8",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Pegfilgrastim",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "until disease progression or unacceptable toxicity (usually 6 cycles)",
                    "dose": "6 mg",
                    "day": "9",
                    "route": "Subcut"
                }
            ],
            [
                {
                    "drug_name": "Gemcitabine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "until disease progression or unacceptable toxicity (usually 6 cycles)",
                    "dose": "900 mg/m2 *",
                    "day": "1 and 8",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "DOCEtaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "until disease progression or unacceptable toxicity (usually 6 cycles)",
                    "dose": "75 mg/m2 *",
                    "day": "8",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Pegfilgrastim",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "until disease progression or unacceptable toxicity (usually 6 cycles)",
                    "dose": "6 mg",
                    "day": "9",
                    "route": "Subcut"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "gynaecological",
        "url": "https://www.eviq.org.au/medical-oncology/gynaecological/endometrial/3551-1898-redirect"
    },
    {
        "protocol_id": "672 v.7",
        "protocol_status": "Superseded",
        "drug_sequence": [
            [
                {
                    "drug_name": "DOXOrubicin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6",
                    "dose": "60 mg/m2",
                    "day": "1",
                    "route": "IV"
                },
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6",
                    "dose": "50 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "DOXOrubicin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6",
                    "dose": "60 mg/m2",
                    "day": "1",
                    "route": "IV"
                },
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6",
                    "dose": "50 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "gynaecological",
        "url": "https://www.eviq.org.au/medical-oncology/gynaecological/endometrial/672-endometrial-recurrent-or-metastatic-ap-doxoru"
    },
    {
        "protocol_id": "599 v.6",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "daCTINomycin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous for 3 cycles beyond normal \u00df-hCG",
                    "dose": "0.5 mg",
                    "day": "1 and 2",
                    "route": "IV"
                },
                {
                    "drug_name": "Etoposide *",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous for 3 cycles beyond normal \u00df-hCG",
                    "dose": "100 mg/m2",
                    "day": "1 and 2",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Methotrexate",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous for 3 cycles beyond normal \u00df-hCG",
                    "dose": "300 mg/m2",
                    "day": "1",
                    "route": "IV infusion over 12 hours"
                },
                {
                    "drug_name": "Filgrastim",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous for 3 cycles beyond normal \u00df-hCG",
                    "dose": "5 micrograms/kg",
                    "day": "3 to 5 and 9 to 11 **",
                    "route": "Subcut"
                },
                {
                    "drug_name": "Calcium folinate (Leucovorin)",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous for 3 cycles beyond normal \u00df-hCG",
                    "dose": "15 mg every 12 hours for 4 doses (to be commenced 24 hours after the start of methotrexate)",
                    "day": "2",
                    "route": "PO"
                },
                {
                    "drug_name": "vinCRISTine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous for 3 cycles beyond normal \u00df-hCG",
                    "dose": "1 mg/m2\n(Cap dose at 2 mg)",
                    "day": "8",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "CYCLOPHOSPHamide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous for 3 cycles beyond normal \u00df-hCG",
                    "dose": "600 mg/m2",
                    "day": "8",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "daCTINomycin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous for 3 cycles beyond normal \u00df-hCG",
                    "dose": "0.5 mg",
                    "day": "1 and 2",
                    "route": "IV"
                },
                {
                    "drug_name": "Etoposide *",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous for 3 cycles beyond normal \u00df-hCG",
                    "dose": "100 mg/m2",
                    "day": "1 and 2",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Methotrexate",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous for 3 cycles beyond normal \u00df-hCG",
                    "dose": "300 mg/m2",
                    "day": "1",
                    "route": "IV infusion over 12 hours"
                },
                {
                    "drug_name": "Filgrastim",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous for 3 cycles beyond normal \u00df-hCG",
                    "dose": "5 micrograms/kg",
                    "day": "3 to 5 and 9 to 11 **",
                    "route": "Subcut"
                },
                {
                    "drug_name": "Calcium folinate (Leucovorin)",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous for 3 cycles beyond normal \u00df-hCG",
                    "dose": "15 mg every 12 hours for 4 doses (to be commenced 24 hours after the start of methotrexate)",
                    "day": "2",
                    "route": "PO"
                },
                {
                    "drug_name": "vinCRISTine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous for 3 cycles beyond normal \u00df-hCG",
                    "dose": "1 mg/m2\n(Cap dose at 2 mg)",
                    "day": "8",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "CYCLOPHOSPHamide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous for 3 cycles beyond normal \u00df-hCG",
                    "dose": "600 mg/m2",
                    "day": "8",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "gynaecological",
        "url": "https://www.eviq.org.au/medical-oncology/gynaecological/gestational-trophoblastic-disease/599-gestational-trophoblastic-disease-high-risk-em"
    },
    {
        "protocol_id": "1378 v.6",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Etoposide *",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous for 3 cycles beyond normal \u00df-hCG",
                    "dose": "150 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous for 3 cycles beyond normal \u00df-hCG",
                    "dose": "75 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Filgrastim",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous for 3 cycles beyond normal \u00df-hCG",
                    "dose": "5 micrograms/kg",
                    "day": "2 to 4 and 9 to 11 **",
                    "route": "Subcut"
                },
                {
                    "drug_name": "daCTINomycin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous for 3 cycles beyond normal \u00df-hCG",
                    "dose": "0.5 mg",
                    "day": "8",
                    "route": "IV"
                },
                {
                    "drug_name": "Etoposide *",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous for 3 cycles beyond normal \u00df-hCG",
                    "dose": "100 mg/m2",
                    "day": "8",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Methotrexate",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous for 3 cycles beyond normal \u00df-hCG",
                    "dose": "300 mg/m2",
                    "day": "8",
                    "route": "IV infusion over 12 hours"
                },
                {
                    "drug_name": "Calcium folinate (Leucovorin)",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous for 3 cycles beyond normal \u00df-hCG",
                    "dose": "15 mg every 12 hours for 4 doses (to be commenced 24 hours after the start of methotrexate)",
                    "day": "9",
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Etoposide *",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous for 3 cycles beyond normal \u00df-hCG",
                    "dose": "150 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous for 3 cycles beyond normal \u00df-hCG",
                    "dose": "75 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Filgrastim",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous for 3 cycles beyond normal \u00df-hCG",
                    "dose": "5 micrograms/kg",
                    "day": "2 to 4 and 9 to 11 **",
                    "route": "Subcut"
                },
                {
                    "drug_name": "daCTINomycin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous for 3 cycles beyond normal \u00df-hCG",
                    "dose": "0.5 mg",
                    "day": "8",
                    "route": "IV"
                },
                {
                    "drug_name": "Etoposide *",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous for 3 cycles beyond normal \u00df-hCG",
                    "dose": "100 mg/m2",
                    "day": "8",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Methotrexate",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous for 3 cycles beyond normal \u00df-hCG",
                    "dose": "300 mg/m2",
                    "day": "8",
                    "route": "IV infusion over 12 hours"
                },
                {
                    "drug_name": "Calcium folinate (Leucovorin)",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous for 3 cycles beyond normal \u00df-hCG",
                    "dose": "15 mg every 12 hours for 4 doses (to be commenced 24 hours after the start of methotrexate)",
                    "day": "9",
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "gynaecological",
        "url": "https://www.eviq.org.au/medical-oncology/gynaecological/gestational-trophoblastic-disease/1378-gestational-trophoblastic-disease-high-risk-e"
    },
    {
        "protocol_id": "1018 v.6",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "daCTINomycin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous for 3 cycles beyond normal \u00df-hCG",
                    "dose": "1.25 mg/m2 (cap at 2 mg)",
                    "day": "1",
                    "route": "IV"
                }
            ],
            [
                {
                    "drug_name": "daCTINomycin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous for 3 cycles beyond normal \u00df-hCG",
                    "dose": "1.25 mg/m2 (cap at 2 mg)",
                    "day": "1",
                    "route": "IV"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "gynaecological",
        "url": "https://www.eviq.org.au/medical-oncology/gynaecological/gestational-trophoblastic-disease/1018-gestational-trophoblastic-disease-low-risk-da"
    },
    {
        "protocol_id": "668 v.4",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Methotrexate",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous for 3 cycles beyond normal \u00df-hCG",
                    "dose": "50 mg",
                    "day": "1, 3, 5, 7 **",
                    "route": "IM *"
                },
                {
                    "drug_name": "Calcium folinate (Leucovorin)",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous for 3 cycles beyond normal \u00df-hCG",
                    "dose": "15 mg (24 hours post methotrexate)",
                    "day": "2, 4, 6, 8 **",
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Methotrexate",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous for 3 cycles beyond normal \u00df-hCG",
                    "dose": "50 mg",
                    "day": "1, 3, 5, 7 **",
                    "route": "IM *"
                },
                {
                    "drug_name": "Calcium folinate (Leucovorin)",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous for 3 cycles beyond normal \u00df-hCG",
                    "dose": "15 mg (24 hours post methotrexate)",
                    "day": "2, 4, 6, 8 **",
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "gynaecological",
        "url": "https://www.eviq.org.au/medical-oncology/gynaecological/gestational-trophoblastic-disease/668-gestational-trophoblastic-disease-low-risk-met"
    },
    {
        "protocol_id": "1347 v.3",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Etoposide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "7 days",
                    "cycles": "until well enough to commence treatment with EMA-CO",
                    "dose": "100 mg/m2 *",
                    "day": "1 and 2",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "7 days",
                    "cycles": "until well enough to commence treatment with EMA-CO",
                    "dose": "20 mg/m2",
                    "day": "1 and 2",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Etoposide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "7 days",
                    "cycles": "until well enough to commence treatment with EMA-CO",
                    "dose": "100 mg/m2 *",
                    "day": "1 and 2",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "7 days",
                    "cycles": "until well enough to commence treatment with EMA-CO",
                    "dose": "20 mg/m2",
                    "day": "1 and 2",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "gynaecological",
        "url": "https://www.eviq.org.au/medical-oncology/gynaecological/gestational-trophoblastic-disease/1347-gestational-trophoblastic-disease-very-high-r"
    },
    {
        "protocol_id": "3737 v.4",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Olaparib (tablets)",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "300 mg TWICE a day",
                    "day": null,
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Olaparib (tablets)",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "300 mg TWICE a day",
                    "day": null,
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "gynaecological",
        "url": "https://www.eviq.org.au/medical-oncology/gynaecological/ovarian/3737-advanced-metastatic-or-recurrent-olaparib"
    },
    {
        "protocol_id": "259 v.9",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "DOCEtaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity. Maximum of 6 cycles",
                    "dose": "75 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity. Maximum of 6 cycles",
                    "dose": "5 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "DOCEtaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity. Maximum of 6 cycles",
                    "dose": "75 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity. Maximum of 6 cycles",
                    "dose": "5 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "gynaecological",
        "url": "https://www.eviq.org.au/medical-oncology/gynaecological/ovarian/259-ovarian-advanced-carboplatin-and-docetaxel"
    },
    {
        "protocol_id": "252 v.11",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "PACLitaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity; usually 6 cycles",
                    "dose": "175 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity; usually 6 cycles",
                    "dose": "5 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "PACLitaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity; usually 6 cycles",
                    "dose": "175 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity; usually 6 cycles",
                    "dose": "5 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "gynaecological",
        "url": "https://www.eviq.org.au/medical-oncology/gynaecological/ovarian/252-ovarian-advanced-carboplatin-and-paclitaxel-th"
    },
    {
        "protocol_id": "1897 v.7",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "PACLitaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "7 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (18 cycles were administered in the clinical trial)",
                    "dose": "60 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "7 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (18 cycles were administered in the clinical trial)",
                    "dose": "2 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "PACLitaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "7 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (18 cycles were administered in the clinical trial)",
                    "dose": "60 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "7 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (18 cycles were administered in the clinical trial)",
                    "dose": "2 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "gynaecological",
        "url": "https://www.eviq.org.au/medical-oncology/gynaecological/ovarian/1897-ovarian-advanced-carboplatin-and-paclitaxel-w"
    },
    {
        "protocol_id": "1016 v.11",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "PACLitaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity; usually 6 cycles",
                    "dose": "80 mg/m2",
                    "day": "1, 8, 15",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity; usually 6 cycles",
                    "dose": "5 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "PACLitaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity; usually 6 cycles",
                    "dose": "80 mg/m2",
                    "day": "1, 8, 15",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity; usually 6 cycles",
                    "dose": "5 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "gynaecological",
        "url": "https://www.eviq.org.au/medical-oncology/gynaecological/ovarian/1016-ovarian-advanced-carboplatin-three-weekly-and"
    },
    {
        "protocol_id": "1601 v.13",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "PACLitaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "19(1 cycle of carboplatin and paclitaxel, followed by 5 cycles of carboplatin, paclitaxel and bevacizumab, followed by 13 cycles of bevacizumab unless disease progression or unacceptable toxicity)",
                    "dose": "175 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "19(1 cycle of carboplatin and paclitaxel, followed by 5 cycles of carboplatin, paclitaxel and bevacizumab, followed by 13 cycles of bevacizumab unless disease progression or unacceptable toxicity)",
                    "dose": "5 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "beVACizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "19(1 cycle of carboplatin and paclitaxel, followed by 5 cycles of carboplatin, paclitaxel and bevacizumab, followed by 13 cycles of bevacizumab unless disease progression or unacceptable toxicity)",
                    "dose": "7.5 mg/kg",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "PACLitaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "19(1 cycle of carboplatin and paclitaxel, followed by 5 cycles of carboplatin, paclitaxel and bevacizumab, followed by 13 cycles of bevacizumab unless disease progression or unacceptable toxicity)",
                    "dose": "175 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "19(1 cycle of carboplatin and paclitaxel, followed by 5 cycles of carboplatin, paclitaxel and bevacizumab, followed by 13 cycles of bevacizumab unless disease progression or unacceptable toxicity)",
                    "dose": "5 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "beVACizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "19(1 cycle of carboplatin and paclitaxel, followed by 5 cycles of carboplatin, paclitaxel and bevacizumab, followed by 13 cycles of bevacizumab unless disease progression or unacceptable toxicity)",
                    "dose": "7.5 mg/kg",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "PACLitaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "19(1 cycle of carboplatin and paclitaxel, followed by 5 cycles of carboplatin, paclitaxel and bevacizumab, followed by 13 cycles of bevacizumab unless disease progression or unacceptable toxicity)",
                    "dose": "175 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "19(1 cycle of carboplatin and paclitaxel, followed by 5 cycles of carboplatin, paclitaxel and bevacizumab, followed by 13 cycles of bevacizumab unless disease progression or unacceptable toxicity)",
                    "dose": "5 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "beVACizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "19(1 cycle of carboplatin and paclitaxel, followed by 5 cycles of carboplatin, paclitaxel and bevacizumab, followed by 13 cycles of bevacizumab unless disease progression or unacceptable toxicity)",
                    "dose": "7.5 mg/kg",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "PACLitaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "19(1 cycle of carboplatin and paclitaxel, followed by 5 cycles of carboplatin, paclitaxel and bevacizumab, followed by 13 cycles of bevacizumab unless disease progression or unacceptable toxicity)",
                    "dose": "175 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "19(1 cycle of carboplatin and paclitaxel, followed by 5 cycles of carboplatin, paclitaxel and bevacizumab, followed by 13 cycles of bevacizumab unless disease progression or unacceptable toxicity)",
                    "dose": "5 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "beVACizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "19(1 cycle of carboplatin and paclitaxel, followed by 5 cycles of carboplatin, paclitaxel and bevacizumab, followed by 13 cycles of bevacizumab unless disease progression or unacceptable toxicity)",
                    "dose": "7.5 mg/kg",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "gynaecological",
        "url": "https://www.eviq.org.au/medical-oncology/gynaecological/ovarian/1601-ovarian-advanced-carboplatin-paclitaxel-and"
    },
    {
        "protocol_id": "265 v.9",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "PACLitaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6",
                    "dose": "135 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6",
                    "dose": "75 mg/m2 *",
                    "day": "2",
                    "route": "Intraperitoneal"
                },
                {
                    "drug_name": "PACLitaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6",
                    "dose": "60 mg/m2",
                    "day": "8",
                    "route": "Intraperitoneal"
                }
            ],
            [
                {
                    "drug_name": "PACLitaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6",
                    "dose": "135 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6",
                    "dose": "75 mg/m2 *",
                    "day": "2",
                    "route": "Intraperitoneal"
                },
                {
                    "drug_name": "PACLitaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6",
                    "dose": "60 mg/m2",
                    "day": "8",
                    "route": "Intraperitoneal"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "gynaecological",
        "url": "https://www.eviq.org.au/medical-oncology/gynaecological/ovarian/265-ovarian-advanced-combined-intravenous-and-intr"
    },
    {
        "protocol_id": "4158 v.2",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "beVACizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity. (In the PAOLA-1 clinical trial olaparib was continued up to 24 months and bevacizumab up to 15 months)",
                    "dose": "15 mg/kg *",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Olaparib (tablets)",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity. (In the PAOLA-1 clinical trial olaparib was continued up to 24 months and bevacizumab up to 15 months)",
                    "dose": "300 mg TWICE a day **",
                    "day": "1 to 21",
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "beVACizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity. (In the PAOLA-1 clinical trial olaparib was continued up to 24 months and bevacizumab up to 15 months)",
                    "dose": "15 mg/kg *",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Olaparib (tablets)",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity. (In the PAOLA-1 clinical trial olaparib was continued up to 24 months and bevacizumab up to 15 months)",
                    "dose": "300 mg TWICE a day **",
                    "day": "1 to 21",
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "gynaecological",
        "url": "https://www.eviq.org.au/medical-oncology/gynaecological/ovarian/4158-ovarian-advanced-olaparib-and-bevacizumab"
    },
    {
        "protocol_id": "4166 v.2",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Niraparib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "200 mg ONCE a day *#",
                    "day": null,
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Niraparib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "200 mg ONCE a day *#",
                    "day": null,
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "gynaecological",
        "url": "https://www.eviq.org.au/medical-oncology/gynaecological/ovarian/4166-ovarian-advanced-or-recurrent-niraparib"
    },
    {
        "protocol_id": "260 v.8",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity. Maximum of 6 cycles.",
                    "dose": "5 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity. Maximum of 6 cycles.",
                    "dose": "5 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "gynaecological",
        "url": "https://www.eviq.org.au/medical-oncology/gynaecological/ovarian/260-ovarian-advanced-primary-carboplatin"
    },
    {
        "protocol_id": "689 v.8",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Bleomycin #",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "3for good-risk disease (4 cycles for intermediate or poor risk disease)",
                    "dose": "30,000 International Units",
                    "day": "1, 8, 15",
                    "route": "IM/IV"
                },
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "3for good-risk disease (4 cycles for intermediate or poor risk disease)",
                    "dose": "20 mg/m2",
                    "day": "1 to 5",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Etoposide *",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "3for good-risk disease (4 cycles for intermediate or poor risk disease)",
                    "dose": "100 mg/m2",
                    "day": "1 to 5",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Pegfilgrastim **",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "3for good-risk disease (4 cycles for intermediate or poor risk disease)",
                    "dose": "6 mg",
                    "day": "6",
                    "route": "Subcut"
                }
            ],
            [
                {
                    "drug_name": "Bleomycin #",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "3for good-risk disease (4 cycles for intermediate or poor risk disease)",
                    "dose": "30,000 International Units",
                    "day": "1, 8, 15",
                    "route": "IM/IV"
                },
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "3for good-risk disease (4 cycles for intermediate or poor risk disease)",
                    "dose": "20 mg/m2",
                    "day": "1 to 5",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Etoposide *",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "3for good-risk disease (4 cycles for intermediate or poor risk disease)",
                    "dose": "100 mg/m2",
                    "day": "1 to 5",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Pegfilgrastim **",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "3for good-risk disease (4 cycles for intermediate or poor risk disease)",
                    "dose": "6 mg",
                    "day": "6",
                    "route": "Subcut"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "gynaecological",
        "url": "https://www.eviq.org.au/medical-oncology/gynaecological/ovarian/689-ovarian-dysgerminoma-advanced-or-metastatic-be"
    },
    {
        "protocol_id": "251 v.12",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "PACLitaxel",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4-6",
                    "dose": "175 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4-6",
                    "dose": "5 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "PACLitaxel",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4-6",
                    "dose": "175 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4-6",
                    "dose": "5 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "gynaecological",
        "url": "https://www.eviq.org.au/medical-oncology/gynaecological/ovarian/251-ovarian-high-risk-stage-1-adjuvant-carboplatin"
    },
    {
        "protocol_id": "1088 v.7",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "5 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "5 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "gynaecological",
        "url": "https://www.eviq.org.au/medical-oncology/gynaecological/ovarian/1088-ovarian-recurrent-carboplatin"
    },
    {
        "protocol_id": "1010 v.7",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "DOXOrubicin liposomal",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "30 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "5 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "DOXOrubicin liposomal",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "30 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "5 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "gynaecological",
        "url": "https://www.eviq.org.au/medical-oncology/gynaecological/ovarian/1010-ovarian-recurrent-carboplatin-and-doxorubicin"
    },
    {
        "protocol_id": "1680 v.6",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Gemcitabine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity, usually up to 6 cycles",
                    "dose": "1,000 mg/m2",
                    "day": "1 and 8",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity, usually up to 6 cycles",
                    "dose": "4 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Gemcitabine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity, usually up to 6 cycles",
                    "dose": "1,000 mg/m2",
                    "day": "1 and 8",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity, usually up to 6 cycles",
                    "dose": "4 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "gynaecological",
        "url": "https://www.eviq.org.au/medical-oncology/gynaecological/ovarian/1680-ovarian-recurrent-carboplatin-and-gemcitabine"
    },
    {
        "protocol_id": "4391 v.1",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "beVACizumab *",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "6",
                    "dose": "10 mg/kg",
                    "day": "1 and 15",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "DOXOrubicin liposomal",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "6",
                    "dose": "30 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "6",
                    "dose": "5 AUC **",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "beVACizumab *",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "6",
                    "dose": "10 mg/kg",
                    "day": "1 and 15",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "DOXOrubicin liposomal",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "6",
                    "dose": "30 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "6",
                    "dose": "5 AUC **",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "gynaecological",
        "url": "https://www.eviq.org.au/medical-oncology/gynaecological/ovarian/4391-ovarian-recurrent-carboplatin-doxorubicin-pe"
    },
    {
        "protocol_id": "4002 v.2",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "beVACizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "15 mg/kg",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Gemcitabine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "1,000 mg/m2",
                    "day": "1 and 8",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "4 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "beVACizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "15 mg/kg",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "beVACizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "15 mg/kg",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Gemcitabine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "1,000 mg/m2",
                    "day": "1 and 8",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "4 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "beVACizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "15 mg/kg",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "gynaecological",
        "url": "https://www.eviq.org.au/medical-oncology/gynaecological/ovarian/4002-ovarian-recurrent-carboplatin-gemcitabine-an"
    },
    {
        "protocol_id": "266 v.7",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "DOXOrubicin liposomal",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "40 mg/m2 *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "DOXOrubicin liposomal",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "40 mg/m2 *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "gynaecological",
        "url": "https://www.eviq.org.au/medical-oncology/gynaecological/ovarian/266-ovarian-recurrent-doxorubicin-pegylated-liposo"
    },
    {
        "protocol_id": "3985 v.3",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "beVACizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "10 mg/kg",
                    "day": "1 and 15",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "DOXOrubicin liposomal",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "40 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "beVACizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "10 mg/kg",
                    "day": "1 and 15",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "DOXOrubicin liposomal",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "40 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "gynaecological",
        "url": "https://www.eviq.org.au/medical-oncology/gynaecological/ovarian/3985-ovarian-recurrent-doxorubicin-pegylated-lipos"
    },
    {
        "protocol_id": "264 v.8",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Gemcitabine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity; up to 6 cycles",
                    "dose": "1,000 mg/m2",
                    "day": "1, 8, 15 *",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Gemcitabine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity; up to 6 cycles",
                    "dose": "1,000 mg/m2",
                    "day": "1, 8, 15 *",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "gynaecological",
        "url": "https://www.eviq.org.au/medical-oncology/gynaecological/ovarian/264-ovarian-recurrent-gemcitabine"
    },
    {
        "protocol_id": "255 v.10",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "PACLitaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "7 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "80 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "PACLitaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "7 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "80 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "gynaecological",
        "url": "https://www.eviq.org.au/medical-oncology/gynaecological/ovarian/255-ovarian-recurrent-paclitaxel-weekly"
    },
    {
        "protocol_id": "3986 v.5",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "beVACizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "10 mg/kg",
                    "day": "1 and 15",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "PACLitaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "80 mg/m2",
                    "day": "1, 8, 15, 22",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "beVACizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "10 mg/kg",
                    "day": "1 and 15",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "PACLitaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "80 mg/m2",
                    "day": "1, 8, 15, 22",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "gynaecological",
        "url": "https://www.eviq.org.au/medical-oncology/gynaecological/ovarian/3986-ovarian-recurrent-paclitaxel-weekly-and-bevac"
    },
    {
        "protocol_id": "267 v.7",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Topotecan",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity. Maximum 6 cycles",
                    "dose": "1.5 mg/m2 *",
                    "day": "1 to 3 *",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Topotecan",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity. Maximum 6 cycles",
                    "dose": "1.5 mg/m2 *",
                    "day": "1 to 3 *",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "gynaecological",
        "url": "https://www.eviq.org.au/medical-oncology/gynaecological/ovarian/267-ovarian-recurrent-topotecan-modified-three-w"
    },
    {
        "protocol_id": "1037 v.6",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Topotecan",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity. Maximum 6 cycles",
                    "dose": "4 mg/m2 *",
                    "day": "1, 8, 15",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Topotecan",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity. Maximum 6 cycles",
                    "dose": "4 mg/m2 *",
                    "day": "1, 8, 15",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "gynaecological",
        "url": "https://www.eviq.org.au/medical-oncology/gynaecological/ovarian/1037-ovarian-recurrent-topotecan-weekly"
    },
    {
        "protocol_id": "4042 v.2",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "beVACizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "10 mg/kg",
                    "day": "1 and 15",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Topotecan",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "4 mg/m2 *",
                    "day": "1, 8, 15",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "beVACizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "10 mg/kg",
                    "day": "1 and 15",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Topotecan",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "4 mg/m2 *",
                    "day": "1, 8, 15",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "gynaecological",
        "url": "https://www.eviq.org.au/medical-oncology/gynaecological/ovarian/4042-ovarian-recurrent-topotecan-weekly-and-bevaci"
    },
    {
        "protocol_id": "261 v.4",
        "protocol_status": "Discontinued",
        "drug_sequence": [],
        "section_name": "medical-oncology",
        "category_name": "gynaecological",
        "url": "https://www.eviq.org.au/medical-oncology/gynaecological/ovarian/261-ovarian-recurrent-carboplatin-and-gemcitabine"
    },
    {
        "protocol_id": "270 v.3",
        "protocol_status": "Discontinued",
        "drug_sequence": [],
        "section_name": "medical-oncology",
        "category_name": "gynaecological",
        "url": "https://www.eviq.org.au/medical-oncology/gynaecological/ovarian/270-ovarian-recurrent-cisplatin-and-etoposide-par"
    },
    {
        "protocol_id": "271 v.3",
        "protocol_status": "Discontinued",
        "drug_sequence": [],
        "section_name": "medical-oncology",
        "category_name": "gynaecological",
        "url": "https://www.eviq.org.au/medical-oncology/gynaecological/ovarian/271-ovarian-recurrent-etoposide-oral-part-2-disc"
    },
    {
        "protocol_id": "2026 v.3",
        "protocol_status": "Discontinued",
        "drug_sequence": [],
        "section_name": "medical-oncology",
        "category_name": "gynaecological",
        "url": "https://www.eviq.org.au/medical-oncology/gynaecological/ovarian/2026-ovarian-recurrent-olaparib-capsule-disconti"
    },
    {
        "protocol_id": "254 v.4",
        "protocol_status": "Discontinued",
        "drug_sequence": [],
        "section_name": "medical-oncology",
        "category_name": "gynaecological",
        "url": "https://www.eviq.org.au/medical-oncology/gynaecological/ovarian/254-ovarian-recurrent-paclitaxel-three-weekly-disc"
    },
    {
        "protocol_id": "1529 v.7",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "7 days",
                    "cycles": "Continuous with concurrent radiation therapy; usually 5 or 6 cycles depending on the duration of radiation therapy.",
                    "dose": "40 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "7 days",
                    "cycles": "Continuous with concurrent radiation therapy; usually 5 or 6 cycles depending on the duration of radiation therapy.",
                    "dose": "40 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "gynaecological",
        "url": "https://www.eviq.org.au/medical-oncology/gynaecological/vulval/1529-vulval-advanced-cisplatin-chemoradiation"
    },
    {
        "protocol_id": "336 v.9",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "7 days",
                    "cycles": "Continuous with concurrent radiation therapy; usually 5 or 6 cycles depending on duration of radiation therapy",
                    "dose": "40 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "7 days",
                    "cycles": "Continuous with concurrent radiation therapy; usually 5 or 6 cycles depending on duration of radiation therapy",
                    "dose": "40 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "gynaecological",
        "url": "https://www.eviq.org.au/medical-oncology/gynaecological/cervical/336-cervical-locally-advanced-scc-cisplatin-chemor"
    },
    {
        "protocol_id": "667 v.8",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "PACLitaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity; usually 6 cycles",
                    "dose": "175 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity; usually 6 cycles",
                    "dose": "5 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "PACLitaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity; usually 6 cycles",
                    "dose": "175 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity; usually 6 cycles",
                    "dose": "5 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "gynaecological",
        "url": "https://www.eviq.org.au/medical-oncology/gynaecological/cervical/667-cervical-recurrent-or-metastatic-carboplatin-a"
    },
    {
        "protocol_id": "1989 v.11",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "beVACizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "15 mg/kg",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "PACLitaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "175 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "5 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "beVACizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "15 mg/kg",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "PACLitaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "175 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "5 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "gynaecological",
        "url": "https://www.eviq.org.au/medical-oncology/gynaecological/cervical/1989-cervical-recurrent-or-metastatic-carboplatin"
    },
    {
        "protocol_id": "4170 v.3",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Pembrolizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease recurrence or unacceptable toxicity. In the Keynote-826 clinical trial, 6 cycles of carboplatin, paclitaxel and pembrolizumab were given, after which pembrolizumab was continued up to a maximum of 35 cycles. Patients with ongoing clinical benefit could continue carboplatin and paclitaxel beyond 6 cycles at clinician discretion.",
                    "dose": "200 mg",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "PACLitaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease recurrence or unacceptable toxicity. In the Keynote-826 clinical trial, 6 cycles of carboplatin, paclitaxel and pembrolizumab were given, after which pembrolizumab was continued up to a maximum of 35 cycles. Patients with ongoing clinical benefit could continue carboplatin and paclitaxel beyond 6 cycles at clinician discretion.",
                    "dose": "175 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin *",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease recurrence or unacceptable toxicity. In the Keynote-826 clinical trial, 6 cycles of carboplatin, paclitaxel and pembrolizumab were given, after which pembrolizumab was continued up to a maximum of 35 cycles. Patients with ongoing clinical benefit could continue carboplatin and paclitaxel beyond 6 cycles at clinician discretion.",
                    "dose": "5 AUC **",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Pembrolizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease recurrence or unacceptable toxicity. In the Keynote-826 clinical trial, 6 cycles of carboplatin, paclitaxel and pembrolizumab were given, after which pembrolizumab was continued up to a maximum of 35 cycles. Patients with ongoing clinical benefit could continue carboplatin and paclitaxel beyond 6 cycles at clinician discretion.",
                    "dose": "200 mg ***",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Pembrolizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease recurrence or unacceptable toxicity. In the Keynote-826 clinical trial, 6 cycles of carboplatin, paclitaxel and pembrolizumab were given, after which pembrolizumab was continued up to a maximum of 35 cycles. Patients with ongoing clinical benefit could continue carboplatin and paclitaxel beyond 6 cycles at clinician discretion.",
                    "dose": "200 mg",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "PACLitaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease recurrence or unacceptable toxicity. In the Keynote-826 clinical trial, 6 cycles of carboplatin, paclitaxel and pembrolizumab were given, after which pembrolizumab was continued up to a maximum of 35 cycles. Patients with ongoing clinical benefit could continue carboplatin and paclitaxel beyond 6 cycles at clinician discretion.",
                    "dose": "175 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin *",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease recurrence or unacceptable toxicity. In the Keynote-826 clinical trial, 6 cycles of carboplatin, paclitaxel and pembrolizumab were given, after which pembrolizumab was continued up to a maximum of 35 cycles. Patients with ongoing clinical benefit could continue carboplatin and paclitaxel beyond 6 cycles at clinician discretion.",
                    "dose": "5 AUC **",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Pembrolizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease recurrence or unacceptable toxicity. In the Keynote-826 clinical trial, 6 cycles of carboplatin, paclitaxel and pembrolizumab were given, after which pembrolizumab was continued up to a maximum of 35 cycles. Patients with ongoing clinical benefit could continue carboplatin and paclitaxel beyond 6 cycles at clinician discretion.",
                    "dose": "200 mg ***",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "gynaecological",
        "url": "https://www.eviq.org.au/medical-oncology/gynaecological/cervical/4170-cervical-recurrent-or-metastatic-carboplatin"
    },
    {
        "protocol_id": "4169 v.3",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Pembrolizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease recurrence or unacceptable toxicity. In the Keynote-826 clinical trial, 6 cycles of carboplatin, paclitaxel, bevacizumab and pembrolizumab were given, after which bevacizumab and pembrolizumab were continued up to a maximum of 35 cycles. Patients with ongoing clinical benefit could continue carboplatin and paclitaxel beyond 6 cycles at clinician discretion.",
                    "dose": "200 mg",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "beVACizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease recurrence or unacceptable toxicity. In the Keynote-826 clinical trial, 6 cycles of carboplatin, paclitaxel, bevacizumab and pembrolizumab were given, after which bevacizumab and pembrolizumab were continued up to a maximum of 35 cycles. Patients with ongoing clinical benefit could continue carboplatin and paclitaxel beyond 6 cycles at clinician discretion.",
                    "dose": "15 mg/kg",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "PACLitaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease recurrence or unacceptable toxicity. In the Keynote-826 clinical trial, 6 cycles of carboplatin, paclitaxel, bevacizumab and pembrolizumab were given, after which bevacizumab and pembrolizumab were continued up to a maximum of 35 cycles. Patients with ongoing clinical benefit could continue carboplatin and paclitaxel beyond 6 cycles at clinician discretion.",
                    "dose": "175 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin *",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease recurrence or unacceptable toxicity. In the Keynote-826 clinical trial, 6 cycles of carboplatin, paclitaxel, bevacizumab and pembrolizumab were given, after which bevacizumab and pembrolizumab were continued up to a maximum of 35 cycles. Patients with ongoing clinical benefit could continue carboplatin and paclitaxel beyond 6 cycles at clinician discretion.",
                    "dose": "5 AUC **",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Pembrolizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease recurrence or unacceptable toxicity. In the Keynote-826 clinical trial, 6 cycles of carboplatin, paclitaxel, bevacizumab and pembrolizumab were given, after which bevacizumab and pembrolizumab were continued up to a maximum of 35 cycles. Patients with ongoing clinical benefit could continue carboplatin and paclitaxel beyond 6 cycles at clinician discretion.",
                    "dose": "200 mg",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "beVACizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease recurrence or unacceptable toxicity. In the Keynote-826 clinical trial, 6 cycles of carboplatin, paclitaxel, bevacizumab and pembrolizumab were given, after which bevacizumab and pembrolizumab were continued up to a maximum of 35 cycles. Patients with ongoing clinical benefit could continue carboplatin and paclitaxel beyond 6 cycles at clinician discretion.",
                    "dose": "15 mg/kg",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Pembrolizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease recurrence or unacceptable toxicity. In the Keynote-826 clinical trial, 6 cycles of carboplatin, paclitaxel, bevacizumab and pembrolizumab were given, after which bevacizumab and pembrolizumab were continued up to a maximum of 35 cycles. Patients with ongoing clinical benefit could continue carboplatin and paclitaxel beyond 6 cycles at clinician discretion.",
                    "dose": "200 mg",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "beVACizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease recurrence or unacceptable toxicity. In the Keynote-826 clinical trial, 6 cycles of carboplatin, paclitaxel, bevacizumab and pembrolizumab were given, after which bevacizumab and pembrolizumab were continued up to a maximum of 35 cycles. Patients with ongoing clinical benefit could continue carboplatin and paclitaxel beyond 6 cycles at clinician discretion.",
                    "dose": "15 mg/kg",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "PACLitaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease recurrence or unacceptable toxicity. In the Keynote-826 clinical trial, 6 cycles of carboplatin, paclitaxel, bevacizumab and pembrolizumab were given, after which bevacizumab and pembrolizumab were continued up to a maximum of 35 cycles. Patients with ongoing clinical benefit could continue carboplatin and paclitaxel beyond 6 cycles at clinician discretion.",
                    "dose": "175 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin *",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease recurrence or unacceptable toxicity. In the Keynote-826 clinical trial, 6 cycles of carboplatin, paclitaxel, bevacizumab and pembrolizumab were given, after which bevacizumab and pembrolizumab were continued up to a maximum of 35 cycles. Patients with ongoing clinical benefit could continue carboplatin and paclitaxel beyond 6 cycles at clinician discretion.",
                    "dose": "5 AUC **",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Pembrolizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease recurrence or unacceptable toxicity. In the Keynote-826 clinical trial, 6 cycles of carboplatin, paclitaxel, bevacizumab and pembrolizumab were given, after which bevacizumab and pembrolizumab were continued up to a maximum of 35 cycles. Patients with ongoing clinical benefit could continue carboplatin and paclitaxel beyond 6 cycles at clinician discretion.",
                    "dose": "200 mg",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "beVACizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease recurrence or unacceptable toxicity. In the Keynote-826 clinical trial, 6 cycles of carboplatin, paclitaxel, bevacizumab and pembrolizumab were given, after which bevacizumab and pembrolizumab were continued up to a maximum of 35 cycles. Patients with ongoing clinical benefit could continue carboplatin and paclitaxel beyond 6 cycles at clinician discretion.",
                    "dose": "15 mg/kg",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "gynaecological",
        "url": "https://www.eviq.org.au/medical-oncology/gynaecological/cervical/4169-cervical-recurrent-or-metastatic-carboplatin"
    },
    {
        "protocol_id": "1988 v.10",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "beVACizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "15 mg/kg",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "PACLitaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "175 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "50 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "beVACizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "15 mg/kg",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "PACLitaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "175 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "50 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "gynaecological",
        "url": "https://www.eviq.org.au/medical-oncology/gynaecological/cervical/1988-cervical-recurrent-or-metastatic-cisplatin-p"
    },
    {
        "protocol_id": "4181 v.3",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Pembrolizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity. In the Keynote-826 clinical trial, 6 cycles of cisplatin, paclitaxel and pembrolizumab were given, after which pembrolizumab was continued up to a maximum of 35 cycles. Patients with ongoing clinical benefit could continue cisplatin and paclitaxel beyond 6 cycles at clinician discretion.",
                    "dose": "200 mg",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "PACLitaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity. In the Keynote-826 clinical trial, 6 cycles of cisplatin, paclitaxel and pembrolizumab were given, after which pembrolizumab was continued up to a maximum of 35 cycles. Patients with ongoing clinical benefit could continue cisplatin and paclitaxel beyond 6 cycles at clinician discretion.",
                    "dose": "175 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "ciSplatin *",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity. In the Keynote-826 clinical trial, 6 cycles of cisplatin, paclitaxel and pembrolizumab were given, after which pembrolizumab was continued up to a maximum of 35 cycles. Patients with ongoing clinical benefit could continue cisplatin and paclitaxel beyond 6 cycles at clinician discretion.",
                    "dose": "50 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Pembrolizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity. In the Keynote-826 clinical trial, 6 cycles of cisplatin, paclitaxel and pembrolizumab were given, after which pembrolizumab was continued up to a maximum of 35 cycles. Patients with ongoing clinical benefit could continue cisplatin and paclitaxel beyond 6 cycles at clinician discretion.",
                    "dose": "200 mg **",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Pembrolizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity. In the Keynote-826 clinical trial, 6 cycles of cisplatin, paclitaxel and pembrolizumab were given, after which pembrolizumab was continued up to a maximum of 35 cycles. Patients with ongoing clinical benefit could continue cisplatin and paclitaxel beyond 6 cycles at clinician discretion.",
                    "dose": "200 mg",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "PACLitaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity. In the Keynote-826 clinical trial, 6 cycles of cisplatin, paclitaxel and pembrolizumab were given, after which pembrolizumab was continued up to a maximum of 35 cycles. Patients with ongoing clinical benefit could continue cisplatin and paclitaxel beyond 6 cycles at clinician discretion.",
                    "dose": "175 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "ciSplatin *",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity. In the Keynote-826 clinical trial, 6 cycles of cisplatin, paclitaxel and pembrolizumab were given, after which pembrolizumab was continued up to a maximum of 35 cycles. Patients with ongoing clinical benefit could continue cisplatin and paclitaxel beyond 6 cycles at clinician discretion.",
                    "dose": "50 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Pembrolizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity. In the Keynote-826 clinical trial, 6 cycles of cisplatin, paclitaxel and pembrolizumab were given, after which pembrolizumab was continued up to a maximum of 35 cycles. Patients with ongoing clinical benefit could continue cisplatin and paclitaxel beyond 6 cycles at clinician discretion.",
                    "dose": "200 mg **",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "gynaecological",
        "url": "https://www.eviq.org.au/medical-oncology/gynaecological/cervical/4181-cervical-recurrent-or-metastatic-cisplatin-p"
    },
    {
        "protocol_id": "4180 v.3",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Pembrolizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity. In the Keynote-826 clinical trial, 6 cycles of cisplatin, paclitaxel, bevacizumab and pembrolizumab were given, after which bevacizumab and pembrolizumab were continued up to a maximum of 35 cycles. Patients with ongoing clinical benefit could continue cisplatin and paclitaxel beyond 6 cycles at clinician discretion",
                    "dose": "200 mg",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "beVACizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity. In the Keynote-826 clinical trial, 6 cycles of cisplatin, paclitaxel, bevacizumab and pembrolizumab were given, after which bevacizumab and pembrolizumab were continued up to a maximum of 35 cycles. Patients with ongoing clinical benefit could continue cisplatin and paclitaxel beyond 6 cycles at clinician discretion",
                    "dose": "15 mg/kg",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "PACLitaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity. In the Keynote-826 clinical trial, 6 cycles of cisplatin, paclitaxel, bevacizumab and pembrolizumab were given, after which bevacizumab and pembrolizumab were continued up to a maximum of 35 cycles. Patients with ongoing clinical benefit could continue cisplatin and paclitaxel beyond 6 cycles at clinician discretion",
                    "dose": "175 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "ciSplatin *",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity. In the Keynote-826 clinical trial, 6 cycles of cisplatin, paclitaxel, bevacizumab and pembrolizumab were given, after which bevacizumab and pembrolizumab were continued up to a maximum of 35 cycles. Patients with ongoing clinical benefit could continue cisplatin and paclitaxel beyond 6 cycles at clinician discretion",
                    "dose": "50 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Pembrolizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity. In the Keynote-826 clinical trial, 6 cycles of cisplatin, paclitaxel, bevacizumab and pembrolizumab were given, after which bevacizumab and pembrolizumab were continued up to a maximum of 35 cycles. Patients with ongoing clinical benefit could continue cisplatin and paclitaxel beyond 6 cycles at clinician discretion",
                    "dose": "200 mg",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "beVACizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity. In the Keynote-826 clinical trial, 6 cycles of cisplatin, paclitaxel, bevacizumab and pembrolizumab were given, after which bevacizumab and pembrolizumab were continued up to a maximum of 35 cycles. Patients with ongoing clinical benefit could continue cisplatin and paclitaxel beyond 6 cycles at clinician discretion",
                    "dose": "15 mg/kg",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Pembrolizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity. In the Keynote-826 clinical trial, 6 cycles of cisplatin, paclitaxel, bevacizumab and pembrolizumab were given, after which bevacizumab and pembrolizumab were continued up to a maximum of 35 cycles. Patients with ongoing clinical benefit could continue cisplatin and paclitaxel beyond 6 cycles at clinician discretion",
                    "dose": "200 mg",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "beVACizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity. In the Keynote-826 clinical trial, 6 cycles of cisplatin, paclitaxel, bevacizumab and pembrolizumab were given, after which bevacizumab and pembrolizumab were continued up to a maximum of 35 cycles. Patients with ongoing clinical benefit could continue cisplatin and paclitaxel beyond 6 cycles at clinician discretion",
                    "dose": "15 mg/kg",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "PACLitaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity. In the Keynote-826 clinical trial, 6 cycles of cisplatin, paclitaxel, bevacizumab and pembrolizumab were given, after which bevacizumab and pembrolizumab were continued up to a maximum of 35 cycles. Patients with ongoing clinical benefit could continue cisplatin and paclitaxel beyond 6 cycles at clinician discretion",
                    "dose": "175 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "ciSplatin *",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity. In the Keynote-826 clinical trial, 6 cycles of cisplatin, paclitaxel, bevacizumab and pembrolizumab were given, after which bevacizumab and pembrolizumab were continued up to a maximum of 35 cycles. Patients with ongoing clinical benefit could continue cisplatin and paclitaxel beyond 6 cycles at clinician discretion",
                    "dose": "50 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Pembrolizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity. In the Keynote-826 clinical trial, 6 cycles of cisplatin, paclitaxel, bevacizumab and pembrolizumab were given, after which bevacizumab and pembrolizumab were continued up to a maximum of 35 cycles. Patients with ongoing clinical benefit could continue cisplatin and paclitaxel beyond 6 cycles at clinician discretion",
                    "dose": "200 mg",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "beVACizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity. In the Keynote-826 clinical trial, 6 cycles of cisplatin, paclitaxel, bevacizumab and pembrolizumab were given, after which bevacizumab and pembrolizumab were continued up to a maximum of 35 cycles. Patients with ongoing clinical benefit could continue cisplatin and paclitaxel beyond 6 cycles at clinician discretion",
                    "dose": "15 mg/kg",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "gynaecological",
        "url": "https://www.eviq.org.au/medical-oncology/gynaecological/cervical/4180-cervical-recurrent-or-metastatic-cisplatin-p"
    },
    {
        "protocol_id": "3730 v.4",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "PACLitaxel",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6",
                    "dose": "175 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6",
                    "dose": "6 AUC *#",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "PACLitaxel",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6",
                    "dose": "175 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6",
                    "dose": "6 AUC *#",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "gynaecological",
        "url": "https://www.eviq.org.au/medical-oncology/gynaecological/endometrial/3730-endometrial-adjuvant-carboplatin-and-paclitax"
    },
    {
        "protocol_id": "3664 v.5",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "PACLitaxel",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4(this treatment is commenced within 3 weeks after the completion of radiation therapy)",
                    "dose": "175 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4(this treatment is commenced within 3 weeks after the completion of radiation therapy)",
                    "dose": "5 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "PACLitaxel",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4(this treatment is commenced within 3 weeks after the completion of radiation therapy)",
                    "dose": "175 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4(this treatment is commenced within 3 weeks after the completion of radiation therapy)",
                    "dose": "5 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "gynaecological",
        "url": "https://www.eviq.org.au/medical-oncology/gynaecological/endometrial/3664-endometrial-adjuvant-carboplatin-and-paclitax"
    },
    {
        "protocol_id": "3663 v.4",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": "1with concurrent radiation therapy (week 1 and 4) (this treatment is followed by chemotherapy commencing within 3 weeks after the completion of radiation therapy)",
                    "dose": "50 mg/m2",
                    "day": "1 and 22",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": "1with concurrent radiation therapy (week 1 and 4) (this treatment is followed by chemotherapy commencing within 3 weeks after the completion of radiation therapy)",
                    "dose": "50 mg/m2",
                    "day": "1 and 22",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "gynaecological",
        "url": "https://www.eviq.org.au/medical-oncology/gynaecological/endometrial/3663-endometrial-adjuvant-cisplatin-chemoradiation"
    },
    {
        "protocol_id": "3661 v.1",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "cisplatin",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "21days",
                    "cycles": "1",
                    "dose": "",
                    "day": 1,
                    "route": "IV"
                }
            ],
            [
                {
                    "drug_name": "paclitaxel",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "21days",
                    "cycles": "1",
                    "dose": "",
                    "day": 1,
                    "route": "IV"
                },
                {
                    "drug_name": "carboplatin",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "21days",
                    "cycles": "1",
                    "dose": "",
                    "day": 1,
                    "route": "IV"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "gynaecological",
        "url": "https://www.eviq.org.au/medical-oncology/gynaecological/endometrial/3661-endometrial-adjuvant-cisplatin-chemoradiation"
    },
    {
        "protocol_id": "1914 v.3",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Medroxyprogesterone acetate",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "200 mg ONCE a day",
                    "day": null,
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Medroxyprogesterone acetate",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "200 mg ONCE a day",
                    "day": null,
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "gynaecological",
        "url": "https://www.eviq.org.au/medical-oncology/gynaecological/endometrial/1914-endometrial-recurrent-medroxyprogesterone-ace"
    },
    {
        "protocol_id": "708 v.8",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "PACLitaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity; usually 6 cycles",
                    "dose": "175 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity; usually 6 cycles",
                    "dose": "5 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "PACLitaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity; usually 6 cycles",
                    "dose": "175 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity; usually 6 cycles",
                    "dose": "5 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "gynaecological",
        "url": "https://www.eviq.org.au/medical-oncology/gynaecological/endometrial/708-endometrial-recurrent-or-metastatic-carboplati"
    },
    {
        "protocol_id": "4322 v.1",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Pembrolizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (up to 35 cycles of pembrolizumab). Lenvatinib monotherapy can be continued beyond 35 cycles until disease progression or unacceptable toxicity.",
                    "dose": "200 mg *",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "leNVAtinib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (up to 35 cycles of pembrolizumab). Lenvatinib monotherapy can be continued beyond 35 cycles until disease progression or unacceptable toxicity.",
                    "dose": "20 mg ONCE a day **",
                    "day": "1 to 21",
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Pembrolizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (up to 35 cycles of pembrolizumab). Lenvatinib monotherapy can be continued beyond 35 cycles until disease progression or unacceptable toxicity.",
                    "dose": "200 mg *",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "leNVAtinib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (up to 35 cycles of pembrolizumab). Lenvatinib monotherapy can be continued beyond 35 cycles until disease progression or unacceptable toxicity.",
                    "dose": "20 mg ONCE a day **",
                    "day": "1 to 21",
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "gynaecological",
        "url": "https://www.eviq.org.au/medical-oncology/gynaecological/endometrial/4163-redirect-id-4322"
    },
    {
        "protocol_id": "1602 v.5",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "pAZOPanib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "800 mg ONCE a day",
                    "day": null,
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "pAZOPanib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "800 mg ONCE a day",
                    "day": null,
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "gynaecological",
        "url": "https://www.eviq.org.au/medical-oncology/gynaecological/endometrial/3394-1602-redirect"
    },
    {
        "protocol_id": "1554 v.5",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "DOXOrubicin *",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (up to 6 cycles)",
                    "dose": "75 mg/m2",
                    "day": "1",
                    "route": "IV **"
                },
                {
                    "drug_name": "Pegfilgrastim",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (up to 6 cycles)",
                    "dose": "6 mg",
                    "day": "2",
                    "route": "Subcut"
                }
            ],
            [
                {
                    "drug_name": "DOXOrubicin *",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (up to 6 cycles)",
                    "dose": "75 mg/m2",
                    "day": "1",
                    "route": "IV **"
                },
                {
                    "drug_name": "Pegfilgrastim",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (up to 6 cycles)",
                    "dose": "6 mg",
                    "day": "2",
                    "route": "Subcut"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "gynaecological",
        "url": "https://www.eviq.org.au/medical-oncology/gynaecological/endometrial/3395-1554-redirect"
    },
    {
        "protocol_id": "1659 v.8",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "DOXOrubicin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (maximum 6 cycles)",
                    "dose": "25 mg/m2",
                    "day": "1 to 3",
                    "route": "IV"
                },
                {
                    "drug_name": "Mesna",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (maximum 6 cycles)",
                    "dose": "500 mg/m2",
                    "day": "1 to 4",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "iFOSFamide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (maximum 6 cycles)",
                    "dose": "2,500 mg/m2",
                    "day": "1 to 4",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Mesna *",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (maximum 6 cycles)",
                    "dose": "1,500 mg/m2",
                    "day": "1 to 4",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Mesna **",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (maximum 6 cycles)",
                    "dose": "2,000 mg",
                    "day": "1 to 4",
                    "route": "PO"
                },
                {
                    "drug_name": "Pegfilgrastim",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (maximum 6 cycles)",
                    "dose": "6 mg",
                    "day": "5",
                    "route": "Subcut"
                }
            ],
            [
                {
                    "drug_name": "DOXOrubicin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (maximum 6 cycles)",
                    "dose": "25 mg/m2",
                    "day": "1 to 3",
                    "route": "IV"
                },
                {
                    "drug_name": "Mesna",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (maximum 6 cycles)",
                    "dose": "500 mg/m2",
                    "day": "1 to 4",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "iFOSFamide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (maximum 6 cycles)",
                    "dose": "2,500 mg/m2",
                    "day": "1 to 4",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Mesna *",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (maximum 6 cycles)",
                    "dose": "1,500 mg/m2",
                    "day": "1 to 4",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Mesna **",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (maximum 6 cycles)",
                    "dose": "2,000 mg",
                    "day": "1 to 4",
                    "route": "PO"
                },
                {
                    "drug_name": "Pegfilgrastim",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (maximum 6 cycles)",
                    "dose": "6 mg",
                    "day": "5",
                    "route": "Subcut"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "gynaecological",
        "url": "https://www.eviq.org.au/medical-oncology/gynaecological/endometrial/3396-1659-redirect"
    },
    {
        "protocol_id": "1898 v.5",
        "protocol_status": "Under review",
        "drug_sequence": [
            [
                {
                    "drug_name": "Gemcitabine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "until disease progression or unacceptable toxicity (usually 6 cycles)",
                    "dose": "900 mg/m2 *",
                    "day": "1 and 8",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "DOCEtaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "until disease progression or unacceptable toxicity (usually 6 cycles)",
                    "dose": "75 mg/m2 *",
                    "day": "8",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Pegfilgrastim",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "until disease progression or unacceptable toxicity (usually 6 cycles)",
                    "dose": "6 mg",
                    "day": "9",
                    "route": "Subcut"
                }
            ],
            [
                {
                    "drug_name": "Gemcitabine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "until disease progression or unacceptable toxicity (usually 6 cycles)",
                    "dose": "900 mg/m2 *",
                    "day": "1 and 8",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "DOCEtaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "until disease progression or unacceptable toxicity (usually 6 cycles)",
                    "dose": "75 mg/m2 *",
                    "day": "8",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Pegfilgrastim",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "until disease progression or unacceptable toxicity (usually 6 cycles)",
                    "dose": "6 mg",
                    "day": "9",
                    "route": "Subcut"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "gynaecological",
        "url": "https://www.eviq.org.au/medical-oncology/gynaecological/endometrial/3551-1898-redirect"
    },
    {
        "protocol_id": "672 v.7",
        "protocol_status": "Superseded",
        "drug_sequence": [
            [
                {
                    "drug_name": "DOXOrubicin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6",
                    "dose": "60 mg/m2",
                    "day": "1",
                    "route": "IV"
                },
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6",
                    "dose": "50 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "DOXOrubicin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6",
                    "dose": "60 mg/m2",
                    "day": "1",
                    "route": "IV"
                },
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6",
                    "dose": "50 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "gynaecological",
        "url": "https://www.eviq.org.au/medical-oncology/gynaecological/endometrial/672-endometrial-recurrent-or-metastatic-ap-doxoru"
    },
    {
        "protocol_id": "599 v.6",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "daCTINomycin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous for 3 cycles beyond normal \u00df-hCG",
                    "dose": "0.5 mg",
                    "day": "1 and 2",
                    "route": "IV"
                },
                {
                    "drug_name": "Etoposide *",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous for 3 cycles beyond normal \u00df-hCG",
                    "dose": "100 mg/m2",
                    "day": "1 and 2",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Methotrexate",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous for 3 cycles beyond normal \u00df-hCG",
                    "dose": "300 mg/m2",
                    "day": "1",
                    "route": "IV infusion over 12 hours"
                },
                {
                    "drug_name": "Filgrastim",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous for 3 cycles beyond normal \u00df-hCG",
                    "dose": "5 micrograms/kg",
                    "day": "3 to 5 and 9 to 11 **",
                    "route": "Subcut"
                },
                {
                    "drug_name": "Calcium folinate (Leucovorin)",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous for 3 cycles beyond normal \u00df-hCG",
                    "dose": "15 mg every 12 hours for 4 doses (to be commenced 24 hours after the start of methotrexate)",
                    "day": "2",
                    "route": "PO"
                },
                {
                    "drug_name": "vinCRISTine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous for 3 cycles beyond normal \u00df-hCG",
                    "dose": "1 mg/m2\n(Cap dose at 2 mg)",
                    "day": "8",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "CYCLOPHOSPHamide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous for 3 cycles beyond normal \u00df-hCG",
                    "dose": "600 mg/m2",
                    "day": "8",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "daCTINomycin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous for 3 cycles beyond normal \u00df-hCG",
                    "dose": "0.5 mg",
                    "day": "1 and 2",
                    "route": "IV"
                },
                {
                    "drug_name": "Etoposide *",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous for 3 cycles beyond normal \u00df-hCG",
                    "dose": "100 mg/m2",
                    "day": "1 and 2",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Methotrexate",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous for 3 cycles beyond normal \u00df-hCG",
                    "dose": "300 mg/m2",
                    "day": "1",
                    "route": "IV infusion over 12 hours"
                },
                {
                    "drug_name": "Filgrastim",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous for 3 cycles beyond normal \u00df-hCG",
                    "dose": "5 micrograms/kg",
                    "day": "3 to 5 and 9 to 11 **",
                    "route": "Subcut"
                },
                {
                    "drug_name": "Calcium folinate (Leucovorin)",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous for 3 cycles beyond normal \u00df-hCG",
                    "dose": "15 mg every 12 hours for 4 doses (to be commenced 24 hours after the start of methotrexate)",
                    "day": "2",
                    "route": "PO"
                },
                {
                    "drug_name": "vinCRISTine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous for 3 cycles beyond normal \u00df-hCG",
                    "dose": "1 mg/m2\n(Cap dose at 2 mg)",
                    "day": "8",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "CYCLOPHOSPHamide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous for 3 cycles beyond normal \u00df-hCG",
                    "dose": "600 mg/m2",
                    "day": "8",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "gynaecological",
        "url": "https://www.eviq.org.au/medical-oncology/gynaecological/gestational-trophoblastic-disease/599-gestational-trophoblastic-disease-high-risk-em"
    },
    {
        "protocol_id": "1378 v.6",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Etoposide *",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous for 3 cycles beyond normal \u00df-hCG",
                    "dose": "150 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous for 3 cycles beyond normal \u00df-hCG",
                    "dose": "75 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Filgrastim",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous for 3 cycles beyond normal \u00df-hCG",
                    "dose": "5 micrograms/kg",
                    "day": "2 to 4 and 9 to 11 **",
                    "route": "Subcut"
                },
                {
                    "drug_name": "daCTINomycin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous for 3 cycles beyond normal \u00df-hCG",
                    "dose": "0.5 mg",
                    "day": "8",
                    "route": "IV"
                },
                {
                    "drug_name": "Etoposide *",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous for 3 cycles beyond normal \u00df-hCG",
                    "dose": "100 mg/m2",
                    "day": "8",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Methotrexate",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous for 3 cycles beyond normal \u00df-hCG",
                    "dose": "300 mg/m2",
                    "day": "8",
                    "route": "IV infusion over 12 hours"
                },
                {
                    "drug_name": "Calcium folinate (Leucovorin)",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous for 3 cycles beyond normal \u00df-hCG",
                    "dose": "15 mg every 12 hours for 4 doses (to be commenced 24 hours after the start of methotrexate)",
                    "day": "9",
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Etoposide *",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous for 3 cycles beyond normal \u00df-hCG",
                    "dose": "150 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous for 3 cycles beyond normal \u00df-hCG",
                    "dose": "75 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Filgrastim",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous for 3 cycles beyond normal \u00df-hCG",
                    "dose": "5 micrograms/kg",
                    "day": "2 to 4 and 9 to 11 **",
                    "route": "Subcut"
                },
                {
                    "drug_name": "daCTINomycin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous for 3 cycles beyond normal \u00df-hCG",
                    "dose": "0.5 mg",
                    "day": "8",
                    "route": "IV"
                },
                {
                    "drug_name": "Etoposide *",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous for 3 cycles beyond normal \u00df-hCG",
                    "dose": "100 mg/m2",
                    "day": "8",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Methotrexate",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous for 3 cycles beyond normal \u00df-hCG",
                    "dose": "300 mg/m2",
                    "day": "8",
                    "route": "IV infusion over 12 hours"
                },
                {
                    "drug_name": "Calcium folinate (Leucovorin)",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous for 3 cycles beyond normal \u00df-hCG",
                    "dose": "15 mg every 12 hours for 4 doses (to be commenced 24 hours after the start of methotrexate)",
                    "day": "9",
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "gynaecological",
        "url": "https://www.eviq.org.au/medical-oncology/gynaecological/gestational-trophoblastic-disease/1378-gestational-trophoblastic-disease-high-risk-e"
    },
    {
        "protocol_id": "1018 v.6",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "daCTINomycin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous for 3 cycles beyond normal \u00df-hCG",
                    "dose": "1.25 mg/m2 (cap at 2 mg)",
                    "day": "1",
                    "route": "IV"
                }
            ],
            [
                {
                    "drug_name": "daCTINomycin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous for 3 cycles beyond normal \u00df-hCG",
                    "dose": "1.25 mg/m2 (cap at 2 mg)",
                    "day": "1",
                    "route": "IV"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "gynaecological",
        "url": "https://www.eviq.org.au/medical-oncology/gynaecological/gestational-trophoblastic-disease/1018-gestational-trophoblastic-disease-low-risk-da"
    },
    {
        "protocol_id": "668 v.4",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Methotrexate",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous for 3 cycles beyond normal \u00df-hCG",
                    "dose": "50 mg",
                    "day": "1, 3, 5, 7 **",
                    "route": "IM *"
                },
                {
                    "drug_name": "Calcium folinate (Leucovorin)",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous for 3 cycles beyond normal \u00df-hCG",
                    "dose": "15 mg (24 hours post methotrexate)",
                    "day": "2, 4, 6, 8 **",
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Methotrexate",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous for 3 cycles beyond normal \u00df-hCG",
                    "dose": "50 mg",
                    "day": "1, 3, 5, 7 **",
                    "route": "IM *"
                },
                {
                    "drug_name": "Calcium folinate (Leucovorin)",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous for 3 cycles beyond normal \u00df-hCG",
                    "dose": "15 mg (24 hours post methotrexate)",
                    "day": "2, 4, 6, 8 **",
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "gynaecological",
        "url": "https://www.eviq.org.au/medical-oncology/gynaecological/gestational-trophoblastic-disease/668-gestational-trophoblastic-disease-low-risk-met"
    },
    {
        "protocol_id": "1347 v.3",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Etoposide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "7 days",
                    "cycles": "until well enough to commence treatment with EMA-CO",
                    "dose": "100 mg/m2 *",
                    "day": "1 and 2",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "7 days",
                    "cycles": "until well enough to commence treatment with EMA-CO",
                    "dose": "20 mg/m2",
                    "day": "1 and 2",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Etoposide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "7 days",
                    "cycles": "until well enough to commence treatment with EMA-CO",
                    "dose": "100 mg/m2 *",
                    "day": "1 and 2",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "7 days",
                    "cycles": "until well enough to commence treatment with EMA-CO",
                    "dose": "20 mg/m2",
                    "day": "1 and 2",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "gynaecological",
        "url": "https://www.eviq.org.au/medical-oncology/gynaecological/gestational-trophoblastic-disease/1347-gestational-trophoblastic-disease-very-high-r"
    },
    {
        "protocol_id": "3737 v.4",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Olaparib (tablets)",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "300 mg TWICE a day",
                    "day": null,
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Olaparib (tablets)",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "300 mg TWICE a day",
                    "day": null,
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "gynaecological",
        "url": "https://www.eviq.org.au/medical-oncology/gynaecological/ovarian/3737-advanced-metastatic-or-recurrent-olaparib"
    },
    {
        "protocol_id": "259 v.9",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "DOCEtaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity. Maximum of 6 cycles",
                    "dose": "75 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity. Maximum of 6 cycles",
                    "dose": "5 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "DOCEtaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity. Maximum of 6 cycles",
                    "dose": "75 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity. Maximum of 6 cycles",
                    "dose": "5 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "gynaecological",
        "url": "https://www.eviq.org.au/medical-oncology/gynaecological/ovarian/259-ovarian-advanced-carboplatin-and-docetaxel"
    },
    {
        "protocol_id": "252 v.11",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "PACLitaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity; usually 6 cycles",
                    "dose": "175 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity; usually 6 cycles",
                    "dose": "5 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "PACLitaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity; usually 6 cycles",
                    "dose": "175 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity; usually 6 cycles",
                    "dose": "5 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "gynaecological",
        "url": "https://www.eviq.org.au/medical-oncology/gynaecological/ovarian/252-ovarian-advanced-carboplatin-and-paclitaxel-th"
    },
    {
        "protocol_id": "1897 v.7",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "PACLitaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "7 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (18 cycles were administered in the clinical trial)",
                    "dose": "60 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "7 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (18 cycles were administered in the clinical trial)",
                    "dose": "2 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "PACLitaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "7 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (18 cycles were administered in the clinical trial)",
                    "dose": "60 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "7 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (18 cycles were administered in the clinical trial)",
                    "dose": "2 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "gynaecological",
        "url": "https://www.eviq.org.au/medical-oncology/gynaecological/ovarian/1897-ovarian-advanced-carboplatin-and-paclitaxel-w"
    },
    {
        "protocol_id": "1016 v.11",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "PACLitaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity; usually 6 cycles",
                    "dose": "80 mg/m2",
                    "day": "1, 8, 15",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity; usually 6 cycles",
                    "dose": "5 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "PACLitaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity; usually 6 cycles",
                    "dose": "80 mg/m2",
                    "day": "1, 8, 15",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity; usually 6 cycles",
                    "dose": "5 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "gynaecological",
        "url": "https://www.eviq.org.au/medical-oncology/gynaecological/ovarian/1016-ovarian-advanced-carboplatin-three-weekly-and"
    },
    {
        "protocol_id": "1601 v.13",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "PACLitaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "19(1 cycle of carboplatin and paclitaxel, followed by 5 cycles of carboplatin, paclitaxel and bevacizumab, followed by 13 cycles of bevacizumab unless disease progression or unacceptable toxicity)",
                    "dose": "175 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "19(1 cycle of carboplatin and paclitaxel, followed by 5 cycles of carboplatin, paclitaxel and bevacizumab, followed by 13 cycles of bevacizumab unless disease progression or unacceptable toxicity)",
                    "dose": "5 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "beVACizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "19(1 cycle of carboplatin and paclitaxel, followed by 5 cycles of carboplatin, paclitaxel and bevacizumab, followed by 13 cycles of bevacizumab unless disease progression or unacceptable toxicity)",
                    "dose": "7.5 mg/kg",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "PACLitaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "19(1 cycle of carboplatin and paclitaxel, followed by 5 cycles of carboplatin, paclitaxel and bevacizumab, followed by 13 cycles of bevacizumab unless disease progression or unacceptable toxicity)",
                    "dose": "175 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "19(1 cycle of carboplatin and paclitaxel, followed by 5 cycles of carboplatin, paclitaxel and bevacizumab, followed by 13 cycles of bevacizumab unless disease progression or unacceptable toxicity)",
                    "dose": "5 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "beVACizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "19(1 cycle of carboplatin and paclitaxel, followed by 5 cycles of carboplatin, paclitaxel and bevacizumab, followed by 13 cycles of bevacizumab unless disease progression or unacceptable toxicity)",
                    "dose": "7.5 mg/kg",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "PACLitaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "19(1 cycle of carboplatin and paclitaxel, followed by 5 cycles of carboplatin, paclitaxel and bevacizumab, followed by 13 cycles of bevacizumab unless disease progression or unacceptable toxicity)",
                    "dose": "175 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "19(1 cycle of carboplatin and paclitaxel, followed by 5 cycles of carboplatin, paclitaxel and bevacizumab, followed by 13 cycles of bevacizumab unless disease progression or unacceptable toxicity)",
                    "dose": "5 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "beVACizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "19(1 cycle of carboplatin and paclitaxel, followed by 5 cycles of carboplatin, paclitaxel and bevacizumab, followed by 13 cycles of bevacizumab unless disease progression or unacceptable toxicity)",
                    "dose": "7.5 mg/kg",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "PACLitaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "19(1 cycle of carboplatin and paclitaxel, followed by 5 cycles of carboplatin, paclitaxel and bevacizumab, followed by 13 cycles of bevacizumab unless disease progression or unacceptable toxicity)",
                    "dose": "175 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "19(1 cycle of carboplatin and paclitaxel, followed by 5 cycles of carboplatin, paclitaxel and bevacizumab, followed by 13 cycles of bevacizumab unless disease progression or unacceptable toxicity)",
                    "dose": "5 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "beVACizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "19(1 cycle of carboplatin and paclitaxel, followed by 5 cycles of carboplatin, paclitaxel and bevacizumab, followed by 13 cycles of bevacizumab unless disease progression or unacceptable toxicity)",
                    "dose": "7.5 mg/kg",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "gynaecological",
        "url": "https://www.eviq.org.au/medical-oncology/gynaecological/ovarian/1601-ovarian-advanced-carboplatin-paclitaxel-and"
    },
    {
        "protocol_id": "265 v.9",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "PACLitaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6",
                    "dose": "135 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6",
                    "dose": "75 mg/m2 *",
                    "day": "2",
                    "route": "Intraperitoneal"
                },
                {
                    "drug_name": "PACLitaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6",
                    "dose": "60 mg/m2",
                    "day": "8",
                    "route": "Intraperitoneal"
                }
            ],
            [
                {
                    "drug_name": "PACLitaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6",
                    "dose": "135 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6",
                    "dose": "75 mg/m2 *",
                    "day": "2",
                    "route": "Intraperitoneal"
                },
                {
                    "drug_name": "PACLitaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6",
                    "dose": "60 mg/m2",
                    "day": "8",
                    "route": "Intraperitoneal"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "gynaecological",
        "url": "https://www.eviq.org.au/medical-oncology/gynaecological/ovarian/265-ovarian-advanced-combined-intravenous-and-intr"
    },
    {
        "protocol_id": "4158 v.2",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "beVACizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity. (In the PAOLA-1 clinical trial olaparib was continued up to 24 months and bevacizumab up to 15 months)",
                    "dose": "15 mg/kg *",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Olaparib (tablets)",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity. (In the PAOLA-1 clinical trial olaparib was continued up to 24 months and bevacizumab up to 15 months)",
                    "dose": "300 mg TWICE a day **",
                    "day": "1 to 21",
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "beVACizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity. (In the PAOLA-1 clinical trial olaparib was continued up to 24 months and bevacizumab up to 15 months)",
                    "dose": "15 mg/kg *",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Olaparib (tablets)",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity. (In the PAOLA-1 clinical trial olaparib was continued up to 24 months and bevacizumab up to 15 months)",
                    "dose": "300 mg TWICE a day **",
                    "day": "1 to 21",
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "gynaecological",
        "url": "https://www.eviq.org.au/medical-oncology/gynaecological/ovarian/4158-ovarian-advanced-olaparib-and-bevacizumab"
    },
    {
        "protocol_id": "4166 v.2",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Niraparib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "200 mg ONCE a day *#",
                    "day": null,
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Niraparib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "200 mg ONCE a day *#",
                    "day": null,
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "gynaecological",
        "url": "https://www.eviq.org.au/medical-oncology/gynaecological/ovarian/4166-ovarian-advanced-or-recurrent-niraparib"
    },
    {
        "protocol_id": "260 v.8",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity. Maximum of 6 cycles.",
                    "dose": "5 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity. Maximum of 6 cycles.",
                    "dose": "5 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "gynaecological",
        "url": "https://www.eviq.org.au/medical-oncology/gynaecological/ovarian/260-ovarian-advanced-primary-carboplatin"
    },
    {
        "protocol_id": "689 v.8",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Bleomycin #",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "3for good-risk disease (4 cycles for intermediate or poor risk disease)",
                    "dose": "30,000 International Units",
                    "day": "1, 8, 15",
                    "route": "IM/IV"
                },
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "3for good-risk disease (4 cycles for intermediate or poor risk disease)",
                    "dose": "20 mg/m2",
                    "day": "1 to 5",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Etoposide *",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "3for good-risk disease (4 cycles for intermediate or poor risk disease)",
                    "dose": "100 mg/m2",
                    "day": "1 to 5",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Pegfilgrastim **",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "3for good-risk disease (4 cycles for intermediate or poor risk disease)",
                    "dose": "6 mg",
                    "day": "6",
                    "route": "Subcut"
                }
            ],
            [
                {
                    "drug_name": "Bleomycin #",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "3for good-risk disease (4 cycles for intermediate or poor risk disease)",
                    "dose": "30,000 International Units",
                    "day": "1, 8, 15",
                    "route": "IM/IV"
                },
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "3for good-risk disease (4 cycles for intermediate or poor risk disease)",
                    "dose": "20 mg/m2",
                    "day": "1 to 5",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Etoposide *",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "3for good-risk disease (4 cycles for intermediate or poor risk disease)",
                    "dose": "100 mg/m2",
                    "day": "1 to 5",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Pegfilgrastim **",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "3for good-risk disease (4 cycles for intermediate or poor risk disease)",
                    "dose": "6 mg",
                    "day": "6",
                    "route": "Subcut"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "gynaecological",
        "url": "https://www.eviq.org.au/medical-oncology/gynaecological/ovarian/689-ovarian-dysgerminoma-advanced-or-metastatic-be"
    },
    {
        "protocol_id": "251 v.12",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "PACLitaxel",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4-6",
                    "dose": "175 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4-6",
                    "dose": "5 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "PACLitaxel",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4-6",
                    "dose": "175 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4-6",
                    "dose": "5 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "gynaecological",
        "url": "https://www.eviq.org.au/medical-oncology/gynaecological/ovarian/251-ovarian-high-risk-stage-1-adjuvant-carboplatin"
    },
    {
        "protocol_id": "1088 v.7",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "5 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "5 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "gynaecological",
        "url": "https://www.eviq.org.au/medical-oncology/gynaecological/ovarian/1088-ovarian-recurrent-carboplatin"
    },
    {
        "protocol_id": "1010 v.7",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "DOXOrubicin liposomal",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "30 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "5 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "DOXOrubicin liposomal",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "30 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "5 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "gynaecological",
        "url": "https://www.eviq.org.au/medical-oncology/gynaecological/ovarian/1010-ovarian-recurrent-carboplatin-and-doxorubicin"
    },
    {
        "protocol_id": "1680 v.6",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Gemcitabine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity, usually up to 6 cycles",
                    "dose": "1,000 mg/m2",
                    "day": "1 and 8",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity, usually up to 6 cycles",
                    "dose": "4 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Gemcitabine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity, usually up to 6 cycles",
                    "dose": "1,000 mg/m2",
                    "day": "1 and 8",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity, usually up to 6 cycles",
                    "dose": "4 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "gynaecological",
        "url": "https://www.eviq.org.au/medical-oncology/gynaecological/ovarian/1680-ovarian-recurrent-carboplatin-and-gemcitabine"
    },
    {
        "protocol_id": "4391 v.1",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "beVACizumab *",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "6",
                    "dose": "10 mg/kg",
                    "day": "1 and 15",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "DOXOrubicin liposomal",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "6",
                    "dose": "30 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "6",
                    "dose": "5 AUC **",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "beVACizumab *",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "6",
                    "dose": "10 mg/kg",
                    "day": "1 and 15",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "DOXOrubicin liposomal",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "6",
                    "dose": "30 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "6",
                    "dose": "5 AUC **",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "gynaecological",
        "url": "https://www.eviq.org.au/medical-oncology/gynaecological/ovarian/4391-ovarian-recurrent-carboplatin-doxorubicin-pe"
    },
    {
        "protocol_id": "4002 v.2",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "beVACizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "15 mg/kg",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Gemcitabine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "1,000 mg/m2",
                    "day": "1 and 8",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "4 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "beVACizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "15 mg/kg",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "beVACizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "15 mg/kg",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Gemcitabine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "1,000 mg/m2",
                    "day": "1 and 8",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "4 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "beVACizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "15 mg/kg",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "gynaecological",
        "url": "https://www.eviq.org.au/medical-oncology/gynaecological/ovarian/4002-ovarian-recurrent-carboplatin-gemcitabine-an"
    },
    {
        "protocol_id": "266 v.7",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "DOXOrubicin liposomal",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "40 mg/m2 *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "DOXOrubicin liposomal",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "40 mg/m2 *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "gynaecological",
        "url": "https://www.eviq.org.au/medical-oncology/gynaecological/ovarian/266-ovarian-recurrent-doxorubicin-pegylated-liposo"
    },
    {
        "protocol_id": "3985 v.3",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "beVACizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "10 mg/kg",
                    "day": "1 and 15",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "DOXOrubicin liposomal",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "40 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "beVACizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "10 mg/kg",
                    "day": "1 and 15",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "DOXOrubicin liposomal",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "40 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "gynaecological",
        "url": "https://www.eviq.org.au/medical-oncology/gynaecological/ovarian/3985-ovarian-recurrent-doxorubicin-pegylated-lipos"
    },
    {
        "protocol_id": "264 v.8",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Gemcitabine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity; up to 6 cycles",
                    "dose": "1,000 mg/m2",
                    "day": "1, 8, 15 *",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Gemcitabine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity; up to 6 cycles",
                    "dose": "1,000 mg/m2",
                    "day": "1, 8, 15 *",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "gynaecological",
        "url": "https://www.eviq.org.au/medical-oncology/gynaecological/ovarian/264-ovarian-recurrent-gemcitabine"
    },
    {
        "protocol_id": "255 v.10",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "PACLitaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "7 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "80 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "PACLitaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "7 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "80 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "gynaecological",
        "url": "https://www.eviq.org.au/medical-oncology/gynaecological/ovarian/255-ovarian-recurrent-paclitaxel-weekly"
    },
    {
        "protocol_id": "3986 v.5",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "beVACizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "10 mg/kg",
                    "day": "1 and 15",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "PACLitaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "80 mg/m2",
                    "day": "1, 8, 15, 22",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "beVACizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "10 mg/kg",
                    "day": "1 and 15",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "PACLitaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "80 mg/m2",
                    "day": "1, 8, 15, 22",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "gynaecological",
        "url": "https://www.eviq.org.au/medical-oncology/gynaecological/ovarian/3986-ovarian-recurrent-paclitaxel-weekly-and-bevac"
    },
    {
        "protocol_id": "267 v.7",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Topotecan",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity. Maximum 6 cycles",
                    "dose": "1.5 mg/m2 *",
                    "day": "1 to 3 *",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Topotecan",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity. Maximum 6 cycles",
                    "dose": "1.5 mg/m2 *",
                    "day": "1 to 3 *",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "gynaecological",
        "url": "https://www.eviq.org.au/medical-oncology/gynaecological/ovarian/267-ovarian-recurrent-topotecan-modified-three-w"
    },
    {
        "protocol_id": "1037 v.6",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Topotecan",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity. Maximum 6 cycles",
                    "dose": "4 mg/m2 *",
                    "day": "1, 8, 15",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Topotecan",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity. Maximum 6 cycles",
                    "dose": "4 mg/m2 *",
                    "day": "1, 8, 15",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "gynaecological",
        "url": "https://www.eviq.org.au/medical-oncology/gynaecological/ovarian/1037-ovarian-recurrent-topotecan-weekly"
    },
    {
        "protocol_id": "4042 v.2",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "beVACizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "10 mg/kg",
                    "day": "1 and 15",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Topotecan",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "4 mg/m2 *",
                    "day": "1, 8, 15",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "beVACizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "10 mg/kg",
                    "day": "1 and 15",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Topotecan",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "4 mg/m2 *",
                    "day": "1, 8, 15",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "gynaecological",
        "url": "https://www.eviq.org.au/medical-oncology/gynaecological/ovarian/4042-ovarian-recurrent-topotecan-weekly-and-bevaci"
    },
    {
        "protocol_id": "261 v.4",
        "protocol_status": "Discontinued",
        "drug_sequence": [],
        "section_name": "medical-oncology",
        "category_name": "gynaecological",
        "url": "https://www.eviq.org.au/medical-oncology/gynaecological/ovarian/261-ovarian-recurrent-carboplatin-and-gemcitabine"
    },
    {
        "protocol_id": "270 v.3",
        "protocol_status": "Discontinued",
        "drug_sequence": [],
        "section_name": "medical-oncology",
        "category_name": "gynaecological",
        "url": "https://www.eviq.org.au/medical-oncology/gynaecological/ovarian/270-ovarian-recurrent-cisplatin-and-etoposide-par"
    },
    {
        "protocol_id": "271 v.3",
        "protocol_status": "Discontinued",
        "drug_sequence": [],
        "section_name": "medical-oncology",
        "category_name": "gynaecological",
        "url": "https://www.eviq.org.au/medical-oncology/gynaecological/ovarian/271-ovarian-recurrent-etoposide-oral-part-2-disc"
    },
    {
        "protocol_id": "2026 v.3",
        "protocol_status": "Discontinued",
        "drug_sequence": [],
        "section_name": "medical-oncology",
        "category_name": "gynaecological",
        "url": "https://www.eviq.org.au/medical-oncology/gynaecological/ovarian/2026-ovarian-recurrent-olaparib-capsule-disconti"
    },
    {
        "protocol_id": "254 v.4",
        "protocol_status": "Discontinued",
        "drug_sequence": [],
        "section_name": "medical-oncology",
        "category_name": "gynaecological",
        "url": "https://www.eviq.org.au/medical-oncology/gynaecological/ovarian/254-ovarian-recurrent-paclitaxel-three-weekly-disc"
    },
    {
        "protocol_id": "1529 v.7",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "7 days",
                    "cycles": "Continuous with concurrent radiation therapy; usually 5 or 6 cycles depending on the duration of radiation therapy.",
                    "dose": "40 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "7 days",
                    "cycles": "Continuous with concurrent radiation therapy; usually 5 or 6 cycles depending on the duration of radiation therapy.",
                    "dose": "40 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "gynaecological",
        "url": "https://www.eviq.org.au/medical-oncology/gynaecological/vulval/1529-vulval-advanced-cisplatin-chemoradiation"
    },
    {
        "protocol_id": "732 v.7",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "7 days",
                    "cycles": "with concurrent radiation therapy (commencing 3 to 4 weeks after the completion of induction chemotherapy with TPF)",
                    "dose": "1.5 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "7 days",
                    "cycles": "with concurrent radiation therapy (commencing 3 to 4 weeks after the completion of induction chemotherapy with TPF)",
                    "dose": "1.5 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "head-and-neck",
        "url": "https://www.eviq.org.au/medical-oncology/head-and-neck/definitive-chemoradiation/732-head-and-neck-scc-locally-advanced-carboplatin"
    },
    {
        "protocol_id": "282 v.8",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "3with concurrent radiation therapy",
                    "dose": "4 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "3with concurrent radiation therapy",
                    "dose": "2,400 mg/m2 (equivalent to 600mg/m2/day)",
                    "day": "1",
                    "route": "CIV via pump over 96 hours"
                }
            ],
            [
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "3with concurrent radiation therapy",
                    "dose": "4 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "3with concurrent radiation therapy",
                    "dose": "2,400 mg/m2 (equivalent to 600mg/m2/day)",
                    "day": "1",
                    "route": "CIV via pump over 96 hours"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "head-and-neck",
        "url": "https://www.eviq.org.au/medical-oncology/head-and-neck/definitive-chemoradiation/282-head-and-neck-scc-locally-advanced-definitive"
    },
    {
        "protocol_id": "291 v.8",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "3with concurrent radiation therapy",
                    "dose": "100 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "3with concurrent radiation therapy",
                    "dose": "100 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "head-and-neck",
        "url": "https://www.eviq.org.au/medical-oncology/head-and-neck/definitive-chemoradiation/291-head-and-neck-scc-locally-advanced-definitive"
    },
    {
        "protocol_id": "292 v.9",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "7 days",
                    "cycles": "continuous with concurrent radiation therapy, usually 6 weeks",
                    "dose": "40 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "7 days",
                    "cycles": "continuous with concurrent radiation therapy, usually 6 weeks",
                    "dose": "40 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "head-and-neck",
        "url": "https://www.eviq.org.au/medical-oncology/head-and-neck/definitive-chemoradiation/292-head-and-neck-scc-locally-advanced-definitive"
    },
    {
        "protocol_id": "284 v.9",
        "protocol_status": "Superseded",
        "drug_sequence": [
            [
                {
                    "drug_name": "Cetuximab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "7 days",
                    "cycles": "Continuous with concurrent radiation therapy",
                    "dose": "400 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Cetuximab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "7 days",
                    "cycles": "Continuous with concurrent radiation therapy",
                    "dose": "250 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Cetuximab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "7 days",
                    "cycles": "Continuous with concurrent radiation therapy",
                    "dose": "400 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Cetuximab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "7 days",
                    "cycles": "Continuous with concurrent radiation therapy",
                    "dose": "250 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "head-and-neck",
        "url": "https://www.eviq.org.au/medical-oncology/head-and-neck/definitive-chemoradiation/284-head-and-neck-scc-locally-advanced-definitive"
    },
    {
        "protocol_id": "1157 v.5",
        "protocol_status": "Discontinued",
        "drug_sequence": [],
        "section_name": "medical-oncology",
        "category_name": "head-and-neck",
        "url": "https://www.eviq.org.au/medical-oncology/head-and-neck/definitive-chemoradiation/1157-head-and-neck-scc-locally-advanced-cetuximab"
    },
    {
        "protocol_id": "588 v.9",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "DOCEtaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "3(this treatment is followed by chemoradiation commencing 3 to 4 weeks after the completion of induction chemotherapy)",
                    "dose": "75 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "3(this treatment is followed by chemoradiation commencing 3 to 4 weeks after the completion of induction chemotherapy)",
                    "dose": "100 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "3(this treatment is followed by chemoradiation commencing 3 to 4 weeks after the completion of induction chemotherapy)",
                    "dose": "4,000 mg/m2 (equivalent to 1000 mg/m2/day)",
                    "day": "1",
                    "route": "CIV via pump over 96 hours"
                }
            ],
            [
                {
                    "drug_name": "DOCEtaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "3(this treatment is followed by chemoradiation commencing 3 to 4 weeks after the completion of induction chemotherapy)",
                    "dose": "75 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "3(this treatment is followed by chemoradiation commencing 3 to 4 weeks after the completion of induction chemotherapy)",
                    "dose": "100 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "3(this treatment is followed by chemoradiation commencing 3 to 4 weeks after the completion of induction chemotherapy)",
                    "dose": "4,000 mg/m2 (equivalent to 1000 mg/m2/day)",
                    "day": "1",
                    "route": "CIV via pump over 96 hours"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "head-and-neck",
        "url": "https://www.eviq.org.au/medical-oncology/head-and-neck/induction-chemotherapy/588-head-and-neck-scc-local-advanced-induction-tpf"
    },
    {
        "protocol_id": "1226 v.5",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "cisplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "3 (this treatment is followed by chemoradiation commencing 3 to 4 weeksafter the completion ofinduction chemotherapy)",
                    "dose": "",
                    "day": 1,
                    "route": "IV"
                },
                {
                    "drug_name": "docetaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "3 (this treatment is followed by chemoradiation commencing 3 to 4 weeksafter the completion ofinduction chemotherapy)",
                    "dose": "",
                    "day": 1,
                    "route": "IV"
                },
                {
                    "drug_name": "fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "3 (this treatment is followed by chemoradiation commencing 3 to 4 weeksafter the completion ofinduction chemotherapy)",
                    "dose": "",
                    "day": 1,
                    "route": "IV"
                }
            ],
            [
                {
                    "drug_name": "carboplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "3 (this treatment is followed by chemoradiation commencing 3 to 4 weeksafter the completion ofinduction chemotherapy)",
                    "dose": "",
                    "day": 1,
                    "route": "IV"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "head-and-neck",
        "url": "https://www.eviq.org.au/medical-oncology/head-and-neck/induction-chemotherapy/1226-head-and-neck-scc-locally-advanced-induction"
    },
    {
        "protocol_id": "4281 v.2",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Capecitabine",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "650 mg/m2 TWICE a day *",
                    "day": null,
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Capecitabine",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "650 mg/m2 TWICE a day *",
                    "day": null,
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "head-and-neck",
        "url": "https://www.eviq.org.au/medical-oncology/head-and-neck/nasopharyngeal/4281-nasopharyngeal-locally-advanced-adjuvant-cape"
    },
    {
        "protocol_id": "1154 v.6",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "3(this protocol follows chemoradiation after a 3 to 4 week break)",
                    "dose": "80 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "3(this protocol follows chemoradiation after a 3 to 4 week break)",
                    "dose": "4,000 mg/m2 (equivalent to 1000 mg/m2/day)",
                    "day": "1",
                    "route": "CIV over 96 hours"
                }
            ],
            [
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "3(this protocol follows chemoradiation after a 3 to 4 week break)",
                    "dose": "80 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "3(this protocol follows chemoradiation after a 3 to 4 week break)",
                    "dose": "4,000 mg/m2 (equivalent to 1000 mg/m2/day)",
                    "day": "1",
                    "route": "CIV over 96 hours"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "head-and-neck",
        "url": "https://www.eviq.org.au/medical-oncology/head-and-neck/nasopharyngeal/1154-nasopharyngeal-locally-advanced-adjuvant-cisp"
    },
    {
        "protocol_id": "1206 v.5",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "7 days",
                    "cycles": "6with concurrent radiation therapy (this protocol is usually followed by adjuvant chemotherapy with carboplatin and fluorouracil after a 3 to 4 week break)",
                    "dose": "2 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "7 days",
                    "cycles": "6with concurrent radiation therapy (this protocol is usually followed by adjuvant chemotherapy with carboplatin and fluorouracil after a 3 to 4 week break)",
                    "dose": "2 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "head-and-neck",
        "url": "https://www.eviq.org.au/medical-oncology/head-and-neck/nasopharyngeal/1206-nasopharyngeal-locally-advanced-carboplatin"
    },
    {
        "protocol_id": "277 v.6",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "3with concurrent radiation therapy (this protocol is usually followed by adjuvant chemotherapy with cisplatin and fluorouracil after a 3 to 4 week break)",
                    "dose": "100 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "3with concurrent radiation therapy (this protocol is usually followed by adjuvant chemotherapy with cisplatin and fluorouracil after a 3 to 4 week break)",
                    "dose": "100 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "head-and-neck",
        "url": "https://www.eviq.org.au/medical-oncology/head-and-neck/nasopharyngeal/277-nasopharyngeal-locally-advanced-cisplatin-thr"
    },
    {
        "protocol_id": "278 v.7",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "7 days",
                    "cycles": "Continuous with concurrent radiation therapy (up to 8 cycles)",
                    "dose": "40 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "7 days",
                    "cycles": "Continuous with concurrent radiation therapy (up to 8 cycles)",
                    "dose": "40 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "head-and-neck",
        "url": "https://www.eviq.org.au/medical-oncology/head-and-neck/nasopharyngeal/278-nasopharyngeal-locally-advanced-cisplatin-wee"
    },
    {
        "protocol_id": "3992 v.2",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "3unless disease progression or unacceptable toxicity",
                    "dose": "100 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Capecitabine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "3unless disease progression or unacceptable toxicity",
                    "dose": "1,000 mg/m2 TWICE a day *",
                    "day": "1 to 14",
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "3unless disease progression or unacceptable toxicity",
                    "dose": "100 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Capecitabine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "3unless disease progression or unacceptable toxicity",
                    "dose": "1,000 mg/m2 TWICE a day *",
                    "day": "1 to 14",
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "head-and-neck",
        "url": "https://www.eviq.org.au/medical-oncology/head-and-neck/nasopharyngeal/3992-nasopharyngeal-locally-advanced-cisplatin-and"
    },
    {
        "protocol_id": "3674 v.2",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Gemcitabine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "3(This treatment is followed by chemoradiation commencing 21 to 28days after the first day of the last cycle of inductionchemotherapy)",
                    "dose": "1,000 mg/m2",
                    "day": "1 and 8",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "ciSplatin *",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "3(This treatment is followed by chemoradiation commencing 21 to 28days after the first day of the last cycle of inductionchemotherapy)",
                    "dose": "80 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Gemcitabine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "3(This treatment is followed by chemoradiation commencing 21 to 28days after the first day of the last cycle of inductionchemotherapy)",
                    "dose": "1,000 mg/m2",
                    "day": "1 and 8",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "ciSplatin *",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "3(This treatment is followed by chemoradiation commencing 21 to 28days after the first day of the last cycle of inductionchemotherapy)",
                    "dose": "80 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "head-and-neck",
        "url": "https://www.eviq.org.au/medical-oncology/head-and-neck/nasopharyngeal/3674-nasopharyngeal-locally-advanced-cisplatin-and"
    },
    {
        "protocol_id": "1384 v.5",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Gemcitabine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4to 6",
                    "dose": "1,000 mg/m2",
                    "day": "1 and 8",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "ciSplatin *",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4to 6",
                    "dose": "80 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Gemcitabine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4to 6",
                    "dose": "1,000 mg/m2",
                    "day": "1 and 8",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "ciSplatin *",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4to 6",
                    "dose": "80 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "head-and-neck",
        "url": "https://www.eviq.org.au/medical-oncology/head-and-neck/nasopharyngeal/1384-nasopharyngeal-recurrent-or-metastatic-cispla"
    },
    {
        "protocol_id": "1510 v.5",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Gemcitabine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "until disease progression or unacceptable toxicity; usually 6 cycles",
                    "dose": "1,000 mg/m2 *",
                    "day": "1, 8, 15",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Gemcitabine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "until disease progression or unacceptable toxicity; usually 6 cycles",
                    "dose": "1,000 mg/m2 *",
                    "day": "1, 8, 15",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "head-and-neck",
        "url": "https://www.eviq.org.au/medical-oncology/head-and-neck/nasopharyngeal/1510-nasopharyngeal-recurrent-or-metastatic-gemcit"
    },
    {
        "protocol_id": "1208 v.6",
        "protocol_status": "Superseded",
        "drug_sequence": [
            [
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "3(this protocol follows chemoradiation after a 3 to 4 week break)",
                    "dose": "5 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "3(this protocol follows chemoradiation after a 3 to 4 week break)",
                    "dose": "4,000 mg/m2 (equivalent to 1000 mg/m2/day)",
                    "day": "1",
                    "route": "CIV via pump over 96 hours"
                }
            ],
            [
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "3(this protocol follows chemoradiation after a 3 to 4 week break)",
                    "dose": "5 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "3(this protocol follows chemoradiation after a 3 to 4 week break)",
                    "dose": "4,000 mg/m2 (equivalent to 1000 mg/m2/day)",
                    "day": "1",
                    "route": "CIV via pump over 96 hours"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "head-and-neck",
        "url": "https://www.eviq.org.au/medical-oncology/head-and-neck/nasopharyngeal/1208-nasopharyngeal-locally-advanced-adjuvant-carb"
    },
    {
        "protocol_id": "276 v.8",
        "protocol_status": "Superseded",
        "drug_sequence": [
            [
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "3",
                    "dose": "25 mg/m2",
                    "day": "1 to 4",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "3",
                    "dose": "25 mg/m2",
                    "day": "1 to 4",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "head-and-neck",
        "url": "https://www.eviq.org.au/medical-oncology/head-and-neck/nasopharyngeal/276-nasopharyngeal-locally-advanced-cisplatin-fra"
    },
    {
        "protocol_id": "286 v.7",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "3with concurrent radiation therapy (in practice, if radiation therapy is given for ~6 weeks then only 2 cycles of chemotherapy is given)",
                    "dose": "100 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "3with concurrent radiation therapy (in practice, if radiation therapy is given for ~6 weeks then only 2 cycles of chemotherapy is given)",
                    "dose": "100 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "head-and-neck",
        "url": "https://www.eviq.org.au/medical-oncology/head-and-neck/post-operative-chemoradiation/286-head-and-neck-scc-locally-advanced-post-operat"
    },
    {
        "protocol_id": "287 v.7",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "7 days",
                    "cycles": "continuous with concurrent radiation therapy",
                    "dose": "40 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "7 days",
                    "cycles": "continuous with concurrent radiation therapy",
                    "dose": "40 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "head-and-neck",
        "url": "https://www.eviq.org.au/medical-oncology/head-and-neck/post-operative-chemoradiation/287-head-and-neck-scc-locally-advanced-post-operat"
    },
    {
        "protocol_id": "283 v.6",
        "protocol_status": "Superseded",
        "drug_sequence": [
            [
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "7 days",
                    "cycles": "Continuous with concurrent radiation therapy",
                    "dose": "2 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "7 days",
                    "cycles": "Continuous with concurrent radiation therapy",
                    "dose": "2 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "head-and-neck",
        "url": "https://www.eviq.org.au/medical-oncology/head-and-neck/post-operative-chemoradiation/283-head-and-neck-scc-locally-advanced-post-operat"
    },
    {
        "protocol_id": "3594 v.8",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Nivolumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "480 mg * #",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Nivolumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "480 mg * #",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "head-and-neck",
        "url": "https://www.eviq.org.au/medical-oncology/head-and-neck/recurrent-or-metastatic/3622-redirect-id-3594"
    },
    {
        "protocol_id": "3555 v.9",
        "protocol_status": "Superseded",
        "drug_sequence": [
            [
                {
                    "drug_name": "Nivolumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "3 mg/kg",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Nivolumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "3 mg/kg",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "head-and-neck",
        "url": "https://www.eviq.org.au/medical-oncology/head-and-neck/recurrent-or-metastatic/3606-redirect-id-3555"
    },
    {
        "protocol_id": "3840 v.9",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Pembrolizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (see Indications and patient population section)",
                    "dose": "200 mg *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Pembrolizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (see Indications and patient population section)",
                    "dose": "200 mg *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "head-and-neck",
        "url": "https://www.eviq.org.au/medical-oncology/head-and-neck/recurrent-or-metastatic/1966-redirect-id-3840"
    },
    {
        "protocol_id": "280 v.7",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 daysor 28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (reassess response after 2 to 3 cycles; up to 6 cycles in responding patients)",
                    "dose": "5 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 daysor 28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (reassess response after 2 to 3 cycles; up to 6 cycles in responding patients)",
                    "dose": "4,000 mg/m2 (equivalent to 1000 mg/m2/day)",
                    "day": "1",
                    "route": "CIV via pump over 96 hours"
                }
            ],
            [
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 daysor 28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (reassess response after 2 to 3 cycles; up to 6 cycles in responding patients)",
                    "dose": "5 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 daysor 28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (reassess response after 2 to 3 cycles; up to 6 cycles in responding patients)",
                    "dose": "4,000 mg/m2 (equivalent to 1000 mg/m2/day)",
                    "day": "1",
                    "route": "CIV via pump over 96 hours"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "head-and-neck",
        "url": "https://www.eviq.org.au/medical-oncology/head-and-neck/recurrent-or-metastatic/280-head-and-neck-scc-recurrent-or-metastatic-carb"
    },
    {
        "protocol_id": "3579 v.3",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "PACLitaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4to 6 unless disease progression or unacceptable toxicity",
                    "dose": "175 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4to 6 unless disease progression or unacceptable toxicity",
                    "dose": "5 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "PACLitaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4to 6 unless disease progression or unacceptable toxicity",
                    "dose": "175 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4to 6 unless disease progression or unacceptable toxicity",
                    "dose": "5 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "head-and-neck",
        "url": "https://www.eviq.org.au/medical-oncology/head-and-neck/recurrent-or-metastatic/3579-head-and-neck-squamous-cell-carcinoma-metasta"
    },
    {
        "protocol_id": "1204 v.8",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Cetuximab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "up to 6 cycles in responding patients and consider maintenance cetuximab until disease progression or unacceptable toxicity",
                    "dose": "400 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "up to 6 cycles in responding patients and consider maintenance cetuximab until disease progression or unacceptable toxicity",
                    "dose": "5 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "up to 6 cycles in responding patients and consider maintenance cetuximab until disease progression or unacceptable toxicity",
                    "dose": "4,000 mg/m2 (equivalent to 1000 mg/m2/day)",
                    "day": "1",
                    "route": "CIV"
                },
                {
                    "drug_name": "Cetuximab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "up to 6 cycles in responding patients and consider maintenance cetuximab until disease progression or unacceptable toxicity",
                    "dose": "250 mg/m2",
                    "day": "8 and 15",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Cetuximab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "up to 6 cycles in responding patients and consider maintenance cetuximab until disease progression or unacceptable toxicity",
                    "dose": "250 mg/m2",
                    "day": "1, 8, 15",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "up to 6 cycles in responding patients and consider maintenance cetuximab until disease progression or unacceptable toxicity",
                    "dose": "5 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "up to 6 cycles in responding patients and consider maintenance cetuximab until disease progression or unacceptable toxicity",
                    "dose": "4,000 mg/m2 (equivalent to 1000 mg/m2/day)",
                    "day": "1",
                    "route": "CIV"
                }
            ],
            [
                {
                    "drug_name": "Cetuximab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "up to 6 cycles in responding patients and consider maintenance cetuximab until disease progression or unacceptable toxicity",
                    "dose": "400 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "up to 6 cycles in responding patients and consider maintenance cetuximab until disease progression or unacceptable toxicity",
                    "dose": "5 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "up to 6 cycles in responding patients and consider maintenance cetuximab until disease progression or unacceptable toxicity",
                    "dose": "4,000 mg/m2 (equivalent to 1000 mg/m2/day)",
                    "day": "1",
                    "route": "CIV"
                },
                {
                    "drug_name": "Cetuximab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "up to 6 cycles in responding patients and consider maintenance cetuximab until disease progression or unacceptable toxicity",
                    "dose": "250 mg/m2",
                    "day": "8 and 15",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Cetuximab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "up to 6 cycles in responding patients and consider maintenance cetuximab until disease progression or unacceptable toxicity",
                    "dose": "250 mg/m2",
                    "day": "1, 8, 15",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "up to 6 cycles in responding patients and consider maintenance cetuximab until disease progression or unacceptable toxicity",
                    "dose": "5 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "up to 6 cycles in responding patients and consider maintenance cetuximab until disease progression or unacceptable toxicity",
                    "dose": "4,000 mg/m2 (equivalent to 1000 mg/m2/day)",
                    "day": "1",
                    "route": "CIV"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "head-and-neck",
        "url": "https://www.eviq.org.au/medical-oncology/head-and-neck/recurrent-or-metastatic/1204-head-and-neck-scc-recurrent-or-metastatic-car"
    },
    {
        "protocol_id": "3982 v.3",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Pembrolizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (in the clinical trial [KEYNOTE-048] cisplatin, fluorouracil and pembrolizumab were given for 6 cycles, after which pembrolizumab monotherapy was continued in patients who were responding to treatment up to a maximum of 35 cycles).",
                    "dose": "200 mg",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (in the clinical trial [KEYNOTE-048] cisplatin, fluorouracil and pembrolizumab were given for 6 cycles, after which pembrolizumab monotherapy was continued in patients who were responding to treatment up to a maximum of 35 cycles).",
                    "dose": "5 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (in the clinical trial [KEYNOTE-048] cisplatin, fluorouracil and pembrolizumab were given for 6 cycles, after which pembrolizumab monotherapy was continued in patients who were responding to treatment up to a maximum of 35 cycles).",
                    "dose": "4,000 mg/m2 (equivalent to 1000 mg/m2/day)",
                    "day": "1",
                    "route": "CIV via pump over 96 hours"
                }
            ],
            [
                {
                    "drug_name": "Pembrolizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (in the clinical trial [KEYNOTE-048] cisplatin, fluorouracil and pembrolizumab were given for 6 cycles, after which pembrolizumab monotherapy was continued in patients who were responding to treatment up to a maximum of 35 cycles).",
                    "dose": "200 mg",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Pembrolizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (in the clinical trial [KEYNOTE-048] cisplatin, fluorouracil and pembrolizumab were given for 6 cycles, after which pembrolizumab monotherapy was continued in patients who were responding to treatment up to a maximum of 35 cycles).",
                    "dose": "200 mg",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (in the clinical trial [KEYNOTE-048] cisplatin, fluorouracil and pembrolizumab were given for 6 cycles, after which pembrolizumab monotherapy was continued in patients who were responding to treatment up to a maximum of 35 cycles).",
                    "dose": "5 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (in the clinical trial [KEYNOTE-048] cisplatin, fluorouracil and pembrolizumab were given for 6 cycles, after which pembrolizumab monotherapy was continued in patients who were responding to treatment up to a maximum of 35 cycles).",
                    "dose": "4,000 mg/m2 (equivalent to 1000 mg/m2/day)",
                    "day": "1",
                    "route": "CIV via pump over 96 hours"
                }
            ],
            [
                {
                    "drug_name": "Pembrolizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (in the clinical trial [KEYNOTE-048] cisplatin, fluorouracil and pembrolizumab were given for 6 cycles, after which pembrolizumab monotherapy was continued in patients who were responding to treatment up to a maximum of 35 cycles).",
                    "dose": "200 mg",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "head-and-neck",
        "url": "https://www.eviq.org.au/medical-oncology/head-and-neck/recurrent-or-metastatic/3982-head-and-neck-scc-recurrent-or-metastatic-car"
    },
    {
        "protocol_id": "4363 v.3",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Pembrolizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (in the clinical trial [KEYNOTE B10] carboplatin, paclitaxel and pembrolizumab were given for 6 cycles, after which pembrolizumab monotherapy was continued in patients who were responding to treatment up to a maximum of 35 cycles).",
                    "dose": "200 mg",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "PACLitaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (in the clinical trial [KEYNOTE B10] carboplatin, paclitaxel and pembrolizumab were given for 6 cycles, after which pembrolizumab monotherapy was continued in patients who were responding to treatment up to a maximum of 35 cycles).",
                    "dose": "175 mg/m2 *",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (in the clinical trial [KEYNOTE B10] carboplatin, paclitaxel and pembrolizumab were given for 6 cycles, after which pembrolizumab monotherapy was continued in patients who were responding to treatment up to a maximum of 35 cycles).",
                    "dose": "5 AUC **",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Pembrolizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (in the clinical trial [KEYNOTE B10] carboplatin, paclitaxel and pembrolizumab were given for 6 cycles, after which pembrolizumab monotherapy was continued in patients who were responding to treatment up to a maximum of 35 cycles).",
                    "dose": "200 mg ***",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Pembrolizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (in the clinical trial [KEYNOTE B10] carboplatin, paclitaxel and pembrolizumab were given for 6 cycles, after which pembrolizumab monotherapy was continued in patients who were responding to treatment up to a maximum of 35 cycles).",
                    "dose": "200 mg",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "PACLitaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (in the clinical trial [KEYNOTE B10] carboplatin, paclitaxel and pembrolizumab were given for 6 cycles, after which pembrolizumab monotherapy was continued in patients who were responding to treatment up to a maximum of 35 cycles).",
                    "dose": "175 mg/m2 *",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (in the clinical trial [KEYNOTE B10] carboplatin, paclitaxel and pembrolizumab were given for 6 cycles, after which pembrolizumab monotherapy was continued in patients who were responding to treatment up to a maximum of 35 cycles).",
                    "dose": "5 AUC **",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Pembrolizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (in the clinical trial [KEYNOTE B10] carboplatin, paclitaxel and pembrolizumab were given for 6 cycles, after which pembrolizumab monotherapy was continued in patients who were responding to treatment up to a maximum of 35 cycles).",
                    "dose": "200 mg ***",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "head-and-neck",
        "url": "https://www.eviq.org.au/medical-oncology/head-and-neck/recurrent-or-metastatic/4363-head-and-neck-scc-recurrent-or-metastatic-car"
    },
    {
        "protocol_id": "288 v.6",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "continuous until disease progression or unacceptable toxicity (reassess response after 2 to 3 cycles; up to 6 cycles in responding patients)",
                    "dose": "75 mg/m2 *",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "continuous until disease progression or unacceptable toxicity (reassess response after 2 to 3 cycles; up to 6 cycles in responding patients)",
                    "dose": "4,000 mg/m2 (equivalent to 1000 mg/m2/day)",
                    "day": "1",
                    "route": "CIV via pump over 96 hours"
                }
            ],
            [
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "continuous until disease progression or unacceptable toxicity (reassess response after 2 to 3 cycles; up to 6 cycles in responding patients)",
                    "dose": "75 mg/m2 *",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "continuous until disease progression or unacceptable toxicity (reassess response after 2 to 3 cycles; up to 6 cycles in responding patients)",
                    "dose": "4,000 mg/m2 (equivalent to 1000 mg/m2/day)",
                    "day": "1",
                    "route": "CIV via pump over 96 hours"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "head-and-neck",
        "url": "https://www.eviq.org.au/medical-oncology/head-and-neck/recurrent-or-metastatic/288-head-and-neck-scc-recurrent-or-metastatic-cisp"
    },
    {
        "protocol_id": "3567 v.2",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4to 6 unless disease progression or unacceptable toxicity",
                    "dose": "75 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Capecitabine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4to 6 unless disease progression or unacceptable toxicity",
                    "dose": "1,000 mg/m2 TWICE a day *",
                    "day": "1 to 14",
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4to 6 unless disease progression or unacceptable toxicity",
                    "dose": "75 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Capecitabine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4to 6 unless disease progression or unacceptable toxicity",
                    "dose": "1,000 mg/m2 TWICE a day *",
                    "day": "1 to 14",
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "head-and-neck",
        "url": "https://www.eviq.org.au/medical-oncology/head-and-neck/recurrent-or-metastatic/3567-head-and-neck-squamous-cell-carcinoma-recurre"
    },
    {
        "protocol_id": "1138 v.8",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Cetuximab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "up to 6 cycles in responding patients and consider maintenance cetuximab until disease progression or unacceptable toxicity",
                    "dose": "400 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "up to 6 cycles in responding patients and consider maintenance cetuximab until disease progression or unacceptable toxicity",
                    "dose": "100 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "up to 6 cycles in responding patients and consider maintenance cetuximab until disease progression or unacceptable toxicity",
                    "dose": "4,000 mg/m2 over 96 hours (equivalent to 1000 mg/m2/day)",
                    "day": "1",
                    "route": "CIV"
                },
                {
                    "drug_name": "Cetuximab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "up to 6 cycles in responding patients and consider maintenance cetuximab until disease progression or unacceptable toxicity",
                    "dose": "250 mg/m2",
                    "day": "8 and 15",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Cetuximab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "up to 6 cycles in responding patients and consider maintenance cetuximab until disease progression or unacceptable toxicity",
                    "dose": "250 mg/m2",
                    "day": "1, 8, 15",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "up to 6 cycles in responding patients and consider maintenance cetuximab until disease progression or unacceptable toxicity",
                    "dose": "100 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "up to 6 cycles in responding patients and consider maintenance cetuximab until disease progression or unacceptable toxicity",
                    "dose": "4,000 mg/m2 over 96 hours (equivalent to 1000 mg/m2/day)",
                    "day": "1",
                    "route": "CIV"
                }
            ],
            [
                {
                    "drug_name": "Cetuximab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "up to 6 cycles in responding patients and consider maintenance cetuximab until disease progression or unacceptable toxicity",
                    "dose": "400 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "up to 6 cycles in responding patients and consider maintenance cetuximab until disease progression or unacceptable toxicity",
                    "dose": "100 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "up to 6 cycles in responding patients and consider maintenance cetuximab until disease progression or unacceptable toxicity",
                    "dose": "4,000 mg/m2 over 96 hours (equivalent to 1000 mg/m2/day)",
                    "day": "1",
                    "route": "CIV"
                },
                {
                    "drug_name": "Cetuximab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "up to 6 cycles in responding patients and consider maintenance cetuximab until disease progression or unacceptable toxicity",
                    "dose": "250 mg/m2",
                    "day": "8 and 15",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Cetuximab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "up to 6 cycles in responding patients and consider maintenance cetuximab until disease progression or unacceptable toxicity",
                    "dose": "250 mg/m2",
                    "day": "1, 8, 15",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "up to 6 cycles in responding patients and consider maintenance cetuximab until disease progression or unacceptable toxicity",
                    "dose": "100 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "up to 6 cycles in responding patients and consider maintenance cetuximab until disease progression or unacceptable toxicity",
                    "dose": "4,000 mg/m2 over 96 hours (equivalent to 1000 mg/m2/day)",
                    "day": "1",
                    "route": "CIV"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "head-and-neck",
        "url": "https://www.eviq.org.au/medical-oncology/head-and-neck/recurrent-or-metastatic/1138-head-and-neck-scc-recurrent-or-metastatic-cis"
    },
    {
        "protocol_id": "3836 v.3",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Pembrolizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (in the clinical trial [KEYNOTE-048] cisplatin, fluorouracil and pembrolizumab were given for 6 cycles, after which pembrolizumab monotherapy was continued in patients who were responding to treatment up to a maximum of 35 cycles).",
                    "dose": "200 mg",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (in the clinical trial [KEYNOTE-048] cisplatin, fluorouracil and pembrolizumab were given for 6 cycles, after which pembrolizumab monotherapy was continued in patients who were responding to treatment up to a maximum of 35 cycles).",
                    "dose": "100 mg/m2 *",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (in the clinical trial [KEYNOTE-048] cisplatin, fluorouracil and pembrolizumab were given for 6 cycles, after which pembrolizumab monotherapy was continued in patients who were responding to treatment up to a maximum of 35 cycles).",
                    "dose": "4,000 mg/m2 (equivalent to 1000 mg/m2/day)",
                    "day": "1",
                    "route": "CIV via pump over 96 hours"
                }
            ],
            [
                {
                    "drug_name": "Pembrolizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (in the clinical trial [KEYNOTE-048] cisplatin, fluorouracil and pembrolizumab were given for 6 cycles, after which pembrolizumab monotherapy was continued in patients who were responding to treatment up to a maximum of 35 cycles).",
                    "dose": "200 mg",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Pembrolizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (in the clinical trial [KEYNOTE-048] cisplatin, fluorouracil and pembrolizumab were given for 6 cycles, after which pembrolizumab monotherapy was continued in patients who were responding to treatment up to a maximum of 35 cycles).",
                    "dose": "200 mg",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (in the clinical trial [KEYNOTE-048] cisplatin, fluorouracil and pembrolizumab were given for 6 cycles, after which pembrolizumab monotherapy was continued in patients who were responding to treatment up to a maximum of 35 cycles).",
                    "dose": "100 mg/m2 *",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (in the clinical trial [KEYNOTE-048] cisplatin, fluorouracil and pembrolizumab were given for 6 cycles, after which pembrolizumab monotherapy was continued in patients who were responding to treatment up to a maximum of 35 cycles).",
                    "dose": "4,000 mg/m2 (equivalent to 1000 mg/m2/day)",
                    "day": "1",
                    "route": "CIV via pump over 96 hours"
                }
            ],
            [
                {
                    "drug_name": "Pembrolizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (in the clinical trial [KEYNOTE-048] cisplatin, fluorouracil and pembrolizumab were given for 6 cycles, after which pembrolizumab monotherapy was continued in patients who were responding to treatment up to a maximum of 35 cycles).",
                    "dose": "200 mg",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "head-and-neck",
        "url": "https://www.eviq.org.au/medical-oncology/head-and-neck/recurrent-or-metastatic/3836-head-and-neck-scc-recurrent-or-metastatic-cis"
    },
    {
        "protocol_id": "290 v.7",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Methotrexate",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "7 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (consider escalating to 50 mg/m2 if patient does not experience any mucositis)",
                    "dose": "40 mg/m2",
                    "day": "1",
                    "route": "IV bolus"
                }
            ],
            [
                {
                    "drug_name": "Methotrexate",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "7 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (consider escalating to 50 mg/m2 if patient does not experience any mucositis)",
                    "dose": "40 mg/m2",
                    "day": "1",
                    "route": "IV bolus"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "head-and-neck",
        "url": "https://www.eviq.org.au/medical-oncology/head-and-neck/recurrent-or-metastatic/290-head-and-neck-scc-recurrent-or-metastatic-meth"
    },
    {
        "protocol_id": "1948 v.6",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "PACLitaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "7 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "80 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "PACLitaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "7 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "80 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "head-and-neck",
        "url": "https://www.eviq.org.au/medical-oncology/head-and-neck/recurrent-or-metastatic/1948-head-and-neck-scc-recurrent-or-metastatic-pac"
    },
    {
        "protocol_id": "289 v.5",
        "protocol_status": "Discontinued",
        "drug_sequence": [],
        "section_name": "medical-oncology",
        "category_name": "head-and-neck",
        "url": "https://www.eviq.org.au/medical-oncology/head-and-neck/recurrent-or-metastatic/289-head-and-neck-scc-recurrent-or-metastatic-cisp"
    },
    {
        "protocol_id": "658 v.5",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "DOXOrubicin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Until disease progression or unacceptable toxicity, up to 6 cycles",
                    "dose": "50 mg/m2",
                    "day": "1",
                    "route": "IV"
                },
                {
                    "drug_name": "CYCLOPHOSPHamide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Until disease progression or unacceptable toxicity, up to 6 cycles",
                    "dose": "500 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Until disease progression or unacceptable toxicity, up to 6 cycles",
                    "dose": "50 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "DOXOrubicin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Until disease progression or unacceptable toxicity, up to 6 cycles",
                    "dose": "50 mg/m2",
                    "day": "1",
                    "route": "IV"
                },
                {
                    "drug_name": "CYCLOPHOSPHamide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Until disease progression or unacceptable toxicity, up to 6 cycles",
                    "dose": "500 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Until disease progression or unacceptable toxicity, up to 6 cycles",
                    "dose": "50 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "head-and-neck",
        "url": "https://www.eviq.org.au/medical-oncology/head-and-neck/salivary-gland/658-head-and-neck-salivary-gland-advanced-cap-cyc"
    },
    {
        "protocol_id": "3559 v.2",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "vinORELBine *",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4to 6 unless disease progression or unacceptable toxicity",
                    "dose": "25 mg/m2",
                    "day": "1 and 8",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4to 6 unless disease progression or unacceptable toxicity",
                    "dose": "80 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "vinORELBine *",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4to 6 unless disease progression or unacceptable toxicity",
                    "dose": "25 mg/m2",
                    "day": "1 and 8",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4to 6 unless disease progression or unacceptable toxicity",
                    "dose": "80 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "head-and-neck",
        "url": "https://www.eviq.org.au/medical-oncology/head-and-neck/salivary-gland/3559-head-and-neck-salivary-gland-advanced-or-meta"
    },
    {
        "protocol_id": "1919 v.5",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "leNVAtinib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "24 mg ONCE a day",
                    "day": null,
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "leNVAtinib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "24 mg ONCE a day",
                    "day": null,
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "head-and-neck",
        "url": "https://www.eviq.org.au/medical-oncology/head-and-neck/thyroid/1919-thyroid-locally-advanced-or-metastatic-lenvat"
    },
    {
        "protocol_id": "1726 v.6",
        "protocol_status": "Discontinued",
        "drug_sequence": [],
        "section_name": "medical-oncology",
        "category_name": "head-and-neck",
        "url": "https://www.eviq.org.au/medical-oncology/head-and-neck/thyroid/1726-thyroid-locally-advanced-or-metastatic-sorafe"
    },
    {
        "protocol_id": "1727 v.6",
        "protocol_status": "Discontinued",
        "drug_sequence": [],
        "section_name": "medical-oncology",
        "category_name": "head-and-neck",
        "url": "https://www.eviq.org.au/medical-oncology/head-and-neck/thyroid/1727-thyroid-locally-advanced-or-metastatic-vandet"
    },
    {
        "protocol_id": "732 v.7",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "7 days",
                    "cycles": "with concurrent radiation therapy (commencing 3 to 4 weeks after the completion of induction chemotherapy with TPF)",
                    "dose": "1.5 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "7 days",
                    "cycles": "with concurrent radiation therapy (commencing 3 to 4 weeks after the completion of induction chemotherapy with TPF)",
                    "dose": "1.5 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "head-and-neck",
        "url": "https://www.eviq.org.au/medical-oncology/head-and-neck/definitive-chemoradiation/732-head-and-neck-scc-locally-advanced-carboplatin"
    },
    {
        "protocol_id": "282 v.8",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "3with concurrent radiation therapy",
                    "dose": "4 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "3with concurrent radiation therapy",
                    "dose": "2,400 mg/m2 (equivalent to 600mg/m2/day)",
                    "day": "1",
                    "route": "CIV via pump over 96 hours"
                }
            ],
            [
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "3with concurrent radiation therapy",
                    "dose": "4 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "3with concurrent radiation therapy",
                    "dose": "2,400 mg/m2 (equivalent to 600mg/m2/day)",
                    "day": "1",
                    "route": "CIV via pump over 96 hours"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "head-and-neck",
        "url": "https://www.eviq.org.au/medical-oncology/head-and-neck/definitive-chemoradiation/282-head-and-neck-scc-locally-advanced-definitive"
    },
    {
        "protocol_id": "291 v.8",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "3with concurrent radiation therapy",
                    "dose": "100 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "3with concurrent radiation therapy",
                    "dose": "100 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "head-and-neck",
        "url": "https://www.eviq.org.au/medical-oncology/head-and-neck/definitive-chemoradiation/291-head-and-neck-scc-locally-advanced-definitive"
    },
    {
        "protocol_id": "292 v.9",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "7 days",
                    "cycles": "continuous with concurrent radiation therapy, usually 6 weeks",
                    "dose": "40 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "7 days",
                    "cycles": "continuous with concurrent radiation therapy, usually 6 weeks",
                    "dose": "40 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "head-and-neck",
        "url": "https://www.eviq.org.au/medical-oncology/head-and-neck/definitive-chemoradiation/292-head-and-neck-scc-locally-advanced-definitive"
    },
    {
        "protocol_id": "284 v.9",
        "protocol_status": "Superseded",
        "drug_sequence": [
            [
                {
                    "drug_name": "Cetuximab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "7 days",
                    "cycles": "Continuous with concurrent radiation therapy",
                    "dose": "400 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Cetuximab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "7 days",
                    "cycles": "Continuous with concurrent radiation therapy",
                    "dose": "250 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Cetuximab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "7 days",
                    "cycles": "Continuous with concurrent radiation therapy",
                    "dose": "400 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Cetuximab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "7 days",
                    "cycles": "Continuous with concurrent radiation therapy",
                    "dose": "250 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "head-and-neck",
        "url": "https://www.eviq.org.au/medical-oncology/head-and-neck/definitive-chemoradiation/284-head-and-neck-scc-locally-advanced-definitive"
    },
    {
        "protocol_id": "1157 v.5",
        "protocol_status": "Discontinued",
        "drug_sequence": [],
        "section_name": "medical-oncology",
        "category_name": "head-and-neck",
        "url": "https://www.eviq.org.au/medical-oncology/head-and-neck/definitive-chemoradiation/1157-head-and-neck-scc-locally-advanced-cetuximab"
    },
    {
        "protocol_id": "588 v.9",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "DOCEtaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "3(this treatment is followed by chemoradiation commencing 3 to 4 weeks after the completion of induction chemotherapy)",
                    "dose": "75 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "3(this treatment is followed by chemoradiation commencing 3 to 4 weeks after the completion of induction chemotherapy)",
                    "dose": "100 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "3(this treatment is followed by chemoradiation commencing 3 to 4 weeks after the completion of induction chemotherapy)",
                    "dose": "4,000 mg/m2 (equivalent to 1000 mg/m2/day)",
                    "day": "1",
                    "route": "CIV via pump over 96 hours"
                }
            ],
            [
                {
                    "drug_name": "DOCEtaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "3(this treatment is followed by chemoradiation commencing 3 to 4 weeks after the completion of induction chemotherapy)",
                    "dose": "75 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "3(this treatment is followed by chemoradiation commencing 3 to 4 weeks after the completion of induction chemotherapy)",
                    "dose": "100 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "3(this treatment is followed by chemoradiation commencing 3 to 4 weeks after the completion of induction chemotherapy)",
                    "dose": "4,000 mg/m2 (equivalent to 1000 mg/m2/day)",
                    "day": "1",
                    "route": "CIV via pump over 96 hours"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "head-and-neck",
        "url": "https://www.eviq.org.au/medical-oncology/head-and-neck/induction-chemotherapy/588-head-and-neck-scc-local-advanced-induction-tpf"
    },
    {
        "protocol_id": "1226 v.5",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "cisplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "3 (this treatment is followed by chemoradiation commencing 3 to 4 weeksafter the completion ofinduction chemotherapy)",
                    "dose": "",
                    "day": 1,
                    "route": "IV"
                },
                {
                    "drug_name": "docetaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "3 (this treatment is followed by chemoradiation commencing 3 to 4 weeksafter the completion ofinduction chemotherapy)",
                    "dose": "",
                    "day": 1,
                    "route": "IV"
                },
                {
                    "drug_name": "fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "3 (this treatment is followed by chemoradiation commencing 3 to 4 weeksafter the completion ofinduction chemotherapy)",
                    "dose": "",
                    "day": 1,
                    "route": "IV"
                }
            ],
            [
                {
                    "drug_name": "carboplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "3 (this treatment is followed by chemoradiation commencing 3 to 4 weeksafter the completion ofinduction chemotherapy)",
                    "dose": "",
                    "day": 1,
                    "route": "IV"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "head-and-neck",
        "url": "https://www.eviq.org.au/medical-oncology/head-and-neck/induction-chemotherapy/1226-head-and-neck-scc-locally-advanced-induction"
    },
    {
        "protocol_id": "4281 v.2",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Capecitabine",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "650 mg/m2 TWICE a day *",
                    "day": null,
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Capecitabine",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "650 mg/m2 TWICE a day *",
                    "day": null,
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "head-and-neck",
        "url": "https://www.eviq.org.au/medical-oncology/head-and-neck/nasopharyngeal/4281-nasopharyngeal-locally-advanced-adjuvant-cape"
    },
    {
        "protocol_id": "1154 v.6",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "3(this protocol follows chemoradiation after a 3 to 4 week break)",
                    "dose": "80 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "3(this protocol follows chemoradiation after a 3 to 4 week break)",
                    "dose": "4,000 mg/m2 (equivalent to 1000 mg/m2/day)",
                    "day": "1",
                    "route": "CIV over 96 hours"
                }
            ],
            [
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "3(this protocol follows chemoradiation after a 3 to 4 week break)",
                    "dose": "80 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "3(this protocol follows chemoradiation after a 3 to 4 week break)",
                    "dose": "4,000 mg/m2 (equivalent to 1000 mg/m2/day)",
                    "day": "1",
                    "route": "CIV over 96 hours"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "head-and-neck",
        "url": "https://www.eviq.org.au/medical-oncology/head-and-neck/nasopharyngeal/1154-nasopharyngeal-locally-advanced-adjuvant-cisp"
    },
    {
        "protocol_id": "1206 v.5",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "7 days",
                    "cycles": "6with concurrent radiation therapy (this protocol is usually followed by adjuvant chemotherapy with carboplatin and fluorouracil after a 3 to 4 week break)",
                    "dose": "2 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "7 days",
                    "cycles": "6with concurrent radiation therapy (this protocol is usually followed by adjuvant chemotherapy with carboplatin and fluorouracil after a 3 to 4 week break)",
                    "dose": "2 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "head-and-neck",
        "url": "https://www.eviq.org.au/medical-oncology/head-and-neck/nasopharyngeal/1206-nasopharyngeal-locally-advanced-carboplatin"
    },
    {
        "protocol_id": "277 v.6",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "3with concurrent radiation therapy (this protocol is usually followed by adjuvant chemotherapy with cisplatin and fluorouracil after a 3 to 4 week break)",
                    "dose": "100 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "3with concurrent radiation therapy (this protocol is usually followed by adjuvant chemotherapy with cisplatin and fluorouracil after a 3 to 4 week break)",
                    "dose": "100 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "head-and-neck",
        "url": "https://www.eviq.org.au/medical-oncology/head-and-neck/nasopharyngeal/277-nasopharyngeal-locally-advanced-cisplatin-thr"
    },
    {
        "protocol_id": "278 v.7",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "7 days",
                    "cycles": "Continuous with concurrent radiation therapy (up to 8 cycles)",
                    "dose": "40 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "7 days",
                    "cycles": "Continuous with concurrent radiation therapy (up to 8 cycles)",
                    "dose": "40 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "head-and-neck",
        "url": "https://www.eviq.org.au/medical-oncology/head-and-neck/nasopharyngeal/278-nasopharyngeal-locally-advanced-cisplatin-wee"
    },
    {
        "protocol_id": "3992 v.2",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "3unless disease progression or unacceptable toxicity",
                    "dose": "100 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Capecitabine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "3unless disease progression or unacceptable toxicity",
                    "dose": "1,000 mg/m2 TWICE a day *",
                    "day": "1 to 14",
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "3unless disease progression or unacceptable toxicity",
                    "dose": "100 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Capecitabine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "3unless disease progression or unacceptable toxicity",
                    "dose": "1,000 mg/m2 TWICE a day *",
                    "day": "1 to 14",
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "head-and-neck",
        "url": "https://www.eviq.org.au/medical-oncology/head-and-neck/nasopharyngeal/3992-nasopharyngeal-locally-advanced-cisplatin-and"
    },
    {
        "protocol_id": "3674 v.2",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Gemcitabine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "3(This treatment is followed by chemoradiation commencing 21 to 28days after the first day of the last cycle of inductionchemotherapy)",
                    "dose": "1,000 mg/m2",
                    "day": "1 and 8",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "ciSplatin *",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "3(This treatment is followed by chemoradiation commencing 21 to 28days after the first day of the last cycle of inductionchemotherapy)",
                    "dose": "80 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Gemcitabine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "3(This treatment is followed by chemoradiation commencing 21 to 28days after the first day of the last cycle of inductionchemotherapy)",
                    "dose": "1,000 mg/m2",
                    "day": "1 and 8",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "ciSplatin *",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "3(This treatment is followed by chemoradiation commencing 21 to 28days after the first day of the last cycle of inductionchemotherapy)",
                    "dose": "80 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "head-and-neck",
        "url": "https://www.eviq.org.au/medical-oncology/head-and-neck/nasopharyngeal/3674-nasopharyngeal-locally-advanced-cisplatin-and"
    },
    {
        "protocol_id": "1384 v.5",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Gemcitabine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4to 6",
                    "dose": "1,000 mg/m2",
                    "day": "1 and 8",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "ciSplatin *",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4to 6",
                    "dose": "80 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Gemcitabine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4to 6",
                    "dose": "1,000 mg/m2",
                    "day": "1 and 8",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "ciSplatin *",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4to 6",
                    "dose": "80 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "head-and-neck",
        "url": "https://www.eviq.org.au/medical-oncology/head-and-neck/nasopharyngeal/1384-nasopharyngeal-recurrent-or-metastatic-cispla"
    },
    {
        "protocol_id": "1510 v.5",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Gemcitabine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "until disease progression or unacceptable toxicity; usually 6 cycles",
                    "dose": "1,000 mg/m2 *",
                    "day": "1, 8, 15",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Gemcitabine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "until disease progression or unacceptable toxicity; usually 6 cycles",
                    "dose": "1,000 mg/m2 *",
                    "day": "1, 8, 15",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "head-and-neck",
        "url": "https://www.eviq.org.au/medical-oncology/head-and-neck/nasopharyngeal/1510-nasopharyngeal-recurrent-or-metastatic-gemcit"
    },
    {
        "protocol_id": "1208 v.6",
        "protocol_status": "Superseded",
        "drug_sequence": [
            [
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "3(this protocol follows chemoradiation after a 3 to 4 week break)",
                    "dose": "5 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "3(this protocol follows chemoradiation after a 3 to 4 week break)",
                    "dose": "4,000 mg/m2 (equivalent to 1000 mg/m2/day)",
                    "day": "1",
                    "route": "CIV via pump over 96 hours"
                }
            ],
            [
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "3(this protocol follows chemoradiation after a 3 to 4 week break)",
                    "dose": "5 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "3(this protocol follows chemoradiation after a 3 to 4 week break)",
                    "dose": "4,000 mg/m2 (equivalent to 1000 mg/m2/day)",
                    "day": "1",
                    "route": "CIV via pump over 96 hours"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "head-and-neck",
        "url": "https://www.eviq.org.au/medical-oncology/head-and-neck/nasopharyngeal/1208-nasopharyngeal-locally-advanced-adjuvant-carb"
    },
    {
        "protocol_id": "276 v.8",
        "protocol_status": "Superseded",
        "drug_sequence": [
            [
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "3",
                    "dose": "25 mg/m2",
                    "day": "1 to 4",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "3",
                    "dose": "25 mg/m2",
                    "day": "1 to 4",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "head-and-neck",
        "url": "https://www.eviq.org.au/medical-oncology/head-and-neck/nasopharyngeal/276-nasopharyngeal-locally-advanced-cisplatin-fra"
    },
    {
        "protocol_id": "286 v.7",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "3with concurrent radiation therapy (in practice, if radiation therapy is given for ~6 weeks then only 2 cycles of chemotherapy is given)",
                    "dose": "100 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "3with concurrent radiation therapy (in practice, if radiation therapy is given for ~6 weeks then only 2 cycles of chemotherapy is given)",
                    "dose": "100 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "head-and-neck",
        "url": "https://www.eviq.org.au/medical-oncology/head-and-neck/post-operative-chemoradiation/286-head-and-neck-scc-locally-advanced-post-operat"
    },
    {
        "protocol_id": "287 v.7",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "7 days",
                    "cycles": "continuous with concurrent radiation therapy",
                    "dose": "40 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "7 days",
                    "cycles": "continuous with concurrent radiation therapy",
                    "dose": "40 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "head-and-neck",
        "url": "https://www.eviq.org.au/medical-oncology/head-and-neck/post-operative-chemoradiation/287-head-and-neck-scc-locally-advanced-post-operat"
    },
    {
        "protocol_id": "283 v.6",
        "protocol_status": "Superseded",
        "drug_sequence": [
            [
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "7 days",
                    "cycles": "Continuous with concurrent radiation therapy",
                    "dose": "2 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "7 days",
                    "cycles": "Continuous with concurrent radiation therapy",
                    "dose": "2 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "head-and-neck",
        "url": "https://www.eviq.org.au/medical-oncology/head-and-neck/post-operative-chemoradiation/283-head-and-neck-scc-locally-advanced-post-operat"
    },
    {
        "protocol_id": "3594 v.8",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Nivolumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "480 mg * #",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Nivolumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "480 mg * #",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "head-and-neck",
        "url": "https://www.eviq.org.au/medical-oncology/head-and-neck/recurrent-or-metastatic/3622-redirect-id-3594"
    },
    {
        "protocol_id": "3555 v.9",
        "protocol_status": "Superseded",
        "drug_sequence": [
            [
                {
                    "drug_name": "Nivolumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "3 mg/kg",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Nivolumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "3 mg/kg",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "head-and-neck",
        "url": "https://www.eviq.org.au/medical-oncology/head-and-neck/recurrent-or-metastatic/3606-redirect-id-3555"
    },
    {
        "protocol_id": "3840 v.9",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Pembrolizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (see Indications and patient population section)",
                    "dose": "200 mg *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Pembrolizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (see Indications and patient population section)",
                    "dose": "200 mg *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "head-and-neck",
        "url": "https://www.eviq.org.au/medical-oncology/head-and-neck/recurrent-or-metastatic/1966-redirect-id-3840"
    },
    {
        "protocol_id": "280 v.7",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 daysor 28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (reassess response after 2 to 3 cycles; up to 6 cycles in responding patients)",
                    "dose": "5 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 daysor 28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (reassess response after 2 to 3 cycles; up to 6 cycles in responding patients)",
                    "dose": "4,000 mg/m2 (equivalent to 1000 mg/m2/day)",
                    "day": "1",
                    "route": "CIV via pump over 96 hours"
                }
            ],
            [
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 daysor 28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (reassess response after 2 to 3 cycles; up to 6 cycles in responding patients)",
                    "dose": "5 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 daysor 28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (reassess response after 2 to 3 cycles; up to 6 cycles in responding patients)",
                    "dose": "4,000 mg/m2 (equivalent to 1000 mg/m2/day)",
                    "day": "1",
                    "route": "CIV via pump over 96 hours"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "head-and-neck",
        "url": "https://www.eviq.org.au/medical-oncology/head-and-neck/recurrent-or-metastatic/280-head-and-neck-scc-recurrent-or-metastatic-carb"
    },
    {
        "protocol_id": "3579 v.3",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "PACLitaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4to 6 unless disease progression or unacceptable toxicity",
                    "dose": "175 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4to 6 unless disease progression or unacceptable toxicity",
                    "dose": "5 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "PACLitaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4to 6 unless disease progression or unacceptable toxicity",
                    "dose": "175 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4to 6 unless disease progression or unacceptable toxicity",
                    "dose": "5 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "head-and-neck",
        "url": "https://www.eviq.org.au/medical-oncology/head-and-neck/recurrent-or-metastatic/3579-head-and-neck-squamous-cell-carcinoma-metasta"
    },
    {
        "protocol_id": "1204 v.8",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Cetuximab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "up to 6 cycles in responding patients and consider maintenance cetuximab until disease progression or unacceptable toxicity",
                    "dose": "400 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "up to 6 cycles in responding patients and consider maintenance cetuximab until disease progression or unacceptable toxicity",
                    "dose": "5 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "up to 6 cycles in responding patients and consider maintenance cetuximab until disease progression or unacceptable toxicity",
                    "dose": "4,000 mg/m2 (equivalent to 1000 mg/m2/day)",
                    "day": "1",
                    "route": "CIV"
                },
                {
                    "drug_name": "Cetuximab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "up to 6 cycles in responding patients and consider maintenance cetuximab until disease progression or unacceptable toxicity",
                    "dose": "250 mg/m2",
                    "day": "8 and 15",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Cetuximab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "up to 6 cycles in responding patients and consider maintenance cetuximab until disease progression or unacceptable toxicity",
                    "dose": "250 mg/m2",
                    "day": "1, 8, 15",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "up to 6 cycles in responding patients and consider maintenance cetuximab until disease progression or unacceptable toxicity",
                    "dose": "5 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "up to 6 cycles in responding patients and consider maintenance cetuximab until disease progression or unacceptable toxicity",
                    "dose": "4,000 mg/m2 (equivalent to 1000 mg/m2/day)",
                    "day": "1",
                    "route": "CIV"
                }
            ],
            [
                {
                    "drug_name": "Cetuximab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "up to 6 cycles in responding patients and consider maintenance cetuximab until disease progression or unacceptable toxicity",
                    "dose": "400 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "up to 6 cycles in responding patients and consider maintenance cetuximab until disease progression or unacceptable toxicity",
                    "dose": "5 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "up to 6 cycles in responding patients and consider maintenance cetuximab until disease progression or unacceptable toxicity",
                    "dose": "4,000 mg/m2 (equivalent to 1000 mg/m2/day)",
                    "day": "1",
                    "route": "CIV"
                },
                {
                    "drug_name": "Cetuximab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "up to 6 cycles in responding patients and consider maintenance cetuximab until disease progression or unacceptable toxicity",
                    "dose": "250 mg/m2",
                    "day": "8 and 15",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Cetuximab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "up to 6 cycles in responding patients and consider maintenance cetuximab until disease progression or unacceptable toxicity",
                    "dose": "250 mg/m2",
                    "day": "1, 8, 15",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "up to 6 cycles in responding patients and consider maintenance cetuximab until disease progression or unacceptable toxicity",
                    "dose": "5 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "up to 6 cycles in responding patients and consider maintenance cetuximab until disease progression or unacceptable toxicity",
                    "dose": "4,000 mg/m2 (equivalent to 1000 mg/m2/day)",
                    "day": "1",
                    "route": "CIV"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "head-and-neck",
        "url": "https://www.eviq.org.au/medical-oncology/head-and-neck/recurrent-or-metastatic/1204-head-and-neck-scc-recurrent-or-metastatic-car"
    },
    {
        "protocol_id": "3982 v.3",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Pembrolizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (in the clinical trial [KEYNOTE-048] cisplatin, fluorouracil and pembrolizumab were given for 6 cycles, after which pembrolizumab monotherapy was continued in patients who were responding to treatment up to a maximum of 35 cycles).",
                    "dose": "200 mg",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (in the clinical trial [KEYNOTE-048] cisplatin, fluorouracil and pembrolizumab were given for 6 cycles, after which pembrolizumab monotherapy was continued in patients who were responding to treatment up to a maximum of 35 cycles).",
                    "dose": "5 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (in the clinical trial [KEYNOTE-048] cisplatin, fluorouracil and pembrolizumab were given for 6 cycles, after which pembrolizumab monotherapy was continued in patients who were responding to treatment up to a maximum of 35 cycles).",
                    "dose": "4,000 mg/m2 (equivalent to 1000 mg/m2/day)",
                    "day": "1",
                    "route": "CIV via pump over 96 hours"
                }
            ],
            [
                {
                    "drug_name": "Pembrolizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (in the clinical trial [KEYNOTE-048] cisplatin, fluorouracil and pembrolizumab were given for 6 cycles, after which pembrolizumab monotherapy was continued in patients who were responding to treatment up to a maximum of 35 cycles).",
                    "dose": "200 mg",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Pembrolizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (in the clinical trial [KEYNOTE-048] cisplatin, fluorouracil and pembrolizumab were given for 6 cycles, after which pembrolizumab monotherapy was continued in patients who were responding to treatment up to a maximum of 35 cycles).",
                    "dose": "200 mg",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (in the clinical trial [KEYNOTE-048] cisplatin, fluorouracil and pembrolizumab were given for 6 cycles, after which pembrolizumab monotherapy was continued in patients who were responding to treatment up to a maximum of 35 cycles).",
                    "dose": "5 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (in the clinical trial [KEYNOTE-048] cisplatin, fluorouracil and pembrolizumab were given for 6 cycles, after which pembrolizumab monotherapy was continued in patients who were responding to treatment up to a maximum of 35 cycles).",
                    "dose": "4,000 mg/m2 (equivalent to 1000 mg/m2/day)",
                    "day": "1",
                    "route": "CIV via pump over 96 hours"
                }
            ],
            [
                {
                    "drug_name": "Pembrolizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (in the clinical trial [KEYNOTE-048] cisplatin, fluorouracil and pembrolizumab were given for 6 cycles, after which pembrolizumab monotherapy was continued in patients who were responding to treatment up to a maximum of 35 cycles).",
                    "dose": "200 mg",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "head-and-neck",
        "url": "https://www.eviq.org.au/medical-oncology/head-and-neck/recurrent-or-metastatic/3982-head-and-neck-scc-recurrent-or-metastatic-car"
    },
    {
        "protocol_id": "4363 v.3",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Pembrolizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (in the clinical trial [KEYNOTE B10] carboplatin, paclitaxel and pembrolizumab were given for 6 cycles, after which pembrolizumab monotherapy was continued in patients who were responding to treatment up to a maximum of 35 cycles).",
                    "dose": "200 mg",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "PACLitaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (in the clinical trial [KEYNOTE B10] carboplatin, paclitaxel and pembrolizumab were given for 6 cycles, after which pembrolizumab monotherapy was continued in patients who were responding to treatment up to a maximum of 35 cycles).",
                    "dose": "175 mg/m2 *",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (in the clinical trial [KEYNOTE B10] carboplatin, paclitaxel and pembrolizumab were given for 6 cycles, after which pembrolizumab monotherapy was continued in patients who were responding to treatment up to a maximum of 35 cycles).",
                    "dose": "5 AUC **",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Pembrolizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (in the clinical trial [KEYNOTE B10] carboplatin, paclitaxel and pembrolizumab were given for 6 cycles, after which pembrolizumab monotherapy was continued in patients who were responding to treatment up to a maximum of 35 cycles).",
                    "dose": "200 mg ***",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Pembrolizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (in the clinical trial [KEYNOTE B10] carboplatin, paclitaxel and pembrolizumab were given for 6 cycles, after which pembrolizumab monotherapy was continued in patients who were responding to treatment up to a maximum of 35 cycles).",
                    "dose": "200 mg",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "PACLitaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (in the clinical trial [KEYNOTE B10] carboplatin, paclitaxel and pembrolizumab were given for 6 cycles, after which pembrolizumab monotherapy was continued in patients who were responding to treatment up to a maximum of 35 cycles).",
                    "dose": "175 mg/m2 *",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (in the clinical trial [KEYNOTE B10] carboplatin, paclitaxel and pembrolizumab were given for 6 cycles, after which pembrolizumab monotherapy was continued in patients who were responding to treatment up to a maximum of 35 cycles).",
                    "dose": "5 AUC **",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Pembrolizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (in the clinical trial [KEYNOTE B10] carboplatin, paclitaxel and pembrolizumab were given for 6 cycles, after which pembrolizumab monotherapy was continued in patients who were responding to treatment up to a maximum of 35 cycles).",
                    "dose": "200 mg ***",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "head-and-neck",
        "url": "https://www.eviq.org.au/medical-oncology/head-and-neck/recurrent-or-metastatic/4363-head-and-neck-scc-recurrent-or-metastatic-car"
    },
    {
        "protocol_id": "288 v.6",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "continuous until disease progression or unacceptable toxicity (reassess response after 2 to 3 cycles; up to 6 cycles in responding patients)",
                    "dose": "75 mg/m2 *",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "continuous until disease progression or unacceptable toxicity (reassess response after 2 to 3 cycles; up to 6 cycles in responding patients)",
                    "dose": "4,000 mg/m2 (equivalent to 1000 mg/m2/day)",
                    "day": "1",
                    "route": "CIV via pump over 96 hours"
                }
            ],
            [
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "continuous until disease progression or unacceptable toxicity (reassess response after 2 to 3 cycles; up to 6 cycles in responding patients)",
                    "dose": "75 mg/m2 *",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "continuous until disease progression or unacceptable toxicity (reassess response after 2 to 3 cycles; up to 6 cycles in responding patients)",
                    "dose": "4,000 mg/m2 (equivalent to 1000 mg/m2/day)",
                    "day": "1",
                    "route": "CIV via pump over 96 hours"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "head-and-neck",
        "url": "https://www.eviq.org.au/medical-oncology/head-and-neck/recurrent-or-metastatic/288-head-and-neck-scc-recurrent-or-metastatic-cisp"
    },
    {
        "protocol_id": "3567 v.2",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4to 6 unless disease progression or unacceptable toxicity",
                    "dose": "75 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Capecitabine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4to 6 unless disease progression or unacceptable toxicity",
                    "dose": "1,000 mg/m2 TWICE a day *",
                    "day": "1 to 14",
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4to 6 unless disease progression or unacceptable toxicity",
                    "dose": "75 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Capecitabine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4to 6 unless disease progression or unacceptable toxicity",
                    "dose": "1,000 mg/m2 TWICE a day *",
                    "day": "1 to 14",
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "head-and-neck",
        "url": "https://www.eviq.org.au/medical-oncology/head-and-neck/recurrent-or-metastatic/3567-head-and-neck-squamous-cell-carcinoma-recurre"
    },
    {
        "protocol_id": "1138 v.8",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Cetuximab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "up to 6 cycles in responding patients and consider maintenance cetuximab until disease progression or unacceptable toxicity",
                    "dose": "400 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "up to 6 cycles in responding patients and consider maintenance cetuximab until disease progression or unacceptable toxicity",
                    "dose": "100 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "up to 6 cycles in responding patients and consider maintenance cetuximab until disease progression or unacceptable toxicity",
                    "dose": "4,000 mg/m2 over 96 hours (equivalent to 1000 mg/m2/day)",
                    "day": "1",
                    "route": "CIV"
                },
                {
                    "drug_name": "Cetuximab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "up to 6 cycles in responding patients and consider maintenance cetuximab until disease progression or unacceptable toxicity",
                    "dose": "250 mg/m2",
                    "day": "8 and 15",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Cetuximab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "up to 6 cycles in responding patients and consider maintenance cetuximab until disease progression or unacceptable toxicity",
                    "dose": "250 mg/m2",
                    "day": "1, 8, 15",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "up to 6 cycles in responding patients and consider maintenance cetuximab until disease progression or unacceptable toxicity",
                    "dose": "100 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "up to 6 cycles in responding patients and consider maintenance cetuximab until disease progression or unacceptable toxicity",
                    "dose": "4,000 mg/m2 over 96 hours (equivalent to 1000 mg/m2/day)",
                    "day": "1",
                    "route": "CIV"
                }
            ],
            [
                {
                    "drug_name": "Cetuximab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "up to 6 cycles in responding patients and consider maintenance cetuximab until disease progression or unacceptable toxicity",
                    "dose": "400 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "up to 6 cycles in responding patients and consider maintenance cetuximab until disease progression or unacceptable toxicity",
                    "dose": "100 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "up to 6 cycles in responding patients and consider maintenance cetuximab until disease progression or unacceptable toxicity",
                    "dose": "4,000 mg/m2 over 96 hours (equivalent to 1000 mg/m2/day)",
                    "day": "1",
                    "route": "CIV"
                },
                {
                    "drug_name": "Cetuximab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "up to 6 cycles in responding patients and consider maintenance cetuximab until disease progression or unacceptable toxicity",
                    "dose": "250 mg/m2",
                    "day": "8 and 15",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Cetuximab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "up to 6 cycles in responding patients and consider maintenance cetuximab until disease progression or unacceptable toxicity",
                    "dose": "250 mg/m2",
                    "day": "1, 8, 15",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "up to 6 cycles in responding patients and consider maintenance cetuximab until disease progression or unacceptable toxicity",
                    "dose": "100 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "up to 6 cycles in responding patients and consider maintenance cetuximab until disease progression or unacceptable toxicity",
                    "dose": "4,000 mg/m2 over 96 hours (equivalent to 1000 mg/m2/day)",
                    "day": "1",
                    "route": "CIV"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "head-and-neck",
        "url": "https://www.eviq.org.au/medical-oncology/head-and-neck/recurrent-or-metastatic/1138-head-and-neck-scc-recurrent-or-metastatic-cis"
    },
    {
        "protocol_id": "3836 v.3",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Pembrolizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (in the clinical trial [KEYNOTE-048] cisplatin, fluorouracil and pembrolizumab were given for 6 cycles, after which pembrolizumab monotherapy was continued in patients who were responding to treatment up to a maximum of 35 cycles).",
                    "dose": "200 mg",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (in the clinical trial [KEYNOTE-048] cisplatin, fluorouracil and pembrolizumab were given for 6 cycles, after which pembrolizumab monotherapy was continued in patients who were responding to treatment up to a maximum of 35 cycles).",
                    "dose": "100 mg/m2 *",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (in the clinical trial [KEYNOTE-048] cisplatin, fluorouracil and pembrolizumab were given for 6 cycles, after which pembrolizumab monotherapy was continued in patients who were responding to treatment up to a maximum of 35 cycles).",
                    "dose": "4,000 mg/m2 (equivalent to 1000 mg/m2/day)",
                    "day": "1",
                    "route": "CIV via pump over 96 hours"
                }
            ],
            [
                {
                    "drug_name": "Pembrolizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (in the clinical trial [KEYNOTE-048] cisplatin, fluorouracil and pembrolizumab were given for 6 cycles, after which pembrolizumab monotherapy was continued in patients who were responding to treatment up to a maximum of 35 cycles).",
                    "dose": "200 mg",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Pembrolizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (in the clinical trial [KEYNOTE-048] cisplatin, fluorouracil and pembrolizumab were given for 6 cycles, after which pembrolizumab monotherapy was continued in patients who were responding to treatment up to a maximum of 35 cycles).",
                    "dose": "200 mg",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (in the clinical trial [KEYNOTE-048] cisplatin, fluorouracil and pembrolizumab were given for 6 cycles, after which pembrolizumab monotherapy was continued in patients who were responding to treatment up to a maximum of 35 cycles).",
                    "dose": "100 mg/m2 *",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (in the clinical trial [KEYNOTE-048] cisplatin, fluorouracil and pembrolizumab were given for 6 cycles, after which pembrolizumab monotherapy was continued in patients who were responding to treatment up to a maximum of 35 cycles).",
                    "dose": "4,000 mg/m2 (equivalent to 1000 mg/m2/day)",
                    "day": "1",
                    "route": "CIV via pump over 96 hours"
                }
            ],
            [
                {
                    "drug_name": "Pembrolizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (in the clinical trial [KEYNOTE-048] cisplatin, fluorouracil and pembrolizumab were given for 6 cycles, after which pembrolizumab monotherapy was continued in patients who were responding to treatment up to a maximum of 35 cycles).",
                    "dose": "200 mg",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "head-and-neck",
        "url": "https://www.eviq.org.au/medical-oncology/head-and-neck/recurrent-or-metastatic/3836-head-and-neck-scc-recurrent-or-metastatic-cis"
    },
    {
        "protocol_id": "290 v.7",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Methotrexate",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "7 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (consider escalating to 50 mg/m2 if patient does not experience any mucositis)",
                    "dose": "40 mg/m2",
                    "day": "1",
                    "route": "IV bolus"
                }
            ],
            [
                {
                    "drug_name": "Methotrexate",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "7 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (consider escalating to 50 mg/m2 if patient does not experience any mucositis)",
                    "dose": "40 mg/m2",
                    "day": "1",
                    "route": "IV bolus"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "head-and-neck",
        "url": "https://www.eviq.org.au/medical-oncology/head-and-neck/recurrent-or-metastatic/290-head-and-neck-scc-recurrent-or-metastatic-meth"
    },
    {
        "protocol_id": "1948 v.6",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "PACLitaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "7 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "80 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "PACLitaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "7 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "80 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "head-and-neck",
        "url": "https://www.eviq.org.au/medical-oncology/head-and-neck/recurrent-or-metastatic/1948-head-and-neck-scc-recurrent-or-metastatic-pac"
    },
    {
        "protocol_id": "289 v.5",
        "protocol_status": "Discontinued",
        "drug_sequence": [],
        "section_name": "medical-oncology",
        "category_name": "head-and-neck",
        "url": "https://www.eviq.org.au/medical-oncology/head-and-neck/recurrent-or-metastatic/289-head-and-neck-scc-recurrent-or-metastatic-cisp"
    },
    {
        "protocol_id": "658 v.5",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "DOXOrubicin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Until disease progression or unacceptable toxicity, up to 6 cycles",
                    "dose": "50 mg/m2",
                    "day": "1",
                    "route": "IV"
                },
                {
                    "drug_name": "CYCLOPHOSPHamide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Until disease progression or unacceptable toxicity, up to 6 cycles",
                    "dose": "500 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Until disease progression or unacceptable toxicity, up to 6 cycles",
                    "dose": "50 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "DOXOrubicin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Until disease progression or unacceptable toxicity, up to 6 cycles",
                    "dose": "50 mg/m2",
                    "day": "1",
                    "route": "IV"
                },
                {
                    "drug_name": "CYCLOPHOSPHamide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Until disease progression or unacceptable toxicity, up to 6 cycles",
                    "dose": "500 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Until disease progression or unacceptable toxicity, up to 6 cycles",
                    "dose": "50 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "head-and-neck",
        "url": "https://www.eviq.org.au/medical-oncology/head-and-neck/salivary-gland/658-head-and-neck-salivary-gland-advanced-cap-cyc"
    },
    {
        "protocol_id": "3559 v.2",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "vinORELBine *",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4to 6 unless disease progression or unacceptable toxicity",
                    "dose": "25 mg/m2",
                    "day": "1 and 8",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4to 6 unless disease progression or unacceptable toxicity",
                    "dose": "80 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "vinORELBine *",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4to 6 unless disease progression or unacceptable toxicity",
                    "dose": "25 mg/m2",
                    "day": "1 and 8",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4to 6 unless disease progression or unacceptable toxicity",
                    "dose": "80 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "head-and-neck",
        "url": "https://www.eviq.org.au/medical-oncology/head-and-neck/salivary-gland/3559-head-and-neck-salivary-gland-advanced-or-meta"
    },
    {
        "protocol_id": "1919 v.5",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "leNVAtinib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "24 mg ONCE a day",
                    "day": null,
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "leNVAtinib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "24 mg ONCE a day",
                    "day": null,
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "head-and-neck",
        "url": "https://www.eviq.org.au/medical-oncology/head-and-neck/thyroid/1919-thyroid-locally-advanced-or-metastatic-lenvat"
    },
    {
        "protocol_id": "1726 v.6",
        "protocol_status": "Discontinued",
        "drug_sequence": [],
        "section_name": "medical-oncology",
        "category_name": "head-and-neck",
        "url": "https://www.eviq.org.au/medical-oncology/head-and-neck/thyroid/1726-thyroid-locally-advanced-or-metastatic-sorafe"
    },
    {
        "protocol_id": "1727 v.6",
        "protocol_status": "Discontinued",
        "drug_sequence": [],
        "section_name": "medical-oncology",
        "category_name": "head-and-neck",
        "url": "https://www.eviq.org.au/medical-oncology/head-and-neck/thyroid/1727-thyroid-locally-advanced-or-metastatic-vandet"
    },
    {
        "protocol_id": "2046 v.3",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Temozolomide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "12",
                    "dose": "150 mg/m2 ONCE a day *",
                    "day": "1 to 5",
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Temozolomide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "12",
                    "dose": "200 mg/m2 ONCE a day *",
                    "day": "1 to 5",
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Temozolomide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "12",
                    "dose": "150 mg/m2 ONCE a day *",
                    "day": "1 to 5",
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Temozolomide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "12",
                    "dose": "200 mg/m2 ONCE a day *",
                    "day": "1 to 5",
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "neurological",
        "url": "https://www.eviq.org.au/medical-oncology/neurological/glioma/2046-astrocytoma-temozolomide-following-radiation"
    },
    {
        "protocol_id": "4136 v.1",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Lomustine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "42 days",
                    "cycles": "6(cycle 1 with concurrent radiation therapy, cycle 2 to 6 following chemoradiation)",
                    "dose": "100 mg/m2 ONCE a day",
                    "day": "1 *",
                    "route": "PO"
                },
                {
                    "drug_name": "Temozolomide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "42 days",
                    "cycles": "6(cycle 1 with concurrent radiation therapy, cycle 2 to 6 following chemoradiation)",
                    "dose": "100 mg/m2 ONCE a day",
                    "day": "2 to 6 *",
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Lomustine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "42 days",
                    "cycles": "6(cycle 1 with concurrent radiation therapy, cycle 2 to 6 following chemoradiation)",
                    "dose": "100 mg/m2 ONCE a day",
                    "day": "1",
                    "route": "PO"
                },
                {
                    "drug_name": "Temozolomide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "42 days",
                    "cycles": "6(cycle 1 with concurrent radiation therapy, cycle 2 to 6 following chemoradiation)",
                    "dose": "100 mg/m2 ONCE a day **",
                    "day": "2 to 6",
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Lomustine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "42 days",
                    "cycles": "6(cycle 1 with concurrent radiation therapy, cycle 2 to 6 following chemoradiation)",
                    "dose": "100 mg/m2 ONCE a day",
                    "day": "1 *",
                    "route": "PO"
                },
                {
                    "drug_name": "Temozolomide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "42 days",
                    "cycles": "6(cycle 1 with concurrent radiation therapy, cycle 2 to 6 following chemoradiation)",
                    "dose": "100 mg/m2 ONCE a day",
                    "day": "2 to 6 *",
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Lomustine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "42 days",
                    "cycles": "6(cycle 1 with concurrent radiation therapy, cycle 2 to 6 following chemoradiation)",
                    "dose": "100 mg/m2 ONCE a day",
                    "day": "1",
                    "route": "PO"
                },
                {
                    "drug_name": "Temozolomide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "42 days",
                    "cycles": "6(cycle 1 with concurrent radiation therapy, cycle 2 to 6 following chemoradiation)",
                    "dose": "100 mg/m2 ONCE a day **",
                    "day": "2 to 6",
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "neurological",
        "url": "https://www.eviq.org.au/medical-oncology/neurological/glioma/4136-glioblastoma-lomustine-and-temozolomide-chemo"
    },
    {
        "protocol_id": "733 v.8",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "beVACizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "10 mg/kg *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "beVACizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "10 mg/kg *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "neurological",
        "url": "https://www.eviq.org.au/medical-oncology/neurological/glioma/733-glioblastoma-recurrent-bevacizumab"
    },
    {
        "protocol_id": "3363 v.1",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Lomustine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "6 weeks",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "110 mg/m2 *",
                    "day": "1",
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Lomustine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "6 weeks",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "110 mg/m2 *",
                    "day": "1",
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "neurological",
        "url": "https://www.eviq.org.au/medical-oncology/neurological/glioma/3363-glioblastoma-recurrent-lomustine-110mg-m2"
    },
    {
        "protocol_id": "4135 v.1",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Lomustine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "42 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "90 mg/m2\n(Cap dose at 160 mg)",
                    "day": "1",
                    "route": "PO"
                },
                {
                    "drug_name": "beVACizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "42 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "10 mg/kg",
                    "day": "1, 15, 29",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Lomustine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "42 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "90 mg/m2\n(Cap dose at 160 mg)",
                    "day": "1",
                    "route": "PO"
                },
                {
                    "drug_name": "beVACizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "42 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "10 mg/kg",
                    "day": "1, 15, 29",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "neurological",
        "url": "https://www.eviq.org.au/medical-oncology/neurological/glioma/4135-glioblastoma-recurrent-lomustine-and-bevacizu"
    },
    {
        "protocol_id": "365 v.7",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Temozolomide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": "1with concurrent radiation therapy (usually 6 weeks)",
                    "dose": "75 mg/m2 ONCE a day throughout radiation therapy",
                    "day": "1 to 42 *",
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Temozolomide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": "1with concurrent radiation therapy (usually 6 weeks)",
                    "dose": "75 mg/m2 ONCE a day throughout radiation therapy",
                    "day": "1 to 42 *",
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "neurological",
        "url": "https://www.eviq.org.au/medical-oncology/neurological/glioma/365-glioblastoma-temozolomide-chemoradiation-part"
    },
    {
        "protocol_id": "3364 v.1",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "temozolomide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "1 (42 days)",
                    "dose": "",
                    "day": 1,
                    "route": "IV"
                }
            ],
            [
                {
                    "drug_name": "temozolomide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "1 (42 days)",
                    "dose": "",
                    "day": 1,
                    "route": "IV"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "neurological",
        "url": "https://www.eviq.org.au/medical-oncology/neurological/glioma/3364-glioblastoma-temozolomide-chemoradiation-foll"
    },
    {
        "protocol_id": "366 v.6",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Temozolomide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "6(consider continuing for up to 12 cycles at clinician discretion)",
                    "dose": "150 mg/m2 ONCE a day *",
                    "day": "1 to 5",
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Temozolomide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "6(consider continuing for up to 12 cycles at clinician discretion)",
                    "dose": "200 mg/m2 ONCE a day *",
                    "day": "1 to 5",
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Temozolomide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "6(consider continuing for up to 12 cycles at clinician discretion)",
                    "dose": "150 mg/m2 ONCE a day *",
                    "day": "1 to 5",
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Temozolomide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "6(consider continuing for up to 12 cycles at clinician discretion)",
                    "dose": "200 mg/m2 ONCE a day *",
                    "day": "1 to 5",
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "neurological",
        "url": "https://www.eviq.org.au/medical-oncology/neurological/glioma/366-glioblastoma-temozolomide-following-chemoradia"
    },
    {
        "protocol_id": "2034 v.2",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Temozolomide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "12(up to 12 cycles were allowed in the clinical trial but this may not be achievable in this patient population in clinical practice)",
                    "dose": "150 mg/m2 ONCE a day *",
                    "day": "1 to 5",
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Temozolomide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "12(up to 12 cycles were allowed in the clinical trial but this may not be achievable in this patient population in clinical practice)",
                    "dose": "200 mg/m2 ONCE a day *",
                    "day": "1 to 5",
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Temozolomide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "12(up to 12 cycles were allowed in the clinical trial but this may not be achievable in this patient population in clinical practice)",
                    "dose": "150 mg/m2 ONCE a day *",
                    "day": "1 to 5",
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Temozolomide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "12(up to 12 cycles were allowed in the clinical trial but this may not be achievable in this patient population in clinical practice)",
                    "dose": "200 mg/m2 ONCE a day *",
                    "day": "1 to 5",
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "neurological",
        "url": "https://www.eviq.org.au/medical-oncology/neurological/glioma/2034-glioblastoma-temozolomide-following-short-cou"
    },
    {
        "protocol_id": "2033 v.3",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Temozolomide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": "1with concurrent radiation therapy (usually 3 weeks)",
                    "dose": "75 mg/m2 ONCE a day throughout radiation therapy",
                    "day": "1 to 21 *",
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Temozolomide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": "1with concurrent radiation therapy (usually 3 weeks)",
                    "dose": "75 mg/m2 ONCE a day throughout radiation therapy",
                    "day": "1 to 21 *",
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "neurological",
        "url": "https://www.eviq.org.au/medical-oncology/neurological/glioma/2033-glioblastoma-temozolomide-short-course-chemor"
    },
    {
        "protocol_id": "3365 v.1",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "temozolomide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "1 (21 days)",
                    "dose": "",
                    "day": 1,
                    "route": "IV"
                }
            ],
            [
                {
                    "drug_name": "temozolomide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "1 (21 days)",
                    "dose": "",
                    "day": 1,
                    "route": "IV"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "neurological",
        "url": "https://www.eviq.org.au/medical-oncology/neurological/glioma/3365-glioblastoma-temozolomide-short-course-chemor"
    },
    {
        "protocol_id": "367 v.5",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Temozolomide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "6(consider continuing to 12 cycles and beyond if tolerated and of benefit)",
                    "dose": "200 mg/m2 ONCE a day *",
                    "day": "1 to 5",
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Temozolomide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "6(consider continuing to 12 cycles and beyond if tolerated and of benefit)",
                    "dose": "200 mg/m2 ONCE a day *",
                    "day": "1 to 5",
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "neurological",
        "url": "https://www.eviq.org.au/medical-oncology/neurological/glioma/367-glioma-high-grade-or-recurrent-temozolomide"
    },
    {
        "protocol_id": "2044 v.2",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Lomustine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "8 weeks(some patients may have treatment every 6 weeks at clinician discretion)",
                    "cycles": "6(trial protocol specified 6 cycles but this is achievable only in selected patients in clinical practice)",
                    "dose": "110 mg/m2 ONCE a day",
                    "day": "1",
                    "route": "PO"
                },
                {
                    "drug_name": "vinCRISTine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "8 weeks(some patients may have treatment every 6 weeks at clinician discretion)",
                    "cycles": "6(trial protocol specified 6 cycles but this is achievable only in selected patients in clinical practice)",
                    "dose": "1.4 mg/m2\n(Cap dose at 2 mg)",
                    "day": "8 and 29",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Procarbazine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "8 weeks(some patients may have treatment every 6 weeks at clinician discretion)",
                    "cycles": "6(trial protocol specified 6 cycles but this is achievable only in selected patients in clinical practice)",
                    "dose": "60 mg/m2 ONCE a day",
                    "day": "8 to 21",
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Lomustine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "8 weeks(some patients may have treatment every 6 weeks at clinician discretion)",
                    "cycles": "6(trial protocol specified 6 cycles but this is achievable only in selected patients in clinical practice)",
                    "dose": "110 mg/m2 ONCE a day",
                    "day": "1",
                    "route": "PO"
                },
                {
                    "drug_name": "vinCRISTine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "8 weeks(some patients may have treatment every 6 weeks at clinician discretion)",
                    "cycles": "6(trial protocol specified 6 cycles but this is achievable only in selected patients in clinical practice)",
                    "dose": "1.4 mg/m2\n(Cap dose at 2 mg)",
                    "day": "8 and 29",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Procarbazine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "8 weeks(some patients may have treatment every 6 weeks at clinician discretion)",
                    "cycles": "6(trial protocol specified 6 cycles but this is achievable only in selected patients in clinical practice)",
                    "dose": "60 mg/m2 ONCE a day",
                    "day": "8 to 21",
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "neurological",
        "url": "https://www.eviq.org.au/medical-oncology/neurological/glioma/2044-glioma-low-grade-pcv-procarbazine-lomustine"
    },
    {
        "protocol_id": "2045 v.4",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Lomustine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "6 weeks",
                    "cycles": "6(EORTC 26951 trial protocol specified 6 cycles but this is achievable only in selected patients in clinical practice)",
                    "dose": "110 mg/m2 ONCE a day",
                    "day": "1",
                    "route": "PO"
                },
                {
                    "drug_name": "vinCRISTine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "6 weeks",
                    "cycles": "6(EORTC 26951 trial protocol specified 6 cycles but this is achievable only in selected patients in clinical practice)",
                    "dose": "1.4 mg/m2\n(Cap dose at 2 mg)",
                    "day": "8 and 29",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Procarbazine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "6 weeks",
                    "cycles": "6(EORTC 26951 trial protocol specified 6 cycles but this is achievable only in selected patients in clinical practice)",
                    "dose": "60 mg/m2 ONCE a day",
                    "day": "8 to 21",
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Lomustine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "6 weeks",
                    "cycles": "6(EORTC 26951 trial protocol specified 6 cycles but this is achievable only in selected patients in clinical practice)",
                    "dose": "110 mg/m2 ONCE a day",
                    "day": "1",
                    "route": "PO"
                },
                {
                    "drug_name": "vinCRISTine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "6 weeks",
                    "cycles": "6(EORTC 26951 trial protocol specified 6 cycles but this is achievable only in selected patients in clinical practice)",
                    "dose": "1.4 mg/m2\n(Cap dose at 2 mg)",
                    "day": "8 and 29",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Procarbazine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "6 weeks",
                    "cycles": "6(EORTC 26951 trial protocol specified 6 cycles but this is achievable only in selected patients in clinical practice)",
                    "dose": "60 mg/m2 ONCE a day",
                    "day": "8 to 21",
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "neurological",
        "url": "https://www.eviq.org.au/medical-oncology/neurological/glioma/2045-oligodendroglioma-pcv-procarbazine-lomustine"
    },
    {
        "protocol_id": "1675 v.3",
        "protocol_status": "Superseded",
        "drug_sequence": [
            [
                {
                    "drug_name": "Carmustine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "6 weeks",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "200 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Carmustine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "6 weeks",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "200 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "neurological",
        "url": "https://www.eviq.org.au/medical-oncology/neurological/glioma/1675-glioma-high-grade-recurrent-carmustine-supers"
    },
    {
        "protocol_id": "1673 v.5",
        "protocol_status": "Superseded",
        "drug_sequence": [
            [
                {
                    "drug_name": "Lomustine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "6 weeks",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (up to 6 cycles)",
                    "dose": "110 mg/m2 ONCE a day",
                    "day": "1",
                    "route": "PO"
                },
                {
                    "drug_name": "vinCRISTine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "6 weeks",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (up to 6 cycles)",
                    "dose": "1.4 mg/m2\n(Cap dose at 2 mg)",
                    "day": "8 and 29",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Procarbazine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "6 weeks",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (up to 6 cycles)",
                    "dose": "60 mg/m2 ONCE a day",
                    "day": "8 to 21",
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Lomustine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "6 weeks",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (up to 6 cycles)",
                    "dose": "110 mg/m2 ONCE a day",
                    "day": "1",
                    "route": "PO"
                },
                {
                    "drug_name": "vinCRISTine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "6 weeks",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (up to 6 cycles)",
                    "dose": "1.4 mg/m2\n(Cap dose at 2 mg)",
                    "day": "8 and 29",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Procarbazine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "6 weeks",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (up to 6 cycles)",
                    "dose": "60 mg/m2 ONCE a day",
                    "day": "8 to 21",
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "neurological",
        "url": "https://www.eviq.org.au/medical-oncology/neurological/glioma/1673-glioma-high-grade-recurrent-pcv-procarbazine"
    },
    {
        "protocol_id": "1671 v.3",
        "protocol_status": "Discontinued",
        "drug_sequence": [],
        "section_name": "medical-oncology",
        "category_name": "neurological",
        "url": "https://www.eviq.org.au/medical-oncology/neurological/glioma/1671-glioblastoma-recurrent-single-agent-lomustine"
    },
    {
        "protocol_id": "634 v.3",
        "protocol_status": "Discontinued",
        "drug_sequence": [],
        "section_name": "medical-oncology",
        "category_name": "neurological",
        "url": "https://www.eviq.org.au/medical-oncology/neurological/glioma/634-glioma-adjuvant-pcv-procarbazine-lomustine-vi"
    },
    {
        "protocol_id": "2046 v.3",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Temozolomide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "12",
                    "dose": "150 mg/m2 ONCE a day *",
                    "day": "1 to 5",
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Temozolomide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "12",
                    "dose": "200 mg/m2 ONCE a day *",
                    "day": "1 to 5",
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Temozolomide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "12",
                    "dose": "150 mg/m2 ONCE a day *",
                    "day": "1 to 5",
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Temozolomide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "12",
                    "dose": "200 mg/m2 ONCE a day *",
                    "day": "1 to 5",
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "neurological",
        "url": "https://www.eviq.org.au/medical-oncology/neurological/glioma/2046-astrocytoma-temozolomide-following-radiation"
    },
    {
        "protocol_id": "4136 v.1",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Lomustine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "42 days",
                    "cycles": "6(cycle 1 with concurrent radiation therapy, cycle 2 to 6 following chemoradiation)",
                    "dose": "100 mg/m2 ONCE a day",
                    "day": "1 *",
                    "route": "PO"
                },
                {
                    "drug_name": "Temozolomide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "42 days",
                    "cycles": "6(cycle 1 with concurrent radiation therapy, cycle 2 to 6 following chemoradiation)",
                    "dose": "100 mg/m2 ONCE a day",
                    "day": "2 to 6 *",
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Lomustine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "42 days",
                    "cycles": "6(cycle 1 with concurrent radiation therapy, cycle 2 to 6 following chemoradiation)",
                    "dose": "100 mg/m2 ONCE a day",
                    "day": "1",
                    "route": "PO"
                },
                {
                    "drug_name": "Temozolomide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "42 days",
                    "cycles": "6(cycle 1 with concurrent radiation therapy, cycle 2 to 6 following chemoradiation)",
                    "dose": "100 mg/m2 ONCE a day **",
                    "day": "2 to 6",
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Lomustine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "42 days",
                    "cycles": "6(cycle 1 with concurrent radiation therapy, cycle 2 to 6 following chemoradiation)",
                    "dose": "100 mg/m2 ONCE a day",
                    "day": "1 *",
                    "route": "PO"
                },
                {
                    "drug_name": "Temozolomide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "42 days",
                    "cycles": "6(cycle 1 with concurrent radiation therapy, cycle 2 to 6 following chemoradiation)",
                    "dose": "100 mg/m2 ONCE a day",
                    "day": "2 to 6 *",
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Lomustine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "42 days",
                    "cycles": "6(cycle 1 with concurrent radiation therapy, cycle 2 to 6 following chemoradiation)",
                    "dose": "100 mg/m2 ONCE a day",
                    "day": "1",
                    "route": "PO"
                },
                {
                    "drug_name": "Temozolomide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "42 days",
                    "cycles": "6(cycle 1 with concurrent radiation therapy, cycle 2 to 6 following chemoradiation)",
                    "dose": "100 mg/m2 ONCE a day **",
                    "day": "2 to 6",
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "neurological",
        "url": "https://www.eviq.org.au/medical-oncology/neurological/glioma/4136-glioblastoma-lomustine-and-temozolomide-chemo"
    },
    {
        "protocol_id": "733 v.8",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "beVACizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "10 mg/kg *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "beVACizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "10 mg/kg *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "neurological",
        "url": "https://www.eviq.org.au/medical-oncology/neurological/glioma/733-glioblastoma-recurrent-bevacizumab"
    },
    {
        "protocol_id": "3363 v.1",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Lomustine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "6 weeks",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "110 mg/m2 *",
                    "day": "1",
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Lomustine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "6 weeks",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "110 mg/m2 *",
                    "day": "1",
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "neurological",
        "url": "https://www.eviq.org.au/medical-oncology/neurological/glioma/3363-glioblastoma-recurrent-lomustine-110mg-m2"
    },
    {
        "protocol_id": "4135 v.1",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Lomustine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "42 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "90 mg/m2\n(Cap dose at 160 mg)",
                    "day": "1",
                    "route": "PO"
                },
                {
                    "drug_name": "beVACizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "42 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "10 mg/kg",
                    "day": "1, 15, 29",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Lomustine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "42 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "90 mg/m2\n(Cap dose at 160 mg)",
                    "day": "1",
                    "route": "PO"
                },
                {
                    "drug_name": "beVACizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "42 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "10 mg/kg",
                    "day": "1, 15, 29",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "neurological",
        "url": "https://www.eviq.org.au/medical-oncology/neurological/glioma/4135-glioblastoma-recurrent-lomustine-and-bevacizu"
    },
    {
        "protocol_id": "365 v.7",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Temozolomide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": "1with concurrent radiation therapy (usually 6 weeks)",
                    "dose": "75 mg/m2 ONCE a day throughout radiation therapy",
                    "day": "1 to 42 *",
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Temozolomide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": "1with concurrent radiation therapy (usually 6 weeks)",
                    "dose": "75 mg/m2 ONCE a day throughout radiation therapy",
                    "day": "1 to 42 *",
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "neurological",
        "url": "https://www.eviq.org.au/medical-oncology/neurological/glioma/365-glioblastoma-temozolomide-chemoradiation-part"
    },
    {
        "protocol_id": "3364 v.1",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "temozolomide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "1 (42 days)",
                    "dose": "",
                    "day": 1,
                    "route": "IV"
                }
            ],
            [
                {
                    "drug_name": "temozolomide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "1 (42 days)",
                    "dose": "",
                    "day": 1,
                    "route": "IV"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "neurological",
        "url": "https://www.eviq.org.au/medical-oncology/neurological/glioma/3364-glioblastoma-temozolomide-chemoradiation-foll"
    },
    {
        "protocol_id": "366 v.6",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Temozolomide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "6(consider continuing for up to 12 cycles at clinician discretion)",
                    "dose": "150 mg/m2 ONCE a day *",
                    "day": "1 to 5",
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Temozolomide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "6(consider continuing for up to 12 cycles at clinician discretion)",
                    "dose": "200 mg/m2 ONCE a day *",
                    "day": "1 to 5",
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Temozolomide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "6(consider continuing for up to 12 cycles at clinician discretion)",
                    "dose": "150 mg/m2 ONCE a day *",
                    "day": "1 to 5",
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Temozolomide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "6(consider continuing for up to 12 cycles at clinician discretion)",
                    "dose": "200 mg/m2 ONCE a day *",
                    "day": "1 to 5",
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "neurological",
        "url": "https://www.eviq.org.au/medical-oncology/neurological/glioma/366-glioblastoma-temozolomide-following-chemoradia"
    },
    {
        "protocol_id": "2034 v.2",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Temozolomide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "12(up to 12 cycles were allowed in the clinical trial but this may not be achievable in this patient population in clinical practice)",
                    "dose": "150 mg/m2 ONCE a day *",
                    "day": "1 to 5",
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Temozolomide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "12(up to 12 cycles were allowed in the clinical trial but this may not be achievable in this patient population in clinical practice)",
                    "dose": "200 mg/m2 ONCE a day *",
                    "day": "1 to 5",
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Temozolomide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "12(up to 12 cycles were allowed in the clinical trial but this may not be achievable in this patient population in clinical practice)",
                    "dose": "150 mg/m2 ONCE a day *",
                    "day": "1 to 5",
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Temozolomide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "12(up to 12 cycles were allowed in the clinical trial but this may not be achievable in this patient population in clinical practice)",
                    "dose": "200 mg/m2 ONCE a day *",
                    "day": "1 to 5",
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "neurological",
        "url": "https://www.eviq.org.au/medical-oncology/neurological/glioma/2034-glioblastoma-temozolomide-following-short-cou"
    },
    {
        "protocol_id": "2033 v.3",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Temozolomide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": "1with concurrent radiation therapy (usually 3 weeks)",
                    "dose": "75 mg/m2 ONCE a day throughout radiation therapy",
                    "day": "1 to 21 *",
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Temozolomide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": "1with concurrent radiation therapy (usually 3 weeks)",
                    "dose": "75 mg/m2 ONCE a day throughout radiation therapy",
                    "day": "1 to 21 *",
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "neurological",
        "url": "https://www.eviq.org.au/medical-oncology/neurological/glioma/2033-glioblastoma-temozolomide-short-course-chemor"
    },
    {
        "protocol_id": "3365 v.1",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "temozolomide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "1 (21 days)",
                    "dose": "",
                    "day": 1,
                    "route": "IV"
                }
            ],
            [
                {
                    "drug_name": "temozolomide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "1 (21 days)",
                    "dose": "",
                    "day": 1,
                    "route": "IV"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "neurological",
        "url": "https://www.eviq.org.au/medical-oncology/neurological/glioma/3365-glioblastoma-temozolomide-short-course-chemor"
    },
    {
        "protocol_id": "367 v.5",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Temozolomide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "6(consider continuing to 12 cycles and beyond if tolerated and of benefit)",
                    "dose": "200 mg/m2 ONCE a day *",
                    "day": "1 to 5",
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Temozolomide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "6(consider continuing to 12 cycles and beyond if tolerated and of benefit)",
                    "dose": "200 mg/m2 ONCE a day *",
                    "day": "1 to 5",
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "neurological",
        "url": "https://www.eviq.org.au/medical-oncology/neurological/glioma/367-glioma-high-grade-or-recurrent-temozolomide"
    },
    {
        "protocol_id": "2044 v.2",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Lomustine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "8 weeks(some patients may have treatment every 6 weeks at clinician discretion)",
                    "cycles": "6(trial protocol specified 6 cycles but this is achievable only in selected patients in clinical practice)",
                    "dose": "110 mg/m2 ONCE a day",
                    "day": "1",
                    "route": "PO"
                },
                {
                    "drug_name": "vinCRISTine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "8 weeks(some patients may have treatment every 6 weeks at clinician discretion)",
                    "cycles": "6(trial protocol specified 6 cycles but this is achievable only in selected patients in clinical practice)",
                    "dose": "1.4 mg/m2\n(Cap dose at 2 mg)",
                    "day": "8 and 29",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Procarbazine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "8 weeks(some patients may have treatment every 6 weeks at clinician discretion)",
                    "cycles": "6(trial protocol specified 6 cycles but this is achievable only in selected patients in clinical practice)",
                    "dose": "60 mg/m2 ONCE a day",
                    "day": "8 to 21",
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Lomustine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "8 weeks(some patients may have treatment every 6 weeks at clinician discretion)",
                    "cycles": "6(trial protocol specified 6 cycles but this is achievable only in selected patients in clinical practice)",
                    "dose": "110 mg/m2 ONCE a day",
                    "day": "1",
                    "route": "PO"
                },
                {
                    "drug_name": "vinCRISTine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "8 weeks(some patients may have treatment every 6 weeks at clinician discretion)",
                    "cycles": "6(trial protocol specified 6 cycles but this is achievable only in selected patients in clinical practice)",
                    "dose": "1.4 mg/m2\n(Cap dose at 2 mg)",
                    "day": "8 and 29",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Procarbazine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "8 weeks(some patients may have treatment every 6 weeks at clinician discretion)",
                    "cycles": "6(trial protocol specified 6 cycles but this is achievable only in selected patients in clinical practice)",
                    "dose": "60 mg/m2 ONCE a day",
                    "day": "8 to 21",
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "neurological",
        "url": "https://www.eviq.org.au/medical-oncology/neurological/glioma/2044-glioma-low-grade-pcv-procarbazine-lomustine"
    },
    {
        "protocol_id": "2045 v.4",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Lomustine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "6 weeks",
                    "cycles": "6(EORTC 26951 trial protocol specified 6 cycles but this is achievable only in selected patients in clinical practice)",
                    "dose": "110 mg/m2 ONCE a day",
                    "day": "1",
                    "route": "PO"
                },
                {
                    "drug_name": "vinCRISTine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "6 weeks",
                    "cycles": "6(EORTC 26951 trial protocol specified 6 cycles but this is achievable only in selected patients in clinical practice)",
                    "dose": "1.4 mg/m2\n(Cap dose at 2 mg)",
                    "day": "8 and 29",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Procarbazine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "6 weeks",
                    "cycles": "6(EORTC 26951 trial protocol specified 6 cycles but this is achievable only in selected patients in clinical practice)",
                    "dose": "60 mg/m2 ONCE a day",
                    "day": "8 to 21",
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Lomustine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "6 weeks",
                    "cycles": "6(EORTC 26951 trial protocol specified 6 cycles but this is achievable only in selected patients in clinical practice)",
                    "dose": "110 mg/m2 ONCE a day",
                    "day": "1",
                    "route": "PO"
                },
                {
                    "drug_name": "vinCRISTine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "6 weeks",
                    "cycles": "6(EORTC 26951 trial protocol specified 6 cycles but this is achievable only in selected patients in clinical practice)",
                    "dose": "1.4 mg/m2\n(Cap dose at 2 mg)",
                    "day": "8 and 29",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Procarbazine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "6 weeks",
                    "cycles": "6(EORTC 26951 trial protocol specified 6 cycles but this is achievable only in selected patients in clinical practice)",
                    "dose": "60 mg/m2 ONCE a day",
                    "day": "8 to 21",
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "neurological",
        "url": "https://www.eviq.org.au/medical-oncology/neurological/glioma/2045-oligodendroglioma-pcv-procarbazine-lomustine"
    },
    {
        "protocol_id": "1675 v.3",
        "protocol_status": "Superseded",
        "drug_sequence": [
            [
                {
                    "drug_name": "Carmustine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "6 weeks",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "200 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Carmustine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "6 weeks",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "200 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "neurological",
        "url": "https://www.eviq.org.au/medical-oncology/neurological/glioma/1675-glioma-high-grade-recurrent-carmustine-supers"
    },
    {
        "protocol_id": "1673 v.5",
        "protocol_status": "Superseded",
        "drug_sequence": [
            [
                {
                    "drug_name": "Lomustine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "6 weeks",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (up to 6 cycles)",
                    "dose": "110 mg/m2 ONCE a day",
                    "day": "1",
                    "route": "PO"
                },
                {
                    "drug_name": "vinCRISTine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "6 weeks",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (up to 6 cycles)",
                    "dose": "1.4 mg/m2\n(Cap dose at 2 mg)",
                    "day": "8 and 29",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Procarbazine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "6 weeks",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (up to 6 cycles)",
                    "dose": "60 mg/m2 ONCE a day",
                    "day": "8 to 21",
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Lomustine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "6 weeks",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (up to 6 cycles)",
                    "dose": "110 mg/m2 ONCE a day",
                    "day": "1",
                    "route": "PO"
                },
                {
                    "drug_name": "vinCRISTine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "6 weeks",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (up to 6 cycles)",
                    "dose": "1.4 mg/m2\n(Cap dose at 2 mg)",
                    "day": "8 and 29",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Procarbazine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "6 weeks",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (up to 6 cycles)",
                    "dose": "60 mg/m2 ONCE a day",
                    "day": "8 to 21",
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "neurological",
        "url": "https://www.eviq.org.au/medical-oncology/neurological/glioma/1673-glioma-high-grade-recurrent-pcv-procarbazine"
    },
    {
        "protocol_id": "1671 v.3",
        "protocol_status": "Discontinued",
        "drug_sequence": [],
        "section_name": "medical-oncology",
        "category_name": "neurological",
        "url": "https://www.eviq.org.au/medical-oncology/neurological/glioma/1671-glioblastoma-recurrent-single-agent-lomustine"
    },
    {
        "protocol_id": "634 v.3",
        "protocol_status": "Discontinued",
        "drug_sequence": [],
        "section_name": "medical-oncology",
        "category_name": "neurological",
        "url": "https://www.eviq.org.au/medical-oncology/neurological/glioma/634-glioma-adjuvant-pcv-procarbazine-lomustine-vi"
    },
    {
        "protocol_id": "230 v.8",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Pemetrexed",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6unless otherwise indicated",
                    "dose": "500 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6unless otherwise indicated",
                    "dose": "5 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Pemetrexed",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6unless otherwise indicated",
                    "dose": "500 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6unless otherwise indicated",
                    "dose": "5 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "respiratory",
        "url": "https://www.eviq.org.au/medical-oncology/respiratory/mesothelioma/230-mesothelioma-carboplatin-and-pemetrexed"
    },
    {
        "protocol_id": "4143 v.2",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "beVACizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6 with chemotherapy combination, followed by continuous treatment with bevacizumab until disease progression or unacceptable toxicity",
                    "dose": "15 mg/kg",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Pemetrexed",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6 with chemotherapy combination, followed by continuous treatment with bevacizumab until disease progression or unacceptable toxicity",
                    "dose": "500 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6 with chemotherapy combination, followed by continuous treatment with bevacizumab until disease progression or unacceptable toxicity",
                    "dose": "5 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "beVACizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6 with chemotherapy combination, followed by continuous treatment with bevacizumab until disease progression or unacceptable toxicity",
                    "dose": "15 mg/kg",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "beVACizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6 with chemotherapy combination, followed by continuous treatment with bevacizumab until disease progression or unacceptable toxicity",
                    "dose": "15 mg/kg",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Pemetrexed",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6 with chemotherapy combination, followed by continuous treatment with bevacizumab until disease progression or unacceptable toxicity",
                    "dose": "500 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6 with chemotherapy combination, followed by continuous treatment with bevacizumab until disease progression or unacceptable toxicity",
                    "dose": "5 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "beVACizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6 with chemotherapy combination, followed by continuous treatment with bevacizumab until disease progression or unacceptable toxicity",
                    "dose": "15 mg/kg",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "respiratory",
        "url": "https://www.eviq.org.au/medical-oncology/respiratory/mesothelioma/4143-mesothelioma-carboplatin-pemetrexed-and-bevac"
    },
    {
        "protocol_id": "229 v.6",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Pemetrexed",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6unless otherwise indicated",
                    "dose": "500 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6unless otherwise indicated",
                    "dose": "75 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Pemetrexed",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6unless otherwise indicated",
                    "dose": "500 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6unless otherwise indicated",
                    "dose": "75 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "respiratory",
        "url": "https://www.eviq.org.au/medical-oncology/respiratory/mesothelioma/229-mesothelioma-cisplatin-and-pemetrexed"
    },
    {
        "protocol_id": "4022 v.2",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "beVACizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6 with chemotherapy combination, followed by continuous treatment with  bevacizumab until disease progression or unacceptable toxicity",
                    "dose": "15 mg/kg",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Pemetrexed",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6 with chemotherapy combination, followed by continuous treatment with  bevacizumab until disease progression or unacceptable toxicity",
                    "dose": "500 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6 with chemotherapy combination, followed by continuous treatment with  bevacizumab until disease progression or unacceptable toxicity",
                    "dose": "75 mg/m2 *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "beVACizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6 with chemotherapy combination, followed by continuous treatment with  bevacizumab until disease progression or unacceptable toxicity",
                    "dose": "15 mg/kg",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "beVACizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6 with chemotherapy combination, followed by continuous treatment with  bevacizumab until disease progression or unacceptable toxicity",
                    "dose": "15 mg/kg",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Pemetrexed",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6 with chemotherapy combination, followed by continuous treatment with  bevacizumab until disease progression or unacceptable toxicity",
                    "dose": "500 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6 with chemotherapy combination, followed by continuous treatment with  bevacizumab until disease progression or unacceptable toxicity",
                    "dose": "75 mg/m2 *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "beVACizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6 with chemotherapy combination, followed by continuous treatment with  bevacizumab until disease progression or unacceptable toxicity",
                    "dose": "15 mg/kg",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "respiratory",
        "url": "https://www.eviq.org.au/medical-oncology/respiratory/mesothelioma/4022-mesothelioma-cisplatin-pemetrexed-and-bevaciz"
    },
    {
        "protocol_id": "4013 v.3",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Nivolumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "42 days",
                    "cycles": "17or until disease progression or unacceptable toxicity for up to 2 years",
                    "dose": "360 mg",
                    "day": "1 and 22",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Ipilimumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "42 days",
                    "cycles": "17or until disease progression or unacceptable toxicity for up to 2 years",
                    "dose": "1 mg/kg",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Nivolumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "42 days",
                    "cycles": "17or until disease progression or unacceptable toxicity for up to 2 years",
                    "dose": "360 mg",
                    "day": "1 and 22",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Ipilimumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "42 days",
                    "cycles": "17or until disease progression or unacceptable toxicity for up to 2 years",
                    "dose": "1 mg/kg",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "respiratory",
        "url": "https://www.eviq.org.au/medical-oncology/respiratory/mesothelioma/4013-mesothelioma-ipilimumab-and-nivolumab-flat-d"
    },
    {
        "protocol_id": "1472 v.5",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "vinORELBine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity, usually 6 cycles",
                    "dose": "25 mg/m2",
                    "day": "1 and 8",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "vinORELBine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity, usually 6 cycles",
                    "dose": "25 mg/m2",
                    "day": "1 and 8",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "respiratory",
        "url": "https://www.eviq.org.au/medical-oncology/respiratory/mesothelioma/1472-mesothelioma-vinorelbine"
    },
    {
        "protocol_id": "4408 v.1",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Nivolumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "42 days",
                    "cycles": "17or until disease progression or unacceptable toxicity for up to 2 years",
                    "dose": "3 mg/kg",
                    "day": "1, 15, 29",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Ipilimumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "42 days",
                    "cycles": "17or until disease progression or unacceptable toxicity for up to 2 years",
                    "dose": "1 mg/kg",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Nivolumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "42 days",
                    "cycles": "17or until disease progression or unacceptable toxicity for up to 2 years",
                    "dose": "3 mg/kg",
                    "day": "1, 15, 29",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Ipilimumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "42 days",
                    "cycles": "17or until disease progression or unacceptable toxicity for up to 2 years",
                    "dose": "1 mg/kg",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "respiratory",
        "url": "https://www.eviq.org.au/medical-oncology/respiratory/mesothelioma/3957-redirect-id-4408"
    },
    {
        "protocol_id": "4291 v.2",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Atezolizumab",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Up to 12 months of treatment or until disease progression or unacceptable toxicity whichever comes first",
                    "dose": "1,200 mg *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Atezolizumab",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Up to 12 months of treatment or until disease progression or unacceptable toxicity whichever comes first",
                    "dose": "1,200 mg *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "respiratory",
        "url": "https://www.eviq.org.au/medical-oncology/respiratory/non-small-cell-lung-cancer-adjuvant-neoadjuvant/4291-non-small-cell-lung-cancer-adjuvant-atezolizu"
    },
    {
        "protocol_id": "3802 v.3",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Pemetrexed",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4unless otherwise indicated",
                    "dose": "500 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4unless otherwise indicated",
                    "dose": "75 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Pemetrexed",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4unless otherwise indicated",
                    "dose": "500 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4unless otherwise indicated",
                    "dose": "75 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "respiratory",
        "url": "https://www.eviq.org.au/medical-oncology/respiratory/non-small-cell-lung-cancer-adjuvant-neoadjuvant/3802-nsclc-adjuvant-cisplatin-and-pemetrexed"
    },
    {
        "protocol_id": "237 v.6",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "vinORELBine *",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4unless otherwise indicated",
                    "dose": "25 mg/m2",
                    "day": "1 and 8",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4unless otherwise indicated",
                    "dose": "80 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "vinORELBine *",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4unless otherwise indicated",
                    "dose": "25 mg/m2",
                    "day": "1 and 8",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4unless otherwise indicated",
                    "dose": "80 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "respiratory",
        "url": "https://www.eviq.org.au/medical-oncology/respiratory/non-small-cell-lung-cancer-adjuvant-neoadjuvant/237-nsclc-adjuvant-cisplatin-and-vinorelbine"
    },
    {
        "protocol_id": "4132 v.3",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Osimertinib",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "80 mg ONCE a day",
                    "day": null,
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Osimertinib",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "80 mg ONCE a day",
                    "day": null,
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "respiratory",
        "url": "https://www.eviq.org.au/medical-oncology/respiratory/non-small-cell-lung-cancer-adjuvant-neoadjuvant/4132-nsclc-adjuvant-osimertinib"
    },
    {
        "protocol_id": "4318 v.2",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Nivolumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "3",
                    "dose": "360 mg",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "PACLitaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "3",
                    "dose": "200 mg/m2 ^",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "3",
                    "dose": "6 AUC ^ *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Nivolumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "3",
                    "dose": "360 mg",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "PACLitaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "3",
                    "dose": "200 mg/m2 ^",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "3",
                    "dose": "6 AUC ^ *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "respiratory",
        "url": "https://www.eviq.org.au/medical-oncology/respiratory/non-small-cell-lung-cancer-adjuvant-neoadjuvant/4318-nsclc-neoadjuvant-carboplatin-paclitaxel-and"
    },
    {
        "protocol_id": "4316 v.2",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Nivolumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "3",
                    "dose": "360 mg",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Gemcitabine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "3",
                    "dose": "1,250 mg/m2 *",
                    "day": "1 and 8",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "3",
                    "dose": "75 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Nivolumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "3",
                    "dose": "360 mg",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Gemcitabine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "3",
                    "dose": "1,250 mg/m2 *",
                    "day": "1 and 8",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "3",
                    "dose": "75 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "respiratory",
        "url": "https://www.eviq.org.au/medical-oncology/respiratory/non-small-cell-lung-cancer-adjuvant-neoadjuvant/4316-nsclc-neoadjuvant-cisplatin-gemcitabine-and"
    },
    {
        "protocol_id": "4314 v.2",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Nivolumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "3",
                    "dose": "360 mg",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Pemetrexed",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "3",
                    "dose": "500 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "3",
                    "dose": "75 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Nivolumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "3",
                    "dose": "360 mg",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Pemetrexed",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "3",
                    "dose": "500 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "3",
                    "dose": "75 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "respiratory",
        "url": "https://www.eviq.org.au/medical-oncology/respiratory/non-small-cell-lung-cancer-adjuvant-neoadjuvant/4314-nsclc-neoadjuvant-cisplatin-pemetrexed-and-n"
    },
    {
        "protocol_id": "378 v.6",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": "1(concurrent with radiation therapy)",
                    "dose": "50 mg/m2",
                    "day": "1, 8, 29, 36",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Etoposide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": "1(concurrent with radiation therapy)",
                    "dose": "50 mg/m2 *",
                    "day": "1 to 5 and 29 to 33",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": "1(concurrent with radiation therapy)",
                    "dose": "50 mg/m2",
                    "day": "1, 8, 29, 36",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Etoposide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": "1(concurrent with radiation therapy)",
                    "dose": "50 mg/m2 *",
                    "day": "1 to 5 and 29 to 33",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "respiratory",
        "url": "https://www.eviq.org.au/medical-oncology/respiratory/non-small-cell-lung-cancer-adjuvant-neoadjuvant/378-nsclc-superior-sulcus-pancoast-cisplatin-and"
    },
    {
        "protocol_id": "3594 v.8",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Nivolumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "480 mg * #",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Nivolumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "480 mg * #",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "respiratory",
        "url": "https://www.eviq.org.au/medical-oncology/respiratory/non-small-cell-lung-cancer-advanced-metastatic/3623-redirect-id-3594"
    },
    {
        "protocol_id": "3840 v.9",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Pembrolizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (see Indications and patient population section)",
                    "dose": "200 mg *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Pembrolizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (see Indications and patient population section)",
                    "dose": "200 mg *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "respiratory",
        "url": "https://www.eviq.org.au/medical-oncology/respiratory/non-small-cell-lung-cancer-advanced-metastatic/2032-redirect-id-3840"
    },
    {
        "protocol_id": "4151 v.2",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Cemiplimab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (up to 2 years)",
                    "dose": "350 mg",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Cemiplimab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (up to 2 years)",
                    "dose": "350 mg",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "respiratory",
        "url": "https://www.eviq.org.au/medical-oncology/respiratory/non-small-cell-lung-cancer-advanced-metastatic/4151-locally-advanced-or-metastatic-cemiplimab"
    },
    {
        "protocol_id": "1436 v.8",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "PACLitaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "7 days",
                    "cycles": "6with concurrent radiation therapy",
                    "dose": "45 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "7 days",
                    "cycles": "6with concurrent radiation therapy",
                    "dose": "2 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "PACLitaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "7 days",
                    "cycles": "6with concurrent radiation therapy",
                    "dose": "45 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "7 days",
                    "cycles": "6with concurrent radiation therapy",
                    "dose": "2 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "respiratory",
        "url": "https://www.eviq.org.au/medical-oncology/respiratory/non-small-cell-lung-cancer-advanced-metastatic/1436-nsclc-locally-advanced-definitive-carboplatin"
    },
    {
        "protocol_id": "379 v.7",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": "1concurrent with radiation therapy",
                    "dose": "50 mg/m2",
                    "day": "1, 8, 29, 36",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Etoposide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": "1concurrent with radiation therapy",
                    "dose": "50 mg/m2 *",
                    "day": "1 to 5 and 29 to 33",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": "1concurrent with radiation therapy",
                    "dose": "50 mg/m2",
                    "day": "1, 8, 29, 36",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Etoposide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": "1concurrent with radiation therapy",
                    "dose": "50 mg/m2 *",
                    "day": "1 to 5 and 29 to 33",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "respiratory",
        "url": "https://www.eviq.org.au/medical-oncology/respiratory/non-small-cell-lung-cancer-advanced-metastatic/379-nsclc-locally-advanced-definitive-cisplatin-an"
    },
    {
        "protocol_id": "4179 v.2",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Durvalumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "13or until disease progression or unacceptable toxicity",
                    "dose": "1,500 mg",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Durvalumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "13or until disease progression or unacceptable toxicity",
                    "dose": "1,500 mg",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "respiratory",
        "url": "https://www.eviq.org.au/medical-oncology/respiratory/non-small-cell-lung-cancer-advanced-metastatic/4179-nsclc-locally-advanced-durvalumab-flat-dosin"
    },
    {
        "protocol_id": "3512 v.6",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Durvalumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "26or until disease progression or unacceptable toxicity",
                    "dose": "10 mg/kg",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Durvalumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "26or until disease progression or unacceptable toxicity",
                    "dose": "10 mg/kg",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "respiratory",
        "url": "https://www.eviq.org.au/medical-oncology/respiratory/non-small-cell-lung-cancer-advanced-metastatic/3512-nsclc-locally-advanced-durvalumab-weight-bas"
    },
    {
        "protocol_id": "3409 v.5",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Alectinib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "600 mg TWICE a day *",
                    "day": null,
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Alectinib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "600 mg TWICE a day *",
                    "day": null,
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "respiratory",
        "url": "https://www.eviq.org.au/medical-oncology/respiratory/non-small-cell-lung-cancer-advanced-metastatic/3409-nsclc-locally-advanced-or-metastatic-alectini"
    },
    {
        "protocol_id": "3408 v.5",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Atezolizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "1,200 mg *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Atezolizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "1,200 mg *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "respiratory",
        "url": "https://www.eviq.org.au/medical-oncology/respiratory/non-small-cell-lung-cancer-advanced-metastatic/3408-nsclc-locally-advanced-or-metastatic-atezoliz"
    },
    {
        "protocol_id": "3789 v.2",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Brigatinib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "90 mg ONCE a day *",
                    "day": "1 to 7",
                    "route": "PO"
                },
                {
                    "drug_name": "Brigatinib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "180 mg ONCE a day",
                    "day": "8 to 28",
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Brigatinib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "180 mg ONCE a day",
                    "day": "1 to 28",
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Brigatinib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "90 mg ONCE a day *",
                    "day": "1 to 7",
                    "route": "PO"
                },
                {
                    "drug_name": "Brigatinib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "180 mg ONCE a day",
                    "day": "8 to 28",
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Brigatinib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "180 mg ONCE a day",
                    "day": "1 to 28",
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "respiratory",
        "url": "https://www.eviq.org.au/medical-oncology/respiratory/non-small-cell-lung-cancer-advanced-metastatic/3789-nsclc-metastatic-brigatinib"
    },
    {
        "protocol_id": "226 v.7",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "DOCEtaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4unless otherwise indicated",
                    "dose": "75 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4unless otherwise indicated",
                    "dose": "5 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "DOCEtaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4unless otherwise indicated",
                    "dose": "75 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4unless otherwise indicated",
                    "dose": "5 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "respiratory",
        "url": "https://www.eviq.org.au/medical-oncology/respiratory/non-small-cell-lung-cancer-advanced-metastatic/226-nsclc-locally-advanced-or-metastatic-carboplat"
    },
    {
        "protocol_id": "1432 v.6",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Gemcitabine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4unless otherwise indicated",
                    "dose": "1,000 mg/m2",
                    "day": "1 and 8",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4unless otherwise indicated",
                    "dose": "5 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Gemcitabine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4unless otherwise indicated",
                    "dose": "1,000 mg/m2",
                    "day": "1 and 8",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4unless otherwise indicated",
                    "dose": "5 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "respiratory",
        "url": "https://www.eviq.org.au/medical-oncology/respiratory/non-small-cell-lung-cancer-advanced-metastatic/1432-nsclc-locally-advanced-or-metastatic-carbopla"
    },
    {
        "protocol_id": "238 v.10",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "PACLitaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4unless otherwise indicated",
                    "dose": "200 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4unless otherwise indicated",
                    "dose": "6 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "PACLitaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4unless otherwise indicated",
                    "dose": "200 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4unless otherwise indicated",
                    "dose": "6 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "respiratory",
        "url": "https://www.eviq.org.au/medical-oncology/respiratory/non-small-cell-lung-cancer-advanced-metastatic/238-nsclc-locally-advanced-or-metastatic-carboplat"
    },
    {
        "protocol_id": "1261 v.3",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Pemetrexed",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4to 6 cycles (if clinically indicated) followed by maintenance pemetrexed in non-progressing patients",
                    "dose": "500 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4to 6 cycles (if clinically indicated) followed by maintenance pemetrexed in non-progressing patients",
                    "dose": "5 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Pemetrexed",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4to 6 cycles (if clinically indicated) followed by maintenance pemetrexed in non-progressing patients",
                    "dose": "500 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4to 6 cycles (if clinically indicated) followed by maintenance pemetrexed in non-progressing patients",
                    "dose": "5 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "respiratory",
        "url": "https://www.eviq.org.au/medical-oncology/respiratory/non-small-cell-lung-cancer-advanced-metastatic/1261-nsclc-locally-advanced-or-metastatic-carbopla"
    },
    {
        "protocol_id": "1470 v.9",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "PACLitaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "4unless otherwise indicated",
                    "dose": "90 mg/m2",
                    "day": "1, 8, 15",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "4unless otherwise indicated",
                    "dose": "6 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "PACLitaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "4unless otherwise indicated",
                    "dose": "90 mg/m2",
                    "day": "1, 8, 15",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "4unless otherwise indicated",
                    "dose": "6 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "respiratory",
        "url": "https://www.eviq.org.au/medical-oncology/respiratory/non-small-cell-lung-cancer-advanced-metastatic/1470-nsclc-locally-advanced-or-metastatic-carbopla"
    },
    {
        "protocol_id": "1434 v.6",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Gemcitabine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4unless otherwise indicated",
                    "dose": "1,250 mg/m2",
                    "day": "1 and 8",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4unless otherwise indicated",
                    "dose": "80 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Gemcitabine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4unless otherwise indicated",
                    "dose": "1,250 mg/m2",
                    "day": "1 and 8",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4unless otherwise indicated",
                    "dose": "80 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "respiratory",
        "url": "https://www.eviq.org.au/medical-oncology/respiratory/non-small-cell-lung-cancer-advanced-metastatic/1434-nsclc-locally-advanced-or-metastatic-cisplati"
    },
    {
        "protocol_id": "88 v.7",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Pemetrexed",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4unless otherwise indicated followed by maintenance pemetrexed in non-progressing patients",
                    "dose": "500 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4unless otherwise indicated followed by maintenance pemetrexed in non-progressing patients",
                    "dose": "75 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Pemetrexed",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4unless otherwise indicated followed by maintenance pemetrexed in non-progressing patients",
                    "dose": "500 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4unless otherwise indicated followed by maintenance pemetrexed in non-progressing patients",
                    "dose": "75 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "respiratory",
        "url": "https://www.eviq.org.au/medical-oncology/respiratory/non-small-cell-lung-cancer-advanced-metastatic/88-nsclc-locally-advanced-or-metastatic-cisplatin"
    },
    {
        "protocol_id": "3958 v.2",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Entrectinib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "600 mg ONCE a day",
                    "day": null,
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Entrectinib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "600 mg ONCE a day",
                    "day": null,
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "respiratory",
        "url": "https://www.eviq.org.au/medical-oncology/respiratory/non-small-cell-lung-cancer-advanced-metastatic/3958-nsclc-locally-advanced-or-metastatic-entrecti"
    },
    {
        "protocol_id": "3790 v.4",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Lorlatinib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "100 mg ONCE a day",
                    "day": null,
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Lorlatinib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "100 mg ONCE a day",
                    "day": null,
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "respiratory",
        "url": "https://www.eviq.org.au/medical-oncology/respiratory/non-small-cell-lung-cancer-advanced-metastatic/3790-nsclc-metastatic-lorlatinib"
    },
    {
        "protocol_id": "1996 v.3",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Osimertinib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "80 mg ONCE a day",
                    "day": null,
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Osimertinib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "80 mg ONCE a day",
                    "day": null,
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "respiratory",
        "url": "https://www.eviq.org.au/medical-oncology/respiratory/non-small-cell-lung-cancer-advanced-metastatic/1996-nsclc-locally-advanced-or-metastatic-osimerti"
    },
    {
        "protocol_id": "4121 v.3",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Sotorasib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "960 mg ONCE a day *",
                    "day": null,
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Sotorasib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "960 mg ONCE a day *",
                    "day": null,
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "respiratory",
        "url": "https://www.eviq.org.au/medical-oncology/respiratory/non-small-cell-lung-cancer-advanced-metastatic/4121-nsclc-locally-advanced-or-metastatic-sotorasi"
    },
    {
        "protocol_id": "4122 v.2",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Tepotinib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "450 mg ONCE a day *",
                    "day": null,
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Tepotinib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "450 mg ONCE a day *",
                    "day": null,
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "respiratory",
        "url": "https://www.eviq.org.au/medical-oncology/respiratory/non-small-cell-lung-cancer-advanced-metastatic/4122-nsclc-locally-advanced-or-metastatic-tepotini"
    },
    {
        "protocol_id": "1600 v.5",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "aFATinib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "40 mg ONCE a day",
                    "day": null,
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "aFATinib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "40 mg ONCE a day",
                    "day": null,
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "respiratory",
        "url": "https://www.eviq.org.au/medical-oncology/respiratory/non-small-cell-lung-cancer-advanced-metastatic/1600-nsclc-metastatic-afatinib"
    },
    {
        "protocol_id": "3626 v.9",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Atezolizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4 (up to 6 if clinically indicated) with chemotherapy combination, followed by continuous treatment with atezolizumab and bevacizumab until disease progression or unacceptable toxicity",
                    "dose": "1,200 mg",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "beVACizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4 (up to 6 if clinically indicated) with chemotherapy combination, followed by continuous treatment with atezolizumab and bevacizumab until disease progression or unacceptable toxicity",
                    "dose": "15 mg/kg",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "PACLitaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4 (up to 6 if clinically indicated) with chemotherapy combination, followed by continuous treatment with atezolizumab and bevacizumab until disease progression or unacceptable toxicity",
                    "dose": "200 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4 (up to 6 if clinically indicated) with chemotherapy combination, followed by continuous treatment with atezolizumab and bevacizumab until disease progression or unacceptable toxicity",
                    "dose": "6 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Atezolizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4 (up to 6 if clinically indicated) with chemotherapy combination, followed by continuous treatment with atezolizumab and bevacizumab until disease progression or unacceptable toxicity",
                    "dose": "1,200 mg",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "beVACizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4 (up to 6 if clinically indicated) with chemotherapy combination, followed by continuous treatment with atezolizumab and bevacizumab until disease progression or unacceptable toxicity",
                    "dose": "15 mg/kg",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Atezolizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4 (up to 6 if clinically indicated) with chemotherapy combination, followed by continuous treatment with atezolizumab and bevacizumab until disease progression or unacceptable toxicity",
                    "dose": "1,200 mg",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "beVACizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4 (up to 6 if clinically indicated) with chemotherapy combination, followed by continuous treatment with atezolizumab and bevacizumab until disease progression or unacceptable toxicity",
                    "dose": "15 mg/kg",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "PACLitaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4 (up to 6 if clinically indicated) with chemotherapy combination, followed by continuous treatment with atezolizumab and bevacizumab until disease progression or unacceptable toxicity",
                    "dose": "200 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4 (up to 6 if clinically indicated) with chemotherapy combination, followed by continuous treatment with atezolizumab and bevacizumab until disease progression or unacceptable toxicity",
                    "dose": "6 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Atezolizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4 (up to 6 if clinically indicated) with chemotherapy combination, followed by continuous treatment with atezolizumab and bevacizumab until disease progression or unacceptable toxicity",
                    "dose": "1,200 mg",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "beVACizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4 (up to 6 if clinically indicated) with chemotherapy combination, followed by continuous treatment with atezolizumab and bevacizumab until disease progression or unacceptable toxicity",
                    "dose": "15 mg/kg",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "respiratory",
        "url": "https://www.eviq.org.au/medical-oncology/respiratory/non-small-cell-lung-cancer-advanced-metastatic/3626-nsclc-metastatic-carboplatin-paclitaxel-atezo"
    },
    {
        "protocol_id": "3955 v.5",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Nivolumab #",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "42 days(the eviQ protocol cycle is 42 days, however in Checkmate 9LA trial and PBS criteria a cycle is 21 days)",
                    "cycles": "17(1 cycle with chemotherapy combination, followed by continuous treatment with nivolumab and ipilimumab until disease progression or unacceptable toxicity for up to 2 years)",
                    "dose": "360 mg",
                    "day": "1 and 22",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Ipilimumab #",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "42 days(the eviQ protocol cycle is 42 days, however in Checkmate 9LA trial and PBS criteria a cycle is 21 days)",
                    "cycles": "17(1 cycle with chemotherapy combination, followed by continuous treatment with nivolumab and ipilimumab until disease progression or unacceptable toxicity for up to 2 years)",
                    "dose": "1 mg/kg",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "PACLitaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "42 days(the eviQ protocol cycle is 42 days, however in Checkmate 9LA trial and PBS criteria a cycle is 21 days)",
                    "cycles": "17(1 cycle with chemotherapy combination, followed by continuous treatment with nivolumab and ipilimumab until disease progression or unacceptable toxicity for up to 2 years)",
                    "dose": "200 mg/m2",
                    "day": "1 and 22",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "42 days(the eviQ protocol cycle is 42 days, however in Checkmate 9LA trial and PBS criteria a cycle is 21 days)",
                    "cycles": "17(1 cycle with chemotherapy combination, followed by continuous treatment with nivolumab and ipilimumab until disease progression or unacceptable toxicity for up to 2 years)",
                    "dose": "6 AUC *",
                    "day": "1 and 22",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Nivolumab #",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "42 days(the eviQ protocol cycle is 42 days, however in Checkmate 9LA trial and PBS criteria a cycle is 21 days)",
                    "cycles": "17(1 cycle with chemotherapy combination, followed by continuous treatment with nivolumab and ipilimumab until disease progression or unacceptable toxicity for up to 2 years)",
                    "dose": "360 mg",
                    "day": "1 and 22",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Ipilimumab #",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "42 days(the eviQ protocol cycle is 42 days, however in Checkmate 9LA trial and PBS criteria a cycle is 21 days)",
                    "cycles": "17(1 cycle with chemotherapy combination, followed by continuous treatment with nivolumab and ipilimumab until disease progression or unacceptable toxicity for up to 2 years)",
                    "dose": "1 mg/kg",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Nivolumab #",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "42 days(the eviQ protocol cycle is 42 days, however in Checkmate 9LA trial and PBS criteria a cycle is 21 days)",
                    "cycles": "17(1 cycle with chemotherapy combination, followed by continuous treatment with nivolumab and ipilimumab until disease progression or unacceptable toxicity for up to 2 years)",
                    "dose": "360 mg",
                    "day": "1 and 22",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Ipilimumab #",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "42 days(the eviQ protocol cycle is 42 days, however in Checkmate 9LA trial and PBS criteria a cycle is 21 days)",
                    "cycles": "17(1 cycle with chemotherapy combination, followed by continuous treatment with nivolumab and ipilimumab until disease progression or unacceptable toxicity for up to 2 years)",
                    "dose": "1 mg/kg",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "PACLitaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "42 days(the eviQ protocol cycle is 42 days, however in Checkmate 9LA trial and PBS criteria a cycle is 21 days)",
                    "cycles": "17(1 cycle with chemotherapy combination, followed by continuous treatment with nivolumab and ipilimumab until disease progression or unacceptable toxicity for up to 2 years)",
                    "dose": "200 mg/m2",
                    "day": "1 and 22",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "42 days(the eviQ protocol cycle is 42 days, however in Checkmate 9LA trial and PBS criteria a cycle is 21 days)",
                    "cycles": "17(1 cycle with chemotherapy combination, followed by continuous treatment with nivolumab and ipilimumab until disease progression or unacceptable toxicity for up to 2 years)",
                    "dose": "6 AUC *",
                    "day": "1 and 22",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Nivolumab #",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "42 days(the eviQ protocol cycle is 42 days, however in Checkmate 9LA trial and PBS criteria a cycle is 21 days)",
                    "cycles": "17(1 cycle with chemotherapy combination, followed by continuous treatment with nivolumab and ipilimumab until disease progression or unacceptable toxicity for up to 2 years)",
                    "dose": "360 mg",
                    "day": "1 and 22",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Ipilimumab #",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "42 days(the eviQ protocol cycle is 42 days, however in Checkmate 9LA trial and PBS criteria a cycle is 21 days)",
                    "cycles": "17(1 cycle with chemotherapy combination, followed by continuous treatment with nivolumab and ipilimumab until disease progression or unacceptable toxicity for up to 2 years)",
                    "dose": "1 mg/kg",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "respiratory",
        "url": "https://www.eviq.org.au/medical-oncology/respiratory/non-small-cell-lung-cancer-advanced-metastatic/3955-nsclc-metastatic-carboplatin-paclitaxel-ipili"
    },
    {
        "protocol_id": "4407 v.1",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Atezolizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4 (up to 6 if clinically indicated) with chemotherapy combination, followed by continuous treatment with pemetrexed, atezolizumab and bevacizumab until disease progression or unacceptable toxicity",
                    "dose": "1,200 mg",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "beVACizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4 (up to 6 if clinically indicated) with chemotherapy combination, followed by continuous treatment with pemetrexed, atezolizumab and bevacizumab until disease progression or unacceptable toxicity",
                    "dose": "7.5 mg/kg",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Pemetrexed",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4 (up to 6 if clinically indicated) with chemotherapy combination, followed by continuous treatment with pemetrexed, atezolizumab and bevacizumab until disease progression or unacceptable toxicity",
                    "dose": "500 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4 (up to 6 if clinically indicated) with chemotherapy combination, followed by continuous treatment with pemetrexed, atezolizumab and bevacizumab until disease progression or unacceptable toxicity",
                    "dose": "5 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Atezolizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4 (up to 6 if clinically indicated) with chemotherapy combination, followed by continuous treatment with pemetrexed, atezolizumab and bevacizumab until disease progression or unacceptable toxicity",
                    "dose": "1,200 mg",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "beVACizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4 (up to 6 if clinically indicated) with chemotherapy combination, followed by continuous treatment with pemetrexed, atezolizumab and bevacizumab until disease progression or unacceptable toxicity",
                    "dose": "7.5 mg/kg",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Pemetrexed",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4 (up to 6 if clinically indicated) with chemotherapy combination, followed by continuous treatment with pemetrexed, atezolizumab and bevacizumab until disease progression or unacceptable toxicity",
                    "dose": "500 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Atezolizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4 (up to 6 if clinically indicated) with chemotherapy combination, followed by continuous treatment with pemetrexed, atezolizumab and bevacizumab until disease progression or unacceptable toxicity",
                    "dose": "1,200 mg",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "beVACizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4 (up to 6 if clinically indicated) with chemotherapy combination, followed by continuous treatment with pemetrexed, atezolizumab and bevacizumab until disease progression or unacceptable toxicity",
                    "dose": "7.5 mg/kg",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Pemetrexed",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4 (up to 6 if clinically indicated) with chemotherapy combination, followed by continuous treatment with pemetrexed, atezolizumab and bevacizumab until disease progression or unacceptable toxicity",
                    "dose": "500 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4 (up to 6 if clinically indicated) with chemotherapy combination, followed by continuous treatment with pemetrexed, atezolizumab and bevacizumab until disease progression or unacceptable toxicity",
                    "dose": "5 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Atezolizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4 (up to 6 if clinically indicated) with chemotherapy combination, followed by continuous treatment with pemetrexed, atezolizumab and bevacizumab until disease progression or unacceptable toxicity",
                    "dose": "1,200 mg",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "beVACizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4 (up to 6 if clinically indicated) with chemotherapy combination, followed by continuous treatment with pemetrexed, atezolizumab and bevacizumab until disease progression or unacceptable toxicity",
                    "dose": "7.5 mg/kg",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Pemetrexed",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4 (up to 6 if clinically indicated) with chemotherapy combination, followed by continuous treatment with pemetrexed, atezolizumab and bevacizumab until disease progression or unacceptable toxicity",
                    "dose": "500 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "respiratory",
        "url": "https://www.eviq.org.au/medical-oncology/respiratory/non-small-cell-lung-cancer-advanced-metastatic/4407-nsclc-metastatic-carboplatin-pemetrexed-atezo"
    },
    {
        "protocol_id": "3502 v.7",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Pembrolizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "35or until disease progression or unacceptable toxicity (total maximum of 35 doses or 24 months treatment with pembrolizumab)",
                    "dose": "200 mg",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "PACLitaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "35or until disease progression or unacceptable toxicity (total maximum of 35 doses or 24 months treatment with pembrolizumab)",
                    "dose": "200 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "35or until disease progression or unacceptable toxicity (total maximum of 35 doses or 24 months treatment with pembrolizumab)",
                    "dose": "6 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Pembrolizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "35or until disease progression or unacceptable toxicity (total maximum of 35 doses or 24 months treatment with pembrolizumab)",
                    "dose": "200 mg **",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Pembrolizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "35or until disease progression or unacceptable toxicity (total maximum of 35 doses or 24 months treatment with pembrolizumab)",
                    "dose": "200 mg",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "PACLitaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "35or until disease progression or unacceptable toxicity (total maximum of 35 doses or 24 months treatment with pembrolizumab)",
                    "dose": "200 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "35or until disease progression or unacceptable toxicity (total maximum of 35 doses or 24 months treatment with pembrolizumab)",
                    "dose": "6 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Pembrolizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "35or until disease progression or unacceptable toxicity (total maximum of 35 doses or 24 months treatment with pembrolizumab)",
                    "dose": "200 mg **",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "respiratory",
        "url": "https://www.eviq.org.au/medical-oncology/respiratory/non-small-cell-lung-cancer-advanced-metastatic/3502-nsclc-metastatic-carboplatin-paclitaxel-and-p"
    },
    {
        "protocol_id": "3510 v.7",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Pembrolizumab #",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "35or until disease progression or unacceptable toxicity",
                    "dose": "200 mg",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Pemetrexed",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "35or until disease progression or unacceptable toxicity",
                    "dose": "500 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "35or until disease progression or unacceptable toxicity",
                    "dose": "5 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Pembrolizumab #",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "35or until disease progression or unacceptable toxicity",
                    "dose": "200 mg",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Pemetrexed",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "35or until disease progression or unacceptable toxicity",
                    "dose": "500 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Pembrolizumab #",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "35or until disease progression or unacceptable toxicity",
                    "dose": "200 mg",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Pemetrexed",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "35or until disease progression or unacceptable toxicity",
                    "dose": "500 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "35or until disease progression or unacceptable toxicity",
                    "dose": "5 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Pembrolizumab #",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "35or until disease progression or unacceptable toxicity",
                    "dose": "200 mg",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Pemetrexed",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "35or until disease progression or unacceptable toxicity",
                    "dose": "500 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "respiratory",
        "url": "https://www.eviq.org.au/medical-oncology/respiratory/non-small-cell-lung-cancer-advanced-metastatic/3510-nsclc-metastatic-carboplatin-pemetrexed-and-p"
    },
    {
        "protocol_id": "3545 v.6",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Pembrolizumab #",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "35or until disease progression or unacceptable toxicity",
                    "dose": "200 mg",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Pemetrexed",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "35or until disease progression or unacceptable toxicity",
                    "dose": "500 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "35or until disease progression or unacceptable toxicity",
                    "dose": "75 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Pembrolizumab #",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "35or until disease progression or unacceptable toxicity",
                    "dose": "200 mg",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Pemetrexed",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "35or until disease progression or unacceptable toxicity",
                    "dose": "500 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Pembrolizumab #",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "35or until disease progression or unacceptable toxicity",
                    "dose": "200 mg",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Pemetrexed",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "35or until disease progression or unacceptable toxicity",
                    "dose": "500 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "35or until disease progression or unacceptable toxicity",
                    "dose": "75 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Pembrolizumab #",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "35or until disease progression or unacceptable toxicity",
                    "dose": "200 mg",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Pemetrexed",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "35or until disease progression or unacceptable toxicity",
                    "dose": "500 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "respiratory",
        "url": "https://www.eviq.org.au/medical-oncology/respiratory/non-small-cell-lung-cancer-advanced-metastatic/3545-nsclc-metastatic-cisplatin-pemetrexed-and-pem"
    },
    {
        "protocol_id": "213 v.5",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "DOCEtaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4unless otherwise indicated",
                    "dose": "75 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "DOCEtaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4unless otherwise indicated",
                    "dose": "75 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "respiratory",
        "url": "https://www.eviq.org.au/medical-oncology/respiratory/non-small-cell-lung-cancer-advanced-metastatic/213-nsclc-metastatic-docetaxel-three-weekly"
    },
    {
        "protocol_id": "156 v.5",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Gemcitabine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "4unless otherwise indicated",
                    "dose": "1,000 mg/m2",
                    "day": "1, 8, 15",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Gemcitabine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "4unless otherwise indicated",
                    "dose": "1,000 mg/m2",
                    "day": "1, 8, 15",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "respiratory",
        "url": "https://www.eviq.org.au/medical-oncology/respiratory/non-small-cell-lung-cancer-advanced-metastatic/156-nsclc-metastatic-gemcitabine"
    },
    {
        "protocol_id": "236 v.7",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Pemetrexed",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "500 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Pemetrexed",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "500 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "respiratory",
        "url": "https://www.eviq.org.au/medical-oncology/respiratory/non-small-cell-lung-cancer-advanced-metastatic/236-nsclc-metastatic-pemetrexed"
    },
    {
        "protocol_id": "248 v.5",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "vinORELBine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4unless otherwise indicated",
                    "dose": "30 mg/m2 *",
                    "day": "1 and 8",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "vinORELBine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4unless otherwise indicated",
                    "dose": "30 mg/m2 *",
                    "day": "1 and 8",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "respiratory",
        "url": "https://www.eviq.org.au/medical-oncology/respiratory/non-small-cell-lung-cancer-advanced-metastatic/248-nsclc-metastatic-vinorelbine-intravenous"
    },
    {
        "protocol_id": "309 v.6",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "vinORELBine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "7 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "60 mg/m2 ONCE a week *",
                    "day": "1",
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "vinORELBine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "7 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "60 mg/m2 ONCE a week *",
                    "day": "1",
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "respiratory",
        "url": "https://www.eviq.org.au/medical-oncology/respiratory/non-small-cell-lung-cancer-advanced-metastatic/309-nsclc-metastatic-vinorelbine-oral"
    },
    {
        "protocol_id": "3555 v.9",
        "protocol_status": "Superseded",
        "drug_sequence": [
            [
                {
                    "drug_name": "Nivolumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "3 mg/kg",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Nivolumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "3 mg/kg",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "respiratory",
        "url": "https://www.eviq.org.au/medical-oncology/respiratory/non-small-cell-lung-cancer-advanced-metastatic/1856-redirect-id-3555"
    },
    {
        "protocol_id": "245 v.9",
        "protocol_status": "Superseded",
        "drug_sequence": [
            [
                {
                    "drug_name": "vinORELBine *",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4unless otherwise indicated",
                    "dose": "25 mg/m2",
                    "day": "1 and 8",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4unless otherwise indicated",
                    "dose": "5 AUC **",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "vinORELBine *",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4unless otherwise indicated",
                    "dose": "25 mg/m2",
                    "day": "1 and 8",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4unless otherwise indicated",
                    "dose": "5 AUC **",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "respiratory",
        "url": "https://www.eviq.org.au/medical-oncology/respiratory/non-small-cell-lung-cancer-advanced-metastatic/245-nsclc-locally-advanced-or-metastatic-carboplat"
    },
    {
        "protocol_id": "2035 v.4",
        "protocol_status": "Superseded",
        "drug_sequence": [
            [
                {
                    "drug_name": "Ceritinib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "750 mg ONCE a day",
                    "day": null,
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Ceritinib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "750 mg ONCE a day",
                    "day": null,
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "respiratory",
        "url": "https://www.eviq.org.au/medical-oncology/respiratory/non-small-cell-lung-cancer-advanced-metastatic/2035-nsclc-locally-advanced-or-metastatic-ceritini"
    },
    {
        "protocol_id": "239 v.8",
        "protocol_status": "Superseded",
        "drug_sequence": [
            [
                {
                    "drug_name": "vinORELBine *",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4unless otherwise indicated",
                    "dose": "25 mg/m2",
                    "day": "1 and 8",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4unless otherwise indicated",
                    "dose": "80 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "vinORELBine *",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4unless otherwise indicated",
                    "dose": "25 mg/m2",
                    "day": "1 and 8",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4unless otherwise indicated",
                    "dose": "80 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "respiratory",
        "url": "https://www.eviq.org.au/medical-oncology/respiratory/non-small-cell-lung-cancer-advanced-metastatic/239-nsclc-locally-advanced-or-metastatic-cisplatin"
    },
    {
        "protocol_id": "1351 v.6",
        "protocol_status": "Superseded",
        "drug_sequence": [
            [
                {
                    "drug_name": "Crizotinib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "250 mg TWICE a day",
                    "day": null,
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Crizotinib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "250 mg TWICE a day",
                    "day": null,
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "respiratory",
        "url": "https://www.eviq.org.au/medical-oncology/respiratory/non-small-cell-lung-cancer-advanced-metastatic/1351-nsclc-metastatic-crizotinib-superseded"
    },
    {
        "protocol_id": "224 v.6",
        "protocol_status": "Superseded",
        "drug_sequence": [
            [
                {
                    "drug_name": "DOCEtaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "4unless otherwise indicated",
                    "dose": "35 mg/m2",
                    "day": "1, 8, 15",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "DOCEtaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "4unless otherwise indicated",
                    "dose": "35 mg/m2",
                    "day": "1, 8, 15",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "respiratory",
        "url": "https://www.eviq.org.au/medical-oncology/respiratory/non-small-cell-lung-cancer-advanced-metastatic/224-nsclc-metastatic-docetaxel-weekly-superseded"
    },
    {
        "protocol_id": "380 v.6",
        "protocol_status": "Superseded",
        "drug_sequence": [
            [
                {
                    "drug_name": "Erlotinib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "150 mg ONCE a day",
                    "day": null,
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Erlotinib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "150 mg ONCE a day",
                    "day": null,
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "respiratory",
        "url": "https://www.eviq.org.au/medical-oncology/respiratory/non-small-cell-lung-cancer-advanced-metastatic/380-nsclc-metastatic-erlotinib-superseded"
    },
    {
        "protocol_id": "381 v.6",
        "protocol_status": "Superseded",
        "drug_sequence": [
            [
                {
                    "drug_name": "Gefitinib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "250 mg ONCE a day",
                    "day": null,
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Gefitinib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "250 mg ONCE a day",
                    "day": null,
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "respiratory",
        "url": "https://www.eviq.org.au/medical-oncology/respiratory/non-small-cell-lung-cancer-advanced-metastatic/381-nsclc-metastatic-gefitinib-superseded"
    },
    {
        "protocol_id": "263 v.6",
        "protocol_status": "Discontinued",
        "drug_sequence": [],
        "section_name": "medical-oncology",
        "category_name": "respiratory",
        "url": "https://www.eviq.org.au/medical-oncology/respiratory/non-small-cell-lung-cancer-advanced-metastatic/263-nsclc-metastatic-carboplatin-and-gemcitabine"
    },
    {
        "protocol_id": "227 v.4",
        "protocol_status": "Discontinued",
        "drug_sequence": [],
        "section_name": "medical-oncology",
        "category_name": "respiratory",
        "url": "https://www.eviq.org.au/medical-oncology/respiratory/non-small-cell-lung-cancer-advanced-metastatic/227-nsclc-metastatic-cisplatin-and-docetaxel-disco"
    },
    {
        "protocol_id": "262 v.5",
        "protocol_status": "Discontinued",
        "drug_sequence": [],
        "section_name": "medical-oncology",
        "category_name": "respiratory",
        "url": "https://www.eviq.org.au/medical-oncology/respiratory/non-small-cell-lung-cancer-advanced-metastatic/262-nsclc-metastatic-cisplatin-and-gemcitabine-da"
    },
    {
        "protocol_id": "377 v.5",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Topotecan",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4unless otherwise indicated",
                    "dose": "1.5 mg/m2",
                    "day": "1 to 3",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Topotecan",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4unless otherwise indicated",
                    "dose": "1.5 mg/m2",
                    "day": "1 to 3",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "respiratory",
        "url": "https://www.eviq.org.au/medical-oncology/respiratory/small-cell-lung-cancer/377-sclc-advanced-topotecan-modified"
    },
    {
        "protocol_id": "215 v.6",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4unless otherwise indicated",
                    "dose": "5 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Etoposide **",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4unless otherwise indicated",
                    "dose": "100 mg/m2",
                    "day": "1 to 3",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4unless otherwise indicated",
                    "dose": "5 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Etoposide **",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4unless otherwise indicated",
                    "dose": "100 mg/m2",
                    "day": "1 to 3",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "respiratory",
        "url": "https://www.eviq.org.au/medical-oncology/respiratory/small-cell-lung-cancer/215-sclc-extensive-disease-carboplatin-and-etoposi"
    },
    {
        "protocol_id": "340 v.6",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4unless otherwise indicated",
                    "dose": "5 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Etoposide **",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4unless otherwise indicated",
                    "dose": "100 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Etoposide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4unless otherwise indicated",
                    "dose": "200 mg/m2 ONCE a day ^",
                    "day": "2 and 3",
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4unless otherwise indicated",
                    "dose": "5 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Etoposide **",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4unless otherwise indicated",
                    "dose": "100 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Etoposide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4unless otherwise indicated",
                    "dose": "200 mg/m2 ONCE a day ^",
                    "day": "2 and 3",
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "respiratory",
        "url": "https://www.eviq.org.au/medical-oncology/respiratory/small-cell-lung-cancer/340-sclc-extensive-disease-carboplatin-and-oral-et"
    },
    {
        "protocol_id": "3731 v.5",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Atezolizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4 of chemotherapy combination, followed by continuous treatment with atezolizumab until disease progression or unacceptable toxicity",
                    "dose": "1,200 mg #",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4 of chemotherapy combination, followed by continuous treatment with atezolizumab until disease progression or unacceptable toxicity",
                    "dose": "5 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Etoposide **",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4 of chemotherapy combination, followed by continuous treatment with atezolizumab until disease progression or unacceptable toxicity",
                    "dose": "100 mg/m2",
                    "day": "1 to 3",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Atezolizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4 of chemotherapy combination, followed by continuous treatment with atezolizumab until disease progression or unacceptable toxicity",
                    "dose": "1,200 mg #",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Atezolizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4 of chemotherapy combination, followed by continuous treatment with atezolizumab until disease progression or unacceptable toxicity",
                    "dose": "1,200 mg #",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4 of chemotherapy combination, followed by continuous treatment with atezolizumab until disease progression or unacceptable toxicity",
                    "dose": "5 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Etoposide **",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4 of chemotherapy combination, followed by continuous treatment with atezolizumab until disease progression or unacceptable toxicity",
                    "dose": "100 mg/m2",
                    "day": "1 to 3",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Atezolizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4 of chemotherapy combination, followed by continuous treatment with atezolizumab until disease progression or unacceptable toxicity",
                    "dose": "1,200 mg #",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "respiratory",
        "url": "https://www.eviq.org.au/medical-oncology/respiratory/small-cell-lung-cancer/3731-sclc-extensive-disease-carboplatin-etoposide"
    },
    {
        "protocol_id": "3921 v.3",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Durvalumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "4of chemotherapy combination, followed by continuous treatment with durvalumab until disease progression or unacceptable toxicity",
                    "dose": "1,500 mg",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "4of chemotherapy combination, followed by continuous treatment with durvalumab until disease progression or unacceptable toxicity",
                    "dose": "5 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Etoposide **",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "4of chemotherapy combination, followed by continuous treatment with durvalumab until disease progression or unacceptable toxicity",
                    "dose": "100 mg/m2",
                    "day": "1 to 3",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Durvalumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "4of chemotherapy combination, followed by continuous treatment with durvalumab until disease progression or unacceptable toxicity",
                    "dose": "1,500 mg",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "4of chemotherapy combination, followed by continuous treatment with durvalumab until disease progression or unacceptable toxicity",
                    "dose": "5 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Etoposide **",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "4of chemotherapy combination, followed by continuous treatment with durvalumab until disease progression or unacceptable toxicity",
                    "dose": "100 mg/m2",
                    "day": "1 to 3",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "respiratory",
        "url": "https://www.eviq.org.au/medical-oncology/respiratory/small-cell-lung-cancer/3921-sclc-extensive-disease-carboplatin-etoposide"
    },
    {
        "protocol_id": "533 v.5",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "DOXOrubicin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4unless otherwise indicated",
                    "dose": "40 mg/m2",
                    "day": "1",
                    "route": "IV"
                },
                {
                    "drug_name": "vinCRISTine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4unless otherwise indicated",
                    "dose": "2 mg",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "CYCLOPHOSPHamide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4unless otherwise indicated",
                    "dose": "750 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "DOXOrubicin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4unless otherwise indicated",
                    "dose": "40 mg/m2",
                    "day": "1",
                    "route": "IV"
                },
                {
                    "drug_name": "vinCRISTine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4unless otherwise indicated",
                    "dose": "2 mg",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "CYCLOPHOSPHamide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4unless otherwise indicated",
                    "dose": "750 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "respiratory",
        "url": "https://www.eviq.org.au/medical-oncology/respiratory/small-cell-lung-cancer/533-sclc-extensive-disease-cav-cyclophosphamide-d"
    },
    {
        "protocol_id": "1716 v.5",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Irinotecan",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4unless otherwise indicated",
                    "dose": "65 mg/m2",
                    "day": "1 and 8",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "ciSplatin *",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4unless otherwise indicated",
                    "dose": "30 mg/m2",
                    "day": "1 and 8",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Irinotecan",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4unless otherwise indicated",
                    "dose": "65 mg/m2",
                    "day": "1 and 8",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "ciSplatin *",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4unless otherwise indicated",
                    "dose": "30 mg/m2",
                    "day": "1 and 8",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "respiratory",
        "url": "https://www.eviq.org.au/medical-oncology/respiratory/small-cell-lung-cancer/1716-sclc-extensive-disease-cisplatin-and-irinotec"
    },
    {
        "protocol_id": "374 v.6",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4unless otherwise indicated",
                    "dose": "5 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Etoposide **",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4unless otherwise indicated",
                    "dose": "100 mg/m2",
                    "day": "1 to 3",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4unless otherwise indicated",
                    "dose": "5 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Etoposide **",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4unless otherwise indicated",
                    "dose": "100 mg/m2",
                    "day": "1 to 3",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "respiratory",
        "url": "https://www.eviq.org.au/medical-oncology/respiratory/small-cell-lung-cancer/374-sclc-limited-disease-carboplatin-and-etoposide"
    },
    {
        "protocol_id": "375 v.5",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4unless otherwise indicated",
                    "dose": "80 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Etoposide *",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4unless otherwise indicated",
                    "dose": "100 mg/m2",
                    "day": "1 to 3",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4unless otherwise indicated",
                    "dose": "80 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Etoposide *",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4unless otherwise indicated",
                    "dose": "100 mg/m2",
                    "day": "1 to 3",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "respiratory",
        "url": "https://www.eviq.org.au/medical-oncology/respiratory/small-cell-lung-cancer/375-sclc-limited-disease-cisplatin-and-etoposide"
    },
    {
        "protocol_id": "376 v.5",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4(chemotherapy can be commenced promptly and radiation therapy scheduled to start concurrently. See evidence section)",
                    "dose": "60 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Etoposide *",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4(chemotherapy can be commenced promptly and radiation therapy scheduled to start concurrently. See evidence section)",
                    "dose": "120 mg/m2",
                    "day": "1 to 3",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4(chemotherapy can be commenced promptly and radiation therapy scheduled to start concurrently. See evidence section)",
                    "dose": "60 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Etoposide *",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4(chemotherapy can be commenced promptly and radiation therapy scheduled to start concurrently. See evidence section)",
                    "dose": "120 mg/m2",
                    "day": "1 to 3",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "respiratory",
        "url": "https://www.eviq.org.au/medical-oncology/respiratory/small-cell-lung-cancer/376-sclc-limited-disease-cisplatin-and-etoposide-c"
    },
    {
        "protocol_id": "230 v.8",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Pemetrexed",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6unless otherwise indicated",
                    "dose": "500 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6unless otherwise indicated",
                    "dose": "5 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Pemetrexed",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6unless otherwise indicated",
                    "dose": "500 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6unless otherwise indicated",
                    "dose": "5 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "respiratory",
        "url": "https://www.eviq.org.au/medical-oncology/respiratory/mesothelioma/230-mesothelioma-carboplatin-and-pemetrexed"
    },
    {
        "protocol_id": "4143 v.2",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "beVACizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6 with chemotherapy combination, followed by continuous treatment with bevacizumab until disease progression or unacceptable toxicity",
                    "dose": "15 mg/kg",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Pemetrexed",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6 with chemotherapy combination, followed by continuous treatment with bevacizumab until disease progression or unacceptable toxicity",
                    "dose": "500 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6 with chemotherapy combination, followed by continuous treatment with bevacizumab until disease progression or unacceptable toxicity",
                    "dose": "5 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "beVACizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6 with chemotherapy combination, followed by continuous treatment with bevacizumab until disease progression or unacceptable toxicity",
                    "dose": "15 mg/kg",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "beVACizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6 with chemotherapy combination, followed by continuous treatment with bevacizumab until disease progression or unacceptable toxicity",
                    "dose": "15 mg/kg",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Pemetrexed",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6 with chemotherapy combination, followed by continuous treatment with bevacizumab until disease progression or unacceptable toxicity",
                    "dose": "500 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6 with chemotherapy combination, followed by continuous treatment with bevacizumab until disease progression or unacceptable toxicity",
                    "dose": "5 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "beVACizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6 with chemotherapy combination, followed by continuous treatment with bevacizumab until disease progression or unacceptable toxicity",
                    "dose": "15 mg/kg",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "respiratory",
        "url": "https://www.eviq.org.au/medical-oncology/respiratory/mesothelioma/4143-mesothelioma-carboplatin-pemetrexed-and-bevac"
    },
    {
        "protocol_id": "229 v.6",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Pemetrexed",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6unless otherwise indicated",
                    "dose": "500 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6unless otherwise indicated",
                    "dose": "75 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Pemetrexed",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6unless otherwise indicated",
                    "dose": "500 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6unless otherwise indicated",
                    "dose": "75 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "respiratory",
        "url": "https://www.eviq.org.au/medical-oncology/respiratory/mesothelioma/229-mesothelioma-cisplatin-and-pemetrexed"
    },
    {
        "protocol_id": "4022 v.2",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "beVACizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6 with chemotherapy combination, followed by continuous treatment with  bevacizumab until disease progression or unacceptable toxicity",
                    "dose": "15 mg/kg",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Pemetrexed",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6 with chemotherapy combination, followed by continuous treatment with  bevacizumab until disease progression or unacceptable toxicity",
                    "dose": "500 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6 with chemotherapy combination, followed by continuous treatment with  bevacizumab until disease progression or unacceptable toxicity",
                    "dose": "75 mg/m2 *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "beVACizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6 with chemotherapy combination, followed by continuous treatment with  bevacizumab until disease progression or unacceptable toxicity",
                    "dose": "15 mg/kg",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "beVACizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6 with chemotherapy combination, followed by continuous treatment with  bevacizumab until disease progression or unacceptable toxicity",
                    "dose": "15 mg/kg",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Pemetrexed",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6 with chemotherapy combination, followed by continuous treatment with  bevacizumab until disease progression or unacceptable toxicity",
                    "dose": "500 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6 with chemotherapy combination, followed by continuous treatment with  bevacizumab until disease progression or unacceptable toxicity",
                    "dose": "75 mg/m2 *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "beVACizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6 with chemotherapy combination, followed by continuous treatment with  bevacizumab until disease progression or unacceptable toxicity",
                    "dose": "15 mg/kg",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "respiratory",
        "url": "https://www.eviq.org.au/medical-oncology/respiratory/mesothelioma/4022-mesothelioma-cisplatin-pemetrexed-and-bevaciz"
    },
    {
        "protocol_id": "4013 v.3",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Nivolumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "42 days",
                    "cycles": "17or until disease progression or unacceptable toxicity for up to 2 years",
                    "dose": "360 mg",
                    "day": "1 and 22",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Ipilimumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "42 days",
                    "cycles": "17or until disease progression or unacceptable toxicity for up to 2 years",
                    "dose": "1 mg/kg",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Nivolumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "42 days",
                    "cycles": "17or until disease progression or unacceptable toxicity for up to 2 years",
                    "dose": "360 mg",
                    "day": "1 and 22",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Ipilimumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "42 days",
                    "cycles": "17or until disease progression or unacceptable toxicity for up to 2 years",
                    "dose": "1 mg/kg",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "respiratory",
        "url": "https://www.eviq.org.au/medical-oncology/respiratory/mesothelioma/4013-mesothelioma-ipilimumab-and-nivolumab-flat-d"
    },
    {
        "protocol_id": "1472 v.5",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "vinORELBine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity, usually 6 cycles",
                    "dose": "25 mg/m2",
                    "day": "1 and 8",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "vinORELBine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity, usually 6 cycles",
                    "dose": "25 mg/m2",
                    "day": "1 and 8",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "respiratory",
        "url": "https://www.eviq.org.au/medical-oncology/respiratory/mesothelioma/1472-mesothelioma-vinorelbine"
    },
    {
        "protocol_id": "4408 v.1",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Nivolumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "42 days",
                    "cycles": "17or until disease progression or unacceptable toxicity for up to 2 years",
                    "dose": "3 mg/kg",
                    "day": "1, 15, 29",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Ipilimumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "42 days",
                    "cycles": "17or until disease progression or unacceptable toxicity for up to 2 years",
                    "dose": "1 mg/kg",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Nivolumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "42 days",
                    "cycles": "17or until disease progression or unacceptable toxicity for up to 2 years",
                    "dose": "3 mg/kg",
                    "day": "1, 15, 29",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Ipilimumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "42 days",
                    "cycles": "17or until disease progression or unacceptable toxicity for up to 2 years",
                    "dose": "1 mg/kg",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "respiratory",
        "url": "https://www.eviq.org.au/medical-oncology/respiratory/mesothelioma/3957-redirect-id-4408"
    },
    {
        "protocol_id": "4291 v.2",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Atezolizumab",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Up to 12 months of treatment or until disease progression or unacceptable toxicity whichever comes first",
                    "dose": "1,200 mg *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Atezolizumab",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Up to 12 months of treatment or until disease progression or unacceptable toxicity whichever comes first",
                    "dose": "1,200 mg *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "respiratory",
        "url": "https://www.eviq.org.au/medical-oncology/respiratory/non-small-cell-lung-cancer-adjuvant-neoadjuvant/4291-non-small-cell-lung-cancer-adjuvant-atezolizu"
    },
    {
        "protocol_id": "3802 v.3",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Pemetrexed",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4unless otherwise indicated",
                    "dose": "500 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4unless otherwise indicated",
                    "dose": "75 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Pemetrexed",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4unless otherwise indicated",
                    "dose": "500 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4unless otherwise indicated",
                    "dose": "75 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "respiratory",
        "url": "https://www.eviq.org.au/medical-oncology/respiratory/non-small-cell-lung-cancer-adjuvant-neoadjuvant/3802-nsclc-adjuvant-cisplatin-and-pemetrexed"
    },
    {
        "protocol_id": "237 v.6",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "vinORELBine *",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4unless otherwise indicated",
                    "dose": "25 mg/m2",
                    "day": "1 and 8",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4unless otherwise indicated",
                    "dose": "80 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "vinORELBine *",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4unless otherwise indicated",
                    "dose": "25 mg/m2",
                    "day": "1 and 8",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4unless otherwise indicated",
                    "dose": "80 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "respiratory",
        "url": "https://www.eviq.org.au/medical-oncology/respiratory/non-small-cell-lung-cancer-adjuvant-neoadjuvant/237-nsclc-adjuvant-cisplatin-and-vinorelbine"
    },
    {
        "protocol_id": "4132 v.3",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Osimertinib",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "80 mg ONCE a day",
                    "day": null,
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Osimertinib",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "80 mg ONCE a day",
                    "day": null,
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "respiratory",
        "url": "https://www.eviq.org.au/medical-oncology/respiratory/non-small-cell-lung-cancer-adjuvant-neoadjuvant/4132-nsclc-adjuvant-osimertinib"
    },
    {
        "protocol_id": "4318 v.2",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Nivolumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "3",
                    "dose": "360 mg",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "PACLitaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "3",
                    "dose": "200 mg/m2 ^",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "3",
                    "dose": "6 AUC ^ *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Nivolumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "3",
                    "dose": "360 mg",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "PACLitaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "3",
                    "dose": "200 mg/m2 ^",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "3",
                    "dose": "6 AUC ^ *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "respiratory",
        "url": "https://www.eviq.org.au/medical-oncology/respiratory/non-small-cell-lung-cancer-adjuvant-neoadjuvant/4318-nsclc-neoadjuvant-carboplatin-paclitaxel-and"
    },
    {
        "protocol_id": "4316 v.2",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Nivolumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "3",
                    "dose": "360 mg",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Gemcitabine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "3",
                    "dose": "1,250 mg/m2 *",
                    "day": "1 and 8",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "3",
                    "dose": "75 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Nivolumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "3",
                    "dose": "360 mg",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Gemcitabine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "3",
                    "dose": "1,250 mg/m2 *",
                    "day": "1 and 8",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "3",
                    "dose": "75 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "respiratory",
        "url": "https://www.eviq.org.au/medical-oncology/respiratory/non-small-cell-lung-cancer-adjuvant-neoadjuvant/4316-nsclc-neoadjuvant-cisplatin-gemcitabine-and"
    },
    {
        "protocol_id": "4314 v.2",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Nivolumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "3",
                    "dose": "360 mg",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Pemetrexed",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "3",
                    "dose": "500 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "3",
                    "dose": "75 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Nivolumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "3",
                    "dose": "360 mg",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Pemetrexed",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "3",
                    "dose": "500 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "3",
                    "dose": "75 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "respiratory",
        "url": "https://www.eviq.org.au/medical-oncology/respiratory/non-small-cell-lung-cancer-adjuvant-neoadjuvant/4314-nsclc-neoadjuvant-cisplatin-pemetrexed-and-n"
    },
    {
        "protocol_id": "378 v.6",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": "1(concurrent with radiation therapy)",
                    "dose": "50 mg/m2",
                    "day": "1, 8, 29, 36",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Etoposide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": "1(concurrent with radiation therapy)",
                    "dose": "50 mg/m2 *",
                    "day": "1 to 5 and 29 to 33",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": "1(concurrent with radiation therapy)",
                    "dose": "50 mg/m2",
                    "day": "1, 8, 29, 36",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Etoposide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": "1(concurrent with radiation therapy)",
                    "dose": "50 mg/m2 *",
                    "day": "1 to 5 and 29 to 33",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "respiratory",
        "url": "https://www.eviq.org.au/medical-oncology/respiratory/non-small-cell-lung-cancer-adjuvant-neoadjuvant/378-nsclc-superior-sulcus-pancoast-cisplatin-and"
    },
    {
        "protocol_id": "3594 v.8",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Nivolumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "480 mg * #",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Nivolumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "480 mg * #",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "respiratory",
        "url": "https://www.eviq.org.au/medical-oncology/respiratory/non-small-cell-lung-cancer-advanced-metastatic/3623-redirect-id-3594"
    },
    {
        "protocol_id": "3840 v.9",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Pembrolizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (see Indications and patient population section)",
                    "dose": "200 mg *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Pembrolizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (see Indications and patient population section)",
                    "dose": "200 mg *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "respiratory",
        "url": "https://www.eviq.org.au/medical-oncology/respiratory/non-small-cell-lung-cancer-advanced-metastatic/2032-redirect-id-3840"
    },
    {
        "protocol_id": "4151 v.2",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Cemiplimab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (up to 2 years)",
                    "dose": "350 mg",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Cemiplimab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (up to 2 years)",
                    "dose": "350 mg",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "respiratory",
        "url": "https://www.eviq.org.au/medical-oncology/respiratory/non-small-cell-lung-cancer-advanced-metastatic/4151-locally-advanced-or-metastatic-cemiplimab"
    },
    {
        "protocol_id": "1436 v.8",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "PACLitaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "7 days",
                    "cycles": "6with concurrent radiation therapy",
                    "dose": "45 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "7 days",
                    "cycles": "6with concurrent radiation therapy",
                    "dose": "2 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "PACLitaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "7 days",
                    "cycles": "6with concurrent radiation therapy",
                    "dose": "45 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "7 days",
                    "cycles": "6with concurrent radiation therapy",
                    "dose": "2 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "respiratory",
        "url": "https://www.eviq.org.au/medical-oncology/respiratory/non-small-cell-lung-cancer-advanced-metastatic/1436-nsclc-locally-advanced-definitive-carboplatin"
    },
    {
        "protocol_id": "379 v.7",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": "1concurrent with radiation therapy",
                    "dose": "50 mg/m2",
                    "day": "1, 8, 29, 36",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Etoposide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": "1concurrent with radiation therapy",
                    "dose": "50 mg/m2 *",
                    "day": "1 to 5 and 29 to 33",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": "1concurrent with radiation therapy",
                    "dose": "50 mg/m2",
                    "day": "1, 8, 29, 36",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Etoposide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": "1concurrent with radiation therapy",
                    "dose": "50 mg/m2 *",
                    "day": "1 to 5 and 29 to 33",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "respiratory",
        "url": "https://www.eviq.org.au/medical-oncology/respiratory/non-small-cell-lung-cancer-advanced-metastatic/379-nsclc-locally-advanced-definitive-cisplatin-an"
    },
    {
        "protocol_id": "4179 v.2",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Durvalumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "13or until disease progression or unacceptable toxicity",
                    "dose": "1,500 mg",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Durvalumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "13or until disease progression or unacceptable toxicity",
                    "dose": "1,500 mg",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "respiratory",
        "url": "https://www.eviq.org.au/medical-oncology/respiratory/non-small-cell-lung-cancer-advanced-metastatic/4179-nsclc-locally-advanced-durvalumab-flat-dosin"
    },
    {
        "protocol_id": "3512 v.6",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Durvalumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "26or until disease progression or unacceptable toxicity",
                    "dose": "10 mg/kg",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Durvalumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "26or until disease progression or unacceptable toxicity",
                    "dose": "10 mg/kg",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "respiratory",
        "url": "https://www.eviq.org.au/medical-oncology/respiratory/non-small-cell-lung-cancer-advanced-metastatic/3512-nsclc-locally-advanced-durvalumab-weight-bas"
    },
    {
        "protocol_id": "3409 v.5",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Alectinib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "600 mg TWICE a day *",
                    "day": null,
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Alectinib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "600 mg TWICE a day *",
                    "day": null,
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "respiratory",
        "url": "https://www.eviq.org.au/medical-oncology/respiratory/non-small-cell-lung-cancer-advanced-metastatic/3409-nsclc-locally-advanced-or-metastatic-alectini"
    },
    {
        "protocol_id": "3408 v.5",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Atezolizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "1,200 mg *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Atezolizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "1,200 mg *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "respiratory",
        "url": "https://www.eviq.org.au/medical-oncology/respiratory/non-small-cell-lung-cancer-advanced-metastatic/3408-nsclc-locally-advanced-or-metastatic-atezoliz"
    },
    {
        "protocol_id": "3789 v.2",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Brigatinib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "90 mg ONCE a day *",
                    "day": "1 to 7",
                    "route": "PO"
                },
                {
                    "drug_name": "Brigatinib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "180 mg ONCE a day",
                    "day": "8 to 28",
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Brigatinib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "180 mg ONCE a day",
                    "day": "1 to 28",
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Brigatinib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "90 mg ONCE a day *",
                    "day": "1 to 7",
                    "route": "PO"
                },
                {
                    "drug_name": "Brigatinib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "180 mg ONCE a day",
                    "day": "8 to 28",
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Brigatinib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "180 mg ONCE a day",
                    "day": "1 to 28",
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "respiratory",
        "url": "https://www.eviq.org.au/medical-oncology/respiratory/non-small-cell-lung-cancer-advanced-metastatic/3789-nsclc-metastatic-brigatinib"
    },
    {
        "protocol_id": "226 v.7",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "DOCEtaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4unless otherwise indicated",
                    "dose": "75 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4unless otherwise indicated",
                    "dose": "5 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "DOCEtaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4unless otherwise indicated",
                    "dose": "75 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4unless otherwise indicated",
                    "dose": "5 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "respiratory",
        "url": "https://www.eviq.org.au/medical-oncology/respiratory/non-small-cell-lung-cancer-advanced-metastatic/226-nsclc-locally-advanced-or-metastatic-carboplat"
    },
    {
        "protocol_id": "1432 v.6",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Gemcitabine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4unless otherwise indicated",
                    "dose": "1,000 mg/m2",
                    "day": "1 and 8",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4unless otherwise indicated",
                    "dose": "5 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Gemcitabine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4unless otherwise indicated",
                    "dose": "1,000 mg/m2",
                    "day": "1 and 8",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4unless otherwise indicated",
                    "dose": "5 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "respiratory",
        "url": "https://www.eviq.org.au/medical-oncology/respiratory/non-small-cell-lung-cancer-advanced-metastatic/1432-nsclc-locally-advanced-or-metastatic-carbopla"
    },
    {
        "protocol_id": "238 v.10",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "PACLitaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4unless otherwise indicated",
                    "dose": "200 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4unless otherwise indicated",
                    "dose": "6 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "PACLitaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4unless otherwise indicated",
                    "dose": "200 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4unless otherwise indicated",
                    "dose": "6 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "respiratory",
        "url": "https://www.eviq.org.au/medical-oncology/respiratory/non-small-cell-lung-cancer-advanced-metastatic/238-nsclc-locally-advanced-or-metastatic-carboplat"
    },
    {
        "protocol_id": "1261 v.3",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Pemetrexed",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4to 6 cycles (if clinically indicated) followed by maintenance pemetrexed in non-progressing patients",
                    "dose": "500 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4to 6 cycles (if clinically indicated) followed by maintenance pemetrexed in non-progressing patients",
                    "dose": "5 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Pemetrexed",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4to 6 cycles (if clinically indicated) followed by maintenance pemetrexed in non-progressing patients",
                    "dose": "500 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4to 6 cycles (if clinically indicated) followed by maintenance pemetrexed in non-progressing patients",
                    "dose": "5 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "respiratory",
        "url": "https://www.eviq.org.au/medical-oncology/respiratory/non-small-cell-lung-cancer-advanced-metastatic/1261-nsclc-locally-advanced-or-metastatic-carbopla"
    },
    {
        "protocol_id": "1470 v.9",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "PACLitaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "4unless otherwise indicated",
                    "dose": "90 mg/m2",
                    "day": "1, 8, 15",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "4unless otherwise indicated",
                    "dose": "6 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "PACLitaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "4unless otherwise indicated",
                    "dose": "90 mg/m2",
                    "day": "1, 8, 15",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "4unless otherwise indicated",
                    "dose": "6 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "respiratory",
        "url": "https://www.eviq.org.au/medical-oncology/respiratory/non-small-cell-lung-cancer-advanced-metastatic/1470-nsclc-locally-advanced-or-metastatic-carbopla"
    },
    {
        "protocol_id": "1434 v.6",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Gemcitabine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4unless otherwise indicated",
                    "dose": "1,250 mg/m2",
                    "day": "1 and 8",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4unless otherwise indicated",
                    "dose": "80 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Gemcitabine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4unless otherwise indicated",
                    "dose": "1,250 mg/m2",
                    "day": "1 and 8",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4unless otherwise indicated",
                    "dose": "80 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "respiratory",
        "url": "https://www.eviq.org.au/medical-oncology/respiratory/non-small-cell-lung-cancer-advanced-metastatic/1434-nsclc-locally-advanced-or-metastatic-cisplati"
    },
    {
        "protocol_id": "88 v.7",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Pemetrexed",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4unless otherwise indicated followed by maintenance pemetrexed in non-progressing patients",
                    "dose": "500 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4unless otherwise indicated followed by maintenance pemetrexed in non-progressing patients",
                    "dose": "75 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Pemetrexed",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4unless otherwise indicated followed by maintenance pemetrexed in non-progressing patients",
                    "dose": "500 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4unless otherwise indicated followed by maintenance pemetrexed in non-progressing patients",
                    "dose": "75 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "respiratory",
        "url": "https://www.eviq.org.au/medical-oncology/respiratory/non-small-cell-lung-cancer-advanced-metastatic/88-nsclc-locally-advanced-or-metastatic-cisplatin"
    },
    {
        "protocol_id": "3958 v.2",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Entrectinib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "600 mg ONCE a day",
                    "day": null,
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Entrectinib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "600 mg ONCE a day",
                    "day": null,
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "respiratory",
        "url": "https://www.eviq.org.au/medical-oncology/respiratory/non-small-cell-lung-cancer-advanced-metastatic/3958-nsclc-locally-advanced-or-metastatic-entrecti"
    },
    {
        "protocol_id": "3790 v.4",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Lorlatinib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "100 mg ONCE a day",
                    "day": null,
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Lorlatinib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "100 mg ONCE a day",
                    "day": null,
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "respiratory",
        "url": "https://www.eviq.org.au/medical-oncology/respiratory/non-small-cell-lung-cancer-advanced-metastatic/3790-nsclc-metastatic-lorlatinib"
    },
    {
        "protocol_id": "1996 v.3",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Osimertinib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "80 mg ONCE a day",
                    "day": null,
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Osimertinib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "80 mg ONCE a day",
                    "day": null,
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "respiratory",
        "url": "https://www.eviq.org.au/medical-oncology/respiratory/non-small-cell-lung-cancer-advanced-metastatic/1996-nsclc-locally-advanced-or-metastatic-osimerti"
    },
    {
        "protocol_id": "4121 v.3",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Sotorasib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "960 mg ONCE a day *",
                    "day": null,
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Sotorasib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "960 mg ONCE a day *",
                    "day": null,
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "respiratory",
        "url": "https://www.eviq.org.au/medical-oncology/respiratory/non-small-cell-lung-cancer-advanced-metastatic/4121-nsclc-locally-advanced-or-metastatic-sotorasi"
    },
    {
        "protocol_id": "4122 v.2",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Tepotinib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "450 mg ONCE a day *",
                    "day": null,
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Tepotinib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "450 mg ONCE a day *",
                    "day": null,
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "respiratory",
        "url": "https://www.eviq.org.au/medical-oncology/respiratory/non-small-cell-lung-cancer-advanced-metastatic/4122-nsclc-locally-advanced-or-metastatic-tepotini"
    },
    {
        "protocol_id": "1600 v.5",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "aFATinib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "40 mg ONCE a day",
                    "day": null,
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "aFATinib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "40 mg ONCE a day",
                    "day": null,
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "respiratory",
        "url": "https://www.eviq.org.au/medical-oncology/respiratory/non-small-cell-lung-cancer-advanced-metastatic/1600-nsclc-metastatic-afatinib"
    },
    {
        "protocol_id": "3626 v.9",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Atezolizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4 (up to 6 if clinically indicated) with chemotherapy combination, followed by continuous treatment with atezolizumab and bevacizumab until disease progression or unacceptable toxicity",
                    "dose": "1,200 mg",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "beVACizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4 (up to 6 if clinically indicated) with chemotherapy combination, followed by continuous treatment with atezolizumab and bevacizumab until disease progression or unacceptable toxicity",
                    "dose": "15 mg/kg",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "PACLitaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4 (up to 6 if clinically indicated) with chemotherapy combination, followed by continuous treatment with atezolizumab and bevacizumab until disease progression or unacceptable toxicity",
                    "dose": "200 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4 (up to 6 if clinically indicated) with chemotherapy combination, followed by continuous treatment with atezolizumab and bevacizumab until disease progression or unacceptable toxicity",
                    "dose": "6 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Atezolizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4 (up to 6 if clinically indicated) with chemotherapy combination, followed by continuous treatment with atezolizumab and bevacizumab until disease progression or unacceptable toxicity",
                    "dose": "1,200 mg",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "beVACizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4 (up to 6 if clinically indicated) with chemotherapy combination, followed by continuous treatment with atezolizumab and bevacizumab until disease progression or unacceptable toxicity",
                    "dose": "15 mg/kg",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Atezolizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4 (up to 6 if clinically indicated) with chemotherapy combination, followed by continuous treatment with atezolizumab and bevacizumab until disease progression or unacceptable toxicity",
                    "dose": "1,200 mg",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "beVACizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4 (up to 6 if clinically indicated) with chemotherapy combination, followed by continuous treatment with atezolizumab and bevacizumab until disease progression or unacceptable toxicity",
                    "dose": "15 mg/kg",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "PACLitaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4 (up to 6 if clinically indicated) with chemotherapy combination, followed by continuous treatment with atezolizumab and bevacizumab until disease progression or unacceptable toxicity",
                    "dose": "200 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4 (up to 6 if clinically indicated) with chemotherapy combination, followed by continuous treatment with atezolizumab and bevacizumab until disease progression or unacceptable toxicity",
                    "dose": "6 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Atezolizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4 (up to 6 if clinically indicated) with chemotherapy combination, followed by continuous treatment with atezolizumab and bevacizumab until disease progression or unacceptable toxicity",
                    "dose": "1,200 mg",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "beVACizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4 (up to 6 if clinically indicated) with chemotherapy combination, followed by continuous treatment with atezolizumab and bevacizumab until disease progression or unacceptable toxicity",
                    "dose": "15 mg/kg",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "respiratory",
        "url": "https://www.eviq.org.au/medical-oncology/respiratory/non-small-cell-lung-cancer-advanced-metastatic/3626-nsclc-metastatic-carboplatin-paclitaxel-atezo"
    },
    {
        "protocol_id": "3955 v.5",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Nivolumab #",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "42 days(the eviQ protocol cycle is 42 days, however in Checkmate 9LA trial and PBS criteria a cycle is 21 days)",
                    "cycles": "17(1 cycle with chemotherapy combination, followed by continuous treatment with nivolumab and ipilimumab until disease progression or unacceptable toxicity for up to 2 years)",
                    "dose": "360 mg",
                    "day": "1 and 22",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Ipilimumab #",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "42 days(the eviQ protocol cycle is 42 days, however in Checkmate 9LA trial and PBS criteria a cycle is 21 days)",
                    "cycles": "17(1 cycle with chemotherapy combination, followed by continuous treatment with nivolumab and ipilimumab until disease progression or unacceptable toxicity for up to 2 years)",
                    "dose": "1 mg/kg",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "PACLitaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "42 days(the eviQ protocol cycle is 42 days, however in Checkmate 9LA trial and PBS criteria a cycle is 21 days)",
                    "cycles": "17(1 cycle with chemotherapy combination, followed by continuous treatment with nivolumab and ipilimumab until disease progression or unacceptable toxicity for up to 2 years)",
                    "dose": "200 mg/m2",
                    "day": "1 and 22",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "42 days(the eviQ protocol cycle is 42 days, however in Checkmate 9LA trial and PBS criteria a cycle is 21 days)",
                    "cycles": "17(1 cycle with chemotherapy combination, followed by continuous treatment with nivolumab and ipilimumab until disease progression or unacceptable toxicity for up to 2 years)",
                    "dose": "6 AUC *",
                    "day": "1 and 22",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Nivolumab #",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "42 days(the eviQ protocol cycle is 42 days, however in Checkmate 9LA trial and PBS criteria a cycle is 21 days)",
                    "cycles": "17(1 cycle with chemotherapy combination, followed by continuous treatment with nivolumab and ipilimumab until disease progression or unacceptable toxicity for up to 2 years)",
                    "dose": "360 mg",
                    "day": "1 and 22",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Ipilimumab #",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "42 days(the eviQ protocol cycle is 42 days, however in Checkmate 9LA trial and PBS criteria a cycle is 21 days)",
                    "cycles": "17(1 cycle with chemotherapy combination, followed by continuous treatment with nivolumab and ipilimumab until disease progression or unacceptable toxicity for up to 2 years)",
                    "dose": "1 mg/kg",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Nivolumab #",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "42 days(the eviQ protocol cycle is 42 days, however in Checkmate 9LA trial and PBS criteria a cycle is 21 days)",
                    "cycles": "17(1 cycle with chemotherapy combination, followed by continuous treatment with nivolumab and ipilimumab until disease progression or unacceptable toxicity for up to 2 years)",
                    "dose": "360 mg",
                    "day": "1 and 22",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Ipilimumab #",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "42 days(the eviQ protocol cycle is 42 days, however in Checkmate 9LA trial and PBS criteria a cycle is 21 days)",
                    "cycles": "17(1 cycle with chemotherapy combination, followed by continuous treatment with nivolumab and ipilimumab until disease progression or unacceptable toxicity for up to 2 years)",
                    "dose": "1 mg/kg",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "PACLitaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "42 days(the eviQ protocol cycle is 42 days, however in Checkmate 9LA trial and PBS criteria a cycle is 21 days)",
                    "cycles": "17(1 cycle with chemotherapy combination, followed by continuous treatment with nivolumab and ipilimumab until disease progression or unacceptable toxicity for up to 2 years)",
                    "dose": "200 mg/m2",
                    "day": "1 and 22",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "42 days(the eviQ protocol cycle is 42 days, however in Checkmate 9LA trial and PBS criteria a cycle is 21 days)",
                    "cycles": "17(1 cycle with chemotherapy combination, followed by continuous treatment with nivolumab and ipilimumab until disease progression or unacceptable toxicity for up to 2 years)",
                    "dose": "6 AUC *",
                    "day": "1 and 22",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Nivolumab #",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "42 days(the eviQ protocol cycle is 42 days, however in Checkmate 9LA trial and PBS criteria a cycle is 21 days)",
                    "cycles": "17(1 cycle with chemotherapy combination, followed by continuous treatment with nivolumab and ipilimumab until disease progression or unacceptable toxicity for up to 2 years)",
                    "dose": "360 mg",
                    "day": "1 and 22",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Ipilimumab #",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "42 days(the eviQ protocol cycle is 42 days, however in Checkmate 9LA trial and PBS criteria a cycle is 21 days)",
                    "cycles": "17(1 cycle with chemotherapy combination, followed by continuous treatment with nivolumab and ipilimumab until disease progression or unacceptable toxicity for up to 2 years)",
                    "dose": "1 mg/kg",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "respiratory",
        "url": "https://www.eviq.org.au/medical-oncology/respiratory/non-small-cell-lung-cancer-advanced-metastatic/3955-nsclc-metastatic-carboplatin-paclitaxel-ipili"
    },
    {
        "protocol_id": "4407 v.1",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Atezolizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4 (up to 6 if clinically indicated) with chemotherapy combination, followed by continuous treatment with pemetrexed, atezolizumab and bevacizumab until disease progression or unacceptable toxicity",
                    "dose": "1,200 mg",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "beVACizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4 (up to 6 if clinically indicated) with chemotherapy combination, followed by continuous treatment with pemetrexed, atezolizumab and bevacizumab until disease progression or unacceptable toxicity",
                    "dose": "7.5 mg/kg",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Pemetrexed",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4 (up to 6 if clinically indicated) with chemotherapy combination, followed by continuous treatment with pemetrexed, atezolizumab and bevacizumab until disease progression or unacceptable toxicity",
                    "dose": "500 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4 (up to 6 if clinically indicated) with chemotherapy combination, followed by continuous treatment with pemetrexed, atezolizumab and bevacizumab until disease progression or unacceptable toxicity",
                    "dose": "5 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Atezolizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4 (up to 6 if clinically indicated) with chemotherapy combination, followed by continuous treatment with pemetrexed, atezolizumab and bevacizumab until disease progression or unacceptable toxicity",
                    "dose": "1,200 mg",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "beVACizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4 (up to 6 if clinically indicated) with chemotherapy combination, followed by continuous treatment with pemetrexed, atezolizumab and bevacizumab until disease progression or unacceptable toxicity",
                    "dose": "7.5 mg/kg",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Pemetrexed",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4 (up to 6 if clinically indicated) with chemotherapy combination, followed by continuous treatment with pemetrexed, atezolizumab and bevacizumab until disease progression or unacceptable toxicity",
                    "dose": "500 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Atezolizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4 (up to 6 if clinically indicated) with chemotherapy combination, followed by continuous treatment with pemetrexed, atezolizumab and bevacizumab until disease progression or unacceptable toxicity",
                    "dose": "1,200 mg",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "beVACizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4 (up to 6 if clinically indicated) with chemotherapy combination, followed by continuous treatment with pemetrexed, atezolizumab and bevacizumab until disease progression or unacceptable toxicity",
                    "dose": "7.5 mg/kg",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Pemetrexed",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4 (up to 6 if clinically indicated) with chemotherapy combination, followed by continuous treatment with pemetrexed, atezolizumab and bevacizumab until disease progression or unacceptable toxicity",
                    "dose": "500 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4 (up to 6 if clinically indicated) with chemotherapy combination, followed by continuous treatment with pemetrexed, atezolizumab and bevacizumab until disease progression or unacceptable toxicity",
                    "dose": "5 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Atezolizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4 (up to 6 if clinically indicated) with chemotherapy combination, followed by continuous treatment with pemetrexed, atezolizumab and bevacizumab until disease progression or unacceptable toxicity",
                    "dose": "1,200 mg",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "beVACizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4 (up to 6 if clinically indicated) with chemotherapy combination, followed by continuous treatment with pemetrexed, atezolizumab and bevacizumab until disease progression or unacceptable toxicity",
                    "dose": "7.5 mg/kg",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Pemetrexed",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4 (up to 6 if clinically indicated) with chemotherapy combination, followed by continuous treatment with pemetrexed, atezolizumab and bevacizumab until disease progression or unacceptable toxicity",
                    "dose": "500 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "respiratory",
        "url": "https://www.eviq.org.au/medical-oncology/respiratory/non-small-cell-lung-cancer-advanced-metastatic/4407-nsclc-metastatic-carboplatin-pemetrexed-atezo"
    },
    {
        "protocol_id": "3502 v.7",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Pembrolizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "35or until disease progression or unacceptable toxicity (total maximum of 35 doses or 24 months treatment with pembrolizumab)",
                    "dose": "200 mg",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "PACLitaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "35or until disease progression or unacceptable toxicity (total maximum of 35 doses or 24 months treatment with pembrolizumab)",
                    "dose": "200 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "35or until disease progression or unacceptable toxicity (total maximum of 35 doses or 24 months treatment with pembrolizumab)",
                    "dose": "6 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Pembrolizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "35or until disease progression or unacceptable toxicity (total maximum of 35 doses or 24 months treatment with pembrolizumab)",
                    "dose": "200 mg **",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Pembrolizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "35or until disease progression or unacceptable toxicity (total maximum of 35 doses or 24 months treatment with pembrolizumab)",
                    "dose": "200 mg",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "PACLitaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "35or until disease progression or unacceptable toxicity (total maximum of 35 doses or 24 months treatment with pembrolizumab)",
                    "dose": "200 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "35or until disease progression or unacceptable toxicity (total maximum of 35 doses or 24 months treatment with pembrolizumab)",
                    "dose": "6 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Pembrolizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "35or until disease progression or unacceptable toxicity (total maximum of 35 doses or 24 months treatment with pembrolizumab)",
                    "dose": "200 mg **",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "respiratory",
        "url": "https://www.eviq.org.au/medical-oncology/respiratory/non-small-cell-lung-cancer-advanced-metastatic/3502-nsclc-metastatic-carboplatin-paclitaxel-and-p"
    },
    {
        "protocol_id": "3510 v.7",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Pembrolizumab #",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "35or until disease progression or unacceptable toxicity",
                    "dose": "200 mg",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Pemetrexed",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "35or until disease progression or unacceptable toxicity",
                    "dose": "500 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "35or until disease progression or unacceptable toxicity",
                    "dose": "5 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Pembrolizumab #",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "35or until disease progression or unacceptable toxicity",
                    "dose": "200 mg",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Pemetrexed",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "35or until disease progression or unacceptable toxicity",
                    "dose": "500 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Pembrolizumab #",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "35or until disease progression or unacceptable toxicity",
                    "dose": "200 mg",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Pemetrexed",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "35or until disease progression or unacceptable toxicity",
                    "dose": "500 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "35or until disease progression or unacceptable toxicity",
                    "dose": "5 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Pembrolizumab #",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "35or until disease progression or unacceptable toxicity",
                    "dose": "200 mg",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Pemetrexed",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "35or until disease progression or unacceptable toxicity",
                    "dose": "500 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "respiratory",
        "url": "https://www.eviq.org.au/medical-oncology/respiratory/non-small-cell-lung-cancer-advanced-metastatic/3510-nsclc-metastatic-carboplatin-pemetrexed-and-p"
    },
    {
        "protocol_id": "3545 v.6",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Pembrolizumab #",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "35or until disease progression or unacceptable toxicity",
                    "dose": "200 mg",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Pemetrexed",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "35or until disease progression or unacceptable toxicity",
                    "dose": "500 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "35or until disease progression or unacceptable toxicity",
                    "dose": "75 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Pembrolizumab #",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "35or until disease progression or unacceptable toxicity",
                    "dose": "200 mg",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Pemetrexed",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "35or until disease progression or unacceptable toxicity",
                    "dose": "500 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Pembrolizumab #",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "35or until disease progression or unacceptable toxicity",
                    "dose": "200 mg",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Pemetrexed",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "35or until disease progression or unacceptable toxicity",
                    "dose": "500 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "35or until disease progression or unacceptable toxicity",
                    "dose": "75 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Pembrolizumab #",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "35or until disease progression or unacceptable toxicity",
                    "dose": "200 mg",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Pemetrexed",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "35or until disease progression or unacceptable toxicity",
                    "dose": "500 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "respiratory",
        "url": "https://www.eviq.org.au/medical-oncology/respiratory/non-small-cell-lung-cancer-advanced-metastatic/3545-nsclc-metastatic-cisplatin-pemetrexed-and-pem"
    },
    {
        "protocol_id": "213 v.5",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "DOCEtaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4unless otherwise indicated",
                    "dose": "75 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "DOCEtaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4unless otherwise indicated",
                    "dose": "75 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "respiratory",
        "url": "https://www.eviq.org.au/medical-oncology/respiratory/non-small-cell-lung-cancer-advanced-metastatic/213-nsclc-metastatic-docetaxel-three-weekly"
    },
    {
        "protocol_id": "156 v.5",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Gemcitabine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "4unless otherwise indicated",
                    "dose": "1,000 mg/m2",
                    "day": "1, 8, 15",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Gemcitabine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "4unless otherwise indicated",
                    "dose": "1,000 mg/m2",
                    "day": "1, 8, 15",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "respiratory",
        "url": "https://www.eviq.org.au/medical-oncology/respiratory/non-small-cell-lung-cancer-advanced-metastatic/156-nsclc-metastatic-gemcitabine"
    },
    {
        "protocol_id": "236 v.7",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Pemetrexed",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "500 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Pemetrexed",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "500 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "respiratory",
        "url": "https://www.eviq.org.au/medical-oncology/respiratory/non-small-cell-lung-cancer-advanced-metastatic/236-nsclc-metastatic-pemetrexed"
    },
    {
        "protocol_id": "248 v.5",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "vinORELBine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4unless otherwise indicated",
                    "dose": "30 mg/m2 *",
                    "day": "1 and 8",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "vinORELBine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4unless otherwise indicated",
                    "dose": "30 mg/m2 *",
                    "day": "1 and 8",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "respiratory",
        "url": "https://www.eviq.org.au/medical-oncology/respiratory/non-small-cell-lung-cancer-advanced-metastatic/248-nsclc-metastatic-vinorelbine-intravenous"
    },
    {
        "protocol_id": "309 v.6",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "vinORELBine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "7 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "60 mg/m2 ONCE a week *",
                    "day": "1",
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "vinORELBine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "7 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "60 mg/m2 ONCE a week *",
                    "day": "1",
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "respiratory",
        "url": "https://www.eviq.org.au/medical-oncology/respiratory/non-small-cell-lung-cancer-advanced-metastatic/309-nsclc-metastatic-vinorelbine-oral"
    },
    {
        "protocol_id": "3555 v.9",
        "protocol_status": "Superseded",
        "drug_sequence": [
            [
                {
                    "drug_name": "Nivolumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "3 mg/kg",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Nivolumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "3 mg/kg",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "respiratory",
        "url": "https://www.eviq.org.au/medical-oncology/respiratory/non-small-cell-lung-cancer-advanced-metastatic/1856-redirect-id-3555"
    },
    {
        "protocol_id": "245 v.9",
        "protocol_status": "Superseded",
        "drug_sequence": [
            [
                {
                    "drug_name": "vinORELBine *",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4unless otherwise indicated",
                    "dose": "25 mg/m2",
                    "day": "1 and 8",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4unless otherwise indicated",
                    "dose": "5 AUC **",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "vinORELBine *",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4unless otherwise indicated",
                    "dose": "25 mg/m2",
                    "day": "1 and 8",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4unless otherwise indicated",
                    "dose": "5 AUC **",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "respiratory",
        "url": "https://www.eviq.org.au/medical-oncology/respiratory/non-small-cell-lung-cancer-advanced-metastatic/245-nsclc-locally-advanced-or-metastatic-carboplat"
    },
    {
        "protocol_id": "2035 v.4",
        "protocol_status": "Superseded",
        "drug_sequence": [
            [
                {
                    "drug_name": "Ceritinib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "750 mg ONCE a day",
                    "day": null,
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Ceritinib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "750 mg ONCE a day",
                    "day": null,
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "respiratory",
        "url": "https://www.eviq.org.au/medical-oncology/respiratory/non-small-cell-lung-cancer-advanced-metastatic/2035-nsclc-locally-advanced-or-metastatic-ceritini"
    },
    {
        "protocol_id": "239 v.8",
        "protocol_status": "Superseded",
        "drug_sequence": [
            [
                {
                    "drug_name": "vinORELBine *",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4unless otherwise indicated",
                    "dose": "25 mg/m2",
                    "day": "1 and 8",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4unless otherwise indicated",
                    "dose": "80 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "vinORELBine *",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4unless otherwise indicated",
                    "dose": "25 mg/m2",
                    "day": "1 and 8",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4unless otherwise indicated",
                    "dose": "80 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "respiratory",
        "url": "https://www.eviq.org.au/medical-oncology/respiratory/non-small-cell-lung-cancer-advanced-metastatic/239-nsclc-locally-advanced-or-metastatic-cisplatin"
    },
    {
        "protocol_id": "1351 v.6",
        "protocol_status": "Superseded",
        "drug_sequence": [
            [
                {
                    "drug_name": "Crizotinib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "250 mg TWICE a day",
                    "day": null,
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Crizotinib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "250 mg TWICE a day",
                    "day": null,
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "respiratory",
        "url": "https://www.eviq.org.au/medical-oncology/respiratory/non-small-cell-lung-cancer-advanced-metastatic/1351-nsclc-metastatic-crizotinib-superseded"
    },
    {
        "protocol_id": "224 v.6",
        "protocol_status": "Superseded",
        "drug_sequence": [
            [
                {
                    "drug_name": "DOCEtaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "4unless otherwise indicated",
                    "dose": "35 mg/m2",
                    "day": "1, 8, 15",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "DOCEtaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "4unless otherwise indicated",
                    "dose": "35 mg/m2",
                    "day": "1, 8, 15",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "respiratory",
        "url": "https://www.eviq.org.au/medical-oncology/respiratory/non-small-cell-lung-cancer-advanced-metastatic/224-nsclc-metastatic-docetaxel-weekly-superseded"
    },
    {
        "protocol_id": "380 v.6",
        "protocol_status": "Superseded",
        "drug_sequence": [
            [
                {
                    "drug_name": "Erlotinib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "150 mg ONCE a day",
                    "day": null,
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Erlotinib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "150 mg ONCE a day",
                    "day": null,
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "respiratory",
        "url": "https://www.eviq.org.au/medical-oncology/respiratory/non-small-cell-lung-cancer-advanced-metastatic/380-nsclc-metastatic-erlotinib-superseded"
    },
    {
        "protocol_id": "381 v.6",
        "protocol_status": "Superseded",
        "drug_sequence": [
            [
                {
                    "drug_name": "Gefitinib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "250 mg ONCE a day",
                    "day": null,
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Gefitinib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "250 mg ONCE a day",
                    "day": null,
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "respiratory",
        "url": "https://www.eviq.org.au/medical-oncology/respiratory/non-small-cell-lung-cancer-advanced-metastatic/381-nsclc-metastatic-gefitinib-superseded"
    },
    {
        "protocol_id": "263 v.6",
        "protocol_status": "Discontinued",
        "drug_sequence": [],
        "section_name": "medical-oncology",
        "category_name": "respiratory",
        "url": "https://www.eviq.org.au/medical-oncology/respiratory/non-small-cell-lung-cancer-advanced-metastatic/263-nsclc-metastatic-carboplatin-and-gemcitabine"
    },
    {
        "protocol_id": "227 v.4",
        "protocol_status": "Discontinued",
        "drug_sequence": [],
        "section_name": "medical-oncology",
        "category_name": "respiratory",
        "url": "https://www.eviq.org.au/medical-oncology/respiratory/non-small-cell-lung-cancer-advanced-metastatic/227-nsclc-metastatic-cisplatin-and-docetaxel-disco"
    },
    {
        "protocol_id": "262 v.5",
        "protocol_status": "Discontinued",
        "drug_sequence": [],
        "section_name": "medical-oncology",
        "category_name": "respiratory",
        "url": "https://www.eviq.org.au/medical-oncology/respiratory/non-small-cell-lung-cancer-advanced-metastatic/262-nsclc-metastatic-cisplatin-and-gemcitabine-da"
    },
    {
        "protocol_id": "377 v.5",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Topotecan",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4unless otherwise indicated",
                    "dose": "1.5 mg/m2",
                    "day": "1 to 3",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Topotecan",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4unless otherwise indicated",
                    "dose": "1.5 mg/m2",
                    "day": "1 to 3",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "respiratory",
        "url": "https://www.eviq.org.au/medical-oncology/respiratory/small-cell-lung-cancer/377-sclc-advanced-topotecan-modified"
    },
    {
        "protocol_id": "215 v.6",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4unless otherwise indicated",
                    "dose": "5 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Etoposide **",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4unless otherwise indicated",
                    "dose": "100 mg/m2",
                    "day": "1 to 3",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4unless otherwise indicated",
                    "dose": "5 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Etoposide **",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4unless otherwise indicated",
                    "dose": "100 mg/m2",
                    "day": "1 to 3",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "respiratory",
        "url": "https://www.eviq.org.au/medical-oncology/respiratory/small-cell-lung-cancer/215-sclc-extensive-disease-carboplatin-and-etoposi"
    },
    {
        "protocol_id": "340 v.6",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4unless otherwise indicated",
                    "dose": "5 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Etoposide **",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4unless otherwise indicated",
                    "dose": "100 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Etoposide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4unless otherwise indicated",
                    "dose": "200 mg/m2 ONCE a day ^",
                    "day": "2 and 3",
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4unless otherwise indicated",
                    "dose": "5 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Etoposide **",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4unless otherwise indicated",
                    "dose": "100 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Etoposide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4unless otherwise indicated",
                    "dose": "200 mg/m2 ONCE a day ^",
                    "day": "2 and 3",
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "respiratory",
        "url": "https://www.eviq.org.au/medical-oncology/respiratory/small-cell-lung-cancer/340-sclc-extensive-disease-carboplatin-and-oral-et"
    },
    {
        "protocol_id": "3731 v.5",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Atezolizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4 of chemotherapy combination, followed by continuous treatment with atezolizumab until disease progression or unacceptable toxicity",
                    "dose": "1,200 mg #",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4 of chemotherapy combination, followed by continuous treatment with atezolizumab until disease progression or unacceptable toxicity",
                    "dose": "5 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Etoposide **",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4 of chemotherapy combination, followed by continuous treatment with atezolizumab until disease progression or unacceptable toxicity",
                    "dose": "100 mg/m2",
                    "day": "1 to 3",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Atezolizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4 of chemotherapy combination, followed by continuous treatment with atezolizumab until disease progression or unacceptable toxicity",
                    "dose": "1,200 mg #",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Atezolizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4 of chemotherapy combination, followed by continuous treatment with atezolizumab until disease progression or unacceptable toxicity",
                    "dose": "1,200 mg #",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4 of chemotherapy combination, followed by continuous treatment with atezolizumab until disease progression or unacceptable toxicity",
                    "dose": "5 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Etoposide **",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4 of chemotherapy combination, followed by continuous treatment with atezolizumab until disease progression or unacceptable toxicity",
                    "dose": "100 mg/m2",
                    "day": "1 to 3",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Atezolizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4 of chemotherapy combination, followed by continuous treatment with atezolizumab until disease progression or unacceptable toxicity",
                    "dose": "1,200 mg #",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "respiratory",
        "url": "https://www.eviq.org.au/medical-oncology/respiratory/small-cell-lung-cancer/3731-sclc-extensive-disease-carboplatin-etoposide"
    },
    {
        "protocol_id": "3921 v.3",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Durvalumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "4of chemotherapy combination, followed by continuous treatment with durvalumab until disease progression or unacceptable toxicity",
                    "dose": "1,500 mg",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "4of chemotherapy combination, followed by continuous treatment with durvalumab until disease progression or unacceptable toxicity",
                    "dose": "5 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Etoposide **",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "4of chemotherapy combination, followed by continuous treatment with durvalumab until disease progression or unacceptable toxicity",
                    "dose": "100 mg/m2",
                    "day": "1 to 3",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Durvalumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "4of chemotherapy combination, followed by continuous treatment with durvalumab until disease progression or unacceptable toxicity",
                    "dose": "1,500 mg",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "4of chemotherapy combination, followed by continuous treatment with durvalumab until disease progression or unacceptable toxicity",
                    "dose": "5 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Etoposide **",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "4of chemotherapy combination, followed by continuous treatment with durvalumab until disease progression or unacceptable toxicity",
                    "dose": "100 mg/m2",
                    "day": "1 to 3",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "respiratory",
        "url": "https://www.eviq.org.au/medical-oncology/respiratory/small-cell-lung-cancer/3921-sclc-extensive-disease-carboplatin-etoposide"
    },
    {
        "protocol_id": "533 v.5",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "DOXOrubicin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4unless otherwise indicated",
                    "dose": "40 mg/m2",
                    "day": "1",
                    "route": "IV"
                },
                {
                    "drug_name": "vinCRISTine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4unless otherwise indicated",
                    "dose": "2 mg",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "CYCLOPHOSPHamide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4unless otherwise indicated",
                    "dose": "750 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "DOXOrubicin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4unless otherwise indicated",
                    "dose": "40 mg/m2",
                    "day": "1",
                    "route": "IV"
                },
                {
                    "drug_name": "vinCRISTine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4unless otherwise indicated",
                    "dose": "2 mg",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "CYCLOPHOSPHamide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4unless otherwise indicated",
                    "dose": "750 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "respiratory",
        "url": "https://www.eviq.org.au/medical-oncology/respiratory/small-cell-lung-cancer/533-sclc-extensive-disease-cav-cyclophosphamide-d"
    },
    {
        "protocol_id": "1716 v.5",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Irinotecan",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4unless otherwise indicated",
                    "dose": "65 mg/m2",
                    "day": "1 and 8",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "ciSplatin *",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4unless otherwise indicated",
                    "dose": "30 mg/m2",
                    "day": "1 and 8",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Irinotecan",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4unless otherwise indicated",
                    "dose": "65 mg/m2",
                    "day": "1 and 8",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "ciSplatin *",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4unless otherwise indicated",
                    "dose": "30 mg/m2",
                    "day": "1 and 8",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "respiratory",
        "url": "https://www.eviq.org.au/medical-oncology/respiratory/small-cell-lung-cancer/1716-sclc-extensive-disease-cisplatin-and-irinotec"
    },
    {
        "protocol_id": "374 v.6",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4unless otherwise indicated",
                    "dose": "5 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Etoposide **",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4unless otherwise indicated",
                    "dose": "100 mg/m2",
                    "day": "1 to 3",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4unless otherwise indicated",
                    "dose": "5 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Etoposide **",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4unless otherwise indicated",
                    "dose": "100 mg/m2",
                    "day": "1 to 3",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "respiratory",
        "url": "https://www.eviq.org.au/medical-oncology/respiratory/small-cell-lung-cancer/374-sclc-limited-disease-carboplatin-and-etoposide"
    },
    {
        "protocol_id": "375 v.5",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4unless otherwise indicated",
                    "dose": "80 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Etoposide *",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4unless otherwise indicated",
                    "dose": "100 mg/m2",
                    "day": "1 to 3",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4unless otherwise indicated",
                    "dose": "80 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Etoposide *",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4unless otherwise indicated",
                    "dose": "100 mg/m2",
                    "day": "1 to 3",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "respiratory",
        "url": "https://www.eviq.org.au/medical-oncology/respiratory/small-cell-lung-cancer/375-sclc-limited-disease-cisplatin-and-etoposide"
    },
    {
        "protocol_id": "376 v.5",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4(chemotherapy can be commenced promptly and radiation therapy scheduled to start concurrently. See evidence section)",
                    "dose": "60 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Etoposide *",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4(chemotherapy can be commenced promptly and radiation therapy scheduled to start concurrently. See evidence section)",
                    "dose": "120 mg/m2",
                    "day": "1 to 3",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4(chemotherapy can be commenced promptly and radiation therapy scheduled to start concurrently. See evidence section)",
                    "dose": "60 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Etoposide *",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4(chemotherapy can be commenced promptly and radiation therapy scheduled to start concurrently. See evidence section)",
                    "dose": "120 mg/m2",
                    "day": "1 to 3",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "respiratory",
        "url": "https://www.eviq.org.au/medical-oncology/respiratory/small-cell-lung-cancer/376-sclc-limited-disease-cisplatin-and-etoposide-c"
    },
    {
        "protocol_id": "1900 v.7",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "PACLitaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (up to 6 cycles)",
                    "dose": "80 mg/m2",
                    "day": "1, 8, 15",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "PACLitaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (up to 6 cycles)",
                    "dose": "80 mg/m2",
                    "day": "1, 8, 15",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "sarcoma",
        "url": "https://www.eviq.org.au/medical-oncology/sarcoma/soft-tissue-sarcoma/1900-angiosarcoma-locally-advanced-or-metastatic-p"
    },
    {
        "protocol_id": "3462 v.3",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Eribulin mesilate",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "1.4 mg/m2",
                    "day": "1 and 8",
                    "route": "IV"
                }
            ],
            [
                {
                    "drug_name": "Eribulin mesilate",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "1.4 mg/m2",
                    "day": "1 and 8",
                    "route": "IV"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "sarcoma",
        "url": "https://www.eviq.org.au/medical-oncology/sarcoma/soft-tissue-sarcoma/3462-liposarcoma-advanced-or-metastatic-eribulin"
    },
    {
        "protocol_id": "1602 v.5",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "pAZOPanib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "800 mg ONCE a day",
                    "day": null,
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "pAZOPanib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "800 mg ONCE a day",
                    "day": null,
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "sarcoma",
        "url": "https://www.eviq.org.au/medical-oncology/sarcoma/soft-tissue-sarcoma/1602-soft-tissue-sarcoma-advanced-or-metastatic-pa"
    },
    {
        "protocol_id": "3474 v.1",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Trabectedin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "1.5 mg/m2",
                    "day": "1",
                    "route": "CIV over 24 hours"
                }
            ],
            [
                {
                    "drug_name": "Trabectedin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "1.5 mg/m2",
                    "day": "1",
                    "route": "CIV over 24 hours"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "sarcoma",
        "url": "https://www.eviq.org.au/medical-oncology/sarcoma/soft-tissue-sarcoma/3474-soft-tissue-sarcoma-advanced-or-metastatic-tr"
    },
    {
        "protocol_id": "1554 v.5",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "DOXOrubicin *",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (up to 6 cycles)",
                    "dose": "75 mg/m2",
                    "day": "1",
                    "route": "IV **"
                },
                {
                    "drug_name": "Pegfilgrastim",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (up to 6 cycles)",
                    "dose": "6 mg",
                    "day": "2",
                    "route": "Subcut"
                }
            ],
            [
                {
                    "drug_name": "DOXOrubicin *",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (up to 6 cycles)",
                    "dose": "75 mg/m2",
                    "day": "1",
                    "route": "IV **"
                },
                {
                    "drug_name": "Pegfilgrastim",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (up to 6 cycles)",
                    "dose": "6 mg",
                    "day": "2",
                    "route": "Subcut"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "sarcoma",
        "url": "https://www.eviq.org.au/medical-oncology/sarcoma/soft-tissue-sarcoma/1554-soft-tissue-sarcoma-locally-advanced-or-metas"
    },
    {
        "protocol_id": "1659 v.8",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "DOXOrubicin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (maximum 6 cycles)",
                    "dose": "25 mg/m2",
                    "day": "1 to 3",
                    "route": "IV"
                },
                {
                    "drug_name": "Mesna",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (maximum 6 cycles)",
                    "dose": "500 mg/m2",
                    "day": "1 to 4",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "iFOSFamide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (maximum 6 cycles)",
                    "dose": "2,500 mg/m2",
                    "day": "1 to 4",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Mesna *",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (maximum 6 cycles)",
                    "dose": "1,500 mg/m2",
                    "day": "1 to 4",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Mesna **",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (maximum 6 cycles)",
                    "dose": "2,000 mg",
                    "day": "1 to 4",
                    "route": "PO"
                },
                {
                    "drug_name": "Pegfilgrastim",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (maximum 6 cycles)",
                    "dose": "6 mg",
                    "day": "5",
                    "route": "Subcut"
                }
            ],
            [
                {
                    "drug_name": "DOXOrubicin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (maximum 6 cycles)",
                    "dose": "25 mg/m2",
                    "day": "1 to 3",
                    "route": "IV"
                },
                {
                    "drug_name": "Mesna",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (maximum 6 cycles)",
                    "dose": "500 mg/m2",
                    "day": "1 to 4",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "iFOSFamide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (maximum 6 cycles)",
                    "dose": "2,500 mg/m2",
                    "day": "1 to 4",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Mesna *",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (maximum 6 cycles)",
                    "dose": "1,500 mg/m2",
                    "day": "1 to 4",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Mesna **",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (maximum 6 cycles)",
                    "dose": "2,000 mg",
                    "day": "1 to 4",
                    "route": "PO"
                },
                {
                    "drug_name": "Pegfilgrastim",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (maximum 6 cycles)",
                    "dose": "6 mg",
                    "day": "5",
                    "route": "Subcut"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "sarcoma",
        "url": "https://www.eviq.org.au/medical-oncology/sarcoma/soft-tissue-sarcoma/1659-soft-tissue-sarcoma-locally-advanced-or-metas"
    },
    {
        "protocol_id": "1898 v.5",
        "protocol_status": "Under review",
        "drug_sequence": [
            [
                {
                    "drug_name": "Gemcitabine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "until disease progression or unacceptable toxicity (usually 6 cycles)",
                    "dose": "900 mg/m2 *",
                    "day": "1 and 8",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "DOCEtaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "until disease progression or unacceptable toxicity (usually 6 cycles)",
                    "dose": "75 mg/m2 *",
                    "day": "8",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Pegfilgrastim",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "until disease progression or unacceptable toxicity (usually 6 cycles)",
                    "dose": "6 mg",
                    "day": "9",
                    "route": "Subcut"
                }
            ],
            [
                {
                    "drug_name": "Gemcitabine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "until disease progression or unacceptable toxicity (usually 6 cycles)",
                    "dose": "900 mg/m2 *",
                    "day": "1 and 8",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "DOCEtaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "until disease progression or unacceptable toxicity (usually 6 cycles)",
                    "dose": "75 mg/m2 *",
                    "day": "8",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Pegfilgrastim",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "until disease progression or unacceptable toxicity (usually 6 cycles)",
                    "dose": "6 mg",
                    "day": "9",
                    "route": "Subcut"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "sarcoma",
        "url": "https://www.eviq.org.au/medical-oncology/sarcoma/soft-tissue-sarcoma/1898-soft-tissue-sarcoma-metastatic-docetaxel-and"
    },
    {
        "protocol_id": "589 v.3",
        "protocol_status": "Discontinued",
        "drug_sequence": [],
        "section_name": "medical-oncology",
        "category_name": "sarcoma",
        "url": "https://www.eviq.org.au/medical-oncology/sarcoma/soft-tissue-sarcoma/589-soft-tissue-sarcoma-advanced-doxorubicin-and-f"
    },
    {
        "protocol_id": "3465 v.5",
        "protocol_status": "Under review",
        "drug_sequence": [
            [
                {
                    "drug_name": "Etoposide *",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "7(Alternating with ID 1916 Ewing sarcoma VDC (vinCRIStine, DOXOrubicin, CYCLOPHOSPHamide) (part 1 of VDC/IE))",
                    "dose": "100 mg/m2",
                    "day": "1 to 5",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Mesna",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "7(Alternating with ID 1916 Ewing sarcoma VDC (vinCRIStine, DOXOrubicin, CYCLOPHOSPHamide) (part 1 of VDC/IE))",
                    "dose": "600 mg/m2",
                    "day": "1 to 5",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "iFOSFamide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "7(Alternating with ID 1916 Ewing sarcoma VDC (vinCRIStine, DOXOrubicin, CYCLOPHOSPHamide) (part 1 of VDC/IE))",
                    "dose": "1,800 mg/m2",
                    "day": "1 to 5",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Mesna",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "7(Alternating with ID 1916 Ewing sarcoma VDC (vinCRIStine, DOXOrubicin, CYCLOPHOSPHamide) (part 1 of VDC/IE))",
                    "dose": "600 mg/m2 at 4 and 8 hours after the initiation of ifosfamide",
                    "day": "1 to 5",
                    "route": "IV infusion #"
                },
                {
                    "drug_name": "Pegfilgrastim",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "7(Alternating with ID 1916 Ewing sarcoma VDC (vinCRIStine, DOXOrubicin, CYCLOPHOSPHamide) (part 1 of VDC/IE))",
                    "dose": "6 mg",
                    "day": "6",
                    "route": "Subcut"
                }
            ],
            [
                {
                    "drug_name": "Etoposide *",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "7(Alternating with ID 1916 Ewing sarcoma VDC (vinCRIStine, DOXOrubicin, CYCLOPHOSPHamide) (part 1 of VDC/IE))",
                    "dose": "100 mg/m2",
                    "day": "1 to 5",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Mesna",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "7(Alternating with ID 1916 Ewing sarcoma VDC (vinCRIStine, DOXOrubicin, CYCLOPHOSPHamide) (part 1 of VDC/IE))",
                    "dose": "600 mg/m2",
                    "day": "1 to 5",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "iFOSFamide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "7(Alternating with ID 1916 Ewing sarcoma VDC (vinCRIStine, DOXOrubicin, CYCLOPHOSPHamide) (part 1 of VDC/IE))",
                    "dose": "1,800 mg/m2",
                    "day": "1 to 5",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Mesna",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "7(Alternating with ID 1916 Ewing sarcoma VDC (vinCRIStine, DOXOrubicin, CYCLOPHOSPHamide) (part 1 of VDC/IE))",
                    "dose": "600 mg/m2 at 4 and 8 hours after the initiation of ifosfamide",
                    "day": "1 to 5",
                    "route": "IV infusion #"
                },
                {
                    "drug_name": "Pegfilgrastim",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "7(Alternating with ID 1916 Ewing sarcoma VDC (vinCRIStine, DOXOrubicin, CYCLOPHOSPHamide) (part 1 of VDC/IE))",
                    "dose": "6 mg",
                    "day": "6",
                    "route": "Subcut"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "sarcoma",
        "url": "https://www.eviq.org.au/medical-oncology/sarcoma/bone-sarcoma/3465-ewing-sarcoma-ie-ifosfamide-and-etoposide"
    },
    {
        "protocol_id": "3620 v.2",
        "protocol_status": "Under review",
        "drug_sequence": [
            [
                {
                    "drug_name": "Temozolomide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6or until disease progression or unacceptable toxicity (decision to treat beyond 6 cycles at clinician\u2019s discretion)",
                    "dose": "100 mg/m2 ONCE a day",
                    "day": "1 to 5",
                    "route": "PO ^"
                },
                {
                    "drug_name": "Irinotecan",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6or until disease progression or unacceptable toxicity (decision to treat beyond 6 cycles at clinician\u2019s discretion)",
                    "dose": "50 mg/m2 *",
                    "day": "1 to 5",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Temozolomide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6or until disease progression or unacceptable toxicity (decision to treat beyond 6 cycles at clinician\u2019s discretion)",
                    "dose": "100 mg/m2 ONCE a day",
                    "day": "1 to 5",
                    "route": "PO ^"
                },
                {
                    "drug_name": "Irinotecan",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6or until disease progression or unacceptable toxicity (decision to treat beyond 6 cycles at clinician\u2019s discretion)",
                    "dose": "50 mg/m2 *",
                    "day": "1 to 5",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "sarcoma",
        "url": "https://www.eviq.org.au/medical-oncology/sarcoma/bone-sarcoma/3620-ewing-sarcoma-recurrent-or-metastatic-irinote"
    },
    {
        "protocol_id": "4245 v.1",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Topotecan",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (In the rEECur trial, in the absence of disease progression,6 cycles of topotecan and cyclophosphamide (TC) were given. Decision to treat beyond 6 cycles at clinician discretion.)",
                    "dose": "0.75 mg/m2",
                    "day": "1 to 5",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "CYCLOPHOSPHamide *",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (In the rEECur trial, in the absence of disease progression,6 cycles of topotecan and cyclophosphamide (TC) were given. Decision to treat beyond 6 cycles at clinician discretion.)",
                    "dose": "250 mg/m2",
                    "day": "1 to 5",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Pegfilgrastim",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (In the rEECur trial, in the absence of disease progression,6 cycles of topotecan and cyclophosphamide (TC) were given. Decision to treat beyond 6 cycles at clinician discretion.)",
                    "dose": "6 mg",
                    "day": "6",
                    "route": "Subcut"
                }
            ],
            [
                {
                    "drug_name": "Topotecan",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (In the rEECur trial, in the absence of disease progression,6 cycles of topotecan and cyclophosphamide (TC) were given. Decision to treat beyond 6 cycles at clinician discretion.)",
                    "dose": "0.75 mg/m2",
                    "day": "1 to 5",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "CYCLOPHOSPHamide *",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (In the rEECur trial, in the absence of disease progression,6 cycles of topotecan and cyclophosphamide (TC) were given. Decision to treat beyond 6 cycles at clinician discretion.)",
                    "dose": "250 mg/m2",
                    "day": "1 to 5",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Pegfilgrastim",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (In the rEECur trial, in the absence of disease progression,6 cycles of topotecan and cyclophosphamide (TC) were given. Decision to treat beyond 6 cycles at clinician discretion.)",
                    "dose": "6 mg",
                    "day": "6",
                    "route": "Subcut"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "sarcoma",
        "url": "https://www.eviq.org.au/medical-oncology/sarcoma/bone-sarcoma/4245-es-recurrent-or-metastatic-tc-topotecan-and"
    },
    {
        "protocol_id": "1916 v.6",
        "protocol_status": "Under review",
        "drug_sequence": [
            [
                {
                    "drug_name": "DOXOrubicin #",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "7(Alternating with ID 3465Ewing sarcoma iFOSFamide and etoposide(part 2 of VDC/IE))",
                    "dose": "37.5 mg/m2",
                    "day": "1 and 2",
                    "route": "IV ##"
                },
                {
                    "drug_name": "vinCRISTine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "7(Alternating with ID 3465Ewing sarcoma iFOSFamide and etoposide(part 2 of VDC/IE))",
                    "dose": "1.5 mg/m2\n(Cap dose at 2 mg)",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Mesna",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "7(Alternating with ID 3465Ewing sarcoma iFOSFamide and etoposide(part 2 of VDC/IE))",
                    "dose": "400 mg/m2 *",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "CYCLOPHOSPHamide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "7(Alternating with ID 3465Ewing sarcoma iFOSFamide and etoposide(part 2 of VDC/IE))",
                    "dose": "1,200 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Mesna",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "7(Alternating with ID 3465Ewing sarcoma iFOSFamide and etoposide(part 2 of VDC/IE))",
                    "dose": "800 mg/m2",
                    "day": "1",
                    "route": "PO"
                },
                {
                    "drug_name": "Pegfilgrastim",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "7(Alternating with ID 3465Ewing sarcoma iFOSFamide and etoposide(part 2 of VDC/IE))",
                    "dose": "6 mg",
                    "day": "3",
                    "route": "Subcut"
                }
            ],
            [
                {
                    "drug_name": "DOXOrubicin #",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "7(Alternating with ID 3465Ewing sarcoma iFOSFamide and etoposide(part 2 of VDC/IE))",
                    "dose": "37.5 mg/m2",
                    "day": "1 and 2",
                    "route": "IV ##"
                },
                {
                    "drug_name": "vinCRISTine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "7(Alternating with ID 3465Ewing sarcoma iFOSFamide and etoposide(part 2 of VDC/IE))",
                    "dose": "1.5 mg/m2\n(Cap dose at 2 mg)",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Mesna",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "7(Alternating with ID 3465Ewing sarcoma iFOSFamide and etoposide(part 2 of VDC/IE))",
                    "dose": "400 mg/m2 *",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "CYCLOPHOSPHamide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "7(Alternating with ID 3465Ewing sarcoma iFOSFamide and etoposide(part 2 of VDC/IE))",
                    "dose": "1,200 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Mesna",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "7(Alternating with ID 3465Ewing sarcoma iFOSFamide and etoposide(part 2 of VDC/IE))",
                    "dose": "800 mg/m2",
                    "day": "1",
                    "route": "PO"
                },
                {
                    "drug_name": "Pegfilgrastim",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "7(Alternating with ID 3465Ewing sarcoma iFOSFamide and etoposide(part 2 of VDC/IE))",
                    "dose": "6 mg",
                    "day": "3",
                    "route": "Subcut"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "sarcoma",
        "url": "https://www.eviq.org.au/medical-oncology/sarcoma/bone-sarcoma/1916-ewing-sarcoma-vdc-vincristine-doxorubicin"
    },
    {
        "protocol_id": "3464 v.1",
        "protocol_status": "Under review",
        "drug_sequence": [
            [
                {
                    "drug_name": "cyclophosphamide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "7",
                    "dose": "",
                    "day": 1,
                    "route": "IV"
                }
            ],
            [
                {
                    "drug_name": "etoposide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "7",
                    "dose": "",
                    "day": 1,
                    "route": "IV"
                },
                {
                    "drug_name": "ifosfamide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "7",
                    "dose": "",
                    "day": 1,
                    "route": "IV"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "sarcoma",
        "url": "https://www.eviq.org.au/medical-oncology/sarcoma/bone-sarcoma/3464-ewing-sarcoma-vdc-ie-overview"
    },
    {
        "protocol_id": "3467 v.2",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Denosumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until unacceptable toxicity, disease progression or patient preference to cease treatment.",
                    "dose": "120 mg",
                    "day": "1, 8, 15",
                    "route": "Subcut"
                }
            ],
            [
                {
                    "drug_name": "Denosumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until unacceptable toxicity, disease progression or patient preference to cease treatment.",
                    "dose": "120 mg",
                    "day": "1",
                    "route": "Subcut"
                }
            ],
            [
                {
                    "drug_name": "Denosumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until unacceptable toxicity, disease progression or patient preference to cease treatment.",
                    "dose": "120 mg",
                    "day": "1, 8, 15",
                    "route": "Subcut"
                }
            ],
            [
                {
                    "drug_name": "Denosumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until unacceptable toxicity, disease progression or patient preference to cease treatment.",
                    "dose": "120 mg",
                    "day": "1",
                    "route": "Subcut"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "sarcoma",
        "url": "https://www.eviq.org.au/medical-oncology/sarcoma/bone-sarcoma/3467-giant-cell-tumour-of-bone-denosumab"
    },
    {
        "protocol_id": "1901 v.5",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "DOXOrubicin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "35 days",
                    "cycles": "4",
                    "dose": "37.5 mg/m2",
                    "day": "1 and 2",
                    "route": "IV *"
                },
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "35 days",
                    "cycles": "4",
                    "dose": "60 mg/m2",
                    "day": "1 and 2",
                    "route": "IV infusion **"
                },
                {
                    "drug_name": "Pegfilgrastim",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "35 days",
                    "cycles": "4",
                    "dose": "6 mg",
                    "day": "3",
                    "route": "Subcut"
                },
                {
                    "drug_name": "Methotrexate",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "35 days",
                    "cycles": "4",
                    "dose": "12,000 mg/m2 (maximum 20,000 mg)",
                    "day": "22 and 29",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Calcium folinate (Leucovorin)",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "35 days",
                    "cycles": "4",
                    "dose": "15 mg/m2 every 6 hours (for 4 doses) ***",
                    "day": "23 and 30",
                    "route": "IV bolus"
                }
            ],
            [
                {
                    "drug_name": "DOXOrubicin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "35 days",
                    "cycles": "4",
                    "dose": "37.5 mg/m2",
                    "day": "1 and 2",
                    "route": "IV *"
                },
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "35 days",
                    "cycles": "4",
                    "dose": "60 mg/m2",
                    "day": "1 and 2",
                    "route": "IV infusion **"
                },
                {
                    "drug_name": "Pegfilgrastim",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "35 days",
                    "cycles": "4",
                    "dose": "6 mg",
                    "day": "3",
                    "route": "Subcut"
                },
                {
                    "drug_name": "Methotrexate",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "35 days",
                    "cycles": "4",
                    "dose": "12,000 mg/m2 (maximum 20,000 mg)",
                    "day": "22 and 29",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Calcium folinate (Leucovorin)",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "35 days",
                    "cycles": "4",
                    "dose": "15 mg/m2 every 6 hours (for 4 doses) ***",
                    "day": "23 and 30",
                    "route": "IV bolus"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "sarcoma",
        "url": "https://www.eviq.org.au/medical-oncology/sarcoma/bone-sarcoma/1901-osteosarcoma-map-methotrexate-doxorubicin"
    },
    {
        "protocol_id": "3472 v.9",
        "protocol_status": "Discontinued",
        "drug_sequence": [],
        "section_name": "medical-oncology",
        "category_name": "sarcoma",
        "url": "https://www.eviq.org.au/medical-oncology/sarcoma/bone-sarcoma/3472-ewing-sarcoma-vac-vincristine-dactinomycin-c"
    },
    {
        "protocol_id": "3473 v.8",
        "protocol_status": "Discontinued",
        "drug_sequence": [],
        "section_name": "medical-oncology",
        "category_name": "sarcoma",
        "url": "https://www.eviq.org.au/medical-oncology/sarcoma/bone-sarcoma/3473-ewing-sarcoma-vai-vincristine-dactinomycin-i"
    },
    {
        "protocol_id": "3471 v.6",
        "protocol_status": "Discontinued",
        "drug_sequence": [],
        "section_name": "medical-oncology",
        "category_name": "sarcoma",
        "url": "https://www.eviq.org.au/medical-oncology/sarcoma/bone-sarcoma/3471-ewing-sarcoma-vide-vincristine-ifosfamide-do"
    },
    {
        "protocol_id": "3470 v.3",
        "protocol_status": "Discontinued",
        "drug_sequence": [
            [
                {
                    "drug_name": "etoposide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6",
                    "dose": "",
                    "day": 1,
                    "route": "IV"
                },
                {
                    "drug_name": "ifosfamide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6",
                    "dose": "",
                    "day": 1,
                    "route": "IV"
                },
                {
                    "drug_name": "vide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6",
                    "dose": "",
                    "day": 1,
                    "route": "IV"
                },
                {
                    "drug_name": "doxorubicin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6",
                    "dose": "",
                    "day": 1,
                    "route": "IV"
                },
                {
                    "drug_name": "vincristine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6",
                    "dose": "",
                    "day": 1,
                    "route": "IV"
                }
            ],
            [
                {
                    "drug_name": "dactinomycin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6",
                    "dose": "",
                    "day": 1,
                    "route": "IV"
                },
                {
                    "drug_name": "cyclophosphamide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6",
                    "dose": "",
                    "day": 1,
                    "route": "IV"
                },
                {
                    "drug_name": "vincristine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6",
                    "dose": "",
                    "day": 1,
                    "route": "IV"
                }
            ],
            [
                {
                    "drug_name": "dactinomycin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6",
                    "dose": "",
                    "day": 1,
                    "route": "IV"
                },
                {
                    "drug_name": "ifosfamide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6",
                    "dose": "",
                    "day": 1,
                    "route": "IV"
                },
                {
                    "drug_name": "vincristine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6",
                    "dose": "",
                    "day": 1,
                    "route": "IV"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "sarcoma",
        "url": "https://www.eviq.org.au/medical-oncology/sarcoma/bone-sarcoma/3470-ewing-sarcoma-vide-followed-by-vac-or-vai-ove"
    },
    {
        "protocol_id": "1900 v.7",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "PACLitaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (up to 6 cycles)",
                    "dose": "80 mg/m2",
                    "day": "1, 8, 15",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "PACLitaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (up to 6 cycles)",
                    "dose": "80 mg/m2",
                    "day": "1, 8, 15",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "sarcoma",
        "url": "https://www.eviq.org.au/medical-oncology/sarcoma/soft-tissue-sarcoma/1900-angiosarcoma-locally-advanced-or-metastatic-p"
    },
    {
        "protocol_id": "3462 v.3",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Eribulin mesilate",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "1.4 mg/m2",
                    "day": "1 and 8",
                    "route": "IV"
                }
            ],
            [
                {
                    "drug_name": "Eribulin mesilate",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "1.4 mg/m2",
                    "day": "1 and 8",
                    "route": "IV"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "sarcoma",
        "url": "https://www.eviq.org.au/medical-oncology/sarcoma/soft-tissue-sarcoma/3462-liposarcoma-advanced-or-metastatic-eribulin"
    },
    {
        "protocol_id": "1602 v.5",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "pAZOPanib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "800 mg ONCE a day",
                    "day": null,
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "pAZOPanib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "800 mg ONCE a day",
                    "day": null,
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "sarcoma",
        "url": "https://www.eviq.org.au/medical-oncology/sarcoma/soft-tissue-sarcoma/1602-soft-tissue-sarcoma-advanced-or-metastatic-pa"
    },
    {
        "protocol_id": "3474 v.1",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Trabectedin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "1.5 mg/m2",
                    "day": "1",
                    "route": "CIV over 24 hours"
                }
            ],
            [
                {
                    "drug_name": "Trabectedin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "1.5 mg/m2",
                    "day": "1",
                    "route": "CIV over 24 hours"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "sarcoma",
        "url": "https://www.eviq.org.au/medical-oncology/sarcoma/soft-tissue-sarcoma/3474-soft-tissue-sarcoma-advanced-or-metastatic-tr"
    },
    {
        "protocol_id": "1554 v.5",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "DOXOrubicin *",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (up to 6 cycles)",
                    "dose": "75 mg/m2",
                    "day": "1",
                    "route": "IV **"
                },
                {
                    "drug_name": "Pegfilgrastim",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (up to 6 cycles)",
                    "dose": "6 mg",
                    "day": "2",
                    "route": "Subcut"
                }
            ],
            [
                {
                    "drug_name": "DOXOrubicin *",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (up to 6 cycles)",
                    "dose": "75 mg/m2",
                    "day": "1",
                    "route": "IV **"
                },
                {
                    "drug_name": "Pegfilgrastim",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (up to 6 cycles)",
                    "dose": "6 mg",
                    "day": "2",
                    "route": "Subcut"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "sarcoma",
        "url": "https://www.eviq.org.au/medical-oncology/sarcoma/soft-tissue-sarcoma/1554-soft-tissue-sarcoma-locally-advanced-or-metas"
    },
    {
        "protocol_id": "1659 v.8",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "DOXOrubicin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (maximum 6 cycles)",
                    "dose": "25 mg/m2",
                    "day": "1 to 3",
                    "route": "IV"
                },
                {
                    "drug_name": "Mesna",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (maximum 6 cycles)",
                    "dose": "500 mg/m2",
                    "day": "1 to 4",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "iFOSFamide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (maximum 6 cycles)",
                    "dose": "2,500 mg/m2",
                    "day": "1 to 4",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Mesna *",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (maximum 6 cycles)",
                    "dose": "1,500 mg/m2",
                    "day": "1 to 4",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Mesna **",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (maximum 6 cycles)",
                    "dose": "2,000 mg",
                    "day": "1 to 4",
                    "route": "PO"
                },
                {
                    "drug_name": "Pegfilgrastim",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (maximum 6 cycles)",
                    "dose": "6 mg",
                    "day": "5",
                    "route": "Subcut"
                }
            ],
            [
                {
                    "drug_name": "DOXOrubicin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (maximum 6 cycles)",
                    "dose": "25 mg/m2",
                    "day": "1 to 3",
                    "route": "IV"
                },
                {
                    "drug_name": "Mesna",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (maximum 6 cycles)",
                    "dose": "500 mg/m2",
                    "day": "1 to 4",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "iFOSFamide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (maximum 6 cycles)",
                    "dose": "2,500 mg/m2",
                    "day": "1 to 4",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Mesna *",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (maximum 6 cycles)",
                    "dose": "1,500 mg/m2",
                    "day": "1 to 4",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Mesna **",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (maximum 6 cycles)",
                    "dose": "2,000 mg",
                    "day": "1 to 4",
                    "route": "PO"
                },
                {
                    "drug_name": "Pegfilgrastim",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (maximum 6 cycles)",
                    "dose": "6 mg",
                    "day": "5",
                    "route": "Subcut"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "sarcoma",
        "url": "https://www.eviq.org.au/medical-oncology/sarcoma/soft-tissue-sarcoma/1659-soft-tissue-sarcoma-locally-advanced-or-metas"
    },
    {
        "protocol_id": "1898 v.5",
        "protocol_status": "Under review",
        "drug_sequence": [
            [
                {
                    "drug_name": "Gemcitabine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "until disease progression or unacceptable toxicity (usually 6 cycles)",
                    "dose": "900 mg/m2 *",
                    "day": "1 and 8",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "DOCEtaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "until disease progression or unacceptable toxicity (usually 6 cycles)",
                    "dose": "75 mg/m2 *",
                    "day": "8",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Pegfilgrastim",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "until disease progression or unacceptable toxicity (usually 6 cycles)",
                    "dose": "6 mg",
                    "day": "9",
                    "route": "Subcut"
                }
            ],
            [
                {
                    "drug_name": "Gemcitabine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "until disease progression or unacceptable toxicity (usually 6 cycles)",
                    "dose": "900 mg/m2 *",
                    "day": "1 and 8",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "DOCEtaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "until disease progression or unacceptable toxicity (usually 6 cycles)",
                    "dose": "75 mg/m2 *",
                    "day": "8",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Pegfilgrastim",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "until disease progression or unacceptable toxicity (usually 6 cycles)",
                    "dose": "6 mg",
                    "day": "9",
                    "route": "Subcut"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "sarcoma",
        "url": "https://www.eviq.org.au/medical-oncology/sarcoma/soft-tissue-sarcoma/1898-soft-tissue-sarcoma-metastatic-docetaxel-and"
    },
    {
        "protocol_id": "589 v.3",
        "protocol_status": "Discontinued",
        "drug_sequence": [],
        "section_name": "medical-oncology",
        "category_name": "sarcoma",
        "url": "https://www.eviq.org.au/medical-oncology/sarcoma/soft-tissue-sarcoma/589-soft-tissue-sarcoma-advanced-doxorubicin-and-f"
    },
    {
        "protocol_id": "3465 v.5",
        "protocol_status": "Under review",
        "drug_sequence": [
            [
                {
                    "drug_name": "Etoposide *",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "7(Alternating with ID 1916 Ewing sarcoma VDC (vinCRIStine, DOXOrubicin, CYCLOPHOSPHamide) (part 1 of VDC/IE))",
                    "dose": "100 mg/m2",
                    "day": "1 to 5",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Mesna",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "7(Alternating with ID 1916 Ewing sarcoma VDC (vinCRIStine, DOXOrubicin, CYCLOPHOSPHamide) (part 1 of VDC/IE))",
                    "dose": "600 mg/m2",
                    "day": "1 to 5",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "iFOSFamide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "7(Alternating with ID 1916 Ewing sarcoma VDC (vinCRIStine, DOXOrubicin, CYCLOPHOSPHamide) (part 1 of VDC/IE))",
                    "dose": "1,800 mg/m2",
                    "day": "1 to 5",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Mesna",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "7(Alternating with ID 1916 Ewing sarcoma VDC (vinCRIStine, DOXOrubicin, CYCLOPHOSPHamide) (part 1 of VDC/IE))",
                    "dose": "600 mg/m2 at 4 and 8 hours after the initiation of ifosfamide",
                    "day": "1 to 5",
                    "route": "IV infusion #"
                },
                {
                    "drug_name": "Pegfilgrastim",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "7(Alternating with ID 1916 Ewing sarcoma VDC (vinCRIStine, DOXOrubicin, CYCLOPHOSPHamide) (part 1 of VDC/IE))",
                    "dose": "6 mg",
                    "day": "6",
                    "route": "Subcut"
                }
            ],
            [
                {
                    "drug_name": "Etoposide *",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "7(Alternating with ID 1916 Ewing sarcoma VDC (vinCRIStine, DOXOrubicin, CYCLOPHOSPHamide) (part 1 of VDC/IE))",
                    "dose": "100 mg/m2",
                    "day": "1 to 5",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Mesna",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "7(Alternating with ID 1916 Ewing sarcoma VDC (vinCRIStine, DOXOrubicin, CYCLOPHOSPHamide) (part 1 of VDC/IE))",
                    "dose": "600 mg/m2",
                    "day": "1 to 5",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "iFOSFamide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "7(Alternating with ID 1916 Ewing sarcoma VDC (vinCRIStine, DOXOrubicin, CYCLOPHOSPHamide) (part 1 of VDC/IE))",
                    "dose": "1,800 mg/m2",
                    "day": "1 to 5",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Mesna",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "7(Alternating with ID 1916 Ewing sarcoma VDC (vinCRIStine, DOXOrubicin, CYCLOPHOSPHamide) (part 1 of VDC/IE))",
                    "dose": "600 mg/m2 at 4 and 8 hours after the initiation of ifosfamide",
                    "day": "1 to 5",
                    "route": "IV infusion #"
                },
                {
                    "drug_name": "Pegfilgrastim",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "7(Alternating with ID 1916 Ewing sarcoma VDC (vinCRIStine, DOXOrubicin, CYCLOPHOSPHamide) (part 1 of VDC/IE))",
                    "dose": "6 mg",
                    "day": "6",
                    "route": "Subcut"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "sarcoma",
        "url": "https://www.eviq.org.au/medical-oncology/sarcoma/bone-sarcoma/3465-ewing-sarcoma-ie-ifosfamide-and-etoposide"
    },
    {
        "protocol_id": "3620 v.2",
        "protocol_status": "Under review",
        "drug_sequence": [
            [
                {
                    "drug_name": "Temozolomide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6or until disease progression or unacceptable toxicity (decision to treat beyond 6 cycles at clinician\u2019s discretion)",
                    "dose": "100 mg/m2 ONCE a day",
                    "day": "1 to 5",
                    "route": "PO ^"
                },
                {
                    "drug_name": "Irinotecan",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6or until disease progression or unacceptable toxicity (decision to treat beyond 6 cycles at clinician\u2019s discretion)",
                    "dose": "50 mg/m2 *",
                    "day": "1 to 5",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Temozolomide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6or until disease progression or unacceptable toxicity (decision to treat beyond 6 cycles at clinician\u2019s discretion)",
                    "dose": "100 mg/m2 ONCE a day",
                    "day": "1 to 5",
                    "route": "PO ^"
                },
                {
                    "drug_name": "Irinotecan",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6or until disease progression or unacceptable toxicity (decision to treat beyond 6 cycles at clinician\u2019s discretion)",
                    "dose": "50 mg/m2 *",
                    "day": "1 to 5",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "sarcoma",
        "url": "https://www.eviq.org.au/medical-oncology/sarcoma/bone-sarcoma/3620-ewing-sarcoma-recurrent-or-metastatic-irinote"
    },
    {
        "protocol_id": "4245 v.1",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Topotecan",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (In the rEECur trial, in the absence of disease progression,6 cycles of topotecan and cyclophosphamide (TC) were given. Decision to treat beyond 6 cycles at clinician discretion.)",
                    "dose": "0.75 mg/m2",
                    "day": "1 to 5",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "CYCLOPHOSPHamide *",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (In the rEECur trial, in the absence of disease progression,6 cycles of topotecan and cyclophosphamide (TC) were given. Decision to treat beyond 6 cycles at clinician discretion.)",
                    "dose": "250 mg/m2",
                    "day": "1 to 5",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Pegfilgrastim",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (In the rEECur trial, in the absence of disease progression,6 cycles of topotecan and cyclophosphamide (TC) were given. Decision to treat beyond 6 cycles at clinician discretion.)",
                    "dose": "6 mg",
                    "day": "6",
                    "route": "Subcut"
                }
            ],
            [
                {
                    "drug_name": "Topotecan",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (In the rEECur trial, in the absence of disease progression,6 cycles of topotecan and cyclophosphamide (TC) were given. Decision to treat beyond 6 cycles at clinician discretion.)",
                    "dose": "0.75 mg/m2",
                    "day": "1 to 5",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "CYCLOPHOSPHamide *",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (In the rEECur trial, in the absence of disease progression,6 cycles of topotecan and cyclophosphamide (TC) were given. Decision to treat beyond 6 cycles at clinician discretion.)",
                    "dose": "250 mg/m2",
                    "day": "1 to 5",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Pegfilgrastim",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (In the rEECur trial, in the absence of disease progression,6 cycles of topotecan and cyclophosphamide (TC) were given. Decision to treat beyond 6 cycles at clinician discretion.)",
                    "dose": "6 mg",
                    "day": "6",
                    "route": "Subcut"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "sarcoma",
        "url": "https://www.eviq.org.au/medical-oncology/sarcoma/bone-sarcoma/4245-es-recurrent-or-metastatic-tc-topotecan-and"
    },
    {
        "protocol_id": "1916 v.6",
        "protocol_status": "Under review",
        "drug_sequence": [
            [
                {
                    "drug_name": "DOXOrubicin #",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "7(Alternating with ID 3465Ewing sarcoma iFOSFamide and etoposide(part 2 of VDC/IE))",
                    "dose": "37.5 mg/m2",
                    "day": "1 and 2",
                    "route": "IV ##"
                },
                {
                    "drug_name": "vinCRISTine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "7(Alternating with ID 3465Ewing sarcoma iFOSFamide and etoposide(part 2 of VDC/IE))",
                    "dose": "1.5 mg/m2\n(Cap dose at 2 mg)",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Mesna",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "7(Alternating with ID 3465Ewing sarcoma iFOSFamide and etoposide(part 2 of VDC/IE))",
                    "dose": "400 mg/m2 *",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "CYCLOPHOSPHamide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "7(Alternating with ID 3465Ewing sarcoma iFOSFamide and etoposide(part 2 of VDC/IE))",
                    "dose": "1,200 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Mesna",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "7(Alternating with ID 3465Ewing sarcoma iFOSFamide and etoposide(part 2 of VDC/IE))",
                    "dose": "800 mg/m2",
                    "day": "1",
                    "route": "PO"
                },
                {
                    "drug_name": "Pegfilgrastim",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "7(Alternating with ID 3465Ewing sarcoma iFOSFamide and etoposide(part 2 of VDC/IE))",
                    "dose": "6 mg",
                    "day": "3",
                    "route": "Subcut"
                }
            ],
            [
                {
                    "drug_name": "DOXOrubicin #",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "7(Alternating with ID 3465Ewing sarcoma iFOSFamide and etoposide(part 2 of VDC/IE))",
                    "dose": "37.5 mg/m2",
                    "day": "1 and 2",
                    "route": "IV ##"
                },
                {
                    "drug_name": "vinCRISTine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "7(Alternating with ID 3465Ewing sarcoma iFOSFamide and etoposide(part 2 of VDC/IE))",
                    "dose": "1.5 mg/m2\n(Cap dose at 2 mg)",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Mesna",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "7(Alternating with ID 3465Ewing sarcoma iFOSFamide and etoposide(part 2 of VDC/IE))",
                    "dose": "400 mg/m2 *",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "CYCLOPHOSPHamide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "7(Alternating with ID 3465Ewing sarcoma iFOSFamide and etoposide(part 2 of VDC/IE))",
                    "dose": "1,200 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Mesna",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "7(Alternating with ID 3465Ewing sarcoma iFOSFamide and etoposide(part 2 of VDC/IE))",
                    "dose": "800 mg/m2",
                    "day": "1",
                    "route": "PO"
                },
                {
                    "drug_name": "Pegfilgrastim",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "7(Alternating with ID 3465Ewing sarcoma iFOSFamide and etoposide(part 2 of VDC/IE))",
                    "dose": "6 mg",
                    "day": "3",
                    "route": "Subcut"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "sarcoma",
        "url": "https://www.eviq.org.au/medical-oncology/sarcoma/bone-sarcoma/1916-ewing-sarcoma-vdc-vincristine-doxorubicin"
    },
    {
        "protocol_id": "3464 v.1",
        "protocol_status": "Under review",
        "drug_sequence": [
            [
                {
                    "drug_name": "cyclophosphamide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "7",
                    "dose": "",
                    "day": 1,
                    "route": "IV"
                }
            ],
            [
                {
                    "drug_name": "etoposide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "7",
                    "dose": "",
                    "day": 1,
                    "route": "IV"
                },
                {
                    "drug_name": "ifosfamide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "7",
                    "dose": "",
                    "day": 1,
                    "route": "IV"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "sarcoma",
        "url": "https://www.eviq.org.au/medical-oncology/sarcoma/bone-sarcoma/3464-ewing-sarcoma-vdc-ie-overview"
    },
    {
        "protocol_id": "3467 v.2",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Denosumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until unacceptable toxicity, disease progression or patient preference to cease treatment.",
                    "dose": "120 mg",
                    "day": "1, 8, 15",
                    "route": "Subcut"
                }
            ],
            [
                {
                    "drug_name": "Denosumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until unacceptable toxicity, disease progression or patient preference to cease treatment.",
                    "dose": "120 mg",
                    "day": "1",
                    "route": "Subcut"
                }
            ],
            [
                {
                    "drug_name": "Denosumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until unacceptable toxicity, disease progression or patient preference to cease treatment.",
                    "dose": "120 mg",
                    "day": "1, 8, 15",
                    "route": "Subcut"
                }
            ],
            [
                {
                    "drug_name": "Denosumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until unacceptable toxicity, disease progression or patient preference to cease treatment.",
                    "dose": "120 mg",
                    "day": "1",
                    "route": "Subcut"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "sarcoma",
        "url": "https://www.eviq.org.au/medical-oncology/sarcoma/bone-sarcoma/3467-giant-cell-tumour-of-bone-denosumab"
    },
    {
        "protocol_id": "1901 v.5",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "DOXOrubicin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "35 days",
                    "cycles": "4",
                    "dose": "37.5 mg/m2",
                    "day": "1 and 2",
                    "route": "IV *"
                },
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "35 days",
                    "cycles": "4",
                    "dose": "60 mg/m2",
                    "day": "1 and 2",
                    "route": "IV infusion **"
                },
                {
                    "drug_name": "Pegfilgrastim",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "35 days",
                    "cycles": "4",
                    "dose": "6 mg",
                    "day": "3",
                    "route": "Subcut"
                },
                {
                    "drug_name": "Methotrexate",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "35 days",
                    "cycles": "4",
                    "dose": "12,000 mg/m2 (maximum 20,000 mg)",
                    "day": "22 and 29",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Calcium folinate (Leucovorin)",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "35 days",
                    "cycles": "4",
                    "dose": "15 mg/m2 every 6 hours (for 4 doses) ***",
                    "day": "23 and 30",
                    "route": "IV bolus"
                }
            ],
            [
                {
                    "drug_name": "DOXOrubicin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "35 days",
                    "cycles": "4",
                    "dose": "37.5 mg/m2",
                    "day": "1 and 2",
                    "route": "IV *"
                },
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "35 days",
                    "cycles": "4",
                    "dose": "60 mg/m2",
                    "day": "1 and 2",
                    "route": "IV infusion **"
                },
                {
                    "drug_name": "Pegfilgrastim",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "35 days",
                    "cycles": "4",
                    "dose": "6 mg",
                    "day": "3",
                    "route": "Subcut"
                },
                {
                    "drug_name": "Methotrexate",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "35 days",
                    "cycles": "4",
                    "dose": "12,000 mg/m2 (maximum 20,000 mg)",
                    "day": "22 and 29",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Calcium folinate (Leucovorin)",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "35 days",
                    "cycles": "4",
                    "dose": "15 mg/m2 every 6 hours (for 4 doses) ***",
                    "day": "23 and 30",
                    "route": "IV bolus"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "sarcoma",
        "url": "https://www.eviq.org.au/medical-oncology/sarcoma/bone-sarcoma/1901-osteosarcoma-map-methotrexate-doxorubicin"
    },
    {
        "protocol_id": "3472 v.9",
        "protocol_status": "Discontinued",
        "drug_sequence": [],
        "section_name": "medical-oncology",
        "category_name": "sarcoma",
        "url": "https://www.eviq.org.au/medical-oncology/sarcoma/bone-sarcoma/3472-ewing-sarcoma-vac-vincristine-dactinomycin-c"
    },
    {
        "protocol_id": "3473 v.8",
        "protocol_status": "Discontinued",
        "drug_sequence": [],
        "section_name": "medical-oncology",
        "category_name": "sarcoma",
        "url": "https://www.eviq.org.au/medical-oncology/sarcoma/bone-sarcoma/3473-ewing-sarcoma-vai-vincristine-dactinomycin-i"
    },
    {
        "protocol_id": "3471 v.6",
        "protocol_status": "Discontinued",
        "drug_sequence": [],
        "section_name": "medical-oncology",
        "category_name": "sarcoma",
        "url": "https://www.eviq.org.au/medical-oncology/sarcoma/bone-sarcoma/3471-ewing-sarcoma-vide-vincristine-ifosfamide-do"
    },
    {
        "protocol_id": "3470 v.3",
        "protocol_status": "Discontinued",
        "drug_sequence": [
            [
                {
                    "drug_name": "etoposide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6",
                    "dose": "",
                    "day": 1,
                    "route": "IV"
                },
                {
                    "drug_name": "ifosfamide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6",
                    "dose": "",
                    "day": 1,
                    "route": "IV"
                },
                {
                    "drug_name": "vide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6",
                    "dose": "",
                    "day": 1,
                    "route": "IV"
                },
                {
                    "drug_name": "doxorubicin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6",
                    "dose": "",
                    "day": 1,
                    "route": "IV"
                },
                {
                    "drug_name": "vincristine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6",
                    "dose": "",
                    "day": 1,
                    "route": "IV"
                }
            ],
            [
                {
                    "drug_name": "dactinomycin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6",
                    "dose": "",
                    "day": 1,
                    "route": "IV"
                },
                {
                    "drug_name": "cyclophosphamide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6",
                    "dose": "",
                    "day": 1,
                    "route": "IV"
                },
                {
                    "drug_name": "vincristine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6",
                    "dose": "",
                    "day": 1,
                    "route": "IV"
                }
            ],
            [
                {
                    "drug_name": "dactinomycin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6",
                    "dose": "",
                    "day": 1,
                    "route": "IV"
                },
                {
                    "drug_name": "ifosfamide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6",
                    "dose": "",
                    "day": 1,
                    "route": "IV"
                },
                {
                    "drug_name": "vincristine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6",
                    "dose": "",
                    "day": 1,
                    "route": "IV"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "sarcoma",
        "url": "https://www.eviq.org.au/medical-oncology/sarcoma/bone-sarcoma/3470-ewing-sarcoma-vide-followed-by-vac-or-vai-ove"
    },
    {
        "protocol_id": "4406 v.2",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Nivolumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "13",
                    "dose": "480 mg * #",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Nivolumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "13",
                    "dose": "480 mg * #",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "skin",
        "url": "https://www.eviq.org.au/medical-oncology/skin/melanoma-neoadjuvant-adjuvant/3635-redirect-id-4406"
    },
    {
        "protocol_id": "3678 v.2",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "daBRAFEnib",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "150 mg TWICE a day",
                    "day": null,
                    "route": "PO"
                },
                {
                    "drug_name": "tRAMEtinib",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "2 mg ONCE a day",
                    "day": null,
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "daBRAFEnib",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "150 mg TWICE a day",
                    "day": null,
                    "route": "PO"
                },
                {
                    "drug_name": "tRAMEtinib",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "2 mg ONCE a day",
                    "day": null,
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "skin",
        "url": "https://www.eviq.org.au/medical-oncology/skin/melanoma-neoadjuvant-adjuvant/3678-melanoma-adjuvant-dabrafenib-and-trametinib"
    },
    {
        "protocol_id": "4362 v.1",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Pembrolizumab",
                    "is_adjuvant": true,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "18(for neoadjuvant/adjuvant indication aim for 3 cycles prior to surgery and 15 cycles post surgery)",
                    "dose": "200 mg",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Pembrolizumab",
                    "is_adjuvant": true,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "18(for neoadjuvant/adjuvant indication aim for 3 cycles prior to surgery and 15 cycles post surgery)",
                    "dose": "200 mg",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "skin",
        "url": "https://www.eviq.org.au/medical-oncology/skin/melanoma-neoadjuvant-adjuvant/4362-melanoma-neoadjuvant-adjuvant-pembrolizumab"
    },
    {
        "protocol_id": "3469 v.7",
        "protocol_status": "Superseded",
        "drug_sequence": [
            [
                {
                    "drug_name": "Nivolumab",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "26",
                    "dose": "3 mg/kg",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Nivolumab",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "26",
                    "dose": "3 mg/kg",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "skin",
        "url": "https://www.eviq.org.au/medical-oncology/skin/melanoma-neoadjuvant-adjuvant/3469-melanoma-adjuvant-nivolumab-weight-based-dos"
    },
    {
        "protocol_id": "1292 v.4",
        "protocol_status": "Discontinued",
        "drug_sequence": [],
        "section_name": "medical-oncology",
        "category_name": "skin",
        "url": "https://www.eviq.org.au/medical-oncology/skin/melanoma-neoadjuvant-adjuvant/1292-malignant-melanoma-adjuvant-interferon-alfa-2"
    },
    {
        "protocol_id": "3594 v.8",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Nivolumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "480 mg * #",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Nivolumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "480 mg * #",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "skin",
        "url": "https://www.eviq.org.au/medical-oncology/skin/melanoma-metastatic/3594-advanced-or-metastatic-nivolumab-flat-dosing"
    },
    {
        "protocol_id": "3840 v.9",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Pembrolizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (see Indications and patient population section)",
                    "dose": "200 mg *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Pembrolizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (see Indications and patient population section)",
                    "dose": "200 mg *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "skin",
        "url": "https://www.eviq.org.au/medical-oncology/skin/melanoma-metastatic/3840-advanced-metastatic-or-recurrent-pembrolizum"
    },
    {
        "protocol_id": "3600 v.3",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "biNIMEtinib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "45 mg TWICE a day",
                    "day": null,
                    "route": "PO"
                },
                {
                    "drug_name": "Encorafenib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "450 mg ONCE a day",
                    "day": null,
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "biNIMEtinib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "45 mg TWICE a day",
                    "day": null,
                    "route": "PO"
                },
                {
                    "drug_name": "Encorafenib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "450 mg ONCE a day",
                    "day": null,
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "skin",
        "url": "https://www.eviq.org.au/medical-oncology/skin/melanoma-metastatic/3600-melanoma-metastatic-binimetinib-and-encorafen"
    },
    {
        "protocol_id": "2037 v.3",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "cOBIMEtinib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "60 mg ONCE a day",
                    "day": "1 to 21",
                    "route": "PO"
                },
                {
                    "drug_name": "Vemurafenib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "960 mg TWICE a day *",
                    "day": "1 to 28",
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "cOBIMEtinib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "60 mg ONCE a day",
                    "day": "1 to 21",
                    "route": "PO"
                },
                {
                    "drug_name": "Vemurafenib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "960 mg TWICE a day *",
                    "day": "1 to 28",
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "skin",
        "url": "https://www.eviq.org.au/medical-oncology/skin/melanoma-metastatic/2037-melanoma-metastatic-cobimetinib-and-vemurafen"
    },
    {
        "protocol_id": "1619 v.5",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "daBRAFEnib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "150 mg TWICE a day",
                    "day": null,
                    "route": "PO"
                },
                {
                    "drug_name": "tRAMEtinib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "2 mg ONCE a day",
                    "day": null,
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "daBRAFEnib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "150 mg TWICE a day",
                    "day": null,
                    "route": "PO"
                },
                {
                    "drug_name": "tRAMEtinib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "2 mg ONCE a day",
                    "day": null,
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "skin",
        "url": "https://www.eviq.org.au/medical-oncology/skin/melanoma-metastatic/1619-melanoma-metastatic-dabrafenib-and-trametinib"
    },
    {
        "protocol_id": "1307 v.10",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Ipilimumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4",
                    "dose": "3 mg/kg",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Ipilimumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4",
                    "dose": "3 mg/kg",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "skin",
        "url": "https://www.eviq.org.au/medical-oncology/skin/melanoma-metastatic/1307-melanoma-metastatic-ipilimumab"
    },
    {
        "protocol_id": "1694 v.10",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Nivolumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4",
                    "dose": "1 mg/kg",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Ipilimumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4",
                    "dose": "3 mg/kg",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Nivolumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4",
                    "dose": "1 mg/kg",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Ipilimumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4",
                    "dose": "3 mg/kg",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "skin",
        "url": "https://www.eviq.org.au/medical-oncology/skin/melanoma-metastatic/1694-melanoma-metastatic-ipilimumab-and-nivolumab"
    },
    {
        "protocol_id": "4313 v.2",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Nivolumab (fixed dose preparation with relatlimab)",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "480 mg",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Relatlimab (fixed dose preparation with nivolumab)",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "160 mg",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Nivolumab (fixed dose preparation with relatlimab)",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "480 mg",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Relatlimab (fixed dose preparation with nivolumab)",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "160 mg",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "skin",
        "url": "https://www.eviq.org.au/medical-oncology/skin/melanoma-metastatic/4313-melanoma-metastatic-nivolumab-relatlimab"
    },
    {
        "protocol_id": "3677 v.7",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Nivolumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity. Treatment cessation after 2 years of therapy may be considered.",
                    "dose": "480 mg * #",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Nivolumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity. Treatment cessation after 2 years of therapy may be considered.",
                    "dose": "480 mg * #",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "skin",
        "url": "https://www.eviq.org.au/medical-oncology/skin/melanoma-metastatic/3677-metastatic-nivolumab-maintenance-flat-dosing"
    },
    {
        "protocol_id": "3555 v.9",
        "protocol_status": "Superseded",
        "drug_sequence": [
            [
                {
                    "drug_name": "Nivolumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "3 mg/kg",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Nivolumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "3 mg/kg",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "skin",
        "url": "https://www.eviq.org.au/medical-oncology/skin/melanoma-metastatic/3555-advanced-or-metastatic-nivolumab-weight-base"
    },
    {
        "protocol_id": "1591 v.5",
        "protocol_status": "Superseded",
        "drug_sequence": [
            [
                {
                    "drug_name": "daBRAFEnib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "150 mg TWICE a day",
                    "day": null,
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "daBRAFEnib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "150 mg TWICE a day",
                    "day": null,
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "skin",
        "url": "https://www.eviq.org.au/medical-oncology/skin/melanoma-metastatic/1591-melanoma-metastatic-dabrafenib-superseded"
    },
    {
        "protocol_id": "337 v.7",
        "protocol_status": "Superseded",
        "drug_sequence": [
            [
                {
                    "drug_name": "Dacarbazine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "1,000 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Dacarbazine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "1,000 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "skin",
        "url": "https://www.eviq.org.au/medical-oncology/skin/melanoma-metastatic/337-melanoma-metastatic-dacarbazine-superseded"
    },
    {
        "protocol_id": "338 v.6",
        "protocol_status": "Superseded",
        "drug_sequence": [
            [
                {
                    "drug_name": "Fotemustine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "7 days",
                    "cycles": "3followed by a 5 week break, then fotemustine 3 weekly maintenance therapy",
                    "dose": "100 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Fotemustine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "7 days",
                    "cycles": "3followed by a 5 week break, then fotemustine 3 weekly maintenance therapy",
                    "dose": "100 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "skin",
        "url": "https://www.eviq.org.au/medical-oncology/skin/melanoma-metastatic/338-melanoma-metastatic-fotemustine-weekly-induct"
    },
    {
        "protocol_id": "244 v.5",
        "protocol_status": "Superseded",
        "drug_sequence": [
            [
                {
                    "drug_name": "Fotemustine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (this is part 2 of the treatment which follows part 1 after a 5 week break)",
                    "dose": "100 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Fotemustine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (this is part 2 of the treatment which follows part 1 after a 5 week break)",
                    "dose": "100 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "skin",
        "url": "https://www.eviq.org.au/medical-oncology/skin/melanoma-metastatic/244-melanoma-metastatic-fotemustine-three-weekly-m"
    },
    {
        "protocol_id": "1309 v.5",
        "protocol_status": "Superseded",
        "drug_sequence": [
            [
                {
                    "drug_name": "Temozolomide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (reassess after 2 to 3 cycles and discontinue if no response)",
                    "dose": "200 mg/m2 ONCE a day *",
                    "day": "1 to 5",
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Temozolomide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (reassess after 2 to 3 cycles and discontinue if no response)",
                    "dose": "200 mg/m2 ONCE a day *",
                    "day": "1 to 5",
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "skin",
        "url": "https://www.eviq.org.au/medical-oncology/skin/melanoma-metastatic/1309-melanoma-metastatic-temozolomide-superseded"
    },
    {
        "protocol_id": "1308 v.4",
        "protocol_status": "Superseded",
        "drug_sequence": [
            [
                {
                    "drug_name": "Vemurafenib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "960 mg TWICE a day *",
                    "day": null,
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Vemurafenib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "960 mg TWICE a day *",
                    "day": null,
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "skin",
        "url": "https://www.eviq.org.au/medical-oncology/skin/melanoma-metastatic/1308-melanoma-metastatic-vemurafenib-superseded"
    },
    {
        "protocol_id": "3682 v.6",
        "protocol_status": "Superseded",
        "drug_sequence": [
            [
                {
                    "drug_name": "Nivolumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity. Treatment cessation after 2 years of therapy may be considered.",
                    "dose": "3 mg/kg",
                    "day": "1 *",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Nivolumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity. Treatment cessation after 2 years of therapy may be considered.",
                    "dose": "3 mg/kg",
                    "day": "1 *",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "skin",
        "url": "https://www.eviq.org.au/medical-oncology/skin/melanoma-metastatic/3682-metastatic-nivolumab-maintenance-weight-base"
    },
    {
        "protocol_id": "1729 v.6",
        "protocol_status": "Discontinued",
        "drug_sequence": [],
        "section_name": "medical-oncology",
        "category_name": "skin",
        "url": "https://www.eviq.org.au/medical-oncology/skin/melanoma-metastatic/1729-melanoma-metastatic-pembrolizumab-weight-bas"
    },
    {
        "protocol_id": "3840 v.9",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Pembrolizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (see Indications and patient population section)",
                    "dose": "200 mg *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Pembrolizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (see Indications and patient population section)",
                    "dose": "200 mg *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "skin",
        "url": "https://www.eviq.org.au/medical-oncology/skin/non-melanoma/4293-redirect-id-3840"
    },
    {
        "protocol_id": "3410 v.3",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "soNIDEGib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "200 mg ONCE a day",
                    "day": null,
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "soNIDEGib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "200 mg ONCE a day",
                    "day": null,
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "skin",
        "url": "https://www.eviq.org.au/medical-oncology/skin/non-melanoma/3410-basal-cell-carcinoma-locally-advanced-or-meta"
    },
    {
        "protocol_id": "1918 v.3",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Vismodegib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "150 mg ONCE a day",
                    "day": null,
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Vismodegib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "150 mg ONCE a day",
                    "day": null,
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "skin",
        "url": "https://www.eviq.org.au/medical-oncology/skin/non-melanoma/1918-basal-cell-carcinoma-locally-advanced-or-meta"
    },
    {
        "protocol_id": "4151 v.2",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Cemiplimab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (up to 2 years)",
                    "dose": "350 mg",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Cemiplimab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (up to 2 years)",
                    "dose": "350 mg",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "skin",
        "url": "https://www.eviq.org.au/medical-oncology/skin/non-melanoma/3876-redirect-id-4151"
    },
    {
        "protocol_id": "3463 v.10",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Avelumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "10 mg/kg *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Avelumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "10 mg/kg *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "skin",
        "url": "https://www.eviq.org.au/medical-oncology/skin/non-melanoma/3463-merkel-cell-carcinoma-metastatic-avelumab"
    },
    {
        "protocol_id": "4406 v.2",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Nivolumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "13",
                    "dose": "480 mg * #",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Nivolumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "13",
                    "dose": "480 mg * #",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "skin",
        "url": "https://www.eviq.org.au/medical-oncology/skin/melanoma-neoadjuvant-adjuvant/3635-redirect-id-4406"
    },
    {
        "protocol_id": "3678 v.2",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "daBRAFEnib",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "150 mg TWICE a day",
                    "day": null,
                    "route": "PO"
                },
                {
                    "drug_name": "tRAMEtinib",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "2 mg ONCE a day",
                    "day": null,
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "daBRAFEnib",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "150 mg TWICE a day",
                    "day": null,
                    "route": "PO"
                },
                {
                    "drug_name": "tRAMEtinib",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "2 mg ONCE a day",
                    "day": null,
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "skin",
        "url": "https://www.eviq.org.au/medical-oncology/skin/melanoma-neoadjuvant-adjuvant/3678-melanoma-adjuvant-dabrafenib-and-trametinib"
    },
    {
        "protocol_id": "4362 v.1",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Pembrolizumab",
                    "is_adjuvant": true,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "18(for neoadjuvant/adjuvant indication aim for 3 cycles prior to surgery and 15 cycles post surgery)",
                    "dose": "200 mg",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Pembrolizumab",
                    "is_adjuvant": true,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "18(for neoadjuvant/adjuvant indication aim for 3 cycles prior to surgery and 15 cycles post surgery)",
                    "dose": "200 mg",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "skin",
        "url": "https://www.eviq.org.au/medical-oncology/skin/melanoma-neoadjuvant-adjuvant/4362-melanoma-neoadjuvant-adjuvant-pembrolizumab"
    },
    {
        "protocol_id": "3469 v.7",
        "protocol_status": "Superseded",
        "drug_sequence": [
            [
                {
                    "drug_name": "Nivolumab",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "26",
                    "dose": "3 mg/kg",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Nivolumab",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "26",
                    "dose": "3 mg/kg",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "skin",
        "url": "https://www.eviq.org.au/medical-oncology/skin/melanoma-neoadjuvant-adjuvant/3469-melanoma-adjuvant-nivolumab-weight-based-dos"
    },
    {
        "protocol_id": "1292 v.4",
        "protocol_status": "Discontinued",
        "drug_sequence": [],
        "section_name": "medical-oncology",
        "category_name": "skin",
        "url": "https://www.eviq.org.au/medical-oncology/skin/melanoma-neoadjuvant-adjuvant/1292-malignant-melanoma-adjuvant-interferon-alfa-2"
    },
    {
        "protocol_id": "3594 v.8",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Nivolumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "480 mg * #",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Nivolumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "480 mg * #",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "skin",
        "url": "https://www.eviq.org.au/medical-oncology/skin/melanoma-metastatic/3594-advanced-or-metastatic-nivolumab-flat-dosing"
    },
    {
        "protocol_id": "3840 v.9",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Pembrolizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (see Indications and patient population section)",
                    "dose": "200 mg *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Pembrolizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (see Indications and patient population section)",
                    "dose": "200 mg *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "skin",
        "url": "https://www.eviq.org.au/medical-oncology/skin/melanoma-metastatic/3840-advanced-metastatic-or-recurrent-pembrolizum"
    },
    {
        "protocol_id": "3600 v.3",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "biNIMEtinib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "45 mg TWICE a day",
                    "day": null,
                    "route": "PO"
                },
                {
                    "drug_name": "Encorafenib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "450 mg ONCE a day",
                    "day": null,
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "biNIMEtinib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "45 mg TWICE a day",
                    "day": null,
                    "route": "PO"
                },
                {
                    "drug_name": "Encorafenib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "450 mg ONCE a day",
                    "day": null,
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "skin",
        "url": "https://www.eviq.org.au/medical-oncology/skin/melanoma-metastatic/3600-melanoma-metastatic-binimetinib-and-encorafen"
    },
    {
        "protocol_id": "2037 v.3",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "cOBIMEtinib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "60 mg ONCE a day",
                    "day": "1 to 21",
                    "route": "PO"
                },
                {
                    "drug_name": "Vemurafenib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "960 mg TWICE a day *",
                    "day": "1 to 28",
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "cOBIMEtinib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "60 mg ONCE a day",
                    "day": "1 to 21",
                    "route": "PO"
                },
                {
                    "drug_name": "Vemurafenib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "960 mg TWICE a day *",
                    "day": "1 to 28",
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "skin",
        "url": "https://www.eviq.org.au/medical-oncology/skin/melanoma-metastatic/2037-melanoma-metastatic-cobimetinib-and-vemurafen"
    },
    {
        "protocol_id": "1619 v.5",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "daBRAFEnib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "150 mg TWICE a day",
                    "day": null,
                    "route": "PO"
                },
                {
                    "drug_name": "tRAMEtinib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "2 mg ONCE a day",
                    "day": null,
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "daBRAFEnib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "150 mg TWICE a day",
                    "day": null,
                    "route": "PO"
                },
                {
                    "drug_name": "tRAMEtinib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "2 mg ONCE a day",
                    "day": null,
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "skin",
        "url": "https://www.eviq.org.au/medical-oncology/skin/melanoma-metastatic/1619-melanoma-metastatic-dabrafenib-and-trametinib"
    },
    {
        "protocol_id": "1307 v.10",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Ipilimumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4",
                    "dose": "3 mg/kg",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Ipilimumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4",
                    "dose": "3 mg/kg",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "skin",
        "url": "https://www.eviq.org.au/medical-oncology/skin/melanoma-metastatic/1307-melanoma-metastatic-ipilimumab"
    },
    {
        "protocol_id": "1694 v.10",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Nivolumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4",
                    "dose": "1 mg/kg",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Ipilimumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4",
                    "dose": "3 mg/kg",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Nivolumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4",
                    "dose": "1 mg/kg",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Ipilimumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4",
                    "dose": "3 mg/kg",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "skin",
        "url": "https://www.eviq.org.au/medical-oncology/skin/melanoma-metastatic/1694-melanoma-metastatic-ipilimumab-and-nivolumab"
    },
    {
        "protocol_id": "4313 v.2",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Nivolumab (fixed dose preparation with relatlimab)",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "480 mg",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Relatlimab (fixed dose preparation with nivolumab)",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "160 mg",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Nivolumab (fixed dose preparation with relatlimab)",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "480 mg",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Relatlimab (fixed dose preparation with nivolumab)",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "160 mg",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "skin",
        "url": "https://www.eviq.org.au/medical-oncology/skin/melanoma-metastatic/4313-melanoma-metastatic-nivolumab-relatlimab"
    },
    {
        "protocol_id": "3677 v.7",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Nivolumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity. Treatment cessation after 2 years of therapy may be considered.",
                    "dose": "480 mg * #",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Nivolumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity. Treatment cessation after 2 years of therapy may be considered.",
                    "dose": "480 mg * #",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "skin",
        "url": "https://www.eviq.org.au/medical-oncology/skin/melanoma-metastatic/3677-metastatic-nivolumab-maintenance-flat-dosing"
    },
    {
        "protocol_id": "3555 v.9",
        "protocol_status": "Superseded",
        "drug_sequence": [
            [
                {
                    "drug_name": "Nivolumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "3 mg/kg",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Nivolumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "3 mg/kg",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "skin",
        "url": "https://www.eviq.org.au/medical-oncology/skin/melanoma-metastatic/3555-advanced-or-metastatic-nivolumab-weight-base"
    },
    {
        "protocol_id": "1591 v.5",
        "protocol_status": "Superseded",
        "drug_sequence": [
            [
                {
                    "drug_name": "daBRAFEnib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "150 mg TWICE a day",
                    "day": null,
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "daBRAFEnib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "150 mg TWICE a day",
                    "day": null,
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "skin",
        "url": "https://www.eviq.org.au/medical-oncology/skin/melanoma-metastatic/1591-melanoma-metastatic-dabrafenib-superseded"
    },
    {
        "protocol_id": "337 v.7",
        "protocol_status": "Superseded",
        "drug_sequence": [
            [
                {
                    "drug_name": "Dacarbazine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "1,000 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Dacarbazine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "1,000 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "skin",
        "url": "https://www.eviq.org.au/medical-oncology/skin/melanoma-metastatic/337-melanoma-metastatic-dacarbazine-superseded"
    },
    {
        "protocol_id": "338 v.6",
        "protocol_status": "Superseded",
        "drug_sequence": [
            [
                {
                    "drug_name": "Fotemustine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "7 days",
                    "cycles": "3followed by a 5 week break, then fotemustine 3 weekly maintenance therapy",
                    "dose": "100 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Fotemustine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "7 days",
                    "cycles": "3followed by a 5 week break, then fotemustine 3 weekly maintenance therapy",
                    "dose": "100 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "skin",
        "url": "https://www.eviq.org.au/medical-oncology/skin/melanoma-metastatic/338-melanoma-metastatic-fotemustine-weekly-induct"
    },
    {
        "protocol_id": "244 v.5",
        "protocol_status": "Superseded",
        "drug_sequence": [
            [
                {
                    "drug_name": "Fotemustine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (this is part 2 of the treatment which follows part 1 after a 5 week break)",
                    "dose": "100 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Fotemustine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (this is part 2 of the treatment which follows part 1 after a 5 week break)",
                    "dose": "100 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "skin",
        "url": "https://www.eviq.org.au/medical-oncology/skin/melanoma-metastatic/244-melanoma-metastatic-fotemustine-three-weekly-m"
    },
    {
        "protocol_id": "1309 v.5",
        "protocol_status": "Superseded",
        "drug_sequence": [
            [
                {
                    "drug_name": "Temozolomide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (reassess after 2 to 3 cycles and discontinue if no response)",
                    "dose": "200 mg/m2 ONCE a day *",
                    "day": "1 to 5",
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Temozolomide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (reassess after 2 to 3 cycles and discontinue if no response)",
                    "dose": "200 mg/m2 ONCE a day *",
                    "day": "1 to 5",
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "skin",
        "url": "https://www.eviq.org.au/medical-oncology/skin/melanoma-metastatic/1309-melanoma-metastatic-temozolomide-superseded"
    },
    {
        "protocol_id": "1308 v.4",
        "protocol_status": "Superseded",
        "drug_sequence": [
            [
                {
                    "drug_name": "Vemurafenib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "960 mg TWICE a day *",
                    "day": null,
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Vemurafenib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "960 mg TWICE a day *",
                    "day": null,
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "skin",
        "url": "https://www.eviq.org.au/medical-oncology/skin/melanoma-metastatic/1308-melanoma-metastatic-vemurafenib-superseded"
    },
    {
        "protocol_id": "3682 v.6",
        "protocol_status": "Superseded",
        "drug_sequence": [
            [
                {
                    "drug_name": "Nivolumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity. Treatment cessation after 2 years of therapy may be considered.",
                    "dose": "3 mg/kg",
                    "day": "1 *",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Nivolumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity. Treatment cessation after 2 years of therapy may be considered.",
                    "dose": "3 mg/kg",
                    "day": "1 *",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "skin",
        "url": "https://www.eviq.org.au/medical-oncology/skin/melanoma-metastatic/3682-metastatic-nivolumab-maintenance-weight-base"
    },
    {
        "protocol_id": "1729 v.6",
        "protocol_status": "Discontinued",
        "drug_sequence": [],
        "section_name": "medical-oncology",
        "category_name": "skin",
        "url": "https://www.eviq.org.au/medical-oncology/skin/melanoma-metastatic/1729-melanoma-metastatic-pembrolizumab-weight-bas"
    },
    {
        "protocol_id": "3840 v.9",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Pembrolizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (see Indications and patient population section)",
                    "dose": "200 mg *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Pembrolizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (see Indications and patient population section)",
                    "dose": "200 mg *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "skin",
        "url": "https://www.eviq.org.au/medical-oncology/skin/non-melanoma/4293-redirect-id-3840"
    },
    {
        "protocol_id": "3410 v.3",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "soNIDEGib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "200 mg ONCE a day",
                    "day": null,
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "soNIDEGib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "200 mg ONCE a day",
                    "day": null,
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "skin",
        "url": "https://www.eviq.org.au/medical-oncology/skin/non-melanoma/3410-basal-cell-carcinoma-locally-advanced-or-meta"
    },
    {
        "protocol_id": "1918 v.3",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Vismodegib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "150 mg ONCE a day",
                    "day": null,
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Vismodegib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "150 mg ONCE a day",
                    "day": null,
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "skin",
        "url": "https://www.eviq.org.au/medical-oncology/skin/non-melanoma/1918-basal-cell-carcinoma-locally-advanced-or-meta"
    },
    {
        "protocol_id": "4151 v.2",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Cemiplimab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (up to 2 years)",
                    "dose": "350 mg",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Cemiplimab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (up to 2 years)",
                    "dose": "350 mg",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "skin",
        "url": "https://www.eviq.org.au/medical-oncology/skin/non-melanoma/3876-redirect-id-4151"
    },
    {
        "protocol_id": "3463 v.10",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Avelumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "10 mg/kg *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Avelumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "10 mg/kg *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "skin",
        "url": "https://www.eviq.org.au/medical-oncology/skin/non-melanoma/3463-merkel-cell-carcinoma-metastatic-avelumab"
    },
    {
        "protocol_id": "4019 v.6",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Oxaliplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "8",
                    "dose": "130 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Capecitabine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "8",
                    "dose": "1,000 mg/m2 TWICE a day *",
                    "day": "1 to 14",
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Oxaliplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "8",
                    "dose": "130 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Capecitabine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "8",
                    "dose": "1,000 mg/m2 TWICE a day *",
                    "day": "1 to 14",
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "upper-gastrointestinal",
        "url": "https://www.eviq.org.au/medical-oncology/upper-gastrointestinal/gastric-and-oesophageal-adjuvant-and-neoadjuvant/1707-redirect-id-4019"
    },
    {
        "protocol_id": "1994 v.4",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "60 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Capecitabine",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "1,000 mg/m2 TWICE a day *",
                    "day": "1 to 14",
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": null,
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": null,
                    "day": null,
                    "route": null
                }
            ],
            [
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "60 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Capecitabine",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "1,000 mg/m2 TWICE a day *",
                    "day": "1 to 14",
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": null,
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": null,
                    "day": null,
                    "route": null
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "upper-gastrointestinal",
        "url": "https://www.eviq.org.au/medical-oncology/upper-gastrointestinal/gastric-and-oesophageal-adjuvant-and-neoadjuvant/1994-gastric-adjuvant-cisplatin-and-capecitabine-c"
    },
    {
        "protocol_id": "2038 v.6",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "DOCEtaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "14 days",
                    "cycles": "8(4 neoadjuvant, 4 adjuvant)",
                    "dose": "50 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Oxaliplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "14 days",
                    "cycles": "8(4 neoadjuvant, 4 adjuvant)",
                    "dose": "85 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Calcium folinate (Leucovorin)",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "14 days",
                    "cycles": "8(4 neoadjuvant, 4 adjuvant)",
                    "dose": "50 mg *",
                    "day": "1",
                    "route": "IV bolus"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "14 days",
                    "cycles": "8(4 neoadjuvant, 4 adjuvant)",
                    "dose": "2,600 mg/m2",
                    "day": "1",
                    "route": "CIV via pump over 24 hours"
                }
            ],
            [
                {
                    "drug_name": "DOCEtaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "14 days",
                    "cycles": "8(4 neoadjuvant, 4 adjuvant)",
                    "dose": "50 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Oxaliplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "14 days",
                    "cycles": "8(4 neoadjuvant, 4 adjuvant)",
                    "dose": "85 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Calcium folinate (Leucovorin)",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "14 days",
                    "cycles": "8(4 neoadjuvant, 4 adjuvant)",
                    "dose": "50 mg *",
                    "day": "1",
                    "route": "IV bolus"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "14 days",
                    "cycles": "8(4 neoadjuvant, 4 adjuvant)",
                    "dose": "2,600 mg/m2",
                    "day": "1",
                    "route": "CIV via pump over 24 hours"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "upper-gastrointestinal",
        "url": "https://www.eviq.org.au/medical-oncology/upper-gastrointestinal/gastric-and-oesophageal-adjuvant-and-neoadjuvant/2038-gastric-and-gastroesophageal-neoadjuvant-adju"
    },
    {
        "protocol_id": "4108 v.2",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Nivolumab",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "13",
                    "dose": "240 mg *",
                    "day": "1 and 15",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Nivolumab",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "13",
                    "dose": "480 mg *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Nivolumab",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "13",
                    "dose": "240 mg *",
                    "day": "1 and 15",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Nivolumab",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "13",
                    "dose": "480 mg *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "upper-gastrointestinal",
        "url": "https://www.eviq.org.au/medical-oncology/upper-gastrointestinal/gastric-and-oesophageal-adjuvant-and-neoadjuvant/4108-gastroesophageal-and-oesophageal-adjuvant-niv"
    },
    {
        "protocol_id": "2041 v.5",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "75 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "4,000 mg/m2 (equivalent to 1000 mg/m\u00b2/day)",
                    "day": "1",
                    "route": "CIV via pump over 96 hours"
                }
            ],
            [
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "75 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "4,000 mg/m2 (equivalent to 1000 mg/m\u00b2/day)",
                    "day": "1",
                    "route": "CIV via pump over 96 hours"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "upper-gastrointestinal",
        "url": "https://www.eviq.org.au/medical-oncology/upper-gastrointestinal/gastric-and-oesophageal-adjuvant-and-neoadjuvant/2041-oesophageal-definitive-cisplatin-fluorouracil"
    },
    {
        "protocol_id": "1704 v.6",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Oxaliplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "6(3 cycles with concurrent radiation therapy)",
                    "dose": "85 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Calcium folinate (Leucovorin)",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "6(3 cycles with concurrent radiation therapy)",
                    "dose": "50 mg *",
                    "day": "1",
                    "route": "IV bolus"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "6(3 cycles with concurrent radiation therapy)",
                    "dose": "400 mg/m2",
                    "day": "1",
                    "route": "IV"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "6(3 cycles with concurrent radiation therapy)",
                    "dose": "1,600 mg/m2",
                    "day": "1",
                    "route": "CIV via pump over 46 hours"
                }
            ],
            [
                {
                    "drug_name": "Oxaliplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "6(3 cycles with concurrent radiation therapy)",
                    "dose": "85 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Calcium folinate (Leucovorin)",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "6(3 cycles with concurrent radiation therapy)",
                    "dose": "50 mg *",
                    "day": "1",
                    "route": "IV bolus"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "6(3 cycles with concurrent radiation therapy)",
                    "dose": "400 mg/m2",
                    "day": "1",
                    "route": "IV"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "6(3 cycles with concurrent radiation therapy)",
                    "dose": "1,600 mg/m2",
                    "day": "1",
                    "route": "CIV via pump over 46 hours"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "upper-gastrointestinal",
        "url": "https://www.eviq.org.au/medical-oncology/upper-gastrointestinal/gastric-and-oesophageal-adjuvant-and-neoadjuvant/1704-oesophageal-definitive-folfox6-modified-fl"
    },
    {
        "protocol_id": "4008 v.3",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "PACLitaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "7 days",
                    "cycles": "5with concurrent radiation therapy",
                    "dose": "50 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "7 days",
                    "cycles": "5with concurrent radiation therapy",
                    "dose": "2 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "PACLitaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "7 days",
                    "cycles": "5with concurrent radiation therapy",
                    "dose": "50 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "7 days",
                    "cycles": "5with concurrent radiation therapy",
                    "dose": "2 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "upper-gastrointestinal",
        "url": "https://www.eviq.org.au/medical-oncology/upper-gastrointestinal/gastric-and-oesophageal-adjuvant-and-neoadjuvant/4008-oesophageal-definitive-or-neoadjuvant-carbopl"
    },
    {
        "protocol_id": "1250 v.6",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "28 days",
                    "cycles": "2with concurrent radiation therapy",
                    "dose": "75 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "28 days",
                    "cycles": "2with concurrent radiation therapy",
                    "dose": "4,000 mg/m2 (equivalent to 1000 mg/m\u00b2/day)",
                    "day": "1",
                    "route": "CIV via pump over 96 hours"
                }
            ],
            [
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "28 days",
                    "cycles": "2with concurrent radiation therapy",
                    "dose": "75 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "28 days",
                    "cycles": "2with concurrent radiation therapy",
                    "dose": "4,000 mg/m2 (equivalent to 1000 mg/m\u00b2/day)",
                    "day": "1",
                    "route": "CIV via pump over 96 hours"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "upper-gastrointestinal",
        "url": "https://www.eviq.org.au/medical-oncology/upper-gastrointestinal/gastric-and-oesophageal-adjuvant-and-neoadjuvant/1250-oesophageal-neoadjuvant-cisplatin-and-fluorou"
    },
    {
        "protocol_id": "553 v.9",
        "protocol_status": "Discontinued",
        "drug_sequence": [],
        "section_name": "medical-oncology",
        "category_name": "upper-gastrointestinal",
        "url": "https://www.eviq.org.au/medical-oncology/upper-gastrointestinal/gastric-and-oesophageal-adjuvant-and-neoadjuvant/553-gastric-adjuvant-macdonald-modified-fluorou"
    },
    {
        "protocol_id": "1907 v.6",
        "protocol_status": "Discontinued",
        "drug_sequence": [],
        "section_name": "medical-oncology",
        "category_name": "upper-gastrointestinal",
        "url": "https://www.eviq.org.au/medical-oncology/upper-gastrointestinal/gastric-and-oesophageal-adjuvant-and-neoadjuvant/1907-gastric-and-oesophageal-neoadjuvant-adjuvant"
    },
    {
        "protocol_id": "326 v.7",
        "protocol_status": "Discontinued",
        "drug_sequence": [],
        "section_name": "medical-oncology",
        "category_name": "upper-gastrointestinal",
        "url": "https://www.eviq.org.au/medical-oncology/upper-gastrointestinal/gastric-and-oesophageal-adjuvant-and-neoadjuvant/326-gastric-oesophageal-neoadjuvant-adjuvant-ecf"
    },
    {
        "protocol_id": "328 v.3",
        "protocol_status": "Discontinued",
        "drug_sequence": [],
        "section_name": "medical-oncology",
        "category_name": "upper-gastrointestinal",
        "url": "https://www.eviq.org.au/medical-oncology/upper-gastrointestinal/gastric-and-oesophageal-adjuvant-and-neoadjuvant/328-oesophageal-definitive-cisplatin-fractionated"
    },
    {
        "protocol_id": "4043 v.2",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Irinotecan",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "180 mg/m2 *",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Calcium folinate (Leucovorin)",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "50 mg **",
                    "day": "1",
                    "route": "IV bolus"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "400 mg/m2",
                    "day": "1",
                    "route": "IV"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "2,400 mg/m2",
                    "day": "1",
                    "route": "CIV via pump over 46 hours"
                }
            ],
            [
                {
                    "drug_name": "Irinotecan",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "180 mg/m2 *",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Calcium folinate (Leucovorin)",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "50 mg **",
                    "day": "1",
                    "route": "IV bolus"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "400 mg/m2",
                    "day": "1",
                    "route": "IV"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "2,400 mg/m2",
                    "day": "1",
                    "route": "CIV via pump over 46 hours"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "upper-gastrointestinal",
        "url": "https://www.eviq.org.au/medical-oncology/upper-gastrointestinal/gastric-and-oesophageal-metastatic/4043-advanced-or-metastatic-folfiri-modified-fl"
    },
    {
        "protocol_id": "4408 v.1",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Nivolumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "42 days",
                    "cycles": "17or until disease progression or unacceptable toxicity for up to 2 years",
                    "dose": "3 mg/kg",
                    "day": "1, 15, 29",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Ipilimumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "42 days",
                    "cycles": "17or until disease progression or unacceptable toxicity for up to 2 years",
                    "dose": "1 mg/kg",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Nivolumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "42 days",
                    "cycles": "17or until disease progression or unacceptable toxicity for up to 2 years",
                    "dose": "3 mg/kg",
                    "day": "1, 15, 29",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Ipilimumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "42 days",
                    "cycles": "17or until disease progression or unacceptable toxicity for up to 2 years",
                    "dose": "1 mg/kg",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "upper-gastrointestinal",
        "url": "https://www.eviq.org.au/medical-oncology/upper-gastrointestinal/gastric-and-oesophageal-metastatic/4408-advanced-or-metastatic-ipilimumab-and-nivolum"
    },
    {
        "protocol_id": "3594 v.8",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Nivolumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "480 mg * #",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Nivolumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "480 mg * #",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "upper-gastrointestinal",
        "url": "https://www.eviq.org.au/medical-oncology/upper-gastrointestinal/gastric-and-oesophageal-metastatic/4059-redirect-id-3594"
    },
    {
        "protocol_id": "3809 v.3",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Oxaliplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (up to 8 cycles)",
                    "dose": "130 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Capecitabine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (up to 8 cycles)",
                    "dose": "1,000 mg/m2 TWICE a day *",
                    "day": "1 to 14",
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Oxaliplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (up to 8 cycles)",
                    "dose": "130 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Capecitabine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (up to 8 cycles)",
                    "dose": "1,000 mg/m2 TWICE a day *",
                    "day": "1 to 14",
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "upper-gastrointestinal",
        "url": "https://www.eviq.org.au/medical-oncology/upper-gastrointestinal/gastric-and-oesophageal-metastatic/3809-gastric-and-gastroesophageal-metastatic-capox"
    },
    {
        "protocol_id": "4045 v.3",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Nivolumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "35(6 cycles with chemotherapy combination, followed by continuous treatment with nivolumab until disease progression or unacceptable toxicity for up to 2 years).",
                    "dose": "360 mg",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Oxaliplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "35(6 cycles with chemotherapy combination, followed by continuous treatment with nivolumab until disease progression or unacceptable toxicity for up to 2 years).",
                    "dose": "130 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Capecitabine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "35(6 cycles with chemotherapy combination, followed by continuous treatment with nivolumab until disease progression or unacceptable toxicity for up to 2 years).",
                    "dose": "1,000 mg/m2 TWICE a day *",
                    "day": "1 to 14",
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Nivolumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "35(6 cycles with chemotherapy combination, followed by continuous treatment with nivolumab until disease progression or unacceptable toxicity for up to 2 years).",
                    "dose": "360 mg **",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Nivolumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "35(6 cycles with chemotherapy combination, followed by continuous treatment with nivolumab until disease progression or unacceptable toxicity for up to 2 years).",
                    "dose": "360 mg",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Oxaliplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "35(6 cycles with chemotherapy combination, followed by continuous treatment with nivolumab until disease progression or unacceptable toxicity for up to 2 years).",
                    "dose": "130 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Capecitabine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "35(6 cycles with chemotherapy combination, followed by continuous treatment with nivolumab until disease progression or unacceptable toxicity for up to 2 years).",
                    "dose": "1,000 mg/m2 TWICE a day *",
                    "day": "1 to 14",
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Nivolumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "35(6 cycles with chemotherapy combination, followed by continuous treatment with nivolumab until disease progression or unacceptable toxicity for up to 2 years).",
                    "dose": "360 mg **",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "upper-gastrointestinal",
        "url": "https://www.eviq.org.au/medical-oncology/upper-gastrointestinal/gastric-and-oesophageal-metastatic/4045-gastric-and-gastroesophageal-metastatic-capox"
    },
    {
        "protocol_id": "3896 v.4",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Trastuzumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (up to 8 cycles). Consider continuation of trastuzumab monotherapy in patients who are responding to treatment.",
                    "dose": "8 mg/kg (loading dose only)",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Oxaliplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (up to 8 cycles). Consider continuation of trastuzumab monotherapy in patients who are responding to treatment.",
                    "dose": "130 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Capecitabine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (up to 8 cycles). Consider continuation of trastuzumab monotherapy in patients who are responding to treatment.",
                    "dose": "1,000 mg/m2 TWICE a day *",
                    "day": "1 to 14",
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Trastuzumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (up to 8 cycles). Consider continuation of trastuzumab monotherapy in patients who are responding to treatment.",
                    "dose": "6 mg/kg (subsequent doses)",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Oxaliplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (up to 8 cycles). Consider continuation of trastuzumab monotherapy in patients who are responding to treatment.",
                    "dose": "130 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Capecitabine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (up to 8 cycles). Consider continuation of trastuzumab monotherapy in patients who are responding to treatment.",
                    "dose": "1,000 mg/m2 TWICE a day *",
                    "day": "1 to 14",
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Trastuzumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (up to 8 cycles). Consider continuation of trastuzumab monotherapy in patients who are responding to treatment.",
                    "dose": "8 mg/kg (loading dose only)",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Oxaliplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (up to 8 cycles). Consider continuation of trastuzumab monotherapy in patients who are responding to treatment.",
                    "dose": "130 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Capecitabine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (up to 8 cycles). Consider continuation of trastuzumab monotherapy in patients who are responding to treatment.",
                    "dose": "1,000 mg/m2 TWICE a day *",
                    "day": "1 to 14",
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Trastuzumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (up to 8 cycles). Consider continuation of trastuzumab monotherapy in patients who are responding to treatment.",
                    "dose": "6 mg/kg (subsequent doses)",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Oxaliplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (up to 8 cycles). Consider continuation of trastuzumab monotherapy in patients who are responding to treatment.",
                    "dose": "130 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Capecitabine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (up to 8 cycles). Consider continuation of trastuzumab monotherapy in patients who are responding to treatment.",
                    "dose": "1,000 mg/m2 TWICE a day *",
                    "day": "1 to 14",
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "upper-gastrointestinal",
        "url": "https://www.eviq.org.au/medical-oncology/upper-gastrointestinal/gastric-and-oesophageal-metastatic/3896-gastric-and-gastroesophageal-metastatic-capox"
    },
    {
        "protocol_id": "1216 v.9",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Trastuzumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (in the clinical trial cisplatin, capecitabine and trastuzumab were given for 6 cycles, after which trastuzumab monotherapy should be continued in patients who are responding to treatment)",
                    "dose": "8 mg/kg (loading dose only)",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (in the clinical trial cisplatin, capecitabine and trastuzumab were given for 6 cycles, after which trastuzumab monotherapy should be continued in patients who are responding to treatment)",
                    "dose": "80 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Capecitabine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (in the clinical trial cisplatin, capecitabine and trastuzumab were given for 6 cycles, after which trastuzumab monotherapy should be continued in patients who are responding to treatment)",
                    "dose": "1,000 mg/m2 TWICE a day *",
                    "day": "1 to 14",
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Trastuzumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (in the clinical trial cisplatin, capecitabine and trastuzumab were given for 6 cycles, after which trastuzumab monotherapy should be continued in patients who are responding to treatment)",
                    "dose": "6 mg/kg (subsequent doses)",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (in the clinical trial cisplatin, capecitabine and trastuzumab were given for 6 cycles, after which trastuzumab monotherapy should be continued in patients who are responding to treatment)",
                    "dose": "80 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Capecitabine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (in the clinical trial cisplatin, capecitabine and trastuzumab were given for 6 cycles, after which trastuzumab monotherapy should be continued in patients who are responding to treatment)",
                    "dose": "1,000 mg/m2 TWICE a day *",
                    "day": "1 to 14",
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Trastuzumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (in the clinical trial cisplatin, capecitabine and trastuzumab were given for 6 cycles, after which trastuzumab monotherapy should be continued in patients who are responding to treatment)",
                    "dose": "6 mg/kg (subsequent doses)",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Trastuzumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (in the clinical trial cisplatin, capecitabine and trastuzumab were given for 6 cycles, after which trastuzumab monotherapy should be continued in patients who are responding to treatment)",
                    "dose": "8 mg/kg (loading dose only)",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (in the clinical trial cisplatin, capecitabine and trastuzumab were given for 6 cycles, after which trastuzumab monotherapy should be continued in patients who are responding to treatment)",
                    "dose": "80 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Capecitabine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (in the clinical trial cisplatin, capecitabine and trastuzumab were given for 6 cycles, after which trastuzumab monotherapy should be continued in patients who are responding to treatment)",
                    "dose": "1,000 mg/m2 TWICE a day *",
                    "day": "1 to 14",
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Trastuzumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (in the clinical trial cisplatin, capecitabine and trastuzumab were given for 6 cycles, after which trastuzumab monotherapy should be continued in patients who are responding to treatment)",
                    "dose": "6 mg/kg (subsequent doses)",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (in the clinical trial cisplatin, capecitabine and trastuzumab were given for 6 cycles, after which trastuzumab monotherapy should be continued in patients who are responding to treatment)",
                    "dose": "80 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Capecitabine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (in the clinical trial cisplatin, capecitabine and trastuzumab were given for 6 cycles, after which trastuzumab monotherapy should be continued in patients who are responding to treatment)",
                    "dose": "1,000 mg/m2 TWICE a day *",
                    "day": "1 to 14",
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Trastuzumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (in the clinical trial cisplatin, capecitabine and trastuzumab were given for 6 cycles, after which trastuzumab monotherapy should be continued in patients who are responding to treatment)",
                    "dose": "6 mg/kg (subsequent doses)",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "upper-gastrointestinal",
        "url": "https://www.eviq.org.au/medical-oncology/upper-gastrointestinal/gastric-and-oesophageal-metastatic/1216-gastric-and-gastroesophageal-metastatic-cispl"
    },
    {
        "protocol_id": "1217 v.9",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Trastuzumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (in the clinical trial cisplatin, fluorouracil and trastuzumab were given for 6 cycles, after which trastuzumab monotherapy should be continued in patients who are responding to treatment)",
                    "dose": "8 mg/kg (loading dose only)",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (in the clinical trial cisplatin, fluorouracil and trastuzumab were given for 6 cycles, after which trastuzumab monotherapy should be continued in patients who are responding to treatment)",
                    "dose": "80 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (in the clinical trial cisplatin, fluorouracil and trastuzumab were given for 6 cycles, after which trastuzumab monotherapy should be continued in patients who are responding to treatment)",
                    "dose": "4,000 mg/m2 (equivalent to 1000 mg/m2/day)",
                    "day": "1",
                    "route": "CIV via pump over 96 hours*"
                }
            ],
            [
                {
                    "drug_name": "Trastuzumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (in the clinical trial cisplatin, fluorouracil and trastuzumab were given for 6 cycles, after which trastuzumab monotherapy should be continued in patients who are responding to treatment)",
                    "dose": "6 mg/kg (subsequent doses)",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (in the clinical trial cisplatin, fluorouracil and trastuzumab were given for 6 cycles, after which trastuzumab monotherapy should be continued in patients who are responding to treatment)",
                    "dose": "80 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (in the clinical trial cisplatin, fluorouracil and trastuzumab were given for 6 cycles, after which trastuzumab monotherapy should be continued in patients who are responding to treatment)",
                    "dose": "4,000 mg/m2 (equivalent to 1000 mg/m2/day)",
                    "day": "1",
                    "route": "CIV via pump over 96 hours*"
                }
            ],
            [
                {
                    "drug_name": "Trastuzumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (in the clinical trial cisplatin, fluorouracil and trastuzumab were given for 6 cycles, after which trastuzumab monotherapy should be continued in patients who are responding to treatment)",
                    "dose": "6 mg/kg (subsequent doses)",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Trastuzumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (in the clinical trial cisplatin, fluorouracil and trastuzumab were given for 6 cycles, after which trastuzumab monotherapy should be continued in patients who are responding to treatment)",
                    "dose": "8 mg/kg (loading dose only)",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (in the clinical trial cisplatin, fluorouracil and trastuzumab were given for 6 cycles, after which trastuzumab monotherapy should be continued in patients who are responding to treatment)",
                    "dose": "80 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (in the clinical trial cisplatin, fluorouracil and trastuzumab were given for 6 cycles, after which trastuzumab monotherapy should be continued in patients who are responding to treatment)",
                    "dose": "4,000 mg/m2 (equivalent to 1000 mg/m2/day)",
                    "day": "1",
                    "route": "CIV via pump over 96 hours*"
                }
            ],
            [
                {
                    "drug_name": "Trastuzumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (in the clinical trial cisplatin, fluorouracil and trastuzumab were given for 6 cycles, after which trastuzumab monotherapy should be continued in patients who are responding to treatment)",
                    "dose": "6 mg/kg (subsequent doses)",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (in the clinical trial cisplatin, fluorouracil and trastuzumab were given for 6 cycles, after which trastuzumab monotherapy should be continued in patients who are responding to treatment)",
                    "dose": "80 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (in the clinical trial cisplatin, fluorouracil and trastuzumab were given for 6 cycles, after which trastuzumab monotherapy should be continued in patients who are responding to treatment)",
                    "dose": "4,000 mg/m2 (equivalent to 1000 mg/m2/day)",
                    "day": "1",
                    "route": "CIV via pump over 96 hours*"
                }
            ],
            [
                {
                    "drug_name": "Trastuzumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (in the clinical trial cisplatin, fluorouracil and trastuzumab were given for 6 cycles, after which trastuzumab monotherapy should be continued in patients who are responding to treatment)",
                    "dose": "6 mg/kg (subsequent doses)",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "upper-gastrointestinal",
        "url": "https://www.eviq.org.au/medical-oncology/upper-gastrointestinal/gastric-and-oesophageal-metastatic/1217-gastric-and-gastroesophageal-metastatic-cispl"
    },
    {
        "protocol_id": "1706 v.5",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "DOCEtaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "75 mg/m2 *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "DOCEtaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "75 mg/m2 *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "upper-gastrointestinal",
        "url": "https://www.eviq.org.au/medical-oncology/upper-gastrointestinal/gastric-and-oesophageal-metastatic/1706-gastric-and-gastroesophageal-metastatic-docet"
    },
    {
        "protocol_id": "1731 v.7",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Oxaliplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (up to 12 cycles)",
                    "dose": "85 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Calcium folinate (Leucovorin)",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (up to 12 cycles)",
                    "dose": "50 mg *",
                    "day": "1",
                    "route": "IV bolus"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (up to 12 cycles)",
                    "dose": "400 mg/m2 *",
                    "day": "1",
                    "route": "IV"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (up to 12 cycles)",
                    "dose": "2,400 mg/m2 *",
                    "day": "1",
                    "route": "CIV via pump over 46 hours"
                }
            ],
            [
                {
                    "drug_name": "Oxaliplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (up to 12 cycles)",
                    "dose": "85 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Calcium folinate (Leucovorin)",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (up to 12 cycles)",
                    "dose": "50 mg *",
                    "day": "1",
                    "route": "IV bolus"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (up to 12 cycles)",
                    "dose": "400 mg/m2 *",
                    "day": "1",
                    "route": "IV"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (up to 12 cycles)",
                    "dose": "2,400 mg/m2 *",
                    "day": "1",
                    "route": "CIV via pump over 46 hours"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "upper-gastrointestinal",
        "url": "https://www.eviq.org.au/medical-oncology/upper-gastrointestinal/gastric-and-oesophageal-metastatic/1731-gastric-and-gastroesophageal-metastatic-folfo"
    },
    {
        "protocol_id": "4068 v.3",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Nivolumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "52(12 cycles with chemotherapy combination, followed by continuous treatment with nivolumab until disease progression or unacceptable toxicity for up to 2 years).",
                    "dose": "240 mg",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Oxaliplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "52(12 cycles with chemotherapy combination, followed by continuous treatment with nivolumab until disease progression or unacceptable toxicity for up to 2 years).",
                    "dose": "85 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Calcium folinate (Leucovorin)",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "52(12 cycles with chemotherapy combination, followed by continuous treatment with nivolumab until disease progression or unacceptable toxicity for up to 2 years).",
                    "dose": "50 mg *",
                    "day": "1",
                    "route": "IV bolus"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "52(12 cycles with chemotherapy combination, followed by continuous treatment with nivolumab until disease progression or unacceptable toxicity for up to 2 years).",
                    "dose": "400 mg/m2 **",
                    "day": "1",
                    "route": "IV"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "52(12 cycles with chemotherapy combination, followed by continuous treatment with nivolumab until disease progression or unacceptable toxicity for up to 2 years).",
                    "dose": "2,400 mg/m2 **",
                    "day": "1",
                    "route": "CIV via pump over 46 hours"
                }
            ],
            [
                {
                    "drug_name": "Nivolumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "52(12 cycles with chemotherapy combination, followed by continuous treatment with nivolumab until disease progression or unacceptable toxicity for up to 2 years).",
                    "dose": "240 mg ****",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Nivolumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "52(12 cycles with chemotherapy combination, followed by continuous treatment with nivolumab until disease progression or unacceptable toxicity for up to 2 years).",
                    "dose": "240 mg",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Oxaliplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "52(12 cycles with chemotherapy combination, followed by continuous treatment with nivolumab until disease progression or unacceptable toxicity for up to 2 years).",
                    "dose": "85 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Calcium folinate (Leucovorin)",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "52(12 cycles with chemotherapy combination, followed by continuous treatment with nivolumab until disease progression or unacceptable toxicity for up to 2 years).",
                    "dose": "50 mg *",
                    "day": "1",
                    "route": "IV bolus"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "52(12 cycles with chemotherapy combination, followed by continuous treatment with nivolumab until disease progression or unacceptable toxicity for up to 2 years).",
                    "dose": "400 mg/m2 **",
                    "day": "1",
                    "route": "IV"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "52(12 cycles with chemotherapy combination, followed by continuous treatment with nivolumab until disease progression or unacceptable toxicity for up to 2 years).",
                    "dose": "2,400 mg/m2 **",
                    "day": "1",
                    "route": "CIV via pump over 46 hours"
                }
            ],
            [
                {
                    "drug_name": "Nivolumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "52(12 cycles with chemotherapy combination, followed by continuous treatment with nivolumab until disease progression or unacceptable toxicity for up to 2 years).",
                    "dose": "240 mg ****",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "upper-gastrointestinal",
        "url": "https://www.eviq.org.au/medical-oncology/upper-gastrointestinal/gastric-and-oesophageal-metastatic/4068-gastric-and-gastroesophageal-metastatic-folfo"
    },
    {
        "protocol_id": "3805 v.4",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Trastuzumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (up to 12 cycles). Consider continuation of trastuzumab monotherapy in patients who are responding to treatment.",
                    "dose": "6 mg/kg (loading dose only)",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Oxaliplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (up to 12 cycles). Consider continuation of trastuzumab monotherapy in patients who are responding to treatment.",
                    "dose": "85 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Calcium folinate (Leucovorin)",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (up to 12 cycles). Consider continuation of trastuzumab monotherapy in patients who are responding to treatment.",
                    "dose": "50 mg *",
                    "day": "1",
                    "route": "IV bolus"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (up to 12 cycles). Consider continuation of trastuzumab monotherapy in patients who are responding to treatment.",
                    "dose": "400 mg/m2",
                    "day": "1",
                    "route": "IV"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (up to 12 cycles). Consider continuation of trastuzumab monotherapy in patients who are responding to treatment.",
                    "dose": "2,400 mg/m2",
                    "day": "1",
                    "route": "CIV via pump over 46 hours"
                }
            ],
            [
                {
                    "drug_name": "Trastuzumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (up to 12 cycles). Consider continuation of trastuzumab monotherapy in patients who are responding to treatment.",
                    "dose": "4 mg/kg (subsequent doses)",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Oxaliplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (up to 12 cycles). Consider continuation of trastuzumab monotherapy in patients who are responding to treatment.",
                    "dose": "85 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Calcium folinate (Leucovorin)",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (up to 12 cycles). Consider continuation of trastuzumab monotherapy in patients who are responding to treatment.",
                    "dose": "50 mg *",
                    "day": "1",
                    "route": "IV bolus"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (up to 12 cycles). Consider continuation of trastuzumab monotherapy in patients who are responding to treatment.",
                    "dose": "400 mg/m2",
                    "day": "1",
                    "route": "IV"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (up to 12 cycles). Consider continuation of trastuzumab monotherapy in patients who are responding to treatment.",
                    "dose": "2,400 mg/m2",
                    "day": "1",
                    "route": "CIV via pump over 46 hours"
                }
            ],
            [
                {
                    "drug_name": "Trastuzumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (up to 12 cycles). Consider continuation of trastuzumab monotherapy in patients who are responding to treatment.",
                    "dose": "6 mg/kg (loading dose only)",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Oxaliplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (up to 12 cycles). Consider continuation of trastuzumab monotherapy in patients who are responding to treatment.",
                    "dose": "85 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Calcium folinate (Leucovorin)",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (up to 12 cycles). Consider continuation of trastuzumab monotherapy in patients who are responding to treatment.",
                    "dose": "50 mg *",
                    "day": "1",
                    "route": "IV bolus"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (up to 12 cycles). Consider continuation of trastuzumab monotherapy in patients who are responding to treatment.",
                    "dose": "400 mg/m2",
                    "day": "1",
                    "route": "IV"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (up to 12 cycles). Consider continuation of trastuzumab monotherapy in patients who are responding to treatment.",
                    "dose": "2,400 mg/m2",
                    "day": "1",
                    "route": "CIV via pump over 46 hours"
                }
            ],
            [
                {
                    "drug_name": "Trastuzumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (up to 12 cycles). Consider continuation of trastuzumab monotherapy in patients who are responding to treatment.",
                    "dose": "4 mg/kg (subsequent doses)",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Oxaliplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (up to 12 cycles). Consider continuation of trastuzumab monotherapy in patients who are responding to treatment.",
                    "dose": "85 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Calcium folinate (Leucovorin)",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (up to 12 cycles). Consider continuation of trastuzumab monotherapy in patients who are responding to treatment.",
                    "dose": "50 mg *",
                    "day": "1",
                    "route": "IV bolus"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (up to 12 cycles). Consider continuation of trastuzumab monotherapy in patients who are responding to treatment.",
                    "dose": "400 mg/m2",
                    "day": "1",
                    "route": "IV"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (up to 12 cycles). Consider continuation of trastuzumab monotherapy in patients who are responding to treatment.",
                    "dose": "2,400 mg/m2",
                    "day": "1",
                    "route": "CIV via pump over 46 hours"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "upper-gastrointestinal",
        "url": "https://www.eviq.org.au/medical-oncology/upper-gastrointestinal/gastric-and-oesophageal-metastatic/3805-gastric-and-gastroesophageal-metastatic-folfo"
    },
    {
        "protocol_id": "1705 v.5",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Irinotecan",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "150 mg/m2 *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Irinotecan",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "150 mg/m2 *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "upper-gastrointestinal",
        "url": "https://www.eviq.org.au/medical-oncology/upper-gastrointestinal/gastric-and-oesophageal-metastatic/1705-gastric-and-gastroesophageal-metastatic-irino"
    },
    {
        "protocol_id": "1904 v.6",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "raMUCIRumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "8 mg/kg",
                    "day": "1 and 15",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "PACLitaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "80 mg/m2",
                    "day": "1, 8, 15",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "raMUCIRumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "8 mg/kg",
                    "day": "1 and 15",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "PACLitaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "80 mg/m2",
                    "day": "1, 8, 15",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "upper-gastrointestinal",
        "url": "https://www.eviq.org.au/medical-oncology/upper-gastrointestinal/gastric-and-oesophageal-metastatic/1904-gastric-and-gastroesophageal-metastatic-pacli"
    },
    {
        "protocol_id": "1730 v.7",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "PACLitaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "80 mg/m2",
                    "day": "1, 8, 15",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "PACLitaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "80 mg/m2",
                    "day": "1, 8, 15",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "upper-gastrointestinal",
        "url": "https://www.eviq.org.au/medical-oncology/upper-gastrointestinal/gastric-and-oesophageal-metastatic/1730-gastric-and-gastroesophageal-metastatic-pacli"
    },
    {
        "protocol_id": "1903 v.3",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "raMUCIRumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "8 mg/kg",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "raMUCIRumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "8 mg/kg",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "upper-gastrointestinal",
        "url": "https://www.eviq.org.au/medical-oncology/upper-gastrointestinal/gastric-and-oesophageal-metastatic/1903-gastric-and-gastroesophageal-metastatic-ramuc"
    },
    {
        "protocol_id": "1214 v.5",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6or until disease progression or unacceptable toxicity",
                    "dose": "80 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Capecitabine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6or until disease progression or unacceptable toxicity",
                    "dose": "1,000 mg/m2 TWICE a day *",
                    "day": "1 to 14",
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6or until disease progression or unacceptable toxicity",
                    "dose": "80 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Capecitabine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6or until disease progression or unacceptable toxicity",
                    "dose": "1,000 mg/m2 TWICE a day *",
                    "day": "1 to 14",
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "upper-gastrointestinal",
        "url": "https://www.eviq.org.au/medical-oncology/upper-gastrointestinal/gastric-and-oesophageal-metastatic/1214-gastric-and-oesophageal-metastatic-cisplatin"
    },
    {
        "protocol_id": "701 v.5",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6or until disease progression or unacceptable toxicity",
                    "dose": "80 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6or until disease progression or unacceptable toxicity",
                    "dose": "4,000 mg/m2 (equivalent to 1000 mg/m\u00b2/day)",
                    "day": "1",
                    "route": "CIV via pump over 96 hours"
                }
            ],
            [
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6or until disease progression or unacceptable toxicity",
                    "dose": "80 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6or until disease progression or unacceptable toxicity",
                    "dose": "4,000 mg/m2 (equivalent to 1000 mg/m\u00b2/day)",
                    "day": "1",
                    "route": "CIV via pump over 96 hours"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "upper-gastrointestinal",
        "url": "https://www.eviq.org.au/medical-oncology/upper-gastrointestinal/gastric-and-oesophageal-metastatic/701-gastric-and-oesophageal-metastatic-cisplatin-a"
    },
    {
        "protocol_id": "4325 v.1",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Pembrolizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "35 or until disease progression or unacceptable toxicity (total maximum of 35 doses or 24 months treatment with pembrolizumab)",
                    "dose": "200 mg",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "35 or until disease progression or unacceptable toxicity (total maximum of 35 doses or 24 months treatment with pembrolizumab)",
                    "dose": "80 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "35 or until disease progression or unacceptable toxicity (total maximum of 35 doses or 24 months treatment with pembrolizumab)",
                    "dose": "4,000 mg/m2 (equivalent to 800 mg/m2/day)",
                    "day": "1",
                    "route": "CIV via pump over 120 hours"
                }
            ],
            [
                {
                    "drug_name": "Pembrolizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "35 or until disease progression or unacceptable toxicity (total maximum of 35 doses or 24 months treatment with pembrolizumab)",
                    "dose": "200 mg",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "35 or until disease progression or unacceptable toxicity (total maximum of 35 doses or 24 months treatment with pembrolizumab)",
                    "dose": "4,000 mg/m2 (equivalent to 800 mg/m2/day)",
                    "day": "1",
                    "route": "CIV via pump over 120 hours"
                }
            ],
            [
                {
                    "drug_name": "Pembrolizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "35 or until disease progression or unacceptable toxicity (total maximum of 35 doses or 24 months treatment with pembrolizumab)",
                    "dose": "200 mg",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "35 or until disease progression or unacceptable toxicity (total maximum of 35 doses or 24 months treatment with pembrolizumab)",
                    "dose": "80 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "35 or until disease progression or unacceptable toxicity (total maximum of 35 doses or 24 months treatment with pembrolizumab)",
                    "dose": "4,000 mg/m2 (equivalent to 800 mg/m2/day)",
                    "day": "1",
                    "route": "CIV via pump over 120 hours"
                }
            ],
            [
                {
                    "drug_name": "Pembrolizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "35 or until disease progression or unacceptable toxicity (total maximum of 35 doses or 24 months treatment with pembrolizumab)",
                    "dose": "200 mg",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "35 or until disease progression or unacceptable toxicity (total maximum of 35 doses or 24 months treatment with pembrolizumab)",
                    "dose": "4,000 mg/m2 (equivalent to 800 mg/m2/day)",
                    "day": "1",
                    "route": "CIV via pump over 120 hours"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "upper-gastrointestinal",
        "url": "https://www.eviq.org.au/medical-oncology/upper-gastrointestinal/gastric-and-oesophageal-metastatic/4325-gastroesophageal-and-oesophageal-metastatic-c"
    },
    {
        "protocol_id": "3806 v.2",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Trifluridine/tipiracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "35 mg/m2 TWICE a day *\n                            \n                                (Cap dose at 80 mg)",
                    "day": "1 to 5 and 8 to 12",
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Trifluridine/tipiracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "35 mg/m2 TWICE a day *\n                            \n                                (Cap dose at 80 mg)",
                    "day": "1 to 5 and 8 to 12",
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "upper-gastrointestinal",
        "url": "https://www.eviq.org.au/medical-oncology/upper-gastrointestinal/gastric-and-oesophageal-metastatic/3806-metastatic-trifluridine-tipiracil"
    },
    {
        "protocol_id": "4385 v.1",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Nivolumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity. Cisplatin and fluorouracil usually 6 cycles. Nivolumab was continued for 24 months in CheckMate 648 trial.",
                    "dose": "240 mg *",
                    "day": "1 and 15",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity. Cisplatin and fluorouracil usually 6 cycles. Nivolumab was continued for 24 months in CheckMate 648 trial.",
                    "dose": "80 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity. Cisplatin and fluorouracil usually 6 cycles. Nivolumab was continued for 24 months in CheckMate 648 trial.",
                    "dose": "4,000 mg/m2 (equivalent to 800 mg/m2/day)",
                    "day": "1",
                    "route": "CIV via pump over 120 hours"
                }
            ],
            [
                {
                    "drug_name": "Nivolumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity. Cisplatin and fluorouracil usually 6 cycles. Nivolumab was continued for 24 months in CheckMate 648 trial.",
                    "dose": "240 mg *",
                    "day": "1 and 15",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity. Cisplatin and fluorouracil usually 6 cycles. Nivolumab was continued for 24 months in CheckMate 648 trial.",
                    "dose": "80 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity. Cisplatin and fluorouracil usually 6 cycles. Nivolumab was continued for 24 months in CheckMate 648 trial.",
                    "dose": "4,000 mg/m2 (equivalent to 800 mg/m2/day)",
                    "day": "1",
                    "route": "CIV via pump over 120 hours"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "upper-gastrointestinal",
        "url": "https://www.eviq.org.au/medical-oncology/upper-gastrointestinal/gastric-and-oesophageal-metastatic/4385-oesophageal-metastatic-cisplatin-fluorouracil"
    },
    {
        "protocol_id": "327 v.4",
        "protocol_status": "Discontinued",
        "drug_sequence": [],
        "section_name": "medical-oncology",
        "category_name": "upper-gastrointestinal",
        "url": "https://www.eviq.org.au/medical-oncology/upper-gastrointestinal/gastric-and-oesophageal-metastatic/327-gastric-and-oesophageal-metastatic-ecf-epirub"
    },
    {
        "protocol_id": "526 v.4",
        "protocol_status": "Discontinued",
        "drug_sequence": [],
        "section_name": "medical-oncology",
        "category_name": "upper-gastrointestinal",
        "url": "https://www.eviq.org.au/medical-oncology/upper-gastrointestinal/gastric-and-oesophageal-metastatic/526-gastric-and-oesophageal-metastatic-ecx-epirub"
    },
    {
        "protocol_id": "1631 v.3",
        "protocol_status": "Discontinued",
        "drug_sequence": [],
        "section_name": "medical-oncology",
        "category_name": "upper-gastrointestinal",
        "url": "https://www.eviq.org.au/medical-oncology/upper-gastrointestinal/gastric-and-oesophageal-metastatic/1631-gastric-and-oesophageal-metastatic-eof-epiru"
    },
    {
        "protocol_id": "528 v.5",
        "protocol_status": "Discontinued",
        "drug_sequence": [],
        "section_name": "medical-oncology",
        "category_name": "upper-gastrointestinal",
        "url": "https://www.eviq.org.au/medical-oncology/upper-gastrointestinal/gastric-and-oesophageal-metastatic/528-gastric-and-oesophageal-metastatic-eox-epirub"
    },
    {
        "protocol_id": "1222 v.7",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Imatinib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "400 mg ONCE a day",
                    "day": null,
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Imatinib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "400 mg ONCE a day",
                    "day": null,
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "upper-gastrointestinal",
        "url": "https://www.eviq.org.au/medical-oncology/upper-gastrointestinal/gastrointestinal-stromal-cell-tumours/1222-gastrointestinal-stromal-cell-tumour-gist-a"
    },
    {
        "protocol_id": "330 v.7",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Imatinib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "400 mg ONCE a day",
                    "day": null,
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Imatinib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "400 mg ONCE a day",
                    "day": null,
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "upper-gastrointestinal",
        "url": "https://www.eviq.org.au/medical-oncology/upper-gastrointestinal/gastrointestinal-stromal-cell-tumours/330-gastrointestinal-stromal-cell-tumour-gist-me"
    },
    {
        "protocol_id": "1902 v.3",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Regorafenib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "160 mg ONCE a day *",
                    "day": "1 to 21 **",
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Regorafenib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "160 mg ONCE a day *",
                    "day": "1 to 21 **",
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "upper-gastrointestinal",
        "url": "https://www.eviq.org.au/medical-oncology/upper-gastrointestinal/gastrointestinal-stromal-cell-tumours/1902-gastrointestinal-stromal-cell-tumour-gist-m"
    },
    {
        "protocol_id": "4112 v.3",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Ripretinib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "150 mg ONCE a day *",
                    "day": null,
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Ripretinib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "150 mg ONCE a day *",
                    "day": null,
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "upper-gastrointestinal",
        "url": "https://www.eviq.org.au/medical-oncology/upper-gastrointestinal/gastrointestinal-stromal-cell-tumours/4112-gastrointestinal-stromal-cell-tumour-gist-m"
    },
    {
        "protocol_id": "329 v.7",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "sUNITinib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "42 days(sunitinib is taken daily for 4 weeks then 2 weeks break)",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "50 mg *",
                    "day": "1 to 28",
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "sUNITinib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "42 days(sunitinib is taken daily for 4 weeks then 2 weeks break)",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "50 mg *",
                    "day": "1 to 28",
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "upper-gastrointestinal",
        "url": "https://www.eviq.org.au/medical-oncology/upper-gastrointestinal/gastrointestinal-stromal-cell-tumours/329-gastrointestinal-stromal-cell-tumour-gist-me"
    },
    {
        "protocol_id": "3594 v.8",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Nivolumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "480 mg * #",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Nivolumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "480 mg * #",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "upper-gastrointestinal",
        "url": "https://www.eviq.org.au/medical-oncology/upper-gastrointestinal/hepatic/3807-redirect-id-3594"
    },
    {
        "protocol_id": "3555 v.9",
        "protocol_status": "Superseded",
        "drug_sequence": [
            [
                {
                    "drug_name": "Nivolumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "3 mg/kg",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Nivolumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "3 mg/kg",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "upper-gastrointestinal",
        "url": "https://www.eviq.org.au/medical-oncology/upper-gastrointestinal/hepatic/3799-redirect-id-3555"
    },
    {
        "protocol_id": "3881 v.5",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Atezolizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "1,200 mg",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "beVACizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "15 mg/kg *#",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Atezolizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "1,200 mg",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "beVACizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "15 mg/kg *#",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "upper-gastrointestinal",
        "url": "https://www.eviq.org.au/medical-oncology/upper-gastrointestinal/hepatic/3881-hcc-advanced-or-metastatic-atezolizumab-and-b"
    },
    {
        "protocol_id": "3603 v.2",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "leNVAtinib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "12 mg ONCE a day",
                    "day": null,
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "leNVAtinib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "12 mg ONCE a day",
                    "day": null,
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "upper-gastrointestinal",
        "url": "https://www.eviq.org.au/medical-oncology/upper-gastrointestinal/hepatic/3603-hepatic-advanced-or-metastatic-lenvatinib"
    },
    {
        "protocol_id": "92 v.5",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "soRAFENib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "400 mg TWICE a day",
                    "day": null,
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "soRAFENib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "400 mg TWICE a day",
                    "day": null,
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "upper-gastrointestinal",
        "url": "https://www.eviq.org.au/medical-oncology/upper-gastrointestinal/hepatic/92-hepatic-advanced-sorafenib"
    },
    {
        "protocol_id": "1784 v.6",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Capecitabine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "750 mg/m2 TWICE a day *\n                            \n                                (Cap dose at 2500 mg/day)",
                    "day": "1 to 14",
                    "route": "PO"
                },
                {
                    "drug_name": "Temozolomide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "100 mg/m2 TWICE a day * #",
                    "day": "10 to 14",
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Capecitabine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "750 mg/m2 TWICE a day *\n                            \n                                (Cap dose at 2500 mg/day)",
                    "day": "1 to 14",
                    "route": "PO"
                },
                {
                    "drug_name": "Temozolomide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "100 mg/m2 TWICE a day * #",
                    "day": "10 to 14",
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "upper-gastrointestinal",
        "url": "https://www.eviq.org.au/medical-oncology/upper-gastrointestinal/neuroendocrine/1784-neuroendocrine-advanced-capecitabine-and-temo"
    },
    {
        "protocol_id": "1549 v.7",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6or until disease progression or unacceptable toxicity",
                    "dose": "5 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Etoposide **",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6or until disease progression or unacceptable toxicity",
                    "dose": "100 mg/m2",
                    "day": "1 to 3",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6or until disease progression or unacceptable toxicity",
                    "dose": "5 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Etoposide **",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6or until disease progression or unacceptable toxicity",
                    "dose": "100 mg/m2",
                    "day": "1 to 3",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "upper-gastrointestinal",
        "url": "https://www.eviq.org.au/medical-oncology/upper-gastrointestinal/neuroendocrine/1549-neuroendocrine-advanced-carboplatin-and-etopo"
    },
    {
        "protocol_id": "1220 v.6",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6or until disease progression or unacceptable toxicity",
                    "dose": "80 mg/m2 *",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Etoposide **",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6or until disease progression or unacceptable toxicity",
                    "dose": "100 mg/m2",
                    "day": "1 to 3",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6or until disease progression or unacceptable toxicity",
                    "dose": "80 mg/m2 *",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Etoposide **",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6or until disease progression or unacceptable toxicity",
                    "dose": "100 mg/m2",
                    "day": "1 to 3",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "upper-gastrointestinal",
        "url": "https://www.eviq.org.au/medical-oncology/upper-gastrointestinal/neuroendocrine/1220-neuroendocrine-advanced-cisplatin-and-etoposi"
    },
    {
        "protocol_id": "3841 v.3",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Lanreotide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous as clinically indicated and/or until disease progression or unacceptable toxicity",
                    "dose": "120 mg",
                    "day": "1",
                    "route": "Subcut"
                }
            ],
            [
                {
                    "drug_name": "Lanreotide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous as clinically indicated and/or until disease progression or unacceptable toxicity",
                    "dose": "120 mg",
                    "day": "1",
                    "route": "Subcut"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "upper-gastrointestinal",
        "url": "https://www.eviq.org.au/medical-oncology/upper-gastrointestinal/neuroendocrine/3841-neuroendocrine-advanced-lanreotide"
    },
    {
        "protocol_id": "706 v.7",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Octreotide (modified release) *",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous as clinically indicated and/or until disease progression or unacceptable toxicity",
                    "dose": "30 mg",
                    "day": "1",
                    "route": "IM"
                }
            ],
            [
                {
                    "drug_name": "Octreotide (modified release) *",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous as clinically indicated and/or until disease progression or unacceptable toxicity",
                    "dose": "30 mg",
                    "day": "1",
                    "route": "IM"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "upper-gastrointestinal",
        "url": "https://www.eviq.org.au/medical-oncology/upper-gastrointestinal/neuroendocrine/706-neuroendocrine-advanced-octreotide"
    },
    {
        "protocol_id": "3636 v.2",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Telotristat ethyl",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "250 mg THREE times a day",
                    "day": null,
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Telotristat ethyl",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "250 mg THREE times a day",
                    "day": null,
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "upper-gastrointestinal",
        "url": "https://www.eviq.org.au/medical-oncology/upper-gastrointestinal/neuroendocrine/3636-neuroendocrine-advanced-telotristat-ethyl"
    },
    {
        "protocol_id": "1543 v.5",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Everolimus",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "10 mg ONCE a day",
                    "day": null,
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Everolimus",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "10 mg ONCE a day",
                    "day": null,
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "upper-gastrointestinal",
        "url": "https://www.eviq.org.au/medical-oncology/upper-gastrointestinal/neuroendocrine/1543-neuroendocrine-pancreatic-advanced-everolimus"
    },
    {
        "protocol_id": "1221 v.7",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "sUNITinib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "37.5 mg ONCE a day *",
                    "day": null,
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "sUNITinib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "37.5 mg ONCE a day *",
                    "day": null,
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "upper-gastrointestinal",
        "url": "https://www.eviq.org.au/medical-oncology/upper-gastrointestinal/neuroendocrine/1221-neuroendocrine-pancreatic-advanced-sunitinib"
    },
    {
        "protocol_id": "774 v.6",
        "protocol_status": "Discontinued",
        "drug_sequence": [],
        "section_name": "medical-oncology",
        "category_name": "upper-gastrointestinal",
        "url": "https://www.eviq.org.au/medical-oncology/upper-gastrointestinal/neuroendocrine/774-neuroendocrine-advanced-lanreotide-90-mg-disco"
    },
    {
        "protocol_id": "4043 v.2",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Irinotecan",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "180 mg/m2 *",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Calcium folinate (Leucovorin)",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "50 mg **",
                    "day": "1",
                    "route": "IV bolus"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "400 mg/m2",
                    "day": "1",
                    "route": "IV"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "2,400 mg/m2",
                    "day": "1",
                    "route": "CIV via pump over 46 hours"
                }
            ],
            [
                {
                    "drug_name": "Irinotecan",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "180 mg/m2 *",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Calcium folinate (Leucovorin)",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "50 mg **",
                    "day": "1",
                    "route": "IV bolus"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "400 mg/m2",
                    "day": "1",
                    "route": "IV"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "2,400 mg/m2",
                    "day": "1",
                    "route": "CIV via pump over 46 hours"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "upper-gastrointestinal",
        "url": "https://www.eviq.org.au/medical-oncology/upper-gastrointestinal/pancreas-and-biliary/3386-redirect-id-4043"
    },
    {
        "protocol_id": "3385 v.6",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Capecitabine",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "8",
                    "dose": "1,250 mg/m2 TWICE a day *",
                    "day": "1 to 14",
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Capecitabine",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "8",
                    "dose": "1,250 mg/m2 TWICE a day *",
                    "day": "1 to 14",
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "upper-gastrointestinal",
        "url": "https://www.eviq.org.au/medical-oncology/upper-gastrointestinal/pancreas-and-biliary/3385-biliary-and-gallbladder-adjuvant-capecitabine"
    },
    {
        "protocol_id": "699 v.6",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Gemcitabine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "1,000 mg/m2",
                    "day": "1 and 8",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "5 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Gemcitabine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "1,000 mg/m2",
                    "day": "1 and 8",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "5 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "upper-gastrointestinal",
        "url": "https://www.eviq.org.au/medical-oncology/upper-gastrointestinal/pancreas-and-biliary/699-biliary-and-gallbladder-advanced-carboplatin-a"
    },
    {
        "protocol_id": "1200 v.5",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Gemcitabine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (maximum 8 cycles)",
                    "dose": "1,000 mg/m2",
                    "day": "1 and 8",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (maximum 8 cycles)",
                    "dose": "25 mg/m2",
                    "day": "1 and 8",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Gemcitabine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (maximum 8 cycles)",
                    "dose": "1,000 mg/m2",
                    "day": "1 and 8",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (maximum 8 cycles)",
                    "dose": "25 mg/m2",
                    "day": "1 and 8",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "upper-gastrointestinal",
        "url": "https://www.eviq.org.au/medical-oncology/upper-gastrointestinal/pancreas-and-biliary/1200-biliary-and-gallbladder-advanced-cisplatin-an"
    },
    {
        "protocol_id": "4301 v.2",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Durvalumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "8 (up to a maximum of 8 cycles)",
                    "dose": "1,500 mg",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Gemcitabine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "8 (up to a maximum of 8 cycles)",
                    "dose": "1,000 mg/m2",
                    "day": "1 and 8",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "8 (up to a maximum of 8 cycles)",
                    "dose": "25 mg/m2",
                    "day": "1 and 8",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Durvalumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "8 (up to a maximum of 8 cycles)",
                    "dose": "1,500 mg",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Gemcitabine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "8 (up to a maximum of 8 cycles)",
                    "dose": "1,000 mg/m2",
                    "day": "1 and 8",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "8 (up to a maximum of 8 cycles)",
                    "dose": "25 mg/m2",
                    "day": "1 and 8",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "upper-gastrointestinal",
        "url": "https://www.eviq.org.au/medical-oncology/upper-gastrointestinal/pancreas-and-biliary/4301-biliary-and-gallbladder-advanced-cisplatin-g"
    },
    {
        "protocol_id": "3875 v.4",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Oxaliplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (up to 12 cycles)",
                    "dose": "85 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Calcium folinate (Leucovorin)",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (up to 12 cycles)",
                    "dose": "50 mg *",
                    "day": "1",
                    "route": "IV bolus"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (up to 12 cycles)",
                    "dose": "400 mg/m2",
                    "day": "1",
                    "route": "IV"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (up to 12 cycles)",
                    "dose": "2,400 mg/m2",
                    "day": "1",
                    "route": "CIV via pump over 46 hours"
                }
            ],
            [
                {
                    "drug_name": "Oxaliplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (up to 12 cycles)",
                    "dose": "85 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Calcium folinate (Leucovorin)",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (up to 12 cycles)",
                    "dose": "50 mg *",
                    "day": "1",
                    "route": "IV bolus"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (up to 12 cycles)",
                    "dose": "400 mg/m2",
                    "day": "1",
                    "route": "IV"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (up to 12 cycles)",
                    "dose": "2,400 mg/m2",
                    "day": "1",
                    "route": "CIV via pump over 46 hours"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "upper-gastrointestinal",
        "url": "https://www.eviq.org.au/medical-oncology/upper-gastrointestinal/pancreas-and-biliary/3875-biliary-and-gallbladder-advanced-folfox6-mod"
    },
    {
        "protocol_id": "700 v.5",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Gemcitabine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "1,000 mg/m2",
                    "day": "1, 8, 15",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Gemcitabine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "1,000 mg/m2",
                    "day": "1, 8, 15",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "upper-gastrointestinal",
        "url": "https://www.eviq.org.au/medical-oncology/upper-gastrointestinal/pancreas-and-biliary/700-biliary-and-gallbladder-advanced-gemcitabine"
    },
    {
        "protocol_id": "4387 v.1",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Pemigatinib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continue until disease progression or unacceptable toxicity",
                    "dose": "13.5 mg",
                    "day": "1 to 14 *",
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Pemigatinib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continue until disease progression or unacceptable toxicity",
                    "dose": "13.5 mg",
                    "day": "1 to 14 *",
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "upper-gastrointestinal",
        "url": "https://www.eviq.org.au/medical-oncology/upper-gastrointestinal/pancreas-and-biliary/4387-biliary-and-gallbladder-advanced-pemigatinib"
    },
    {
        "protocol_id": "1945 v.6",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Gemcitabine",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "6",
                    "dose": "1,000 mg/m2",
                    "day": "1, 8, 15",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Capecitabine",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "6",
                    "dose": "830 mg/m2 TWICE a day",
                    "day": "1 to 21 *",
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Gemcitabine",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "6",
                    "dose": "1,000 mg/m2",
                    "day": "1, 8, 15",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Capecitabine",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "6",
                    "dose": "830 mg/m2 TWICE a day",
                    "day": "1 to 21 *",
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "upper-gastrointestinal",
        "url": "https://www.eviq.org.au/medical-oncology/upper-gastrointestinal/pancreas-and-biliary/1945-pancreas-adjuvant-capecitabine-and-gemcitabin"
    },
    {
        "protocol_id": "3521 v.6",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Oxaliplatin",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "12",
                    "dose": "85 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Irinotecan",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "12",
                    "dose": "150 mg/m2 ^",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Calcium folinate (Leucovorin)",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "12",
                    "dose": "50 mg *",
                    "day": "1",
                    "route": "IV bolus"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "12",
                    "dose": "2,400 mg/m2",
                    "day": "1",
                    "route": "CIV via pump over 46 hours"
                },
                {
                    "drug_name": "Pegfilgrastim",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "12",
                    "dose": "6 mg",
                    "day": "4",
                    "route": "Subcut"
                }
            ],
            [
                {
                    "drug_name": "Oxaliplatin",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "12",
                    "dose": "85 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Irinotecan",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "12",
                    "dose": "150 mg/m2 ^",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Calcium folinate (Leucovorin)",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "12",
                    "dose": "50 mg *",
                    "day": "1",
                    "route": "IV bolus"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "12",
                    "dose": "2,400 mg/m2",
                    "day": "1",
                    "route": "CIV via pump over 46 hours"
                },
                {
                    "drug_name": "Pegfilgrastim",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "12",
                    "dose": "6 mg",
                    "day": "4",
                    "route": "Subcut"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "upper-gastrointestinal",
        "url": "https://www.eviq.org.au/medical-oncology/upper-gastrointestinal/pancreas-and-biliary/3521-pancreas-adjuvant-folfirinox-modified-fluo"
    },
    {
        "protocol_id": "1218 v.7",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Gemcitabine",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "6",
                    "dose": "1,000 mg/m2",
                    "day": "1, 8, 15",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Gemcitabine",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "6",
                    "dose": "1,000 mg/m2",
                    "day": "1, 8, 15",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "upper-gastrointestinal",
        "url": "https://www.eviq.org.au/medical-oncology/upper-gastrointestinal/pancreas-and-biliary/1218-pancreas-adjuvant-gemcitabine"
    },
    {
        "protocol_id": "1757 v.6",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Capecitabine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "7 days",
                    "cycles": "with concurrent radiation therapy (usually 5 to 6 weeks)",
                    "dose": "830 mg/m2 TWICE a day *",
                    "day": "1 to 5",
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Capecitabine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "7 days",
                    "cycles": "with concurrent radiation therapy (usually 5 to 6 weeks)",
                    "dose": "830 mg/m2 TWICE a day *",
                    "day": "1 to 5",
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "upper-gastrointestinal",
        "url": "https://www.eviq.org.au/medical-oncology/upper-gastrointestinal/pancreas-and-biliary/1757-pancreas-advanced-capecitabine-chemoradiation"
    },
    {
        "protocol_id": "718 v.6",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "7 days",
                    "cycles": "with concurrent radiation therapy (usually 5 to 6 weeks)",
                    "dose": "1,575 mg/m2 (equivalent to 225 mg/m2/day) *",
                    "day": "1",
                    "route": "CIV over 7 days"
                }
            ],
            [
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "7 days",
                    "cycles": "with concurrent radiation therapy (usually 5 to 6 weeks)",
                    "dose": "1,575 mg/m2 (equivalent to 225 mg/m2/day) *",
                    "day": "1",
                    "route": "CIV over 7 days"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "upper-gastrointestinal",
        "url": "https://www.eviq.org.au/medical-oncology/upper-gastrointestinal/pancreas-and-biliary/718-pancreas-advanced-fluorouracil-chemoradiation"
    },
    {
        "protocol_id": "333 v.7",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Gemcitabine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "1,000 mg/m2",
                    "day": "1, 8, 15 *",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Gemcitabine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "1,000 mg/m2",
                    "day": "1, 8, 15 *",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "upper-gastrointestinal",
        "url": "https://www.eviq.org.au/medical-oncology/upper-gastrointestinal/pancreas-and-biliary/333-pancreas-advanced-gemcitabine"
    },
    {
        "protocol_id": "1512 v.6",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Oxaliplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (up to 12 cycles)",
                    "dose": "85 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Irinotecan",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (up to 12 cycles)",
                    "dose": "180 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Calcium folinate (Leucovorin)",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (up to 12 cycles)",
                    "dose": "50 mg *",
                    "day": "1",
                    "route": "IV bolus"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (up to 12 cycles)",
                    "dose": "400 mg/m2",
                    "day": "1",
                    "route": "IV"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (up to 12 cycles)",
                    "dose": "2,400 mg/m2",
                    "day": "1",
                    "route": "CIV via pump over 46 hours"
                }
            ],
            [
                {
                    "drug_name": "Oxaliplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (up to 12 cycles)",
                    "dose": "85 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Irinotecan",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (up to 12 cycles)",
                    "dose": "180 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Calcium folinate (Leucovorin)",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (up to 12 cycles)",
                    "dose": "50 mg *",
                    "day": "1",
                    "route": "IV bolus"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (up to 12 cycles)",
                    "dose": "400 mg/m2",
                    "day": "1",
                    "route": "IV"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (up to 12 cycles)",
                    "dose": "2,400 mg/m2",
                    "day": "1",
                    "route": "CIV via pump over 46 hours"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "upper-gastrointestinal",
        "url": "https://www.eviq.org.au/medical-oncology/upper-gastrointestinal/pancreas-and-biliary/1512-pancreas-metastatic-folfirinox-modified-fl"
    },
    {
        "protocol_id": "1375 v.4",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "nab-PACLitaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "125 mg/m2",
                    "day": "1, 8, 15",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Gemcitabine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "1,000 mg/m2",
                    "day": "1, 8, 15",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "nab-PACLitaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "125 mg/m2",
                    "day": "1, 8, 15",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Gemcitabine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "1,000 mg/m2",
                    "day": "1, 8, 15",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "upper-gastrointestinal",
        "url": "https://www.eviq.org.au/medical-oncology/upper-gastrointestinal/pancreas-and-biliary/1375-pancreas-metastatic-gemcitabine-and-nab-pacli"
    },
    {
        "protocol_id": "3387 v.3",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Irinotecan nanoliposomal",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "70 mg/m2 *",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Calcium folinate (Leucovorin)",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "50 mg **",
                    "day": "1",
                    "route": "IV bolus"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "2,400 mg/m2",
                    "day": "1",
                    "route": "CIV via pump over 46 hours"
                }
            ],
            [
                {
                    "drug_name": "Irinotecan nanoliposomal",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "70 mg/m2 *",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Calcium folinate (Leucovorin)",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "50 mg **",
                    "day": "1",
                    "route": "IV bolus"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "2,400 mg/m2",
                    "day": "1",
                    "route": "CIV via pump over 46 hours"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "upper-gastrointestinal",
        "url": "https://www.eviq.org.au/medical-oncology/upper-gastrointestinal/pancreas-and-biliary/3387-pancreas-metastatic-irinotecan-nanoliposomal"
    },
    {
        "protocol_id": "1548 v.5",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Calcium folinate (Leucovorin)",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "42 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "50 mg *",
                    "day": "1, 8, 15, 22",
                    "route": "IV bolus"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "42 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "2,000 mg/m2",
                    "day": "1, 8, 15, 22",
                    "route": "CIV via pump over 24 hours"
                },
                {
                    "drug_name": "Oxaliplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "42 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "85 mg/m2",
                    "day": "8 and 22",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Calcium folinate (Leucovorin)",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "42 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "50 mg *",
                    "day": "1, 8, 15, 22",
                    "route": "IV bolus"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "42 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "2,000 mg/m2",
                    "day": "1, 8, 15, 22",
                    "route": "CIV via pump over 24 hours"
                },
                {
                    "drug_name": "Oxaliplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "42 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "85 mg/m2",
                    "day": "8 and 22",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "upper-gastrointestinal",
        "url": "https://www.eviq.org.au/medical-oncology/upper-gastrointestinal/pancreas-and-biliary/1548-pancreas-metastatic-off-oxaliplatin-fluorour"
    },
    {
        "protocol_id": "4384 v.2",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Oxaliplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "14 days",
                    "cycles": "8(up to 12 cycles can be considered)",
                    "dose": "85 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Irinotecan",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "14 days",
                    "cycles": "8(up to 12 cycles can be considered)",
                    "dose": "150 mg/m2 *",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Calcium folinate (Leucovorin)",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "14 days",
                    "cycles": "8(up to 12 cycles can be considered)",
                    "dose": "50 mg **",
                    "day": "1",
                    "route": "IV bolus"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "14 days",
                    "cycles": "8(up to 12 cycles can be considered)",
                    "dose": "2,400 mg/m2",
                    "day": "1",
                    "route": "CIV via pump over 46 hours"
                },
                {
                    "drug_name": "Pegfilgrastim",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "14 days",
                    "cycles": "8(up to 12 cycles can be considered)",
                    "dose": "6 mg",
                    "day": "4",
                    "route": "Subcut"
                }
            ],
            [
                {
                    "drug_name": "Oxaliplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "14 days",
                    "cycles": "8(up to 12 cycles can be considered)",
                    "dose": "85 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Irinotecan",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "14 days",
                    "cycles": "8(up to 12 cycles can be considered)",
                    "dose": "150 mg/m2 *",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Calcium folinate (Leucovorin)",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "14 days",
                    "cycles": "8(up to 12 cycles can be considered)",
                    "dose": "50 mg **",
                    "day": "1",
                    "route": "IV bolus"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "14 days",
                    "cycles": "8(up to 12 cycles can be considered)",
                    "dose": "2,400 mg/m2",
                    "day": "1",
                    "route": "CIV via pump over 46 hours"
                },
                {
                    "drug_name": "Pegfilgrastim",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "14 days",
                    "cycles": "8(up to 12 cycles can be considered)",
                    "dose": "6 mg",
                    "day": "4",
                    "route": "Subcut"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "upper-gastrointestinal",
        "url": "https://www.eviq.org.au/medical-oncology/upper-gastrointestinal/pancreas-and-biliary/4384-pancreas-neoadjuvant-folfirinox-modified"
    },
    {
        "protocol_id": "1561 v.6",
        "protocol_status": "Superseded",
        "drug_sequence": [
            [
                {
                    "drug_name": "Oxaliplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "85 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Calcium folinate (Leucovorin)",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "50 mg *",
                    "day": "1",
                    "route": "IV bolus"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "400 mg/m2",
                    "day": "1",
                    "route": "IV"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "2,400 mg/m2",
                    "day": "1",
                    "route": "CIV via pump over 46 hours"
                }
            ],
            [
                {
                    "drug_name": "Oxaliplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "85 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Calcium folinate (Leucovorin)",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "50 mg *",
                    "day": "1",
                    "route": "IV bolus"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "400 mg/m2",
                    "day": "1",
                    "route": "IV"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "2,400 mg/m2",
                    "day": "1",
                    "route": "CIV via pump over 46 hours"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "upper-gastrointestinal",
        "url": "https://www.eviq.org.au/medical-oncology/upper-gastrointestinal/pancreas-and-biliary/1561-pancreas-metastatic-folfox6-modified-fluor"
    },
    {
        "protocol_id": "331 v.3",
        "protocol_status": "Discontinued",
        "drug_sequence": [],
        "section_name": "medical-oncology",
        "category_name": "upper-gastrointestinal",
        "url": "https://www.eviq.org.au/medical-oncology/upper-gastrointestinal/pancreas-and-biliary/331-pancreas-adjuvant-fluorouracil-leucovorin-disc"
    },
    {
        "protocol_id": "332 v.4",
        "protocol_status": "Discontinued",
        "drug_sequence": [],
        "section_name": "medical-oncology",
        "category_name": "upper-gastrointestinal",
        "url": "https://www.eviq.org.au/medical-oncology/upper-gastrointestinal/pancreas-and-biliary/332-pancreas-advanced-gemcitabine-fixed-dose-rate"
    },
    {
        "protocol_id": "4019 v.6",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Oxaliplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "8",
                    "dose": "130 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Capecitabine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "8",
                    "dose": "1,000 mg/m2 TWICE a day *",
                    "day": "1 to 14",
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Oxaliplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "8",
                    "dose": "130 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Capecitabine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "8",
                    "dose": "1,000 mg/m2 TWICE a day *",
                    "day": "1 to 14",
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "upper-gastrointestinal",
        "url": "https://www.eviq.org.au/medical-oncology/upper-gastrointestinal/gastric-and-oesophageal-adjuvant-and-neoadjuvant/1707-redirect-id-4019"
    },
    {
        "protocol_id": "1994 v.4",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "60 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Capecitabine",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "1,000 mg/m2 TWICE a day *",
                    "day": "1 to 14",
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": null,
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": null,
                    "day": null,
                    "route": null
                }
            ],
            [
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "60 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Capecitabine",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "1,000 mg/m2 TWICE a day *",
                    "day": "1 to 14",
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": null,
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": null,
                    "day": null,
                    "route": null
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "upper-gastrointestinal",
        "url": "https://www.eviq.org.au/medical-oncology/upper-gastrointestinal/gastric-and-oesophageal-adjuvant-and-neoadjuvant/1994-gastric-adjuvant-cisplatin-and-capecitabine-c"
    },
    {
        "protocol_id": "2038 v.6",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "DOCEtaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "14 days",
                    "cycles": "8(4 neoadjuvant, 4 adjuvant)",
                    "dose": "50 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Oxaliplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "14 days",
                    "cycles": "8(4 neoadjuvant, 4 adjuvant)",
                    "dose": "85 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Calcium folinate (Leucovorin)",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "14 days",
                    "cycles": "8(4 neoadjuvant, 4 adjuvant)",
                    "dose": "50 mg *",
                    "day": "1",
                    "route": "IV bolus"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "14 days",
                    "cycles": "8(4 neoadjuvant, 4 adjuvant)",
                    "dose": "2,600 mg/m2",
                    "day": "1",
                    "route": "CIV via pump over 24 hours"
                }
            ],
            [
                {
                    "drug_name": "DOCEtaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "14 days",
                    "cycles": "8(4 neoadjuvant, 4 adjuvant)",
                    "dose": "50 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Oxaliplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "14 days",
                    "cycles": "8(4 neoadjuvant, 4 adjuvant)",
                    "dose": "85 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Calcium folinate (Leucovorin)",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "14 days",
                    "cycles": "8(4 neoadjuvant, 4 adjuvant)",
                    "dose": "50 mg *",
                    "day": "1",
                    "route": "IV bolus"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "14 days",
                    "cycles": "8(4 neoadjuvant, 4 adjuvant)",
                    "dose": "2,600 mg/m2",
                    "day": "1",
                    "route": "CIV via pump over 24 hours"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "upper-gastrointestinal",
        "url": "https://www.eviq.org.au/medical-oncology/upper-gastrointestinal/gastric-and-oesophageal-adjuvant-and-neoadjuvant/2038-gastric-and-gastroesophageal-neoadjuvant-adju"
    },
    {
        "protocol_id": "4108 v.2",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Nivolumab",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "13",
                    "dose": "240 mg *",
                    "day": "1 and 15",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Nivolumab",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "13",
                    "dose": "480 mg *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Nivolumab",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "13",
                    "dose": "240 mg *",
                    "day": "1 and 15",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Nivolumab",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "13",
                    "dose": "480 mg *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "upper-gastrointestinal",
        "url": "https://www.eviq.org.au/medical-oncology/upper-gastrointestinal/gastric-and-oesophageal-adjuvant-and-neoadjuvant/4108-gastroesophageal-and-oesophageal-adjuvant-niv"
    },
    {
        "protocol_id": "2041 v.5",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "75 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "4,000 mg/m2 (equivalent to 1000 mg/m\u00b2/day)",
                    "day": "1",
                    "route": "CIV via pump over 96 hours"
                }
            ],
            [
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "75 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "4,000 mg/m2 (equivalent to 1000 mg/m\u00b2/day)",
                    "day": "1",
                    "route": "CIV via pump over 96 hours"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "upper-gastrointestinal",
        "url": "https://www.eviq.org.au/medical-oncology/upper-gastrointestinal/gastric-and-oesophageal-adjuvant-and-neoadjuvant/2041-oesophageal-definitive-cisplatin-fluorouracil"
    },
    {
        "protocol_id": "1704 v.6",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Oxaliplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "6(3 cycles with concurrent radiation therapy)",
                    "dose": "85 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Calcium folinate (Leucovorin)",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "6(3 cycles with concurrent radiation therapy)",
                    "dose": "50 mg *",
                    "day": "1",
                    "route": "IV bolus"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "6(3 cycles with concurrent radiation therapy)",
                    "dose": "400 mg/m2",
                    "day": "1",
                    "route": "IV"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "6(3 cycles with concurrent radiation therapy)",
                    "dose": "1,600 mg/m2",
                    "day": "1",
                    "route": "CIV via pump over 46 hours"
                }
            ],
            [
                {
                    "drug_name": "Oxaliplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "6(3 cycles with concurrent radiation therapy)",
                    "dose": "85 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Calcium folinate (Leucovorin)",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "6(3 cycles with concurrent radiation therapy)",
                    "dose": "50 mg *",
                    "day": "1",
                    "route": "IV bolus"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "6(3 cycles with concurrent radiation therapy)",
                    "dose": "400 mg/m2",
                    "day": "1",
                    "route": "IV"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "6(3 cycles with concurrent radiation therapy)",
                    "dose": "1,600 mg/m2",
                    "day": "1",
                    "route": "CIV via pump over 46 hours"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "upper-gastrointestinal",
        "url": "https://www.eviq.org.au/medical-oncology/upper-gastrointestinal/gastric-and-oesophageal-adjuvant-and-neoadjuvant/1704-oesophageal-definitive-folfox6-modified-fl"
    },
    {
        "protocol_id": "4008 v.3",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "PACLitaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "7 days",
                    "cycles": "5with concurrent radiation therapy",
                    "dose": "50 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "7 days",
                    "cycles": "5with concurrent radiation therapy",
                    "dose": "2 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "PACLitaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "7 days",
                    "cycles": "5with concurrent radiation therapy",
                    "dose": "50 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "7 days",
                    "cycles": "5with concurrent radiation therapy",
                    "dose": "2 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "upper-gastrointestinal",
        "url": "https://www.eviq.org.au/medical-oncology/upper-gastrointestinal/gastric-and-oesophageal-adjuvant-and-neoadjuvant/4008-oesophageal-definitive-or-neoadjuvant-carbopl"
    },
    {
        "protocol_id": "1250 v.6",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "28 days",
                    "cycles": "2with concurrent radiation therapy",
                    "dose": "75 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "28 days",
                    "cycles": "2with concurrent radiation therapy",
                    "dose": "4,000 mg/m2 (equivalent to 1000 mg/m\u00b2/day)",
                    "day": "1",
                    "route": "CIV via pump over 96 hours"
                }
            ],
            [
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "28 days",
                    "cycles": "2with concurrent radiation therapy",
                    "dose": "75 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "28 days",
                    "cycles": "2with concurrent radiation therapy",
                    "dose": "4,000 mg/m2 (equivalent to 1000 mg/m\u00b2/day)",
                    "day": "1",
                    "route": "CIV via pump over 96 hours"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "upper-gastrointestinal",
        "url": "https://www.eviq.org.au/medical-oncology/upper-gastrointestinal/gastric-and-oesophageal-adjuvant-and-neoadjuvant/1250-oesophageal-neoadjuvant-cisplatin-and-fluorou"
    },
    {
        "protocol_id": "553 v.9",
        "protocol_status": "Discontinued",
        "drug_sequence": [],
        "section_name": "medical-oncology",
        "category_name": "upper-gastrointestinal",
        "url": "https://www.eviq.org.au/medical-oncology/upper-gastrointestinal/gastric-and-oesophageal-adjuvant-and-neoadjuvant/553-gastric-adjuvant-macdonald-modified-fluorou"
    },
    {
        "protocol_id": "1907 v.6",
        "protocol_status": "Discontinued",
        "drug_sequence": [],
        "section_name": "medical-oncology",
        "category_name": "upper-gastrointestinal",
        "url": "https://www.eviq.org.au/medical-oncology/upper-gastrointestinal/gastric-and-oesophageal-adjuvant-and-neoadjuvant/1907-gastric-and-oesophageal-neoadjuvant-adjuvant"
    },
    {
        "protocol_id": "326 v.7",
        "protocol_status": "Discontinued",
        "drug_sequence": [],
        "section_name": "medical-oncology",
        "category_name": "upper-gastrointestinal",
        "url": "https://www.eviq.org.au/medical-oncology/upper-gastrointestinal/gastric-and-oesophageal-adjuvant-and-neoadjuvant/326-gastric-oesophageal-neoadjuvant-adjuvant-ecf"
    },
    {
        "protocol_id": "328 v.3",
        "protocol_status": "Discontinued",
        "drug_sequence": [],
        "section_name": "medical-oncology",
        "category_name": "upper-gastrointestinal",
        "url": "https://www.eviq.org.au/medical-oncology/upper-gastrointestinal/gastric-and-oesophageal-adjuvant-and-neoadjuvant/328-oesophageal-definitive-cisplatin-fractionated"
    },
    {
        "protocol_id": "4043 v.2",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Irinotecan",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "180 mg/m2 *",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Calcium folinate (Leucovorin)",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "50 mg **",
                    "day": "1",
                    "route": "IV bolus"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "400 mg/m2",
                    "day": "1",
                    "route": "IV"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "2,400 mg/m2",
                    "day": "1",
                    "route": "CIV via pump over 46 hours"
                }
            ],
            [
                {
                    "drug_name": "Irinotecan",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "180 mg/m2 *",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Calcium folinate (Leucovorin)",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "50 mg **",
                    "day": "1",
                    "route": "IV bolus"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "400 mg/m2",
                    "day": "1",
                    "route": "IV"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "2,400 mg/m2",
                    "day": "1",
                    "route": "CIV via pump over 46 hours"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "upper-gastrointestinal",
        "url": "https://www.eviq.org.au/medical-oncology/upper-gastrointestinal/gastric-and-oesophageal-metastatic/4043-advanced-or-metastatic-folfiri-modified-fl"
    },
    {
        "protocol_id": "4408 v.1",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Nivolumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "42 days",
                    "cycles": "17or until disease progression or unacceptable toxicity for up to 2 years",
                    "dose": "3 mg/kg",
                    "day": "1, 15, 29",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Ipilimumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "42 days",
                    "cycles": "17or until disease progression or unacceptable toxicity for up to 2 years",
                    "dose": "1 mg/kg",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Nivolumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "42 days",
                    "cycles": "17or until disease progression or unacceptable toxicity for up to 2 years",
                    "dose": "3 mg/kg",
                    "day": "1, 15, 29",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Ipilimumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "42 days",
                    "cycles": "17or until disease progression or unacceptable toxicity for up to 2 years",
                    "dose": "1 mg/kg",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "upper-gastrointestinal",
        "url": "https://www.eviq.org.au/medical-oncology/upper-gastrointestinal/gastric-and-oesophageal-metastatic/4408-advanced-or-metastatic-ipilimumab-and-nivolum"
    },
    {
        "protocol_id": "3594 v.8",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Nivolumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "480 mg * #",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Nivolumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "480 mg * #",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "upper-gastrointestinal",
        "url": "https://www.eviq.org.au/medical-oncology/upper-gastrointestinal/gastric-and-oesophageal-metastatic/4059-redirect-id-3594"
    },
    {
        "protocol_id": "3809 v.3",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Oxaliplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (up to 8 cycles)",
                    "dose": "130 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Capecitabine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (up to 8 cycles)",
                    "dose": "1,000 mg/m2 TWICE a day *",
                    "day": "1 to 14",
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Oxaliplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (up to 8 cycles)",
                    "dose": "130 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Capecitabine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (up to 8 cycles)",
                    "dose": "1,000 mg/m2 TWICE a day *",
                    "day": "1 to 14",
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "upper-gastrointestinal",
        "url": "https://www.eviq.org.au/medical-oncology/upper-gastrointestinal/gastric-and-oesophageal-metastatic/3809-gastric-and-gastroesophageal-metastatic-capox"
    },
    {
        "protocol_id": "4045 v.3",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Nivolumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "35(6 cycles with chemotherapy combination, followed by continuous treatment with nivolumab until disease progression or unacceptable toxicity for up to 2 years).",
                    "dose": "360 mg",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Oxaliplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "35(6 cycles with chemotherapy combination, followed by continuous treatment with nivolumab until disease progression or unacceptable toxicity for up to 2 years).",
                    "dose": "130 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Capecitabine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "35(6 cycles with chemotherapy combination, followed by continuous treatment with nivolumab until disease progression or unacceptable toxicity for up to 2 years).",
                    "dose": "1,000 mg/m2 TWICE a day *",
                    "day": "1 to 14",
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Nivolumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "35(6 cycles with chemotherapy combination, followed by continuous treatment with nivolumab until disease progression or unacceptable toxicity for up to 2 years).",
                    "dose": "360 mg **",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Nivolumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "35(6 cycles with chemotherapy combination, followed by continuous treatment with nivolumab until disease progression or unacceptable toxicity for up to 2 years).",
                    "dose": "360 mg",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Oxaliplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "35(6 cycles with chemotherapy combination, followed by continuous treatment with nivolumab until disease progression or unacceptable toxicity for up to 2 years).",
                    "dose": "130 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Capecitabine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "35(6 cycles with chemotherapy combination, followed by continuous treatment with nivolumab until disease progression or unacceptable toxicity for up to 2 years).",
                    "dose": "1,000 mg/m2 TWICE a day *",
                    "day": "1 to 14",
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Nivolumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "35(6 cycles with chemotherapy combination, followed by continuous treatment with nivolumab until disease progression or unacceptable toxicity for up to 2 years).",
                    "dose": "360 mg **",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "upper-gastrointestinal",
        "url": "https://www.eviq.org.au/medical-oncology/upper-gastrointestinal/gastric-and-oesophageal-metastatic/4045-gastric-and-gastroesophageal-metastatic-capox"
    },
    {
        "protocol_id": "3896 v.4",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Trastuzumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (up to 8 cycles). Consider continuation of trastuzumab monotherapy in patients who are responding to treatment.",
                    "dose": "8 mg/kg (loading dose only)",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Oxaliplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (up to 8 cycles). Consider continuation of trastuzumab monotherapy in patients who are responding to treatment.",
                    "dose": "130 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Capecitabine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (up to 8 cycles). Consider continuation of trastuzumab monotherapy in patients who are responding to treatment.",
                    "dose": "1,000 mg/m2 TWICE a day *",
                    "day": "1 to 14",
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Trastuzumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (up to 8 cycles). Consider continuation of trastuzumab monotherapy in patients who are responding to treatment.",
                    "dose": "6 mg/kg (subsequent doses)",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Oxaliplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (up to 8 cycles). Consider continuation of trastuzumab monotherapy in patients who are responding to treatment.",
                    "dose": "130 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Capecitabine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (up to 8 cycles). Consider continuation of trastuzumab monotherapy in patients who are responding to treatment.",
                    "dose": "1,000 mg/m2 TWICE a day *",
                    "day": "1 to 14",
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Trastuzumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (up to 8 cycles). Consider continuation of trastuzumab monotherapy in patients who are responding to treatment.",
                    "dose": "8 mg/kg (loading dose only)",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Oxaliplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (up to 8 cycles). Consider continuation of trastuzumab monotherapy in patients who are responding to treatment.",
                    "dose": "130 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Capecitabine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (up to 8 cycles). Consider continuation of trastuzumab monotherapy in patients who are responding to treatment.",
                    "dose": "1,000 mg/m2 TWICE a day *",
                    "day": "1 to 14",
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Trastuzumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (up to 8 cycles). Consider continuation of trastuzumab monotherapy in patients who are responding to treatment.",
                    "dose": "6 mg/kg (subsequent doses)",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Oxaliplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (up to 8 cycles). Consider continuation of trastuzumab monotherapy in patients who are responding to treatment.",
                    "dose": "130 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Capecitabine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (up to 8 cycles). Consider continuation of trastuzumab monotherapy in patients who are responding to treatment.",
                    "dose": "1,000 mg/m2 TWICE a day *",
                    "day": "1 to 14",
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "upper-gastrointestinal",
        "url": "https://www.eviq.org.au/medical-oncology/upper-gastrointestinal/gastric-and-oesophageal-metastatic/3896-gastric-and-gastroesophageal-metastatic-capox"
    },
    {
        "protocol_id": "1216 v.9",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Trastuzumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (in the clinical trial cisplatin, capecitabine and trastuzumab were given for 6 cycles, after which trastuzumab monotherapy should be continued in patients who are responding to treatment)",
                    "dose": "8 mg/kg (loading dose only)",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (in the clinical trial cisplatin, capecitabine and trastuzumab were given for 6 cycles, after which trastuzumab monotherapy should be continued in patients who are responding to treatment)",
                    "dose": "80 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Capecitabine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (in the clinical trial cisplatin, capecitabine and trastuzumab were given for 6 cycles, after which trastuzumab monotherapy should be continued in patients who are responding to treatment)",
                    "dose": "1,000 mg/m2 TWICE a day *",
                    "day": "1 to 14",
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Trastuzumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (in the clinical trial cisplatin, capecitabine and trastuzumab were given for 6 cycles, after which trastuzumab monotherapy should be continued in patients who are responding to treatment)",
                    "dose": "6 mg/kg (subsequent doses)",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (in the clinical trial cisplatin, capecitabine and trastuzumab were given for 6 cycles, after which trastuzumab monotherapy should be continued in patients who are responding to treatment)",
                    "dose": "80 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Capecitabine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (in the clinical trial cisplatin, capecitabine and trastuzumab were given for 6 cycles, after which trastuzumab monotherapy should be continued in patients who are responding to treatment)",
                    "dose": "1,000 mg/m2 TWICE a day *",
                    "day": "1 to 14",
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Trastuzumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (in the clinical trial cisplatin, capecitabine and trastuzumab were given for 6 cycles, after which trastuzumab monotherapy should be continued in patients who are responding to treatment)",
                    "dose": "6 mg/kg (subsequent doses)",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Trastuzumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (in the clinical trial cisplatin, capecitabine and trastuzumab were given for 6 cycles, after which trastuzumab monotherapy should be continued in patients who are responding to treatment)",
                    "dose": "8 mg/kg (loading dose only)",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (in the clinical trial cisplatin, capecitabine and trastuzumab were given for 6 cycles, after which trastuzumab monotherapy should be continued in patients who are responding to treatment)",
                    "dose": "80 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Capecitabine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (in the clinical trial cisplatin, capecitabine and trastuzumab were given for 6 cycles, after which trastuzumab monotherapy should be continued in patients who are responding to treatment)",
                    "dose": "1,000 mg/m2 TWICE a day *",
                    "day": "1 to 14",
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Trastuzumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (in the clinical trial cisplatin, capecitabine and trastuzumab were given for 6 cycles, after which trastuzumab monotherapy should be continued in patients who are responding to treatment)",
                    "dose": "6 mg/kg (subsequent doses)",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (in the clinical trial cisplatin, capecitabine and trastuzumab were given for 6 cycles, after which trastuzumab monotherapy should be continued in patients who are responding to treatment)",
                    "dose": "80 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Capecitabine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (in the clinical trial cisplatin, capecitabine and trastuzumab were given for 6 cycles, after which trastuzumab monotherapy should be continued in patients who are responding to treatment)",
                    "dose": "1,000 mg/m2 TWICE a day *",
                    "day": "1 to 14",
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Trastuzumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (in the clinical trial cisplatin, capecitabine and trastuzumab were given for 6 cycles, after which trastuzumab monotherapy should be continued in patients who are responding to treatment)",
                    "dose": "6 mg/kg (subsequent doses)",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "upper-gastrointestinal",
        "url": "https://www.eviq.org.au/medical-oncology/upper-gastrointestinal/gastric-and-oesophageal-metastatic/1216-gastric-and-gastroesophageal-metastatic-cispl"
    },
    {
        "protocol_id": "1217 v.9",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Trastuzumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (in the clinical trial cisplatin, fluorouracil and trastuzumab were given for 6 cycles, after which trastuzumab monotherapy should be continued in patients who are responding to treatment)",
                    "dose": "8 mg/kg (loading dose only)",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (in the clinical trial cisplatin, fluorouracil and trastuzumab were given for 6 cycles, after which trastuzumab monotherapy should be continued in patients who are responding to treatment)",
                    "dose": "80 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (in the clinical trial cisplatin, fluorouracil and trastuzumab were given for 6 cycles, after which trastuzumab monotherapy should be continued in patients who are responding to treatment)",
                    "dose": "4,000 mg/m2 (equivalent to 1000 mg/m2/day)",
                    "day": "1",
                    "route": "CIV via pump over 96 hours*"
                }
            ],
            [
                {
                    "drug_name": "Trastuzumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (in the clinical trial cisplatin, fluorouracil and trastuzumab were given for 6 cycles, after which trastuzumab monotherapy should be continued in patients who are responding to treatment)",
                    "dose": "6 mg/kg (subsequent doses)",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (in the clinical trial cisplatin, fluorouracil and trastuzumab were given for 6 cycles, after which trastuzumab monotherapy should be continued in patients who are responding to treatment)",
                    "dose": "80 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (in the clinical trial cisplatin, fluorouracil and trastuzumab were given for 6 cycles, after which trastuzumab monotherapy should be continued in patients who are responding to treatment)",
                    "dose": "4,000 mg/m2 (equivalent to 1000 mg/m2/day)",
                    "day": "1",
                    "route": "CIV via pump over 96 hours*"
                }
            ],
            [
                {
                    "drug_name": "Trastuzumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (in the clinical trial cisplatin, fluorouracil and trastuzumab were given for 6 cycles, after which trastuzumab monotherapy should be continued in patients who are responding to treatment)",
                    "dose": "6 mg/kg (subsequent doses)",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Trastuzumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (in the clinical trial cisplatin, fluorouracil and trastuzumab were given for 6 cycles, after which trastuzumab monotherapy should be continued in patients who are responding to treatment)",
                    "dose": "8 mg/kg (loading dose only)",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (in the clinical trial cisplatin, fluorouracil and trastuzumab were given for 6 cycles, after which trastuzumab monotherapy should be continued in patients who are responding to treatment)",
                    "dose": "80 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (in the clinical trial cisplatin, fluorouracil and trastuzumab were given for 6 cycles, after which trastuzumab monotherapy should be continued in patients who are responding to treatment)",
                    "dose": "4,000 mg/m2 (equivalent to 1000 mg/m2/day)",
                    "day": "1",
                    "route": "CIV via pump over 96 hours*"
                }
            ],
            [
                {
                    "drug_name": "Trastuzumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (in the clinical trial cisplatin, fluorouracil and trastuzumab were given for 6 cycles, after which trastuzumab monotherapy should be continued in patients who are responding to treatment)",
                    "dose": "6 mg/kg (subsequent doses)",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (in the clinical trial cisplatin, fluorouracil and trastuzumab were given for 6 cycles, after which trastuzumab monotherapy should be continued in patients who are responding to treatment)",
                    "dose": "80 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (in the clinical trial cisplatin, fluorouracil and trastuzumab were given for 6 cycles, after which trastuzumab monotherapy should be continued in patients who are responding to treatment)",
                    "dose": "4,000 mg/m2 (equivalent to 1000 mg/m2/day)",
                    "day": "1",
                    "route": "CIV via pump over 96 hours*"
                }
            ],
            [
                {
                    "drug_name": "Trastuzumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (in the clinical trial cisplatin, fluorouracil and trastuzumab were given for 6 cycles, after which trastuzumab monotherapy should be continued in patients who are responding to treatment)",
                    "dose": "6 mg/kg (subsequent doses)",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "upper-gastrointestinal",
        "url": "https://www.eviq.org.au/medical-oncology/upper-gastrointestinal/gastric-and-oesophageal-metastatic/1217-gastric-and-gastroesophageal-metastatic-cispl"
    },
    {
        "protocol_id": "1706 v.5",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "DOCEtaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "75 mg/m2 *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "DOCEtaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "75 mg/m2 *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "upper-gastrointestinal",
        "url": "https://www.eviq.org.au/medical-oncology/upper-gastrointestinal/gastric-and-oesophageal-metastatic/1706-gastric-and-gastroesophageal-metastatic-docet"
    },
    {
        "protocol_id": "1731 v.7",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Oxaliplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (up to 12 cycles)",
                    "dose": "85 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Calcium folinate (Leucovorin)",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (up to 12 cycles)",
                    "dose": "50 mg *",
                    "day": "1",
                    "route": "IV bolus"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (up to 12 cycles)",
                    "dose": "400 mg/m2 *",
                    "day": "1",
                    "route": "IV"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (up to 12 cycles)",
                    "dose": "2,400 mg/m2 *",
                    "day": "1",
                    "route": "CIV via pump over 46 hours"
                }
            ],
            [
                {
                    "drug_name": "Oxaliplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (up to 12 cycles)",
                    "dose": "85 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Calcium folinate (Leucovorin)",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (up to 12 cycles)",
                    "dose": "50 mg *",
                    "day": "1",
                    "route": "IV bolus"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (up to 12 cycles)",
                    "dose": "400 mg/m2 *",
                    "day": "1",
                    "route": "IV"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (up to 12 cycles)",
                    "dose": "2,400 mg/m2 *",
                    "day": "1",
                    "route": "CIV via pump over 46 hours"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "upper-gastrointestinal",
        "url": "https://www.eviq.org.au/medical-oncology/upper-gastrointestinal/gastric-and-oesophageal-metastatic/1731-gastric-and-gastroesophageal-metastatic-folfo"
    },
    {
        "protocol_id": "4068 v.3",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Nivolumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "52(12 cycles with chemotherapy combination, followed by continuous treatment with nivolumab until disease progression or unacceptable toxicity for up to 2 years).",
                    "dose": "240 mg",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Oxaliplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "52(12 cycles with chemotherapy combination, followed by continuous treatment with nivolumab until disease progression or unacceptable toxicity for up to 2 years).",
                    "dose": "85 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Calcium folinate (Leucovorin)",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "52(12 cycles with chemotherapy combination, followed by continuous treatment with nivolumab until disease progression or unacceptable toxicity for up to 2 years).",
                    "dose": "50 mg *",
                    "day": "1",
                    "route": "IV bolus"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "52(12 cycles with chemotherapy combination, followed by continuous treatment with nivolumab until disease progression or unacceptable toxicity for up to 2 years).",
                    "dose": "400 mg/m2 **",
                    "day": "1",
                    "route": "IV"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "52(12 cycles with chemotherapy combination, followed by continuous treatment with nivolumab until disease progression or unacceptable toxicity for up to 2 years).",
                    "dose": "2,400 mg/m2 **",
                    "day": "1",
                    "route": "CIV via pump over 46 hours"
                }
            ],
            [
                {
                    "drug_name": "Nivolumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "52(12 cycles with chemotherapy combination, followed by continuous treatment with nivolumab until disease progression or unacceptable toxicity for up to 2 years).",
                    "dose": "240 mg ****",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Nivolumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "52(12 cycles with chemotherapy combination, followed by continuous treatment with nivolumab until disease progression or unacceptable toxicity for up to 2 years).",
                    "dose": "240 mg",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Oxaliplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "52(12 cycles with chemotherapy combination, followed by continuous treatment with nivolumab until disease progression or unacceptable toxicity for up to 2 years).",
                    "dose": "85 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Calcium folinate (Leucovorin)",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "52(12 cycles with chemotherapy combination, followed by continuous treatment with nivolumab until disease progression or unacceptable toxicity for up to 2 years).",
                    "dose": "50 mg *",
                    "day": "1",
                    "route": "IV bolus"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "52(12 cycles with chemotherapy combination, followed by continuous treatment with nivolumab until disease progression or unacceptable toxicity for up to 2 years).",
                    "dose": "400 mg/m2 **",
                    "day": "1",
                    "route": "IV"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "52(12 cycles with chemotherapy combination, followed by continuous treatment with nivolumab until disease progression or unacceptable toxicity for up to 2 years).",
                    "dose": "2,400 mg/m2 **",
                    "day": "1",
                    "route": "CIV via pump over 46 hours"
                }
            ],
            [
                {
                    "drug_name": "Nivolumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "52(12 cycles with chemotherapy combination, followed by continuous treatment with nivolumab until disease progression or unacceptable toxicity for up to 2 years).",
                    "dose": "240 mg ****",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "upper-gastrointestinal",
        "url": "https://www.eviq.org.au/medical-oncology/upper-gastrointestinal/gastric-and-oesophageal-metastatic/4068-gastric-and-gastroesophageal-metastatic-folfo"
    },
    {
        "protocol_id": "3805 v.4",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Trastuzumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (up to 12 cycles). Consider continuation of trastuzumab monotherapy in patients who are responding to treatment.",
                    "dose": "6 mg/kg (loading dose only)",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Oxaliplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (up to 12 cycles). Consider continuation of trastuzumab monotherapy in patients who are responding to treatment.",
                    "dose": "85 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Calcium folinate (Leucovorin)",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (up to 12 cycles). Consider continuation of trastuzumab monotherapy in patients who are responding to treatment.",
                    "dose": "50 mg *",
                    "day": "1",
                    "route": "IV bolus"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (up to 12 cycles). Consider continuation of trastuzumab monotherapy in patients who are responding to treatment.",
                    "dose": "400 mg/m2",
                    "day": "1",
                    "route": "IV"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (up to 12 cycles). Consider continuation of trastuzumab monotherapy in patients who are responding to treatment.",
                    "dose": "2,400 mg/m2",
                    "day": "1",
                    "route": "CIV via pump over 46 hours"
                }
            ],
            [
                {
                    "drug_name": "Trastuzumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (up to 12 cycles). Consider continuation of trastuzumab monotherapy in patients who are responding to treatment.",
                    "dose": "4 mg/kg (subsequent doses)",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Oxaliplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (up to 12 cycles). Consider continuation of trastuzumab monotherapy in patients who are responding to treatment.",
                    "dose": "85 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Calcium folinate (Leucovorin)",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (up to 12 cycles). Consider continuation of trastuzumab monotherapy in patients who are responding to treatment.",
                    "dose": "50 mg *",
                    "day": "1",
                    "route": "IV bolus"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (up to 12 cycles). Consider continuation of trastuzumab monotherapy in patients who are responding to treatment.",
                    "dose": "400 mg/m2",
                    "day": "1",
                    "route": "IV"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (up to 12 cycles). Consider continuation of trastuzumab monotherapy in patients who are responding to treatment.",
                    "dose": "2,400 mg/m2",
                    "day": "1",
                    "route": "CIV via pump over 46 hours"
                }
            ],
            [
                {
                    "drug_name": "Trastuzumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (up to 12 cycles). Consider continuation of trastuzumab monotherapy in patients who are responding to treatment.",
                    "dose": "6 mg/kg (loading dose only)",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Oxaliplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (up to 12 cycles). Consider continuation of trastuzumab monotherapy in patients who are responding to treatment.",
                    "dose": "85 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Calcium folinate (Leucovorin)",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (up to 12 cycles). Consider continuation of trastuzumab monotherapy in patients who are responding to treatment.",
                    "dose": "50 mg *",
                    "day": "1",
                    "route": "IV bolus"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (up to 12 cycles). Consider continuation of trastuzumab monotherapy in patients who are responding to treatment.",
                    "dose": "400 mg/m2",
                    "day": "1",
                    "route": "IV"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (up to 12 cycles). Consider continuation of trastuzumab monotherapy in patients who are responding to treatment.",
                    "dose": "2,400 mg/m2",
                    "day": "1",
                    "route": "CIV via pump over 46 hours"
                }
            ],
            [
                {
                    "drug_name": "Trastuzumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (up to 12 cycles). Consider continuation of trastuzumab monotherapy in patients who are responding to treatment.",
                    "dose": "4 mg/kg (subsequent doses)",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Oxaliplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (up to 12 cycles). Consider continuation of trastuzumab monotherapy in patients who are responding to treatment.",
                    "dose": "85 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Calcium folinate (Leucovorin)",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (up to 12 cycles). Consider continuation of trastuzumab monotherapy in patients who are responding to treatment.",
                    "dose": "50 mg *",
                    "day": "1",
                    "route": "IV bolus"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (up to 12 cycles). Consider continuation of trastuzumab monotherapy in patients who are responding to treatment.",
                    "dose": "400 mg/m2",
                    "day": "1",
                    "route": "IV"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (up to 12 cycles). Consider continuation of trastuzumab monotherapy in patients who are responding to treatment.",
                    "dose": "2,400 mg/m2",
                    "day": "1",
                    "route": "CIV via pump over 46 hours"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "upper-gastrointestinal",
        "url": "https://www.eviq.org.au/medical-oncology/upper-gastrointestinal/gastric-and-oesophageal-metastatic/3805-gastric-and-gastroesophageal-metastatic-folfo"
    },
    {
        "protocol_id": "1705 v.5",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Irinotecan",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "150 mg/m2 *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Irinotecan",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "150 mg/m2 *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "upper-gastrointestinal",
        "url": "https://www.eviq.org.au/medical-oncology/upper-gastrointestinal/gastric-and-oesophageal-metastatic/1705-gastric-and-gastroesophageal-metastatic-irino"
    },
    {
        "protocol_id": "1904 v.6",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "raMUCIRumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "8 mg/kg",
                    "day": "1 and 15",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "PACLitaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "80 mg/m2",
                    "day": "1, 8, 15",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "raMUCIRumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "8 mg/kg",
                    "day": "1 and 15",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "PACLitaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "80 mg/m2",
                    "day": "1, 8, 15",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "upper-gastrointestinal",
        "url": "https://www.eviq.org.au/medical-oncology/upper-gastrointestinal/gastric-and-oesophageal-metastatic/1904-gastric-and-gastroesophageal-metastatic-pacli"
    },
    {
        "protocol_id": "1730 v.7",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "PACLitaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "80 mg/m2",
                    "day": "1, 8, 15",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "PACLitaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "80 mg/m2",
                    "day": "1, 8, 15",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "upper-gastrointestinal",
        "url": "https://www.eviq.org.au/medical-oncology/upper-gastrointestinal/gastric-and-oesophageal-metastatic/1730-gastric-and-gastroesophageal-metastatic-pacli"
    },
    {
        "protocol_id": "1903 v.3",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "raMUCIRumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "8 mg/kg",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "raMUCIRumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "8 mg/kg",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "upper-gastrointestinal",
        "url": "https://www.eviq.org.au/medical-oncology/upper-gastrointestinal/gastric-and-oesophageal-metastatic/1903-gastric-and-gastroesophageal-metastatic-ramuc"
    },
    {
        "protocol_id": "1214 v.5",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6or until disease progression or unacceptable toxicity",
                    "dose": "80 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Capecitabine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6or until disease progression or unacceptable toxicity",
                    "dose": "1,000 mg/m2 TWICE a day *",
                    "day": "1 to 14",
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6or until disease progression or unacceptable toxicity",
                    "dose": "80 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Capecitabine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6or until disease progression or unacceptable toxicity",
                    "dose": "1,000 mg/m2 TWICE a day *",
                    "day": "1 to 14",
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "upper-gastrointestinal",
        "url": "https://www.eviq.org.au/medical-oncology/upper-gastrointestinal/gastric-and-oesophageal-metastatic/1214-gastric-and-oesophageal-metastatic-cisplatin"
    },
    {
        "protocol_id": "701 v.5",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6or until disease progression or unacceptable toxicity",
                    "dose": "80 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6or until disease progression or unacceptable toxicity",
                    "dose": "4,000 mg/m2 (equivalent to 1000 mg/m\u00b2/day)",
                    "day": "1",
                    "route": "CIV via pump over 96 hours"
                }
            ],
            [
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6or until disease progression or unacceptable toxicity",
                    "dose": "80 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6or until disease progression or unacceptable toxicity",
                    "dose": "4,000 mg/m2 (equivalent to 1000 mg/m\u00b2/day)",
                    "day": "1",
                    "route": "CIV via pump over 96 hours"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "upper-gastrointestinal",
        "url": "https://www.eviq.org.au/medical-oncology/upper-gastrointestinal/gastric-and-oesophageal-metastatic/701-gastric-and-oesophageal-metastatic-cisplatin-a"
    },
    {
        "protocol_id": "4325 v.1",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Pembrolizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "35 or until disease progression or unacceptable toxicity (total maximum of 35 doses or 24 months treatment with pembrolizumab)",
                    "dose": "200 mg",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "35 or until disease progression or unacceptable toxicity (total maximum of 35 doses or 24 months treatment with pembrolizumab)",
                    "dose": "80 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "35 or until disease progression or unacceptable toxicity (total maximum of 35 doses or 24 months treatment with pembrolizumab)",
                    "dose": "4,000 mg/m2 (equivalent to 800 mg/m2/day)",
                    "day": "1",
                    "route": "CIV via pump over 120 hours"
                }
            ],
            [
                {
                    "drug_name": "Pembrolizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "35 or until disease progression or unacceptable toxicity (total maximum of 35 doses or 24 months treatment with pembrolizumab)",
                    "dose": "200 mg",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "35 or until disease progression or unacceptable toxicity (total maximum of 35 doses or 24 months treatment with pembrolizumab)",
                    "dose": "4,000 mg/m2 (equivalent to 800 mg/m2/day)",
                    "day": "1",
                    "route": "CIV via pump over 120 hours"
                }
            ],
            [
                {
                    "drug_name": "Pembrolizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "35 or until disease progression or unacceptable toxicity (total maximum of 35 doses or 24 months treatment with pembrolizumab)",
                    "dose": "200 mg",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "35 or until disease progression or unacceptable toxicity (total maximum of 35 doses or 24 months treatment with pembrolizumab)",
                    "dose": "80 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "35 or until disease progression or unacceptable toxicity (total maximum of 35 doses or 24 months treatment with pembrolizumab)",
                    "dose": "4,000 mg/m2 (equivalent to 800 mg/m2/day)",
                    "day": "1",
                    "route": "CIV via pump over 120 hours"
                }
            ],
            [
                {
                    "drug_name": "Pembrolizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "35 or until disease progression or unacceptable toxicity (total maximum of 35 doses or 24 months treatment with pembrolizumab)",
                    "dose": "200 mg",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "35 or until disease progression or unacceptable toxicity (total maximum of 35 doses or 24 months treatment with pembrolizumab)",
                    "dose": "4,000 mg/m2 (equivalent to 800 mg/m2/day)",
                    "day": "1",
                    "route": "CIV via pump over 120 hours"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "upper-gastrointestinal",
        "url": "https://www.eviq.org.au/medical-oncology/upper-gastrointestinal/gastric-and-oesophageal-metastatic/4325-gastroesophageal-and-oesophageal-metastatic-c"
    },
    {
        "protocol_id": "3806 v.2",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Trifluridine/tipiracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "35 mg/m2 TWICE a day *\n                            \n                                (Cap dose at 80 mg)",
                    "day": "1 to 5 and 8 to 12",
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Trifluridine/tipiracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "35 mg/m2 TWICE a day *\n                            \n                                (Cap dose at 80 mg)",
                    "day": "1 to 5 and 8 to 12",
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "upper-gastrointestinal",
        "url": "https://www.eviq.org.au/medical-oncology/upper-gastrointestinal/gastric-and-oesophageal-metastatic/3806-metastatic-trifluridine-tipiracil"
    },
    {
        "protocol_id": "4385 v.1",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Nivolumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity. Cisplatin and fluorouracil usually 6 cycles. Nivolumab was continued for 24 months in CheckMate 648 trial.",
                    "dose": "240 mg *",
                    "day": "1 and 15",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity. Cisplatin and fluorouracil usually 6 cycles. Nivolumab was continued for 24 months in CheckMate 648 trial.",
                    "dose": "80 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity. Cisplatin and fluorouracil usually 6 cycles. Nivolumab was continued for 24 months in CheckMate 648 trial.",
                    "dose": "4,000 mg/m2 (equivalent to 800 mg/m2/day)",
                    "day": "1",
                    "route": "CIV via pump over 120 hours"
                }
            ],
            [
                {
                    "drug_name": "Nivolumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity. Cisplatin and fluorouracil usually 6 cycles. Nivolumab was continued for 24 months in CheckMate 648 trial.",
                    "dose": "240 mg *",
                    "day": "1 and 15",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity. Cisplatin and fluorouracil usually 6 cycles. Nivolumab was continued for 24 months in CheckMate 648 trial.",
                    "dose": "80 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity. Cisplatin and fluorouracil usually 6 cycles. Nivolumab was continued for 24 months in CheckMate 648 trial.",
                    "dose": "4,000 mg/m2 (equivalent to 800 mg/m2/day)",
                    "day": "1",
                    "route": "CIV via pump over 120 hours"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "upper-gastrointestinal",
        "url": "https://www.eviq.org.au/medical-oncology/upper-gastrointestinal/gastric-and-oesophageal-metastatic/4385-oesophageal-metastatic-cisplatin-fluorouracil"
    },
    {
        "protocol_id": "327 v.4",
        "protocol_status": "Discontinued",
        "drug_sequence": [],
        "section_name": "medical-oncology",
        "category_name": "upper-gastrointestinal",
        "url": "https://www.eviq.org.au/medical-oncology/upper-gastrointestinal/gastric-and-oesophageal-metastatic/327-gastric-and-oesophageal-metastatic-ecf-epirub"
    },
    {
        "protocol_id": "526 v.4",
        "protocol_status": "Discontinued",
        "drug_sequence": [],
        "section_name": "medical-oncology",
        "category_name": "upper-gastrointestinal",
        "url": "https://www.eviq.org.au/medical-oncology/upper-gastrointestinal/gastric-and-oesophageal-metastatic/526-gastric-and-oesophageal-metastatic-ecx-epirub"
    },
    {
        "protocol_id": "1631 v.3",
        "protocol_status": "Discontinued",
        "drug_sequence": [],
        "section_name": "medical-oncology",
        "category_name": "upper-gastrointestinal",
        "url": "https://www.eviq.org.au/medical-oncology/upper-gastrointestinal/gastric-and-oesophageal-metastatic/1631-gastric-and-oesophageal-metastatic-eof-epiru"
    },
    {
        "protocol_id": "528 v.5",
        "protocol_status": "Discontinued",
        "drug_sequence": [],
        "section_name": "medical-oncology",
        "category_name": "upper-gastrointestinal",
        "url": "https://www.eviq.org.au/medical-oncology/upper-gastrointestinal/gastric-and-oesophageal-metastatic/528-gastric-and-oesophageal-metastatic-eox-epirub"
    },
    {
        "protocol_id": "1222 v.7",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Imatinib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "400 mg ONCE a day",
                    "day": null,
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Imatinib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "400 mg ONCE a day",
                    "day": null,
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "upper-gastrointestinal",
        "url": "https://www.eviq.org.au/medical-oncology/upper-gastrointestinal/gastrointestinal-stromal-cell-tumours/1222-gastrointestinal-stromal-cell-tumour-gist-a"
    },
    {
        "protocol_id": "330 v.7",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Imatinib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "400 mg ONCE a day",
                    "day": null,
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Imatinib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "400 mg ONCE a day",
                    "day": null,
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "upper-gastrointestinal",
        "url": "https://www.eviq.org.au/medical-oncology/upper-gastrointestinal/gastrointestinal-stromal-cell-tumours/330-gastrointestinal-stromal-cell-tumour-gist-me"
    },
    {
        "protocol_id": "1902 v.3",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Regorafenib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "160 mg ONCE a day *",
                    "day": "1 to 21 **",
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Regorafenib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "160 mg ONCE a day *",
                    "day": "1 to 21 **",
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "upper-gastrointestinal",
        "url": "https://www.eviq.org.au/medical-oncology/upper-gastrointestinal/gastrointestinal-stromal-cell-tumours/1902-gastrointestinal-stromal-cell-tumour-gist-m"
    },
    {
        "protocol_id": "4112 v.3",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Ripretinib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "150 mg ONCE a day *",
                    "day": null,
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Ripretinib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "150 mg ONCE a day *",
                    "day": null,
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "upper-gastrointestinal",
        "url": "https://www.eviq.org.au/medical-oncology/upper-gastrointestinal/gastrointestinal-stromal-cell-tumours/4112-gastrointestinal-stromal-cell-tumour-gist-m"
    },
    {
        "protocol_id": "329 v.7",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "sUNITinib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "42 days(sunitinib is taken daily for 4 weeks then 2 weeks break)",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "50 mg *",
                    "day": "1 to 28",
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "sUNITinib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "42 days(sunitinib is taken daily for 4 weeks then 2 weeks break)",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "50 mg *",
                    "day": "1 to 28",
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "upper-gastrointestinal",
        "url": "https://www.eviq.org.au/medical-oncology/upper-gastrointestinal/gastrointestinal-stromal-cell-tumours/329-gastrointestinal-stromal-cell-tumour-gist-me"
    },
    {
        "protocol_id": "3594 v.8",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Nivolumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "480 mg * #",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Nivolumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "480 mg * #",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "upper-gastrointestinal",
        "url": "https://www.eviq.org.au/medical-oncology/upper-gastrointestinal/hepatic/3807-redirect-id-3594"
    },
    {
        "protocol_id": "3555 v.9",
        "protocol_status": "Superseded",
        "drug_sequence": [
            [
                {
                    "drug_name": "Nivolumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "3 mg/kg",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Nivolumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "3 mg/kg",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "upper-gastrointestinal",
        "url": "https://www.eviq.org.au/medical-oncology/upper-gastrointestinal/hepatic/3799-redirect-id-3555"
    },
    {
        "protocol_id": "3881 v.5",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Atezolizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "1,200 mg",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "beVACizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "15 mg/kg *#",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Atezolizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "1,200 mg",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "beVACizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "15 mg/kg *#",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "upper-gastrointestinal",
        "url": "https://www.eviq.org.au/medical-oncology/upper-gastrointestinal/hepatic/3881-hcc-advanced-or-metastatic-atezolizumab-and-b"
    },
    {
        "protocol_id": "3603 v.2",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "leNVAtinib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "12 mg ONCE a day",
                    "day": null,
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "leNVAtinib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "12 mg ONCE a day",
                    "day": null,
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "upper-gastrointestinal",
        "url": "https://www.eviq.org.au/medical-oncology/upper-gastrointestinal/hepatic/3603-hepatic-advanced-or-metastatic-lenvatinib"
    },
    {
        "protocol_id": "92 v.5",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "soRAFENib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "400 mg TWICE a day",
                    "day": null,
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "soRAFENib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "400 mg TWICE a day",
                    "day": null,
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "upper-gastrointestinal",
        "url": "https://www.eviq.org.au/medical-oncology/upper-gastrointestinal/hepatic/92-hepatic-advanced-sorafenib"
    },
    {
        "protocol_id": "1784 v.6",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Capecitabine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "750 mg/m2 TWICE a day *\n                            \n                                (Cap dose at 2500 mg/day)",
                    "day": "1 to 14",
                    "route": "PO"
                },
                {
                    "drug_name": "Temozolomide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "100 mg/m2 TWICE a day * #",
                    "day": "10 to 14",
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Capecitabine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "750 mg/m2 TWICE a day *\n                            \n                                (Cap dose at 2500 mg/day)",
                    "day": "1 to 14",
                    "route": "PO"
                },
                {
                    "drug_name": "Temozolomide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "100 mg/m2 TWICE a day * #",
                    "day": "10 to 14",
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "upper-gastrointestinal",
        "url": "https://www.eviq.org.au/medical-oncology/upper-gastrointestinal/neuroendocrine/1784-neuroendocrine-advanced-capecitabine-and-temo"
    },
    {
        "protocol_id": "1549 v.7",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6or until disease progression or unacceptable toxicity",
                    "dose": "5 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Etoposide **",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6or until disease progression or unacceptable toxicity",
                    "dose": "100 mg/m2",
                    "day": "1 to 3",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6or until disease progression or unacceptable toxicity",
                    "dose": "5 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Etoposide **",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6or until disease progression or unacceptable toxicity",
                    "dose": "100 mg/m2",
                    "day": "1 to 3",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "upper-gastrointestinal",
        "url": "https://www.eviq.org.au/medical-oncology/upper-gastrointestinal/neuroendocrine/1549-neuroendocrine-advanced-carboplatin-and-etopo"
    },
    {
        "protocol_id": "1220 v.6",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6or until disease progression or unacceptable toxicity",
                    "dose": "80 mg/m2 *",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Etoposide **",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6or until disease progression or unacceptable toxicity",
                    "dose": "100 mg/m2",
                    "day": "1 to 3",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6or until disease progression or unacceptable toxicity",
                    "dose": "80 mg/m2 *",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Etoposide **",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6or until disease progression or unacceptable toxicity",
                    "dose": "100 mg/m2",
                    "day": "1 to 3",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "upper-gastrointestinal",
        "url": "https://www.eviq.org.au/medical-oncology/upper-gastrointestinal/neuroendocrine/1220-neuroendocrine-advanced-cisplatin-and-etoposi"
    },
    {
        "protocol_id": "3841 v.3",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Lanreotide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous as clinically indicated and/or until disease progression or unacceptable toxicity",
                    "dose": "120 mg",
                    "day": "1",
                    "route": "Subcut"
                }
            ],
            [
                {
                    "drug_name": "Lanreotide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous as clinically indicated and/or until disease progression or unacceptable toxicity",
                    "dose": "120 mg",
                    "day": "1",
                    "route": "Subcut"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "upper-gastrointestinal",
        "url": "https://www.eviq.org.au/medical-oncology/upper-gastrointestinal/neuroendocrine/3841-neuroendocrine-advanced-lanreotide"
    },
    {
        "protocol_id": "706 v.7",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Octreotide (modified release) *",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous as clinically indicated and/or until disease progression or unacceptable toxicity",
                    "dose": "30 mg",
                    "day": "1",
                    "route": "IM"
                }
            ],
            [
                {
                    "drug_name": "Octreotide (modified release) *",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous as clinically indicated and/or until disease progression or unacceptable toxicity",
                    "dose": "30 mg",
                    "day": "1",
                    "route": "IM"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "upper-gastrointestinal",
        "url": "https://www.eviq.org.au/medical-oncology/upper-gastrointestinal/neuroendocrine/706-neuroendocrine-advanced-octreotide"
    },
    {
        "protocol_id": "3636 v.2",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Telotristat ethyl",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "250 mg THREE times a day",
                    "day": null,
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Telotristat ethyl",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "250 mg THREE times a day",
                    "day": null,
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "upper-gastrointestinal",
        "url": "https://www.eviq.org.au/medical-oncology/upper-gastrointestinal/neuroendocrine/3636-neuroendocrine-advanced-telotristat-ethyl"
    },
    {
        "protocol_id": "1543 v.5",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Everolimus",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "10 mg ONCE a day",
                    "day": null,
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Everolimus",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "10 mg ONCE a day",
                    "day": null,
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "upper-gastrointestinal",
        "url": "https://www.eviq.org.au/medical-oncology/upper-gastrointestinal/neuroendocrine/1543-neuroendocrine-pancreatic-advanced-everolimus"
    },
    {
        "protocol_id": "1221 v.7",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "sUNITinib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "37.5 mg ONCE a day *",
                    "day": null,
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "sUNITinib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "37.5 mg ONCE a day *",
                    "day": null,
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "upper-gastrointestinal",
        "url": "https://www.eviq.org.au/medical-oncology/upper-gastrointestinal/neuroendocrine/1221-neuroendocrine-pancreatic-advanced-sunitinib"
    },
    {
        "protocol_id": "774 v.6",
        "protocol_status": "Discontinued",
        "drug_sequence": [],
        "section_name": "medical-oncology",
        "category_name": "upper-gastrointestinal",
        "url": "https://www.eviq.org.au/medical-oncology/upper-gastrointestinal/neuroendocrine/774-neuroendocrine-advanced-lanreotide-90-mg-disco"
    },
    {
        "protocol_id": "4043 v.2",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Irinotecan",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "180 mg/m2 *",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Calcium folinate (Leucovorin)",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "50 mg **",
                    "day": "1",
                    "route": "IV bolus"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "400 mg/m2",
                    "day": "1",
                    "route": "IV"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "2,400 mg/m2",
                    "day": "1",
                    "route": "CIV via pump over 46 hours"
                }
            ],
            [
                {
                    "drug_name": "Irinotecan",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "180 mg/m2 *",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Calcium folinate (Leucovorin)",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "50 mg **",
                    "day": "1",
                    "route": "IV bolus"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "400 mg/m2",
                    "day": "1",
                    "route": "IV"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "2,400 mg/m2",
                    "day": "1",
                    "route": "CIV via pump over 46 hours"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "upper-gastrointestinal",
        "url": "https://www.eviq.org.au/medical-oncology/upper-gastrointestinal/pancreas-and-biliary/3386-redirect-id-4043"
    },
    {
        "protocol_id": "3385 v.6",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Capecitabine",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "8",
                    "dose": "1,250 mg/m2 TWICE a day *",
                    "day": "1 to 14",
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Capecitabine",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "8",
                    "dose": "1,250 mg/m2 TWICE a day *",
                    "day": "1 to 14",
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "upper-gastrointestinal",
        "url": "https://www.eviq.org.au/medical-oncology/upper-gastrointestinal/pancreas-and-biliary/3385-biliary-and-gallbladder-adjuvant-capecitabine"
    },
    {
        "protocol_id": "699 v.6",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Gemcitabine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "1,000 mg/m2",
                    "day": "1 and 8",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "5 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Gemcitabine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "1,000 mg/m2",
                    "day": "1 and 8",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "5 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "upper-gastrointestinal",
        "url": "https://www.eviq.org.au/medical-oncology/upper-gastrointestinal/pancreas-and-biliary/699-biliary-and-gallbladder-advanced-carboplatin-a"
    },
    {
        "protocol_id": "1200 v.5",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Gemcitabine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (maximum 8 cycles)",
                    "dose": "1,000 mg/m2",
                    "day": "1 and 8",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (maximum 8 cycles)",
                    "dose": "25 mg/m2",
                    "day": "1 and 8",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Gemcitabine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (maximum 8 cycles)",
                    "dose": "1,000 mg/m2",
                    "day": "1 and 8",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (maximum 8 cycles)",
                    "dose": "25 mg/m2",
                    "day": "1 and 8",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "upper-gastrointestinal",
        "url": "https://www.eviq.org.au/medical-oncology/upper-gastrointestinal/pancreas-and-biliary/1200-biliary-and-gallbladder-advanced-cisplatin-an"
    },
    {
        "protocol_id": "4301 v.2",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Durvalumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "8 (up to a maximum of 8 cycles)",
                    "dose": "1,500 mg",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Gemcitabine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "8 (up to a maximum of 8 cycles)",
                    "dose": "1,000 mg/m2",
                    "day": "1 and 8",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "8 (up to a maximum of 8 cycles)",
                    "dose": "25 mg/m2",
                    "day": "1 and 8",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Durvalumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "8 (up to a maximum of 8 cycles)",
                    "dose": "1,500 mg",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Gemcitabine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "8 (up to a maximum of 8 cycles)",
                    "dose": "1,000 mg/m2",
                    "day": "1 and 8",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "8 (up to a maximum of 8 cycles)",
                    "dose": "25 mg/m2",
                    "day": "1 and 8",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "upper-gastrointestinal",
        "url": "https://www.eviq.org.au/medical-oncology/upper-gastrointestinal/pancreas-and-biliary/4301-biliary-and-gallbladder-advanced-cisplatin-g"
    },
    {
        "protocol_id": "3875 v.4",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Oxaliplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (up to 12 cycles)",
                    "dose": "85 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Calcium folinate (Leucovorin)",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (up to 12 cycles)",
                    "dose": "50 mg *",
                    "day": "1",
                    "route": "IV bolus"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (up to 12 cycles)",
                    "dose": "400 mg/m2",
                    "day": "1",
                    "route": "IV"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (up to 12 cycles)",
                    "dose": "2,400 mg/m2",
                    "day": "1",
                    "route": "CIV via pump over 46 hours"
                }
            ],
            [
                {
                    "drug_name": "Oxaliplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (up to 12 cycles)",
                    "dose": "85 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Calcium folinate (Leucovorin)",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (up to 12 cycles)",
                    "dose": "50 mg *",
                    "day": "1",
                    "route": "IV bolus"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (up to 12 cycles)",
                    "dose": "400 mg/m2",
                    "day": "1",
                    "route": "IV"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (up to 12 cycles)",
                    "dose": "2,400 mg/m2",
                    "day": "1",
                    "route": "CIV via pump over 46 hours"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "upper-gastrointestinal",
        "url": "https://www.eviq.org.au/medical-oncology/upper-gastrointestinal/pancreas-and-biliary/3875-biliary-and-gallbladder-advanced-folfox6-mod"
    },
    {
        "protocol_id": "700 v.5",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Gemcitabine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "1,000 mg/m2",
                    "day": "1, 8, 15",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Gemcitabine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "1,000 mg/m2",
                    "day": "1, 8, 15",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "upper-gastrointestinal",
        "url": "https://www.eviq.org.au/medical-oncology/upper-gastrointestinal/pancreas-and-biliary/700-biliary-and-gallbladder-advanced-gemcitabine"
    },
    {
        "protocol_id": "4387 v.1",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Pemigatinib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continue until disease progression or unacceptable toxicity",
                    "dose": "13.5 mg",
                    "day": "1 to 14 *",
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Pemigatinib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continue until disease progression or unacceptable toxicity",
                    "dose": "13.5 mg",
                    "day": "1 to 14 *",
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "upper-gastrointestinal",
        "url": "https://www.eviq.org.au/medical-oncology/upper-gastrointestinal/pancreas-and-biliary/4387-biliary-and-gallbladder-advanced-pemigatinib"
    },
    {
        "protocol_id": "1945 v.6",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Gemcitabine",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "6",
                    "dose": "1,000 mg/m2",
                    "day": "1, 8, 15",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Capecitabine",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "6",
                    "dose": "830 mg/m2 TWICE a day",
                    "day": "1 to 21 *",
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Gemcitabine",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "6",
                    "dose": "1,000 mg/m2",
                    "day": "1, 8, 15",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Capecitabine",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "6",
                    "dose": "830 mg/m2 TWICE a day",
                    "day": "1 to 21 *",
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "upper-gastrointestinal",
        "url": "https://www.eviq.org.au/medical-oncology/upper-gastrointestinal/pancreas-and-biliary/1945-pancreas-adjuvant-capecitabine-and-gemcitabin"
    },
    {
        "protocol_id": "3521 v.6",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Oxaliplatin",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "12",
                    "dose": "85 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Irinotecan",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "12",
                    "dose": "150 mg/m2 ^",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Calcium folinate (Leucovorin)",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "12",
                    "dose": "50 mg *",
                    "day": "1",
                    "route": "IV bolus"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "12",
                    "dose": "2,400 mg/m2",
                    "day": "1",
                    "route": "CIV via pump over 46 hours"
                },
                {
                    "drug_name": "Pegfilgrastim",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "12",
                    "dose": "6 mg",
                    "day": "4",
                    "route": "Subcut"
                }
            ],
            [
                {
                    "drug_name": "Oxaliplatin",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "12",
                    "dose": "85 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Irinotecan",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "12",
                    "dose": "150 mg/m2 ^",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Calcium folinate (Leucovorin)",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "12",
                    "dose": "50 mg *",
                    "day": "1",
                    "route": "IV bolus"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "12",
                    "dose": "2,400 mg/m2",
                    "day": "1",
                    "route": "CIV via pump over 46 hours"
                },
                {
                    "drug_name": "Pegfilgrastim",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "12",
                    "dose": "6 mg",
                    "day": "4",
                    "route": "Subcut"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "upper-gastrointestinal",
        "url": "https://www.eviq.org.au/medical-oncology/upper-gastrointestinal/pancreas-and-biliary/3521-pancreas-adjuvant-folfirinox-modified-fluo"
    },
    {
        "protocol_id": "1218 v.7",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Gemcitabine",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "6",
                    "dose": "1,000 mg/m2",
                    "day": "1, 8, 15",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Gemcitabine",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "6",
                    "dose": "1,000 mg/m2",
                    "day": "1, 8, 15",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "upper-gastrointestinal",
        "url": "https://www.eviq.org.au/medical-oncology/upper-gastrointestinal/pancreas-and-biliary/1218-pancreas-adjuvant-gemcitabine"
    },
    {
        "protocol_id": "1757 v.6",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Capecitabine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "7 days",
                    "cycles": "with concurrent radiation therapy (usually 5 to 6 weeks)",
                    "dose": "830 mg/m2 TWICE a day *",
                    "day": "1 to 5",
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Capecitabine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "7 days",
                    "cycles": "with concurrent radiation therapy (usually 5 to 6 weeks)",
                    "dose": "830 mg/m2 TWICE a day *",
                    "day": "1 to 5",
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "upper-gastrointestinal",
        "url": "https://www.eviq.org.au/medical-oncology/upper-gastrointestinal/pancreas-and-biliary/1757-pancreas-advanced-capecitabine-chemoradiation"
    },
    {
        "protocol_id": "718 v.6",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "7 days",
                    "cycles": "with concurrent radiation therapy (usually 5 to 6 weeks)",
                    "dose": "1,575 mg/m2 (equivalent to 225 mg/m2/day) *",
                    "day": "1",
                    "route": "CIV over 7 days"
                }
            ],
            [
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "7 days",
                    "cycles": "with concurrent radiation therapy (usually 5 to 6 weeks)",
                    "dose": "1,575 mg/m2 (equivalent to 225 mg/m2/day) *",
                    "day": "1",
                    "route": "CIV over 7 days"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "upper-gastrointestinal",
        "url": "https://www.eviq.org.au/medical-oncology/upper-gastrointestinal/pancreas-and-biliary/718-pancreas-advanced-fluorouracil-chemoradiation"
    },
    {
        "protocol_id": "333 v.7",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Gemcitabine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "1,000 mg/m2",
                    "day": "1, 8, 15 *",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Gemcitabine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "1,000 mg/m2",
                    "day": "1, 8, 15 *",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "upper-gastrointestinal",
        "url": "https://www.eviq.org.au/medical-oncology/upper-gastrointestinal/pancreas-and-biliary/333-pancreas-advanced-gemcitabine"
    },
    {
        "protocol_id": "1512 v.6",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Oxaliplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (up to 12 cycles)",
                    "dose": "85 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Irinotecan",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (up to 12 cycles)",
                    "dose": "180 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Calcium folinate (Leucovorin)",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (up to 12 cycles)",
                    "dose": "50 mg *",
                    "day": "1",
                    "route": "IV bolus"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (up to 12 cycles)",
                    "dose": "400 mg/m2",
                    "day": "1",
                    "route": "IV"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (up to 12 cycles)",
                    "dose": "2,400 mg/m2",
                    "day": "1",
                    "route": "CIV via pump over 46 hours"
                }
            ],
            [
                {
                    "drug_name": "Oxaliplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (up to 12 cycles)",
                    "dose": "85 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Irinotecan",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (up to 12 cycles)",
                    "dose": "180 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Calcium folinate (Leucovorin)",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (up to 12 cycles)",
                    "dose": "50 mg *",
                    "day": "1",
                    "route": "IV bolus"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (up to 12 cycles)",
                    "dose": "400 mg/m2",
                    "day": "1",
                    "route": "IV"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (up to 12 cycles)",
                    "dose": "2,400 mg/m2",
                    "day": "1",
                    "route": "CIV via pump over 46 hours"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "upper-gastrointestinal",
        "url": "https://www.eviq.org.au/medical-oncology/upper-gastrointestinal/pancreas-and-biliary/1512-pancreas-metastatic-folfirinox-modified-fl"
    },
    {
        "protocol_id": "1375 v.4",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "nab-PACLitaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "125 mg/m2",
                    "day": "1, 8, 15",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Gemcitabine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "1,000 mg/m2",
                    "day": "1, 8, 15",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "nab-PACLitaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "125 mg/m2",
                    "day": "1, 8, 15",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Gemcitabine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "1,000 mg/m2",
                    "day": "1, 8, 15",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "upper-gastrointestinal",
        "url": "https://www.eviq.org.au/medical-oncology/upper-gastrointestinal/pancreas-and-biliary/1375-pancreas-metastatic-gemcitabine-and-nab-pacli"
    },
    {
        "protocol_id": "3387 v.3",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Irinotecan nanoliposomal",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "70 mg/m2 *",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Calcium folinate (Leucovorin)",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "50 mg **",
                    "day": "1",
                    "route": "IV bolus"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "2,400 mg/m2",
                    "day": "1",
                    "route": "CIV via pump over 46 hours"
                }
            ],
            [
                {
                    "drug_name": "Irinotecan nanoliposomal",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "70 mg/m2 *",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Calcium folinate (Leucovorin)",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "50 mg **",
                    "day": "1",
                    "route": "IV bolus"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "2,400 mg/m2",
                    "day": "1",
                    "route": "CIV via pump over 46 hours"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "upper-gastrointestinal",
        "url": "https://www.eviq.org.au/medical-oncology/upper-gastrointestinal/pancreas-and-biliary/3387-pancreas-metastatic-irinotecan-nanoliposomal"
    },
    {
        "protocol_id": "1548 v.5",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Calcium folinate (Leucovorin)",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "42 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "50 mg *",
                    "day": "1, 8, 15, 22",
                    "route": "IV bolus"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "42 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "2,000 mg/m2",
                    "day": "1, 8, 15, 22",
                    "route": "CIV via pump over 24 hours"
                },
                {
                    "drug_name": "Oxaliplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "42 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "85 mg/m2",
                    "day": "8 and 22",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Calcium folinate (Leucovorin)",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "42 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "50 mg *",
                    "day": "1, 8, 15, 22",
                    "route": "IV bolus"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "42 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "2,000 mg/m2",
                    "day": "1, 8, 15, 22",
                    "route": "CIV via pump over 24 hours"
                },
                {
                    "drug_name": "Oxaliplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "42 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "85 mg/m2",
                    "day": "8 and 22",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "upper-gastrointestinal",
        "url": "https://www.eviq.org.au/medical-oncology/upper-gastrointestinal/pancreas-and-biliary/1548-pancreas-metastatic-off-oxaliplatin-fluorour"
    },
    {
        "protocol_id": "4384 v.2",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Oxaliplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "14 days",
                    "cycles": "8(up to 12 cycles can be considered)",
                    "dose": "85 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Irinotecan",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "14 days",
                    "cycles": "8(up to 12 cycles can be considered)",
                    "dose": "150 mg/m2 *",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Calcium folinate (Leucovorin)",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "14 days",
                    "cycles": "8(up to 12 cycles can be considered)",
                    "dose": "50 mg **",
                    "day": "1",
                    "route": "IV bolus"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "14 days",
                    "cycles": "8(up to 12 cycles can be considered)",
                    "dose": "2,400 mg/m2",
                    "day": "1",
                    "route": "CIV via pump over 46 hours"
                },
                {
                    "drug_name": "Pegfilgrastim",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "14 days",
                    "cycles": "8(up to 12 cycles can be considered)",
                    "dose": "6 mg",
                    "day": "4",
                    "route": "Subcut"
                }
            ],
            [
                {
                    "drug_name": "Oxaliplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "14 days",
                    "cycles": "8(up to 12 cycles can be considered)",
                    "dose": "85 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Irinotecan",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "14 days",
                    "cycles": "8(up to 12 cycles can be considered)",
                    "dose": "150 mg/m2 *",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Calcium folinate (Leucovorin)",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "14 days",
                    "cycles": "8(up to 12 cycles can be considered)",
                    "dose": "50 mg **",
                    "day": "1",
                    "route": "IV bolus"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "14 days",
                    "cycles": "8(up to 12 cycles can be considered)",
                    "dose": "2,400 mg/m2",
                    "day": "1",
                    "route": "CIV via pump over 46 hours"
                },
                {
                    "drug_name": "Pegfilgrastim",
                    "is_adjuvant": false,
                    "is_neoadjuvant": true,
                    "frequency": "14 days",
                    "cycles": "8(up to 12 cycles can be considered)",
                    "dose": "6 mg",
                    "day": "4",
                    "route": "Subcut"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "upper-gastrointestinal",
        "url": "https://www.eviq.org.au/medical-oncology/upper-gastrointestinal/pancreas-and-biliary/4384-pancreas-neoadjuvant-folfirinox-modified"
    },
    {
        "protocol_id": "1561 v.6",
        "protocol_status": "Superseded",
        "drug_sequence": [
            [
                {
                    "drug_name": "Oxaliplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "85 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Calcium folinate (Leucovorin)",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "50 mg *",
                    "day": "1",
                    "route": "IV bolus"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "400 mg/m2",
                    "day": "1",
                    "route": "IV"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "2,400 mg/m2",
                    "day": "1",
                    "route": "CIV via pump over 46 hours"
                }
            ],
            [
                {
                    "drug_name": "Oxaliplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "85 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Calcium folinate (Leucovorin)",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "50 mg *",
                    "day": "1",
                    "route": "IV bolus"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "400 mg/m2",
                    "day": "1",
                    "route": "IV"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "2,400 mg/m2",
                    "day": "1",
                    "route": "CIV via pump over 46 hours"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "upper-gastrointestinal",
        "url": "https://www.eviq.org.au/medical-oncology/upper-gastrointestinal/pancreas-and-biliary/1561-pancreas-metastatic-folfox6-modified-fluor"
    },
    {
        "protocol_id": "331 v.3",
        "protocol_status": "Discontinued",
        "drug_sequence": [],
        "section_name": "medical-oncology",
        "category_name": "upper-gastrointestinal",
        "url": "https://www.eviq.org.au/medical-oncology/upper-gastrointestinal/pancreas-and-biliary/331-pancreas-adjuvant-fluorouracil-leucovorin-disc"
    },
    {
        "protocol_id": "332 v.4",
        "protocol_status": "Discontinued",
        "drug_sequence": [],
        "section_name": "medical-oncology",
        "category_name": "upper-gastrointestinal",
        "url": "https://www.eviq.org.au/medical-oncology/upper-gastrointestinal/pancreas-and-biliary/332-pancreas-advanced-gemcitabine-fixed-dose-rate"
    },
    {
        "protocol_id": "3937 v.2",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Mitotane",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "up to 6",
                    "dose": "1,000 mg",
                    "day": "1 to 3",
                    "route": "PO"
                },
                {
                    "drug_name": "Mitotane",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "up to 6",
                    "dose": "1,500 mg",
                    "day": "4 to 6",
                    "route": "PO"
                },
                {
                    "drug_name": "Mitotane",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "up to 6",
                    "dose": "2,000 mg",
                    "day": "7",
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Mitotane",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "up to 6",
                    "dose": "1,000 mg",
                    "day": "1 to 3",
                    "route": "PO"
                },
                {
                    "drug_name": "Mitotane",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "up to 6",
                    "dose": "1,500 mg",
                    "day": "4 to 6",
                    "route": "PO"
                },
                {
                    "drug_name": "Mitotane",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "up to 6",
                    "dose": "2,000 mg",
                    "day": "7",
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "urogenital",
        "url": "https://www.eviq.org.au/medical-oncology/urogenital/adrenocortical/3937-adrenocortical-carcinoma-metastatic-edp-etop"
    },
    {
        "protocol_id": "4406 v.2",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Nivolumab",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "13",
                    "dose": "480 mg * #",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Nivolumab",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "13",
                    "dose": "480 mg * #",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "urogenital",
        "url": "https://www.eviq.org.au/medical-oncology/urogenital/bladder-and-urothelial/4406-adjuvant-nivolumab-flat-dosing"
    },
    {
        "protocol_id": "3840 v.9",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Pembrolizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (see Indications and patient population section)",
                    "dose": "200 mg *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Pembrolizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (see Indications and patient population section)",
                    "dose": "200 mg *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "urogenital",
        "url": "https://www.eviq.org.au/medical-oncology/urogenital/bladder-and-urothelial/1990-redirect-id-3840"
    },
    {
        "protocol_id": "607 v.3",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Mycobacterium bovis (Bacillus Calmette and Guerin (BCG) strain)",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "7 days",
                    "cycles": "6for induction schedule (to be followed by maintenance schedule)",
                    "dose": "500 million CFU *",
                    "day": "1",
                    "route": "Intravesical"
                }
            ],
            [
                {
                    "drug_name": "Mycobacterium bovis (Bacillus Calmette and Guerin (BCG) strain)",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "7 days",
                    "cycles": "6for induction schedule (to be followed by maintenance schedule)",
                    "dose": "500 million CFU *",
                    "day": "1",
                    "route": "Intravesical"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "urogenital",
        "url": "https://www.eviq.org.au/medical-oncology/urogenital/bladder-and-urothelial/607-bladder-intravesical-bcg-oncotice"
    },
    {
        "protocol_id": "4320 v.1",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Gemcitabine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "7 days",
                    "cycles": "6",
                    "dose": "1,000 mg",
                    "day": "1",
                    "route": "Intravesical"
                },
                {
                    "drug_name": "DOCEtaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "7 days",
                    "cycles": "6",
                    "dose": "37.5 mg *",
                    "day": "1",
                    "route": "Intravesical"
                }
            ],
            [
                {
                    "drug_name": "Gemcitabine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "7 days",
                    "cycles": "6",
                    "dose": "1,000 mg",
                    "day": "1",
                    "route": "Intravesical"
                },
                {
                    "drug_name": "DOCEtaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "7 days",
                    "cycles": "6",
                    "dose": "37.5 mg *",
                    "day": "1",
                    "route": "Intravesical"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "urogenital",
        "url": "https://www.eviq.org.au/medical-oncology/urogenital/bladder-and-urothelial/4320-bladder-intravesical-docetaxel-and-gemcitabin"
    },
    {
        "protocol_id": "1758 v.4",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Gemcitabine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "7 days",
                    "cycles": "6",
                    "dose": "2,000 mg",
                    "day": "1",
                    "route": "Intravesical"
                }
            ],
            [
                {
                    "drug_name": "Gemcitabine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "7 days",
                    "cycles": "6",
                    "dose": "2,000 mg",
                    "day": "1",
                    "route": "Intravesical"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "urogenital",
        "url": "https://www.eviq.org.au/medical-oncology/urogenital/bladder-and-urothelial/1758-bladder-intravesical-gemcitabine"
    },
    {
        "protocol_id": "314 v.5",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Mitomycin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "7 days",
                    "cycles": "6(optimal number of cycles is unclear)",
                    "dose": "40 mg",
                    "day": "1",
                    "route": "Intravesical"
                }
            ],
            [
                {
                    "drug_name": "Mitomycin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "7 days",
                    "cycles": "6(optimal number of cycles is unclear)",
                    "dose": "40 mg",
                    "day": "1",
                    "route": "Intravesical"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "urogenital",
        "url": "https://www.eviq.org.au/medical-oncology/urogenital/bladder-and-urothelial/314-bladder-intravesical-mitomycin"
    },
    {
        "protocol_id": "3378 v.3",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Mitomycin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": "1within 24 hours (preferably within 6 hours) of TURBT",
                    "dose": "40 mg",
                    "day": "1",
                    "route": "Intravesical"
                }
            ],
            [
                {
                    "drug_name": "Mitomycin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": "1within 24 hours (preferably within 6 hours) of TURBT",
                    "dose": "40 mg",
                    "day": "1",
                    "route": "Intravesical"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "urogenital",
        "url": "https://www.eviq.org.au/medical-oncology/urogenital/bladder-and-urothelial/3378-bladder-intravesical-mitomycin-single-dose-po"
    },
    {
        "protocol_id": "1661 v.8",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Methotrexate",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "4",
                    "dose": "30 mg/m2",
                    "day": "1",
                    "route": "IV bolus"
                },
                {
                    "drug_name": "DOXOrubicin",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "4",
                    "dose": "30 mg/m2",
                    "day": "2",
                    "route": "IV"
                },
                {
                    "drug_name": "vinBLASTine",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "4",
                    "dose": "3 mg/m2",
                    "day": "2",
                    "route": "IV"
                },
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "4",
                    "dose": "70 mg/m2",
                    "day": "2",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Pegfilgrastim *",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "4",
                    "dose": "6 mg",
                    "day": "4",
                    "route": "Subcut"
                }
            ],
            [
                {
                    "drug_name": "Methotrexate",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "4",
                    "dose": "30 mg/m2",
                    "day": "1",
                    "route": "IV bolus"
                },
                {
                    "drug_name": "DOXOrubicin",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "4",
                    "dose": "30 mg/m2",
                    "day": "2",
                    "route": "IV"
                },
                {
                    "drug_name": "vinBLASTine",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "4",
                    "dose": "3 mg/m2",
                    "day": "2",
                    "route": "IV"
                },
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "4",
                    "dose": "70 mg/m2",
                    "day": "2",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Pegfilgrastim *",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "4",
                    "dose": "6 mg",
                    "day": "4",
                    "route": "Subcut"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "urogenital",
        "url": "https://www.eviq.org.au/medical-oncology/urogenital/bladder-and-urothelial/1661-bladder-urothelial-adjuvant-ddmvac-dose-dens"
    },
    {
        "protocol_id": "1440 v.7",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Mitomycin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": "1with concurrent radiation therapy",
                    "dose": "12 mg/m2",
                    "day": "1",
                    "route": "IV"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": "1with concurrent radiation therapy",
                    "dose": "2,500 mg/m2 *",
                    "day": "1 and 22",
                    "route": "CIV"
                }
            ],
            [
                {
                    "drug_name": "Mitomycin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": "1with concurrent radiation therapy",
                    "dose": "12 mg/m2",
                    "day": "1",
                    "route": "IV"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": "1with concurrent radiation therapy",
                    "dose": "2,500 mg/m2 *",
                    "day": "1 and 22",
                    "route": "CIV"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "urogenital",
        "url": "https://www.eviq.org.au/medical-oncology/urogenital/bladder-and-urothelial/1440-bladder-urothelial-fluorouracil-and-mitomycin"
    },
    {
        "protocol_id": "1441 v.6",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "7 days",
                    "cycles": "Continuous with concurrent radiation therapy; usually 6 cycles",
                    "dose": "35 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "7 days",
                    "cycles": "Continuous with concurrent radiation therapy; usually 6 cycles",
                    "dose": "35 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "urogenital",
        "url": "https://www.eviq.org.au/medical-oncology/urogenital/bladder-and-urothelial/1441-bladder-urothelial-locally-advanced-definitiv"
    },
    {
        "protocol_id": "4037 v.4",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Avelumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "800 mg",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Avelumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "800 mg",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "urogenital",
        "url": "https://www.eviq.org.au/medical-oncology/urogenital/bladder-and-urothelial/4037-bladder-urothelial-locally-advanced-or-metast"
    },
    {
        "protocol_id": "1446 v.7",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Gemcitabine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity; usually 6 cycles",
                    "dose": "1,000 mg/m2",
                    "day": "1 and 8",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity; usually 6 cycles",
                    "dose": "5 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Gemcitabine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity; usually 6 cycles",
                    "dose": "1,000 mg/m2",
                    "day": "1 and 8",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity; usually 6 cycles",
                    "dose": "5 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "urogenital",
        "url": "https://www.eviq.org.au/medical-oncology/urogenital/bladder-and-urothelial/1446-bladder-urothelial-locally-advanced-or-metast"
    },
    {
        "protocol_id": "312 v.7",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Gemcitabine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity; usually 6 cycles",
                    "dose": "1,000 mg/m2",
                    "day": "1 and 8",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity; usually 6 cycles",
                    "dose": "70 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Gemcitabine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity; usually 6 cycles",
                    "dose": "1,000 mg/m2",
                    "day": "1 and 8",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity; usually 6 cycles",
                    "dose": "70 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "urogenital",
        "url": "https://www.eviq.org.au/medical-oncology/urogenital/bladder-and-urothelial/312-bladder-urothelial-locally-advanced-or-metasta"
    },
    {
        "protocol_id": "4323 v.1",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Enfortumab vedotin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "1.25 mg/kg *\n                            \n                                (Cap dose at 125 mg)",
                    "day": "1, 8, 15",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Enfortumab vedotin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "1.25 mg/kg *\n                            \n                                (Cap dose at 125 mg)",
                    "day": "1, 8, 15",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "urogenital",
        "url": "https://www.eviq.org.au/medical-oncology/urogenital/bladder-and-urothelial/4323-bladder-urothelial-locally-advanced-or-metast"
    },
    {
        "protocol_id": "315 v.6",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "DOXOrubicin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity; up to 6 cycles",
                    "dose": "30 mg/m2",
                    "day": "2",
                    "route": "IV"
                },
                {
                    "drug_name": "vinBLASTine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity; up to 6 cycles",
                    "dose": "3 mg/m2",
                    "day": "2, 15, 22",
                    "route": "IV"
                },
                {
                    "drug_name": "Methotrexate",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity; up to 6 cycles",
                    "dose": "30 mg/m2",
                    "day": "1, 15, 22",
                    "route": "IV bolus"
                },
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity; up to 6 cycles",
                    "dose": "70 mg/m2",
                    "day": "2",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "DOXOrubicin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity; up to 6 cycles",
                    "dose": "30 mg/m2",
                    "day": "2",
                    "route": "IV"
                },
                {
                    "drug_name": "vinBLASTine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity; up to 6 cycles",
                    "dose": "3 mg/m2",
                    "day": "2, 15, 22",
                    "route": "IV"
                },
                {
                    "drug_name": "Methotrexate",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity; up to 6 cycles",
                    "dose": "30 mg/m2",
                    "day": "1, 15, 22",
                    "route": "IV bolus"
                },
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity; up to 6 cycles",
                    "dose": "70 mg/m2",
                    "day": "2",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "urogenital",
        "url": "https://www.eviq.org.au/medical-oncology/urogenital/bladder-and-urothelial/315-bladder-urothelial-metastatic-mvac-methotrexa"
    },
    {
        "protocol_id": "1616 v.10",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Methotrexate",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "3to 6 pre cystectomy",
                    "dose": "30 mg/m2",
                    "day": "1",
                    "route": "IV bolus"
                },
                {
                    "drug_name": "DOXOrubicin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "3to 6 pre cystectomy",
                    "dose": "30 mg/m2",
                    "day": "2",
                    "route": "IV"
                },
                {
                    "drug_name": "vinBLASTine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "3to 6 pre cystectomy",
                    "dose": "3 mg/m2",
                    "day": "2",
                    "route": "IV"
                },
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "3to 6 pre cystectomy",
                    "dose": "70 mg/m2",
                    "day": "2",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Pegfilgrastim *",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "3to 6 pre cystectomy",
                    "dose": "6 mg",
                    "day": "4",
                    "route": "Subcut"
                }
            ],
            [
                {
                    "drug_name": "Methotrexate",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "3to 6 pre cystectomy",
                    "dose": "30 mg/m2",
                    "day": "1",
                    "route": "IV bolus"
                },
                {
                    "drug_name": "DOXOrubicin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "3to 6 pre cystectomy",
                    "dose": "30 mg/m2",
                    "day": "2",
                    "route": "IV"
                },
                {
                    "drug_name": "vinBLASTine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "3to 6 pre cystectomy",
                    "dose": "3 mg/m2",
                    "day": "2",
                    "route": "IV"
                },
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "3to 6 pre cystectomy",
                    "dose": "70 mg/m2",
                    "day": "2",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Pegfilgrastim *",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "3to 6 pre cystectomy",
                    "dose": "6 mg",
                    "day": "4",
                    "route": "Subcut"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "urogenital",
        "url": "https://www.eviq.org.au/medical-oncology/urogenital/bladder-and-urothelial/1616-bladder-urothelial-neoad-ddmvac-dd-methotrex"
    },
    {
        "protocol_id": "4036 v.2",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Gemcitabine",
                    "is_adjuvant": true,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "4",
                    "dose": "1,000 mg/m2",
                    "day": "1 and 8",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": true,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "4",
                    "dose": "70 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Gemcitabine",
                    "is_adjuvant": true,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "4",
                    "dose": "1,000 mg/m2",
                    "day": "1 and 8",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": true,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "4",
                    "dose": "70 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "urogenital",
        "url": "https://www.eviq.org.au/medical-oncology/urogenital/bladder-and-urothelial/4036-bladder-urothelial-neoadjuvant-adjuvant-cispl"
    },
    {
        "protocol_id": "1021 v.7",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4to 6 unless disease progression or unacceptable toxicity",
                    "dose": "5 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Etoposide **",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4to 6 unless disease progression or unacceptable toxicity",
                    "dose": "100 mg/m2",
                    "day": "1 to 3",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4to 6 unless disease progression or unacceptable toxicity",
                    "dose": "5 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Etoposide **",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4to 6 unless disease progression or unacceptable toxicity",
                    "dose": "100 mg/m2",
                    "day": "1 to 3",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "urogenital",
        "url": "https://www.eviq.org.au/medical-oncology/urogenital/bladder-and-urothelial/1021-bladder-urothelial-small-cell-carboplatin-and"
    },
    {
        "protocol_id": "1725 v.6",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4to 6 unless disease progression or unacceptable toxicity",
                    "dose": "75 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Etoposide *",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4to 6 unless disease progression or unacceptable toxicity",
                    "dose": "120 mg/m2",
                    "day": "1 to 3",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4to 6 unless disease progression or unacceptable toxicity",
                    "dose": "75 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Etoposide *",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4to 6 unless disease progression or unacceptable toxicity",
                    "dose": "120 mg/m2",
                    "day": "1 to 3",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "urogenital",
        "url": "https://www.eviq.org.au/medical-oncology/urogenital/bladder-and-urothelial/1725-bladder-urothelial-small-cell-cisplatin-and-e"
    },
    {
        "protocol_id": "4080 v.2",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Gemcitabine",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4",
                    "dose": "1,000 mg/m2",
                    "day": "1 and 8",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4",
                    "dose": "5 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Gemcitabine",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4",
                    "dose": "1,000 mg/m2",
                    "day": "1 and 8",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4",
                    "dose": "5 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "urogenital",
        "url": "https://www.eviq.org.au/medical-oncology/urogenital/bladder-and-urothelial/4080-urothelial-upper-tract-adjuvant-carboplatin-a"
    },
    {
        "protocol_id": "313 v.7",
        "protocol_status": "Superseded",
        "drug_sequence": [
            [
                {
                    "drug_name": "Mycobacterium bovis (Bacillus Calmette and Guerin (BCG) strain) ImmuCyst\u00ae or TheraCys\u00ae*",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "7 days",
                    "cycles": "6for induction schedule (to be followed by maintenance schedule)",
                    "dose": "81 million CFU",
                    "day": "1",
                    "route": "Intravesical"
                }
            ],
            [
                {
                    "drug_name": "Mycobacterium bovis (Bacillus Calmette and Guerin (BCG) strain) ImmuCyst\u00ae or TheraCys\u00ae*",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "7 days",
                    "cycles": "6for induction schedule (to be followed by maintenance schedule)",
                    "dose": "81 million CFU",
                    "day": "1",
                    "route": "Intravesical"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "urogenital",
        "url": "https://www.eviq.org.au/medical-oncology/urogenital/bladder-and-urothelial/313-bladder-intravesical-bcg-connaught-strain-su"
    },
    {
        "protocol_id": "1406 v.5",
        "protocol_status": "Discontinued",
        "drug_sequence": [],
        "section_name": "medical-oncology",
        "category_name": "urogenital",
        "url": "https://www.eviq.org.au/medical-oncology/urogenital/bladder-and-urothelial/1406-bladder-urothelial-advanced-vinflunine-discon"
    },
    {
        "protocol_id": "311 v.6",
        "protocol_status": "Discontinued",
        "drug_sequence": [],
        "section_name": "medical-oncology",
        "category_name": "urogenital",
        "url": "https://www.eviq.org.au/medical-oncology/urogenital/bladder-and-urothelial/311-bladder-urothelial-locally-adv-or-met-carbopla"
    },
    {
        "protocol_id": "1438 v.6",
        "protocol_status": "Discontinued",
        "drug_sequence": [],
        "section_name": "medical-oncology",
        "category_name": "urogenital",
        "url": "https://www.eviq.org.au/medical-oncology/urogenital/bladder-and-urothelial/1438-bladder-urothelial-neoadjuvant-mvac-discontin"
    },
    {
        "protocol_id": "3737 v.4",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Olaparib (tablets)",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "300 mg TWICE a day",
                    "day": null,
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Olaparib (tablets)",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "300 mg TWICE a day",
                    "day": null,
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "urogenital",
        "url": "https://www.eviq.org.au/medical-oncology/urogenital/prostate/2030-redirect-id-3737"
    },
    {
        "protocol_id": "4319 v.1",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Darolutamide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "600 mg TWICE a day *",
                    "day": null,
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Darolutamide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "600 mg TWICE a day *",
                    "day": null,
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "urogenital",
        "url": "https://www.eviq.org.au/medical-oncology/urogenital/prostate/4319-prostate-darolutamide"
    },
    {
        "protocol_id": "4305 v.1",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Enzalutamide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "160 mg ONCE a day *",
                    "day": null,
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Enzalutamide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "160 mg ONCE a day *",
                    "day": null,
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "urogenital",
        "url": "https://www.eviq.org.au/medical-oncology/urogenital/prostate/4305-prostate-enzalutamide"
    },
    {
        "protocol_id": "4040 v.2",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Apalutamide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "240 mg ONCE a day *",
                    "day": null,
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Apalutamide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "240 mg ONCE a day *",
                    "day": null,
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "urogenital",
        "url": "https://www.eviq.org.au/medical-oncology/urogenital/prostate/4040-prostate-locally-advanced-or-metastatic-apalu"
    },
    {
        "protocol_id": "818 v.5",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Degarelix",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "240 mg",
                    "day": "1",
                    "route": "Subcut"
                }
            ],
            [
                {
                    "drug_name": "Degarelix",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "80 mg",
                    "day": "1",
                    "route": "Subcut"
                }
            ],
            [
                {
                    "drug_name": "Degarelix",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "240 mg",
                    "day": "1",
                    "route": "Subcut"
                }
            ],
            [
                {
                    "drug_name": "Degarelix",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "80 mg",
                    "day": "1",
                    "route": "Subcut"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "urogenital",
        "url": "https://www.eviq.org.au/medical-oncology/urogenital/prostate/818-prostate-locally-advanced-or-metastatic-degare"
    },
    {
        "protocol_id": "1476 v.4",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Bicalutamide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "50 mg ONCE a day",
                    "day": null,
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Bicalutamide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "50 mg ONCE a day",
                    "day": null,
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "urogenital",
        "url": "https://www.eviq.org.au/medical-oncology/urogenital/prostate/1476-prostate-metastatic-bicalutamide"
    },
    {
        "protocol_id": "1415 v.6",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Cabazitaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "20 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Prednisolone *",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "10 mg ONCE a day",
                    "day": "1 to 21",
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Cabazitaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "20 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Prednisolone *",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "10 mg ONCE a day",
                    "day": "1 to 21",
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "urogenital",
        "url": "https://www.eviq.org.au/medical-oncology/urogenital/prostate/1415-prostate-metastatic-cabazitaxel-three-weekly"
    },
    {
        "protocol_id": "1417 v.6",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Abiraterone",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "1,000 mg ONCE a day *",
                    "day": null,
                    "route": "PO"
                },
                {
                    "drug_name": "Prednisolone **",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "10 mg ONCE a day",
                    "day": null,
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Abiraterone",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "1,000 mg ONCE a day *",
                    "day": null,
                    "route": "PO"
                },
                {
                    "drug_name": "Prednisolone **",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "10 mg ONCE a day",
                    "day": null,
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "urogenital",
        "url": "https://www.eviq.org.au/medical-oncology/urogenital/prostate/1417-prostate-metastatic-castration-resistant-abir"
    },
    {
        "protocol_id": "4355 v.1",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Abiraterone micronised",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "500 mg ONCE a day *",
                    "day": null,
                    "route": "PO"
                },
                {
                    "drug_name": "Methylprednisolone",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "4 mg TWICE a day **",
                    "day": null,
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Abiraterone micronised",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "500 mg ONCE a day *",
                    "day": null,
                    "route": "PO"
                },
                {
                    "drug_name": "Methylprednisolone",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "4 mg TWICE a day **",
                    "day": null,
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "urogenital",
        "url": "https://www.eviq.org.au/medical-oncology/urogenital/prostate/4355-prostate-metastatic-castration-resistant-abir"
    },
    {
        "protocol_id": "3580 v.3",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Abiraterone",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "1,000 mg ONCE a day *",
                    "day": null,
                    "route": "PO"
                },
                {
                    "drug_name": "Prednisolone **",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "5 mg ONCE a day",
                    "day": null,
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Abiraterone",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "1,000 mg ONCE a day *",
                    "day": null,
                    "route": "PO"
                },
                {
                    "drug_name": "Prednisolone **",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "5 mg ONCE a day",
                    "day": null,
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "urogenital",
        "url": "https://www.eviq.org.au/medical-oncology/urogenital/prostate/3580-prostate-metastatic-castration-sensitive-abir"
    },
    {
        "protocol_id": "4374 v.1",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Abiraterone micronised",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "500 mg ONCE a day *",
                    "day": null,
                    "route": "PO"
                },
                {
                    "drug_name": "Methylprednisolone",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "4 mg ONCE a day **",
                    "day": null,
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Abiraterone micronised",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "500 mg ONCE a day *",
                    "day": null,
                    "route": "PO"
                },
                {
                    "drug_name": "Methylprednisolone",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "4 mg ONCE a day **",
                    "day": null,
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "urogenital",
        "url": "https://www.eviq.org.au/medical-oncology/urogenital/prostate/4374-prostate-metastatic-castration-sensitive-abir"
    },
    {
        "protocol_id": "1664 v.5",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "DOCEtaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6",
                    "dose": "75 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "DOCEtaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6",
                    "dose": "75 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "urogenital",
        "url": "https://www.eviq.org.au/medical-oncology/urogenital/prostate/1664-prostate-metastatic-castration-sensitive-doce"
    },
    {
        "protocol_id": "1301 v.4",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Denosumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until unacceptable toxicity",
                    "dose": "120 mg",
                    "day": "1",
                    "route": "Subcut"
                }
            ],
            [
                {
                    "drug_name": "Denosumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until unacceptable toxicity",
                    "dose": "120 mg",
                    "day": "1",
                    "route": "Subcut"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "urogenital",
        "url": "https://www.eviq.org.au/medical-oncology/urogenital/prostate/1301-prostate-metastatic-denosumab"
    },
    {
        "protocol_id": "249 v.8",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "DOCEtaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity; up to 10 cycles",
                    "dose": "75 mg/m2 *",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Prednisolone",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity; up to 10 cycles",
                    "dose": "10 mg ONCE a day **",
                    "day": "1 to 21",
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "DOCEtaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity; up to 10 cycles",
                    "dose": "75 mg/m2 *",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Prednisolone",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity; up to 10 cycles",
                    "dose": "10 mg ONCE a day **",
                    "day": "1 to 21",
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "urogenital",
        "url": "https://www.eviq.org.au/medical-oncology/urogenital/prostate/249-prostate-metastatic-docetaxel-three-weekly-and"
    },
    {
        "protocol_id": "2028 v.2",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "DOCEtaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "50 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Prednisolone *",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "10 mg ONCE a day",
                    "day": "1 to 14",
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "DOCEtaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "50 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Prednisolone *",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "10 mg ONCE a day",
                    "day": "1 to 14",
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "urogenital",
        "url": "https://www.eviq.org.au/medical-oncology/urogenital/prostate/2028-prostate-metastatic-docetaxel-two-weekly-and"
    },
    {
        "protocol_id": "308 v.5",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Goserelin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "12 weeks",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "10.8 mg",
                    "day": "1",
                    "route": "Subcut"
                }
            ],
            [
                {
                    "drug_name": "Goserelin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "12 weeks",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "10.8 mg",
                    "day": "1",
                    "route": "Subcut"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "urogenital",
        "url": "https://www.eviq.org.au/medical-oncology/urogenital/prostate/308-prostate-metastatic-goserelin"
    },
    {
        "protocol_id": "555 v.5",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Leuprorelin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "12 weeks",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "22.5 mg",
                    "day": "1",
                    "route": "Subcut"
                }
            ],
            [
                {
                    "drug_name": "Leuprorelin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "12 weeks",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "22.5 mg",
                    "day": "1",
                    "route": "Subcut"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "urogenital",
        "url": "https://www.eviq.org.au/medical-oncology/urogenital/prostate/555-prostate-metastatic-leuprorelin-eligard"
    },
    {
        "protocol_id": "321 v.5",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Leuprorelin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "12 weeks",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "22.5 mg",
                    "day": "1",
                    "route": "IM"
                }
            ],
            [
                {
                    "drug_name": "Leuprorelin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "12 weeks",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "22.5 mg",
                    "day": "1",
                    "route": "IM"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "urogenital",
        "url": "https://www.eviq.org.au/medical-oncology/urogenital/prostate/321-prostate-metastatic-leuprorelin-lucrin"
    },
    {
        "protocol_id": "1293 v.3",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Triptorelin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "24 weeks",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "22.5 mg",
                    "day": "1",
                    "route": "IM"
                }
            ],
            [
                {
                    "drug_name": "Triptorelin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "24 weeks",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "22.5 mg",
                    "day": "1",
                    "route": "IM"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "urogenital",
        "url": "https://www.eviq.org.au/medical-oncology/urogenital/prostate/1293-prostate-metastatic-triptorelin"
    },
    {
        "protocol_id": "552 v.6",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Zoledronic acid",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "12 weeks(cycles of 28 days also acceptable)",
                    "cycles": "Continuous",
                    "dose": "4 mg",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Zoledronic acid",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "12 weeks(cycles of 28 days also acceptable)",
                    "cycles": "Continuous",
                    "dose": "4 mg",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "urogenital",
        "url": "https://www.eviq.org.au/medical-oncology/urogenital/prostate/552-prostate-metastatic-zoledronic-acid"
    },
    {
        "protocol_id": "1480 v.4",
        "protocol_status": "Superseded",
        "drug_sequence": [
            [
                {
                    "drug_name": "Cyproterone",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "100 mg TWICE a day *",
                    "day": null,
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Cyproterone",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "100 mg TWICE a day *",
                    "day": null,
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "urogenital",
        "url": "https://www.eviq.org.au/medical-oncology/urogenital/prostate/1480-prostate-metastatic-cyproterone-superseded"
    },
    {
        "protocol_id": "1479 v.5",
        "protocol_status": "Superseded",
        "drug_sequence": [
            [
                {
                    "drug_name": "Flutamide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "250 mg THREE times a day",
                    "day": null,
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Flutamide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "250 mg THREE times a day",
                    "day": null,
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "urogenital",
        "url": "https://www.eviq.org.au/medical-oncology/urogenital/prostate/1479-prostate-metastatic-flutamide-superseded"
    },
    {
        "protocol_id": "256 v.8",
        "protocol_status": "Superseded",
        "drug_sequence": [
            [
                {
                    "drug_name": "Mitozantrone",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "12 mg/m2",
                    "day": "1",
                    "route": "IV"
                },
                {
                    "drug_name": "Prednisolone *",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "5 mg TWICE a day",
                    "day": "1 to 21",
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Mitozantrone",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "12 mg/m2",
                    "day": "1",
                    "route": "IV"
                },
                {
                    "drug_name": "Prednisolone *",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "5 mg TWICE a day",
                    "day": "1 to 21",
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "urogenital",
        "url": "https://www.eviq.org.au/medical-oncology/urogenital/prostate/256-prostate-metastatic-mitozantrone-and-prednisol"
    },
    {
        "protocol_id": "250 v.6",
        "protocol_status": "Discontinued",
        "drug_sequence": [],
        "section_name": "medical-oncology",
        "category_name": "urogenital",
        "url": "https://www.eviq.org.au/medical-oncology/urogenital/prostate/250-prostate-metastatic-docetaxel-weekly-and-predn"
    },
    {
        "protocol_id": "1478 v.3",
        "protocol_status": "Discontinued",
        "drug_sequence": [],
        "section_name": "medical-oncology",
        "category_name": "urogenital",
        "url": "https://www.eviq.org.au/medical-oncology/urogenital/prostate/1478-prostate-metastatic-nilutamide-discontinued"
    },
    {
        "protocol_id": "3594 v.8",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Nivolumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "480 mg * #",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Nivolumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "480 mg * #",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "urogenital",
        "url": "https://www.eviq.org.au/medical-oncology/urogenital/renal/3624-redirect-id-3594"
    },
    {
        "protocol_id": "3555 v.9",
        "protocol_status": "Superseded",
        "drug_sequence": [
            [
                {
                    "drug_name": "Nivolumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "3 mg/kg",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Nivolumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "3 mg/kg",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "urogenital",
        "url": "https://www.eviq.org.au/medical-oncology/urogenital/renal/1896-redirect-id-3555"
    },
    {
        "protocol_id": "3677 v.7",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Nivolumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity. Treatment cessation after 2 years of therapy may be considered.",
                    "dose": "480 mg * #",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Nivolumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity. Treatment cessation after 2 years of therapy may be considered.",
                    "dose": "480 mg * #",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "urogenital",
        "url": "https://www.eviq.org.au/medical-oncology/urogenital/renal/3680-redirect-id-3677"
    },
    {
        "protocol_id": "3682 v.6",
        "protocol_status": "Superseded",
        "drug_sequence": [
            [
                {
                    "drug_name": "Nivolumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity. Treatment cessation after 2 years of therapy may be considered.",
                    "dose": "3 mg/kg",
                    "day": "1 *",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Nivolumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity. Treatment cessation after 2 years of therapy may be considered.",
                    "dose": "3 mg/kg",
                    "day": "1 *",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "urogenital",
        "url": "https://www.eviq.org.au/medical-oncology/urogenital/renal/3563-redirect-id-3682"
    },
    {
        "protocol_id": "4322 v.1",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Pembrolizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (up to 35 cycles of pembrolizumab). Lenvatinib monotherapy can be continued beyond 35 cycles until disease progression or unacceptable toxicity.",
                    "dose": "200 mg *",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "leNVAtinib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (up to 35 cycles of pembrolizumab). Lenvatinib monotherapy can be continued beyond 35 cycles until disease progression or unacceptable toxicity.",
                    "dose": "20 mg ONCE a day **",
                    "day": "1 to 21",
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Pembrolizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (up to 35 cycles of pembrolizumab). Lenvatinib monotherapy can be continued beyond 35 cycles until disease progression or unacceptable toxicity.",
                    "dose": "200 mg *",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "leNVAtinib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (up to 35 cycles of pembrolizumab). Lenvatinib monotherapy can be continued beyond 35 cycles until disease progression or unacceptable toxicity.",
                    "dose": "20 mg ONCE a day **",
                    "day": "1 to 21",
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "urogenital",
        "url": "https://www.eviq.org.au/medical-oncology/urogenital/renal/4322-recurrent-or-metastatic-lenvatinib-and-pembro"
    },
    {
        "protocol_id": "4039 v.3",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Avelumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "800 mg *",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "aXITinib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "5 mg TWICE a day #",
                    "day": "1 to 14",
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Avelumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "800 mg *",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "aXITinib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "5 mg TWICE a day #",
                    "day": "1 to 14",
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "urogenital",
        "url": "https://www.eviq.org.au/medical-oncology/urogenital/renal/4039-renal-cell-metastatic-avelumab-and-axitinib"
    },
    {
        "protocol_id": "1488 v.5",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "aXITinib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "5 mg TWICE a day *",
                    "day": null,
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "aXITinib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "5 mg TWICE a day *",
                    "day": null,
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "urogenital",
        "url": "https://www.eviq.org.au/medical-oncology/urogenital/renal/1488-renal-cell-metastatic-axitinib"
    },
    {
        "protocol_id": "2027 v.4",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "cABOZANtinib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "60 mg ONCE a day *",
                    "day": null,
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "cABOZANtinib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "60 mg ONCE a day *",
                    "day": null,
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "urogenital",
        "url": "https://www.eviq.org.au/medical-oncology/urogenital/renal/2027-renal-cell-metastatic-cabozantinib"
    },
    {
        "protocol_id": "577 v.8",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Everolimus",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "10 mg ONCE a day",
                    "day": null,
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Everolimus",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "10 mg ONCE a day",
                    "day": null,
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "urogenital",
        "url": "https://www.eviq.org.au/medical-oncology/urogenital/renal/577-renal-cell-metastatic-everolimus"
    },
    {
        "protocol_id": "3561 v.10",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Nivolumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4",
                    "dose": "3 mg/kg",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Ipilimumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4",
                    "dose": "1 mg/kg",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Nivolumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4",
                    "dose": "3 mg/kg",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Ipilimumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4",
                    "dose": "1 mg/kg",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "urogenital",
        "url": "https://www.eviq.org.au/medical-oncology/urogenital/renal/3561-renal-cell-metastatic-ipilimumab-and-nivoluma"
    },
    {
        "protocol_id": "820 v.5",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "pAZOPanib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "800 mg ONCE a day",
                    "day": null,
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "pAZOPanib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "800 mg ONCE a day",
                    "day": null,
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "urogenital",
        "url": "https://www.eviq.org.au/medical-oncology/urogenital/renal/820-renal-cell-metastatic-pazopanib"
    },
    {
        "protocol_id": "323 v.6",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "soRAFENib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "400 mg TWICE a day",
                    "day": null,
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "soRAFENib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "400 mg TWICE a day",
                    "day": null,
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "urogenital",
        "url": "https://www.eviq.org.au/medical-oncology/urogenital/renal/323-renal-cell-metastatic-sorafenib"
    },
    {
        "protocol_id": "322 v.7",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "sUNITinib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "42 days(sunitinib is taken daily for 4 weeks then 2 weeks break)",
                    "cycles": "continuous until disease progression or unacceptable toxicity",
                    "dose": "50 mg ONCE a day *",
                    "day": "1 to 28",
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "sUNITinib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "42 days(sunitinib is taken daily for 4 weeks then 2 weeks break)",
                    "cycles": "continuous until disease progression or unacceptable toxicity",
                    "dose": "50 mg ONCE a day *",
                    "day": "1 to 28",
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "urogenital",
        "url": "https://www.eviq.org.au/medical-oncology/urogenital/renal/322-renal-cell-metastatic-sunitinib"
    },
    {
        "protocol_id": "91 v.6",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Temsirolimus",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "7 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "25 mg",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Temsirolimus",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "7 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "25 mg",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "urogenital",
        "url": "https://www.eviq.org.au/medical-oncology/urogenital/renal/91-renal-cell-metastatic-temsirolimus"
    },
    {
        "protocol_id": "576 v.4",
        "protocol_status": "Discontinued",
        "drug_sequence": [],
        "section_name": "medical-oncology",
        "category_name": "urogenital",
        "url": "https://www.eviq.org.au/medical-oncology/urogenital/renal/576-renal-cell-metastatic-bevacizumab-and-interfer"
    },
    {
        "protocol_id": "324 v.4",
        "protocol_status": "Discontinued",
        "drug_sequence": [],
        "section_name": "medical-oncology",
        "category_name": "urogenital",
        "url": "https://www.eviq.org.au/medical-oncology/urogenital/renal/324-renal-cell-metastatic-interferon-alfa-2a-disco"
    },
    {
        "protocol_id": "1176 v.4",
        "protocol_status": "Endorsed",
        "drug_sequence": [],
        "section_name": "medical-oncology",
        "category_name": "urogenital",
        "url": "https://www.eviq.org.au/medical-oncology/urogenital/testicular/3837-redirect-id-1176"
    },
    {
        "protocol_id": "1617 v.8",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "ciSplatin ^",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4",
                    "dose": "20 mg/m2",
                    "day": "1 to 5",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Etoposide ^*",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4",
                    "dose": "100 mg/m2",
                    "day": "1 to 5",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Pegfilgrastim **",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4",
                    "dose": "6 mg",
                    "day": "6",
                    "route": "Subcut"
                }
            ],
            [
                {
                    "drug_name": "ciSplatin ^",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4",
                    "dose": "20 mg/m2",
                    "day": "1 to 5",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Etoposide ^*",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4",
                    "dose": "100 mg/m2",
                    "day": "1 to 5",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Pegfilgrastim **",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4",
                    "dose": "6 mg",
                    "day": "6",
                    "route": "Subcut"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "urogenital",
        "url": "https://www.eviq.org.au/medical-oncology/urogenital/testicular/1617-testicular-germ-cell-advanced-or-metastatic-e"
    },
    {
        "protocol_id": "320 v.8",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Bleomycin #",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "3for good-risk disease (4 cycles for intermediate or poor-risk disease - see notes section below)",
                    "dose": "30,000 International Units",
                    "day": "1, 8, 15",
                    "route": "IM/IV"
                },
                {
                    "drug_name": "ciSplatin ^",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "3for good-risk disease (4 cycles for intermediate or poor-risk disease - see notes section below)",
                    "dose": "20 mg/m2",
                    "day": "1 to 5",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Etoposide ^*",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "3for good-risk disease (4 cycles for intermediate or poor-risk disease - see notes section below)",
                    "dose": "100 mg/m2",
                    "day": "1 to 5",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Pegfilgrastim **",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "3for good-risk disease (4 cycles for intermediate or poor-risk disease - see notes section below)",
                    "dose": "6 mg",
                    "day": "6",
                    "route": "Subcut"
                }
            ],
            [
                {
                    "drug_name": "Bleomycin #",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "3for good-risk disease (4 cycles for intermediate or poor-risk disease - see notes section below)",
                    "dose": "30,000 International Units",
                    "day": "1, 8, 15",
                    "route": "IM/IV"
                },
                {
                    "drug_name": "ciSplatin ^",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "3for good-risk disease (4 cycles for intermediate or poor-risk disease - see notes section below)",
                    "dose": "20 mg/m2",
                    "day": "1 to 5",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Etoposide ^*",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "3for good-risk disease (4 cycles for intermediate or poor-risk disease - see notes section below)",
                    "dose": "100 mg/m2",
                    "day": "1 to 5",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Pegfilgrastim **",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "3for good-risk disease (4 cycles for intermediate or poor-risk disease - see notes section below)",
                    "dose": "6 mg",
                    "day": "6",
                    "route": "Subcut"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "urogenital",
        "url": "https://www.eviq.org.au/medical-oncology/urogenital/testicular/320-testicular-germ-cell-metastatic-bep-bleomycin"
    },
    {
        "protocol_id": "318 v.9",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Etoposide *",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4",
                    "dose": "75 mg/m2",
                    "day": "1 to 5",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4",
                    "dose": "20 mg/m2",
                    "day": "1 to 5",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "iFOSFamide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4",
                    "dose": "1,200 mg/m2",
                    "day": "1 to 5",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Mesna",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4",
                    "dose": "1,200 mg/m2",
                    "day": "1 to 5",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Mesna",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4",
                    "dose": "2,000 mg at 2 hours and 6 hours after completion of ifosfamide infusion",
                    "day": "1 to 5",
                    "route": "PO"
                },
                {
                    "drug_name": "Pegfilgrastim",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4",
                    "dose": "6 mg",
                    "day": "6",
                    "route": "Subcut"
                }
            ],
            [
                {
                    "drug_name": "Etoposide *",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4",
                    "dose": "75 mg/m2",
                    "day": "1 to 5",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4",
                    "dose": "20 mg/m2",
                    "day": "1 to 5",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "iFOSFamide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4",
                    "dose": "1,200 mg/m2",
                    "day": "1 to 5",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Mesna",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4",
                    "dose": "1,200 mg/m2",
                    "day": "1 to 5",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Mesna",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4",
                    "dose": "2,000 mg at 2 hours and 6 hours after completion of ifosfamide infusion",
                    "day": "1 to 5",
                    "route": "PO"
                },
                {
                    "drug_name": "Pegfilgrastim",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4",
                    "dose": "6 mg",
                    "day": "6",
                    "route": "Subcut"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "urogenital",
        "url": "https://www.eviq.org.au/medical-oncology/urogenital/testicular/318-testicular-germ-cell-metastatic-vip-etoposide"
    },
    {
        "protocol_id": "319 v.10",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Bleomycin #",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "1 or 2 cycles",
                    "dose": "30,000 International Units",
                    "day": "1, 8, 15",
                    "route": "IM/IV"
                },
                {
                    "drug_name": "ciSplatin ^",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "1 or 2 cycles",
                    "dose": "20 mg/m2",
                    "day": "1 to 5",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Etoposide ^*",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "1 or 2 cycles",
                    "dose": "100 mg/m2",
                    "day": "1 to 5",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Pegfilgrastim **",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "1 or 2 cycles",
                    "dose": "6 mg",
                    "day": "6",
                    "route": "Subcut"
                }
            ],
            [
                {
                    "drug_name": "Bleomycin #",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "1 or 2 cycles",
                    "dose": "30,000 International Units",
                    "day": "1, 8, 15",
                    "route": "IM/IV"
                },
                {
                    "drug_name": "ciSplatin ^",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "1 or 2 cycles",
                    "dose": "20 mg/m2",
                    "day": "1 to 5",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Etoposide ^*",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "1 or 2 cycles",
                    "dose": "100 mg/m2",
                    "day": "1 to 5",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Pegfilgrastim **",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "1 or 2 cycles",
                    "dose": "6 mg",
                    "day": "6",
                    "route": "Subcut"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "urogenital",
        "url": "https://www.eviq.org.au/medical-oncology/urogenital/testicular/319-testicular-germ-cell-non-seminoma-adjuvant-bep"
    },
    {
        "protocol_id": "316 v.9",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "PACLitaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4",
                    "dose": "175 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4",
                    "dose": "20 mg/m2",
                    "day": "1 to 5",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Mesna",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4",
                    "dose": "400 mg/m2",
                    "day": "1 to 5",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "iFOSFamide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4",
                    "dose": "1,200 mg/m2",
                    "day": "1 to 5",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Mesna *",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4",
                    "dose": "400 mg/m2 at 4 hours and 8 hours after completion of ifosfamide infusion",
                    "day": "1 to 5",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Pegfilgrastim",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4",
                    "dose": "6 mg",
                    "day": "6",
                    "route": "Subcut"
                }
            ],
            [
                {
                    "drug_name": "PACLitaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4",
                    "dose": "175 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4",
                    "dose": "20 mg/m2",
                    "day": "1 to 5",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Mesna",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4",
                    "dose": "400 mg/m2",
                    "day": "1 to 5",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "iFOSFamide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4",
                    "dose": "1,200 mg/m2",
                    "day": "1 to 5",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Mesna *",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4",
                    "dose": "400 mg/m2 at 4 hours and 8 hours after completion of ifosfamide infusion",
                    "day": "1 to 5",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Pegfilgrastim",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4",
                    "dose": "6 mg",
                    "day": "6",
                    "route": "Subcut"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "urogenital",
        "url": "https://www.eviq.org.au/medical-oncology/urogenital/testicular/316-testicular-germ-cell-recurrent-tip-paclitaxel"
    },
    {
        "protocol_id": "317 v.9",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "vinBLASTine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4",
                    "dose": "0.11 mg/kg",
                    "day": "1 and 2",
                    "route": "IV"
                },
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4",
                    "dose": "20 mg/m2",
                    "day": "1 to 5",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "iFOSFamide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4",
                    "dose": "1,200 mg/m2",
                    "day": "1 to 5",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Mesna",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4",
                    "dose": "1,200 mg/m2",
                    "day": "1 to 5",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Mesna",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4",
                    "dose": "2,000 mg at 2 hours and 6 hours after completion of ifosfamide infusion",
                    "day": "1 to 5",
                    "route": "PO"
                },
                {
                    "drug_name": "Pegfilgrastim",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4",
                    "dose": "6 mg",
                    "day": "6",
                    "route": "Subcut"
                }
            ],
            [
                {
                    "drug_name": "vinBLASTine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4",
                    "dose": "0.11 mg/kg",
                    "day": "1 and 2",
                    "route": "IV"
                },
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4",
                    "dose": "20 mg/m2",
                    "day": "1 to 5",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "iFOSFamide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4",
                    "dose": "1,200 mg/m2",
                    "day": "1 to 5",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Mesna",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4",
                    "dose": "1,200 mg/m2",
                    "day": "1 to 5",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Mesna",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4",
                    "dose": "2,000 mg at 2 hours and 6 hours after completion of ifosfamide infusion",
                    "day": "1 to 5",
                    "route": "PO"
                },
                {
                    "drug_name": "Pegfilgrastim",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4",
                    "dose": "6 mg",
                    "day": "6",
                    "route": "Subcut"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "urogenital",
        "url": "https://www.eviq.org.au/medical-oncology/urogenital/testicular/317-testicular-germ-cell-recurrent-veip-vinblasti"
    },
    {
        "protocol_id": "325 v.6",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": "1",
                    "dose": "7 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": "1",
                    "dose": "7 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "urogenital",
        "url": "https://www.eviq.org.au/medical-oncology/urogenital/testicular/325-testicular-germ-cell-seminoma-adjuvant-carbopl"
    },
    {
        "protocol_id": "3937 v.2",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Mitotane",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "up to 6",
                    "dose": "1,000 mg",
                    "day": "1 to 3",
                    "route": "PO"
                },
                {
                    "drug_name": "Mitotane",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "up to 6",
                    "dose": "1,500 mg",
                    "day": "4 to 6",
                    "route": "PO"
                },
                {
                    "drug_name": "Mitotane",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "up to 6",
                    "dose": "2,000 mg",
                    "day": "7",
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Mitotane",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "up to 6",
                    "dose": "1,000 mg",
                    "day": "1 to 3",
                    "route": "PO"
                },
                {
                    "drug_name": "Mitotane",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "up to 6",
                    "dose": "1,500 mg",
                    "day": "4 to 6",
                    "route": "PO"
                },
                {
                    "drug_name": "Mitotane",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "up to 6",
                    "dose": "2,000 mg",
                    "day": "7",
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "urogenital",
        "url": "https://www.eviq.org.au/medical-oncology/urogenital/adrenocortical/3937-adrenocortical-carcinoma-metastatic-edp-etop"
    },
    {
        "protocol_id": "4406 v.2",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Nivolumab",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "13",
                    "dose": "480 mg * #",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Nivolumab",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "13",
                    "dose": "480 mg * #",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "urogenital",
        "url": "https://www.eviq.org.au/medical-oncology/urogenital/bladder-and-urothelial/4406-adjuvant-nivolumab-flat-dosing"
    },
    {
        "protocol_id": "3840 v.9",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Pembrolizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (see Indications and patient population section)",
                    "dose": "200 mg *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Pembrolizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (see Indications and patient population section)",
                    "dose": "200 mg *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "urogenital",
        "url": "https://www.eviq.org.au/medical-oncology/urogenital/bladder-and-urothelial/1990-redirect-id-3840"
    },
    {
        "protocol_id": "607 v.3",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Mycobacterium bovis (Bacillus Calmette and Guerin (BCG) strain)",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "7 days",
                    "cycles": "6for induction schedule (to be followed by maintenance schedule)",
                    "dose": "500 million CFU *",
                    "day": "1",
                    "route": "Intravesical"
                }
            ],
            [
                {
                    "drug_name": "Mycobacterium bovis (Bacillus Calmette and Guerin (BCG) strain)",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "7 days",
                    "cycles": "6for induction schedule (to be followed by maintenance schedule)",
                    "dose": "500 million CFU *",
                    "day": "1",
                    "route": "Intravesical"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "urogenital",
        "url": "https://www.eviq.org.au/medical-oncology/urogenital/bladder-and-urothelial/607-bladder-intravesical-bcg-oncotice"
    },
    {
        "protocol_id": "4320 v.1",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Gemcitabine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "7 days",
                    "cycles": "6",
                    "dose": "1,000 mg",
                    "day": "1",
                    "route": "Intravesical"
                },
                {
                    "drug_name": "DOCEtaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "7 days",
                    "cycles": "6",
                    "dose": "37.5 mg *",
                    "day": "1",
                    "route": "Intravesical"
                }
            ],
            [
                {
                    "drug_name": "Gemcitabine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "7 days",
                    "cycles": "6",
                    "dose": "1,000 mg",
                    "day": "1",
                    "route": "Intravesical"
                },
                {
                    "drug_name": "DOCEtaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "7 days",
                    "cycles": "6",
                    "dose": "37.5 mg *",
                    "day": "1",
                    "route": "Intravesical"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "urogenital",
        "url": "https://www.eviq.org.au/medical-oncology/urogenital/bladder-and-urothelial/4320-bladder-intravesical-docetaxel-and-gemcitabin"
    },
    {
        "protocol_id": "1758 v.4",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Gemcitabine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "7 days",
                    "cycles": "6",
                    "dose": "2,000 mg",
                    "day": "1",
                    "route": "Intravesical"
                }
            ],
            [
                {
                    "drug_name": "Gemcitabine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "7 days",
                    "cycles": "6",
                    "dose": "2,000 mg",
                    "day": "1",
                    "route": "Intravesical"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "urogenital",
        "url": "https://www.eviq.org.au/medical-oncology/urogenital/bladder-and-urothelial/1758-bladder-intravesical-gemcitabine"
    },
    {
        "protocol_id": "314 v.5",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Mitomycin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "7 days",
                    "cycles": "6(optimal number of cycles is unclear)",
                    "dose": "40 mg",
                    "day": "1",
                    "route": "Intravesical"
                }
            ],
            [
                {
                    "drug_name": "Mitomycin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "7 days",
                    "cycles": "6(optimal number of cycles is unclear)",
                    "dose": "40 mg",
                    "day": "1",
                    "route": "Intravesical"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "urogenital",
        "url": "https://www.eviq.org.au/medical-oncology/urogenital/bladder-and-urothelial/314-bladder-intravesical-mitomycin"
    },
    {
        "protocol_id": "3378 v.3",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Mitomycin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": "1within 24 hours (preferably within 6 hours) of TURBT",
                    "dose": "40 mg",
                    "day": "1",
                    "route": "Intravesical"
                }
            ],
            [
                {
                    "drug_name": "Mitomycin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": "1within 24 hours (preferably within 6 hours) of TURBT",
                    "dose": "40 mg",
                    "day": "1",
                    "route": "Intravesical"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "urogenital",
        "url": "https://www.eviq.org.au/medical-oncology/urogenital/bladder-and-urothelial/3378-bladder-intravesical-mitomycin-single-dose-po"
    },
    {
        "protocol_id": "1661 v.8",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Methotrexate",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "4",
                    "dose": "30 mg/m2",
                    "day": "1",
                    "route": "IV bolus"
                },
                {
                    "drug_name": "DOXOrubicin",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "4",
                    "dose": "30 mg/m2",
                    "day": "2",
                    "route": "IV"
                },
                {
                    "drug_name": "vinBLASTine",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "4",
                    "dose": "3 mg/m2",
                    "day": "2",
                    "route": "IV"
                },
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "4",
                    "dose": "70 mg/m2",
                    "day": "2",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Pegfilgrastim *",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "4",
                    "dose": "6 mg",
                    "day": "4",
                    "route": "Subcut"
                }
            ],
            [
                {
                    "drug_name": "Methotrexate",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "4",
                    "dose": "30 mg/m2",
                    "day": "1",
                    "route": "IV bolus"
                },
                {
                    "drug_name": "DOXOrubicin",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "4",
                    "dose": "30 mg/m2",
                    "day": "2",
                    "route": "IV"
                },
                {
                    "drug_name": "vinBLASTine",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "4",
                    "dose": "3 mg/m2",
                    "day": "2",
                    "route": "IV"
                },
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "4",
                    "dose": "70 mg/m2",
                    "day": "2",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Pegfilgrastim *",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "4",
                    "dose": "6 mg",
                    "day": "4",
                    "route": "Subcut"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "urogenital",
        "url": "https://www.eviq.org.au/medical-oncology/urogenital/bladder-and-urothelial/1661-bladder-urothelial-adjuvant-ddmvac-dose-dens"
    },
    {
        "protocol_id": "1440 v.7",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Mitomycin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": "1with concurrent radiation therapy",
                    "dose": "12 mg/m2",
                    "day": "1",
                    "route": "IV"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": "1with concurrent radiation therapy",
                    "dose": "2,500 mg/m2 *",
                    "day": "1 and 22",
                    "route": "CIV"
                }
            ],
            [
                {
                    "drug_name": "Mitomycin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": "1with concurrent radiation therapy",
                    "dose": "12 mg/m2",
                    "day": "1",
                    "route": "IV"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": "1with concurrent radiation therapy",
                    "dose": "2,500 mg/m2 *",
                    "day": "1 and 22",
                    "route": "CIV"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "urogenital",
        "url": "https://www.eviq.org.au/medical-oncology/urogenital/bladder-and-urothelial/1440-bladder-urothelial-fluorouracil-and-mitomycin"
    },
    {
        "protocol_id": "1441 v.6",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "7 days",
                    "cycles": "Continuous with concurrent radiation therapy; usually 6 cycles",
                    "dose": "35 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "7 days",
                    "cycles": "Continuous with concurrent radiation therapy; usually 6 cycles",
                    "dose": "35 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "urogenital",
        "url": "https://www.eviq.org.au/medical-oncology/urogenital/bladder-and-urothelial/1441-bladder-urothelial-locally-advanced-definitiv"
    },
    {
        "protocol_id": "4037 v.4",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Avelumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "800 mg",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Avelumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "800 mg",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "urogenital",
        "url": "https://www.eviq.org.au/medical-oncology/urogenital/bladder-and-urothelial/4037-bladder-urothelial-locally-advanced-or-metast"
    },
    {
        "protocol_id": "1446 v.7",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Gemcitabine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity; usually 6 cycles",
                    "dose": "1,000 mg/m2",
                    "day": "1 and 8",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity; usually 6 cycles",
                    "dose": "5 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Gemcitabine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity; usually 6 cycles",
                    "dose": "1,000 mg/m2",
                    "day": "1 and 8",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity; usually 6 cycles",
                    "dose": "5 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "urogenital",
        "url": "https://www.eviq.org.au/medical-oncology/urogenital/bladder-and-urothelial/1446-bladder-urothelial-locally-advanced-or-metast"
    },
    {
        "protocol_id": "312 v.7",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Gemcitabine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity; usually 6 cycles",
                    "dose": "1,000 mg/m2",
                    "day": "1 and 8",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity; usually 6 cycles",
                    "dose": "70 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Gemcitabine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity; usually 6 cycles",
                    "dose": "1,000 mg/m2",
                    "day": "1 and 8",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity; usually 6 cycles",
                    "dose": "70 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "urogenital",
        "url": "https://www.eviq.org.au/medical-oncology/urogenital/bladder-and-urothelial/312-bladder-urothelial-locally-advanced-or-metasta"
    },
    {
        "protocol_id": "4323 v.1",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Enfortumab vedotin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "1.25 mg/kg *\n                            \n                                (Cap dose at 125 mg)",
                    "day": "1, 8, 15",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Enfortumab vedotin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "1.25 mg/kg *\n                            \n                                (Cap dose at 125 mg)",
                    "day": "1, 8, 15",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "urogenital",
        "url": "https://www.eviq.org.au/medical-oncology/urogenital/bladder-and-urothelial/4323-bladder-urothelial-locally-advanced-or-metast"
    },
    {
        "protocol_id": "315 v.6",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "DOXOrubicin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity; up to 6 cycles",
                    "dose": "30 mg/m2",
                    "day": "2",
                    "route": "IV"
                },
                {
                    "drug_name": "vinBLASTine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity; up to 6 cycles",
                    "dose": "3 mg/m2",
                    "day": "2, 15, 22",
                    "route": "IV"
                },
                {
                    "drug_name": "Methotrexate",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity; up to 6 cycles",
                    "dose": "30 mg/m2",
                    "day": "1, 15, 22",
                    "route": "IV bolus"
                },
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity; up to 6 cycles",
                    "dose": "70 mg/m2",
                    "day": "2",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "DOXOrubicin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity; up to 6 cycles",
                    "dose": "30 mg/m2",
                    "day": "2",
                    "route": "IV"
                },
                {
                    "drug_name": "vinBLASTine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity; up to 6 cycles",
                    "dose": "3 mg/m2",
                    "day": "2, 15, 22",
                    "route": "IV"
                },
                {
                    "drug_name": "Methotrexate",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity; up to 6 cycles",
                    "dose": "30 mg/m2",
                    "day": "1, 15, 22",
                    "route": "IV bolus"
                },
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity; up to 6 cycles",
                    "dose": "70 mg/m2",
                    "day": "2",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "urogenital",
        "url": "https://www.eviq.org.au/medical-oncology/urogenital/bladder-and-urothelial/315-bladder-urothelial-metastatic-mvac-methotrexa"
    },
    {
        "protocol_id": "1616 v.10",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Methotrexate",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "3to 6 pre cystectomy",
                    "dose": "30 mg/m2",
                    "day": "1",
                    "route": "IV bolus"
                },
                {
                    "drug_name": "DOXOrubicin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "3to 6 pre cystectomy",
                    "dose": "30 mg/m2",
                    "day": "2",
                    "route": "IV"
                },
                {
                    "drug_name": "vinBLASTine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "3to 6 pre cystectomy",
                    "dose": "3 mg/m2",
                    "day": "2",
                    "route": "IV"
                },
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "3to 6 pre cystectomy",
                    "dose": "70 mg/m2",
                    "day": "2",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Pegfilgrastim *",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "3to 6 pre cystectomy",
                    "dose": "6 mg",
                    "day": "4",
                    "route": "Subcut"
                }
            ],
            [
                {
                    "drug_name": "Methotrexate",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "3to 6 pre cystectomy",
                    "dose": "30 mg/m2",
                    "day": "1",
                    "route": "IV bolus"
                },
                {
                    "drug_name": "DOXOrubicin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "3to 6 pre cystectomy",
                    "dose": "30 mg/m2",
                    "day": "2",
                    "route": "IV"
                },
                {
                    "drug_name": "vinBLASTine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "3to 6 pre cystectomy",
                    "dose": "3 mg/m2",
                    "day": "2",
                    "route": "IV"
                },
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "3to 6 pre cystectomy",
                    "dose": "70 mg/m2",
                    "day": "2",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Pegfilgrastim *",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "3to 6 pre cystectomy",
                    "dose": "6 mg",
                    "day": "4",
                    "route": "Subcut"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "urogenital",
        "url": "https://www.eviq.org.au/medical-oncology/urogenital/bladder-and-urothelial/1616-bladder-urothelial-neoad-ddmvac-dd-methotrex"
    },
    {
        "protocol_id": "4036 v.2",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Gemcitabine",
                    "is_adjuvant": true,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "4",
                    "dose": "1,000 mg/m2",
                    "day": "1 and 8",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": true,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "4",
                    "dose": "70 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Gemcitabine",
                    "is_adjuvant": true,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "4",
                    "dose": "1,000 mg/m2",
                    "day": "1 and 8",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": true,
                    "is_neoadjuvant": true,
                    "frequency": "21 days",
                    "cycles": "4",
                    "dose": "70 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "urogenital",
        "url": "https://www.eviq.org.au/medical-oncology/urogenital/bladder-and-urothelial/4036-bladder-urothelial-neoadjuvant-adjuvant-cispl"
    },
    {
        "protocol_id": "1021 v.7",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4to 6 unless disease progression or unacceptable toxicity",
                    "dose": "5 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Etoposide **",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4to 6 unless disease progression or unacceptable toxicity",
                    "dose": "100 mg/m2",
                    "day": "1 to 3",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4to 6 unless disease progression or unacceptable toxicity",
                    "dose": "5 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Etoposide **",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4to 6 unless disease progression or unacceptable toxicity",
                    "dose": "100 mg/m2",
                    "day": "1 to 3",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "urogenital",
        "url": "https://www.eviq.org.au/medical-oncology/urogenital/bladder-and-urothelial/1021-bladder-urothelial-small-cell-carboplatin-and"
    },
    {
        "protocol_id": "1725 v.6",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4to 6 unless disease progression or unacceptable toxicity",
                    "dose": "75 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Etoposide *",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4to 6 unless disease progression or unacceptable toxicity",
                    "dose": "120 mg/m2",
                    "day": "1 to 3",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4to 6 unless disease progression or unacceptable toxicity",
                    "dose": "75 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Etoposide *",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4to 6 unless disease progression or unacceptable toxicity",
                    "dose": "120 mg/m2",
                    "day": "1 to 3",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "urogenital",
        "url": "https://www.eviq.org.au/medical-oncology/urogenital/bladder-and-urothelial/1725-bladder-urothelial-small-cell-cisplatin-and-e"
    },
    {
        "protocol_id": "4080 v.2",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Gemcitabine",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4",
                    "dose": "1,000 mg/m2",
                    "day": "1 and 8",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4",
                    "dose": "5 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Gemcitabine",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4",
                    "dose": "1,000 mg/m2",
                    "day": "1 and 8",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4",
                    "dose": "5 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "urogenital",
        "url": "https://www.eviq.org.au/medical-oncology/urogenital/bladder-and-urothelial/4080-urothelial-upper-tract-adjuvant-carboplatin-a"
    },
    {
        "protocol_id": "313 v.7",
        "protocol_status": "Superseded",
        "drug_sequence": [
            [
                {
                    "drug_name": "Mycobacterium bovis (Bacillus Calmette and Guerin (BCG) strain) ImmuCyst\u00ae or TheraCys\u00ae*",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "7 days",
                    "cycles": "6for induction schedule (to be followed by maintenance schedule)",
                    "dose": "81 million CFU",
                    "day": "1",
                    "route": "Intravesical"
                }
            ],
            [
                {
                    "drug_name": "Mycobacterium bovis (Bacillus Calmette and Guerin (BCG) strain) ImmuCyst\u00ae or TheraCys\u00ae*",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "7 days",
                    "cycles": "6for induction schedule (to be followed by maintenance schedule)",
                    "dose": "81 million CFU",
                    "day": "1",
                    "route": "Intravesical"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "urogenital",
        "url": "https://www.eviq.org.au/medical-oncology/urogenital/bladder-and-urothelial/313-bladder-intravesical-bcg-connaught-strain-su"
    },
    {
        "protocol_id": "1406 v.5",
        "protocol_status": "Discontinued",
        "drug_sequence": [],
        "section_name": "medical-oncology",
        "category_name": "urogenital",
        "url": "https://www.eviq.org.au/medical-oncology/urogenital/bladder-and-urothelial/1406-bladder-urothelial-advanced-vinflunine-discon"
    },
    {
        "protocol_id": "311 v.6",
        "protocol_status": "Discontinued",
        "drug_sequence": [],
        "section_name": "medical-oncology",
        "category_name": "urogenital",
        "url": "https://www.eviq.org.au/medical-oncology/urogenital/bladder-and-urothelial/311-bladder-urothelial-locally-adv-or-met-carbopla"
    },
    {
        "protocol_id": "1438 v.6",
        "protocol_status": "Discontinued",
        "drug_sequence": [],
        "section_name": "medical-oncology",
        "category_name": "urogenital",
        "url": "https://www.eviq.org.au/medical-oncology/urogenital/bladder-and-urothelial/1438-bladder-urothelial-neoadjuvant-mvac-discontin"
    },
    {
        "protocol_id": "3737 v.4",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Olaparib (tablets)",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "300 mg TWICE a day",
                    "day": null,
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Olaparib (tablets)",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "300 mg TWICE a day",
                    "day": null,
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "urogenital",
        "url": "https://www.eviq.org.au/medical-oncology/urogenital/prostate/2030-redirect-id-3737"
    },
    {
        "protocol_id": "4319 v.1",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Darolutamide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "600 mg TWICE a day *",
                    "day": null,
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Darolutamide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "600 mg TWICE a day *",
                    "day": null,
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "urogenital",
        "url": "https://www.eviq.org.au/medical-oncology/urogenital/prostate/4319-prostate-darolutamide"
    },
    {
        "protocol_id": "4305 v.1",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Enzalutamide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "160 mg ONCE a day *",
                    "day": null,
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Enzalutamide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "160 mg ONCE a day *",
                    "day": null,
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "urogenital",
        "url": "https://www.eviq.org.au/medical-oncology/urogenital/prostate/4305-prostate-enzalutamide"
    },
    {
        "protocol_id": "4040 v.2",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Apalutamide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "240 mg ONCE a day *",
                    "day": null,
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Apalutamide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "240 mg ONCE a day *",
                    "day": null,
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "urogenital",
        "url": "https://www.eviq.org.au/medical-oncology/urogenital/prostate/4040-prostate-locally-advanced-or-metastatic-apalu"
    },
    {
        "protocol_id": "818 v.5",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Degarelix",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "240 mg",
                    "day": "1",
                    "route": "Subcut"
                }
            ],
            [
                {
                    "drug_name": "Degarelix",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "80 mg",
                    "day": "1",
                    "route": "Subcut"
                }
            ],
            [
                {
                    "drug_name": "Degarelix",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "240 mg",
                    "day": "1",
                    "route": "Subcut"
                }
            ],
            [
                {
                    "drug_name": "Degarelix",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "80 mg",
                    "day": "1",
                    "route": "Subcut"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "urogenital",
        "url": "https://www.eviq.org.au/medical-oncology/urogenital/prostate/818-prostate-locally-advanced-or-metastatic-degare"
    },
    {
        "protocol_id": "1476 v.4",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Bicalutamide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "50 mg ONCE a day",
                    "day": null,
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Bicalutamide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "50 mg ONCE a day",
                    "day": null,
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "urogenital",
        "url": "https://www.eviq.org.au/medical-oncology/urogenital/prostate/1476-prostate-metastatic-bicalutamide"
    },
    {
        "protocol_id": "1415 v.6",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Cabazitaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "20 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Prednisolone *",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "10 mg ONCE a day",
                    "day": "1 to 21",
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Cabazitaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "20 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Prednisolone *",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "10 mg ONCE a day",
                    "day": "1 to 21",
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "urogenital",
        "url": "https://www.eviq.org.au/medical-oncology/urogenital/prostate/1415-prostate-metastatic-cabazitaxel-three-weekly"
    },
    {
        "protocol_id": "1417 v.6",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Abiraterone",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "1,000 mg ONCE a day *",
                    "day": null,
                    "route": "PO"
                },
                {
                    "drug_name": "Prednisolone **",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "10 mg ONCE a day",
                    "day": null,
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Abiraterone",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "1,000 mg ONCE a day *",
                    "day": null,
                    "route": "PO"
                },
                {
                    "drug_name": "Prednisolone **",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "10 mg ONCE a day",
                    "day": null,
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "urogenital",
        "url": "https://www.eviq.org.au/medical-oncology/urogenital/prostate/1417-prostate-metastatic-castration-resistant-abir"
    },
    {
        "protocol_id": "4355 v.1",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Abiraterone micronised",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "500 mg ONCE a day *",
                    "day": null,
                    "route": "PO"
                },
                {
                    "drug_name": "Methylprednisolone",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "4 mg TWICE a day **",
                    "day": null,
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Abiraterone micronised",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "500 mg ONCE a day *",
                    "day": null,
                    "route": "PO"
                },
                {
                    "drug_name": "Methylprednisolone",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "4 mg TWICE a day **",
                    "day": null,
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "urogenital",
        "url": "https://www.eviq.org.au/medical-oncology/urogenital/prostate/4355-prostate-metastatic-castration-resistant-abir"
    },
    {
        "protocol_id": "3580 v.3",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Abiraterone",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "1,000 mg ONCE a day *",
                    "day": null,
                    "route": "PO"
                },
                {
                    "drug_name": "Prednisolone **",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "5 mg ONCE a day",
                    "day": null,
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Abiraterone",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "1,000 mg ONCE a day *",
                    "day": null,
                    "route": "PO"
                },
                {
                    "drug_name": "Prednisolone **",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "5 mg ONCE a day",
                    "day": null,
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "urogenital",
        "url": "https://www.eviq.org.au/medical-oncology/urogenital/prostate/3580-prostate-metastatic-castration-sensitive-abir"
    },
    {
        "protocol_id": "4374 v.1",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Abiraterone micronised",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "500 mg ONCE a day *",
                    "day": null,
                    "route": "PO"
                },
                {
                    "drug_name": "Methylprednisolone",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "4 mg ONCE a day **",
                    "day": null,
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Abiraterone micronised",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "500 mg ONCE a day *",
                    "day": null,
                    "route": "PO"
                },
                {
                    "drug_name": "Methylprednisolone",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "4 mg ONCE a day **",
                    "day": null,
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "urogenital",
        "url": "https://www.eviq.org.au/medical-oncology/urogenital/prostate/4374-prostate-metastatic-castration-sensitive-abir"
    },
    {
        "protocol_id": "1664 v.5",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "DOCEtaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6",
                    "dose": "75 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "DOCEtaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6",
                    "dose": "75 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "urogenital",
        "url": "https://www.eviq.org.au/medical-oncology/urogenital/prostate/1664-prostate-metastatic-castration-sensitive-doce"
    },
    {
        "protocol_id": "1301 v.4",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Denosumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until unacceptable toxicity",
                    "dose": "120 mg",
                    "day": "1",
                    "route": "Subcut"
                }
            ],
            [
                {
                    "drug_name": "Denosumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until unacceptable toxicity",
                    "dose": "120 mg",
                    "day": "1",
                    "route": "Subcut"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "urogenital",
        "url": "https://www.eviq.org.au/medical-oncology/urogenital/prostate/1301-prostate-metastatic-denosumab"
    },
    {
        "protocol_id": "249 v.8",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "DOCEtaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity; up to 10 cycles",
                    "dose": "75 mg/m2 *",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Prednisolone",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity; up to 10 cycles",
                    "dose": "10 mg ONCE a day **",
                    "day": "1 to 21",
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "DOCEtaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity; up to 10 cycles",
                    "dose": "75 mg/m2 *",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Prednisolone",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity; up to 10 cycles",
                    "dose": "10 mg ONCE a day **",
                    "day": "1 to 21",
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "urogenital",
        "url": "https://www.eviq.org.au/medical-oncology/urogenital/prostate/249-prostate-metastatic-docetaxel-three-weekly-and"
    },
    {
        "protocol_id": "2028 v.2",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "DOCEtaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "50 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Prednisolone *",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "10 mg ONCE a day",
                    "day": "1 to 14",
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "DOCEtaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "50 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Prednisolone *",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "10 mg ONCE a day",
                    "day": "1 to 14",
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "urogenital",
        "url": "https://www.eviq.org.au/medical-oncology/urogenital/prostate/2028-prostate-metastatic-docetaxel-two-weekly-and"
    },
    {
        "protocol_id": "308 v.5",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Goserelin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "12 weeks",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "10.8 mg",
                    "day": "1",
                    "route": "Subcut"
                }
            ],
            [
                {
                    "drug_name": "Goserelin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "12 weeks",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "10.8 mg",
                    "day": "1",
                    "route": "Subcut"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "urogenital",
        "url": "https://www.eviq.org.au/medical-oncology/urogenital/prostate/308-prostate-metastatic-goserelin"
    },
    {
        "protocol_id": "555 v.5",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Leuprorelin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "12 weeks",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "22.5 mg",
                    "day": "1",
                    "route": "Subcut"
                }
            ],
            [
                {
                    "drug_name": "Leuprorelin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "12 weeks",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "22.5 mg",
                    "day": "1",
                    "route": "Subcut"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "urogenital",
        "url": "https://www.eviq.org.au/medical-oncology/urogenital/prostate/555-prostate-metastatic-leuprorelin-eligard"
    },
    {
        "protocol_id": "321 v.5",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Leuprorelin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "12 weeks",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "22.5 mg",
                    "day": "1",
                    "route": "IM"
                }
            ],
            [
                {
                    "drug_name": "Leuprorelin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "12 weeks",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "22.5 mg",
                    "day": "1",
                    "route": "IM"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "urogenital",
        "url": "https://www.eviq.org.au/medical-oncology/urogenital/prostate/321-prostate-metastatic-leuprorelin-lucrin"
    },
    {
        "protocol_id": "1293 v.3",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Triptorelin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "24 weeks",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "22.5 mg",
                    "day": "1",
                    "route": "IM"
                }
            ],
            [
                {
                    "drug_name": "Triptorelin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "24 weeks",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "22.5 mg",
                    "day": "1",
                    "route": "IM"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "urogenital",
        "url": "https://www.eviq.org.au/medical-oncology/urogenital/prostate/1293-prostate-metastatic-triptorelin"
    },
    {
        "protocol_id": "552 v.6",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Zoledronic acid",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "12 weeks(cycles of 28 days also acceptable)",
                    "cycles": "Continuous",
                    "dose": "4 mg",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Zoledronic acid",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "12 weeks(cycles of 28 days also acceptable)",
                    "cycles": "Continuous",
                    "dose": "4 mg",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "urogenital",
        "url": "https://www.eviq.org.au/medical-oncology/urogenital/prostate/552-prostate-metastatic-zoledronic-acid"
    },
    {
        "protocol_id": "1480 v.4",
        "protocol_status": "Superseded",
        "drug_sequence": [
            [
                {
                    "drug_name": "Cyproterone",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "100 mg TWICE a day *",
                    "day": null,
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Cyproterone",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "100 mg TWICE a day *",
                    "day": null,
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "urogenital",
        "url": "https://www.eviq.org.au/medical-oncology/urogenital/prostate/1480-prostate-metastatic-cyproterone-superseded"
    },
    {
        "protocol_id": "1479 v.5",
        "protocol_status": "Superseded",
        "drug_sequence": [
            [
                {
                    "drug_name": "Flutamide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "250 mg THREE times a day",
                    "day": null,
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Flutamide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "250 mg THREE times a day",
                    "day": null,
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "urogenital",
        "url": "https://www.eviq.org.au/medical-oncology/urogenital/prostate/1479-prostate-metastatic-flutamide-superseded"
    },
    {
        "protocol_id": "256 v.8",
        "protocol_status": "Superseded",
        "drug_sequence": [
            [
                {
                    "drug_name": "Mitozantrone",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "12 mg/m2",
                    "day": "1",
                    "route": "IV"
                },
                {
                    "drug_name": "Prednisolone *",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "5 mg TWICE a day",
                    "day": "1 to 21",
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Mitozantrone",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "12 mg/m2",
                    "day": "1",
                    "route": "IV"
                },
                {
                    "drug_name": "Prednisolone *",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "5 mg TWICE a day",
                    "day": "1 to 21",
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "urogenital",
        "url": "https://www.eviq.org.au/medical-oncology/urogenital/prostate/256-prostate-metastatic-mitozantrone-and-prednisol"
    },
    {
        "protocol_id": "250 v.6",
        "protocol_status": "Discontinued",
        "drug_sequence": [],
        "section_name": "medical-oncology",
        "category_name": "urogenital",
        "url": "https://www.eviq.org.au/medical-oncology/urogenital/prostate/250-prostate-metastatic-docetaxel-weekly-and-predn"
    },
    {
        "protocol_id": "1478 v.3",
        "protocol_status": "Discontinued",
        "drug_sequence": [],
        "section_name": "medical-oncology",
        "category_name": "urogenital",
        "url": "https://www.eviq.org.au/medical-oncology/urogenital/prostate/1478-prostate-metastatic-nilutamide-discontinued"
    },
    {
        "protocol_id": "3594 v.8",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Nivolumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "480 mg * #",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Nivolumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "480 mg * #",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "urogenital",
        "url": "https://www.eviq.org.au/medical-oncology/urogenital/renal/3624-redirect-id-3594"
    },
    {
        "protocol_id": "3555 v.9",
        "protocol_status": "Superseded",
        "drug_sequence": [
            [
                {
                    "drug_name": "Nivolumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "3 mg/kg",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Nivolumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "3 mg/kg",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "urogenital",
        "url": "https://www.eviq.org.au/medical-oncology/urogenital/renal/1896-redirect-id-3555"
    },
    {
        "protocol_id": "3677 v.7",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Nivolumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity. Treatment cessation after 2 years of therapy may be considered.",
                    "dose": "480 mg * #",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Nivolumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity. Treatment cessation after 2 years of therapy may be considered.",
                    "dose": "480 mg * #",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "urogenital",
        "url": "https://www.eviq.org.au/medical-oncology/urogenital/renal/3680-redirect-id-3677"
    },
    {
        "protocol_id": "3682 v.6",
        "protocol_status": "Superseded",
        "drug_sequence": [
            [
                {
                    "drug_name": "Nivolumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity. Treatment cessation after 2 years of therapy may be considered.",
                    "dose": "3 mg/kg",
                    "day": "1 *",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Nivolumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity. Treatment cessation after 2 years of therapy may be considered.",
                    "dose": "3 mg/kg",
                    "day": "1 *",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "urogenital",
        "url": "https://www.eviq.org.au/medical-oncology/urogenital/renal/3563-redirect-id-3682"
    },
    {
        "protocol_id": "4322 v.1",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Pembrolizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (up to 35 cycles of pembrolizumab). Lenvatinib monotherapy can be continued beyond 35 cycles until disease progression or unacceptable toxicity.",
                    "dose": "200 mg *",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "leNVAtinib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (up to 35 cycles of pembrolizumab). Lenvatinib monotherapy can be continued beyond 35 cycles until disease progression or unacceptable toxicity.",
                    "dose": "20 mg ONCE a day **",
                    "day": "1 to 21",
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Pembrolizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (up to 35 cycles of pembrolizumab). Lenvatinib monotherapy can be continued beyond 35 cycles until disease progression or unacceptable toxicity.",
                    "dose": "200 mg *",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "leNVAtinib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (up to 35 cycles of pembrolizumab). Lenvatinib monotherapy can be continued beyond 35 cycles until disease progression or unacceptable toxicity.",
                    "dose": "20 mg ONCE a day **",
                    "day": "1 to 21",
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "urogenital",
        "url": "https://www.eviq.org.au/medical-oncology/urogenital/renal/4322-recurrent-or-metastatic-lenvatinib-and-pembro"
    },
    {
        "protocol_id": "4039 v.3",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Avelumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "800 mg *",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "aXITinib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "5 mg TWICE a day #",
                    "day": "1 to 14",
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Avelumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "800 mg *",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "aXITinib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "5 mg TWICE a day #",
                    "day": "1 to 14",
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "urogenital",
        "url": "https://www.eviq.org.au/medical-oncology/urogenital/renal/4039-renal-cell-metastatic-avelumab-and-axitinib"
    },
    {
        "protocol_id": "1488 v.5",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "aXITinib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "5 mg TWICE a day *",
                    "day": null,
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "aXITinib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "5 mg TWICE a day *",
                    "day": null,
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "urogenital",
        "url": "https://www.eviq.org.au/medical-oncology/urogenital/renal/1488-renal-cell-metastatic-axitinib"
    },
    {
        "protocol_id": "2027 v.4",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "cABOZANtinib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "60 mg ONCE a day *",
                    "day": null,
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "cABOZANtinib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "60 mg ONCE a day *",
                    "day": null,
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "urogenital",
        "url": "https://www.eviq.org.au/medical-oncology/urogenital/renal/2027-renal-cell-metastatic-cabozantinib"
    },
    {
        "protocol_id": "577 v.8",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Everolimus",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "10 mg ONCE a day",
                    "day": null,
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Everolimus",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "10 mg ONCE a day",
                    "day": null,
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "urogenital",
        "url": "https://www.eviq.org.au/medical-oncology/urogenital/renal/577-renal-cell-metastatic-everolimus"
    },
    {
        "protocol_id": "3561 v.10",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Nivolumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4",
                    "dose": "3 mg/kg",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Ipilimumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4",
                    "dose": "1 mg/kg",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Nivolumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4",
                    "dose": "3 mg/kg",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Ipilimumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4",
                    "dose": "1 mg/kg",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "urogenital",
        "url": "https://www.eviq.org.au/medical-oncology/urogenital/renal/3561-renal-cell-metastatic-ipilimumab-and-nivoluma"
    },
    {
        "protocol_id": "820 v.5",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "pAZOPanib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "800 mg ONCE a day",
                    "day": null,
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "pAZOPanib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "800 mg ONCE a day",
                    "day": null,
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "urogenital",
        "url": "https://www.eviq.org.au/medical-oncology/urogenital/renal/820-renal-cell-metastatic-pazopanib"
    },
    {
        "protocol_id": "323 v.6",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "soRAFENib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "400 mg TWICE a day",
                    "day": null,
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "soRAFENib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "400 mg TWICE a day",
                    "day": null,
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "urogenital",
        "url": "https://www.eviq.org.au/medical-oncology/urogenital/renal/323-renal-cell-metastatic-sorafenib"
    },
    {
        "protocol_id": "322 v.7",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "sUNITinib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "42 days(sunitinib is taken daily for 4 weeks then 2 weeks break)",
                    "cycles": "continuous until disease progression or unacceptable toxicity",
                    "dose": "50 mg ONCE a day *",
                    "day": "1 to 28",
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "sUNITinib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "42 days(sunitinib is taken daily for 4 weeks then 2 weeks break)",
                    "cycles": "continuous until disease progression or unacceptable toxicity",
                    "dose": "50 mg ONCE a day *",
                    "day": "1 to 28",
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "urogenital",
        "url": "https://www.eviq.org.au/medical-oncology/urogenital/renal/322-renal-cell-metastatic-sunitinib"
    },
    {
        "protocol_id": "91 v.6",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Temsirolimus",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "7 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "25 mg",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Temsirolimus",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "7 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "25 mg",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "urogenital",
        "url": "https://www.eviq.org.au/medical-oncology/urogenital/renal/91-renal-cell-metastatic-temsirolimus"
    },
    {
        "protocol_id": "576 v.4",
        "protocol_status": "Discontinued",
        "drug_sequence": [],
        "section_name": "medical-oncology",
        "category_name": "urogenital",
        "url": "https://www.eviq.org.au/medical-oncology/urogenital/renal/576-renal-cell-metastatic-bevacizumab-and-interfer"
    },
    {
        "protocol_id": "324 v.4",
        "protocol_status": "Discontinued",
        "drug_sequence": [],
        "section_name": "medical-oncology",
        "category_name": "urogenital",
        "url": "https://www.eviq.org.au/medical-oncology/urogenital/renal/324-renal-cell-metastatic-interferon-alfa-2a-disco"
    },
    {
        "protocol_id": "1176 v.4",
        "protocol_status": "Endorsed",
        "drug_sequence": [],
        "section_name": "medical-oncology",
        "category_name": "urogenital",
        "url": "https://www.eviq.org.au/medical-oncology/urogenital/testicular/3837-redirect-id-1176"
    },
    {
        "protocol_id": "1617 v.8",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "ciSplatin ^",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4",
                    "dose": "20 mg/m2",
                    "day": "1 to 5",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Etoposide ^*",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4",
                    "dose": "100 mg/m2",
                    "day": "1 to 5",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Pegfilgrastim **",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4",
                    "dose": "6 mg",
                    "day": "6",
                    "route": "Subcut"
                }
            ],
            [
                {
                    "drug_name": "ciSplatin ^",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4",
                    "dose": "20 mg/m2",
                    "day": "1 to 5",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Etoposide ^*",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4",
                    "dose": "100 mg/m2",
                    "day": "1 to 5",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Pegfilgrastim **",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4",
                    "dose": "6 mg",
                    "day": "6",
                    "route": "Subcut"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "urogenital",
        "url": "https://www.eviq.org.au/medical-oncology/urogenital/testicular/1617-testicular-germ-cell-advanced-or-metastatic-e"
    },
    {
        "protocol_id": "320 v.8",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Bleomycin #",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "3for good-risk disease (4 cycles for intermediate or poor-risk disease - see notes section below)",
                    "dose": "30,000 International Units",
                    "day": "1, 8, 15",
                    "route": "IM/IV"
                },
                {
                    "drug_name": "ciSplatin ^",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "3for good-risk disease (4 cycles for intermediate or poor-risk disease - see notes section below)",
                    "dose": "20 mg/m2",
                    "day": "1 to 5",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Etoposide ^*",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "3for good-risk disease (4 cycles for intermediate or poor-risk disease - see notes section below)",
                    "dose": "100 mg/m2",
                    "day": "1 to 5",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Pegfilgrastim **",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "3for good-risk disease (4 cycles for intermediate or poor-risk disease - see notes section below)",
                    "dose": "6 mg",
                    "day": "6",
                    "route": "Subcut"
                }
            ],
            [
                {
                    "drug_name": "Bleomycin #",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "3for good-risk disease (4 cycles for intermediate or poor-risk disease - see notes section below)",
                    "dose": "30,000 International Units",
                    "day": "1, 8, 15",
                    "route": "IM/IV"
                },
                {
                    "drug_name": "ciSplatin ^",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "3for good-risk disease (4 cycles for intermediate or poor-risk disease - see notes section below)",
                    "dose": "20 mg/m2",
                    "day": "1 to 5",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Etoposide ^*",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "3for good-risk disease (4 cycles for intermediate or poor-risk disease - see notes section below)",
                    "dose": "100 mg/m2",
                    "day": "1 to 5",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Pegfilgrastim **",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "3for good-risk disease (4 cycles for intermediate or poor-risk disease - see notes section below)",
                    "dose": "6 mg",
                    "day": "6",
                    "route": "Subcut"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "urogenital",
        "url": "https://www.eviq.org.au/medical-oncology/urogenital/testicular/320-testicular-germ-cell-metastatic-bep-bleomycin"
    },
    {
        "protocol_id": "318 v.9",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Etoposide *",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4",
                    "dose": "75 mg/m2",
                    "day": "1 to 5",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4",
                    "dose": "20 mg/m2",
                    "day": "1 to 5",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "iFOSFamide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4",
                    "dose": "1,200 mg/m2",
                    "day": "1 to 5",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Mesna",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4",
                    "dose": "1,200 mg/m2",
                    "day": "1 to 5",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Mesna",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4",
                    "dose": "2,000 mg at 2 hours and 6 hours after completion of ifosfamide infusion",
                    "day": "1 to 5",
                    "route": "PO"
                },
                {
                    "drug_name": "Pegfilgrastim",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4",
                    "dose": "6 mg",
                    "day": "6",
                    "route": "Subcut"
                }
            ],
            [
                {
                    "drug_name": "Etoposide *",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4",
                    "dose": "75 mg/m2",
                    "day": "1 to 5",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4",
                    "dose": "20 mg/m2",
                    "day": "1 to 5",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "iFOSFamide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4",
                    "dose": "1,200 mg/m2",
                    "day": "1 to 5",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Mesna",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4",
                    "dose": "1,200 mg/m2",
                    "day": "1 to 5",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Mesna",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4",
                    "dose": "2,000 mg at 2 hours and 6 hours after completion of ifosfamide infusion",
                    "day": "1 to 5",
                    "route": "PO"
                },
                {
                    "drug_name": "Pegfilgrastim",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4",
                    "dose": "6 mg",
                    "day": "6",
                    "route": "Subcut"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "urogenital",
        "url": "https://www.eviq.org.au/medical-oncology/urogenital/testicular/318-testicular-germ-cell-metastatic-vip-etoposide"
    },
    {
        "protocol_id": "319 v.10",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Bleomycin #",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "1 or 2 cycles",
                    "dose": "30,000 International Units",
                    "day": "1, 8, 15",
                    "route": "IM/IV"
                },
                {
                    "drug_name": "ciSplatin ^",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "1 or 2 cycles",
                    "dose": "20 mg/m2",
                    "day": "1 to 5",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Etoposide ^*",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "1 or 2 cycles",
                    "dose": "100 mg/m2",
                    "day": "1 to 5",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Pegfilgrastim **",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "1 or 2 cycles",
                    "dose": "6 mg",
                    "day": "6",
                    "route": "Subcut"
                }
            ],
            [
                {
                    "drug_name": "Bleomycin #",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "1 or 2 cycles",
                    "dose": "30,000 International Units",
                    "day": "1, 8, 15",
                    "route": "IM/IV"
                },
                {
                    "drug_name": "ciSplatin ^",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "1 or 2 cycles",
                    "dose": "20 mg/m2",
                    "day": "1 to 5",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Etoposide ^*",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "1 or 2 cycles",
                    "dose": "100 mg/m2",
                    "day": "1 to 5",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Pegfilgrastim **",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "1 or 2 cycles",
                    "dose": "6 mg",
                    "day": "6",
                    "route": "Subcut"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "urogenital",
        "url": "https://www.eviq.org.au/medical-oncology/urogenital/testicular/319-testicular-germ-cell-non-seminoma-adjuvant-bep"
    },
    {
        "protocol_id": "316 v.9",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "PACLitaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4",
                    "dose": "175 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4",
                    "dose": "20 mg/m2",
                    "day": "1 to 5",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Mesna",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4",
                    "dose": "400 mg/m2",
                    "day": "1 to 5",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "iFOSFamide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4",
                    "dose": "1,200 mg/m2",
                    "day": "1 to 5",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Mesna *",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4",
                    "dose": "400 mg/m2 at 4 hours and 8 hours after completion of ifosfamide infusion",
                    "day": "1 to 5",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Pegfilgrastim",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4",
                    "dose": "6 mg",
                    "day": "6",
                    "route": "Subcut"
                }
            ],
            [
                {
                    "drug_name": "PACLitaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4",
                    "dose": "175 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4",
                    "dose": "20 mg/m2",
                    "day": "1 to 5",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Mesna",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4",
                    "dose": "400 mg/m2",
                    "day": "1 to 5",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "iFOSFamide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4",
                    "dose": "1,200 mg/m2",
                    "day": "1 to 5",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Mesna *",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4",
                    "dose": "400 mg/m2 at 4 hours and 8 hours after completion of ifosfamide infusion",
                    "day": "1 to 5",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Pegfilgrastim",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4",
                    "dose": "6 mg",
                    "day": "6",
                    "route": "Subcut"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "urogenital",
        "url": "https://www.eviq.org.au/medical-oncology/urogenital/testicular/316-testicular-germ-cell-recurrent-tip-paclitaxel"
    },
    {
        "protocol_id": "317 v.9",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "vinBLASTine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4",
                    "dose": "0.11 mg/kg",
                    "day": "1 and 2",
                    "route": "IV"
                },
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4",
                    "dose": "20 mg/m2",
                    "day": "1 to 5",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "iFOSFamide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4",
                    "dose": "1,200 mg/m2",
                    "day": "1 to 5",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Mesna",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4",
                    "dose": "1,200 mg/m2",
                    "day": "1 to 5",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Mesna",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4",
                    "dose": "2,000 mg at 2 hours and 6 hours after completion of ifosfamide infusion",
                    "day": "1 to 5",
                    "route": "PO"
                },
                {
                    "drug_name": "Pegfilgrastim",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4",
                    "dose": "6 mg",
                    "day": "6",
                    "route": "Subcut"
                }
            ],
            [
                {
                    "drug_name": "vinBLASTine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4",
                    "dose": "0.11 mg/kg",
                    "day": "1 and 2",
                    "route": "IV"
                },
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4",
                    "dose": "20 mg/m2",
                    "day": "1 to 5",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "iFOSFamide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4",
                    "dose": "1,200 mg/m2",
                    "day": "1 to 5",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Mesna",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4",
                    "dose": "1,200 mg/m2",
                    "day": "1 to 5",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Mesna",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4",
                    "dose": "2,000 mg at 2 hours and 6 hours after completion of ifosfamide infusion",
                    "day": "1 to 5",
                    "route": "PO"
                },
                {
                    "drug_name": "Pegfilgrastim",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4",
                    "dose": "6 mg",
                    "day": "6",
                    "route": "Subcut"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "urogenital",
        "url": "https://www.eviq.org.au/medical-oncology/urogenital/testicular/317-testicular-germ-cell-recurrent-veip-vinblasti"
    },
    {
        "protocol_id": "325 v.6",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": "1",
                    "dose": "7 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": true,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": "1",
                    "dose": "7 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "urogenital",
        "url": "https://www.eviq.org.au/medical-oncology/urogenital/testicular/325-testicular-germ-cell-seminoma-adjuvant-carbopl"
    },
    {
        "protocol_id": "3621 v.3",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "PACLitaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "6unless disease progression or unacceptable toxicity",
                    "dose": "80 mg/m2",
                    "day": "1, 8, 15",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "6unless disease progression or unacceptable toxicity",
                    "dose": "5 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "PACLitaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "6unless disease progression or unacceptable toxicity",
                    "dose": "80 mg/m2",
                    "day": "1, 8, 15",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "6unless disease progression or unacceptable toxicity",
                    "dose": "5 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "rare-cancers",
        "url": "https://www.eviq.org.au/medical-oncology/rare-cancers/colorectal/4206-redirect-id-3621"
    },
    {
        "protocol_id": "81 v.7",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": "1with concurrent radiation therapy",
                    "dose": "60 mg/m2",
                    "day": "1 and 29",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": "1with concurrent radiation therapy",
                    "dose": "4,000 mg/m2 (equivalent to 1000 mg/m2/day)",
                    "day": "1 and 29",
                    "route": "CIV via pump over 96 hours"
                }
            ],
            [
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": "1with concurrent radiation therapy",
                    "dose": "60 mg/m2",
                    "day": "1 and 29",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": "1with concurrent radiation therapy",
                    "dose": "4,000 mg/m2 (equivalent to 1000 mg/m2/day)",
                    "day": "1 and 29",
                    "route": "CIV via pump over 96 hours"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "rare-cancers",
        "url": "https://www.eviq.org.au/medical-oncology/rare-cancers/colorectal/4207-redirect-id-81"
    },
    {
        "protocol_id": "1959 v.5",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Mitomycin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": "1with concurrent radiation therapy",
                    "dose": "12 mg/m2\n(Cap dose at 20 mg)",
                    "day": "1",
                    "route": "IV"
                },
                {
                    "drug_name": "Capecitabine *",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": "1with concurrent radiation therapy",
                    "dose": "825 mg/m2 TWICE a day",
                    "day": "1 to 5, 8 to 12, 15 to 19, 22 to 26, 29 to 33, 36 to 40",
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Mitomycin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": "1with concurrent radiation therapy",
                    "dose": "12 mg/m2\n(Cap dose at 20 mg)",
                    "day": "1",
                    "route": "IV"
                },
                {
                    "drug_name": "Capecitabine *",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": "1with concurrent radiation therapy",
                    "dose": "825 mg/m2 TWICE a day",
                    "day": "1 to 5, 8 to 12, 15 to 19, 22 to 26, 29 to 33, 36 to 40",
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "rare-cancers",
        "url": "https://www.eviq.org.au/medical-oncology/rare-cancers/colorectal/4209-redirect-id-1959"
    },
    {
        "protocol_id": "82 v.7",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Mitomycin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": "1with concurrent radiation therapy",
                    "dose": "12 mg/m2\n(Cap dose at 20 mg)",
                    "day": "1 *",
                    "route": "IV"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": "1with concurrent radiation therapy",
                    "dose": "4,000 mg/m2 (equivalent to 1000 mg/m2/day)",
                    "day": "1 and 29",
                    "route": "CIV via pump over 96 hours"
                }
            ],
            [
                {
                    "drug_name": "Mitomycin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": "1with concurrent radiation therapy",
                    "dose": "12 mg/m2\n(Cap dose at 20 mg)",
                    "day": "1 *",
                    "route": "IV"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": "1with concurrent radiation therapy",
                    "dose": "4,000 mg/m2 (equivalent to 1000 mg/m2/day)",
                    "day": "1 and 29",
                    "route": "CIV via pump over 96 hours"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "rare-cancers",
        "url": "https://www.eviq.org.au/medical-oncology/rare-cancers/colorectal/4208-redirect-id-82"
    },
    {
        "protocol_id": "1529 v.7",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "7 days",
                    "cycles": "Continuous with concurrent radiation therapy; usually 5 or 6 cycles depending on the duration of radiation therapy.",
                    "dose": "40 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "7 days",
                    "cycles": "Continuous with concurrent radiation therapy; usually 5 or 6 cycles depending on the duration of radiation therapy.",
                    "dose": "40 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "rare-cancers",
        "url": "https://www.eviq.org.au/medical-oncology/rare-cancers/gynaecological/4223-redirect-id-1529"
    },
    {
        "protocol_id": "658 v.5",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "DOXOrubicin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Until disease progression or unacceptable toxicity, up to 6 cycles",
                    "dose": "50 mg/m2",
                    "day": "1",
                    "route": "IV"
                },
                {
                    "drug_name": "CYCLOPHOSPHamide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Until disease progression or unacceptable toxicity, up to 6 cycles",
                    "dose": "500 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Until disease progression or unacceptable toxicity, up to 6 cycles",
                    "dose": "50 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "DOXOrubicin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Until disease progression or unacceptable toxicity, up to 6 cycles",
                    "dose": "50 mg/m2",
                    "day": "1",
                    "route": "IV"
                },
                {
                    "drug_name": "CYCLOPHOSPHamide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Until disease progression or unacceptable toxicity, up to 6 cycles",
                    "dose": "500 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Until disease progression or unacceptable toxicity, up to 6 cycles",
                    "dose": "50 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "rare-cancers",
        "url": "https://www.eviq.org.au/medical-oncology/rare-cancers/head-and-neck/4191-redirect-id-658"
    },
    {
        "protocol_id": "3559 v.2",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "vinORELBine *",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4to 6 unless disease progression or unacceptable toxicity",
                    "dose": "25 mg/m2",
                    "day": "1 and 8",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4to 6 unless disease progression or unacceptable toxicity",
                    "dose": "80 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "vinORELBine *",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4to 6 unless disease progression or unacceptable toxicity",
                    "dose": "25 mg/m2",
                    "day": "1 and 8",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4to 6 unless disease progression or unacceptable toxicity",
                    "dose": "80 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "rare-cancers",
        "url": "https://www.eviq.org.au/medical-oncology/rare-cancers/head-and-neck/4192-redirect-id-3559"
    },
    {
        "protocol_id": "4281 v.2",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Capecitabine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "650 mg/m2 TWICE a day *",
                    "day": null,
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Capecitabine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "650 mg/m2 TWICE a day *",
                    "day": null,
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "rare-cancers",
        "url": "https://www.eviq.org.au/medical-oncology/rare-cancers/head-and-neck/4321-redirect-id-4281"
    },
    {
        "protocol_id": "1208 v.6",
        "protocol_status": "Superseded",
        "drug_sequence": [
            [
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "3(this protocol follows chemoradiation after a 3 to 4 week break)",
                    "dose": "5 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "3(this protocol follows chemoradiation after a 3 to 4 week break)",
                    "dose": "4,000 mg/m2 (equivalent to 1000 mg/m2/day)",
                    "day": "1",
                    "route": "CIV via pump over 96 hours"
                }
            ],
            [
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "3(this protocol follows chemoradiation after a 3 to 4 week break)",
                    "dose": "5 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "3(this protocol follows chemoradiation after a 3 to 4 week break)",
                    "dose": "4,000 mg/m2 (equivalent to 1000 mg/m2/day)",
                    "day": "1",
                    "route": "CIV via pump over 96 hours"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "rare-cancers",
        "url": "https://www.eviq.org.au/medical-oncology/rare-cancers/head-and-neck/4224-redirect-id-1208"
    },
    {
        "protocol_id": "1154 v.6",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "3(this protocol follows chemoradiation after a 3 to 4 week break)",
                    "dose": "80 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "3(this protocol follows chemoradiation after a 3 to 4 week break)",
                    "dose": "4,000 mg/m2 (equivalent to 1000 mg/m2/day)",
                    "day": "1",
                    "route": "CIV over 96 hours"
                }
            ],
            [
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "3(this protocol follows chemoradiation after a 3 to 4 week break)",
                    "dose": "80 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "3(this protocol follows chemoradiation after a 3 to 4 week break)",
                    "dose": "4,000 mg/m2 (equivalent to 1000 mg/m2/day)",
                    "day": "1",
                    "route": "CIV over 96 hours"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "rare-cancers",
        "url": "https://www.eviq.org.au/medical-oncology/rare-cancers/head-and-neck/4225-redirect-id-1154"
    },
    {
        "protocol_id": "1206 v.5",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "7 days",
                    "cycles": "6with concurrent radiation therapy (this protocol is usually followed by adjuvant chemotherapy with carboplatin and fluorouracil after a 3 to 4 week break)",
                    "dose": "2 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "7 days",
                    "cycles": "6with concurrent radiation therapy (this protocol is usually followed by adjuvant chemotherapy with carboplatin and fluorouracil after a 3 to 4 week break)",
                    "dose": "2 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "rare-cancers",
        "url": "https://www.eviq.org.au/medical-oncology/rare-cancers/head-and-neck/4226-redirect-id-1206"
    },
    {
        "protocol_id": "276 v.8",
        "protocol_status": "Superseded",
        "drug_sequence": [
            [
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "3",
                    "dose": "25 mg/m2",
                    "day": "1 to 4",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "3",
                    "dose": "25 mg/m2",
                    "day": "1 to 4",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "rare-cancers",
        "url": "https://www.eviq.org.au/medical-oncology/rare-cancers/head-and-neck/4233-redirect-id-276"
    },
    {
        "protocol_id": "277 v.6",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "3with concurrent radiation therapy (this protocol is usually followed by adjuvant chemotherapy with cisplatin and fluorouracil after a 3 to 4 week break)",
                    "dose": "100 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "3with concurrent radiation therapy (this protocol is usually followed by adjuvant chemotherapy with cisplatin and fluorouracil after a 3 to 4 week break)",
                    "dose": "100 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "rare-cancers",
        "url": "https://www.eviq.org.au/medical-oncology/rare-cancers/head-and-neck/4227-redirect-id-277"
    },
    {
        "protocol_id": "278 v.7",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "7 days",
                    "cycles": "Continuous with concurrent radiation therapy (up to 8 cycles)",
                    "dose": "40 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "7 days",
                    "cycles": "Continuous with concurrent radiation therapy (up to 8 cycles)",
                    "dose": "40 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "rare-cancers",
        "url": "https://www.eviq.org.au/medical-oncology/rare-cancers/head-and-neck/4228-redirect-id-278"
    },
    {
        "protocol_id": "3992 v.2",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "3unless disease progression or unacceptable toxicity",
                    "dose": "100 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Capecitabine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "3unless disease progression or unacceptable toxicity",
                    "dose": "1,000 mg/m2 TWICE a day *",
                    "day": "1 to 14",
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "3unless disease progression or unacceptable toxicity",
                    "dose": "100 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Capecitabine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "3unless disease progression or unacceptable toxicity",
                    "dose": "1,000 mg/m2 TWICE a day *",
                    "day": "1 to 14",
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "rare-cancers",
        "url": "https://www.eviq.org.au/medical-oncology/rare-cancers/head-and-neck/4229-redirect-3992"
    },
    {
        "protocol_id": "3674 v.2",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Gemcitabine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "3(This treatment is followed by chemoradiation commencing 21 to 28days after the first day of the last cycle of inductionchemotherapy)",
                    "dose": "1,000 mg/m2",
                    "day": "1 and 8",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "ciSplatin *",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "3(This treatment is followed by chemoradiation commencing 21 to 28days after the first day of the last cycle of inductionchemotherapy)",
                    "dose": "80 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Gemcitabine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "3(This treatment is followed by chemoradiation commencing 21 to 28days after the first day of the last cycle of inductionchemotherapy)",
                    "dose": "1,000 mg/m2",
                    "day": "1 and 8",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "ciSplatin *",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "3(This treatment is followed by chemoradiation commencing 21 to 28days after the first day of the last cycle of inductionchemotherapy)",
                    "dose": "80 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "rare-cancers",
        "url": "https://www.eviq.org.au/medical-oncology/rare-cancers/head-and-neck/4230-redirect-id-3674"
    },
    {
        "protocol_id": "1384 v.5",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Gemcitabine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4to 6",
                    "dose": "1,000 mg/m2",
                    "day": "1 and 8",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "ciSplatin *",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4to 6",
                    "dose": "80 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Gemcitabine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4to 6",
                    "dose": "1,000 mg/m2",
                    "day": "1 and 8",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "ciSplatin *",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4to 6",
                    "dose": "80 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "rare-cancers",
        "url": "https://www.eviq.org.au/medical-oncology/rare-cancers/head-and-neck/4231-redirect-id-1384"
    },
    {
        "protocol_id": "1510 v.5",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Gemcitabine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "until disease progression or unacceptable toxicity; usually 6 cycles",
                    "dose": "1,000 mg/m2 *",
                    "day": "1, 8, 15",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Gemcitabine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "until disease progression or unacceptable toxicity; usually 6 cycles",
                    "dose": "1,000 mg/m2 *",
                    "day": "1, 8, 15",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "rare-cancers",
        "url": "https://www.eviq.org.au/medical-oncology/rare-cancers/head-and-neck/4232-redirect-id-1510"
    },
    {
        "protocol_id": "3463 v.10",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Avelumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "10 mg/kg *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Avelumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "10 mg/kg *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "rare-cancers",
        "url": "https://www.eviq.org.au/medical-oncology/rare-cancers/melanoma/4193-redirect-id-3463"
    },
    {
        "protocol_id": "4136 v.1",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Lomustine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "42 days",
                    "cycles": "6(cycle 1 with concurrent radiation therapy, cycle 2 to 6 following chemoradiation)",
                    "dose": "100 mg/m2 ONCE a day",
                    "day": "1 *",
                    "route": "PO"
                },
                {
                    "drug_name": "Temozolomide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "42 days",
                    "cycles": "6(cycle 1 with concurrent radiation therapy, cycle 2 to 6 following chemoradiation)",
                    "dose": "100 mg/m2 ONCE a day",
                    "day": "2 to 6 *",
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Lomustine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "42 days",
                    "cycles": "6(cycle 1 with concurrent radiation therapy, cycle 2 to 6 following chemoradiation)",
                    "dose": "100 mg/m2 ONCE a day",
                    "day": "1",
                    "route": "PO"
                },
                {
                    "drug_name": "Temozolomide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "42 days",
                    "cycles": "6(cycle 1 with concurrent radiation therapy, cycle 2 to 6 following chemoradiation)",
                    "dose": "100 mg/m2 ONCE a day **",
                    "day": "2 to 6",
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Lomustine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "42 days",
                    "cycles": "6(cycle 1 with concurrent radiation therapy, cycle 2 to 6 following chemoradiation)",
                    "dose": "100 mg/m2 ONCE a day",
                    "day": "1 *",
                    "route": "PO"
                },
                {
                    "drug_name": "Temozolomide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "42 days",
                    "cycles": "6(cycle 1 with concurrent radiation therapy, cycle 2 to 6 following chemoradiation)",
                    "dose": "100 mg/m2 ONCE a day",
                    "day": "2 to 6 *",
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Lomustine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "42 days",
                    "cycles": "6(cycle 1 with concurrent radiation therapy, cycle 2 to 6 following chemoradiation)",
                    "dose": "100 mg/m2 ONCE a day",
                    "day": "1",
                    "route": "PO"
                },
                {
                    "drug_name": "Temozolomide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "42 days",
                    "cycles": "6(cycle 1 with concurrent radiation therapy, cycle 2 to 6 following chemoradiation)",
                    "dose": "100 mg/m2 ONCE a day **",
                    "day": "2 to 6",
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "rare-cancers",
        "url": "https://www.eviq.org.au/medical-oncology/rare-cancers/neurological/4235-redirect-id-4136"
    },
    {
        "protocol_id": "733 v.8",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "beVACizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "10 mg/kg *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "beVACizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "10 mg/kg *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "rare-cancers",
        "url": "https://www.eviq.org.au/medical-oncology/rare-cancers/neurological/4236-redirect-id-733"
    },
    {
        "protocol_id": "3363 v.1",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Lomustine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "6 weeks",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "110 mg/m2 *",
                    "day": "1",
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Lomustine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "6 weeks",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "110 mg/m2 *",
                    "day": "1",
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "rare-cancers",
        "url": "https://www.eviq.org.au/medical-oncology/rare-cancers/neurological/4237-redirect-id-3363"
    },
    {
        "protocol_id": "4135 v.1",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Lomustine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "42 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "90 mg/m2\n(Cap dose at 160 mg)",
                    "day": "1",
                    "route": "PO"
                },
                {
                    "drug_name": "beVACizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "42 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "10 mg/kg",
                    "day": "1, 15, 29",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Lomustine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "42 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "90 mg/m2\n(Cap dose at 160 mg)",
                    "day": "1",
                    "route": "PO"
                },
                {
                    "drug_name": "beVACizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "42 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "10 mg/kg",
                    "day": "1, 15, 29",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "rare-cancers",
        "url": "https://www.eviq.org.au/medical-oncology/rare-cancers/neurological/4234-redirect-id-4135"
    },
    {
        "protocol_id": "365 v.7",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Temozolomide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": "1with concurrent radiation therapy (usually 6 weeks)",
                    "dose": "75 mg/m2 ONCE a day throughout radiation therapy",
                    "day": "1 to 42 *",
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Temozolomide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": "1with concurrent radiation therapy (usually 6 weeks)",
                    "dose": "75 mg/m2 ONCE a day throughout radiation therapy",
                    "day": "1 to 42 *",
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "rare-cancers",
        "url": "https://www.eviq.org.au/medical-oncology/rare-cancers/neurological/4238-redirect-id-365"
    },
    {
        "protocol_id": "3364 v.1",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "temozolomide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "1 (42 days)",
                    "dose": "",
                    "day": 1,
                    "route": "IV"
                }
            ],
            [
                {
                    "drug_name": "temozolomide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "1 (42 days)",
                    "dose": "",
                    "day": 1,
                    "route": "IV"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "rare-cancers",
        "url": "https://www.eviq.org.au/medical-oncology/rare-cancers/neurological/4239-redirect-id-3364"
    },
    {
        "protocol_id": "366 v.6",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Temozolomide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "6(consider continuing for up to 12 cycles at clinician discretion)",
                    "dose": "150 mg/m2 ONCE a day *",
                    "day": "1 to 5",
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Temozolomide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "6(consider continuing for up to 12 cycles at clinician discretion)",
                    "dose": "200 mg/m2 ONCE a day *",
                    "day": "1 to 5",
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Temozolomide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "6(consider continuing for up to 12 cycles at clinician discretion)",
                    "dose": "150 mg/m2 ONCE a day *",
                    "day": "1 to 5",
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Temozolomide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "6(consider continuing for up to 12 cycles at clinician discretion)",
                    "dose": "200 mg/m2 ONCE a day *",
                    "day": "1 to 5",
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "rare-cancers",
        "url": "https://www.eviq.org.au/medical-oncology/rare-cancers/neurological/4240-redirect-id-366"
    },
    {
        "protocol_id": "2034 v.2",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Temozolomide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "12(up to 12 cycles were allowed in the clinical trial but this may not be achievable in this patient population in clinical practice)",
                    "dose": "150 mg/m2 ONCE a day *",
                    "day": "1 to 5",
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Temozolomide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "12(up to 12 cycles were allowed in the clinical trial but this may not be achievable in this patient population in clinical practice)",
                    "dose": "200 mg/m2 ONCE a day *",
                    "day": "1 to 5",
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Temozolomide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "12(up to 12 cycles were allowed in the clinical trial but this may not be achievable in this patient population in clinical practice)",
                    "dose": "150 mg/m2 ONCE a day *",
                    "day": "1 to 5",
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Temozolomide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "12(up to 12 cycles were allowed in the clinical trial but this may not be achievable in this patient population in clinical practice)",
                    "dose": "200 mg/m2 ONCE a day *",
                    "day": "1 to 5",
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "rare-cancers",
        "url": "https://www.eviq.org.au/medical-oncology/rare-cancers/neurological/4241-redirect-id-2034"
    },
    {
        "protocol_id": "2033 v.3",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Temozolomide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": "1with concurrent radiation therapy (usually 3 weeks)",
                    "dose": "75 mg/m2 ONCE a day throughout radiation therapy",
                    "day": "1 to 21 *",
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Temozolomide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": "1with concurrent radiation therapy (usually 3 weeks)",
                    "dose": "75 mg/m2 ONCE a day throughout radiation therapy",
                    "day": "1 to 21 *",
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "rare-cancers",
        "url": "https://www.eviq.org.au/medical-oncology/rare-cancers/neurological/4242-redirect-id-2033"
    },
    {
        "protocol_id": "3365 v.1",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "temozolomide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "1 (21 days)",
                    "dose": "",
                    "day": 1,
                    "route": "IV"
                }
            ],
            [
                {
                    "drug_name": "temozolomide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "1 (21 days)",
                    "dose": "",
                    "day": 1,
                    "route": "IV"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "rare-cancers",
        "url": "https://www.eviq.org.au/medical-oncology/rare-cancers/neurological/4243-ridirect-id-3365"
    },
    {
        "protocol_id": "230 v.8",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Pemetrexed",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6unless otherwise indicated",
                    "dose": "500 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6unless otherwise indicated",
                    "dose": "5 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Pemetrexed",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6unless otherwise indicated",
                    "dose": "500 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6unless otherwise indicated",
                    "dose": "5 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "rare-cancers",
        "url": "https://www.eviq.org.au/medical-oncology/rare-cancers/respiratory/4217-redirect-id-230"
    },
    {
        "protocol_id": "4143 v.2",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "beVACizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6 with chemotherapy combination, followed by continuous treatment with bevacizumab until disease progression or unacceptable toxicity",
                    "dose": "15 mg/kg",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Pemetrexed",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6 with chemotherapy combination, followed by continuous treatment with bevacizumab until disease progression or unacceptable toxicity",
                    "dose": "500 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6 with chemotherapy combination, followed by continuous treatment with bevacizumab until disease progression or unacceptable toxicity",
                    "dose": "5 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "beVACizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6 with chemotherapy combination, followed by continuous treatment with bevacizumab until disease progression or unacceptable toxicity",
                    "dose": "15 mg/kg",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "beVACizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6 with chemotherapy combination, followed by continuous treatment with bevacizumab until disease progression or unacceptable toxicity",
                    "dose": "15 mg/kg",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Pemetrexed",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6 with chemotherapy combination, followed by continuous treatment with bevacizumab until disease progression or unacceptable toxicity",
                    "dose": "500 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6 with chemotherapy combination, followed by continuous treatment with bevacizumab until disease progression or unacceptable toxicity",
                    "dose": "5 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "beVACizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6 with chemotherapy combination, followed by continuous treatment with bevacizumab until disease progression or unacceptable toxicity",
                    "dose": "15 mg/kg",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "rare-cancers",
        "url": "https://www.eviq.org.au/medical-oncology/rare-cancers/respiratory/4256-redirect-id-4143"
    },
    {
        "protocol_id": "229 v.6",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Pemetrexed",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6unless otherwise indicated",
                    "dose": "500 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6unless otherwise indicated",
                    "dose": "75 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Pemetrexed",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6unless otherwise indicated",
                    "dose": "500 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6unless otherwise indicated",
                    "dose": "75 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "rare-cancers",
        "url": "https://www.eviq.org.au/medical-oncology/rare-cancers/respiratory/4218-redirect-id-229"
    },
    {
        "protocol_id": "4022 v.2",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "beVACizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6 with chemotherapy combination, followed by continuous treatment with  bevacizumab until disease progression or unacceptable toxicity",
                    "dose": "15 mg/kg",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Pemetrexed",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6 with chemotherapy combination, followed by continuous treatment with  bevacizumab until disease progression or unacceptable toxicity",
                    "dose": "500 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6 with chemotherapy combination, followed by continuous treatment with  bevacizumab until disease progression or unacceptable toxicity",
                    "dose": "75 mg/m2 *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "beVACizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6 with chemotherapy combination, followed by continuous treatment with  bevacizumab until disease progression or unacceptable toxicity",
                    "dose": "15 mg/kg",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "beVACizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6 with chemotherapy combination, followed by continuous treatment with  bevacizumab until disease progression or unacceptable toxicity",
                    "dose": "15 mg/kg",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Pemetrexed",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6 with chemotherapy combination, followed by continuous treatment with  bevacizumab until disease progression or unacceptable toxicity",
                    "dose": "500 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6 with chemotherapy combination, followed by continuous treatment with  bevacizumab until disease progression or unacceptable toxicity",
                    "dose": "75 mg/m2 *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "beVACizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6 with chemotherapy combination, followed by continuous treatment with  bevacizumab until disease progression or unacceptable toxicity",
                    "dose": "15 mg/kg",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "rare-cancers",
        "url": "https://www.eviq.org.au/medical-oncology/rare-cancers/respiratory/4219-redirect-id-4022"
    },
    {
        "protocol_id": "4013 v.3",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Nivolumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "42 days",
                    "cycles": "17or until disease progression or unacceptable toxicity for up to 2 years",
                    "dose": "360 mg",
                    "day": "1 and 22",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Ipilimumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "42 days",
                    "cycles": "17or until disease progression or unacceptable toxicity for up to 2 years",
                    "dose": "1 mg/kg",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Nivolumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "42 days",
                    "cycles": "17or until disease progression or unacceptable toxicity for up to 2 years",
                    "dose": "360 mg",
                    "day": "1 and 22",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Ipilimumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "42 days",
                    "cycles": "17or until disease progression or unacceptable toxicity for up to 2 years",
                    "dose": "1 mg/kg",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "rare-cancers",
        "url": "https://www.eviq.org.au/medical-oncology/rare-cancers/respiratory/4220-redirect-id-4013"
    },
    {
        "protocol_id": "4408 v.1",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Nivolumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "42 days",
                    "cycles": "17or until disease progression or unacceptable toxicity for up to 2 years",
                    "dose": "3 mg/kg",
                    "day": "1, 15, 29",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Ipilimumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "42 days",
                    "cycles": "17or until disease progression or unacceptable toxicity for up to 2 years",
                    "dose": "1 mg/kg",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Nivolumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "42 days",
                    "cycles": "17or until disease progression or unacceptable toxicity for up to 2 years",
                    "dose": "3 mg/kg",
                    "day": "1, 15, 29",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Ipilimumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "42 days",
                    "cycles": "17or until disease progression or unacceptable toxicity for up to 2 years",
                    "dose": "1 mg/kg",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "rare-cancers",
        "url": "https://www.eviq.org.au/medical-oncology/rare-cancers/respiratory/4221-redirect-id-3957"
    },
    {
        "protocol_id": "1472 v.5",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "vinORELBine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity, usually 6 cycles",
                    "dose": "25 mg/m2",
                    "day": "1 and 8",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "vinORELBine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity, usually 6 cycles",
                    "dose": "25 mg/m2",
                    "day": "1 and 8",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "rare-cancers",
        "url": "https://www.eviq.org.au/medical-oncology/rare-cancers/respiratory/4222-redirect-id-1472"
    },
    {
        "protocol_id": "1900 v.7",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "PACLitaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (up to 6 cycles)",
                    "dose": "80 mg/m2",
                    "day": "1, 8, 15",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "PACLitaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (up to 6 cycles)",
                    "dose": "80 mg/m2",
                    "day": "1, 8, 15",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "rare-cancers",
        "url": "https://www.eviq.org.au/medical-oncology/rare-cancers/sarcoma/4194-redirect-id-1900"
    },
    {
        "protocol_id": "3465 v.5",
        "protocol_status": "Under review",
        "drug_sequence": [
            [
                {
                    "drug_name": "Etoposide *",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "7(Alternating with ID 1916 Ewing sarcoma VDC (vinCRIStine, DOXOrubicin, CYCLOPHOSPHamide) (part 1 of VDC/IE))",
                    "dose": "100 mg/m2",
                    "day": "1 to 5",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Mesna",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "7(Alternating with ID 1916 Ewing sarcoma VDC (vinCRIStine, DOXOrubicin, CYCLOPHOSPHamide) (part 1 of VDC/IE))",
                    "dose": "600 mg/m2",
                    "day": "1 to 5",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "iFOSFamide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "7(Alternating with ID 1916 Ewing sarcoma VDC (vinCRIStine, DOXOrubicin, CYCLOPHOSPHamide) (part 1 of VDC/IE))",
                    "dose": "1,800 mg/m2",
                    "day": "1 to 5",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Mesna",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "7(Alternating with ID 1916 Ewing sarcoma VDC (vinCRIStine, DOXOrubicin, CYCLOPHOSPHamide) (part 1 of VDC/IE))",
                    "dose": "600 mg/m2 at 4 and 8 hours after the initiation of ifosfamide",
                    "day": "1 to 5",
                    "route": "IV infusion #"
                },
                {
                    "drug_name": "Pegfilgrastim",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "7(Alternating with ID 1916 Ewing sarcoma VDC (vinCRIStine, DOXOrubicin, CYCLOPHOSPHamide) (part 1 of VDC/IE))",
                    "dose": "6 mg",
                    "day": "6",
                    "route": "Subcut"
                }
            ],
            [
                {
                    "drug_name": "Etoposide *",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "7(Alternating with ID 1916 Ewing sarcoma VDC (vinCRIStine, DOXOrubicin, CYCLOPHOSPHamide) (part 1 of VDC/IE))",
                    "dose": "100 mg/m2",
                    "day": "1 to 5",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Mesna",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "7(Alternating with ID 1916 Ewing sarcoma VDC (vinCRIStine, DOXOrubicin, CYCLOPHOSPHamide) (part 1 of VDC/IE))",
                    "dose": "600 mg/m2",
                    "day": "1 to 5",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "iFOSFamide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "7(Alternating with ID 1916 Ewing sarcoma VDC (vinCRIStine, DOXOrubicin, CYCLOPHOSPHamide) (part 1 of VDC/IE))",
                    "dose": "1,800 mg/m2",
                    "day": "1 to 5",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Mesna",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "7(Alternating with ID 1916 Ewing sarcoma VDC (vinCRIStine, DOXOrubicin, CYCLOPHOSPHamide) (part 1 of VDC/IE))",
                    "dose": "600 mg/m2 at 4 and 8 hours after the initiation of ifosfamide",
                    "day": "1 to 5",
                    "route": "IV infusion #"
                },
                {
                    "drug_name": "Pegfilgrastim",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "7(Alternating with ID 1916 Ewing sarcoma VDC (vinCRIStine, DOXOrubicin, CYCLOPHOSPHamide) (part 1 of VDC/IE))",
                    "dose": "6 mg",
                    "day": "6",
                    "route": "Subcut"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "rare-cancers",
        "url": "https://www.eviq.org.au/medical-oncology/rare-cancers/sarcoma/4196-redirect-id-3465"
    },
    {
        "protocol_id": "3620 v.2",
        "protocol_status": "Under review",
        "drug_sequence": [
            [
                {
                    "drug_name": "Temozolomide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6or until disease progression or unacceptable toxicity (decision to treat beyond 6 cycles at clinician\u2019s discretion)",
                    "dose": "100 mg/m2 ONCE a day",
                    "day": "1 to 5",
                    "route": "PO ^"
                },
                {
                    "drug_name": "Irinotecan",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6or until disease progression or unacceptable toxicity (decision to treat beyond 6 cycles at clinician\u2019s discretion)",
                    "dose": "50 mg/m2 *",
                    "day": "1 to 5",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Temozolomide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6or until disease progression or unacceptable toxicity (decision to treat beyond 6 cycles at clinician\u2019s discretion)",
                    "dose": "100 mg/m2 ONCE a day",
                    "day": "1 to 5",
                    "route": "PO ^"
                },
                {
                    "drug_name": "Irinotecan",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6or until disease progression or unacceptable toxicity (decision to treat beyond 6 cycles at clinician\u2019s discretion)",
                    "dose": "50 mg/m2 *",
                    "day": "1 to 5",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "rare-cancers",
        "url": "https://www.eviq.org.au/medical-oncology/rare-cancers/sarcoma/4197-redirect-id-3620"
    },
    {
        "protocol_id": "4245 v.1",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Topotecan",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (In the rEECur trial, in the absence of disease progression,6 cycles of topotecan and cyclophosphamide (TC) were given. Decision to treat beyond 6 cycles at clinician discretion.)",
                    "dose": "0.75 mg/m2",
                    "day": "1 to 5",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "CYCLOPHOSPHamide *",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (In the rEECur trial, in the absence of disease progression,6 cycles of topotecan and cyclophosphamide (TC) were given. Decision to treat beyond 6 cycles at clinician discretion.)",
                    "dose": "250 mg/m2",
                    "day": "1 to 5",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Pegfilgrastim",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (In the rEECur trial, in the absence of disease progression,6 cycles of topotecan and cyclophosphamide (TC) were given. Decision to treat beyond 6 cycles at clinician discretion.)",
                    "dose": "6 mg",
                    "day": "6",
                    "route": "Subcut"
                }
            ],
            [
                {
                    "drug_name": "Topotecan",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (In the rEECur trial, in the absence of disease progression,6 cycles of topotecan and cyclophosphamide (TC) were given. Decision to treat beyond 6 cycles at clinician discretion.)",
                    "dose": "0.75 mg/m2",
                    "day": "1 to 5",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "CYCLOPHOSPHamide *",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (In the rEECur trial, in the absence of disease progression,6 cycles of topotecan and cyclophosphamide (TC) were given. Decision to treat beyond 6 cycles at clinician discretion.)",
                    "dose": "250 mg/m2",
                    "day": "1 to 5",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Pegfilgrastim",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (In the rEECur trial, in the absence of disease progression,6 cycles of topotecan and cyclophosphamide (TC) were given. Decision to treat beyond 6 cycles at clinician discretion.)",
                    "dose": "6 mg",
                    "day": "6",
                    "route": "Subcut"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "rare-cancers",
        "url": "https://www.eviq.org.au/medical-oncology/rare-cancers/sarcoma/4290-redirect-id-4245"
    },
    {
        "protocol_id": "1916 v.6",
        "protocol_status": "Under review",
        "drug_sequence": [
            [
                {
                    "drug_name": "DOXOrubicin #",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "7(Alternating with ID 3465Ewing sarcoma iFOSFamide and etoposide(part 2 of VDC/IE))",
                    "dose": "37.5 mg/m2",
                    "day": "1 and 2",
                    "route": "IV ##"
                },
                {
                    "drug_name": "vinCRISTine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "7(Alternating with ID 3465Ewing sarcoma iFOSFamide and etoposide(part 2 of VDC/IE))",
                    "dose": "1.5 mg/m2\n(Cap dose at 2 mg)",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Mesna",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "7(Alternating with ID 3465Ewing sarcoma iFOSFamide and etoposide(part 2 of VDC/IE))",
                    "dose": "400 mg/m2 *",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "CYCLOPHOSPHamide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "7(Alternating with ID 3465Ewing sarcoma iFOSFamide and etoposide(part 2 of VDC/IE))",
                    "dose": "1,200 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Mesna",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "7(Alternating with ID 3465Ewing sarcoma iFOSFamide and etoposide(part 2 of VDC/IE))",
                    "dose": "800 mg/m2",
                    "day": "1",
                    "route": "PO"
                },
                {
                    "drug_name": "Pegfilgrastim",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "7(Alternating with ID 3465Ewing sarcoma iFOSFamide and etoposide(part 2 of VDC/IE))",
                    "dose": "6 mg",
                    "day": "3",
                    "route": "Subcut"
                }
            ],
            [
                {
                    "drug_name": "DOXOrubicin #",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "7(Alternating with ID 3465Ewing sarcoma iFOSFamide and etoposide(part 2 of VDC/IE))",
                    "dose": "37.5 mg/m2",
                    "day": "1 and 2",
                    "route": "IV ##"
                },
                {
                    "drug_name": "vinCRISTine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "7(Alternating with ID 3465Ewing sarcoma iFOSFamide and etoposide(part 2 of VDC/IE))",
                    "dose": "1.5 mg/m2\n(Cap dose at 2 mg)",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Mesna",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "7(Alternating with ID 3465Ewing sarcoma iFOSFamide and etoposide(part 2 of VDC/IE))",
                    "dose": "400 mg/m2 *",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "CYCLOPHOSPHamide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "7(Alternating with ID 3465Ewing sarcoma iFOSFamide and etoposide(part 2 of VDC/IE))",
                    "dose": "1,200 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Mesna",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "7(Alternating with ID 3465Ewing sarcoma iFOSFamide and etoposide(part 2 of VDC/IE))",
                    "dose": "800 mg/m2",
                    "day": "1",
                    "route": "PO"
                },
                {
                    "drug_name": "Pegfilgrastim",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "7(Alternating with ID 3465Ewing sarcoma iFOSFamide and etoposide(part 2 of VDC/IE))",
                    "dose": "6 mg",
                    "day": "3",
                    "route": "Subcut"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "rare-cancers",
        "url": "https://www.eviq.org.au/medical-oncology/rare-cancers/sarcoma/4200-redirect-id-1916"
    },
    {
        "protocol_id": "3464 v.1",
        "protocol_status": "Under review",
        "drug_sequence": [
            [
                {
                    "drug_name": "cyclophosphamide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "7",
                    "dose": "",
                    "day": 1,
                    "route": "IV"
                }
            ],
            [
                {
                    "drug_name": "etoposide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "7",
                    "dose": "",
                    "day": 1,
                    "route": "IV"
                },
                {
                    "drug_name": "ifosfamide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "7",
                    "dose": "",
                    "day": 1,
                    "route": "IV"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "rare-cancers",
        "url": "https://www.eviq.org.au/medical-oncology/rare-cancers/sarcoma/4201-redirect-id-3464"
    },
    {
        "protocol_id": "3467 v.2",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Denosumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until unacceptable toxicity, disease progression or patient preference to cease treatment.",
                    "dose": "120 mg",
                    "day": "1, 8, 15",
                    "route": "Subcut"
                }
            ],
            [
                {
                    "drug_name": "Denosumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until unacceptable toxicity, disease progression or patient preference to cease treatment.",
                    "dose": "120 mg",
                    "day": "1",
                    "route": "Subcut"
                }
            ],
            [
                {
                    "drug_name": "Denosumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until unacceptable toxicity, disease progression or patient preference to cease treatment.",
                    "dose": "120 mg",
                    "day": "1, 8, 15",
                    "route": "Subcut"
                }
            ],
            [
                {
                    "drug_name": "Denosumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until unacceptable toxicity, disease progression or patient preference to cease treatment.",
                    "dose": "120 mg",
                    "day": "1",
                    "route": "Subcut"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "rare-cancers",
        "url": "https://www.eviq.org.au/medical-oncology/rare-cancers/sarcoma/4210-redirect-id-3467"
    },
    {
        "protocol_id": "3462 v.3",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Eribulin mesilate",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "1.4 mg/m2",
                    "day": "1 and 8",
                    "route": "IV"
                }
            ],
            [
                {
                    "drug_name": "Eribulin mesilate",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "1.4 mg/m2",
                    "day": "1 and 8",
                    "route": "IV"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "rare-cancers",
        "url": "https://www.eviq.org.au/medical-oncology/rare-cancers/sarcoma/4195-redirect-id-3462"
    },
    {
        "protocol_id": "1901 v.5",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "DOXOrubicin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "35 days",
                    "cycles": "4",
                    "dose": "37.5 mg/m2",
                    "day": "1 and 2",
                    "route": "IV *"
                },
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "35 days",
                    "cycles": "4",
                    "dose": "60 mg/m2",
                    "day": "1 and 2",
                    "route": "IV infusion **"
                },
                {
                    "drug_name": "Pegfilgrastim",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "35 days",
                    "cycles": "4",
                    "dose": "6 mg",
                    "day": "3",
                    "route": "Subcut"
                },
                {
                    "drug_name": "Methotrexate",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "35 days",
                    "cycles": "4",
                    "dose": "12,000 mg/m2 (maximum 20,000 mg)",
                    "day": "22 and 29",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Calcium folinate (Leucovorin)",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "35 days",
                    "cycles": "4",
                    "dose": "15 mg/m2 every 6 hours (for 4 doses) ***",
                    "day": "23 and 30",
                    "route": "IV bolus"
                }
            ],
            [
                {
                    "drug_name": "DOXOrubicin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "35 days",
                    "cycles": "4",
                    "dose": "37.5 mg/m2",
                    "day": "1 and 2",
                    "route": "IV *"
                },
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "35 days",
                    "cycles": "4",
                    "dose": "60 mg/m2",
                    "day": "1 and 2",
                    "route": "IV infusion **"
                },
                {
                    "drug_name": "Pegfilgrastim",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "35 days",
                    "cycles": "4",
                    "dose": "6 mg",
                    "day": "3",
                    "route": "Subcut"
                },
                {
                    "drug_name": "Methotrexate",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "35 days",
                    "cycles": "4",
                    "dose": "12,000 mg/m2 (maximum 20,000 mg)",
                    "day": "22 and 29",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Calcium folinate (Leucovorin)",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "35 days",
                    "cycles": "4",
                    "dose": "15 mg/m2 every 6 hours (for 4 doses) ***",
                    "day": "23 and 30",
                    "route": "IV bolus"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "rare-cancers",
        "url": "https://www.eviq.org.au/medical-oncology/rare-cancers/sarcoma/4204-redirect-id-1901"
    },
    {
        "protocol_id": "3472 v.9",
        "protocol_status": "Discontinued",
        "drug_sequence": [],
        "section_name": "medical-oncology",
        "category_name": "rare-cancers",
        "url": "https://www.eviq.org.au/medical-oncology/rare-cancers/sarcoma/4198-redirect-id-3472"
    },
    {
        "protocol_id": "3473 v.8",
        "protocol_status": "Discontinued",
        "drug_sequence": [],
        "section_name": "medical-oncology",
        "category_name": "rare-cancers",
        "url": "https://www.eviq.org.au/medical-oncology/rare-cancers/sarcoma/4199-redirect-id-3473"
    },
    {
        "protocol_id": "3471 v.6",
        "protocol_status": "Discontinued",
        "drug_sequence": [],
        "section_name": "medical-oncology",
        "category_name": "rare-cancers",
        "url": "https://www.eviq.org.au/medical-oncology/rare-cancers/sarcoma/4203-redirect-id-3471"
    },
    {
        "protocol_id": "3470 v.3",
        "protocol_status": "Discontinued",
        "drug_sequence": [
            [
                {
                    "drug_name": "etoposide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6",
                    "dose": "",
                    "day": 1,
                    "route": "IV"
                },
                {
                    "drug_name": "ifosfamide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6",
                    "dose": "",
                    "day": 1,
                    "route": "IV"
                },
                {
                    "drug_name": "vide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6",
                    "dose": "",
                    "day": 1,
                    "route": "IV"
                },
                {
                    "drug_name": "doxorubicin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6",
                    "dose": "",
                    "day": 1,
                    "route": "IV"
                },
                {
                    "drug_name": "vincristine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6",
                    "dose": "",
                    "day": 1,
                    "route": "IV"
                }
            ],
            [
                {
                    "drug_name": "dactinomycin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6",
                    "dose": "",
                    "day": 1,
                    "route": "IV"
                },
                {
                    "drug_name": "cyclophosphamide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6",
                    "dose": "",
                    "day": 1,
                    "route": "IV"
                },
                {
                    "drug_name": "vincristine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6",
                    "dose": "",
                    "day": 1,
                    "route": "IV"
                }
            ],
            [
                {
                    "drug_name": "dactinomycin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6",
                    "dose": "",
                    "day": 1,
                    "route": "IV"
                },
                {
                    "drug_name": "ifosfamide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6",
                    "dose": "",
                    "day": 1,
                    "route": "IV"
                },
                {
                    "drug_name": "vincristine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6",
                    "dose": "",
                    "day": 1,
                    "route": "IV"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "rare-cancers",
        "url": "https://www.eviq.org.au/medical-oncology/rare-cancers/sarcoma/4202-redirect-id-3470"
    },
    {
        "protocol_id": "1222 v.7",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Imatinib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "400 mg ONCE a day",
                    "day": null,
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Imatinib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "400 mg ONCE a day",
                    "day": null,
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "rare-cancers",
        "url": "https://www.eviq.org.au/medical-oncology/rare-cancers/upper-gastrointestinal/4211-redirect-id-1222"
    },
    {
        "protocol_id": "330 v.7",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Imatinib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "400 mg ONCE a day",
                    "day": null,
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Imatinib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "400 mg ONCE a day",
                    "day": null,
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "rare-cancers",
        "url": "https://www.eviq.org.au/medical-oncology/rare-cancers/upper-gastrointestinal/4212-redirect-id-330"
    },
    {
        "protocol_id": "1902 v.3",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Regorafenib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "160 mg ONCE a day *",
                    "day": "1 to 21 **",
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Regorafenib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "160 mg ONCE a day *",
                    "day": "1 to 21 **",
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "rare-cancers",
        "url": "https://www.eviq.org.au/medical-oncology/rare-cancers/upper-gastrointestinal/4213-redirect-id-1902"
    },
    {
        "protocol_id": "4112 v.3",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Ripretinib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "150 mg ONCE a day *",
                    "day": null,
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Ripretinib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "150 mg ONCE a day *",
                    "day": null,
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "rare-cancers",
        "url": "https://www.eviq.org.au/medical-oncology/rare-cancers/upper-gastrointestinal/4214-redirect-id-4112"
    },
    {
        "protocol_id": "329 v.7",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "sUNITinib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "42 days(sunitinib is taken daily for 4 weeks then 2 weeks break)",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "50 mg *",
                    "day": "1 to 28",
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "sUNITinib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "42 days(sunitinib is taken daily for 4 weeks then 2 weeks break)",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "50 mg *",
                    "day": "1 to 28",
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "rare-cancers",
        "url": "https://www.eviq.org.au/medical-oncology/rare-cancers/upper-gastrointestinal/4215-redirect-id-329"
    },
    {
        "protocol_id": "3937 v.2",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Mitotane",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "up to 6",
                    "dose": "1,000 mg",
                    "day": "1 to 3",
                    "route": "PO"
                },
                {
                    "drug_name": "Mitotane",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "up to 6",
                    "dose": "1,500 mg",
                    "day": "4 to 6",
                    "route": "PO"
                },
                {
                    "drug_name": "Mitotane",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "up to 6",
                    "dose": "2,000 mg",
                    "day": "7",
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Mitotane",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "up to 6",
                    "dose": "1,000 mg",
                    "day": "1 to 3",
                    "route": "PO"
                },
                {
                    "drug_name": "Mitotane",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "up to 6",
                    "dose": "1,500 mg",
                    "day": "4 to 6",
                    "route": "PO"
                },
                {
                    "drug_name": "Mitotane",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "up to 6",
                    "dose": "2,000 mg",
                    "day": "7",
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "rare-cancers",
        "url": "https://www.eviq.org.au/medical-oncology/rare-cancers/urogenital/4216-redirect-id-3937"
    },
    {
        "protocol_id": "3621 v.3",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "PACLitaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "6unless disease progression or unacceptable toxicity",
                    "dose": "80 mg/m2",
                    "day": "1, 8, 15",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "6unless disease progression or unacceptable toxicity",
                    "dose": "5 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "PACLitaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "6unless disease progression or unacceptable toxicity",
                    "dose": "80 mg/m2",
                    "day": "1, 8, 15",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "6unless disease progression or unacceptable toxicity",
                    "dose": "5 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "rare-cancers",
        "url": "https://www.eviq.org.au/medical-oncology/rare-cancers/colorectal/4206-redirect-id-3621"
    },
    {
        "protocol_id": "81 v.7",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": "1with concurrent radiation therapy",
                    "dose": "60 mg/m2",
                    "day": "1 and 29",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": "1with concurrent radiation therapy",
                    "dose": "4,000 mg/m2 (equivalent to 1000 mg/m2/day)",
                    "day": "1 and 29",
                    "route": "CIV via pump over 96 hours"
                }
            ],
            [
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": "1with concurrent radiation therapy",
                    "dose": "60 mg/m2",
                    "day": "1 and 29",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": "1with concurrent radiation therapy",
                    "dose": "4,000 mg/m2 (equivalent to 1000 mg/m2/day)",
                    "day": "1 and 29",
                    "route": "CIV via pump over 96 hours"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "rare-cancers",
        "url": "https://www.eviq.org.au/medical-oncology/rare-cancers/colorectal/4207-redirect-id-81"
    },
    {
        "protocol_id": "1959 v.5",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Mitomycin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": "1with concurrent radiation therapy",
                    "dose": "12 mg/m2\n(Cap dose at 20 mg)",
                    "day": "1",
                    "route": "IV"
                },
                {
                    "drug_name": "Capecitabine *",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": "1with concurrent radiation therapy",
                    "dose": "825 mg/m2 TWICE a day",
                    "day": "1 to 5, 8 to 12, 15 to 19, 22 to 26, 29 to 33, 36 to 40",
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Mitomycin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": "1with concurrent radiation therapy",
                    "dose": "12 mg/m2\n(Cap dose at 20 mg)",
                    "day": "1",
                    "route": "IV"
                },
                {
                    "drug_name": "Capecitabine *",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": "1with concurrent radiation therapy",
                    "dose": "825 mg/m2 TWICE a day",
                    "day": "1 to 5, 8 to 12, 15 to 19, 22 to 26, 29 to 33, 36 to 40",
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "rare-cancers",
        "url": "https://www.eviq.org.au/medical-oncology/rare-cancers/colorectal/4209-redirect-id-1959"
    },
    {
        "protocol_id": "82 v.7",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Mitomycin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": "1with concurrent radiation therapy",
                    "dose": "12 mg/m2\n(Cap dose at 20 mg)",
                    "day": "1 *",
                    "route": "IV"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": "1with concurrent radiation therapy",
                    "dose": "4,000 mg/m2 (equivalent to 1000 mg/m2/day)",
                    "day": "1 and 29",
                    "route": "CIV via pump over 96 hours"
                }
            ],
            [
                {
                    "drug_name": "Mitomycin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": "1with concurrent radiation therapy",
                    "dose": "12 mg/m2\n(Cap dose at 20 mg)",
                    "day": "1 *",
                    "route": "IV"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": "1with concurrent radiation therapy",
                    "dose": "4,000 mg/m2 (equivalent to 1000 mg/m2/day)",
                    "day": "1 and 29",
                    "route": "CIV via pump over 96 hours"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "rare-cancers",
        "url": "https://www.eviq.org.au/medical-oncology/rare-cancers/colorectal/4208-redirect-id-82"
    },
    {
        "protocol_id": "1529 v.7",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "7 days",
                    "cycles": "Continuous with concurrent radiation therapy; usually 5 or 6 cycles depending on the duration of radiation therapy.",
                    "dose": "40 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "7 days",
                    "cycles": "Continuous with concurrent radiation therapy; usually 5 or 6 cycles depending on the duration of radiation therapy.",
                    "dose": "40 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "rare-cancers",
        "url": "https://www.eviq.org.au/medical-oncology/rare-cancers/gynaecological/4223-redirect-id-1529"
    },
    {
        "protocol_id": "658 v.5",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "DOXOrubicin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Until disease progression or unacceptable toxicity, up to 6 cycles",
                    "dose": "50 mg/m2",
                    "day": "1",
                    "route": "IV"
                },
                {
                    "drug_name": "CYCLOPHOSPHamide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Until disease progression or unacceptable toxicity, up to 6 cycles",
                    "dose": "500 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Until disease progression or unacceptable toxicity, up to 6 cycles",
                    "dose": "50 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "DOXOrubicin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Until disease progression or unacceptable toxicity, up to 6 cycles",
                    "dose": "50 mg/m2",
                    "day": "1",
                    "route": "IV"
                },
                {
                    "drug_name": "CYCLOPHOSPHamide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Until disease progression or unacceptable toxicity, up to 6 cycles",
                    "dose": "500 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Until disease progression or unacceptable toxicity, up to 6 cycles",
                    "dose": "50 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "rare-cancers",
        "url": "https://www.eviq.org.au/medical-oncology/rare-cancers/head-and-neck/4191-redirect-id-658"
    },
    {
        "protocol_id": "3559 v.2",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "vinORELBine *",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4to 6 unless disease progression or unacceptable toxicity",
                    "dose": "25 mg/m2",
                    "day": "1 and 8",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4to 6 unless disease progression or unacceptable toxicity",
                    "dose": "80 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "vinORELBine *",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4to 6 unless disease progression or unacceptable toxicity",
                    "dose": "25 mg/m2",
                    "day": "1 and 8",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4to 6 unless disease progression or unacceptable toxicity",
                    "dose": "80 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "rare-cancers",
        "url": "https://www.eviq.org.au/medical-oncology/rare-cancers/head-and-neck/4192-redirect-id-3559"
    },
    {
        "protocol_id": "4281 v.2",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Capecitabine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "650 mg/m2 TWICE a day *",
                    "day": null,
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Capecitabine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "650 mg/m2 TWICE a day *",
                    "day": null,
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "rare-cancers",
        "url": "https://www.eviq.org.au/medical-oncology/rare-cancers/head-and-neck/4321-redirect-id-4281"
    },
    {
        "protocol_id": "1208 v.6",
        "protocol_status": "Superseded",
        "drug_sequence": [
            [
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "3(this protocol follows chemoradiation after a 3 to 4 week break)",
                    "dose": "5 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "3(this protocol follows chemoradiation after a 3 to 4 week break)",
                    "dose": "4,000 mg/m2 (equivalent to 1000 mg/m2/day)",
                    "day": "1",
                    "route": "CIV via pump over 96 hours"
                }
            ],
            [
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "3(this protocol follows chemoradiation after a 3 to 4 week break)",
                    "dose": "5 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "3(this protocol follows chemoradiation after a 3 to 4 week break)",
                    "dose": "4,000 mg/m2 (equivalent to 1000 mg/m2/day)",
                    "day": "1",
                    "route": "CIV via pump over 96 hours"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "rare-cancers",
        "url": "https://www.eviq.org.au/medical-oncology/rare-cancers/head-and-neck/4224-redirect-id-1208"
    },
    {
        "protocol_id": "1154 v.6",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "3(this protocol follows chemoradiation after a 3 to 4 week break)",
                    "dose": "80 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "3(this protocol follows chemoradiation after a 3 to 4 week break)",
                    "dose": "4,000 mg/m2 (equivalent to 1000 mg/m2/day)",
                    "day": "1",
                    "route": "CIV over 96 hours"
                }
            ],
            [
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "3(this protocol follows chemoradiation after a 3 to 4 week break)",
                    "dose": "80 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Fluorouracil",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "3(this protocol follows chemoradiation after a 3 to 4 week break)",
                    "dose": "4,000 mg/m2 (equivalent to 1000 mg/m2/day)",
                    "day": "1",
                    "route": "CIV over 96 hours"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "rare-cancers",
        "url": "https://www.eviq.org.au/medical-oncology/rare-cancers/head-and-neck/4225-redirect-id-1154"
    },
    {
        "protocol_id": "1206 v.5",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "7 days",
                    "cycles": "6with concurrent radiation therapy (this protocol is usually followed by adjuvant chemotherapy with carboplatin and fluorouracil after a 3 to 4 week break)",
                    "dose": "2 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "7 days",
                    "cycles": "6with concurrent radiation therapy (this protocol is usually followed by adjuvant chemotherapy with carboplatin and fluorouracil after a 3 to 4 week break)",
                    "dose": "2 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "rare-cancers",
        "url": "https://www.eviq.org.au/medical-oncology/rare-cancers/head-and-neck/4226-redirect-id-1206"
    },
    {
        "protocol_id": "276 v.8",
        "protocol_status": "Superseded",
        "drug_sequence": [
            [
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "3",
                    "dose": "25 mg/m2",
                    "day": "1 to 4",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "3",
                    "dose": "25 mg/m2",
                    "day": "1 to 4",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "rare-cancers",
        "url": "https://www.eviq.org.au/medical-oncology/rare-cancers/head-and-neck/4233-redirect-id-276"
    },
    {
        "protocol_id": "277 v.6",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "3with concurrent radiation therapy (this protocol is usually followed by adjuvant chemotherapy with cisplatin and fluorouracil after a 3 to 4 week break)",
                    "dose": "100 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "3with concurrent radiation therapy (this protocol is usually followed by adjuvant chemotherapy with cisplatin and fluorouracil after a 3 to 4 week break)",
                    "dose": "100 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "rare-cancers",
        "url": "https://www.eviq.org.au/medical-oncology/rare-cancers/head-and-neck/4227-redirect-id-277"
    },
    {
        "protocol_id": "278 v.7",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "7 days",
                    "cycles": "Continuous with concurrent radiation therapy (up to 8 cycles)",
                    "dose": "40 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "7 days",
                    "cycles": "Continuous with concurrent radiation therapy (up to 8 cycles)",
                    "dose": "40 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "rare-cancers",
        "url": "https://www.eviq.org.au/medical-oncology/rare-cancers/head-and-neck/4228-redirect-id-278"
    },
    {
        "protocol_id": "3992 v.2",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "3unless disease progression or unacceptable toxicity",
                    "dose": "100 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Capecitabine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "3unless disease progression or unacceptable toxicity",
                    "dose": "1,000 mg/m2 TWICE a day *",
                    "day": "1 to 14",
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "3unless disease progression or unacceptable toxicity",
                    "dose": "100 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Capecitabine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "3unless disease progression or unacceptable toxicity",
                    "dose": "1,000 mg/m2 TWICE a day *",
                    "day": "1 to 14",
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "rare-cancers",
        "url": "https://www.eviq.org.au/medical-oncology/rare-cancers/head-and-neck/4229-redirect-3992"
    },
    {
        "protocol_id": "3674 v.2",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Gemcitabine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "3(This treatment is followed by chemoradiation commencing 21 to 28days after the first day of the last cycle of inductionchemotherapy)",
                    "dose": "1,000 mg/m2",
                    "day": "1 and 8",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "ciSplatin *",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "3(This treatment is followed by chemoradiation commencing 21 to 28days after the first day of the last cycle of inductionchemotherapy)",
                    "dose": "80 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Gemcitabine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "3(This treatment is followed by chemoradiation commencing 21 to 28days after the first day of the last cycle of inductionchemotherapy)",
                    "dose": "1,000 mg/m2",
                    "day": "1 and 8",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "ciSplatin *",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "3(This treatment is followed by chemoradiation commencing 21 to 28days after the first day of the last cycle of inductionchemotherapy)",
                    "dose": "80 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "rare-cancers",
        "url": "https://www.eviq.org.au/medical-oncology/rare-cancers/head-and-neck/4230-redirect-id-3674"
    },
    {
        "protocol_id": "1384 v.5",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Gemcitabine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4to 6",
                    "dose": "1,000 mg/m2",
                    "day": "1 and 8",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "ciSplatin *",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4to 6",
                    "dose": "80 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Gemcitabine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4to 6",
                    "dose": "1,000 mg/m2",
                    "day": "1 and 8",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "ciSplatin *",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "4to 6",
                    "dose": "80 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "rare-cancers",
        "url": "https://www.eviq.org.au/medical-oncology/rare-cancers/head-and-neck/4231-redirect-id-1384"
    },
    {
        "protocol_id": "1510 v.5",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Gemcitabine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "until disease progression or unacceptable toxicity; usually 6 cycles",
                    "dose": "1,000 mg/m2 *",
                    "day": "1, 8, 15",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Gemcitabine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "until disease progression or unacceptable toxicity; usually 6 cycles",
                    "dose": "1,000 mg/m2 *",
                    "day": "1, 8, 15",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "rare-cancers",
        "url": "https://www.eviq.org.au/medical-oncology/rare-cancers/head-and-neck/4232-redirect-id-1510"
    },
    {
        "protocol_id": "3463 v.10",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Avelumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "10 mg/kg *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Avelumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "10 mg/kg *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "rare-cancers",
        "url": "https://www.eviq.org.au/medical-oncology/rare-cancers/melanoma/4193-redirect-id-3463"
    },
    {
        "protocol_id": "4136 v.1",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Lomustine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "42 days",
                    "cycles": "6(cycle 1 with concurrent radiation therapy, cycle 2 to 6 following chemoradiation)",
                    "dose": "100 mg/m2 ONCE a day",
                    "day": "1 *",
                    "route": "PO"
                },
                {
                    "drug_name": "Temozolomide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "42 days",
                    "cycles": "6(cycle 1 with concurrent radiation therapy, cycle 2 to 6 following chemoradiation)",
                    "dose": "100 mg/m2 ONCE a day",
                    "day": "2 to 6 *",
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Lomustine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "42 days",
                    "cycles": "6(cycle 1 with concurrent radiation therapy, cycle 2 to 6 following chemoradiation)",
                    "dose": "100 mg/m2 ONCE a day",
                    "day": "1",
                    "route": "PO"
                },
                {
                    "drug_name": "Temozolomide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "42 days",
                    "cycles": "6(cycle 1 with concurrent radiation therapy, cycle 2 to 6 following chemoradiation)",
                    "dose": "100 mg/m2 ONCE a day **",
                    "day": "2 to 6",
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Lomustine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "42 days",
                    "cycles": "6(cycle 1 with concurrent radiation therapy, cycle 2 to 6 following chemoradiation)",
                    "dose": "100 mg/m2 ONCE a day",
                    "day": "1 *",
                    "route": "PO"
                },
                {
                    "drug_name": "Temozolomide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "42 days",
                    "cycles": "6(cycle 1 with concurrent radiation therapy, cycle 2 to 6 following chemoradiation)",
                    "dose": "100 mg/m2 ONCE a day",
                    "day": "2 to 6 *",
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Lomustine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "42 days",
                    "cycles": "6(cycle 1 with concurrent radiation therapy, cycle 2 to 6 following chemoradiation)",
                    "dose": "100 mg/m2 ONCE a day",
                    "day": "1",
                    "route": "PO"
                },
                {
                    "drug_name": "Temozolomide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "42 days",
                    "cycles": "6(cycle 1 with concurrent radiation therapy, cycle 2 to 6 following chemoradiation)",
                    "dose": "100 mg/m2 ONCE a day **",
                    "day": "2 to 6",
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "rare-cancers",
        "url": "https://www.eviq.org.au/medical-oncology/rare-cancers/neurological/4235-redirect-id-4136"
    },
    {
        "protocol_id": "733 v.8",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "beVACizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "10 mg/kg *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "beVACizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "14 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "10 mg/kg *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "rare-cancers",
        "url": "https://www.eviq.org.au/medical-oncology/rare-cancers/neurological/4236-redirect-id-733"
    },
    {
        "protocol_id": "3363 v.1",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Lomustine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "6 weeks",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "110 mg/m2 *",
                    "day": "1",
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Lomustine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "6 weeks",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "110 mg/m2 *",
                    "day": "1",
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "rare-cancers",
        "url": "https://www.eviq.org.au/medical-oncology/rare-cancers/neurological/4237-redirect-id-3363"
    },
    {
        "protocol_id": "4135 v.1",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Lomustine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "42 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "90 mg/m2\n(Cap dose at 160 mg)",
                    "day": "1",
                    "route": "PO"
                },
                {
                    "drug_name": "beVACizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "42 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "10 mg/kg",
                    "day": "1, 15, 29",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Lomustine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "42 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "90 mg/m2\n(Cap dose at 160 mg)",
                    "day": "1",
                    "route": "PO"
                },
                {
                    "drug_name": "beVACizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "42 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "10 mg/kg",
                    "day": "1, 15, 29",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "rare-cancers",
        "url": "https://www.eviq.org.au/medical-oncology/rare-cancers/neurological/4234-redirect-id-4135"
    },
    {
        "protocol_id": "365 v.7",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Temozolomide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": "1with concurrent radiation therapy (usually 6 weeks)",
                    "dose": "75 mg/m2 ONCE a day throughout radiation therapy",
                    "day": "1 to 42 *",
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Temozolomide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": "1with concurrent radiation therapy (usually 6 weeks)",
                    "dose": "75 mg/m2 ONCE a day throughout radiation therapy",
                    "day": "1 to 42 *",
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "rare-cancers",
        "url": "https://www.eviq.org.au/medical-oncology/rare-cancers/neurological/4238-redirect-id-365"
    },
    {
        "protocol_id": "3364 v.1",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "temozolomide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "1 (42 days)",
                    "dose": "",
                    "day": 1,
                    "route": "IV"
                }
            ],
            [
                {
                    "drug_name": "temozolomide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "1 (42 days)",
                    "dose": "",
                    "day": 1,
                    "route": "IV"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "rare-cancers",
        "url": "https://www.eviq.org.au/medical-oncology/rare-cancers/neurological/4239-redirect-id-3364"
    },
    {
        "protocol_id": "366 v.6",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Temozolomide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "6(consider continuing for up to 12 cycles at clinician discretion)",
                    "dose": "150 mg/m2 ONCE a day *",
                    "day": "1 to 5",
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Temozolomide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "6(consider continuing for up to 12 cycles at clinician discretion)",
                    "dose": "200 mg/m2 ONCE a day *",
                    "day": "1 to 5",
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Temozolomide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "6(consider continuing for up to 12 cycles at clinician discretion)",
                    "dose": "150 mg/m2 ONCE a day *",
                    "day": "1 to 5",
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Temozolomide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "6(consider continuing for up to 12 cycles at clinician discretion)",
                    "dose": "200 mg/m2 ONCE a day *",
                    "day": "1 to 5",
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "rare-cancers",
        "url": "https://www.eviq.org.au/medical-oncology/rare-cancers/neurological/4240-redirect-id-366"
    },
    {
        "protocol_id": "2034 v.2",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Temozolomide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "12(up to 12 cycles were allowed in the clinical trial but this may not be achievable in this patient population in clinical practice)",
                    "dose": "150 mg/m2 ONCE a day *",
                    "day": "1 to 5",
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Temozolomide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "12(up to 12 cycles were allowed in the clinical trial but this may not be achievable in this patient population in clinical practice)",
                    "dose": "200 mg/m2 ONCE a day *",
                    "day": "1 to 5",
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Temozolomide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "12(up to 12 cycles were allowed in the clinical trial but this may not be achievable in this patient population in clinical practice)",
                    "dose": "150 mg/m2 ONCE a day *",
                    "day": "1 to 5",
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Temozolomide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "12(up to 12 cycles were allowed in the clinical trial but this may not be achievable in this patient population in clinical practice)",
                    "dose": "200 mg/m2 ONCE a day *",
                    "day": "1 to 5",
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "rare-cancers",
        "url": "https://www.eviq.org.au/medical-oncology/rare-cancers/neurological/4241-redirect-id-2034"
    },
    {
        "protocol_id": "2033 v.3",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Temozolomide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": "1with concurrent radiation therapy (usually 3 weeks)",
                    "dose": "75 mg/m2 ONCE a day throughout radiation therapy",
                    "day": "1 to 21 *",
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Temozolomide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": "1with concurrent radiation therapy (usually 3 weeks)",
                    "dose": "75 mg/m2 ONCE a day throughout radiation therapy",
                    "day": "1 to 21 *",
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "rare-cancers",
        "url": "https://www.eviq.org.au/medical-oncology/rare-cancers/neurological/4242-redirect-id-2033"
    },
    {
        "protocol_id": "3365 v.1",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "temozolomide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "1 (21 days)",
                    "dose": "",
                    "day": 1,
                    "route": "IV"
                }
            ],
            [
                {
                    "drug_name": "temozolomide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "1 (21 days)",
                    "dose": "",
                    "day": 1,
                    "route": "IV"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "rare-cancers",
        "url": "https://www.eviq.org.au/medical-oncology/rare-cancers/neurological/4243-ridirect-id-3365"
    },
    {
        "protocol_id": "230 v.8",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Pemetrexed",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6unless otherwise indicated",
                    "dose": "500 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6unless otherwise indicated",
                    "dose": "5 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Pemetrexed",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6unless otherwise indicated",
                    "dose": "500 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6unless otherwise indicated",
                    "dose": "5 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "rare-cancers",
        "url": "https://www.eviq.org.au/medical-oncology/rare-cancers/respiratory/4217-redirect-id-230"
    },
    {
        "protocol_id": "4143 v.2",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "beVACizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6 with chemotherapy combination, followed by continuous treatment with bevacizumab until disease progression or unacceptable toxicity",
                    "dose": "15 mg/kg",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Pemetrexed",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6 with chemotherapy combination, followed by continuous treatment with bevacizumab until disease progression or unacceptable toxicity",
                    "dose": "500 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6 with chemotherapy combination, followed by continuous treatment with bevacizumab until disease progression or unacceptable toxicity",
                    "dose": "5 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "beVACizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6 with chemotherapy combination, followed by continuous treatment with bevacizumab until disease progression or unacceptable toxicity",
                    "dose": "15 mg/kg",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "beVACizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6 with chemotherapy combination, followed by continuous treatment with bevacizumab until disease progression or unacceptable toxicity",
                    "dose": "15 mg/kg",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Pemetrexed",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6 with chemotherapy combination, followed by continuous treatment with bevacizumab until disease progression or unacceptable toxicity",
                    "dose": "500 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "cARBOplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6 with chemotherapy combination, followed by continuous treatment with bevacizumab until disease progression or unacceptable toxicity",
                    "dose": "5 AUC *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "beVACizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6 with chemotherapy combination, followed by continuous treatment with bevacizumab until disease progression or unacceptable toxicity",
                    "dose": "15 mg/kg",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "rare-cancers",
        "url": "https://www.eviq.org.au/medical-oncology/rare-cancers/respiratory/4256-redirect-id-4143"
    },
    {
        "protocol_id": "229 v.6",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Pemetrexed",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6unless otherwise indicated",
                    "dose": "500 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6unless otherwise indicated",
                    "dose": "75 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Pemetrexed",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6unless otherwise indicated",
                    "dose": "500 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6unless otherwise indicated",
                    "dose": "75 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "rare-cancers",
        "url": "https://www.eviq.org.au/medical-oncology/rare-cancers/respiratory/4218-redirect-id-229"
    },
    {
        "protocol_id": "4022 v.2",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "beVACizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6 with chemotherapy combination, followed by continuous treatment with  bevacizumab until disease progression or unacceptable toxicity",
                    "dose": "15 mg/kg",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Pemetrexed",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6 with chemotherapy combination, followed by continuous treatment with  bevacizumab until disease progression or unacceptable toxicity",
                    "dose": "500 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6 with chemotherapy combination, followed by continuous treatment with  bevacizumab until disease progression or unacceptable toxicity",
                    "dose": "75 mg/m2 *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "beVACizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6 with chemotherapy combination, followed by continuous treatment with  bevacizumab until disease progression or unacceptable toxicity",
                    "dose": "15 mg/kg",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "beVACizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6 with chemotherapy combination, followed by continuous treatment with  bevacizumab until disease progression or unacceptable toxicity",
                    "dose": "15 mg/kg",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Pemetrexed",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6 with chemotherapy combination, followed by continuous treatment with  bevacizumab until disease progression or unacceptable toxicity",
                    "dose": "500 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6 with chemotherapy combination, followed by continuous treatment with  bevacizumab until disease progression or unacceptable toxicity",
                    "dose": "75 mg/m2 *",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "beVACizumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6 with chemotherapy combination, followed by continuous treatment with  bevacizumab until disease progression or unacceptable toxicity",
                    "dose": "15 mg/kg",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "rare-cancers",
        "url": "https://www.eviq.org.au/medical-oncology/rare-cancers/respiratory/4219-redirect-id-4022"
    },
    {
        "protocol_id": "4013 v.3",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Nivolumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "42 days",
                    "cycles": "17or until disease progression or unacceptable toxicity for up to 2 years",
                    "dose": "360 mg",
                    "day": "1 and 22",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Ipilimumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "42 days",
                    "cycles": "17or until disease progression or unacceptable toxicity for up to 2 years",
                    "dose": "1 mg/kg",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Nivolumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "42 days",
                    "cycles": "17or until disease progression or unacceptable toxicity for up to 2 years",
                    "dose": "360 mg",
                    "day": "1 and 22",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Ipilimumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "42 days",
                    "cycles": "17or until disease progression or unacceptable toxicity for up to 2 years",
                    "dose": "1 mg/kg",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "rare-cancers",
        "url": "https://www.eviq.org.au/medical-oncology/rare-cancers/respiratory/4220-redirect-id-4013"
    },
    {
        "protocol_id": "4408 v.1",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Nivolumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "42 days",
                    "cycles": "17or until disease progression or unacceptable toxicity for up to 2 years",
                    "dose": "3 mg/kg",
                    "day": "1, 15, 29",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Ipilimumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "42 days",
                    "cycles": "17or until disease progression or unacceptable toxicity for up to 2 years",
                    "dose": "1 mg/kg",
                    "day": "1",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Nivolumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "42 days",
                    "cycles": "17or until disease progression or unacceptable toxicity for up to 2 years",
                    "dose": "3 mg/kg",
                    "day": "1, 15, 29",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Ipilimumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "42 days",
                    "cycles": "17or until disease progression or unacceptable toxicity for up to 2 years",
                    "dose": "1 mg/kg",
                    "day": "1",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "rare-cancers",
        "url": "https://www.eviq.org.au/medical-oncology/rare-cancers/respiratory/4221-redirect-id-3957"
    },
    {
        "protocol_id": "1472 v.5",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "vinORELBine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity, usually 6 cycles",
                    "dose": "25 mg/m2",
                    "day": "1 and 8",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "vinORELBine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity, usually 6 cycles",
                    "dose": "25 mg/m2",
                    "day": "1 and 8",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "rare-cancers",
        "url": "https://www.eviq.org.au/medical-oncology/rare-cancers/respiratory/4222-redirect-id-1472"
    },
    {
        "protocol_id": "1900 v.7",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "PACLitaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (up to 6 cycles)",
                    "dose": "80 mg/m2",
                    "day": "1, 8, 15",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "PACLitaxel",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (up to 6 cycles)",
                    "dose": "80 mg/m2",
                    "day": "1, 8, 15",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "rare-cancers",
        "url": "https://www.eviq.org.au/medical-oncology/rare-cancers/sarcoma/4194-redirect-id-1900"
    },
    {
        "protocol_id": "3465 v.5",
        "protocol_status": "Under review",
        "drug_sequence": [
            [
                {
                    "drug_name": "Etoposide *",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "7(Alternating with ID 1916 Ewing sarcoma VDC (vinCRIStine, DOXOrubicin, CYCLOPHOSPHamide) (part 1 of VDC/IE))",
                    "dose": "100 mg/m2",
                    "day": "1 to 5",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Mesna",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "7(Alternating with ID 1916 Ewing sarcoma VDC (vinCRIStine, DOXOrubicin, CYCLOPHOSPHamide) (part 1 of VDC/IE))",
                    "dose": "600 mg/m2",
                    "day": "1 to 5",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "iFOSFamide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "7(Alternating with ID 1916 Ewing sarcoma VDC (vinCRIStine, DOXOrubicin, CYCLOPHOSPHamide) (part 1 of VDC/IE))",
                    "dose": "1,800 mg/m2",
                    "day": "1 to 5",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Mesna",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "7(Alternating with ID 1916 Ewing sarcoma VDC (vinCRIStine, DOXOrubicin, CYCLOPHOSPHamide) (part 1 of VDC/IE))",
                    "dose": "600 mg/m2 at 4 and 8 hours after the initiation of ifosfamide",
                    "day": "1 to 5",
                    "route": "IV infusion #"
                },
                {
                    "drug_name": "Pegfilgrastim",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "7(Alternating with ID 1916 Ewing sarcoma VDC (vinCRIStine, DOXOrubicin, CYCLOPHOSPHamide) (part 1 of VDC/IE))",
                    "dose": "6 mg",
                    "day": "6",
                    "route": "Subcut"
                }
            ],
            [
                {
                    "drug_name": "Etoposide *",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "7(Alternating with ID 1916 Ewing sarcoma VDC (vinCRIStine, DOXOrubicin, CYCLOPHOSPHamide) (part 1 of VDC/IE))",
                    "dose": "100 mg/m2",
                    "day": "1 to 5",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Mesna",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "7(Alternating with ID 1916 Ewing sarcoma VDC (vinCRIStine, DOXOrubicin, CYCLOPHOSPHamide) (part 1 of VDC/IE))",
                    "dose": "600 mg/m2",
                    "day": "1 to 5",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "iFOSFamide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "7(Alternating with ID 1916 Ewing sarcoma VDC (vinCRIStine, DOXOrubicin, CYCLOPHOSPHamide) (part 1 of VDC/IE))",
                    "dose": "1,800 mg/m2",
                    "day": "1 to 5",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Mesna",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "7(Alternating with ID 1916 Ewing sarcoma VDC (vinCRIStine, DOXOrubicin, CYCLOPHOSPHamide) (part 1 of VDC/IE))",
                    "dose": "600 mg/m2 at 4 and 8 hours after the initiation of ifosfamide",
                    "day": "1 to 5",
                    "route": "IV infusion #"
                },
                {
                    "drug_name": "Pegfilgrastim",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "7(Alternating with ID 1916 Ewing sarcoma VDC (vinCRIStine, DOXOrubicin, CYCLOPHOSPHamide) (part 1 of VDC/IE))",
                    "dose": "6 mg",
                    "day": "6",
                    "route": "Subcut"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "rare-cancers",
        "url": "https://www.eviq.org.au/medical-oncology/rare-cancers/sarcoma/4196-redirect-id-3465"
    },
    {
        "protocol_id": "3620 v.2",
        "protocol_status": "Under review",
        "drug_sequence": [
            [
                {
                    "drug_name": "Temozolomide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6or until disease progression or unacceptable toxicity (decision to treat beyond 6 cycles at clinician\u2019s discretion)",
                    "dose": "100 mg/m2 ONCE a day",
                    "day": "1 to 5",
                    "route": "PO ^"
                },
                {
                    "drug_name": "Irinotecan",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6or until disease progression or unacceptable toxicity (decision to treat beyond 6 cycles at clinician\u2019s discretion)",
                    "dose": "50 mg/m2 *",
                    "day": "1 to 5",
                    "route": "IV infusion"
                }
            ],
            [
                {
                    "drug_name": "Temozolomide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6or until disease progression or unacceptable toxicity (decision to treat beyond 6 cycles at clinician\u2019s discretion)",
                    "dose": "100 mg/m2 ONCE a day",
                    "day": "1 to 5",
                    "route": "PO ^"
                },
                {
                    "drug_name": "Irinotecan",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6or until disease progression or unacceptable toxicity (decision to treat beyond 6 cycles at clinician\u2019s discretion)",
                    "dose": "50 mg/m2 *",
                    "day": "1 to 5",
                    "route": "IV infusion"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "rare-cancers",
        "url": "https://www.eviq.org.au/medical-oncology/rare-cancers/sarcoma/4197-redirect-id-3620"
    },
    {
        "protocol_id": "4245 v.1",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Topotecan",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (In the rEECur trial, in the absence of disease progression,6 cycles of topotecan and cyclophosphamide (TC) were given. Decision to treat beyond 6 cycles at clinician discretion.)",
                    "dose": "0.75 mg/m2",
                    "day": "1 to 5",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "CYCLOPHOSPHamide *",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (In the rEECur trial, in the absence of disease progression,6 cycles of topotecan and cyclophosphamide (TC) were given. Decision to treat beyond 6 cycles at clinician discretion.)",
                    "dose": "250 mg/m2",
                    "day": "1 to 5",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Pegfilgrastim",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (In the rEECur trial, in the absence of disease progression,6 cycles of topotecan and cyclophosphamide (TC) were given. Decision to treat beyond 6 cycles at clinician discretion.)",
                    "dose": "6 mg",
                    "day": "6",
                    "route": "Subcut"
                }
            ],
            [
                {
                    "drug_name": "Topotecan",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (In the rEECur trial, in the absence of disease progression,6 cycles of topotecan and cyclophosphamide (TC) were given. Decision to treat beyond 6 cycles at clinician discretion.)",
                    "dose": "0.75 mg/m2",
                    "day": "1 to 5",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "CYCLOPHOSPHamide *",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (In the rEECur trial, in the absence of disease progression,6 cycles of topotecan and cyclophosphamide (TC) were given. Decision to treat beyond 6 cycles at clinician discretion.)",
                    "dose": "250 mg/m2",
                    "day": "1 to 5",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Pegfilgrastim",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity (In the rEECur trial, in the absence of disease progression,6 cycles of topotecan and cyclophosphamide (TC) were given. Decision to treat beyond 6 cycles at clinician discretion.)",
                    "dose": "6 mg",
                    "day": "6",
                    "route": "Subcut"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "rare-cancers",
        "url": "https://www.eviq.org.au/medical-oncology/rare-cancers/sarcoma/4290-redirect-id-4245"
    },
    {
        "protocol_id": "1916 v.6",
        "protocol_status": "Under review",
        "drug_sequence": [
            [
                {
                    "drug_name": "DOXOrubicin #",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "7(Alternating with ID 3465Ewing sarcoma iFOSFamide and etoposide(part 2 of VDC/IE))",
                    "dose": "37.5 mg/m2",
                    "day": "1 and 2",
                    "route": "IV ##"
                },
                {
                    "drug_name": "vinCRISTine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "7(Alternating with ID 3465Ewing sarcoma iFOSFamide and etoposide(part 2 of VDC/IE))",
                    "dose": "1.5 mg/m2\n(Cap dose at 2 mg)",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Mesna",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "7(Alternating with ID 3465Ewing sarcoma iFOSFamide and etoposide(part 2 of VDC/IE))",
                    "dose": "400 mg/m2 *",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "CYCLOPHOSPHamide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "7(Alternating with ID 3465Ewing sarcoma iFOSFamide and etoposide(part 2 of VDC/IE))",
                    "dose": "1,200 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Mesna",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "7(Alternating with ID 3465Ewing sarcoma iFOSFamide and etoposide(part 2 of VDC/IE))",
                    "dose": "800 mg/m2",
                    "day": "1",
                    "route": "PO"
                },
                {
                    "drug_name": "Pegfilgrastim",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "7(Alternating with ID 3465Ewing sarcoma iFOSFamide and etoposide(part 2 of VDC/IE))",
                    "dose": "6 mg",
                    "day": "3",
                    "route": "Subcut"
                }
            ],
            [
                {
                    "drug_name": "DOXOrubicin #",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "7(Alternating with ID 3465Ewing sarcoma iFOSFamide and etoposide(part 2 of VDC/IE))",
                    "dose": "37.5 mg/m2",
                    "day": "1 and 2",
                    "route": "IV ##"
                },
                {
                    "drug_name": "vinCRISTine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "7(Alternating with ID 3465Ewing sarcoma iFOSFamide and etoposide(part 2 of VDC/IE))",
                    "dose": "1.5 mg/m2\n(Cap dose at 2 mg)",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Mesna",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "7(Alternating with ID 3465Ewing sarcoma iFOSFamide and etoposide(part 2 of VDC/IE))",
                    "dose": "400 mg/m2 *",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "CYCLOPHOSPHamide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "7(Alternating with ID 3465Ewing sarcoma iFOSFamide and etoposide(part 2 of VDC/IE))",
                    "dose": "1,200 mg/m2",
                    "day": "1",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Mesna",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "7(Alternating with ID 3465Ewing sarcoma iFOSFamide and etoposide(part 2 of VDC/IE))",
                    "dose": "800 mg/m2",
                    "day": "1",
                    "route": "PO"
                },
                {
                    "drug_name": "Pegfilgrastim",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "7(Alternating with ID 3465Ewing sarcoma iFOSFamide and etoposide(part 2 of VDC/IE))",
                    "dose": "6 mg",
                    "day": "3",
                    "route": "Subcut"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "rare-cancers",
        "url": "https://www.eviq.org.au/medical-oncology/rare-cancers/sarcoma/4200-redirect-id-1916"
    },
    {
        "protocol_id": "3464 v.1",
        "protocol_status": "Under review",
        "drug_sequence": [
            [
                {
                    "drug_name": "cyclophosphamide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "7",
                    "dose": "",
                    "day": 1,
                    "route": "IV"
                }
            ],
            [
                {
                    "drug_name": "etoposide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "7",
                    "dose": "",
                    "day": 1,
                    "route": "IV"
                },
                {
                    "drug_name": "ifosfamide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "7",
                    "dose": "",
                    "day": 1,
                    "route": "IV"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "rare-cancers",
        "url": "https://www.eviq.org.au/medical-oncology/rare-cancers/sarcoma/4201-redirect-id-3464"
    },
    {
        "protocol_id": "3467 v.2",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Denosumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until unacceptable toxicity, disease progression or patient preference to cease treatment.",
                    "dose": "120 mg",
                    "day": "1, 8, 15",
                    "route": "Subcut"
                }
            ],
            [
                {
                    "drug_name": "Denosumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until unacceptable toxicity, disease progression or patient preference to cease treatment.",
                    "dose": "120 mg",
                    "day": "1",
                    "route": "Subcut"
                }
            ],
            [
                {
                    "drug_name": "Denosumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until unacceptable toxicity, disease progression or patient preference to cease treatment.",
                    "dose": "120 mg",
                    "day": "1, 8, 15",
                    "route": "Subcut"
                }
            ],
            [
                {
                    "drug_name": "Denosumab",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until unacceptable toxicity, disease progression or patient preference to cease treatment.",
                    "dose": "120 mg",
                    "day": "1",
                    "route": "Subcut"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "rare-cancers",
        "url": "https://www.eviq.org.au/medical-oncology/rare-cancers/sarcoma/4210-redirect-id-3467"
    },
    {
        "protocol_id": "3462 v.3",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Eribulin mesilate",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "1.4 mg/m2",
                    "day": "1 and 8",
                    "route": "IV"
                }
            ],
            [
                {
                    "drug_name": "Eribulin mesilate",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "1.4 mg/m2",
                    "day": "1 and 8",
                    "route": "IV"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "rare-cancers",
        "url": "https://www.eviq.org.au/medical-oncology/rare-cancers/sarcoma/4195-redirect-id-3462"
    },
    {
        "protocol_id": "1901 v.5",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "DOXOrubicin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "35 days",
                    "cycles": "4",
                    "dose": "37.5 mg/m2",
                    "day": "1 and 2",
                    "route": "IV *"
                },
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "35 days",
                    "cycles": "4",
                    "dose": "60 mg/m2",
                    "day": "1 and 2",
                    "route": "IV infusion **"
                },
                {
                    "drug_name": "Pegfilgrastim",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "35 days",
                    "cycles": "4",
                    "dose": "6 mg",
                    "day": "3",
                    "route": "Subcut"
                },
                {
                    "drug_name": "Methotrexate",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "35 days",
                    "cycles": "4",
                    "dose": "12,000 mg/m2 (maximum 20,000 mg)",
                    "day": "22 and 29",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Calcium folinate (Leucovorin)",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "35 days",
                    "cycles": "4",
                    "dose": "15 mg/m2 every 6 hours (for 4 doses) ***",
                    "day": "23 and 30",
                    "route": "IV bolus"
                }
            ],
            [
                {
                    "drug_name": "DOXOrubicin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "35 days",
                    "cycles": "4",
                    "dose": "37.5 mg/m2",
                    "day": "1 and 2",
                    "route": "IV *"
                },
                {
                    "drug_name": "ciSplatin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "35 days",
                    "cycles": "4",
                    "dose": "60 mg/m2",
                    "day": "1 and 2",
                    "route": "IV infusion **"
                },
                {
                    "drug_name": "Pegfilgrastim",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "35 days",
                    "cycles": "4",
                    "dose": "6 mg",
                    "day": "3",
                    "route": "Subcut"
                },
                {
                    "drug_name": "Methotrexate",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "35 days",
                    "cycles": "4",
                    "dose": "12,000 mg/m2 (maximum 20,000 mg)",
                    "day": "22 and 29",
                    "route": "IV infusion"
                },
                {
                    "drug_name": "Calcium folinate (Leucovorin)",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "35 days",
                    "cycles": "4",
                    "dose": "15 mg/m2 every 6 hours (for 4 doses) ***",
                    "day": "23 and 30",
                    "route": "IV bolus"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "rare-cancers",
        "url": "https://www.eviq.org.au/medical-oncology/rare-cancers/sarcoma/4204-redirect-id-1901"
    },
    {
        "protocol_id": "3472 v.9",
        "protocol_status": "Discontinued",
        "drug_sequence": [],
        "section_name": "medical-oncology",
        "category_name": "rare-cancers",
        "url": "https://www.eviq.org.au/medical-oncology/rare-cancers/sarcoma/4198-redirect-id-3472"
    },
    {
        "protocol_id": "3473 v.8",
        "protocol_status": "Discontinued",
        "drug_sequence": [],
        "section_name": "medical-oncology",
        "category_name": "rare-cancers",
        "url": "https://www.eviq.org.au/medical-oncology/rare-cancers/sarcoma/4199-redirect-id-3473"
    },
    {
        "protocol_id": "3471 v.6",
        "protocol_status": "Discontinued",
        "drug_sequence": [],
        "section_name": "medical-oncology",
        "category_name": "rare-cancers",
        "url": "https://www.eviq.org.au/medical-oncology/rare-cancers/sarcoma/4203-redirect-id-3471"
    },
    {
        "protocol_id": "3470 v.3",
        "protocol_status": "Discontinued",
        "drug_sequence": [
            [
                {
                    "drug_name": "etoposide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6",
                    "dose": "",
                    "day": 1,
                    "route": "IV"
                },
                {
                    "drug_name": "ifosfamide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6",
                    "dose": "",
                    "day": 1,
                    "route": "IV"
                },
                {
                    "drug_name": "vide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6",
                    "dose": "",
                    "day": 1,
                    "route": "IV"
                },
                {
                    "drug_name": "doxorubicin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6",
                    "dose": "",
                    "day": 1,
                    "route": "IV"
                },
                {
                    "drug_name": "vincristine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6",
                    "dose": "",
                    "day": 1,
                    "route": "IV"
                }
            ],
            [
                {
                    "drug_name": "dactinomycin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6",
                    "dose": "",
                    "day": 1,
                    "route": "IV"
                },
                {
                    "drug_name": "cyclophosphamide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6",
                    "dose": "",
                    "day": 1,
                    "route": "IV"
                },
                {
                    "drug_name": "vincristine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6",
                    "dose": "",
                    "day": 1,
                    "route": "IV"
                }
            ],
            [
                {
                    "drug_name": "dactinomycin",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6",
                    "dose": "",
                    "day": 1,
                    "route": "IV"
                },
                {
                    "drug_name": "ifosfamide",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6",
                    "dose": "",
                    "day": 1,
                    "route": "IV"
                },
                {
                    "drug_name": "vincristine",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "21 days",
                    "cycles": "6",
                    "dose": "",
                    "day": 1,
                    "route": "IV"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "rare-cancers",
        "url": "https://www.eviq.org.au/medical-oncology/rare-cancers/sarcoma/4202-redirect-id-3470"
    },
    {
        "protocol_id": "330 v.7",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Imatinib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "400 mg ONCE a day",
                    "day": null,
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Imatinib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "400 mg ONCE a day",
                    "day": null,
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "rare-cancers",
        "url": "https://www.eviq.org.au/medical-oncology/rare-cancers/upper-gastrointestinal/4212-redirect-id-330"
    },
    {
        "protocol_id": "1902 v.3",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Regorafenib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "160 mg ONCE a day *",
                    "day": "1 to 21 **",
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Regorafenib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "160 mg ONCE a day *",
                    "day": "1 to 21 **",
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "rare-cancers",
        "url": "https://www.eviq.org.au/medical-oncology/rare-cancers/upper-gastrointestinal/4213-redirect-id-1902"
    },
    {
        "protocol_id": "4112 v.3",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Ripretinib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "150 mg ONCE a day *",
                    "day": null,
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Ripretinib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": null,
                    "cycles": null,
                    "dose": "150 mg ONCE a day *",
                    "day": null,
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "rare-cancers",
        "url": "https://www.eviq.org.au/medical-oncology/rare-cancers/upper-gastrointestinal/4214-redirect-id-4112"
    },
    {
        "protocol_id": "329 v.7",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "sUNITinib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "42 days(sunitinib is taken daily for 4 weeks then 2 weeks break)",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "50 mg *",
                    "day": "1 to 28",
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "sUNITinib",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "42 days(sunitinib is taken daily for 4 weeks then 2 weeks break)",
                    "cycles": "Continuous until disease progression or unacceptable toxicity",
                    "dose": "50 mg *",
                    "day": "1 to 28",
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "rare-cancers",
        "url": "https://www.eviq.org.au/medical-oncology/rare-cancers/upper-gastrointestinal/4215-redirect-id-329"
    },
    {
        "protocol_id": "3937 v.2",
        "protocol_status": "Endorsed",
        "drug_sequence": [
            [
                {
                    "drug_name": "Mitotane",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "up to 6",
                    "dose": "1,000 mg",
                    "day": "1 to 3",
                    "route": "PO"
                },
                {
                    "drug_name": "Mitotane",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "up to 6",
                    "dose": "1,500 mg",
                    "day": "4 to 6",
                    "route": "PO"
                },
                {
                    "drug_name": "Mitotane",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "up to 6",
                    "dose": "2,000 mg",
                    "day": "7",
                    "route": "PO"
                }
            ],
            [
                {
                    "drug_name": "Mitotane",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "up to 6",
                    "dose": "1,000 mg",
                    "day": "1 to 3",
                    "route": "PO"
                },
                {
                    "drug_name": "Mitotane",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "up to 6",
                    "dose": "1,500 mg",
                    "day": "4 to 6",
                    "route": "PO"
                },
                {
                    "drug_name": "Mitotane",
                    "is_adjuvant": false,
                    "is_neoadjuvant": false,
                    "frequency": "28 days",
                    "cycles": "up to 6",
                    "dose": "2,000 mg",
                    "day": "7",
                    "route": "PO"
                }
            ]
        ],
        "section_name": "medical-oncology",
        "category_name": "rare-cancers",
        "url": "https://www.eviq.org.au/medical-oncology/rare-cancers/urogenital/4216-redirect-id-3937"
    }
]